[{"article_id":836,"discovery_date":"2021-03-29T18:18:54","title":"A systematic review exploring the bidirectional relationship between puberty and autoimmune rheumatic diseases","summary":"Autoimmune rheumatic diseases (ARDs) are associated with a significant sex-bias, which becomes more evident post-puberty. This systematic review aims to elucidate the bidirectional relationship between puberty...","link":"https:&#x2F;&#x2F;ped-rheum.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12969-021-00528-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":835,"discovery_date":"2021-03-29T18:18:54","title":"Viscoelastic properties of white and gray matter-derived microglia differentiate upon treatment with lipopolysaccharide but not upon treatment with myelin","summary":"The biomechanical properties of the brain have increasingly been shown to relate to brain pathology in neurological diseases, including multiple sclerosis (MS). Inflammation and demyelination in MS induce sign...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02134-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":834,"discovery_date":"2021-03-29T18:18:54","title":"Prevalence and factors related to urinary incontinence in older adults women worldwide: a comprehensive systematic review and meta-analysis of observational studies","summary":"Urinary incontinence is a common condition in the general population and, in particular, the older adults population, which reduces the quality of life of these people, so this study aims to systematically exa...","link":"https:&#x2F;&#x2F;bmcgeriatr.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12877-021-02135-8","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":833,"discovery_date":"2021-03-29T17:28:24","title":"Effect of Action Observation Therapy in the Rehabilitation of Neurologic and Musculoskeletal Conditions: A Systematic Review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arch Rehabil Res Clin Transl. 2021 Jan 27;3(1):100106. doi: 10.1016&#x2F;j.arrct.2021.100106. eCollection 2021 Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To investigate the effect of action observation therapy (AOT) in the rehabilitation of neurologic and musculoskeletal conditions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DATA SOURCES: Searches were completed until July 2020 from the electronic databases Allied and Complementary Medicine Database (via OVID SP), Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, EMBASE, MEDLINE, and the Physiotherapy Evidence Database.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STUDY SELECTION: Randomized controlled trials comparing AOT with standard care were assessed. Musculoskeletal (amputee, orthopedic) and neurologic (dementia, cerebral palsy, multiple sclerosis, Parkinson disease, stroke) conditions were included. There were no age limitations. Articles had to be available in English.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DATA EXTRACTION: Two reviewers independently screened titles, abstracts and full extracts of studies for eligibility and assessed the risk of bias of each study using the Cochrane Risk of Bias Tool. Data extraction included participant characteristics and intervention duration, frequency, and type.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The effect of AOT in different outcome measures (OMs) was referenced in terms of body structures and functions, activities and participation, and environmental factors as outlined by the International Classification of Functioning, Disability, and Health (ICF). Of the 3448 articles identified, 36 articles with 1405 patients met the inclusion criteria. Seven of the 11 meta-analyses revealed a significant effect of intervention, with results presented using the mean difference and 95% CI. A best evidence synthesis was used across all OMs. Strong evidence supports the use of AOT in the rehabilitation of individuals with stroke and Parkinson disease; moderate evidence supports AOT in the rehabilitation of populations with orthopedic and multiple sclerosis diagnoses. However, moderate evidence is provided for and against the effect of AOT in persons with Parkinson disease and cerebral palsy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: This review suggests that AOT is advantageous in the rehabilitation of certain conditions in improving ICF domains. No conclusions can be drawn regarding treatment parameters because of the heterogeneity of the intervention. AOT has been considerably less explored in musculoskeletal conditions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33778479&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33778479&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7984987&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7984987&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.arrct.2021.100106&gt;10.1016&#x2F;j.arrct.2021.100106&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33778479&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":832,"discovery_date":"2021-03-29T17:28:24","title":"mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Radiol Imaging Cancer. 2020 Sep 18;2(5):e190091. doi: 10.1148&#x2F;rycan.2020190091. eCollection 2020 Sep.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: To determine the effect of chronic mammalian target of rapamycin (mTOR) inhibition on skeletal muscle mass in patients with tuberous sclerosis complex (TSC).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIALS AND METHODS: In this retrospective study, patients with TSC who were taking mTOR inhibitors and who underwent at least two abdominal CT or MRI examinations between 2005 and 2017 were included (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 24; 14 males; mean age, 14.5 years Â± 7.8 [standard deviation] at first examination). One reviewer drew regions of interest around psoas muscles at L3 to measure cross-sectional area. Multiple linear mixed-effect modeling was performed to evaluate the association between muscle mass and the covariates over time.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The 24 patients underwent a total of 129 abdominal CT or MRI examinations. Median duration of mTOR inhibition at last examination was 106 months (range, 1310-3717 days). There was no significant association between the duration of mTOR inhibitor therapy and psoas muscle area on multiple linear mixed-effect modeling (&lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .055); however, patient height and height squared were significant predictors of psoas area (&lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .014 and &lt;i&gt;P&lt;&#x2F;i&gt; &amp;lt; .0001, respectively).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Duration of mTOR inhibition in TSC was not significantly associated with a decrease in psoas muscle area, suggesting that chronic mTOR inhibition is not associated with sarcopenia.&lt;b&gt;Keywords:&lt;&#x2F;b&gt; CT, MR-Imaging, PediatricsÂ© RSNA, 2020.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33778734&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33778734&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7983794&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7983794&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1148&#x2F;rycan.2020190091&gt;10.1148&#x2F;rycan.2020190091&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33778734&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":831,"discovery_date":"2021-03-29T17:28:24","title":"Interleukin-19 Abrogates Experimental Autoimmune Encephalomyelitis by Attenuating Antigen-Presenting Cell Activation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Mar 11;12:615898. doi: 10.3389&#x2F;fimmu.2021.615898. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Interleukin-19 (IL-19) acts as a negative-feedback regulator to limit proinflammatory response of macrophages and microglia in autocrine&#x2F;paracrine manners in various inflammatory diseases. Multiple sclerosis (MS) is a major neuroinflammatory disease in the central nervous system (CNS), but it remains uncertain how IL-19 contributes to MS pathogenesis. Here, we demonstrate that IL-19 deficiency aggravates experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, by promoting IL-17-producing helper T cell (Th17 cell) infiltration into the CNS. In addition, IL-19-deficient splenic macrophages expressed elevated levels of major histocompatibility complex (MHC) class II, co-stimulatory molecules, and Th17 cell differentiation-associated cytokines such as IL-1Î², IL-6, IL-23, TGF-Î²1, and TNF-Î±. These observations indicated that IL-19 plays a critical role in suppression of MS pathogenesis by inhibiting macrophage antigen presentation, Th17 cell expansion, and subsequent inflammatory responses. Furthermore, treatment with IL-19 significantly abrogated EAE. Our data suggest that IL-19 could provide significant therapeutic benefits in patients with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33776998&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33776998&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7990911&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7990911&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.615898&gt;10.3389&#x2F;fimmu.2021.615898&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33776998&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":830,"discovery_date":"2021-03-29T17:28:24","title":"Multiple sclerosis patients and COVID-19","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):43. doi: 10.1186&#x2F;s41983-021-00287-3. Epub 2021 Mar 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of this article is to discuss what is currently known about the severity of COVID-19 in MS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33776407&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33776407&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7985914&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7985914&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s41983-021-00287-3&gt;10.1186&#x2F;s41983-021-00287-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33776407&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":829,"discovery_date":"2021-03-29T17:28:24","title":"Prospects for the Use of Cannabinoids in Psychiatric Disorders","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Psychiatry. 2021 Mar 12;12:620073. doi: 10.3389&#x2F;fpsyt.2021.620073. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Increasing evidence suggests an essential role of the endocannabinoid system in modulating cognitive abilities, mood, stress, and sleep. The psychoactive effects of cannabis are described as euphoric, calming, anxiolytic, and sleep-inducing and positively affect the mood, but can also adversely affect therapy. The responses to cannabinoid medications depend on the patient&#39;s endocannabinoid system activity, the proportion of phytocannabinoids, the terpenoid composition, and the dose used. There is some evidence for a therapeutic use of phytocannabinoids in psychiatric conditions. THC and CBD may have opposing effects on anxiety. Current guidelines recommend caution in using THC in patients with anxiety or mood disorders. In a small number of clinical trials, cannabinoids used to treat cancer, HIV, multiple sclerosis, hepatitis C, Crohn&#39;s disease, and chronic neuropathic pain report decreases in anxiety or depression symptoms and presented sedative and anxiolytic effects. Several studies have investigated the influence of potential genetic factors on psychosis and schizophrenia development after cannabis use. THC may increase the risk of psychosis, especially in young patients with an immature central nervous system. There is limited evidence from clinical trials that cannabinoids are effective therapy for sleep disorders associated with concomitant conditions. There is evidence for a possible role of cannabis as a substitute for alcohol and drugs, also in the context of the risks of opioid use (e.g., opioid-related mortality). In this narrative review of the recent evidence, we discuss the prospects of using the psychoactive effects of cannabinoids in treating mental and psychiatric disorders. However, this evidence is weak for some clinical conditions and well-designed randomized controlled trials are currently lacking. Furthermore, some disorders may be worsened by cannabis use.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33776815&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33776815&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7994770&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7994770&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fpsyt.2021.620073&gt;10.3389&#x2F;fpsyt.2021.620073&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33776815&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":828,"discovery_date":"2021-03-29T17:28:24","title":"Perioperative Botulinum Toxin Injections to Enhance Surgical Outcomes in Patients With Spasticity: Preoperative, Intraoperative, and Postoperative Case Reports","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arch Rehabil Res Clin Transl. 2021 Jan 12;3(1):100101. doi: 10.1016&#x2F;j.arrct.2021.100101. eCollection 2021 Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Spasticity causes an array of disabilities, which in turn may lead to the need for surgical intervention. Spasticity itself may also negatively affect surgical outcomes. This report reviews the potential benefit of perioperative (before, during, or after surgery) botulinum toxin (BoNT) injections for 3 patients with spasticity due to spinal cord injury, stroke, or multiple sclerosis. We discuss perioperative BoNT in 3 time periods: preoperatively, intraoperatively, and postoperatively. The cases demonstrate the use of perioperative BoNT in decreasing pain, improving wound healing, and improving surgical outcomes. We conclude by discussing the potential use of perioperative BoNT for surgical interventions in patients with spasticity and the need for further high-quality research in this field.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33778474&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33778474&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7984973&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7984973&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.arrct.2021.100101&gt;10.1016&#x2F;j.arrct.2021.100101&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33778474&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":827,"discovery_date":"2021-03-29T17:28:24","title":"Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Mar 10;12:633167. doi: 10.3389&#x2F;fimmu.2021.633167. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis (MS) are characterized by neurological deficits caused by a permanent neuronal damage, clinically quantified by the expanded disability status scale (EDSS). Neuronal tissue damage is also mediated by immune infiltrates producing soluble factors, such as cytokines and chemokines, which are released in the cerebrospinal fluid (CSF). The mechanisms regulating the production of a soluble factor are not completely defined. Using multiplex bead-based assays, we simultaneously measured 27 immune soluble factors in the CSF collected from 38 patients, 26 with PP-MS and 12 with SP-MS. Then, we performed a correlation matrix of all soluble factors expressed in the CSF. The CSF from patients with PP-MS and SP-MS had similar levels of cytokines and chemokines; however, the stratification of patients according to active or inactive magnetic resonance imaging (MRI) unveils some differences. Correlative studies between soluble factors in the CSF of patients with PP-MS and SP-MS revealed two clusters of immune mediators with pro-inflammatory functions, namely IFN-Î³, MCP-1, MIP-1Î±, MIP-1Î², IL-8, IP-10, and TNF-Î± (group 1), and anti-inflammatory functions, namely IL-9, IL-15, VEGF, and IL-1ra (group 2). However, most of the significant correlations between cytokines of group 1 and of group 2 were lost in patients with more severe disability (EDSS â¥ 4) compared to patients with mild to moderate disability (EDSS &amp;lt; 4). These results suggest a common regulation of cytokines and chemokines belonging to the same group and indicate that, in patients with more severe disability, the production of those factors is less coordinated, possibly due to advanced neurodegenerative mechanisms that interfere with the immune response.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33777018&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33777018&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7988186&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7988186&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.633167&gt;10.3389&#x2F;fimmu.2021.633167&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33777018&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":826,"discovery_date":"2021-03-29T17:28:24","title":"Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Cell Dev Biol. 2021 Mar 11;9:630942. doi: 10.3389&#x2F;fcell.2021.630942. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK inhibitors (BTKis) in the clinic has increased considerably and currently amounts to at least 22. First-in-class was ibrutinib, an irreversible binder forming a covalent bond to a cysteine in the catalytic region of the kinase, for which we have identified 228 active trials listed at ClinicalTrials.gov. Next-generation inhibitors, acalabrutinib and zanubrutinib, are approved both in the United States and in Europe, and zanubrutinib also in China, while tirabrutinib is currently only registered in Japan. In most cases, these compounds have been used for the treatment of B-lymphocyte tumors. However, an increasing number of trials instead addresses autoimmunity and inflammation in multiple sclerosis, rheumatoid arthritis, pemphigus and systemic lupus erythematosus with the use of either irreversibly binding inhibitors, e.g., evobrutinib and tolebrutinib, or reversibly binding inhibitors, like fenebrutinib. Adverse effects (AEs) have predominantly implicated inhibition of other kinases with a BTKi-binding cysteine in their catalytic domain. Analysis of the reported AEs suggests that ibrutinib-associated atrial fibrillation is caused by binding to ERBB2&#x2F;HER2 and ERBB4&#x2F;HER4. However, the binding pattern of BTKis to various additional kinases does not correlate with the common assumption that skin manifestations and diarrhoeas are off-target effects related to EGF receptor inhibition. Moreover, dermatological toxicities, diarrhoea, bleedings and invasive fungal infections often develop early after BTKi treatment initiation and subsequently subside. Conversely, cardiovascular AEs, like hypertension and various forms of heart disease, often persist.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33777941&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;33777941&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7991787&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3&quot;&gt;PMC7991787&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fcell.2021.630942&gt;10.3389&#x2F;fcell.2021.630942&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33777941&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329132823&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":825,"discovery_date":"2021-03-29T12:22:38","title":"New insights into the socio-economic aspects of multiple sclerosis in a cohort of Polish patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Agric Environ Med. 2021 Mar 18;28(1):99-106. doi: 10.26444&#x2F;aaem&#x2F;117962. Epub 2020 Feb 24.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION AND OBJECTIVE: The diagnosis of multiple sclerosis (MS) affects the socio-economic aspects of patients&#39; lives and poses new challenges. The objectives of the study were: 1) to determine selected socio-economic aspects of MS in Poland in relation to the disease type and patients&#39; place of residence, and 2) to evaluate the profile of patients via the MS Society (MSS) and the occupational consequences of informing an employer about the diagnosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIAL AND METHODS: A retrospective, observational study was undertaken to assess a cohort of 375 Polish MS patients. Socio-economic data was collected based on the patients&#39; responses to questions on a questionnaire. Clinical data was obtained from available medical records.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Patients with relapsing-remitting MS had a significantly longer time of occupational activity, higher economic status, higher level of education, better relationships with life partner, less likely to benefit from disability benefits, and members of MSS, than patients with progressive types of the disease. The patients living in rural areas had a significantly shorter time of occupational activity, more often experienced a decrease in income, received disability pension, and were less educated than urban residents. Patients who informed their employer about an MS diagnosis significantly more often received support from the company, were professionally active for longer, and less likely to experience a decrease in income. Membership of the MSS were dominated by patients with progressive variants of the disease and advanced disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The disease variant and, to a lesser extent, the place of residence, affected the socio-economic aspects of MS. It might be advantageous for the patient to disclose information about MS diagnosis to the employer.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775074&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3&quot;&gt;33775074&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.26444&#x2F;aaem&#x2F;117962&gt;10.26444&#x2F;aaem&#x2F;117962&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775074&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":824,"discovery_date":"2021-03-29T12:22:38","title":"Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurologia. 2021 Mar 25:S0213-4853(21)00008-6. doi: 10.1016&#x2F;j.nrl.2021.01.003. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: This article analyses the presence of gender bias in clinical trials of monoclonal antibodies used to treat multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIAL AND METHODS: We performed a systematic review of controlled clinical trials of 4 monoclonal antibodies used to treat multiple sclerosis (natalizumab, rituximab, alemtuzumab, and ocrelizumab). We searched the PubMed&#x2F;MEDLINE database for articles published in English before March 2020. The study was conducted in accordance with the relevant international recommendations.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The search identified 89 articles, 55 of which met the inclusion criteria. Of all patients included in these trials, 64.6% were women. The lead authors of 10 of the studies were women. Fifteen of the 55 studies included a sex-based analysis of the primary endpoint. Only 8 articles discussed the results separately for men and for women.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The clinical trials of these 4 monoclonal antibodies present a significant gender bias. In most cases, the primary and secondary endpoints are not analyzed according to patient sex, despite the fact that international recommendations include this as a minimum requirement for ensuring scientific validity and obtaining appropriate results for extrapolation to the wider population.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775476&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3&quot;&gt;33775476&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nrl.2021.01.003&gt;10.1016&#x2F;j.nrl.2021.01.003&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775476&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":823,"discovery_date":"2021-03-29T12:22:38","title":"Direct and indirect effects of microbiota-derived metabolites on neuroinflammation in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Microbes Infect. 2021 Mar 25:104814. doi: 10.1016&#x2F;j.micinf.2021.104814. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) are highly influenced by changes in the microbiota and of microbiota-derived metabolites, including short chain fatty acids, bile acids, and tryptophan derivatives. This review will discuss the effects of microbiota-derived metabolites on neuroinflammation driven by central nervous system-resident cells and peripheral immune cells, and their influence on outcomes of EAE and MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775860&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3&quot;&gt;33775860&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.micinf.2021.104814&gt;10.1016&#x2F;j.micinf.2021.104814&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775860&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":822,"discovery_date":"2021-03-29T12:22:37","title":"Efficacy of allogeneic hematopoietic cell transplantation for autoimmune diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Transplant Cell Ther. 2021 Mar 25:S2666-6367(21)00800-9. doi: 10.1016&#x2F;j.jtct.2021.03.023. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) may be efficacious for autoimmune diseases (AIDs), but the efficacy for each AID is unknown. Factors influencing the likelihood of relapse for each AID are also unknown.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To determine the likelihood of relapse for each common AID, and to generate hypotheses about factors influencing the likelihood of relapse.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We reviewed charts of adult patients with nonhematologic AIDs who had undergone HCT in Alberta (n&#x3D;21) and patients described in the literature (n&#x3D;67). We used stringent inclusion criteria to minimize the inclusion of patients whose AID may have been cured pretransplant. We also used stringent definitions of AID relapse and remission.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: AID relapsed in 2&#x2F;9 (22%) patients with lupus, 4&#x2F;12 (33%) with rheumatoid arthritis (RA), 0&#x2F;4 (0%) with systemic sclerosis (SSc), 3&#x2F;16 (19%) with psoriasis, 1&#x2F;12 (8%) with Behcet&#39;s disease (BD), 1&#x2F;15 (7%) with Crohn&#39;s disease (CD), 0&#x2F;5 (0%) with ulcerative colitis (UC), 4&#x2F;8 (50%) with multiple sclerosis (MS), and 3&#x2F;3 (100%) with type 1 diabetes (T1DM). Among highly informative patients (followed for &amp;gt;1 year after discontinuation of immunosuppressive therapy if no relapse, or donor AID status known if relapse), relapse occurred in 0&#x2F;3 patients with lupus, 2&#x2F;7 with RA, 0&#x2F;2 with SSc, 3&#x2F;6 with psoriasis, 0&#x2F;3 with BD, 0&#x2F;10 with CD, 0&#x2F;3 with UC, 2&#x2F;3 with MS, and 2&#x2F;2 with T1DM. There appeared to be no relation of AID relapse to low intensity of pretransplant chemoradiotherapy, multiple lines of AID therapy (surrogate for AID refractoriness) except perhaps for lupus, absence of serotherapy for graft-vs-host disease (GVHD) prophylaxis, lack of GVHD except perhaps for lupus, or incomplete donor chimerism.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Despite remission commonly occurring after HCT in lupus, RA, SSc, psoriasis, BD, CD, and UC, HCT is efficacious for only a subset of patients. The efficacy appears unrelated to pretransplant therapy, GVHD, or chimerism. Large studies are needed to determine for each AID the characteristics of patients likely to benefit from HCT.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3&quot;&gt;33775907&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jtct.2021.03.023&gt;10.1016&#x2F;j.jtct.2021.03.023&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33775907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329082236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":821,"discovery_date":"2021-03-29T09:08:07","title":"The role of picornavirus infection in epileptogenesis","summary":"Picornaviridae are a family of small positive-strand RNA viruses, and transmitted via the respiratory or fecal-oral route. The neurotropic picornaviruses can induce acute or late recurrent seizures following cent...","link":"https:&#x2F;&#x2F;aepi.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s42494-021-00040-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":820,"discovery_date":"2021-03-29T05:42:37","title":"Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Hepatol. 2021 Mar 24:S0168-8278(21)00219-1. doi: 10.1016&#x2F;j.jhep.2021.03.016. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND AIMS: Little is known on the composition of intrahepatic immune cells and their contribution to the pathogenesis of primary sclerosing cholangitis (PSC). We here aimed to create an atlas of intrahepatic T cells and thereby in detail characterize T cells in human inflamed liver.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Different single-cell RNA sequencing methods were combined with in silico analyses on intrahepatic and peripheral T cells from patients with PSC (n&#x3D;11) and healthy donors (HD, n&#x3D;4). Multi-parameter flow cytometry and functional in vitro experiments were conducted on patients with PSC (n&#x3D;24) and controls (HCV, n&#x3D;5; NASH, n&#x3D;3; ALD, n&#x3D;16; LRM, n&#x3D;10; HD, n&#x3D;10).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We here present the landscape of intrahepatic T cells in PSC and reveal a population of intrahepatic naive-like CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells, which was present in all liver diseases tested, but particularly expanded in PSC. This population had a transcriptome and T cell receptor repertoire similar to circulating naive T cells but expressed a set of genes associated with tissue residency. Their periductal location supported the concept of tissue-resident naive-like T cells in livers of patients with PSC. Trajectory inference suggested a developmental propensity of these cells to acquire a T&lt;sub&gt;H&lt;&#x2F;sub&gt;17 polarization-state. Functional and chromatin accessibility experiments revealed a predisposition of circulating naive T cells from patients with PSC to polarize towards T&lt;sub&gt;H&lt;&#x2F;sub&gt;17 cells.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: We report on the first atlas of intrahepatic T cells in PSC, which led to the identification of a previously unrecognized population of tissue-resident naive-like T cells in the inflamed human liver and to the finding that naive CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells in PSC harbour the propensity to develop into T&lt;sub&gt;H&lt;&#x2F;sub&gt;17 cells.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;LAY SUMMARY: The composition of intrahepatic immune cells in primary sclerosing cholangitis (PSC) and their contribution to disease pathogenesis is widely unknown. We here generated a single-cell atlas of intrahepatic T cells in PSC, a type of immune cells that has previously been involved in the pathogenesis of PSC. This atlas provides a valuable data source to the field. Using that atlas, we identified a population of liver-resident naive-like CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells which are expanded in livers of patients with PSC compared to healthy liver tissue and other liver diseases. Trajectory inference suggest that these cells have a propensity to acquire T&lt;sub&gt;H&lt;&#x2F;sub&gt;17-associated effector functions. Since T&lt;sub&gt;H&lt;&#x2F;sub&gt;17-polarized cells are considered to contribute to the development of PSC, our findings point towards a so far underestimated role of naive T cells in PSC.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33774059&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3&quot;&gt;33774059&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jhep.2021.03.016&gt;10.1016&#x2F;j.jhep.2021.03.016&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33774059&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":819,"discovery_date":"2021-03-29T05:42:37","title":"The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuromuscul Disord. 2021 Feb 9:S0960-8966(21)00034-1. doi: 10.1016&#x2F;j.nmd.2021.02.006. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Patient report outcome measures in Spinal Muscular Atrophy (SMA) represent a potential complement to observer rated scales which can be used to better understand treatment response. We developed, translated and validated an Italian version of the Spinal Muscular Atrophy Health Index (SMAHI), a disease-specific, patient reported outcome measure questionnaire, designed to estimate the patients&#39; perception of disease burden. Test-retest reliability was assessed in 37 patients (16 children aged 12-17 and 21 adults) and was excellent in both cohorts. Internal consistency in an additional 98 patients (24 children, 74 adults) was also excellent (Cronbach&#39;s alpha &#x3D; 0.93 and 0.91 respectively). In children the highest level of disease burden was generated from lower limb dysfunction and fatigue as well as their perception of decreased performance in social situations. Most patients in the adult cohort were sitters and complained of problems with upper limb functions as well as of fatigue. The SMAHI-IT was also able to differentiate between SMA types according to diseases severity. The results of our study demonstrate that the SMAHI can be considered a marker of disease-specific burden in patients with SMA with a high test-retest reliability and internal validity in Italian patients aged 12 and older.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3&quot;&gt;33773884&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nmd.2021.02.006&gt;10.1016&#x2F;j.nmd.2021.02.006&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":818,"discovery_date":"2021-03-29T05:42:37","title":"Abnormal motor surround inhibition associated with cortical and deep grey matter involvement in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Neurophysiol. 2021 Mar 12;132(5):1151-1156. doi: 10.1016&#x2F;j.clinph.2021.01.029. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Motor surround inhibition (mSI) is a physiological mechanism that contributes to hand movement control by focusing voluntary movement. Growing evidence suggests that hand movement control is impaired in multiple sclerosis. The aim of the study was to evaluate mSI in MS and to investigate the brain structures involved in mSI in multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We recruited 33 patients and 23 controls. To investigate mSI, we delivered transcranial magnetic single pulses during index finger flexion. Motor evoked potentials were recorded and first dorsal interosseous (&quot;active muscle&quot;) and from the abductor digiti minimi (&quot;surround muscle&quot;). mSI was expressed as the ratio between Motor evoked potentials recorded from the surround muscle during movement and at rest. Participants underwent a magnetic resonance study.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Patients had impaired mSI as compared with controls. Magnetic resonance showed that basal ganglia had smaller volumes and higher mean diffusivity than controls. Impaired mSI correlated with primary motor cortex and basal ganglia involvement in multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Altered mSI in multiple sclerosis is related to cortical and subcortical grey matter involvement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SIGNIFICANCE: Our study provides the first demonstration of a pathophysiological mechanism underlying hand movement control dysfunction in multiple sclerosis. mSI represents a new therapeutic target of multiple sclerosis rehabilitative approaches.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33774380&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3&quot;&gt;33774380&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.clinph.2021.01.029&gt;10.1016&#x2F;j.clinph.2021.01.029&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33774380&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":817,"discovery_date":"2021-03-29T05:42:37","title":"Virtual visits for chronic neurologic disorders during COVID-19 pandemic","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 27. doi: 10.1007&#x2F;s10072-021-05212-3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: COVID-19 pandemic has boosted telemedicine in medical clinical practice. Experiences in the management of chronic neurological disorders are limited and scattered. The aim of the study was to evaluate feasibility and efficacy of virtual visit for chronic neurological disorders during COVID-19 pandemic.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: All patients scheduled for a visit during the lockdown period were contacted. The patients fell into four categories: (1) long-term follow-up, the patient was re-scheduled; (2) visit was necessary, teleconsultation was accepted; (3) problem was solved by phone call; and (4) visit was necessary and teleconsultation was not feasible, then visit was maintained. Google Meet was used. During the virtual visit, neurological examination was performed, and demographic and clinical characteristics were recorded.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: At the end of May 2020, 184 virtual visits for 178 patients were performed for the following diseases: myasthenia gravis (47 patients), multiple sclerosis (79), epilepsy (12), headache (6), and parkinsonism (34). The patients were 70 males and 108 females with a mean age of 53.5 years (range 13-90). During virtual visit, we were able to obtain a satisfactory neurological examination.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We demonstrated feasibility and effectiveness of virtual visit in the management of a large group of patients with common chronic neurological disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33774762&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3&quot;&gt;33774762&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05212-3&gt;10.1007&#x2F;s10072-021-05212-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33774762&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210329014236&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":816,"discovery_date":"2021-03-28T10:03:06","title":"Sexual dysfunction in men with multiple sclerosis","summary":"","link":"https:&#x2F;&#x2F;systematicreviewsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13643-021-01643-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":815,"discovery_date":"2021-03-28T05:47:36","title":"Current review and next steps for artificial intelligence in multiple sclerosis risk research","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Comput Biol Med. 2021 Mar 13;132:104337. doi: 10.1016&#x2F;j.compbiomed.2021.104337. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In the last few decades, the prevalence of multiple sclerosis (MS), a chronic inflammatory disease of the nervous system, has increased, particularly in Northern European countries, the United States, and United Kingdom. The promise of artificial intelligence (AI) and machine learning (ML) as tools to address problems in MS research has attracted increasing interest in these methods. Bayesian networks offer a clear advantage since they can integrate data and causal knowledge allowing for visualizing interactions between dependent variables and potential confounding factors. A review of AI&#x2F;ML research methods applied to MS found 216 papers using terms &quot;Multiple Sclerosis&quot;, &quot;machine learning&quot;, &quot;artificial intelligence&quot;, &quot;Bayes&quot;, and &quot;Bayesian&quot;, of which 90 were relevant and recently published. More than half of these involve the detection and segmentation of MS lesions for quantitative analysis; however clinical and lifestyle risk factor assessment and prediction have largely been ignored. Of those that address risk factors, most provide only association studies for some factors and often fail to include the potential impact of confounding factors and bias (especially where these have causal explanations) that could affect data interpretation, such as reporting quality and medical care access in various countries. To address these gaps in the literature, we propose a causal Bayesian network approach to assessing risk factors for MS, which can address deficiencies in current epidemiological methods of producing risk measurements and makes better use of observational data.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773193&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3&quot;&gt;33773193&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.compbiomed.2021.104337&gt;10.1016&#x2F;j.compbiomed.2021.104337&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773193&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":814,"discovery_date":"2021-03-28T05:47:36","title":"A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 24;51:102861. doi: 10.1016&#x2F;j.msard.2021.102861. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Biomarkers are a useful and reliable measure of disease activity in many fields of medicine. Axonal and glial biomarkers in multiple sclerosis (MS) are being applied more often as technology is improving and becoming increasingly reliable. Nonclinical studies have shown dimethyl fumarate (DMF) to have cytoprotective and anti-inflammatory effects. The purpose of this study is to explore the pharmacokinetics (PK) of DMF (by measuring MMF, the active compound) in serum and cerebrospinal fluid (CSF) as well as relevant biomarker data for patients with secondary progressive MS (pwSPMS) and whether there is objective evidence for neuroprotection in pwSPMS treated with DMF.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Sixteen pwSPMS had serum and cerebrospinal fluid (CSF) evaluation for PK studies levels of MMF at various time points after ingestion of DMF. The CSF biomarkers neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), ubiquitin carboxyo-terminal hydrolase isozyme L1 (UCH-L1) and total tau (T-tau) were measured at baseline, week 6 and week 28 after initiating DMF with a starting dose of 120 mg twice daily for 4 weeks, followed by a maintenance dose of 240 mg twice daily. Clinical correlation of these patients with EDSS and MRI at these same time periods were made with the biomarkers. Four normal human volunteers had CSF studies for biomarkers at baseline.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: PK data showed CSF MMF concentration 11% of plasma with Tmax of plasma at 5 hr and Tmax of CSF at 7 hr. Biomarker data showed that CS NfL and to a lesser extent, GFAP, but not UCH-L1 nor T-tau showed relevant changes with clinical data. Some pwSPMS receiving DMF showed clinical improvements in Expanded Disability Status Scale (EDSS). Biomarker changes, but not MRI, correlated with clinical measures in this group of pwSPMS over the observation period.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: PK data showed that the Tmax of CSF MMF peaked only 2 hours later than that of plasma with 11% measured in the CSF so that MMF readily crossed the blood brain barrier allowing potential direct penetration into the brain. NfL CSF levels, and to a lesser extent, GFAP CSF levels, showed correlation to disease activity in pwSPMS . These data suggest that DMF may have some benefit in reducing disease activity in pwSPMS if studied for a longer duration and larger well-controlled studies are warranted. DMF was reasonably well tolerated but 3 of the 16 patients did discontinue DMF at 6 weeks due to persistent side effects. NfL appeared to be more clinically relevant biomarker than brain MRI in this this group during the 28-week study period.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773271&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3&quot;&gt;33773271&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102861&gt;10.1016&#x2F;j.msard.2021.102861&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773271&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":813,"discovery_date":"2021-03-28T05:47:36","title":"Cortical activity and gait parameter characteristics in people with multiple sclerosis during unobstructed gait and obstacle avoidance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Gait Posture. 2021 Mar 20;86:226-232. doi: 10.1016&#x2F;j.gaitpost.2021.03.026. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: People with Multiple Sclerosis (PwMS) present higher cortical activity during walking. However, the cortical activity during gait while avoiding an obstacle is still not clear.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To investigate cortical activity and gait spatial-temporal parameters in PwMS during two different gait tasks (i.e., unobstructed and obstacle avoidance).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: Fifteen PwMS and 15 healthy controls (CG) were recruited. Participants performed ten trials in each gait condition, wearing a 64-electrode cap electroencephalogram (EEG) at 1024 Hz. Kinematic data were obtained through 10 ViconÂ® cameras at 200 Hz. EEG was analyzed through four cortical areas (frontal, motor, parietal, and occipital cortex areas) and five frequency bands (delta, theta, alpha, beta, and gamma) obtained through the power spectral density. In addition, spatial-temporal gait parameters (e.g., step length and velocity) were measured. Two-way ANOVA (group x gait condition) and MANOVA (group x gait condition) were used to compare gait and EEG parameters, respectively. One-way ANOVA was used to compare groups in the crossing phase of the obstacle avoidance condition.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: PwMS presented lower step length and velocity, and higher cortical activity in frontal (beta and gamma) and parietal (gamma) cortical areas in both gait conditions compared to CG. Moreover, PwMS presented increased cortical activation (frontal and parietal) and decreased step length and velocity in obstacle avoidance compared with unobstructed gait. In addition, PwMS required more cortical resources (frontal and parietal) than CG to accomplish both gait conditions. During the obstacle avoidance task, it was further observed that PwMS positioned their feet closer to the obstacle, before and after the task, compared to CG.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: PwMS demand higher cortical resources to accomplish gait tasks, mainly when it is necessary to negotiate an obstacle in the pathway. This higher cortical activity may be a compensatory mechanism to deal with damage in subcortical structures caused by multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773240&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3&quot;&gt;33773240&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.gaitpost.2021.03.026&gt;10.1016&#x2F;j.gaitpost.2021.03.026&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773240&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":812,"discovery_date":"2021-03-28T05:47:35","title":"MS and Disability Progression in Latin America, Africa, Asia and the Middle East: A Systematic Review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 9;51:102885. doi: 10.1016&#x2F;j.msard.2021.102885. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: There is evidence of an increased prevalence and disease burden of Multiple Sclerosis (MS) in parts of the world where the risk was once considered low, such as Latin America (LA), Sub-Saharan Africa, Asia and the Middle East-North Africa (MENA). Despite the growing number of clinical reports, the phenotype and course of MS in these regions remains understudied compared with Europe and North America. We aimed to investigate MS phenotypes and long-term clinical outcomes across these regions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: A Boolean search of the medical literature was conducted between January 1980 and April 30, 2020. PubMed, SCOPUS, Global Health, and the Cochrane databases, were used to identify all relevant citations. Articles were collated and managed on CovidenceÂ® software. We independently appraised the articles for meeting study criteria and for quality using the Critical Appraisal Skills Program (CASP) and the Specialist Unit for Review Evidence (SURE) system.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 1,639 studies were imported for screening. After removing 545 duplicates, two authors assessed 1,094 abstracts and selected 515 for full-text screening. 72 articles met study criteria, including 19 studies from LA, 4 from sub-Saharan Africa, 24 from Asia and 25 from MENA. The overall sex ratio was 2.5:1 (female: male). Disability was assessed using the Expanded Disability Status Scale (EDSS). Longitudinal disability progression and time to standard endpoints was compared by region and with relevant Western reports. Patients with MS living in the MENA region appear to reach disability milestones faster than those in the Western world, although this finding is not uniform. South Asia shows distinct disability features compared with East Asia, more closely resembling those of the West. Disease morbidity in East Asia appears more benign than in the West after careful exclusion of neuromyelitis optica spectrum disorder cases. Populations in LA tend to have similar MS features to the Western world, but some exceptions exist, including African descendants that reach disability milestones earlier. Using all studies with appropriate survival analysis, the mean time to EDSS 6.0 was 16.97 years with a heterogeneity index of 24.59.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The clinical phenotypes and disability progression of MS in LA, Africa, Asia and the MENA region have similarities to Western MS. In some regions and subpopulations there is evidence of a more aggressive course, possibly due to a combination of genetic and environmental factors. More population-based longitudinal data are needed, particularly in Sub-Saharan Africa.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773273&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3&quot;&gt;33773273&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102885&gt;10.1016&#x2F;j.msard.2021.102885&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773273&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":811,"discovery_date":"2021-03-28T05:47:35","title":"Integrating patient-reported outcomes and quantitative timed tasks to identify relapsing remitting multiple sclerosis patient subgroups: a latent profile analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 18;51:102912. doi: 10.1016&#x2F;j.msard.2021.102912. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) patients experience wide-ranging symptoms with varied severity, and approaches that integrate patient-reported outcomes and objective quantitative measures will present opportunities for advancing clinical profiling. The primary objective of the current study was to conduct exploratory data analysis using latent variable modeling to empirically identify clusters of relapsing remitting (RR) MS patients with shared impairment patterns across three patient-reported outcomes and two timed task measures.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Latent profile analyses and impairment data for 2,012 RRMS patients identified distinct patient clusters using timed task measures of upper and lower limb performance, and patient-reported outcomes measuring quality of life, depression symptom severity, and perceived global disability. Multinomial logistic regression models were used to characterize associations between socio-demographic attributes and assignment to the patient clusters.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were 6 distinct clusters of RRMS patients that differed by symptom patterns, and by their socio-demographic attributes. Most notable were were no differences in age, sex, or disease duration between the least and most impaired classes, representing 14% and 4% of patients, respectively. Patients in the most impaired class were much more likely to be Black American, have a history of smoking, have a higher body mass index, and be of lower socioeconomic status than the least impaired class. There were positive relationships between age and classification to clusters of increasing moderately severe impairment but not the most severe clusters.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: We present a framework for discerning phenotypic impairment clusters in RRMS. The results demonstrate opportunities for advancing clinical profiling, which is necessary for optimizing personalized MS care models and clinical research.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773274&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3&quot;&gt;33773274&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102912&gt;10.1016&#x2F;j.msard.2021.102912&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33773274&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210328014734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":810,"discovery_date":"2021-03-28T00:27:36","title":"2-(2-Benzofuranyl)-2-Imidazoline Attenuates the Disruption of the Blood-Brain Barrier in EAE via NMDAR","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurochem Res. 2021 Mar 27. doi: 10.1007&#x2F;s11064-021-03304-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Blood-brain barrier (BBB) disruption has been recognized as an early hallmark of multiple sclerosis (MS) pathology. Our previous studies have shown that 2-(2-Benzofuranyl)-2-imidazoline (2-BFI) protected against experimental autoimmune encephalomyelitis (EAE), a classic animal model of MS. However, the potential effects of 2-BFI on BBB permeability have not yet been evaluated in the context of EAE. Herein, we aimed to investigate the effect of 2-BFI on BBB permeability in both an animal model and an in vitro BBB model using TNF-Î± to imitate the inflammatory damage to the BBB in MS. In the animal model, 2-BFI reduced neurological deficits and BBB permeability in EAE mice compared with saline treatment. The Western blot results indicated that 2-BFI not only alleviated the loss of the tight junction protein occludin caused by EAE but also inhibited the activation of the NR1-ERK signaling pathway. In an in vitro BBB model, 2-BFI (100 Î¼M) alleviated the TNF-Î±-induced increase in permeability and reduction in expression of occludin in monolayer bEnd.3 cells. Similar protective effects were also observed after treatment with the NMDAR antagonist MK801. The Western blot results showed that the TNF-Î±-induced BBB breakdown and increase in NMDAR subunit 1 (NR1) levels and ERK phosphorylation could be blocked by pretreatment with 2-BFI or MK801. However, no additional effect was observed on BBB permeability or the expression of occludin and p-ERK after pretreatment with both 2-BFI and MK801. Our study indicates that 2-BFI alleviates the disruption of BBB in the context of inflammatory injury similar to that of MS by targeting NMDAR1, as well as by likely activating the subsequent ERK signaling pathway. These results provide further evidence for 2-BFI as a potential drug for the treatment of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33772673&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327202734&amp;v&#x3D;2.14.3&quot;&gt;33772673&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11064-021-03304-2&gt;10.1007&#x2F;s11064-021-03304-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33772673&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":809,"discovery_date":"2021-03-27T21:47:36","title":"Quantitative MRI texture analysis in chronic active multiple sclerosis lesions","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Magn Reson Imaging. 2021 Mar 23:S0730-725X(21)00048-5. doi: 10.1016&#x2F;j.mri.2021.03.016. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Recently, there has been an increasing interest in &quot;chronic enlarging&quot; or &quot;chronic active&quot; multiple sclerosis (MS) lesions that are associated with clinical disability. However, investigation of dynamic lesion volume changes requires longitudinal MRI data from two or more time points. The aim of this study was to investigate the application of texture analysis (TA) on baseline T1-weighted 3D magnetization-prepared rapid acquisition gradient-echo (MPRAGE) images to differentiate chronic active from chronic stable MS lesions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIAL AND METHODS: To identify chronic active lesions as compared to non-enhancing stable lesions, two MPRAGE datasets acquired on a 3 T MRI at baseline and after 12 months follow-up were applied to the Voxel-Guided Morphometry (VGM) algorithm. TA was performed on the baseline MPRAGE images, 36 texture features were extracted for each lesion.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Overall, 374 chronic MS lesions (155 chronic active and 219 chronic stable lesions) from 60 MS patients were included in the final analysis. Multiple texture features including &quot;DISCRETIZED_HISTO_Energy&quot;, &quot;GLCM_Energy&quot;, &quot;GLCM_Contrast&quot; and &quot;GLCM_Dissimilarity&quot; were significantly higher in chronic active as compared to chronic stable lesions. Partial least squares regression yielded an area under the curve of 0.7 to differentiate both lesion types.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our results suggest that multiple texture features extracted from MPRAGE images indicate higher intralesional heterogeneity, however they demonstrate only a fair accuracy to differentiate chronic active from chronic stable MS lesions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33771609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3&quot;&gt;33771609&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.mri.2021.03.016&gt;10.1016&#x2F;j.mri.2021.03.016&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33771609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":808,"discovery_date":"2021-03-27T21:47:36","title":"A conserved role for the ALS-linked splicing factor SFPQ in repression of pathogenic cryptic last exons","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Commun. 2021 Mar 26;12(1):1918. doi: 10.1038&#x2F;s41467-021-22098-z.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The RNA-binding protein SFPQ plays an important role in neuronal development and has been associated with several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer&#39;s disease. Here, we report that loss of sfpq leads to premature termination of multiple transcripts due to widespread activation of previously unannotated cryptic last exons (CLEs). These SFPQ-inhibited CLEs appear preferentially in long introns of genes with neuronal functions and can dampen gene expression outputs and&#x2F;or give rise to short peptides interfering with the normal gene functions. We show that one such peptide encoded by the CLE-containing epha4b mRNA isoform is responsible for neurodevelopmental defects in the sfpq mutant. The uncovered CLE-repressive activity of SFPQ is conserved in mouse and human, and SFPQ-inhibited CLEs are found expressed across ALS iPSC-derived neurons. These results greatly expand our understanding of SFPQ function and uncover a gene regulation mechanism with wide relevance to human neuropathologies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33771997&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3&quot;&gt;33771997&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41467-021-22098-z&gt;10.1038&#x2F;s41467-021-22098-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33771997&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":807,"discovery_date":"2021-03-27T21:47:36","title":"Overcoming the inhibitory microenvironment surrounding oligodendrocyte progenitor cells following experimental demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Commun. 2021 Mar 26;12(1):1923. doi: 10.1038&#x2F;s41467-021-22263-4.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Chronic demyelination in the human CNS is characterized by an inhibitory microenvironment that impairs recruitment and differentiation of oligodendrocyte progenitor cells (OPCs) leading to failed remyelination and axonal atrophy. By network-based transcriptomics, we identified sulfatase 2 (Sulf2) mRNA in activated human primary OPCs. Sulf2, an extracellular endosulfatase, modulates the signaling microenvironment by editing the pattern of sulfation on heparan sulfate proteoglycans. We found that Sulf2 was increased in demyelinating lesions in multiple sclerosis and was actively secreted by human OPCs. In experimental demyelination, elevated OPC Sulf1&#x2F;2 expression directly impaired progenitor recruitment and subsequent generation of oligodendrocytes thereby limiting remyelination. Sulf1&#x2F;2 potentiates the inhibitory microenvironment by promoting BMP and WNT signaling in OPCs. Importantly, pharmacological sulfatase inhibition using PI-88 accelerated oligodendrocyte recruitment and remyelination by blocking OPC-expressed sulfatases. Our findings define an important inhibitory role of Sulf1&#x2F;2 and highlight the potential for modulation of the heparanome in the treatment of chronic demyelinating disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33772011&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3&quot;&gt;33772011&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41467-021-22263-4&gt;10.1038&#x2F;s41467-021-22263-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33772011&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":806,"discovery_date":"2021-03-27T21:47:36","title":"Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212&#x2F;NXI.0000000000000978. Print 2021 May.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, in participants with neuromyelitis optica spectrum disorder (NMOSD).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Adults (N &#x3D; 230) with aquaporin-4 immunoglobulin G-seropositive NMOSD or -seronegative neuromyelitis optica and an EDSS score â¤8 were randomized (3:1) to receive inebilizumab 300 mg or placebo on days 1 and 15. The randomized controlled period (RCP) was 28 weeks or until adjudicated attack, with an option to enter the inebilizumab open-label period. Three-month EDSS-confirmed disability progression (CDP) was assessed using a Cox proportional hazard model. The effect of baseline subgroups on disability was assessed by interaction tests. mRS scores from the RCP were analyzed by the Wilcoxon-Mann-Whitney odds approach.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Compared with placebo, inebilizumab reduced the risk of 3-month CDP (hazard ratio [HR]: 0.375; 95% CI: 0.148-0.952; &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.0390). Baseline disability, prestudy attack frequency, and disease duration did not affect the treatment effect observed with inebilizumab (HRs: 0.213-0.503; interaction tests: all &lt;i&gt;p&lt;&#x2F;i&gt; &amp;gt; 0.05, indicating no effect of baseline covariates on outcome). Mean EDSS scores improved with longer-term treatment. Inebilizumab-treated participants were more likely to have a favorable mRS outcome at the end of the RCP (OR: 1.663; 95% CI: 1.195-2.385; &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.0023).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Disability outcomes were more favorable with inebilizumab vs placebo in participants with NMOSD.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with NMOSD, inebilizumab reduces the risk of worsening disability. N-MOmentum is registered at ClinicalTrials.gov: NCT02200770.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33771837&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3&quot;&gt;33771837&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXI.0000000000000978&gt;10.1212&#x2F;NXI.0000000000000978&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33771837&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":805,"discovery_date":"2021-03-27T21:47:36","title":"Is there an association between multiple sclerosis and oral health?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Evid Based Dent. 2021 Jan;22(1):44-45. doi: 10.1038&#x2F;s41432-021-0159-1.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Data sources PubMed, Scopus, Web of Science, MEDLINE and CINAHL.Study selection Randomised controlled trials, cross-sectional studies and cohort studies.Data extraction and synthesis Two reviewers independently extracted data using piloted forms and contacted authors if relevant data were missing. Assessment of quality was done using the Newcastle-Ottawa scale (NOS) for both cohort and cross-sectional studies. The score of NOS ranged from 1-9, where 6-7 is considered moderate quality while 8-9 is high quality.Results Seventeen studies were included in the review (13 cross-sectional and four cohort). Seven out of 13 cross-sectional studies scored â¤5 which indicates poor quality. The four case-control studies were of moderate quality. Overall, there is limited evidence that patients with multiple sclerosis (MS) have more dental caries or gingival disease. However, evidence suggests that patients with MS have more risk of periodontal disease and poor oral hygiene. The evidence also suggests a moderate association between MS and temporomandibular disorders (TMD).Conclusions With the exception of TMD, current evidence does not establish an association between MS and most oral health conditions. More high-quality evidence is needed to further explore and establish an association.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33772137&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3&quot;&gt;33772137&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41432-021-0159-1&gt;10.1038&#x2F;s41432-021-0159-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33772137&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327174734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":804,"discovery_date":"2021-03-27T20:18:09","title":"A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn&#39;s disease. Position paper of the Brazilian Society of Bone Marrow Transplantation","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S2531-13792021000100065&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":803,"discovery_date":"2021-03-27T13:47:36","title":"Galangin ameliorates experimental autoimmune encephalomyelitis in mice via modulation of cellular immunity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Immunotoxicol. 2021 Dec;18(1):50-60. doi: 10.1080&#x2F;1547691X.2021.1890863.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) causes neurologic disabilities that effect musculature, sensory systems, and vision. This is largely due to demyelination of nerve fibers caused by chronic inflammation. Corticosteroid treatments ameliorate symptoms of MS, but do not successfully cure the disease itself. In the current study, the application of galangin, a phytochemical flavonoid extracted from the ginger family of &lt;i&gt;Alpinis officinarum&lt;&#x2F;i&gt;, on experimental autoimmune encephalomyelitis (EAE; mouse model for MS) was explored. This study investigated prophylactic and therapeutic activity of the drug and mechanisms by which it acts. The results revealed that galangin at 40 and 80 mg&#x2F;kg could lower the incidence rate of MS, and alleviate clinical&#x2F;pathological manifestations. Mice administered galangin presented with less limb paralysis, lower levels of inflammatory cell infiltrates, and decreased demyelination compared to vehicle controls. Levels of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt;IFNÎ³&lt;sup&gt;+&lt;&#x2F;sup&gt; (T&lt;sub&gt;H&lt;&#x2F;sub&gt;1) and CD4&lt;sup&gt;+&lt;&#x2F;sup&gt;IL-17A&lt;sup&gt;+&lt;&#x2F;sup&gt; (T&lt;sub&gt;H&lt;&#x2F;sub&gt;17) cells in the spinal cords of EAE mice administered galangin were reduced and both cell types were not capable of expansion. More surprisingly, galangin inhibited antigen presentation and cytokine production by dendritic cells (DC). Formation of cytokines like IL-6, IL-12, and IL-23 were significantly decreased due to galangin in co-culture models of DC and T-cells. Taken together, the data lead one to conclude that galangin could potentially be used as a potent immunoregulatory agent to alleviate clinical symptoms and reduce the prevalence of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770444&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3&quot;&gt;33770444&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;1547691X.2021.1890863&gt;10.1080&#x2F;1547691X.2021.1890863&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770444&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":802,"discovery_date":"2021-03-27T13:47:36","title":"Increased brain atrophy and lesion load is associated with stronger lower alpha MEG power in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Mar 17;30:102632. doi: 10.1016&#x2F;j.nicl.2021.102632. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In multiple sclerosis, the interplay of neurodegeneration, demyelination and inflammation leads to changes in neurophysiological functioning. This study aims to characterize the relation between reduced brain volumes and spectral power in multiple sclerosis patients and matched healthy subjects. During resting-state eyes closed, we collected magnetoencephalographic data in 67 multiple sclerosis patients and 47 healthy subjects, matched for age and gender. Additionally, we quantified different brain volumes through magnetic resonance imaging (MRI). First, a principal component analysis of MRI-derived brain volumes demonstrates that atrophy can be largely described by two components: one overall degenerative component that correlates strongly with different cognitive tests, and one component that mainly captures degeneration of the cortical grey matter that strongly correlates with age. A multimodal correlation analysis indicates that increased brain atrophy and lesion load is accompanied by increased spectral power in the lower alpha (8-10 Hz) in the temporoparietal junction (TPJ). Increased lower alpha power in the TPJ was further associated with worse results on verbal and spatial working memory tests, whereas an increased lower&#x2F;upper alpha power ratio was associated with slower information processing speed. In conclusion, multiple sclerosis patients with increased brain atrophy, lesion and thalamic volumes demonstrated increased lower alpha power in the TPJ and reduced cognitive abilities.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770549&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3&quot;&gt;33770549&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nicl.2021.102632&gt;10.1016&#x2F;j.nicl.2021.102632&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770549&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":801,"discovery_date":"2021-03-27T13:47:36","title":"MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Sci. 2021 Mar 6;424:117385. doi: 10.1016&#x2F;j.jns.2021.117385. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Observational, multicentre, retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Three hundred and sixteen patients were enrolled. The median dose interval (MDI) following the 24th infusion was 5 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Patients were grouped into 2 categories according to the mean number of weeks between doses: &amp;lt;5 weeks, SID; â¥5 weeks, EID.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: One hundred and eighty-seven patients were in the SID group (MDI &#x3D; 4.5 weeks) and 129 in the EID group (MDI 6.1 weeks). The risk to develop active lesions on MRI is similar in SID and EID groups during the 6 and 12 months after the 24th natalizumab infusion, respectively 4.27% (95% CI:0.84-7.70) vs 4.71% (95% CI:0.16-9.25%) [p &#x3D; 0.89] and 8.50% (95% CI:4.05-12.95) vs 6.55% (95% CI:2.11-11.00%) [p &#x3D; 0.56]. The EID regimen does not appear to increase the occurrence of MRI activity during follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: There is no evidence of the reduced efficacy of natalizumab in an EID setting regarding the MRI activity. This observation supports the need for a bigger randomized study to assess the need to change the standard of the natalizumab dosing schedule, to better manage JCV-positive patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770708&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3&quot;&gt;33770708&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jns.2021.117385&gt;10.1016&#x2F;j.jns.2021.117385&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770708&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":800,"discovery_date":"2021-03-27T13:47:36","title":"Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: A systematic review of preclinical evidence","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int Immunopharmacol. 2021 Mar 23;95:107562. doi: 10.1016&#x2F;j.intimp.2021.107562. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), an animal model of MS, are diseases resulting in neurological disabilities that are regarded as chronic, inflammatory, and autoimmune diseases of central nervous system (CNS). In this respect, the use of anti-inflammatory compounds including flavonoids, polyphenolic compounds abundantly found in vegetables and fruits, has proposed to combat MS to dampen the inflammation and thereby ameliorating the disease severity. The objective of this study was to clarify the probable therapeutic effect of flavonoids for treatment of MS. Therefore, only English published articles that reported the therapeutic effect of flavonoids alone or in combination with other anti-MS therapeutic agents on MS, were selected by searching scientific electronic databases including PubMed, Scopus and Web of Science. Evaluation of the selected researches (686) showed that a total of 13 studies were suitable to be included in this systematic review. Interestingly, all of the studies (11 studies concerning EAE and 2 studies concerning MS) reported positive outcomes for the therapeutic effect of flavonoids on EAE and MS. All flavonoid compounds which are mentioned herein could successfully decrease the maximum clinical score of EAE, which is particularly connected to the anti-inflammatory property of these compounds. The literature review clearly discloses that flavonoids alone or in combination with other anti-MS therapeutic agents can pave the way for improving MS therapeutic strategies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770729&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3&quot;&gt;33770729&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.intimp.2021.107562&gt;10.1016&#x2F;j.intimp.2021.107562&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770729&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210327094734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":799,"discovery_date":"2021-03-27T13:38:06","title":"Increasing the spectrum of white matter diseases with tigroid pattern on MRI: glutaric aciduria type 1 â case report","summary":"Most white matter diseases present on magnetic resonance imaging as focal or diffuse T2-hyperintensities. However, in a few of them, radially oriented stripes of low (relatively normal) signal intensity are ob...","link":"https:&#x2F;&#x2F;bmcpediatr.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12887-021-02603-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":798,"discovery_date":"2021-03-27T13:38:05","title":"Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study","summary":"Excessive salt intake is thought to exacerbate both development of hypertension and autoimmune diseases in animal models, but the clinical impact of excessive salt in rheumatoid arthritis (RA) patients is stil...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02479-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":797,"discovery_date":"2021-03-27T13:38:05","title":"OPG&#x2F;RANKL&#x2F;RANK gene methylation among alcohol-induced femoral head necrosis in northern Chinese men","summary":"Alcohol-induced osteonecrosis of the femoral head (ONFH) is a complex and heterogeneous disease. Genetic factors and epigenetic modifications are one of the pathogenesis of the disease. However, the influence ...","link":"https:&#x2F;&#x2F;josr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13018-021-02356-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":796,"discovery_date":"2021-03-27T00:27:36","title":"Community qigong for People with Multiple Sclerosis: A Pragmatic Feasibility Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Altern Complement Med. 2021 Mar 26. doi: 10.1089&#x2F;acm.2020.0481. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;&lt;i&gt;Objectives:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; &lt;i&gt;qigong&lt;&#x2F;i&gt;, a traditional Chinese mind-body exercise, has been shown to improve balance and gait in several neurological conditions; however, community-delivered &lt;i&gt;qigong&lt;&#x2F;i&gt; has never been assessed for people with multiple sclerosis (MS). The authors assessed the feasibility of community &lt;i&gt;qigong&lt;&#x2F;i&gt; classes for people with MS and explored outcomes of balance, gait, and quality of life (QOL). &lt;b&gt;&lt;i&gt;Design:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Twenty adults with MS were randomly assigned to 10 weeks of community &lt;i&gt;qigong&lt;&#x2F;i&gt; classes or wait-list control. &lt;b&gt;&lt;i&gt;Settings&#x2F;Location:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Portland, Oregon. &lt;b&gt;&lt;i&gt;Subjects:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; People with MS. &lt;b&gt;&lt;i&gt;Intervention:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Community qigong classes. &lt;b&gt;&lt;i&gt;Outcome measures:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Feasibility criteria included recruitment, retention, adherence, and ability to participate in &lt;i&gt;qigong&lt;&#x2F;i&gt; movements. Secondary outcome measures included physical tests of mobility, gait, and balance and participant-reported mobility, depression, anxiety, fatigue, and QOL. &lt;b&gt;&lt;i&gt;Results:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Recruitment of eligible and interested people with MS was feasible. Retention in the trial was 60%. Completers attended a mean of 7 of 10 classes. All completers participated with no or minor modifications to &lt;i&gt;qigong&lt;&#x2F;i&gt; movements. Exploratory within-group analyses showed trends toward improved mental health, QOL, and reduced fatigue and depression. Several participants spontaneously reported improved energy, flexibility, sleep, and mobility. &lt;b&gt;&lt;i&gt;Conclusions:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Community &lt;i&gt;qigong&lt;&#x2F;i&gt; may be a feasible form of exercise for people with MS. To improve retention and capture potential effects of &lt;i&gt;qigong&lt;&#x2F;i&gt; on physical function and quality of life, future studies might consider pragmatic trials with tiered level classes, simpler forms of &lt;i&gt;qigong&lt;&#x2F;i&gt;, and&#x2F;or refined inclusion criteria (CTR#: NCT04585659).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769837&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3&quot;&gt;33769837&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1089&#x2F;acm.2020.0481&gt;10.1089&#x2F;acm.2020.0481&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769837&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":795,"discovery_date":"2021-03-27T00:27:36","title":"Effectiveness of Brainstem Auditory Evoked Potentials Scoring in Evaluating Brainstem Dysfunction and Disability Among Individuals With Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Am J Audiol. 2021 Mar 26:1-11. doi: 10.1044&#x2F;2020_AJA-20-00155. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Purpose The brainstem dysfunction in multiple sclerosis (MS) often causes significant functional impairment leading to disability. This study aims to explore modified brainstem auditory evoked potential (BAEP) scores based on the pattern of BAEP abnormalities and relate with brainstem symptoms, brainstem functional system scores (BFSS), brainstem lesions, and disability. Method Forty-five participants with relapsing-remitting MS and 45 age- and gender-matched healthy controls underwent case history assessment, otoscopic examination, pure-tone audiometry, and BAEP testing. Also, neurological examination (Expanded Disability Status Scale, FSS scales) and magnetic resonance imaging were carried out on MS participants. Patterns of BAEP abnormalities were categorized and converted to BAEP scores. Results Out of 45 participants&#39; brainstem symptoms, BFSS &amp;gt; 1, brainstem lesions (magnetic resonance imaging), and BAEP abnormalities were observed in 75.6%, 42.2%, 62.2%, and 55.56% of participants, respectively. Waves V and III abnormalities were more common among MS participants and showed a significant difference from the control group in the Mann-Whitney &lt;i&gt;U&lt;&#x2F;i&gt; test. Chi-square test did not show a significant association of BAEP abnormalities with brainstem symptoms and lesions but showed significant association with BFSS. The mean and standard deviation of BAEP scores in MS participants were 1.73 + 2.37. All healthy controls showed BAEP scores of 0. BAEP scores in MS participants showed significant correlation with BFSS scores and predict Expanded Disability Status Scale scores. Conclusion BAEP scores based on the pattern of BAEP abnormality can be a valid and useful measure in evaluating brainstem functions and predicting disability in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769865&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3&quot;&gt;33769865&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1044&#x2F;2020_AJA-20-00155&gt;10.1044&#x2F;2020_AJA-20-00155&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769865&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":794,"discovery_date":"2021-03-27T00:27:36","title":"Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Mar 26. doi: 10.1007&#x2F;s00415-021-10471-3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: A positive MRZ reaction, as defined by intrathecal IgG production against at least two of its constituents, measles virus (M), rubella virus (R) and varicella zoster virus (Z), is detectable in ~ 63% of patients with multiple sclerosis (MS) and is currently considered the laboratory marker with the highest specificity and positive likelihood ratio for MS. However, M, R and Z are only the most well-established constituents of a broader intrathecal humoral immune response in MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To identify additional anti-microbial antibodies inclusion of which in the classical MRZ panel may result in increased sensitivity without compromising the marker&#39;s high specificity for MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We determined the antibody indices (AIs) for 11 viral and bacterial agents (M, R, Z, herpes simplex virus, Epstein-Barr virus, mumps virus, cytomegalovirus, parvovirus B19, Bordetella pertussis, Corynebacterium diphtheriae, and Clostridium tetani) in paired cerebrospinal fluid and serum samples from patients with MS and disease controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A positive &#39;classical&#39; MRZ reaction was found in 17&#x2F;26 (65.4%) MS patients. The five most frequently positive AIs among patients with MS were M (76.9%), Z (61.5%), R (57.7%), parvovirus B19 (42.3%), and mumps (28%). Addition of parvovirus B19 and mumps virus to the MRZ panel resulted in an increase in sensitivity in the MS group from 65.4% to 73.1%, with 22% of the initially MRZ-negative patients exhibiting a de novo-positive response. The extended MRZ panel (&#39;MRZplus&#39;) distinguished sharply between MS (â¥ 3 AIs in 90% of all positives) and controls (varying diagnoses, from migraine to vasculitis; 0-1 AIs; p &amp;lt; 0.000001). The highest median AI in the MS group was found for parvovirus B19 (3.97), followed by measles virus (2.79).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Inclusion of parvovirus B19 and mumps virus in the test panel resulted in an increase in the sensitivity and discriminatory power of MRZ. Our results provide a strong rational for prospective studies investigating the role of extended MRZ panels in the differential diagnosis of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770235&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3&quot;&gt;33770235&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10471-3&gt;10.1007&#x2F;s00415-021-10471-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770235&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":793,"discovery_date":"2021-03-27T00:27:36","title":"Human Endogenous Retrovirus Type W Envelope from Multiple Sclerosis Demyelinating Lesions Shows Unique Solubility and Antigenic Characteristics","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Virol Sin. 2021 Mar 26. doi: 10.1007&#x2F;s12250-021-00372-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In multiple sclerosis (MS), human endogenous retrovirus W family (HERV-W) envelope protein, pHERV-W ENV, limits remyelination and induces microglia-mediated neurodegeneration. To better understand its role, we examined the soluble pHERV-W antigen from MS brain lesions detected by specific antibodies. Physico-chemical and antigenic characteristics confirmed differences between pHERV-W ENV and syncytin-1. pHERV-W ENV monomers and trimers remained associated with membranes, while hexamers self-assembled from monomers into a soluble macrostructure involving sulfatides in MS brain. Extracellular hexamers are stabilized by internal hydrophobic bonds and external hydrophilic moieties. HERV-W studies in MS also suggest that this diffusible antigen may correspond to a previously described high-molecular-weight neurotoxic factor secreted by MS B-cells and thus represents a major agonist in MS pathogenesis. Adapted methods are now needed to identify encoding HERV provirus(es) in affected cells DNA. The properties and origin of MS brain pHERV-W ENV soluble antigen will allow a better understanding of the role of HERVs in MS pathogenesis. The present results anyhow pave the way to an accurate detection of the different forms of pHERV-W ENV antigen with appropriate conditions that remained unseen until now.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770381&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3&quot;&gt;33770381&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s12250-021-00372-0&gt;10.1007&#x2F;s12250-021-00372-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33770381&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":792,"discovery_date":"2021-03-26T20:27:36","title":"Quality of life measures in pediatric multiple sclerosis: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Dev Med Child Neurol. 2021 Mar 26. doi: 10.1111&#x2F;dmcn.14870. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIM: To identify generic measures used to measure quality of life (QoL) in pediatric multiple sclerosis research, estimate an overall score of children and adolescents with pediatric multiple sclerosis, and compare the scores to scores of typically developing children and adolescents.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: A systematic search was conducted on four databases. All studies were included if: the sample was children with pediatric demyelinating disorders; self-reported QoL&#x2F;health-related quality of life (HRQoL) measures or results were reported; and the mean age of the sample was below 21 years. Quality of the included articles was appraised using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist and the Mixed Methods Appraisal Tool checklist. A meta-analysis was also conducted.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 12 full-text articles were included. Content analysis showed that many components of QoL were not included in the measures. Seven studies were included in the meta-analysis. The meta-analyzed score was 75.7 (95% confidence interval 71.2-80.3) with a pooled standard deviation of 16.6. Scores of typically developing children and children with pediatric multiple sclerosis were similar.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: Most measures assessed HRQoL and not QoL. Development of a condition-specific measure of QoL for children and adolescents with pediatric multiple sclerosis would make an important contribution to the field.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769574&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33769574&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;dmcn.14870&gt;10.1111&#x2F;dmcn.14870&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769574&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":791,"discovery_date":"2021-03-26T20:27:36","title":"The effect of fampridine on gait in people with Multiple sclerosis (MS)","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Laeknabladid. 2021 Apr;107(4):179-184. doi: 10.17992/lbl.2021.04.630.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Fampridine is a drug for people with Multiple Sclerosis (MS). It is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to enhance conduction in demyelinated axons, thereby leading to improved gait in patients with MS. The purpose of this study was to examine the effect of fampridine on gait function in people with MS in the end of a 2 weeks trial drug period and to observe how many patients continued drug therapy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIAL AND METHODS: Data from 41 individuals with MS was collected retrospectively for this study. Measurements were administered by physiotherapists and the results from the Timed 25-Foot Walk (T25FW) and 12-item Multiple Sclerosis Walking Scale (MSWS-12) were obtained from medical records from The National University Hospital of Iceland.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The results showed a significant difference in walking speed before and at the end of trial period (p&amp;lt;0.0001). The average improvement in walking speed was 22%. Results also demonstrated a significant difference in MSWS-12 scores before and at the end of treatment (p&amp;lt;0.0001). The average improvement in MSWS-12 was 11.4 points. Eighteen individuals (43.9%) continued treatment after the trial period.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Fampridine can have a positive effect on impaired gait function in people with MS and can be an important adjunct to treatment.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33769308/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210326162734&amp;v=2.14.3&quot;&gt;33769308&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.17992/lbl.2021.04.630&gt;10.17992/lbl.2021.04.630&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33769308/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210326162734&v=2.14.3","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":790,"discovery_date":"2021-03-26T20:27:36","title":"Medial septal GABAergic neurons reduce seizure duration upon optogenetic closed-loop stimulation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 26:awab042. doi: 10.1093&#x2F;brain&#x2F;awab042. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Seizures can emerge from multiple or large foci in temporal lobe epilepsy, complicating focally targeted strategies such as surgical resection or the modulation of the activity of specific hippocampal neuronal populations through genetic or optogenetic techniques. Here, we evaluate a strategy in which optogenetic activation of medial septal GABAergic neurons, which provide extensive projections throughout the hippocampus, is used to control seizures. We utilized the chronic intrahippocampal kainate mouse model of temporal lobe epilepsy, which results in spontaneous seizures and as is often the case in human patients, presents with hippocampal sclerosis. Medial septal GABAergic neuron populations were immunohistochemically labelled and were not reduced in epileptic conditions. Genetic labelling with mRuby of medial septal GABAergic neuron synaptic puncta and imaging across the rostral to caudal extent of the hippocampus, also indicated an unchanged number of putative synapses in epilepsy. Furthermore, optogenetic stimulation of medial septal GABAergic neurons consistently modulated oscillations across multiple hippocampal locations in control and epileptic conditions. Finally, wireless optogenetic stimulation of medial septal GABAergic neurons, upon electrographic detection of spontaneous hippocampal seizures, resulted in reduced seizure durations. We propose medial septal GABAergic neurons as a novel target for optogenetic control of seizures in temporal lobe epilepsy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769452&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33769452&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab042&gt;10.1093&#x2F;brain&#x2F;awab042&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769452&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":789,"discovery_date":"2021-03-26T20:27:36","title":"Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2014043118. doi: 10.1073&#x2F;pnas.2014043118.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CD4&lt;sup&gt;+&lt;&#x2F;sup&gt;Foxp3&lt;sup&gt;+&lt;&#x2F;sup&gt; regulatory T (Treg) cells are central modulators of autoimmune diseases. However, the timing and location of Treg cell-mediated suppression of tissue-specific autoimmunity remain undefined. Here, we addressed these questions by investigating the role of tumor necrosis factor (TNF) receptor 2 (TNFR2) signaling in Treg cells during experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. We found that TNFR2-expressing Treg cells were critical to suppress EAE at peak disease in the central nervous system but had no impact on T cell priming in lymphoid tissues at disease onset. Mechanistically, TNFR2 signaling maintained functional Treg cells with sustained expression of CTLA-4 and Blimp-1, allowing active suppression of pathogenic T cells in the inflamed central nervous system. This late effect of Treg cells was further confirmed by treating mice with TNF and TNFR2 agonists and antagonists. Our findings show that endogenous Treg cells specifically suppress an autoimmune disease by acting in the target tissue during overt inflammation. Moreover, they bring a mechanistic insight to some of the adverse effects of anti-TNF therapy in patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33766913&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33766913&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1073&#x2F;pnas.2014043118&gt;10.1073&#x2F;pnas.2014043118&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33766913&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":788,"discovery_date":"2021-03-26T20:27:36","title":"Recent advances and future directions on the use of optical coherence tomography in neuro-ophthalmology","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Taiwan J Ophthalmol. 2021 Jan 20;11(1):3-15. doi: 10.4103&#x2F;tjo.tjo_76_20. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Optical coherence tomography (OCT) is a noninvasive imaging technique used to qualitatively and quantitatively analyze various layers of the retina. OCT of the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) is particularly useful in neuro-ophthalmology for the evaluation of patients with optic neuropathies and retrochiasmal visual pathway disorders. OCT allows for an objective quantification of edema and atrophy of the RNFL and GCIPL, which may be evident before obvious clinical signs and visual dysfunction develop. Enhanced depth imaging OCT allows for visualization of deep structures of the optic nerve and has emerged as the gold standard for the detection of optic disc drusen. In the evaluation of compressive optic neuropathies, OCT RNFL and GCIPL thicknesses have been established as the most important visual prognostic factor. There is increasing evidence that inclusion of OCT as part of the diagnostic criteria for multiple sclerosis (MS) increases its sensitivity. Moreover, OCT of the RNFL and GCIPL may be helpful in the early detection and monitoring the treatment of conditions such as MS and Alzheimer&#39;s disease. OCT is an important aspect of the neuro-ophthalmologic assessment and its use is likely to increase moving forward.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767951&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33767951&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7971436&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;PMC7971436&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.4103&#x2F;tjo.tjo_76_20&gt;10.4103&#x2F;tjo.tjo_76_20&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767951&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":787,"discovery_date":"2021-03-26T20:27:36","title":"Cannabis for medical purposes: A cross-sectional analysis of health care professionals&#39; knowledge","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Am Assoc Nurse Pract. 2021 Mar 19. doi: 10.1097&#x2F;JXX.0000000000000590. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Legalization of cannabis use and the evidence base supporting both risks and benefits of cannabinoids are expanding, but our understanding of health care professionals&#39; (HCPs) knowledge about cannabis for medical purposes is limited. Understanding of the knowledge base and knowledge gaps about medical cannabis use is critical to advanced practice registered nurses (APRNs) because they are increasingly called on to manage patients taking multiple drugs, including prescribed and unprescribed cannabis and prescription cannabinoids.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: The purpose of this study was to examine HCPs&#39; knowledge of clinical cannabis, including laws and regulations; risks and harms; pharmacology; and effects on pain, multiple sclerosis spasticity, and seizures as assessed with written tests before an in-person, continuing medical education program.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Total scores and differences among professions and topics were compared.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 178 of the 226 program attendees completed the test (79%) (107 [47%] physicians, 30 [13%] APRNs, and 18 [8%] registered nurses). The mean test score was 63.2% (SD &#x3D; 12.7%) without significant differences among professions (F(3, 174) &#x3D; 1.53; p &#x3D; .21) but with significant differences among topics (Ï2(7, 1068) &#x3D; 201.13; p &amp;lt; .001). The score was lowest for effects on seizures (43.8%) and with scores below 70% for all other areas except laws and regulations (85.7%).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;IMPLICATIONS FOR PRACTICE: There are substantial gaps in HCPs&#39; knowledge about the clinical effects of cannabis, especially about risks and harms, pharmacology, and the effects on pain, multiple sclerosis spasticity, and seizures. Further education may help HCPs to understand the risks and benefits of cannabis and cannabinoids across conditions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33767121&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;JXX.0000000000000590&gt;10.1097&#x2F;JXX.0000000000000590&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":786,"discovery_date":"2021-03-26T20:27:36","title":"The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Commun. 2021 Mar 25;12(1):1893. doi: 10.1038&#x2F;s41467-021-22230-z.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;B cells have essential functions in multiple sclerosis and in its mouse model, experimental autoimmune encephalomyelitis, both as drivers and suppressors of the disease. The suppressive effects are driven by a regulatory B cell (Breg) population that functions, primarily but not exclusively, via the production of IL-10. However, the mechanisms modulating IL-10-producing Breg abundance are poorly understood. Here we identify SLAMF5 for controlling IL-10&lt;sup&gt;+&lt;&#x2F;sup&gt; Breg maintenance and function. In EAE, the deficiency of SLAMF5 in B cells causes accumulation of IL10&lt;sup&gt;+&lt;&#x2F;sup&gt; Bregs in the central nervous system and periphery. Blocking SLAMF5 in vitro induces both human and mouse IL-10-producing Breg cells and increases their survival with a concomitant increase of a transcription factor, c-Maf. Finally, in vivo SLAMF5 blocking in EAE elevates IL-10&lt;sup&gt;+&lt;&#x2F;sup&gt; Breg levels and ameliorates disease severity. Our results suggest that SLAMF5 is a negative moderator of IL-10&lt;sup&gt;+&lt;&#x2F;sup&gt; Breg cells, and may serve as a therapeutic target in MS and other autoimmune diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767202&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33767202&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41467-021-22230-z&gt;10.1038&#x2F;s41467-021-22230-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767202&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":785,"discovery_date":"2021-03-26T20:27:36","title":"Estimation and Validation of Ratio-based Conditional Average Treatment Effects Using Observational Data","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Am Stat Assoc. 2021;116(533):335-352. doi: 10.1080&#x2F;01621459.2020.1772080. Epub 2020 Jul 7.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;While sample sizes in randomized clinical trials are large enough to estimate the average treatment effect well, they are often insufficient for estimation of treatment-covariate interactions critical to studying data-driven precision medicine. Observational data from real world practice may play an important role in alleviating this problem. One common approach in trials is to predict the outcome of interest with separate regression models in each treatment arm, and estimate the treatment effect based on the contrast of the predictions. Unfortunately, this simple approach may induce spurious treatment-covariate interaction in observational studies when the regression model is misspecified. Motivated by the need of modeling the number of relapses in multiple sclerosis patients, where the ratio of relapse rates is a natural choice of the treatment effect, we propose to estimate the conditional average treatment effect (CATE) as the ratio of expected potential outcomes, and derive a doubly robust estimator of this CATE in a semiparametric model of treatment-covariate interactions. We also provide a validation procedure to check the quality of the estimator on an independent sample. We conduct simulations to demonstrate the finite sample performance of the proposed methods, and illustrate their advantages on real data by examining the treatment effect of dimethyl fumarate compared to teriflunomide in multiple sclerosis patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767517&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33767517&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7985957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;PMC7985957&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;01621459.2020.1772080&gt;10.1080&#x2F;01621459.2020.1772080&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767517&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":784,"discovery_date":"2021-03-26T20:27:36","title":"Editorial: Vitamin D in Neurological Diseases: From Pathophysiology to Therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 9;12:614900. doi: 10.3389&#x2F;fneur.2021.614900. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767657&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33767657&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7985255&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;PMC7985255&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.614900&gt;10.3389&#x2F;fneur.2021.614900&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767657&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":783,"discovery_date":"2021-03-26T20:27:36","title":"Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon-beta therapy in Latvians","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Exp Ther Med. 2021 May;21(5):478. doi: 10.3892&#x2F;etm.2021.9909. Epub 2021 Mar 12.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Several polymorphisms in genes related to the ubiquitin-proteasome system exhibit an association with pathogenesis and prognosis of various human autoimmune diseases. Our previous study reported the association between multiple sclerosis (MS) and the &lt;i&gt;PSMA3&lt;&#x2F;i&gt;-rs2348071 polymorphism in the Latvian population. The current study aimed to evaluate the &lt;i&gt;PSMA6&lt;&#x2F;i&gt; and &lt;i&gt;PSMC6&lt;&#x2F;i&gt; genetic variations, their interaction between each other and with the rs2348071, on the susceptibility to MS risk and response to therapy in the Latvian population. &lt;i&gt;PSMA6&lt;&#x2F;i&gt;-rs2277460, -rs1048990 and &lt;i&gt;PSMC6&lt;&#x2F;i&gt;-rs2295826, -rs2295827 were genotyped in the MS case&#x2F;control study and analysed in terms of genotype-protein correlation network. The possible association with the disease and alleles, single- and multi-locus genotypes and haplotypes of the studied loci was assessed. Response to therapy was evaluated in terms of &#39;no evidence of disease activity&#39;. To the best of our knowledge, the present study was the first to report that single- and multi-loci variations in the &lt;i&gt;PSMA6, PSMC6&lt;&#x2F;i&gt; and &lt;i&gt;PSMA3&lt;&#x2F;i&gt; proteasome genes may have contributed to the risk of MS in the Latvian population. The results of the current study suggested a potential for the &lt;i&gt;PSMA6&lt;&#x2F;i&gt;-rs1048990 to be an independent marker for the prognosis of interferon-Î² therapy response. The genotype-phenotype network presented in the current study provided a new insight into the pathogenesis of MS and perspectives for future pharmaceutical interventions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767773&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33767773&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7976443&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;PMC7976443&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3892&#x2F;etm.2021.9909&gt;10.3892&#x2F;etm.2021.9909&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33767773&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":782,"discovery_date":"2021-03-26T20:27:36","title":"Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Case Rep Intern Med. 2021 Feb 3;8(3):002190. doi: 10.12890&#x2F;2021_002190. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease which confers an increased risk of malignant tumour development. Relapsing remitting multiple sclerosis (RRMS) is an inflammatory demyelinating disease of the central nervous system. The coexistence of multiple sclerosis and NF1 is rare but has been reported. Here, we describe the case of a 31-year-old man with NF1 and subacute walking problems with proximal pain in the lower limbs who was successfully treated with natalizumab.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;LEARNING POINTS: The coexistence of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) is very rare but has been described in the literature.Follow-up of patients with NF1 is important as the early detection and management of MS can prevent further disability.Appropriate treatment and physical therapy can improve the patient&#39;s activity and social life.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33768065&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33768065&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7977044&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;PMC7977044&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.12890&#x2F;2021_002190&gt;10.12890&#x2F;2021_002190&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33768065&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":781,"discovery_date":"2021-03-26T20:27:36","title":"Sex Therapy as a Reasonable and Necessary Support for Persons with a Disability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Law Med. 2021 Mar;28(2):323-335.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Historically, there has been inadequate recognition of the need for persons with disabilities to have the opportunity for meaningful sexual expression. Many impediments lie in the way of such recognition and, for some with a disability, professional assistance is required. In a precedent-setting decision by the Full Court of the Federal Court of Australia (National Disability Insurance Agency v WRMF (2020) 276 FCR 415; [2020] FCAFC 79) a woman with multiple sclerosis who had been accepted onto the National Disability Insurance Scheme was affirmed to be eligible for taxpayer-funded receipt of services from a sex worker, in spite of the National Disability Insurance Scheme having declined such services as not constituting a reasonable and necessary support. However, it may be that the decision will be overturned by a controversial legislative amendment. This section reviews the reasoning in the decision and the human rights and political issues raised by the decision that require consideration and engagement.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33768744&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33768744&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33768744&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":780,"discovery_date":"2021-03-26T20:27:36","title":"IncobotulinumtoxinA versus OnabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Minerva Urol Nephrol. 2021 Mar 26. doi: 10.23736&#x2F;S2724-6051.21.04227-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: A randomized, double-blind, non-inferiority clinical study was performed on the efficacy and tolerability of IncobotulinumtoxinA vs OnabotulinumtoxinA intradetrusor injections in patients with refractory neurogenic detrusor overactivity incontinence performing intermittent catheterization.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Sixty-four patients with Spinal Cord Injury or Multiple Sclerosis were randomized to receive 30 intradetrusor injections of IncobotulinumtoxinA or OnabotulinumtoxinA 200 U; 28 patients in IncobotulinumtoxinA group and 29 in OnabotulinumtoxinA group completed the study. Primary outcome measure was the noninferior variation from baseline in daily urinary incontinence episodes (week 12), with a non-inferiority margin of one episode&#x2F;day. Secondary outcomes measures were changes in Incontinence- Quality of Life questionnaire, Visual Analog Scale score (bother of symptoms on Quality of Life), urodynamic parameters, occurrence of adverse effects and related costs (week 12).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: At week 12, mean value of difference in urinary incontinence episodes&#x2F;day between the two groups was -0.2 (95% two-sided CI: -1; 0.7); the difference in incontinence episodes&#x2F;day between the two groups was -0.4 with a higher limit of one-sided 95% CI of 0.2 episodes&#x2F;day which was much lower than the non-inferiority margin of one episode&#x2F;day. Total score and subscores of Incontinence- Quality of Life questionnaire, Visual Analog Scale Scores and urodynamics did not show differences between the two groups. Adverse effects were similar for both treatments, with urinary tract infection being the most frequent, localised effect. Minor costs were observed following IncobotulinumtoxinA.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: In patients with refractory neurogenic incontinence due to Spinal Cord Injury or Multiple Sclerosis, IncobotulinumtoxinA was not inferior to OnabotulinumtoxinA in improving clinical and urodynamic findings in the short-term follow-up, with comparable adverse effects but minor costs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769020&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33769020&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.23736&#x2F;S2724-6051.21.04227-2&gt;10.23736&#x2F;S2724-6051.21.04227-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769020&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":779,"discovery_date":"2021-03-26T20:27:36","title":"Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Exp Rheumatol. 2021 Mar 24. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: Systemic sclerosis (SSc) is a rare immune-mediated heterogenous entity characterised by excessive tissue fibrosis and vascular injury. Recently, increased risk of thromboembolic events has been documented in that disease. Our aim was to investigate prothrombotic plasma properties together with selected laboratory biomarkers of endothelial injury in SSc.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In 56 clinically stable SSc patients and 67 well-matched controls we assessed plasma thrombin generation profile and measured circulating vascular cell adhesion molecule-1 (VCAM-1), cellular fibronectin (cFN), and thrombomodulin, as well as analysed their relationships with disease clinical parameters and autoimmune antibodies profile.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: SSc was characterised by 18.3% increased endogenous thrombin potential (ETP), 14.5% higher thrombin peak (p&amp;lt;0.001 both, also after adjustment for potential confounders), and similar endothelial damage biomarkers, as compared to controls. Surprisingly, raised thrombin generation was related to the lower thrombomodulin and VCAM-1. Inflammatory markers, factor VIII activity, and blood eosinophilia predicted positively ETP, whereas platelet count and thrombomodulin had negative impact on that parameter in a multiple regression model. Intriguingly, patient group had also 6.7% extended lag-time (p&#x3D;0.01 after adjustment for confounders) which was independently determined by higher thrombomodulin and cFN, as well as lower VCAM-1. Former cyclophosphamide therapy, thus more severe type of the disease was referred to the increased thrombin generation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: SSc is characterised by enhanced thrombin generation potential which might contribute to the higher risk of thromboembolic events in that disease. Endothelium may play hereby an additional role, although large observational and experimental studies are needed to verify this hypothesis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769265&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33769265&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769265&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":778,"discovery_date":"2021-03-26T20:27:36","title":"Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177&#x2F;13524585211000280. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Disease-modifying therapies (DMTs) can reduce the risk of disability worsening in patients with relapsing forms of multiple sclerosis (RMS). High-efficacy DMTs can lead to confirmed or sustained disability improvement (CDI and SDI).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE AND METHODS: Post hoc analyses of data from the TRANSFORMS, FREEDOMS, and FREEDOMS II trials and their extensions assessed the effects of fingolimod (0.5-1.25 mg&#x2F;day) on stabilizing or improving disability over â©½8 years in participants with RMS. CDI and SDI rates were compared between participants initially randomized to fingolimod, interferon (IFNÎ²-1a), or placebo.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: At 8 years&#39; follow-up in TRANSFORMS, 35.1% (95% confidence interval [CI], 28.2%-43.1%) of assessed participants in the IFNÎ²-1a-fingolimod switch group and 41.9% (36.6%-47.6%) on continuous fingolimod experienced CDI; disability did not worsen in approximately 70%. Similar results were seen in the combined FREEDOMS population. Proportionally fewer TRANSFORMS participants achieved SDI in the IFNÎ²-1a-fingolimod switch group than on continuous fingolimod (5.4% [3.0%-9.5%] vs 14.2% [10.8%-18.4%], &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.01).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: CDI and SDI are outcomes of interest for clinical trials and for long-term follow-up of participants with RMS. Monitoring CDI and SDI in addition to disability worsening may facilitate understanding of the therapeutic benefit of RMS treatments.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769117&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3&quot;&gt;33769117&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211000280&gt;10.1177&#x2F;13524585211000280&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33769117&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326162734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":777,"discovery_date":"2021-03-26T17:13:06","title":"Much ado about nothing? Off-target amplification can lead to false-positive bacterial brain microbiome detection in healthy and Parkinsonâs disease individuals","summary":"Recent studies suggested the existence of (poly-)microbial infections in human brains. These have been described either as putative pathogens linked to the neuro-inflammatory changes seen in Parkinsonâs diseas...","link":"https:&#x2F;&#x2F;microbiomejournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40168-021-01012-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":776,"discovery_date":"2021-03-26T17:13:06","title":"Microglial PGC-1Î± protects against ischemic brain injury by suppressing neuroinflammation","summary":"Neuroinflammation and immune responses occurring minutes to hours after stroke are associated with brain injury after acute ischemic stroke (AIS). PPARÎ³ coactivator-1Î± (PGC-1Î±), as a master coregulator of gene...","link":"https:&#x2F;&#x2F;genomemedicine.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13073-021-00863-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":775,"discovery_date":"2021-03-26T17:13:06","title":"Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders","summary":"People with neurodegenerative disorders show diverse clinical syndromes, genetic heterogeneity, and distinct brain pathological changes, but studies report overlap between these features. DNA methylation (DNAm...","link":"https:&#x2F;&#x2F;genomebiology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13059-021-02275-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":774,"discovery_date":"2021-03-26T17:13:06","title":"Shared decision making and patients satisfaction with strabismus careâa pilot study","summary":"Strabismus is a complex disease that has various treatment approaches each with its own advantages and drawbacks. In this context, shared decisions making (SDM) is a communication process with the provider sha...","link":"https:&#x2F;&#x2F;bmcmedinformdecismak.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12911-021-01469-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":773,"discovery_date":"2021-03-26T12:27:35","title":"Dermoscopic findings in a case of multiple subungual fibromas","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Dermatovenerol Alp Pannonica Adriat. 2021 Mar;30(1):35-37.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Periungual and subungual fibromas, also known as Koenen tumors, are diagnostic findings of tuberous sclerosis. The clinical appearance and histological features that characterize ungual fibromas are well defined. However, dermoscopic findings of these benign tumors have not been reported previously. Here we report a rare presentation of multiple subungual fibromas of all fingers in a developmentally delayed patient with tuberous sclerosis along with the dermoscopic features of the ungual tumors.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765756&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326082734&amp;v&#x3D;2.14.3&quot;&gt;33765756&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765756&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326082734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":772,"discovery_date":"2021-03-26T12:27:35","title":"HIV infection and multiple sclerosis: a case with unexpected &quot;no evidence of disease activity&quot; status","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Int Med Res. 2021 Mar;49(3):300060521999577. doi: 10.1177&#x2F;0300060521999577.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system whose etiology remains unclear. It has been suggested that MS can be triggered by certain viruses; however, human immunodeficiency virus (HIV) infection is associated with reduced incidence of MS. We present the case of a young patient diagnosed with active relapsing-remitting MS whose clinical course substantially improved following HIV infection and treatment. The patient achieved no evidence of disease activity status without any disease-modifying drugs. Both HIV-induced immunosuppression and antiretroviral therapy may have attenuated the clinical course in this patient.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326082734&amp;v&#x3D;2.14.3&quot;&gt;33765893&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;0300060521999577&gt;10.1177&#x2F;0300060521999577&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326082734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":771,"discovery_date":"2021-03-26T05:47:35","title":"Complete Freund&#39;s adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Mar 16;354:577547. doi: 10.1016&#x2F;j.jneuroim.2021.577547. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Experimental autoimmune encephalomyelitis (EAE) is classically induced with complete Freund&#39;s adjuvant (CFA). The immune response against CFA has a confounding influence on the translational capacity of EAE as a multiple sclerosis model. Here, we compare clinical, cellular and molecular properties between syngeneic spinal cord homogenate (SCH)- and SCH + CFA-immunized Dark Agouti rats. EAE signs were observed earlier and the cumulative clinical score was higher without CFA. Also, a higher number of immune cells infiltrates in the spinal cords was noticed at the peak of EAE without CFA. High spinal cord abundance of CD8&lt;sup&gt;+&lt;&#x2F;sup&gt;CD11bc&lt;sup&gt;+&lt;&#x2F;sup&gt;MHC class II&lt;sup&gt;+&lt;&#x2F;sup&gt; cells was detected in SCH-immunized rats. Myelin basic protein -specific response can be elicited in the cells from the lymph nodes draining the site of SCH immunization. This CFA-free EAE is a reliable multiple sclerosis model.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765502&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326014734&amp;v&#x3D;2.14.3&quot;&gt;33765502&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577547&gt;10.1016&#x2F;j.jneuroim.2021.577547&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765502&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210326014734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":770,"discovery_date":"2021-03-26T05:33:05","title":"Cerebrospinal fluid cells immune landscape in multiple sclerosis","summary":"Multiple Sclerosis (MS) is a potentially devastating autoimmune neurological disorder, which characteristically induces demyelination of white matter in the brain and spinal cord.","link":"https:&#x2F;&#x2F;translational-medicine.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12967-021-02804-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":769,"discovery_date":"2021-03-26T05:33:05","title":"Machine learning associated with respiratory oscillometry: a computer-aided diagnosis system for the detection of respiratory abnormalities in systemic sclerosis","summary":"The use of machine learning (ML) methods would improve the diagnosis of respiratory changes in systemic sclerosis (SSc). This paper evaluates the performance of several ML algorithms associated with the respir...","link":"https:&#x2F;&#x2F;biomedical-engineering-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12938-021-00865-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":768,"discovery_date":"2021-03-26T05:33:05","title":"Prediction of a time-sensitive condition among patients with dizziness assessed by the emergency medical services","summary":"Dizziness is a relatively common symptom among patients who call for the emergency medical services (EMS).","link":"https:&#x2F;&#x2F;bmcemergmed.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12873-021-00423-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":767,"discovery_date":"2021-03-26T00:27:36","title":"Vaccination against SARS-CoV-2 in patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588&#x2F;rn.7207.2021097.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: The recent availability of SARS-CoV-2 vaccines has raised concerns in certain patient groups, such as those with multiple sclerosis. However, there are currently few publications that provide information on this issue. We pooled the information available on the safety and efficacy of vaccination against SARS-CoV-2 in patients with multiple sclerosis, with and without disease-modifying therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DEVELOPMENT: The study consisted in a literature search focused on the types of SARS-CoV-2 vaccines, the current status of their approval, and the data available on the safety and efficacy of vaccines in patients with multiple sclerosis, including the new COVID-19 vaccines. Based on this search, the document has been designed taking into account current evidence and expert recommendations. There are no data on the safety and efficacy of SARS-CoV-2 vaccines in patients with multiple sclerosis. However, evidence does exist to suggest that messenger RNA (mRNA) vaccines against SARS-CoV-2 are as safe in these patients as in other individuals. Some therapies with immunosuppressants might reduce the effectiveness of these vaccines and require the scheduling of their administration, preferably before the start of treatment if possible.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The data available make it possible to recommend mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. In patients on fingolimod, cladribine, alemtuzumab, ocrelizumab and rituximab, vaccination prior to the initiation of medication administration would be recommendable whenever possible.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33764494&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325202734&amp;v&#x3D;2.14.3&quot;&gt;33764494&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.33588&#x2F;rn.7207.2021097&gt;10.33588&#x2F;rn.7207.2021097&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33764494&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":766,"discovery_date":"2021-03-26T00:27:36","title":"Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177&#x2F;13524585211005339. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Three-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33764197&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325202734&amp;v&#x3D;2.14.3&quot;&gt;33764197&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211005339&gt;10.1177&#x2F;13524585211005339&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33764197&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":765,"discovery_date":"2021-03-26T00:27:36","title":"Differential diagnostics of autoimmune inflammatory spinal cord diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 25. doi: 10.1007&#x2F;s00115-021-01092-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Myelitis is an acute or subacute inflammatory syndrome of the spinal cord. Myelopathy, often used as a synonym and presenting with similar symptoms in clinical practice, can be caused by numerous, not primarily inflammatory etiologies and might also show a progressive disease course. Within the last decade the spectrum of autoimmune myelitis was significantly broadened as was the spectrum of diagnostic methods. Apart from the characteristic example of multiple sclerosis with short-length myelitis and neuromyelitis optica spectrum disorders with longitudinally extensive transverse myelitis, multiple rare but important differential diagnoses should also be considered. Magnetic resonance imaging and laboratory analyses of serum antibodies and cerebrospinal fluid are the most important diagnostic methods and are fundamental for rapid treatment decisions, subsequently with better prognosis. This article reviews representative diseases within the spectrum of autoimmune spinal cord diseases and their differential diagnoses.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765163&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325202734&amp;v&#x3D;2.14.3&quot;&gt;33765163&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01092-2&gt;10.1007&#x2F;s00115-021-01092-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33765163&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325202734&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":764,"discovery_date":"2021-03-25T19:41:38","title":"p57kip2 nuclear export as a marker of oligodendrocytes differentiation: Towards an innovative phenotyping screening for the identification of myelin repair drugs","summary":"","link":"https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;ebiom&#x2F;article&#x2F;PIIS2352-3964(21)00091-8&#x2F;fulltext","published_date":"","source":"The Lancet","relevant":null,"table_constraints":null},{"article_id":763,"discovery_date":"2021-03-25T18:00:54","title":"Neuron-Oligodendrocyte Interactions in the Structure and Integrity of Axons","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Cell Dev Biol. 2021 Mar 8;9:653101. doi: 10.3389&#x2F;fcell.2021.653101. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The myelination of axons by oligodendrocytes is a highly complex cell-to-cell interaction. Oligodendrocytes and axons have a reciprocal signaling relationship in which oligodendrocytes receive cues from axons that direct their myelination, and oligodendrocytes subsequently shape axonal structure and conduction. Oligodendrocytes are necessary for the maturation of excitatory domains on the axon including nodes of Ranvier, help buffer potassium, and support neuronal energy metabolism. Disruption of the oligodendrocyte-axon unit in traumatic injuries, Alzheimer&#39;s disease and demyelinating diseases such as multiple sclerosis results in axonal dysfunction and can culminate in neurodegeneration. In this review, we discuss the mechanisms by which demyelination and loss of oligodendrocytes compromise axons. We highlight the intra-axonal cascades initiated by demyelination that can result in irreversible axonal damage. Both the restoration of oligodendrocyte myelination or neuroprotective therapies targeting these intra-axonal cascades are likely to have therapeutic potential in disorders in which oligodendrocyte support of axons is disrupted.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763430&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763430&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7982542&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7982542&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fcell.2021.653101&gt;10.3389&#x2F;fcell.2021.653101&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763430&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":762,"discovery_date":"2021-03-25T18:00:54","title":"VIRdb 2.0: Interactive analysis of comorbidity conditions associated with vitiligo pathogenesis using co-expression network-based approach","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;F1000Res. 2020 Aug 27;9:1055. doi: 10.12688&#x2F;f1000research.25713.1. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Vitiligo is a disease of mysterious origins in the context of its occurrence and pathogenesis. The autoinflammatory theory is perhaps the most widely accepted theory that discusses the occurrence of Vitiligo. The theory elaborates the clinical association of vitiligo with autoimmune disorders such as Psoriasis, Multiple Sclerosis and Rheumatoid Arthritis and Diabetes. In the present work, we discuss the comprehensive set of differentially co-expressed genes involved in the crosstalk events between Vitiligo and associated autoimmune disorders (Psoriasis, Multiple Sclerosis and Rheumatoid Arthritis). We progress our previous tool, Vitiligo Information Resource (VIRdb), and incorporate into it a compendium of Vitiligo-related multi-omics datasets and present it as VIRdb 2.0. It is available as a web-resource consisting of statistically sound and manually curated information. VIRdb 2.0 is an integrative database as its datasets are connected to KEGG, STRING, GeneCards, SwissProt, NPASS. Through the present study, we communicate the major updates and expansions in the VIRdb and deliver the new version as VIRdb 2.0. VIRdb 2.0 offers the maximum user interactivity along with ease of navigation. We envision that VIRdb 2.0 will be pertinent for the researchers and clinicians engaged in drug development for vitiligo.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763205&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763205&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7953917&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7953917&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.12688&#x2F;f1000research.25713.1&gt;10.12688&#x2F;f1000research.25713.1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763205&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":761,"discovery_date":"2021-03-25T18:00:54","title":"No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Int. 2021 Mar 8;2021:8813498. doi: 10.1155&#x2F;2021&#x2F;8813498. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A new therapeutic paradigm may be to target this inflammation by injecting immunosuppressive drugs inside the central nervous system compartment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We designed a single-center, open-label, randomized, controlled, phase II study designed to evaluate the safety and efficacy of IT rituximab in progressive MS (EFFRITE trial; ClinicalTrial Registration NCT02545959). Patients were randomized into three arms (1 : 1 : 1): control group, IT rituximab (20 mg, IT) group, and intravenous+IT (IV+IT) group. The main outcome was a change in levels of CSF biomarkers of inflammation (osteopontin). Secondary outcomes were changes in levels of CSF biomarkers of axonal loss (neurofilament light chain) and clinical and MRI changes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Ten patients were included (2 : 4 : 4). No adverse event occurred. OPN level remained stable in CSF at each time point, whereas NFL had slightly decreased (-8.7%) at day 21 (&lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.02). Clinical parameters remained stable and leptomeningeal enhancements remained unchanged.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Clinical outcome and biomarkers of inflammation were not dramatically modified after IT injection of rituximab, probably due to its limited efficiency in CSF. Drug issues for future studies are discussed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763241&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763241&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7964121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7964121&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1155&#x2F;2021&#x2F;8813498&gt;10.1155&#x2F;2021&#x2F;8813498&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763241&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":760,"discovery_date":"2021-03-25T18:00:54","title":"The effect of optic neuritis attacks on choroidal vascularity index in patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Graefes Arch Clin Exp Ophthalmol. 2021 Mar 25. doi: 10.1007&#x2F;s00417-021-05143-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: To investigate the changes in the choroidal vascularity index (CVI) of patients with multiple sclerosis (MS) using binarization on enhanced depth imaging optical coherence tomography (EDI-OCT) images and to evaluate the effect of optic neuritis (ON) attacks on these measurements.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: Three groups were created by including forty eyes of 20 patients diagnosed with relapsing-remitting MS and had a unilateral history of ON attack and the randomly selected eyes of 30 healthy age- and sex-matched control subjects. Group 1 (n &#x3D; 20) consisted of the ON-affected eyes of the MS patients (MSON); group 2 (n &#x3D; 20) included their fellow healthy eyes (MSNON); group 3 (n &#x3D; 30) included the eyes of healthy controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The mean age was 33.3 Â± 9.4 years in the MS group and 33.4 Â± 11.1 years in the healthy control group. Mean choroidal vascularity index (CVI) was significantly lower in the MSON group than the MSNON group (59.6 Â± 3.72 % vs 61.7 Â± 3.16 %, p &#x3D; 0.007). The CVI values of both the MSON and MSNON groups were significantly lower when compared to the controls (63.9 Â± 2.76) (p &amp;lt; 0.001, p &#x3D; 0.030). Compared to controls, the subfoveal total choroidal area and luminal area values were significantly greater in the MSON (p &#x3D; 0.009, p &#x3D; 0.009, respectively) and MSNON groups (p &#x3D; 0.031, p &#x3D; 0.013, respectively).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The presented study demonstrates that, compared to healthy subjects, CVI values are lower in the affected and unaffected eyes of patients who had a history of ON in relation with their MS diagnosis. The presence of significant anatomical changes, especially in the luminal area, may suggest that ON causes vascular disorganization which contributes to MS pathophysiology.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763732&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763732&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00417-021-05143-x&gt;10.1007&#x2F;s00417-021-05143-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763732&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":759,"discovery_date":"2021-03-25T18:00:54","title":"Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arch Microbiol. 2021 Mar 24. doi: 10.1007&#x2F;s00203-021-02276-9. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Increasing incidences of neurological disorders, such as Parkinson&#39;s disease (PD), multiple sclerosis (MS), Alzheimer&#39;s disease (AD) and amyotrophic lateral sclerosis (ALS) are being reported, but an insight into their pathology remains elusive. Findings have suggested that gut microbiota play a major role in regulating brain functions through the gut-brain axis. A unique bidirectional communication between gut microbiota and maintenance of brain health could play a pivotal role in regulating incidences of neurodegenerative diseases. Contrarily, the present life style with changing food habits and disturbed circadian rhythm may contribute to gut homeostatic imbalance and dysbiosis leading to progression of several neurological disorders. Therefore, dysbiosis, as a primary factor behind intestinal disorders, may also augment inflammation, intestinal and blood-brain barrier permeability through microbiota-gut-brain axis. This review primarily focuses on the gut-brain axis functions, specific gut microbial population, metabolites produced by gut microbiota, their role in regulating various metabolic processes and role of gut microbiota towards development of neurodegenerative diseases. However, several studies have reported a decrease in abundance of a specific gut microbial population and a corresponding increase in other microbial family, with few findings revealing some contradictions. Reports also showed that colonization of gut microbiota isolated from patients suffering from neurodegenerative disease leads to the development of enhance pathological outcomes in animal models. Hence, a systematic understanding of the dominant role of specific gut microbiome towards development of different neurodegenerative diseases could possibly provide novel insight into the use of probiotics and microbial transplantation as a substitute approach for treating&#x2F;preventing such health maladies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763767&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763767&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00203-021-02276-9&gt;10.1007&#x2F;s00203-021-02276-9&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763767&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":758,"discovery_date":"2021-03-25T18:00:54","title":"Can diplopia complaint be reduced by telerehabilitation in multiple sclerosis patient during the pandemic?: A case report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 24. doi: 10.1007&#x2F;s10072-021-05194-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Hospital visits and regular rehabilitation of chronic patients due to COVID-19 pose a risk. Therefore, patients with chronic illnesses who need regular rehabilitation have been victims of the pandemic process. Because of their fear of being infected, they were deprived of the chance of their symptoms being rehabilitated. Therefore, it is extremely important to rehabilitate individuals with chronic illnesses in need of rehabilitation through telerehabilitation. In this study, we aimed to show the effect of Cawthorne-Cooksey exercises to be applied through telerehabilitation on eye movements, vision, and quality of life in a patient suffering from diplopia due to multiple sclerosis (MS). It has been found that Cawthorne-Cooksey exercises improve the quality of life and reduce the complaints of diplopia in MS patients with diplopia. In addition, the patient verbally stated that his balance increased after Cawthorne-Cooksey exercises. As a result, Cawthorne-Cooksey exercises are a rehabilitation method that gives positive results in the treatment of diplopia and it is recommended to apply this method via telerehabilitation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763810&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763810&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05194-2&gt;10.1007&#x2F;s10072-021-05194-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763810&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":757,"discovery_date":"2021-03-25T18:00:54","title":"Late Onset Macular Oedema in a Patient with Multiple Sclerosis Treated with Fingolimod","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroophthalmology. 2020 Oct 6;45(1):61-64. doi: 10.1080&#x2F;01658107.2020.1821065. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Macular oedema is a rare complication of fingolimod treatment. It usually presents within 3-4 months, but occasionally presents later. It can resolve without treatment despite continuation of fingolimod treatment. Herein we report a case of very late onset macular oedema in a 49-year-old woman with multiple sclerosis treated with fingolimod for 7 years. The patient presented with blurred vision in both eyes with visual acuities of 20&#x2F;32 in her right eye and 20&#x2F;25 in her left eye. She had macular oedema, that without discontinuing fingolimod treatment, resolved after 1 month.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33762792&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33762792&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7946040&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7946040&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;01658107.2020.1821065&gt;10.1080&#x2F;01658107.2020.1821065&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33762792&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":756,"discovery_date":"2021-03-25T18:00:54","title":"Effects of Transcranial Direct Current Stimulation on Cognition, Mood, Pain, and Fatigue in Multiple Sclerosis: A Systematic Review and Meta-Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 8;12:626113. doi: 10.3389&#x2F;fneur.2021.626113. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; The study aimed to evaluate the effects of transcranial direct current stimulation (tDCS) on cognition, mood disturbance, pain, and fatigue in people with multiple sclerosis (PwMS). &lt;b&gt;Methods:&lt;&#x2F;b&gt; A literature search was performed on articles published between January 1990 and May 2020 in Pubmed, Medline, and Web of Science using the following keywords and their abbreviation in combinations: multiple sclerosis and transcranial direct current stimulation. Mean effect size (ES) and 95% confidence interval were calculated for each domain of interest. &lt;b&gt;Results:&lt;&#x2F;b&gt; Seventeen articles with a total of 383 PwMS were included in this analysis. For cognition, a strong effect size was found for the trial administering the Symbol Digit Modalities Test (ES: 1.15), whereas trials applying the Attention Network Test showed a negative effect size of -0.49. Moderate to strong effect sizes were observed for mood disturbance (mean ES: 0.92), pain (mean ES: 0.59), and fatigue (mean ES: 0.60). Further subgroup analyses for MS-related fatigue showed that both high and low intensities of stimulation lead to nearly the same degree of favorable effects. More pronounced effects were observed in studies administering the Fatigue Severity Scale compared with studies using other fatigue measures such as the Modified Fatigue Impact Scale. &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; These results provide preliminary evidence that tDCS has a favorable effect on cognitive processing speed, mood disturbance, pain, and fatigue in MS. However, the effects on cognition and fatigue vary based on the specific assessment used.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763014&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763014&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7982804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7982804&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.626113&gt;10.3389&#x2F;fneur.2021.626113&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763014&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":755,"discovery_date":"2021-03-25T18:00:54","title":"Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 3;12:637107. doi: 10.3389&#x2F;fneur.2021.637107. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; Fingolimod (GilenyaÂ®) is approved for adult and pediatric patients with highly active relapsing-remitting multiple sclerosis (RRMS). &lt;b&gt;Objectives:&lt;&#x2F;b&gt; The objective was to describe the effectiveness of fingolimod in young adults compared to older patients in clinical practice. &lt;b&gt;Methods:&lt;&#x2F;b&gt; PANGAEA is the largest prospective, multi-center, non-interventional, long-term study evaluating fingolimod in RRMS. We descriptively analyzed demographics, MS characteristics, and severity in two subgroups of young adults (â¤20 and &amp;gt;20 to â¤30 years) and older patients (&amp;gt;30 years). &lt;b&gt;Results:&lt;&#x2F;b&gt; Young adults had lower Expanded Disability Status Scale (EDSS) scores compared to older patients (1.8 and 2.3 vs. 3.2) at baseline. The mean EDSS scores remained stable over 5 years in all subgroups. Young adults had higher annual relapse rates (2.0 and 1.7 vs. 1.4) at study entry, which were reduced by approximately 80% in all subgroups over 5 years. The proportion of patients with no clinical disease activity in year 4 was 52.6 and 73.4 vs. 66.9% in patients â¤20, &amp;gt;20 to â¤30 years and &amp;gt;30 years, respectively. The symbol digit modalities test score increased by 15.25 Â± 8.3 and 8.3 Â± 11.3 (mean Â± SD) from baseline in patients &amp;gt;20 to â¤30 and &amp;gt;30 years. &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Real-world evidence suggests a long-term treatment benefit of fingolimod in young RRMS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763018&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763018&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7982917&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7982917&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.637107&gt;10.3389&#x2F;fneur.2021.637107&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763018&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":754,"discovery_date":"2021-03-25T18:00:54","title":"Multiparametric Quantitative MRI in Neurological Diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 8;12:640239. doi: 10.3389&#x2F;fneur.2021.640239. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Magnetic resonance imaging (MRI) is the gold standard imaging technique for diagnosis and monitoring of many neurological diseases. However, the application of conventional MRI in clinical routine is mainly limited to the visual detection of macroscopic tissue pathology since mixed tissue contrasts depending on hardware and protocol parameters hamper its application for the assessment of subtle or diffuse impairment of the structural tissue integrity. Multiparametric quantitative (q)MRI determines tissue parameters quantitatively, enabling the detection of microstructural processes related to tissue remodeling in aging and neurological diseases. In contrast to measuring tissue atrophy via structural imaging, multiparametric qMRI allows for investigating biologically distinct microstructural processes, which precede changes of the tissue volume. This facilitates a more comprehensive characterization of tissue alterations by revealing early impairment of the microstructural integrity and specific disease-related patterns. So far, qMRI techniques have been employed in a wide range of neurological diseases, including in particular conditions with inflammatory, cerebrovascular and neurodegenerative pathology. Numerous studies suggest that qMRI might add valuable information, including the detection of microstructural tissue damage in areas appearing normal on conventional MRI and unveiling the microstructural correlates of clinical manifestations. This review will give an overview of current qMRI techniques, the most relevant tissue parameters and potential applications in neurological diseases, such as early (differential) diagnosis, monitoring of disease progression, and evaluating effects of therapeutic interventions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763021&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763021&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7982527&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7982527&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.640239&gt;10.3389&#x2F;fneur.2021.640239&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763021&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":753,"discovery_date":"2021-03-25T18:00:54","title":"Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Mar 8;12:611711. doi: 10.3389&#x2F;fimmu.2021.611711. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background and Aims:&lt;&#x2F;b&gt; There is a controversy regarding whether fingolimod is associated with an increased risk of infection in patients with multiple sclerosis (MS). We performed a systematic review and meta-analysis of data from randomized controlled trials (RCTs) to determine the risk of infection in these patients. &lt;b&gt;Methods:&lt;&#x2F;b&gt; We systematically searched PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov from inception to April 8, 2020, to identify RCTs that reported the occurrence of infection in patients with MS treated with fingolimod. Relative risks (RRs) and 95% confidence intervals (95% CIs) were calculated using the random-effects model. &lt;b&gt;Results:&lt;&#x2F;b&gt; Twelve RCTs including 8,448 patients were eligible. Compared with the control (placebo and other active treatments), fingolimod significantly increased the risk of infection (RR, 1.16; 95% CI, 1.07-1.27; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 81%), regardless of whether the infection was a general infection (RR, 1.14; 95% CI, 1.05-1.25; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 78%), or a serious infection (RR, 1.49; 95% CI, 1.06-2.10; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 0%). Analyses of subgroups found that fingolimod significantly increased the risk of lower respiratory infection (RR, 1.48; 95% CI, 1.19-1.85; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 0%) and herpes virus infection (RR, 1.34; 95% CI, 1.01-1.78; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 9%). There appears to be no dose-dependent increase in the risk of infection associated with fingolimod (0.5 mg: RR, 1.15; 95% CI, 1.07-1.25; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 91%; 1.25 mg: RR, 1.11; 95% CI, 0.97-1.28; &lt;i&gt;I&lt;&#x2F;i&gt; &lt;sup&gt;2&lt;&#x2F;sup&gt;, 81%; P&lt;sub&gt;interaction&lt;&#x2F;sub&gt; &#x3D; 0.66). &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Compared with a placebo and other active treatments, fingolimod was associated with a 16% increase in the risk of infection, especially lower respiratory infection and herpes virus infection. The risk of infection associated with fingolimod might not be dose related.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763062&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763062&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7982402&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7982402&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.611711&gt;10.3389&#x2F;fimmu.2021.611711&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763062&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":752,"discovery_date":"2021-03-25T18:00:54","title":"Acute psychotic episode as a primary clinical manifestation of multiple sclerosis-a case report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 24. doi: 10.1007&#x2F;s00115-021-01107-y. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763707&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33763707&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01107-y&gt;10.1007&#x2F;s00115-021-01107-y&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33763707&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":751,"discovery_date":"2021-03-25T18:00:54","title":"Memory in multiple sclerosis: A reappraisal using the item specific deficit approach","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuropsychology. 2021 Feb;35(2):207-219. doi: 10.1037&#x2F;neu0000712.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: As many as 65% of people with multiple sclerosis (MS) have clinically significant memory impairment, but the nature of this deficit is controversial. Some investigations suggest that an inability to retrieve newly learned information from memory is prominent, whereas others imply that compromised acquisition accounts for impairment. Prior research has not simultaneously evaluated acquisition and retrieval processes in MS, and fewer have attempted to account for initial acquisition when studying retrieval. The Item Specific Deficit Approach (ISDA) offers a method of quantifying acquisition, retrieval, and retention processes, with the latter two mechanisms being adjusted for initial acquisition. To simultaneously quantify acquisition and retrieval abilities, the ISDA was applied to list learning performance in two independent samples of people with MS and corresponding healthy comparison groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PARTICIPANTS AND METHODS: Study 1 included 85 people with MS and 47 healthy individuals. Study 2 involved a separate sample of 79 people with MS and 22 healthy people. They were administered neuropsychological batteries, and participants with MS were classified as globally impaired or unimpaired. The California Verbal Learning Test-II was administered to assess new-learning in both studies, and responses were scored using the ISDA.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Both studies revealed that cognitively impaired people with MS manifest weaknesses involving acquisition and retrieval. Nearly identical effect sizes emerged across samples, with cognitive impairment achieving a medium effect upon acquisition and a large effect upon retrieval.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These findings accord well with previous research showing diminished acquisition and retrieval among people with MS. The results may also reconcile contradictory findings in the extant literature by showing that memory impairment in MS is not exclusively attributable to either acquisition or retrieval. Rather, both processes may manifest across people with MS. The replication across samples with nearly identical effect sizes implies that these effects are reliable and possess external validity. These data hold implications for memory rehabilitation interventions involving people with MS, and suggest that acquisition and retrieval processes should be addressed in treatment. (PsycInfo Database Record (c) 2021 APA, all rights reserved).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33764111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3&quot;&gt;33764111&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1037&#x2F;neu0000712&gt;10.1037&#x2F;neu0000712&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33764111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":750,"discovery_date":"2021-03-25T13:56:24","title":"Chronic exposure to PM2.5 aggravates SLE manifestations in lupus-prone mice","summary":"Air pollution causes negative impacts on health. Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations and multifactorial etiology. Recent studies suggest that air po...","link":"https:&#x2F;&#x2F;particleandfibretoxicology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12989-021-00407-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":749,"discovery_date":"2021-03-25T13:56:24","title":"Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort","summary":"Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory disease affecting bone with considerable phenotypic heterogeneity and variable association with other autoinflammatory conditions. Disease pathog...","link":"https:&#x2F;&#x2F;ped-rheum.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12969-021-00530-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":748,"discovery_date":"2021-03-25T13:56:24","title":"Bilateral one-stage single-port sympathicotomy in primary focal hyperhidrosis, a prospective cohort study: treat earlier?","summary":"Primary Focal Hyperhidrosis (PFH) has a detrimental effect on Quality of Life. Repetitive, non-curative symptomatic strategies dominate current treatment of PFH, in spite of the availability of an effective an...","link":"https:&#x2F;&#x2F;cardiothoracicsurgery.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13019-021-01430-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":747,"discovery_date":"2021-03-25T13:56:24","title":"Regulation of autophagy by microRNAs in human breast cancer","summary":"Breast cancer is the most common solid cancer that affects female population globally. MicroRNAs (miRNAs) are short non-coding RNAs that can regulate post-transcriptional modification of multiple downstream ge...","link":"https:&#x2F;&#x2F;jbiomedsci.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12929-021-00715-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":746,"discovery_date":"2021-03-25T13:56:24","title":"Disease-associated metabolic alterations that impact satellite cells and muscle regeneration: perspectives and therapeutic outlook","summary":"Many chronic disease patients experience a concurrent loss of lean muscle mass. Skeletal muscle is a dynamic tissue maintained by continuous protein turnover and progenitor cell activity. Muscle stem cells, or...","link":"https:&#x2F;&#x2F;nutritionandmetabolism.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12986-021-00565-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":745,"discovery_date":"2021-03-25T13:56:24","title":"Health care providersâ experiences of pain management and attitudes towards digitally supported self-management interventions for chronic pain: a qualitative study","summary":"Chronic pain constitutes a significant burden for the individuals affected, and is a frequent reason why patients seek health care services. While in-person psychosocial interventions can be of support to peop...","link":"https:&#x2F;&#x2F;bmchealthservres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12913-021-06278-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":744,"discovery_date":"2021-03-25T00:00:00.000Z","title":"Evidences for Adult Hippocampal Neurogenesis in Humans","summary":"The rodent hippocampus generates new neurons throughout life. This process, named adult hippocampal neurogenesis (AHN), is a striking form of neural plasticity that occurs in the brains of numerous mammalian species. Direct evidence of adult neurogenesis in humans has remained elusive, although the occurrence of this phenomenon in the human dentate gyrus has been demonstrated in seminal studies and recent research that have applied distinct approaches to birthdate newly generated neurons and to validate markers of adult-born neurons. Our data point to the persistence of AHN until the 10th decade of human life, as well as to marked impairments in this process in patients with Alzheimer&#39;s disease. Moreover, our work demonstrates that the methods used to process and analyze postmortem human brain samples can limit the detection of various markers of AHN to the point of making them undetectable. In this Dual Perspectives article, we highlight the critical methodological aspects that should be strictly controlled in human studies and the robust evidence that supports the occurrence of AHN in humans. We also put forward reasons that may account for current discrepancies on this topic. Finally, the unresolved questions and future challenges awaiting the field are highlighted.","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;content&#x2F;41&#x2F;12&#x2F;2541","published_date":"2021-03-24T00:00:00.000Z","source":"jneurosci","relevant":0,"table_constraints":null},{"article_id":743,"discovery_date":"2021-03-25T11:20:54","title":"Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Mar 24;8(3):e981. doi: 10.1212&#x2F;NXI.0000000000000981. Print 2021 May.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess the safety and efficacy of epigallocatechin-3-gallate (EGCG) add-on to glatiramer acetate (GA) in patients with relapsing-remitting multiple sclerosis (RRMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We enrolled patients with RRMS (aged 18-60 years, Expanded Disability Status Scale [EDSS] score 0-6.5), receiving stable GA treatment in a multicenter, prospective, double-blind, phase II, randomized controlled trial. Participants received up to 800 mg oral EGCG daily over a period of 18 months. The primary outcome was the proportion of patients without new hyperintense lesions on T2-weighted (T2w) brain MRI within 18 months. Secondary end points included additional MRI and clinical parameters. Immunologic effects of EGCG were investigated in exploratory experiments.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 122 patients on GA were randomly assigned to EGCG treatment (n &#x3D; 62) or placebo (n &#x3D; 60). We could not demonstrate a difference between groups after 18 months for the primary outcome or other radiologic (T2w lesion volume, T1w hypointense lesion number or volume, number of cumulative contrast-enhancing lesions, percent brain volume change), or clinical (EDSS, MS functional composite, and annualized relapse rate) parameter. EGCG treatment did not affect immune response to GA. Pharmacologic analysis revealed wide ranging EGCG plasma levels. The treatment was well tolerated with a similar incidence of mostly mild adverse events similar in both groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: In RRMS, oral EGCG add-on to GA was not superior to placebo in influencing MRI and clinical disease activity over 18 months. The treatment was safe at a daily dosage up to 800 mg EGCG. It did not influence immune parameters, despite indication of EGCG being bioavailable in patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with RRMS, EGCG added to GA did not significantly affect the development of new hyperintense lesions on T2-weighted brain MRI.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION INFORMATION: Clinical trial registration number: NCT00525668.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33762428&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325072052&amp;v&#x3D;2.14.3&quot;&gt;33762428&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXI.0000000000000981&gt;10.1212&#x2F;NXI.0000000000000981&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33762428&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325072052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":742,"discovery_date":"2021-03-25T11:20:54","title":"Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMC Neurol. 2021 Mar 25;21(1):136. doi: 10.1186&#x2F;s12883-021-02149-0.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Though adherence to disease-modifying therapies (DMTs) among persons with multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on adherence examined predictors beyond demographic and clinical characteristics.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: Identify antecedents to adherence and persistence to DMT in a prospective design among PwMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: PwMS (n &#x3D; 186) were prospectively assessed at three time points: baseline, 6 (Time 1) and 12 months later (Time 2). Clinical, demographic information and patient-reported medication beliefs, illness perceptions, medication habits, perceived health and affect were surveyed in-person. Adherence and persistence were assessed by a combination of self-reports and retrospective review of medication claims.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;FINDINGS: PwMS were 69.9% (Time 1) and 71% (Time 2) adherent to their DMTs and 64.5.9% were persistent. Beliefs about Medications were consistently predictive at both time points (baseline to Time 1 and Time 1 to Time 2) of medication adherence and persistence whereas other perceptions were predictive in some analyses; clinical and demographic characteristics were mostly not predictive of adherence nor persistence. The prospective association of beliefs about medication with adherence held also in multivariate analyses (OR &#x3D; 0.88, 95% CI 0.78-0.99, p &#x3D; 0.029).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Adherence and persistence are predicted by medication beliefs of PwMS. As medication beliefs are modifiable, they should be assessed periodically and targeted as a focus of tailored interventions aimed to improve adherence and consequently health outcomes in PwMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;REGISTRATION: Clinical trials registry # NCT02488343 , date: 06&#x2F;08&#x2F;2015.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33761887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325072052&amp;v&#x3D;2.14.3&quot;&gt;33761887&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s12883-021-02149-0&gt;10.1186&#x2F;s12883-021-02149-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33761887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325072052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":741,"discovery_date":"2021-03-25T11:20:54","title":"Tumefactive demyelinating lesion (TDL)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;No Shinkei Geka. 2021 Mar;49(2):376-382. doi: 10.11477&#x2F;mf.1436204401.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Tumefactive demyelinating lesion(TDL)is defined as a large lesion, size &amp;gt;2 cm, mass effect, perilesional edema and&#x2F;or ring enhancement. TDL could occur in multiple sclerosis(MS), neuromyelitis optica spectrum disorder(NMOSD), acute disseminated encephalomyelitis(ADEM)or other immunological diseases. Non-invasive methods including MR imaging and assay of several autoantibodies(e.g. aquaporin-4 autoantibodies)are recommended when each TDL is identified. The radiological findings on MRI are characterized by size &amp;gt;2 cm, mass effect, perilesional edema, T2 weighted hypointense rim, peripheral diffusion restriction, open ring enhancement, vascular enhancement, and central vein sign. When atypical clinical and radiological presentations are present in patients with TDL, diagnosis may necessitate brain biopsy due to exclude alternative pathology(e.g. primary central nervous system lymphoma). Because treatments and outcomes for patients with TDL are dependent on each disease etiology including MS, NMOSD, ADEM or others, we should always clarify the entire picture behind the disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33762460&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325072052&amp;v&#x3D;2.14.3&quot;&gt;33762460&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.11477&#x2F;mf.1436204401&gt;10.11477&#x2F;mf.1436204401&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33762460&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325072052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":740,"discovery_date":"2021-03-25T06:00:54","title":"Rate, burden, and treatment of sexual dysfunction in multiple sclerosis: The case for exercise training as a new treatment approach","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 2;51:102878. doi: 10.1016&#x2F;j.msard.2021.102878. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a prevalent immune-mediated and neurodegenerative disease of the central nervous system (CNS) among adults in the United States and worldwide. This disease results in impairments of physical, psychological, and social functions that compromise quality of life. This review focuses on sexual dysfunction, including its prevalence, burden, and management, in persons with MS. Sexual dysfunction is defined as sexual behaviors and experiences characterized as insufficient in quality, duration and frequency. Sexual dysfunction occurs in 40-80% percent of women and 50-90% percent of men with MS. The presence of sexual dysfunction is seemingly predicted by psychological and psychiatric issues such as depression and anxiety; sociodemographic dimensions such as older age, unemployment and lower socioeconomic status; and MS-related issues such as fatigue, higher degree of disability and motor impairments. Sexual dysfunction in persons with MS is further associated with decreased psychological and psychosocial wellbeing and impaired quality of life. There is limited research supporting pharmacological and other approaches for managing sexual dysfunction in MS, and we make the case for exercise training based on recent evidence from randomized controlled trials in MS and putative mechanisms of action targeted by exercise training in MS. This paper concludes by providing a research agenda for a deeper and broader understanding of exercise training and sexual function in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33761411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325020052&amp;v&#x3D;2.14.3&quot;&gt;33761411&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102878&gt;10.1016&#x2F;j.msard.2021.102878&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33761411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210325020052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":739,"discovery_date":"2021-03-25T02:16:24","title":"Advances in intranasal application of stem cells in the treatment of central nervous system diseases","summary":"Stem cells are characterized by their self-renewal and multipotency and have great potential in the therapy of various disorders. However, the bloodâbrain barrier (BBB) limits the application of stem cells in ...","link":"https:&#x2F;&#x2F;stemcellres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13287-021-02274-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":738,"discovery_date":"2021-03-25T02:16:24","title":"Early alterations of neurovascular unit in the retina in mouse models of tauopathy","summary":"The retina, as the only visually accessible tissue in the central nervous system, has attracted significant attention for evaluating it as a biomarker for neurodegenerative diseases. Yet, most of studies focus...","link":"https:&#x2F;&#x2F;actaneurocomms.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40478-021-01149-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":737,"discovery_date":"2021-03-25T02:16:24","title":"TDP-43 proteinopathy alters the ribosome association of multiple mRNAs including the glypican Dally-like protein (Dlp)&#x2F;GPC6","summary":"Amyotrophic lateral sclerosis (ALS) is a genetically heterogeneous neurodegenerative disease in which 97% of patients exhibit cytoplasmic aggregates containing the RNA binding protein TDP-43. Using tagged ribo...","link":"https:&#x2F;&#x2F;actaneurocomms.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40478-021-01148-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":736,"discovery_date":"2021-03-24T23:20:54","title":"Guidance and&#x2F;or Decision Coaching with Patient Decision Aids: Scoping Reviews to Inform the International Patient Decision Aid Standards (IPDAS)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Med Decis Making. 2021 Mar 24:272989X21997330. doi: 10.1177&#x2F;0272989X21997330. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: In 2005, the International Patient Decision Aid Standards (IPDAS) collaboration identified guidance and decision coaching as important dimensions of patient decision aids (PtDAs) and developed a set of quality criteria. We sought to update definitions, theoretical rationale, and evidence for guidance and&#x2F;or decision coaching used within or alongside PtDAs for the IPDAS update 2.0.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We conducted 2 scoping reviews on guidance and decision coaching, including systematic searches and a hand search of the Cochrane Review on PtDAs. Eligible studies were randomized controlled trials (RCTs) on guidance or decision coaching used with&#x2F;alongside PtDAs. Data, including conceptual models, were summarized narratively and with meta-analyses when appropriate.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Of 1022 citations, we found no RCTs that evaluated guidance in PtDAs. The 2013 definition for guidance was endorsed, and we made minimal changes to the description of guidance. Of 3039 citations, we identified 21 RCTs on decision coaching informed by 5 conceptual models stating that people exposed to decision coaching are more likely to progress in making informed decisions consistent with their values. Compared to usual care, decision coaching with PtDAs led to improved knowledge mean difference [MD], 19.5&#x2F;100; 95% confidence interval [CI], 10.0-29.0; 5 RCTs). Compared to decision coaching alone, PtDAs led to a small improvement in knowledge (MD, 3.6&#x2F;100; 95% CI, 1.0-6.3; 3 RCTs). There were variable effects on other outcomes. We simplified the decision coaching definition slightly and defined minimal decision coaching elements.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: We found no evidence on which to propose changes in guidance in IPDAS. Decision coaching is continuing to be used alongside PtDAs, but there is inadequate evidence on the added effectiveness compared to PtDAs alone. The decision coaching definition was updated with minimal elements.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759626&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324192052&amp;v&#x3D;2.14.3&quot;&gt;33759626&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;0272989X21997330&gt;10.1177&#x2F;0272989X21997330&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759626&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324192052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":735,"discovery_date":"2021-03-24T23:20:54","title":"Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Ther. 2021 Mar 24. doi: 10.1007&#x2F;s40120-021-00238-3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Injection site reactions (ISRs) and flu-like symptoms (FLS) are common in patients with relapsing forms of multiple sclerosis (MS) treated with peginterferon beta-1a. The purpose of this Delphi analysis was to explore peginterferon beta-1a discontinuation rates across MS treatment centers, to obtain consensus on effective mitigation and management strategies for ISRs and FLS, and to identify areas where additional training and education for nurses and patients could improve treatment outcomes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this modified Delphi process, an international steering committee of eight MS-certified nurses developed two rounds of surveys, which were completed by 262 and 188 MS nurses, respectively, representing nine countries.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: On average, nurses reported that 25% and 30% of patients treated with peginterferon beta-1a experienced ISRs and FLS, respectively. Discontinuation due to severe ISRs or FLS was most common in the first 6 months of treatment, yet follow-up visits typically took place 6 months after peginterferon beta-1a initiation. Preferred management strategies for ISRs included nonsteroidal anti-inflammatory drugs and rotation of the injection site, whereas preferred management strategies for FLS included acetaminophen&#x2F;paracetamol and hydration&#x2F;nutrition. Most nurses (77%) agreed that additional education and training on ISR and FLS management would bolster their confidence in treating patients with these symptoms.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Delphi respondents reached consensus on ISR and FLS management strategies, which can help to inform treatment decisions. The results of this global Delphi analysis indicate that management of ISRs and FLS could be improved with more frequent follow-up visits and individualized training and education.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33761099&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324192052&amp;v&#x3D;2.14.3&quot;&gt;33761099&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s40120-021-00238-3&gt;10.1007&#x2F;s40120-021-00238-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33761099&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324192052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":734,"discovery_date":"2021-03-24T23:20:54","title":"Neurological Causes of Chest Pain","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Pain Headache Rep. 2021 Mar 24;25(5):32. doi: 10.1007&#x2F;s11916-021-00944-5.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: Chest pain is a very common presenting complaint among patients in the hospital, a large proportion of whom have non-cardiac chest pain (NCCP). Neurological causes of NCCP have not been previously reviewed although several causes have been identified.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: Chest pain has been reported as a symptom of multiple neurological conditions such as migraine, epilepsy, and multiple sclerosis, with varying clinical presentations. The affected patients are often not formally diagnosed for long periods of time due to difficulties in recognizing the symptoms as part of neurological disease processes. This paper will briefly summarize well-known etiologies of chest pain and, then, review neurological causes of NCCP, providing an overview of current literature and possible pathophysiologic mechanisms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33760994&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324192052&amp;v&#x3D;2.14.3&quot;&gt;33760994&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11916-021-00944-5&gt;10.1007&#x2F;s11916-021-00944-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33760994&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324192052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":733,"discovery_date":"2021-03-24T20:26:24","title":"Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report","summary":"Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is spreading globally and causes most frequently fever and respiratory symptoms, i.e. Coronavirus disease 2019 (COVID-19), however, distinct neurological ...","link":"https:&#x2F;&#x2F;bmcinfectdis.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12879-021-05987-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":732,"discovery_date":"2021-03-24T20:26:24","title":"How to design a national genomic projectâa systematic review of active projects","summary":"An increasing number of countries are investing efforts to exploit the human genome, in order to improve genetic diagnostics and to pave the way for the integration of precision medicine into health systems. T...","link":"https:&#x2F;&#x2F;humgenomics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40246-021-00315-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":731,"discovery_date":"2021-03-24T20:26:24","title":"Presence and activation of pro-inflammatory macrophages are associated with CRYAB expression in vitro and after peripheral nerve injury","summary":"Inflammation constitutes both positive and negative aspects to recovery following peripheral nerve injury. Following damage to the peripheral nervous system (PNS), immune cells such as macrophages play a benef...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02108-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":730,"discovery_date":"2021-03-24T20:26:24","title":"Do work ability and life satisfaction matter for return to work? Predictive ability of the work ability index and life satisfaction questionnaire among women with long-term musculoskeletal pain","summary":"Impaired work ability and reduced life satisfaction due to long-term musculoskeletal pain, particularly in neck, shoulders and back, are considered occupational health problems that can result in workers takin...","link":"https:&#x2F;&#x2F;bmcpublichealth.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12889-021-10510-8","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":729,"discovery_date":"2021-03-24T18:00:54","title":"Imaging evaluation of hereditary renal tumors: a pictorial review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Jpn J Radiol. 2021 Mar 23. doi: 10.1007&#x2F;s11604-021-01109-5. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;More than 10 hereditary renal tumor syndromes (HRTSs) and related germline mutations have been reported with HRTS-associated renal and extrarenal manifestations with benign and malignant tumors. Radiologists play an important role in detecting solitary or multiple renal masses with or without extrarenal findings on imaging and may raise the possibility of an inherited predisposition to renal cell carcinoma, providing direction for further screening, intervention and surveillance of the patients and their close family members before the development of potentially lethal renal and extrarenal tumors. Renal cell carcinomas (RCCs) associated with von Hippel-Lindau disease are typically slow growing while RCCs associated with HRTSs, such as hereditary leiomyomatosis and renal cell carcinoma syndrome, are highly aggressive. Therefore, radiologists need to be familiar with clinical and imaging findings of renal and extrarenal manifestations of HRTSs. This article reviews clinical and imaging findings for the evaluation of patients with well-established HRTSs from a radiologist&#39;s perspective to facilitate the clinical decision-making process for patient management.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759057&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33759057&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11604-021-01109-5&gt;10.1007&#x2F;s11604-021-01109-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759057&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":728,"discovery_date":"2021-03-24T18:00:54","title":"Microglia clean up toxic lipids in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Neurosci. 2021 Mar 23. doi: 10.1038&#x2F;s41593-021-00829-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758401&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33758401&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41593-021-00829-1&gt;10.1038&#x2F;s41593-021-00829-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758401&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":727,"discovery_date":"2021-03-24T18:00:54","title":"Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Allergy Asthma Rep. 2021 Mar 24;21(3):22. doi: 10.1007&#x2F;s11882-021-00996-y.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: Evidence for hematopoietic stem cell transplantation (HCT) in autoimmune disease has been building since the 1990s; however, many clinicians may not yet be aware of its applications to autoimmune disease. We review the basic tenets of HCT and evidence for autologous HCT in multiple sclerosis (MS), systemic sclerosis (SSc), and lupus with an emphasis on recent advanced phase trials.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: In MS, the phase 3 randomized MIST trial and the phase 2 randomized ASTIMS trial demonstrated the efficacy of autologous HCT in refractory MS over disease-modifying therapies and mitoxantrone, respectively. In SSc, the phase 3 randomized ASTIS trial and the phase 2 randomized SCOT trial demonstrated the efficacy of autologous HCT in advanced SSc compared to cyclophosphamide. The evidence for HCT in autoimmune diseases continues to grow, particularly in MS and SSc. In lupus, large, comparative trials are still needed. Across autoimmune diseases, questions that still remain to be answered include optimizing patient selection to limit TRM, the appropriate use of MAC, and the necessity for graft manipulation. Furthermore, collaboration between disease-specific and transplant physicians is imperative to expand the appropriate use of HCT in routine clinical practice.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759038&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33759038&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11882-021-00996-y&gt;10.1007&#x2F;s11882-021-00996-y&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759038&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":726,"discovery_date":"2021-03-24T18:00:54","title":"HN1L&#x2F;JPT2: A signaling protein that connects NAADP generation to Ca2+ microdomain formation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Signal. 2021 Mar 23;14(675):eabd5647. doi: 10.1126&#x2F;scisignal.abd5647.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;NAADP-evoked Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt; release through type 1 ryanodine receptors (RYR1) is a major mechanism underlying the earliest signals in T cell activation, which are the formation of Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt; microdomains. In our characterization of the molecular machinery underlying NAADP action, we identified an NAADP-binding protein, called hematological and neurological expressed 1-like protein (HN1L) [also known as Jupiter microtubule-associated homolog 2 (JPT2)]. Gene deletion of &lt;i&gt;Hn1l&#x2F;Jpt2&lt;&#x2F;i&gt; in human Jurkat and primary rat T cells resulted in decreased numbers of initial Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt; microdomains and delayed the onset and decreased the amplitude of global Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt; signaling. Photoaffinity labeling demonstrated direct binding of NAADP to recombinant HN1L&#x2F;JPT2. T cell receptor&#x2F;CD3-dependent coprecipitation of HN1L&#x2F;JPT2 with RYRs and colocalization of these proteins suggest that HN1L&#x2F;JPT2 connects NAADP formation with the activation of RYR channels within the first seconds of T cell activation. Thus, HN1L&#x2F;JPT2 enables NAADP to activate Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt; release from the endoplasmic reticulum through RYR.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758062&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33758062&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1126&#x2F;scisignal.abd5647&gt;10.1126&#x2F;scisignal.abd5647&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758062&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":725,"discovery_date":"2021-03-24T18:00:54","title":"Sex differences in the blood-brain barrier and neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;APL Bioeng. 2021 Mar 16;5(1):011509. doi: 10.1063&#x2F;5.0035610. eCollection 2021 Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The number of people diagnosed with neurodegenerative diseases is on the rise. Many of these diseases, including Alzheimer&#39;s disease, Parkinson&#39;s disease, multiple sclerosis, and motor neuron disease, demonstrate clear sexual dimorphisms. While sex as a biological variable must now be included in animal studies, sex is rarely included in &lt;i&gt;in vitro&lt;&#x2F;i&gt; models of human neurodegenerative disease. In this Review, we describe these sex-related differences in neurodegenerative diseases and the blood-brain barrier (BBB), whose dysfunction is linked to neurodegenerative disease development and progression. We explain potential mechanisms by which sex and sex hormones affect BBB integrity. Finally, we summarize current &lt;i&gt;in vitro&lt;&#x2F;i&gt; BBB bioengineered models and highlight their potential to study sex differences in BBB integrity and neurodegenerative disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33758788&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7968933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7968933&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1063&#x2F;5.0035610&gt;10.1063&#x2F;5.0035610&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":724,"discovery_date":"2021-03-24T18:00:54","title":"A Diagnosis of Multiple Sclerosis Following Whiplash Injury: Is There a True Association?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cureus. 2021 Feb 18;13(2):e13411. doi: 10.7759&#x2F;cureus.13411.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We report a case of a previously well, 25-year-old Caucasian female whose diagnosis of multiple sclerosis (MS) followed significant trauma. Her symptoms and signs developed quickly and satisfied the criteria for rapidly evolving relapsing-remitting MS. She was started on natalizumab (Tysabri) and was stabilized. We discuss the existing literature on traumatic demyelination and possible underlying mechanisms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33758706&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7980313&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;PMC7980313&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7759&#x2F;cureus.13411&gt;10.7759&#x2F;cureus.13411&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33758706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":723,"discovery_date":"2021-03-24T18:00:54","title":"Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Exp Immunol. 2021 Mar 24. doi: 10.1111&#x2F;cei.13596. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Follicular T helper (Tfh) and regulatory (Tfr) cells are distinct subsets of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T lymphocytes, regulating humoral immune responses in the germinal center. It is widely accepted that dysregulated Tfh and Tfr cells are associated with autoimmunity. Here, we evaluated the frequencies of circulating CXCR5&lt;sup&gt;+&lt;&#x2F;sup&gt; PD-1&lt;sup&gt;+&lt;&#x2F;sup&gt; Tfh (cTfh) and CXCR5&lt;sup&gt;+&lt;&#x2F;sup&gt; PD-1&lt;sup&gt;+&lt;&#x2F;sup&gt; FoxP3&lt;sup&gt;+&lt;&#x2F;sup&gt; CD25&lt;sup&gt;+&lt;&#x2F;sup&gt; Tfr (cTfr) cells, and their corresponding cytokines from the peripheral blood mononuclear cells of 28 patients with relapsing-remitting multiple sclerosis (MS) and 16 age- and sex-matched healthy controls (HC). Subsets of cTfh cells by Th1 and Th17 related surface markers (CXCR3 and CCR6) were also evaluated. We found that the frequency of cTfh cells was significantly higher in MS patients compared to that of HC. Conversely, the frequency of cTfr cells were lower in MS patients than that of HC. IL-21 producing cTfh cells were significantly increased in MS patients, while IL-10 secreting cTfr cells were lower in MS compared to levels in HC. Among cTfh cells, cTfh17.1 cells were the major subtypes that were significantly increased in MS compared to HC, with the frequency of IL-21 secreting cells being the highest. These results suggest that an imbalanced distribution of cTfh and cTfr exist in MS, which contributes to the reciprocally altered IL-21 and IL-10 production.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3&quot;&gt;33759187&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;cei.13596&gt;10.1111&#x2F;cei.13596&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33759187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324140052&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":722,"discovery_date":"2021-03-24T17:31:24","title":"Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling","summary":"Mitochondrial dysfunction is a common feature of aging, neurodegeneration, and metabolic diseases. Hence, mitotherapeutics may be valuable disease modifiers for a large number of conditions. In this study, we ...","link":"https:&#x2F;&#x2F;bmcbiol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12915-021-00979-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":721,"discovery_date":"2021-03-24T14:36:24","title":"Simultaneous or staged operation for tandem spinal stenosis: surgical strategy and efficacy comparison","summary":"Tandem spinal stenosis (TSS) has a complex clinical presentation, and there is no consensus on the optimal surgical strategy. This study retrospectively compared the efficacy of different staged operations and...","link":"https:&#x2F;&#x2F;josr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13018-021-02357-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":720,"discovery_date":"2021-03-24T11:24:38","title":"Clinically isolated syndrome: diagnosis and risk of developing clinically definite multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurologia. 2021 Mar 20:S0213-4853(21)00028-1. doi: 10.1016&#x2F;j.nrl.2021.01.011. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: In most cases, multiple sclerosis (MS) initially presents as clinically isolated syndrome (CIS). Differentiating CIS from other acute or subacute neurological diseases and estimating the risk of progression to clinically definite MS is essential since presenting a second episode in a short time is associated with poorer long-term prognosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DEVELOPMENT: We conducted a literature review to evaluate the usefulness of different variables in improving diagnostic accuracy and predicting progression from CIS to MS, including magnetic resonance imaging (MRI) and such biofluid markers as oligoclonal IgG and IgM bands, lipid-specific oligoclonal IgM bands in the CSF, CSF kappa free light-chain (KFLC) index, neurofilament light chain (NfL) in the CSF and serum, and chitinase 3-like protein 1 (CHI3L1) in the CSF and serum.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Codetection of oligoclonal IgG bands and MRI lesions reduces diagnostic delays and suggests a high risk of CIS progression to MS. A KFLC index &amp;gt; 10.6 and CSF NfL concentrations &amp;gt; 1150 ng&#x2F;L indicate that CIS is more likely to progress to MS within one year (40-50%); 90% of patients with CIS and serum CHI3L1 levels &amp;gt; 33 ng&#x2F;mL and 100% of those with lipid-specific oligoclonal IgM bands present MS within one year of CIS onset.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757657&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324072437&amp;v&#x3D;2.14.3&quot;&gt;33757657&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nrl.2021.01.011&gt;10.1016&#x2F;j.nrl.2021.01.011&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757657&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324072437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":719,"discovery_date":"2021-03-24T11:24:38","title":"Therapeutic effects of non-invasive, individualized, transcranial neuromodulation treatment for voiding dysfunction in multiple sclerosis patients: study protocol for a pilot clinical trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Pilot Feasibility Stud. 2021 Mar 24;7(1):83. doi: 10.1186&#x2F;s40814-021-00825-z.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Voiding dysfunction (VD) is a common neurogenic lower urinary tract dysfunction (NLUTD) in multiple sclerosis (MS) patients. Currently, the only effective management for VD and urinary retention in MS patients is catheterization, prompting us to look for novel therapeutic options beyond the bladder, such as the brain. Transcranial rotating permanent magnet stimulator (TRPMS) is a non-invasive, portable, multifocal neuromodulator that simultaneously modulates multiple cortical regions, enhancing or attenuating strengths of functional connections between these regions. The objective of this pilot clinical trial is to evaluate the feasibility of a TRPMS trial to address lower urinary tract symptoms in MS patients, through investigating the therapeutic effects of TRPMS in modulating brain regions during voiding initiation and mitigating VD in female MS individuals.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Ten adult female MS patients with VD (defined as having %post-void residual&#x2F;bladder capacity (%PVR&#x2F;BC) â¥ 40% or Liverpool nomogram percentile &amp;lt; 10%) will be recruited for this study. Concurrent urodynamic and functional MRI evaluation with a bladder filling&#x2F;emptying task repeated three to four times will be performed at baseline and post-treatment. Predetermined regions of interest and their blood-oxygen-level-dependent (BOLD) activation at voiding initiation will be identified on each patient&#39;s baseline anatomical and functional MRI scan, corresponding to the microstimulators placement on their individualized TRPMS treatment cap to either stimulate or inhibit these regions. Patients will receive 10 40-min treatment sessions. Non-instrumented uroflow and validated questionnaires will also be collected at baseline and post-treatment to evaluate clinical improvement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DISCUSSION: Despite the crucial role of the central nervous system in urinary control and its sensitivity to MS, there has been no treatment for urinary dysfunction targeting the brain centers that are involved in proper bladder function. This trial, to our knowledge, will be the first of its kind in humans to consider non-invasive and individualized cortical modulation for treating VD in MS patients. Results from this study will provide a better understanding of the brain control of neurogenic bladders and lay the foundation for a potential alternative therapy for VD in MS patients and other NLUTD in a larger neurogenic population in the future.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION: This trial is registered at ClinicalTrials.Gov ( NCT03574610 , 2 July 2018.) and Houston Methodist Research Institute IRB (PRO00019329).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757581&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324072437&amp;v&#x3D;2.14.3&quot;&gt;33757581&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s40814-021-00825-z&gt;10.1186&#x2F;s40814-021-00825-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757581&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324072437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":718,"discovery_date":"2021-03-24T11:24:38","title":"Non-invasive brain stimulation to assess neurophysiologic underpinnings of lower limb motor impairment in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurosci Methods. 2021 Mar 20:109143. doi: 10.1016&#x2F;j.jneumeth.2021.109143. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a neuroinflammatory disease resulting in axonal demyelination and an amalgamation of symptoms which commonly result in decreased quality of life due to mobility dysfunction and limited participation in meaningful activities.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;NEW METHOD: The use of non-invasive brain stimulation (NIBS) techniques, specifically transcranial magnetic and transcranial direct current stimulation, have been essential in understanding the pathophysiological decrements related to disease progression, particularly with regard to motor impairments. Although the research in this area has primarily focused on the upper extremities, new interest has arisen in understanding the neurophysiological underpinnings of lower limb impairment. Therefore, the purpose of this review is to: first, provide an overview of common NIBS techniques used to explore sensorimotor neurophysiology; second, summarize lower limb neuromuscular and mobility impairments typically observed in PwMS; third, review the current knowledge regarding interactions between TMS-assessed neurophysiology and lower limb impairments in PwMS; and fourth, provide recommendations for future NIBS studies based on current gaps in the literature.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: PwMS exhibit reduced excitability and increased inhibitory neurophysiologic function which has been related to disease severity and lower limb motor impairments. Comparison with existing methods: Moreover, promising results indicate that the use of repetitive stimulation and transcranial direct current stimulation may prime neural adaptability and prove useful as a therapeutic tool in ameliorating lower limb impairments.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: While these studies are both informative and promising, additional studies are necessary to be conclusive. As such, studies assessing objective measures of lower limb impairments associated with neurophysiological adaptations need further evaluation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757762&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324072437&amp;v&#x3D;2.14.3&quot;&gt;33757762&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneumeth.2021.109143&gt;10.1016&#x2F;j.jneumeth.2021.109143&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757762&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324072437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":717,"discovery_date":"2021-03-24T06:04:39","title":"The role of immune semaphorins in the pathogenesis of multiple sclerosis: Potential therapeutic targets","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int Immunopharmacol. 2021 Mar 20;95:107556. doi: 10.1016&#x2F;j.intimp.2021.107556. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The immune and nervous systems possess a highly intricate network of synaptic connections, shared messenger molecules, and exquisite communication ways, allowing intercellular signal transduction. The semaphorins (Semas) were initially identified as axonal guidance molecules in the development of the nervous system but later were found to be implicated also in regulating the immune system, known in this case as the &quot;immune Semas&quot; or &quot;immunoregulatory Semas&quot;. Increasingly, these molecules are involved in multiple aspects of both physiological and pathological immune responses and were recently indicated to take part in various immunological disorders, encompassing allergy, cancer, and autoimmunity. Semas transduce signals by connecting to their cognate receptors, namely, plexins and neuropilins. Some of them, like Sema-3F, have been found to function as the inducer of the remyelination process whereas some others, like Sema-3A and Sema-4D, act to inhibit this process, either directly or indirectly. Besides, Sema-4A is crucial to the differentiation of T helper type 1 (Th1) and Th17 cells that are potentially involved in the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. This review aims to reveal the role of immune Semas in the pathogenesis of MS and its animal model, experimental autoimmune encephalomyelitis, focusing on the therapeutic usages of these molecules to treat this neurodegenerative disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756227&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3&quot;&gt;33756227&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.intimp.2021.107556&gt;10.1016&#x2F;j.intimp.2021.107556&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756227&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":716,"discovery_date":"2021-03-24T06:04:38","title":"Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 23:awab132. doi: 10.1093&#x2F;brain&#x2F;awab132. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Although multiple sclerosis (MS) has traditionally been considered a white matter disease, extensive research documents the presence and importance of gray matter injury including cortical and deep regions. The deep gray matter (DGM) exhibits a broad range of pathology and is uniquely suited to study the mechanisms and clinical relevance of tissue injury in MS using magnetic resonance techniques. DGM injury has been associated with clinical and cognitive disability. Recently, MRI characterization of DGM properties, such as thalamic volume, have been tested as potential clinical trial endpoints associated with neurodegenerative aspects of MS. Given this emerging area of interest and its potential clinical trial relevance, the North American Imaging in MS (NAIMS) Cooperative held a workshop and reached consensus on imaging topics related to the DGM. Herein, we review current knowledge regarding DGM injury in MS from an imaging perspective, including insights from histopathology, image acquisition and post-processing for DGM. We discuss the clinical relevance of DGM injury and specific regions of interest within the DGM. We highlight unanswered questions and propose future directions, with the aim of focusing research priorities towards better methods, analysis, and interpretation of results.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757115&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3&quot;&gt;33757115&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab132&gt;10.1093&#x2F;brain&#x2F;awab132&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757115&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":715,"discovery_date":"2021-03-24T06:04:38","title":"Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 10;51:102888. doi: 10.1016&#x2F;j.msard.2021.102888. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Serotonin (5-hydroxytryptamine) (5-HT) is a neurotransmitter, which mediates neuropsychological functions of the central nervous system (CNS). Recent studies have shown the modulatory effect of 5-HT on gut microbiota functions, which play an essential role in developing CNS inflammatory diseases. Finally, 5-HT is a direct mediator of neuroimmune interaction. The article reviews the literature data on the role of 5-HT in the regulation of neuroinflammation in multiple sclerosis (MS). The influence of 5-HT and selective serotonin reuptake inhibitors (SSRIs) on experimental autoimmune encephalomyelitis (EAE) and MS pathogenesis, as well as the therapeutic potential of serotoninergic drugs as a pathogenetic therapy of MS, are discussed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756440&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3&quot;&gt;33756440&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102888&gt;10.1016&#x2F;j.msard.2021.102888&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756440&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":714,"discovery_date":"2021-03-24T06:04:38","title":"Behcet&#39;s Disease Is Associated with Multiple Sclerosis and Rheumatoid Arthritis: A Korean Population-Based Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Dermatology. 2021 Mar 23:1-6. doi: 10.1159&#x2F;000514634. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: No epidemiologic study has previously reported on the associations among BehÃ§et&#39;s disease (BD) and autoimmune disorders.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To investigate the association between BD and the autoimmune disorders multiple sclerosis and rheumatoid arthritis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Medical records of patients newly diagnosed with BD (n &#x3D; 6,214) in 2012-2017 were analyzed using data entered into a large, nationwide database from 2007 to 2017. An age- and sex-matched control population of individuals without BD was sampled at a ratio of controls:BD cases of 3:1 (n &#x3D; 18,642). Both cohorts were analyzed for the presence of multiple sclerosis or rheumatoid arthritis within a minimum of 5 years prior to their BD diagnosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Patients with BD had significantly higher odds ratios (ORs) for multiple sclerosis (8.85 [95% CI 2.36-33.17]) and rheumatoid arthritis (4.62 [95% CI 3.35-6.35]) than the control group after adjustment for diabetes mellitus, hypertension, and dyslipidemia. BD patients aged &amp;lt;40 years had a higher proportion of rheumatoid arthritis (OR 23.91, 95% CI 5.50-103.9) than older patients (OR 3.96, 95% CI 2.83-5.54).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our results suggest that BD is associated with multiple sclerosis and rheumatoid arthritis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756455&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3&quot;&gt;33756455&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000514634&gt;10.1159&#x2F;000514634&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756455&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":713,"discovery_date":"2021-03-24T06:04:38","title":"The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Mar 8;354:577544. doi: 10.1016&#x2F;j.jneuroim.2021.577544. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The antioxidant MnTBAP was previously shown to down-regulate the surface expression of CD4 molecule in T cells. This observation obviously holds great potential impact in a number of pathological human conditions, including autoimmunity. Three different single doses of MnTBAP reduced the frequency of CD4&lt;sup&gt;high&lt;&#x2F;sup&gt; cells. However, when median florescent intensity (MFI) levels were not different. Initiation of in vivo pharmacotherapy or vehicle control was performed inC57BL&#x2F;6 mice that were actively immunized for experimental autoimmune encephalomyelitis (EAE). In contrast to published reports, the mean frequency of CD4&lt;sup&gt;high&lt;&#x2F;sup&gt; cells, and the median fluorescent intensity (MFI) of CD4 was similar in both treatment groups. 25-day survival following active immunization among the MnTBAP treated animals compared to vehicle controls was16.6 Â± 6.9 days vs 23.6 Â± 2.7 days; (P value &amp;lt;0.05). We conclude that MnTBAP (Sack and Herzog, 2009 (Sack and Herzog, 2009)) does not effectively downregulate CD4 expression in T cells in vivo, probably due to extensive mechanism that distinguishes it from an in vitro model (Harding, 1993 (Harding, 1993)) possesses toxic properties that may limit its clinic use in possible doses that could deliver the immunomodulation through down regulation of CD4 expression, and (Saizawa et al., 1987 (Saizawa et al., 1987)) has limited availability in specific tissues, including the CNS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756414&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3&quot;&gt;33756414&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577544&gt;10.1016&#x2F;j.jneuroim.2021.577544&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33756414&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":712,"discovery_date":"2021-03-24T06:04:38","title":"TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 23:awab127. doi: 10.1093&#x2F;brain&#x2F;awab127. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Progressive multifocal leukoencephalopathy (PML) is a severe infection of the central nervous system caused by the polyomavirus JC (JCV) that can occur in multiple sclerosis (MS) patients treated with natalizumab. Clinical management of patients with natalizumab-associated PML is challenging not the least because current imaging tools for the early detection, longitudinal monitoring and differential diagnosis of PML lesions are limited. Here we evaluate whether TSPO positron emission tomography (PET) imaging can be applied to monitor the inflammatory activity of PML lesions over time and differentiate them from MS lesions. For this monocenter pilot study we followed 8 patients with natalizumab-associated PML with PET imaging using the TSPO radioligand [18F]GE-180 combined with frequent 3 T MRI imaging. In addition we compared TSPO PET signals in PML lesions with the signal pattern of MS lesions from 17 independent MS patients. We evaluated the standardized uptake value ratio (SUVR) as well as the morphometry of the TSPO uptake for putative PML and MS lesions areas compared to a radiologically unaffected pseudo-reference region in the cerebrum. Furthermore TSPO expression in situ was immunohistochemically verified by determining the density and cellular identity of TSPO-expressing cells in brain sections from four patients with early natalizumab-associated PML as well as five patients with other forms of PML and six patients with inflammatory demyelinating CNS lesions (clinically isolated syndrome&#x2F;MS). Histological analysis revealed a reticular accumulation of TSPO expressing phagocytes in PML lesions, while such phagocytes showed a more homogenous distribution in putative MS lesions. TSPO PET imaging showed an enhanced tracer uptake in natalizumab-associated PML lesions that was present from the early to the chronic stages (up to 52 months after PML diagnosis). While gadolinium enhancement on MRI rapidly declined to baseline levels, TSPO tracer uptake followed a slow one phase decay curve. A TSPO-based 3-dimensional diagnostic matrix taking into account the uptake levels as well as the shape and texture of the TSPO signal differentiated more than 96% of PML and MS lesions. Indeed, treatment with rituximab after natalizumab-associated PML in three patients did not affect tracer uptake in the assigned PML lesions but reverted tracer uptake to baseline in the assigned active MS lesions. Taken together our study suggests that TSPO PET imaging can reveal CNS inflammation in natalizumab-associated PML. TSPO PET may facilitate longitudinal monitoring of disease activity and help to distinguish recurrent MS activity from PML progression.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757118&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3&quot;&gt;33757118&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab127&gt;10.1093&#x2F;brain&#x2F;awab127&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33757118&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210324020437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":711,"discovery_date":"2021-03-24T03:10:08","title":"Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state","summary":"Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening lung disease with increasing prevalence and incidence worldwide. Increasing evidence suggests that lung microbiomes might play a ...","link":"https:&#x2F;&#x2F;translational-medicine.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12967-021-02788-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":710,"discovery_date":"2021-03-24T00:15:08","title":"ATAV: a comprehensive platform for population-scale genomic analyses","summary":"A common approach for sequencing studies is to do joint-calling and store variants of all samples in a single file. If new samples are continually added or controls are re-used for several studies, the cost an...","link":"https:&#x2F;&#x2F;bmcbioinformatics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12859-021-04071-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":709,"discovery_date":"2021-03-24T00:15:08","title":"Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy","summary":"Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be ca...","link":"https:&#x2F;&#x2F;ijponline.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13052-021-01025-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":708,"discovery_date":"2021-03-23T19:24:39","title":"Bariatric and metabolic surgery in patients with morbid obesity and multiple sclerosis - a nationwide, matched cohort study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Surg Obes Relat Dis. 2021 Feb 17:S1550-7289(21)00095-2. doi: 10.1016&#x2F;j.soard.2021.02.013. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Despite an association between obesity and multiple sclerosis (MS), very little is known regarding the safety and efficacy outcomes for patients with MS and severe obesity undergoing metabolic surgery.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: The aim of the present study was to evaluate early complications and efficacy outcomes of metabolic surgery in patients with severe obesity and MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: Nationwide, Sweden.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this, matched cohort study, 196 patients with an MS diagnosis in the Swedish MS register who were undergoing metabolic surgery (gastric bypass or sleeve gastrectomy) with a registration in the Scandinavian Obesity Surgery Registry (SOReg) were matched 1:10 with a control group without MS diagnosis from the SOReg. A 2-stage matching procedure was used (exact match by surgical method, followed by propensity Score matching, including age, sex, preoperative BMI, surgical center, surgical access, year of surgery, hypertension, diabetes, sleep apnea, and dyslipidemia).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Weight loss at 2 years after surgery was similar for patients with MS and controls (total weight loss 31.6 Â± 9.1 versus 31.8 Â± 9.2, P &#x3D; .735). No significant differences were seen in either the overall postoperative complication rate (7.9% versus 7.2%, P &#x3D; .778), or serious postoperative complications (3.7% versus 2.8%, P &#x3D; .430). All aspects of health-related quality of life (HRQoL) improved in both groups but less so for the physical aspects of HRQoL in patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Metabolic surgery is a safe and efficient treatment for severe obesity in patients with MS, and it leads to subsequent improvements in HRQoL. Further studies addressing the effects of metabolic surgery on MS-related symptoms are needed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753006&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33753006&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.soard.2021.02.013&gt;10.1016&#x2F;j.soard.2021.02.013&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753006&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":707,"discovery_date":"2021-03-23T19:24:39","title":"The first Norwegian doctorate in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Tidsskr Nor Laegeforen. 2021 Mar 22;141(5). doi: 10.4045&#x2F;tidsskr.20.0993. Print 2021 Mar 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754679&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33754679&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.4045&#x2F;tidsskr.20.0993&gt;10.4045&#x2F;tidsskr.20.0993&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754679&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":706,"discovery_date":"2021-03-23T19:24:39","title":"A bioisostere of Dimebon&#x2F;Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;CNS Neurosci Ther. 2021 Mar 23. doi: 10.1111&#x2F;cns.13637. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: To assess effects of DF402, a bioisostere of Dimebon&#x2F;Latrepirdine, on the disease progression in the transgenic model of amyotrophic lateral sclerosis (ALS) caused by expression of pathogenic truncated form of human FUS protein.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Mice received DF402 from the age of 42 days and the onset of clinical signs, the disease duration and animal lifespan were monitored for experimental and control animals, and multiple parameters of their gait were assessed throughout the pre-symptomatic stage using CatWalk system followed by a bioinformatic analysis. RNA-seq was used to compare the spinal cord transcriptomes of wild-type, untreated, and DF402-treated FUS transgenic mice.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: DF402 delays the onset and slows the progression of pathology. We developed a CatWalk analysis protocol that allows detection of gait changes in FUS transgenic mice and the effect of DF402 on their gait already at early pre-symptomatic stage. At this stage, a limited number of genes significantly change expression in transgenic mice and for 60% of these genes, DF402 treatment causes the reversion of the expression pattern.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: DF402 slows down the disease progression in the mouse model of ALS, which is consistent with previously reported neuroprotective properties of Dimebon and its other bioisosteres. These results suggest that these structures can be considered as lead compounds for further optimization to obtain novel medicines that might be used as components of complex ALS therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754495&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33754495&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;cns.13637&gt;10.1111&#x2F;cns.13637&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754495&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":705,"discovery_date":"2021-03-23T19:24:39","title":"Effect of COVID-19 home confinement in people with multiple sclerosis: sleep and cardiac autonomic function monitorization","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Physiol Behav. 2021 Mar 19:113392. doi: 10.1016&#x2F;j.physbeh.2021.113392. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Low sleep quality, cardiac autonomic dysfunction and poor quality of life are some of the most prevalent symptoms in people with Multiple Sclerosis (MS). In addition to the progression of the disease, these symptoms are aggravated by physical inactivity. Therefore, home confinement due to COVID-19 pandemic restrictions could further worsen these symptoms. This study aims to analyze the effect of home confinement on objective and subjective sleep quality, cardiac autonomic control based on heart rate variability (HRV), and health-related quality of life in people with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Actigraphic and subjective sleep quality (Karolinska Sleep Diary, KSD), HRV (Polar-H7), and quality of life (Multiple Sclerosis Quality of Life-54) were measured before and after 2 months of home confinement in 17 people with MS (7:10 men&#x2F;women; age: 43.41Â±10.88 years; body mass index: 24.87Â±3.31 kg&#x2F;m&lt;sup&gt;2&lt;&#x2F;sup&gt;; Expanded Disability Status Scale: 2.85Â±1.34 a.u.).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Actigraphic sleep quality (sleep efficiency: ES&#x3D;1.27, p&#x3D;0.01, sleep time: ES&#x3D;0.81, p&#x3D;0.01) and subjective sleep quality (sleep quality: ES&#x3D;-0.34, p&#x3D;0.05), sleep comfort: ES&#x3D;0.60; p&#x3D;0.03, ease of falling asleep: ES&#x3D;0.70; p&#x3D;0.01, ease of waking up: ES&#x3D;0.87, p&amp;lt;0.01, and having enough sleep: ES&#x3D;0.87, p&amp;lt;0.01) significantly decreased after home confinement. No differences were observed in HRV or quality of life variables (pâ¥0.13).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Home confinement has worsened the sleep quality, but not in cardiac autonomic control or quality of life, in people with MS. These data highlight the importance of implementing home physical training programs in this population when situations similar to home confinement occur, thus minimizing the negative effects of physical inactivity and their associated comorbidities.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753090&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33753090&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.physbeh.2021.113392&gt;10.1016&#x2F;j.physbeh.2021.113392&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753090&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":704,"discovery_date":"2021-03-23T19:24:39","title":"A flow cytometric approach to study glucocorticoid receptor expression in immune cell subpopulations of genetically engineered mice","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Lett. 2021 Mar 19:S0165-2478(21)00048-1. doi: 10.1016&#x2F;j.imlet.2021.03.010. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Glucocorticoids (GCs) constitute one of the most powerful classes of anti-inflammatory agents and are used for the treatment of a plethora of diseases related to autoimmunity, allergy, cancer, and infection. In the last two decades, multiple studies using genetically engineered mice with targeted deletions of the GC receptor (GR) in individual cell types have provided insights into the mechanisms of GCs in the control of the immune system. The characterization of GR expression in these mouse models, however, mostly relied on the analysis of mRNA expression or reporter gene activity. In contrast, approaches directly detecting the GR protein on a cellular level are scarce. Thus, we here used a flow cytometric method to analyze mice in which the GR gene locus was disrupted with the help of a Cre recombinase expressed under the control of either the lck or the lysM promoter. Measuring GR protein expression in immune cell subpopulations unveiled an efficient and highly selective depletion in both strains of knock-out mice in accordance with the expected cellular specificity of the employed promoters for T cells or myeloid cells, respectively. The flow cytometric data were well in line with those from the analysis of GR mRNA expression in magnetically sorted immune cell subpopulations but they could be obtained much more quickly. In summary, our data indicate that flow cytometry is a powerful tool with which to define GR protein content at a single cell level when studying the function of GCs in the immune system.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753134&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33753134&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.imlet.2021.03.010&gt;10.1016&#x2F;j.imlet.2021.03.010&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753134&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":703,"discovery_date":"2021-03-23T19:24:39","title":"Recent advances on optic nerve magnetic resonance imaging and post-processing","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Magn Reson Imaging. 2021 Mar 19:S0730-725X(21)00046-1. doi: 10.1016&#x2F;j.mri.2021.03.014. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The optic nerve is known to be one of the largest nerve bundles in the human central nervous system. There have been many studies of optic nerve imaging and post-processing that have provided insights into pathophysiology of optic neuritis related to multiple sclerosis and neuromyelitis optica spectrum disorder, glaucoma, and Leber&#39;s hereditary optic neuropathy. There are many challenges in optic nerve imaging, due to the morphology of the nerve through its course to the optic chiasm, its mobility due to eye movements and the high signal from cerebrospinal fluid and orbital fat surrounding the optic nerve. Recently, many advanced and fast imaging sequences have been used with post-processing techniques in attempts to produce higher resolution images of the optic nerve for evaluating various diseases. Magnetic resonance imaging (MRI) is one of the most common imaging methodologies for the optic nerve. This review paper will focus on recent MRI advances in optic nerve imaging and explain several post-processing techniques being used for analysis of optic nerve images. Finally, some challenges and potential for future optic nerve studies will be discussed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753137&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33753137&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.mri.2021.03.014&gt;10.1016&#x2F;j.mri.2021.03.014&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753137&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":702,"discovery_date":"2021-03-23T19:24:39","title":"Post-partum relapse in women with multiple sclerosis after neuraxial labour analgesia or neuraxial anaesthesia: a multicentre retrospective cohort study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Anaesth Crit Care Pain Med. 2021 Mar 19:100834. doi: 10.1016&#x2F;j.accpm.2021.100834. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The proportion of women with multiple sclerosis experiencing a relapse in the post-partum period after neuraxial labour analgesia or neuraxial anaesthesia remains uncertain. This study aimed to assess the association between neuraxial labour analgesia or neuraxial anaesthesia and the occurrence of relapse during the first three months post-partum.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this retrospective cohort study, cases of women with a diagnosis of multiple sclerosis delivering between January 2010 and April 2015 were analysed. Demographic, anaesthetic and obstetric characteristics, occurrence and number of relapses in the year preceding pregnancy, during pregnancy, and the first three post-partum months, were recorded. Logistic regression analyses were performed for the identification of factors associated with the occurrence of post-partum relapse.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 118 deliveries in 104 parturients were included, these were 78 (66%) vaginal deliveries and 40 (34%) caesarean deliveries. Neuraxial analgesia was provided in 50 deliveries, and neuraxial anaesthesia in 46 deliveries; no neuraxial anaesthesia or analgesia was administered in remaining 22 deliveries. Post-partum relapse occurred in 31 women (26%). There was no association between obstetric or anaesthetic characteristics and post-partum relapse. Both the occurrence and number of relapses prior to and during pregnancy, and the time between last relapse and delivery, were significantly associated with post-partum relapse in univariate analysis. The occurrence of relapse within the year preceding the pregnancy was the sole independent factor associated with post-partum relapse.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Neuraxial procedures were not associated with increased rate of post-partum relapse; only disease activity prior to pregnancy was predictive of post-partum relapse.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753296&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33753296&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.accpm.2021.100834&gt;10.1016&#x2F;j.accpm.2021.100834&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753296&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":701,"discovery_date":"2021-03-23T19:24:39","title":"Effectiveness of Group Counseling with a Client-Centered Approach Based on the GATHER Principles on Sexual Satisfaction in Women with Multiple Sclerosis: A Randomized Clinical Trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Iran J Med Sci. 2021 Mar;46(2):103-111. doi: 10.30476&#x2F;ijms.2020.82616.1074.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is the most prevalent progressive sensory&#x2F;neurological disability in young adults, with important psychological consequences. The present study was designed to assess the effectiveness of group counseling with a client-centered approach based on the GATHER principles on sexual satisfaction in women with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this clinical trial, conducted from January 2018 to May 2019, in the MS Referral Center of Tehran (Iran), 72 eligible participants were assigned to intervention and control groups (36 in each group) via simple randomization. The intervention group received group counseling based on the client-centered approach, while the control group received routine counseling. Data were collected using the Larson Sexual Satisfaction Questionnaire (LSSQ) at three different time points: before the intervention, after the final session, and one month after the intervention. The collected data were analyzed in SPSS software (version 19). In order to analyze the obtained data, independent t test, Mann-Whitney U test, paired t test, Wilcoxon test, Chi-square test, Fisher exact test, and Friedman test were used.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The mean score of sexual satisfaction before the intervention showed no statistically significant difference between the two groups. Based on the Friedman test in the intervention group, the trend of changes in the mean score of sexual satisfaction had a significant difference before the intervention, after the final session, and one month after the intervention (P&#x3D;0.001); however, no significant difference was observed in the control group.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our results showed the effectiveness of group counseling with a client-centered approach based on the GATHER principles on sexual satisfaction and intimacy among women with MS. Trial Registration Number IRCT20180110038302N3.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33753954&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7966937&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;PMC7966937&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.30476&#x2F;ijms.2020.82616.1074&gt;10.30476&#x2F;ijms.2020.82616.1074&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33753954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":700,"discovery_date":"2021-03-23T19:24:39","title":"Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Stem Cells. 2021 Mar 22. doi: 10.1002&#x2F;stem.3374. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In the inflammatory demyelinating neurodegenerative disease multiple sclerosis (MS), there is increasing interest in gray matter pathology, as neuronal loss and cortical atrophy correlate with disability and disease progression, and MS therapeutics fail to significantly slow or stop neurodegeneration. Microglia, the central nervous system (CNS)-resident macrophages, are extensively involved in white matter MS pathology, but are also implicated in gray matter pathology, similarly to in other neurodegenerative diseases where there is synaptic, axonal, and neuronal degeneration. Microglia display regional heterogeneity within the CNS, which reflects their highly plastic nature and their ability to deliver context-dependent responses tailored to the demands of their microenvironment. Therefore, microglial roles in the MS gray matter in part reflect and in part diverge from those in the white matter. The present review summarizes current knowledge of microglial involvement in gray matter changes in MS, in demyelination, synaptic damage and neurodegeneration, with evidence implicating microglia in pathology, neuroprotection and repair. As our understanding of microglial physiology and pathophysiology increases, we describe how we are moving toward potential therapeutic applications in MS, harnessing microglia to protect and regenerate the CNS. Â© AlphaMed Press 2021 SIGNIFICANCE STATEMENT: Gray matter pathology in multiple sclerosis is of great current interest as recent advances in live brain imaging reveal that this is present from the earliest disease stages, and, unlike white matter pathology, is significantly correlated with disability. Microglia, resident immune cells of the brain, are the first line of defense, with heterogeneity of their responses depending on whether they reside in gray or white matter. Understanding microglial responses to gray matter-specific cues will shed light on multiple sclerosis pathological processes and guide therapeutic strategies targeting the gray matter for neuroprotection-an unmet need to avoid and treat disability.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754376&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33754376&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;stem.3374&gt;10.1002&#x2F;stem.3374&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754376&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":699,"discovery_date":"2021-03-23T19:24:39","title":"Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 23:13524585211002097. doi: 10.1177&#x2F;13524585211002097. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The central vein sign (CVS) and &quot;paramagnetic rim lesions&quot; (PRL) are emerging imaging biomarkers in multiple sclerosis (MS) reflecting perivenular demyelination and chronic, smoldering inflammation. The objective of this study was to assess relationships between cognitive impairment (CI) and the CVS and PRL in radiologically isolated syndrome (RIS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Twenty-seven adults with RIS underwent 3.0 T MRI of the brain and cervical spinal cord (SC) and cognitive assessment using the minimal assessment of cognitive function in MS battery. The CVS and PRL were assessed in white-matter lesions (WMLs) on T2*-weighted segmented echo-planar magnitude and phase images. Multivariable linear regression evaluated relationships between CI and MRI measures.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Global CI was present in 9 (33%) participants with processing speed and visual memory most frequently affected. Most participants (93%) had â©¾ 40% CVS + WML (a threshold distinguishing MS from other WM disorders); 63% demonstrated PRL. Linear regression revealed that CVS + WML predicted performance on verbal memory(&lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D;-0.024, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.03) while PRL predicted performance on verbal memory (&lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.040, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.04) and processing speed (&lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.039, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.03).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: CI is common in RIS and is associated with markers of perivenular demyelination and chronic inflammation in WML, such as CVS + WML and PRL. A prospective follow-up of this cohort will ascertain the importance of CI, CVS, and PRL as risk factors for conversion from RIS to MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3&quot;&gt;33754887&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211002097&gt;10.1177&#x2F;13524585211002097&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33754887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323152437&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":698,"discovery_date":"2021-03-23T18:25:09","title":"Relationship between neighborhood census-tract level socioeconomic status and respiratory syncytial virus-associated hospitalizations in U.S. adults, 2015â2017","summary":"Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality in children and adults. Socioeconomic status (SES) is known to influence many health outcomes, but there have been few stu...","link":"https:&#x2F;&#x2F;bmcinfectdis.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12879-021-05989-w","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":697,"discovery_date":"2021-03-23T15:51:35","title":"SGTA associates with intracellular aggregates in neurodegenerative diseases","summary":"Intracellular aggregates are a common pathological hallmark of neurodegenerative diseases such as polyglutamine (polyQ) diseases, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease (PD), and multiple sys...","link":"https:&#x2F;&#x2F;molecularbrain.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13041-021-00770-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":696,"discovery_date":"2021-03-23T11:36:05","title":"Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Elife. 2021 Mar 23;10:e65469. doi: 10.7554&#x2F;eLife.65469.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The inflammatory environment of demyelinated lesions in multiple sclerosis (MS) patients contributes to remyelination failure. Inflammation activates a cytoprotective pathway, the integrated stress response (ISR), but it remains unclear whether enhancing the ISR can improve remyelination in an inflammatory environment. To examine this possibility, the remyelination stage of experimental autoimmune encephalomyelitis (EAE), as well as a mouse model that incorporates cuprizone-induced demyelination along with CNS delivery of the proinflammatory cytokine IFN-Î³ were used here. We demonstrate that either genetic or pharmacological ISR enhancement significantly increased the number of remyelinating oligodendrocytes and remyelinated axons in the inflammatory lesions. Moreover, the combined treatment of the ISR modulator Sephin1 with the oligodendrocyte differentiation enhancing reagent bazedoxifene increased myelin thickness of remyelinated axons to pre-lesion levels. Taken together, our findings indicate that prolonging the ISR protects remyelinating oligodendrocytes and promotes remyelination in the presence of inflammation, suggesting that ISR enhancement may provide reparative benefit to MS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33752802&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323073603&amp;v&#x3D;2.14.3&quot;&gt;33752802&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7554&#x2F;eLife.65469&gt;10.7554&#x2F;eLife.65469&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33752802&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323073603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":695,"discovery_date":"2021-03-23T06:16:05","title":"The nature of genetic and environmental susceptibility to multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;PLoS One. 2021 Mar 22;16(3):e0246157. doi: 10.1371&#x2F;journal.pone.0246157. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To understand the nature of genetic and environmental susceptibility to multiple sclerosis (MS) and, by extension, susceptibility to other complex genetic diseases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Certain basic epidemiological parameters of MS (e.g., population-prevalence of MS, recurrence-risks for MS in siblings and twins, proportion of women among MS patients, and the time-dependent changes in the sex-ratio) are well-established. In addition, more than 233 genetic-loci have now been identified as being unequivocally MS-associated, including 32 loci within the major histocompatibility complex (MHC), and one locus on the X chromosome. Despite this recent explosion in genetic associations, however, the association of MS with the HLA-DRB1*15:01~HLA-DQB1*06:02~a1 (H+) haplotype has been known for decades.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN&#x2F;METHODS: We define the &quot;genetically-susceptible&quot; subset (G) to include everyone with any non-zero life-time chance of developing MS. Individuals who have no chance of developing MS, regardless of their environmental experiences, belong to the mutually exclusive &quot;non-susceptible&quot; subset (G-). Using these well-established epidemiological parameters, we analyze, mathematically, the implications that these observations have regarding the genetic-susceptibility to MS. In addition, we use the sex-ratio change (observed over a 35-year interval in Canada), to derive the relationship between MS-probability and an increasing likelihood of a sufficient environmental exposure.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We demonstrate that genetic-susceptibitly is confined to less than 7.3% of populations throughout Europe and North America. Consequently, more than 92.7% of individuals in these populations have no chance whatsoever of developing MS, regardless of their environmental experiences. Even among carriers of the HLA-DRB1*15:01~HLA-DQB1*06:02~a1 haplotype, far fewer than 32% can possibly be members the (G) subset. Also, despite the current preponderance of women among MS patients, women are less likely to be in the susceptible (G) subset and have a higher environmental threshold for developing MS compared to men. Nevertheless, the penetrance of MS in susceptible women is considerably greater than it is in men. Moreover, the response-curves for MS-probability in susceptible individuals increases with an increasing likelihood of a sufficient environmental exposure, especially among women. However, these environmental response-curves plateau at under 50% for women and at a significantly lower level for men.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The pathogenesis of MS requires both a genetic predisposition and a suitable environmental exposure. Nevertheless, genetic-susceptibility is rare in the population (&amp;lt; 7.3%) and requires specific combinations of non-additive genetic risk-factors. For example, only a minority of carriers of the HLA-DRB1*15:01~HLA-DQB1*06:02~a1 haplotype are even in the (G) subset and, thus, genetic-susceptibility to MS in these carriers must result from the combined effect this haplotype together with the effects of certain other (as yet, unidentified) genetic factors. By itself, this haplotype poses no MS-risk. By contrast, a sufficient environmental exposure (however many events are involved, whenever these events need to act, and whatever these events might be) is common, currently occurring in, at least, 76% of susceptible individuals. In addition, the fact that environmental response-curves plateau well below 50% (especially in men), indicates that disease pathogenesis is partly stochastic. By extension, other diseases, for which monozygotic-twin recurrence-risks greatly exceed the disease-prevalence (e.g., rheumatoid arthritis, diabetes, and celiac disease), must have a similar genetic basis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33750973&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3&quot;&gt;33750973&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1371&#x2F;journal.pone.0246157&gt;10.1371&#x2F;journal.pone.0246157&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33750973&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":694,"discovery_date":"2021-03-23T06:16:05","title":"Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Mol Life Sci. 2021 Mar 10. doi: 10.1007&#x2F;s00018-021-03802-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Oligodendrocyte precursor cells (OPCs) account for 5% of the resident parenchymal central nervous system glial cells. OPCs are not only a back-up for the loss of oligodendrocytes that occurs due to brain injury or inflammation-induced demyelination (remyelination) but are also pivotal in plastic processes such as learning and memory (adaptive myelination). OPC differentiation into mature myelinating oligodendrocytes is controlled by a complex transcriptional network and depends on high metabolic and mitochondrial demand. Mounting evidence shows that OPC dysfunction, culminating in the lack of OPC differentiation, mediates the progression of neurodegenerative disorders such as multiple sclerosis, Alzheimer&#39;s disease and Parkinson&#39;s disease. Importantly, neurodegeneration is characterised by oxidative and carbonyl stress, which may primarily affect OPC plasticity due to the high metabolic demand and a limited antioxidant capacity associated with this cell type. The underlying mechanisms of how oxidative&#x2F;carbonyl stress disrupt OPC differentiation remain enigmatic and a focus of current research efforts. This review proposes a role for oxidative&#x2F;carbonyl stress in interfering with the transcriptional and metabolic changes required for OPC differentiation. In particular, oligodendrocyte (epi)genetics, cellular defence and repair responses, mitochondrial signalling and respiration, and lipid metabolism represent key mechanisms how oxidative&#x2F;carbonyl stress may hamper OPC differentiation in neurodegenerative disorders. Understanding how oxidative&#x2F;carbonyl stress impacts OPC function may pave the way for future OPC-targeted treatment strategies in neurodegenerative disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751149&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3&quot;&gt;33751149&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00018-021-03802-0&gt;10.1007&#x2F;s00018-021-03802-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751149&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":693,"discovery_date":"2021-03-23T06:16:05","title":"Long-term fingolimod treatment in two pediatric patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 10. doi: 10.1007&#x2F;s10072-021-05116-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Data suggest that patients with pediatric-onset multiple sclerosis (POMS) should initiate treatment with a disease-modifying therapy early to slow progression. The PARADIGMS trial demonstrated that oral fingolimod reduced the annual rate of relapse by 82% compared with intramuscular interferon beta-1a in children with POMS. The PARADIGMS study had a follow-up of 2 years, but no data are available about the safety and efficacy of fingolimod for longer periods in children with POMS. Here we present two cases of children with POMS who achieved sustained clinical benefit from treatment with fingolimod for more than 2 years. The first patient, an 11-year-old male, who participate in the PARADIGMS study, was treatment naÃ¯ve at the time of fingolimod initiation. His clinical condition remained stable over 5 years of treatment, with no relapses and no radiological lesion progression. The second patient was a female who initiated fingolimod at the age of 12 years, 2 years after her POMS diagnosis and after an 8-month trial of interferon beta-1a. The patient had experienced two relapses during interferon beta-1a but had no relapses in more than 2 years of treatment with fingolimod, and her MRI scans showed no new or active lesions. These data show that prolonged treatment with fingolimod can be safe and effective during long-term treatment as first- or second-line therapy in children with POMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751260&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3&quot;&gt;33751260&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05116-2&gt;10.1007&#x2F;s10072-021-05116-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751260&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":692,"discovery_date":"2021-03-23T06:16:05","title":"Improving quality, affordability, and equity of multiple sclerosis care","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Mar 10. doi: 10.1002&#x2F;acn3.51326. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The prevailing approaches to selecting multiple sclerosis (MS) disease modifying therapies (DMTs) have contributed to exponential increases in societal expenditures and out-of-pocket expenses, without compelling evidence of improved outcomes. Guidance is lacking regarding when and in whom the benefits of preventing MS-related disability likely outweighs the risks of highly effective DMTs (HET) and when it is appropriate to consider DMT costs. Our objective was to develop a standardized approach to improve the quality, affordability and equity of MS care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: MS experts partnered with health plan pharmacists to develop an ethical, risk-stratified, cost-sensitive treatment algorithm. We developed a risk-stratification schema to classify patients with relapsing forms of MS as high, intermediate or low risk of disability based on the best available evidence and, when the evidence was poor or lacking, by consensus. DMTs are grouped as highly, modestly or low&#x2F;uncertain effectiveness and preferentially ranked within groups by safety based on pre-specified criteria. We reviewed FDA documents and the published literature. When efficacy and safety are equivalent, the lower cost DMT is preferred.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Assignment to the high-risk group prompts treatment with preferred HETs early in the disease course. For persons in the intermediate- or low-risk groups with cost or health care access barriers, we incorporated induction therapy with an affordable B-cell depleting agent. Based on more favorable safety profiles, our preferred approach prioritizes use of rituximab and natalizumab among HETs and interferon-betas or glatiramer acetate among modestly effective agents.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: The risk-stratified treatment approach we recommend provides clear, measurable guidance in whom and when to prescribe HETs, when to prioritize lower cost DMTs and how to accommodate persons with MS with cost or other barriers to DMT use. It can be adapted to other cost structures and updated quickly as new information emerges. We recommend that physician groups partner with health insurance plans to adapt our approach to their settings, particularly in the United States. Future studies are needed to resolve the considerable uncertainty about how much variability in prognosis specific risk factors explain.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751857&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3&quot;&gt;33751857&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51326&gt;10.1002&#x2F;acn3.51326&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751857&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":691,"discovery_date":"2021-03-23T06:16:05","title":"Investigation of the Less Known Effects of Manual Lymphatic Drainage: A Narrative Review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Lymphat Res Biol. 2021 Mar 22. doi: 10.1089&#x2F;lrb.2019.0091. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;&lt;i&gt;Introduction:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, which is accepted as the gold standard in the treatment of lymphedema, is used for therapeutic purposes in many diseases. The most well-known feature of MLD is that it helps to reduce edema. In addition to reducing edema, MLD has many effects, such as increasing venous flow, reducing fatigue, and raising the pain threshold. To the best of our knowledge, there is no study examining the effects of MLD other than its effects on edema in detail. The aim of this study is to compile effects of MLD and to provide a better understanding of the effects of MLD. &lt;b&gt;&lt;i&gt;Methods:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; A literature search was conducted in Medline, Embase, and the Cochrane Library in July 2019, to identify different effects of MLD. The articles were chosen by, first, reading the abstract and subsequently data were analyzed by reading the entire text through full-text resources. To undertake the study, we have collected information published about different effects of MLD over the last 30 years (1989-2019). According to our results, 20 studies met inclusion criteria. &lt;b&gt;&lt;i&gt;Conclusions:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; This study suggests that MLD can be used in symptomatic treatment of various diseases (multiple sclerosis, Parkinson&#39;s disease) considering the effects of MLD on the systems.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751912&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3&quot;&gt;33751912&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1089&#x2F;lrb.2019.0091&gt;10.1089&#x2F;lrb.2019.0091&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33751912&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":690,"discovery_date":"2021-03-23T06:16:04","title":"High-b diffusivity of MS lesions in cervical spinal cord using ultrahigh-b DWI (UHb-DWI)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Mar 8;30:102610. doi: 10.1016&#x2F;j.nicl.2021.102610. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: The purpose of this study was to investigate UHb-rDWI signal in white matter tracts of the cervical spinal cord (CSC) and compare quantitative values between healthy control WM with both MS NAWM and MS WM lesions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: UHb-rDWI experiments were performed on (a) 7 MS patients with recently active or chronic lesions in CSC and on (b) 7 healthy control of similar age range and gender distribution to MS subjects. All MRI data were acquired using clinical 3T MRI system. Axial high-b diffusion images were acquired using 2D single-shot DW stimulated EPI with reduced FOV and a CSC-dedicated 8 channel array coil. High-b diffusion coefficient D&lt;sub&gt;H&lt;&#x2F;sub&gt; was estimated by fitting the signal-b curve to a double or single-exponential function.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The high-b diffusivity D&lt;sub&gt;H&lt;&#x2F;sub&gt; values were measured as (0.767 Â± 0.297) Ã 10&lt;sup&gt;-3&lt;&#x2F;sup&gt; mm&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x2F;s in the posterior column lesions, averaged over 6 MS patients, and 0.587 Ã 10&lt;sup&gt;-3&lt;&#x2F;sup&gt; mm&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x2F;s in the corticospinal tract for another patient. The averaged D&lt;sub&gt;H&lt;&#x2F;sub&gt; values of the 7 healthy volunteers from the posterior and lateral column were (0.0312 Â± 0.0306) Ã 10&lt;sup&gt;-3&lt;&#x2F;sup&gt; and (0.0505 Â± 0.0205) Ã 10&lt;sup&gt;-3&lt;&#x2F;sup&gt; mm&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x2F;s, respectively. UHb-rDWI signal-b curves of the MS patients revealed to noticeably behave differently to that of the healthy controls. The patient signal-b curves decayed with greater high-b decay constants to reach lower signal intensities relative to signal-b curves of the healthy controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: UHb-DWI of the CSC reveals a marked difference in signal-b-curves and D&lt;sub&gt;H&lt;&#x2F;sub&gt; values in MS lesions compared to NAWM and healthy control WM. Based on physical principles, we interpret these altered observations of quantitative diffusion values to be indicative of demyelination. Further studies in animal models will be required to fully interpret UHb-DWI quantitative diffusion values during demyelination and remyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33752076&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3&quot;&gt;33752076&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nicl.2021.102610&gt;10.1016&#x2F;j.nicl.2021.102610&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33752076&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210323021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":689,"discovery_date":"2021-03-22T23:36:05","title":"Childhood obesity and multiple sclerosis: A Mendelian randomization study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177&#x2F;13524585211001781. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Higher childhood body mass index (BMI) has been associated with an increased risk of multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To evaluate whether childhood BMI has a causal influence on MS, and whether this putative effect is independent from early adult obesity and pubertal timing.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We performed Mendelian randomization (MR) using summary genetic data on 14,802 MS cases and 26,703 controls. Large-scale genome-wide association studies provided estimates for BMI in childhood (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 47,541) and adulthood (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 322,154). In multivariable MR, we examined the direct effects of each timepoint and further adjusted for age at puberty. Findings were replicated using the UK Biobank (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 453,169).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Higher genetically predicted childhood BMI was associated with increased odds of MS (odds ratio (OR) &#x3D; 1.26&#x2F;SD BMI increase, 95% confidence interval (CI): 1.07-1.50). However, there was little evidence of a direct effect after adjusting for adult BMI (OR &#x3D; 1.03, 95% CI: 0.70-1.53). Conversely, the effect of adult BMI persisted independent of childhood BMI (OR &#x3D; 1.43; 95% CI: 1.01-2.03). The addition of age at puberty did not alter the findings. UK Biobank analyses showed consistent results. Sensitivity analyses provided no evidence of pleiotropy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Genetic evidence supports an association between childhood obesity and MS susceptibility, mediated by persistence of obesity into early adulthood but independent of pubertal timing.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749377&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33749377&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211001781&gt;10.1177&#x2F;13524585211001781&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749377&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":688,"discovery_date":"2021-03-22T23:36:04","title":"Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries and case reports","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Expert Rev Neurother. 2021 Mar 22. doi: 10.1080&#x2F;14737175.2021.1904896. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: : Nabiximols oromucosal spray, a cannabis-based medicine containing a balanced ratio of Î-9-tetrahydrocannabinol and cannabidiol, is approved widely as add-on therapy for symptomatic relief of spasticity in persons with multiple sclerosis (MS). Most safety data for nabiximols derive from its use in MS spasticity, with some data available from the analgesia area.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AREAS COVERED: : This review compiles safety and tolerability data from all published observational studies, registry analyses and case reports identified in systematic searches in which nabiximols oromucosal spray was investigated for spasticity (n &#x3D; 20) and&#x2F;or chronic non-cancer pain (n &#x3D; 4). Aligning with the known safety profile of nabiximols as demonstrated in randomised controlled trials, common adverse events reported consistently across studies conducted under clinical practice conditions were dizziness, fatigue and somnolence. The serious adverse events (SAE) rate with nabiximols in observational studies of MS spasticity was 3.1% (137&#x2F;4351). A total of 39 treatment-related SAEs were reported in 32 patients with spasticity, all of which (where specified) were resolved. No treatment-related SAEs were recorded in studies of patients receiving nabiximols for pain.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;EXPERT OPINION: : Real-world experience with nabiximols oromucosal spray in treating spasticity and chronic pain indicates that, overall, it is well tolerated and has a good safety profile.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749480&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33749480&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;14737175.2021.1904896&gt;10.1080&#x2F;14737175.2021.1904896&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749480&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":687,"discovery_date":"2021-03-22T23:36:04","title":"Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the gray-white matter junction correlates with iron-enriched macrophages","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 22:1352458521999651. doi: 10.1177&#x2F;1352458521999651. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Describe magnetic resonance imaging (MRI) susceptibility changes in progressive multifocal leukoencephalopathy (PML) and identify neuropathological correlates.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: PML cases and matched controls with primary central nervous system lymphoma (PCNSL) were retrospectively identified. MRI brain at 3 T and 7 T were reviewed. MRI-pathology correlations in fixed brain autopsy tissue were conducted in three subjects with confirmed PML.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: With PML (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 26 total, &lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 5 multiple sclerosis natalizumab-associated), juxtacortical changes on susceptibility-weighted imaging (SWI) or gradient echo (GRE) sequences were noted in 3&#x2F;3 cases on 7 T MRI and 14&#x2F;22 cases (63.6%) on 1.5 T or 8&#x2F;22 (36.4%) 3 T MRI. Similar findings were only noted in 3&#x2F;25 (12.0%) of PCNSL patients (odds ratio (OR) 12.83, 95% confidence interval (CI), 2.9-56.7, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001) on 1.5 or 3 T MRI. On susceptibility sequences available prior to diagnosis of PML, 7 (87.5%) had changes present on average 2.7 Â± 1.8 months (mean Â± SD) prior to diagnosis. Postmortem 7 T MRI showed SWI changes corresponded to areas of increased iron density along the gray-white matter (GM-WM) junction predominantly in macrophages.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Susceptibility changes in PML along the GM-WM junction can precede noticeable fluid-attenuated inversion recovery (FLAIR) changes and correlates with iron accumulation in macrophages.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749379&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33749379&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521999651&gt;10.1177&#x2F;1352458521999651&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749379&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":686,"discovery_date":"2021-03-22T23:36:04","title":"Cognition in acute relapses: A psychometric evaluation and its correlation with event-related potential, P300 in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Appl Neuropsychol Adult. 2021 Mar 21:1-10. doi: 10.1080&#x2F;23279095.2021.1897815. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: During acute relapses of multiple sclerosis (MS), physical symptoms attract utmost care. However, cognitive impairment may constitute an substantial part of a new relapse. In this study, we evaluated the cognitive status of MS patients during acute relapses.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIALS AND METHODS: We enrolled 35 definite MS patients and 21 healthy subjects. Neuropsychometric tests and the event-related potential, P300 were administered to the MS patients before corticosteroid treatment, and 3 months later. The control subjects were tested only once.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The differences between the scores of the Timed 25-Foot Walk test, the Brief Repeatable Battery subtests (10&#x2F;36 SPART, SDMT, SRT, SRT-LTM) in the relapse and remission phases were statistically significant (&lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; .005, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; .007, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; .05, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; .029, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; .001, respectively). The latencies of P300 waves during the relapses were significantly prolonged than the ones in the remission and the controls&#39; (&lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; .004, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; .001, respectively).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: In this study, we observed a significant involvement of visual-spatial perception, remote memory, and recall, as well as P300 latencies in acute relapses. The inclusion of cognitive assessment during a relapse can provide accurate information on cognitive status for future treatment modalities.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749422&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33749422&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;23279095.2021.1897815&gt;10.1080&#x2F;23279095.2021.1897815&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749422&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":685,"discovery_date":"2021-03-22T23:36:04","title":"Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177&#x2F;13524585211001780. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Myelin water imaging (MWI) was recently optimized to provide quantitative in vivo measurement of spinal cord myelin, which is critically involved in multiple sclerosis (MS) disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess cervical cord myelin measurements in relapsing-remitting multiple sclerosis (RRMS) and progressive multiple sclerosis (ProgMS) participants and evaluate the correlation between myelin measures and clinical disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We used MWI data from 35 RRMS, 30 ProgMS, and 28 healthy control (HC) participants collected at cord level C2&#x2F;C3 on a 3 T magnetic resonance imaging (MRI) scanner. Myelin heterogeneity index (MHI), a measurement of myelin variability, was calculated for whole cervical cord, global white matter, dorsal column, lateral and ventral funiculi. Correlations were assessed between MHI and Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9HPT), timed 25-foot walk, and disease duration.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In various regions of the cervical cord, ProgMS MHI was higher compared to HC (between 9.5% and 31%, &lt;i&gt;p&lt;&#x2F;i&gt; â©½ 0.04) and RRMS (between 13% and 26%, &lt;i&gt;p&lt;&#x2F;i&gt; â©½ 0.02), and ProgMS MHI was associated with EDSS (&lt;i&gt;r&lt;&#x2F;i&gt; &#x3D; 0.42-0.52) and 9HPT (&lt;i&gt;r&lt;&#x2F;i&gt; &#x3D; 0.45-0.52).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Myelin abnormalities within clinically eloquent areas are related to clinical disability. MWI metrics have a potential role for monitoring subclinical disease progression and adjudicating treatment efficacy for new therapies targeting ProgMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749378&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33749378&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211001780&gt;10.1177&#x2F;13524585211001780&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749378&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":684,"discovery_date":"2021-03-22T23:36:04","title":"Usability of a Fall Risk mHealth App for People With Multiple Sclerosis: Mixed Methods Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;JMIR Hum Factors. 2021 Mar 22;8(1):e25604. doi: 10.2196&#x2F;25604.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a chronic, neurodegenerative disease that causes a range of motor, sensory, and cognitive symptoms. Due to these symptoms, people with MS are at a high risk for falls, fall-related injuries, and reductions in quality of life. There is no cure for MS, and managing symptoms and disease progression is important to maintain a high quality of life. Mobile health (mHealth) apps are commonly used by people with MS to help manage their health. However, there are limited health apps for people with MS designed to evaluate fall risk. A fall risk app can increase access to fall risk assessments and improve self-management. When designing mHealth apps, a user-centered approach is critical for improving use and adoption.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The purpose of this study is to undergo a user-centered approach to test and refine the usability of the app through an iterative design process.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The fall risk app Steady-MS is an extension of Steady, a fall risk app for older adults. Steady-MS consists of 2 components: a 25-item questionnaire about demographics and MS symptoms and 5 standing balance tasks. Data from the questionnaire and balance tasks were inputted into an algorithm to compute a fall risk score. Two iterations of semistructured interviews (n&#x3D;5 participants per iteration) were performed to evaluate usability. People with MS used Steady-MS on a smartphone, thinking out loud. Interviews were recorded, transcribed, and developed into codes and themes. People with MS also completed the System Usability Scale.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 3 themes were identified: intuitive navigation, efficiency of use, and perceived value. Overall, the participants found Steady-MS efficient to use and useful to learn their fall risk score. There were challenges related to cognitive overload during the balance tasks. Modifications were made, and after the second iteration, people with MS reported that the app was intuitive and efficient. Average System Usability Scale scores were 95.5 in both iterations, representing excellent usability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Steady-MS is the first mHealth app for people with MS to assess their overall risk of falling and is usable by a subset of people with MS. People with MS found Steady-MS to be usable and useful for understanding their risk of falling. When developing future mHealth apps for people with MS, it is important to prevent cognitive overload through simple and clear instructions and present scores that are understood and interpreted correctly through visuals and text. These findings underscore the importance of user-centered design and provide a foundation for the future development of tools to assess and prevent scalable falls for people with MS. Future steps include understanding the validity of the fall risk algorithm and evaluating the clinical utility of the app.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33749609&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2196&#x2F;25604&gt;10.2196&#x2F;25604&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33749609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":683,"discovery_date":"2021-03-22T23:36:04","title":"Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Rheum Dis. 2021 Mar 22. doi: 10.1111&#x2F;1756-185X.14103. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIM: Systemic sclerosis (SSc) is a chronic autoimmune disease resulting in vasculopathy and fibrosis of the skin and major internal organs. Especially, interstitial lung disease and pulmonary arterial hypertension are the leading causes of mortality. C-C motif ligand 20 (CCL20) is known as a homeostatic and inflammatory chemokine, which is associated with fibrosis and angiogenesis and constantly expressed in organs involved in SSc. Therefore, we investigated the potential contribution of CCL20 to the development of SSc.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: We conducted cross-sectional analyses of 67 SSc patients and 20 healthy controls recruited in a single center for 9 years. Serum CCL20 levels were measured by enzyme-linked immunosorbent assay. Statistical analyses were performed with the Mann-Whitney U test, the Kruskal-Wallis test followed by Dunn&#39;s multiple comparison test, Fisher&#39;s exact probability test and the Spearman&#39;s rank correlation coefficient.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: SSc patients had significantly higher serum CCL20 levels than healthy controls. In SSc patients, serum CCL20 levels correlated inversely with the percentage of predicated diffusion lung capacity for carbon monoxide and positively with mean pulmonary artery pressure (mPAP). In addition, SSc patients with increased serum CCL20 levels had anti-mitochondrial antibody M2 titer significantly elevated relative to those with normal levels, and SSc patients with asymptomatic primary biliary cholangitis (PBC) possessed higher serum CCL20 levels than those without. Importantly, serum CCL20 levels were associated positively with mPAP values and PBC presence by multivariate regression analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Serum CCL20 levels may be involved in the development of pulmonary vascular involvement leading to pulmonary arterial hypertension and asymptomatic PBC in SSc patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33750014&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3&quot;&gt;33750014&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;1756-185X.14103&gt;10.1111&#x2F;1756-185X.14103&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33750014&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":682,"discovery_date":"2021-03-22T19:26:34","title":"CytoGLMM: conditional differential analysis for flow and mass cytometry experiments","summary":"Flow and mass cytometry are important modern immunology tools for measuring expression levels of multiple proteins on single cells. The goal is to better understand the mechanisms of responses on a single cell...","link":"https:&#x2F;&#x2F;bmcbioinformatics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12859-021-04067-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":681,"discovery_date":"2021-03-22T19:26:34","title":"Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report","summary":"A significant portion of critically ill patients with coronavirus disease 2019 (COVID-19) are at high risk of developing intensive care unit (ICU)-acquired swallowing dysfunction (neurogenic dysphagia) as a co...","link":"https:&#x2F;&#x2F;jmedicalcasereports.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13256-021-02763-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":680,"discovery_date":"2021-03-22T18:16:05","title":"Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 3;12:619135. doi: 10.3389&#x2F;fneur.2021.619135. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; Hypointense lesions on T1-weighted images have important clinical relevance in multiple sclerosis patients. Traditionally, spin-echo (SE) sequences are used to assess these lesions (termed black holes), but Fast Spoiled Gradient-Echo (FSPGR) sequences provide an excellent alternative. &lt;b&gt;Objective:&lt;&#x2F;b&gt; To determine whether the contrast difference between T1 hypointense lesions and the surrounding normal white matter is similar on the two sequences, whether different lesion types could be identified, and whether the clinical relevance of these lesions types are different. &lt;b&gt;Methods:&lt;&#x2F;b&gt; Seventy-nine multiple sclerosis patients&#39; lesions were manually segmented, then registered to T1 sequences. Median intensity values of lesions were identified on all sequences, then K-means clustering was applied to assess whether distinct clusters of lesions can be defined based on intensity values on SE, FSPGR, and FLAIR sequences. The standardized intensity of the lesions in each cluster was compared to the intensity of the normal appearing white matter in order to see if lesions stand out from the white matter on a given sequence. &lt;b&gt;Results:&lt;&#x2F;b&gt; 100% of lesions on FSPGR images and 69% on SE sequence in cluster #1 exceeded a standardized lesion distance of &lt;i&gt;Z&lt;&#x2F;i&gt; &#x3D; 2.3 (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.05). In cluster #2, 78.7% of lesions on FSPGR and only 17.7% of lesions on SE sequence were above this cutoff value, meaning that these lesions were not easily seen on SE images. Lesion count in the second cluster (lesions less identifiable on SE) significantly correlated with the Expanded Disability Status Scale (EDSS) (&lt;i&gt;R&lt;&#x2F;i&gt;: 0.30, &lt;i&gt;p&lt;&#x2F;i&gt; â¤ 0.006) and with disease duration (&lt;i&gt;R&lt;&#x2F;i&gt;: 0.33, &lt;i&gt;p&lt;&#x2F;i&gt; â¤ 0.002). &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; We showed that black holes can be separated into two distinct clusters based on their intensity values on various sequences, only one of which is related to clinical parameters. This emphasizes the joint role of FSPGR and SE sequences in the monitoring of MS patients and provides insight into the role of black holes in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746876&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33746876&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7966518&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7966518&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.619135&gt;10.3389&#x2F;fneur.2021.619135&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746876&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":679,"discovery_date":"2021-03-22T18:16:05","title":"Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 5;12:632917. doi: 10.3389&#x2F;fneur.2021.632917. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Only a few studies have evaluated the brain functional changes associated with disease-modifying therapies (DMTs) in multiple sclerosis (MS), though none used a composite measure of clinical and MRI outcomes to evaluate DMT-related brain functional connectivity (FC) measures predictive of short-term outcome. Therefore, we investigated the following: (1) baseline FC differences between patients who showed evidence of disease activity after a specific DMT and those who did not; (2) DMT-related effects on FC, and; (3) possible relationships between DMT-related FC changes and changes in performance. We used a previously analyzed dataset of 30 relapsing MS patients who underwent fingolimod treatment for 6 months and applied the &quot;no evidence of disease activity&quot; (NEDA-3) status as a clinical response indicator of treatment efficacy. Resting-state fMRI data were analyzed to obtain within- and between-network FC measures. After therapy, 14 patients achieved NEDA-3 status (hereinafter NEDA), while 16 did not (EDA). The two groups significantly differed at baseline, with the NEDA group having higher within-network FC in the anterior and posterior default mode, auditory, orbitofrontal, and right frontoparietal networks than the EDA. After therapy, NEDA showed significantly reduced within-network FC in the posterior default mode and left frontoparietal networks and increased between-network FC in the posterior default mode&#x2F;orbitofrontal networks; they also showed PASAT improvement, which was correlated with greater within-network FC decrease in the posterior default mode network and with greater between-network FC increase. No significant longitudinal FC changes were found in the EDA. Taken together, these findings suggest that NEDA status after fingolimod is related to higher within-network FC at baseline and to a consistent functional reorganization after therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33746887&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7973271&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7973271&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.632917&gt;10.3389&#x2F;fneur.2021.632917&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":678,"discovery_date":"2021-03-22T18:16:05","title":"Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Med (N Y). 2021 Mar 12;2(3):296-312.e8. doi: 10.1016&#x2F;j.medj.2021.01.006.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), can be suppressed in its early stages but eventually becomes clinically progressive and unresponsive to therapy. Here, we investigate whether the therapeutic resistance of progressive MS can be attributed to chronic immune cell accumulation behind the blood-brain barrier (BBB).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We systematically track CNS-homing immune cells in the peripheral blood of 31 MS patients and 31 matched healthy individuals in an integrated analysis of 497,705 single-cell transcriptomes and 355,433 surface protein profiles from 71 samples. Through spatial RNA sequencing, we localize these cells in &lt;i&gt;post mortem&lt;&#x2F;i&gt; brain tissue of 6 progressive MS patients contrasted against 4 control brains (20 samples, 85,000 spot transcriptomes).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;FINDINGS: We identify a specific pathogenic CD161+&#x2F;lymphotoxin beta (LTB)+ T cell population that resides in brains of progressive MS patients. Intriguingly, our data suggest that the colonization of the CNS by these T cells may begin earlier in the disease course, as they can be mobilized to the blood by usage of the integrin-blocking antibody natalizumab in relapsing-remitting MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: As a consequence, we lay the groundwork for a therapeutic strategy to deplete CNS-homing T cells before they can fuel treatment-resistant progression.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;FUNDING: This study was supported by funding from the University Medical Center Hamburg-Eppendorf, the Stifterverband fÃ¼r die Deutsche Wissenschaft, the OAK Foundation, Medical Research Council UK, and Wellcome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33748804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33748804&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7966680&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7966680&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.medj.2021.01.006&gt;10.1016&#x2F;j.medj.2021.01.006&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33748804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":677,"discovery_date":"2021-03-22T18:16:05","title":"RAFF-4, Magnetization Transfer and Diffusion Tensor MRI of Lysophosphatidylcholine Induced Demyelination and Remyelination in Rats","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurosci. 2021 Mar 4;15:625167. doi: 10.3389&#x2F;fnins.2021.625167. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Remyelination is a naturally occurring response to demyelination and has a central role in the pathophysiology of multiple sclerosis and traumatic brain injury. Recently we demonstrated that a novel MRI technique entitled Relaxation Along a Fictitious Field (RAFF) in the rotating frame of rank n (RAFFn) achieved exceptional sensitivity in detecting the demyelination processes induced by lysophosphatidylcholine (LPC) in rat brain. In the present work, our aim was to test whether RAFF4, along with magnetization transfer (MT) and diffusion tensor imaging (DTI), would be capable of detecting the changes in the myelin content and microstructure caused by modifications of myelin sheets around axons or by gliosis during the remyelination phase after LPC-induced demyelination in the corpus callosum of rats. We collected MRI data with RAFF4, MT and DTI at 3 days after injection (demyelination stage) and at 38 days after injection (remyelination stage) of LPC (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 12) or vehicle (&lt;i&gt;n&lt;&#x2F;i&gt; &#x3D; 9). Cell density and myelin content were assessed by histology. All MRI metrics detected differences between LPC-injected and control groups of animals in the demyelination stage, on day 3. In the remyelination phase (day 38), RAFF4, MT parameters, fractional anisotropy, and axial diffusivity detected signs of a partial recovery consistent with the remyelination evident in histology. Radial diffusivity had undergone a further increase from day 3 to 38 and mean diffusivity revealed a complete recovery correlating with the histological assessment of cell density attributed to gliosis. The combination of RAFF4, MT and DTI has the potential to differentiate between normal, demyelinated and remyelinated axons and gliosis and thus it may be able to provide a more detailed assessment of white matter pathologies in several neurological diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746698&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33746698&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7969884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7969884&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fnins.2021.625167&gt;10.3389&#x2F;fnins.2021.625167&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746698&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":676,"discovery_date":"2021-03-22T18:16:05","title":"A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon Î²-1a","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Int. 2021 Mar 2;2021:6681431. doi: 10.1155&#x2F;2021&#x2F;6681431. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Few studies examine health-related quality of life (HRQoL) in Arabic-speaking multiple sclerosis (MS) patients. However, HRQoL tools such as the Short Form-36 QoL instrument (SF-36) and the Multiple Sclerosis International QoL (MusiQoL) questionnaire have been validated in other languages. The primary objective of this study was to prospectively assess HRQoL using the MusiQoL questionnaire among Arabic-speaking MS patients treated with subcutaneous interferon (sc IFN &lt;i&gt;Î²&lt;&#x2F;i&gt;-1a) over 12 months, as part of a prospective, multinational, multicenter cohort study. Patients&#39; clinical parameters and HRQoL were assessed at baseline, 6 months, and 12 months. Changes in MusiQoL total and subdomain scores were compared using a Friedman test. Correlation between MusiQoL total score and Expanded Disability Status Score (EDSS) was also evaluated. In total, 439 patients from four Arabic-speaking countries were included. The mean age was 32.44 (Â±0.34) years, 71.5% were female, and 63.1% had an education level of university or above. The mean MS duration was 4.13 (Â±0.12) years, mean age at first attack was 27.35 (Â±0.26) years, and mean baseline EDSS score was 2.05 (Â±0.04). MusiQoL total score significantly improved at 6 months; however, this diminished at 12 months (65.67 Â± 0.8 at baseline vs. 67.21 Â± 0.79 at 6 months and 65.75 Â± 0.8 at 12 months; &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.0015). Several aspects of patients&#39; HRQoL including activity of daily living, physical well-being, symptoms, and coping improved. Overall HRQoL measured using SF-36 remained generally unchanged over time (&lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.215). There was a statistically significant inverse relationship between change in EDSS score over time and change in overall MusiQoL score over time. In summary, findings confirm the utility of using MusiQoL for assessing changes in HRQoL during treatment with sc IFN &lt;i&gt;Î²&lt;&#x2F;i&gt;-1a in Arabic-speaking patients with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33747564&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33747564&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7943271&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7943271&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1155&#x2F;2021&#x2F;6681431&gt;10.1155&#x2F;2021&#x2F;6681431&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33747564&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":675,"discovery_date":"2021-03-22T18:16:04","title":"Predictive Metagenomic Analysis of Autoimmune Disease Identifies Robust Autoimmunity and Disease Specific Microbial Signatures","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Microbiol. 2021 Mar 4;12:621310. doi: 10.3389&#x2F;fmicb.2021.621310. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Within the last decade, numerous studies have demonstrated changes in the gut microbiome associated with specific autoimmune diseases. Due to differences in study design, data quality control, analysis and statistical methods, many results of these studies are inconsistent and incomparable. To better understand the relationship between the intestinal microbiome and autoimmunity, we have completed a comprehensive re-analysis of 42 studies focusing on the gut microbiome in 12 autoimmune diseases to identify a microbial signature predictive of multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and general autoimmune disease using both 16S rRNA sequencing data and shotgun metagenomics data. To do this, we used four machine learning algorithms, random forest, eXtreme Gradient Boosting (XGBoost), ridge regression, and support vector machine with radial kernel and recursive feature elimination to rank disease predictive taxa comparing disease vs. healthy participants and pairwise comparisons of each disease. Comparing the performance of these models, we found the two tree-based methods, XGBoost and random forest, most capable of handling sparse multidimensional data, to consistently produce the best results. Through this modeling, we identified a number of taxa consistently identified as dysregulated in a general autoimmune disease model including &lt;i&gt;Odoribacter, Lachnospiraceae Clostridium&lt;&#x2F;i&gt;, and &lt;i&gt;Mogibacteriaceae&lt;&#x2F;i&gt; implicating all as potential factors connecting the gut microbiome to autoimmune response. Further, we computed pairwise comparison models to identify disease specific taxa signatures highlighting a role for &lt;i&gt;Peptostreptococcaceae&lt;&#x2F;i&gt; and &lt;i&gt;Ruminococcaceae Gemmiger&lt;&#x2F;i&gt; in IBD and &lt;i&gt;Akkermansia, Butyricicoccus, and Mogibacteriaceae&lt;&#x2F;i&gt; in MS. We then connected a subset of these taxa with potential metabolic alterations based on metagenomic&#x2F;metabolomic correlation analysis, identifying 215 metabolites associated with autoimmunity-predictive taxa.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746917&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33746917&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7969817&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7969817&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fmicb.2021.621310&gt;10.3389&#x2F;fmicb.2021.621310&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33746917&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":674,"discovery_date":"2021-03-22T18:16:04","title":"Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ther Adv Neurol Disord. 2021 Mar 6;14:1756286421997372. doi: 10.1177&#x2F;1756286421997372. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND AIMS: Various attempts have been made to support recovery following optic neuritis (ON), but the respective trials have mostly been negative. The aim of this study was to determine whether disease-modifying treatment (DMT) following ON as first manifestation of relapsing-remitting multiple sclerosis influences long-term outcomes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A total of 79 patients with ON were identified and evaluated at relapse, DMT induction, and 12 months following treatment induction with either glatiramer acetate (GLAT), interferon-beta (IFN), or teriflunomide (TRF). Low-contrast letter acuity (LCLA) and full-field visual-evoked potentials (FF-VEP) were compared between treatment groups using multivariable regression models. The impact of TRF treatment induction compared with IFN or GLAT following relapses outside the optic nerves was evaluated in an independent cohort of 122 patients. Magnetic resonance imaging (MRI) outcomes and rates of confirmed improvement of relapse-related disability were evaluated.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: TRF-treated patients exhibited higher LCLA and lower relative P100 latencies normalized to the fellow-eye. Findings were significant following covariate-adjustment by multivariable analyses. Cranial MRI lesion load as well as disability progression rates were not significantly different between groups. The cohort of patients following relapses other than ON showed no differences in confirmed improvement of disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: TRF treatment is associated with favorable outcomes regarding functional optic nerve recovery following ON in early multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33747129&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33747129&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7940774&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;PMC7940774&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1756286421997372&gt;10.1177&#x2F;1756286421997372&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33747129&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":673,"discovery_date":"2021-03-22T18:16:04","title":"Socioeconomic consequences of multiple sclerosis-A systematic literature review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Neurol Scand. 2021 Mar 22. doi: 10.1111&#x2F;ane.13411. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a challenging and disabling condition, predominantly affecting individuals in their early life, and has an impact functionally, financially, and on quality of life. However, there is a lack of systematic approach towards assessing socioeconomic consequences of MS. Our objective was to systematically review observational analytical studies investigating the socioeconomic consequences of MS. We conducted a systematic review on socioeconomic consequences of MS with a focus on employment-, income-, work ability- and relationship-related outcomes between MS and the general population. Additionally, the educational characteristics were extracted. From 4958 studies identified, 187 were assessed for eligibility and a total of 27 studies from eight countries were included in this qualitative assessment; 32 different outcomes were identified. All studies indicated pronounced differences between MS patients and the general population, for example 15%-30% lower employment, lower earnings and higher social benefits, higher absenteeism and presenteeism proportions, higher work disability (eg, sick-leave days) among MS patients. Some studies also indicated differences in the family or relationship characteristics. There were no apparent differences with regard to educational level. In conclusion, socioeconomic data can serve as robust outcome measures to study various aspects of MS reflecting the broader consequences of the disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33748960&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3&quot;&gt;33748960&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ane.13411&gt;10.1111&#x2F;ane.13411&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33748960&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322141603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":672,"discovery_date":"2021-03-22T16:31:34","title":"Diet-induced obesity leads to behavioral indicators of pain preceding structural joint damage in wild-type mice","summary":"Obesity is one of the largest modifiable risk factors for the development of musculoskeletal diseases, including intervertebral disc (IVD) degeneration and back pain. Despite the clinical association, no studi...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02463-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":671,"discovery_date":"2021-03-22T13:36:34","title":"Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy","summary":"While the etiology remains elusive, macrophages and T cells in peripheral nerves are considered as effector cells mediating autoimmune peripheral neuropathy (APN), such as Guillain-Barre syndrome. By recognizi...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02126-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":670,"discovery_date":"2021-03-22T13:36:34","title":"The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy","summary":"Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) consists of various autoimmune subtypes in which the peripheral nervous system (PNS) is attacked. CIDP can follow a relapsing-remitting or progr...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02113-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":669,"discovery_date":"2021-03-22T06:16:05","title":"Sexuality and Multiple Sclerosis: Patient and Doctor Perspectives","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Sex Med. 2021 Mar 17:S1743-6095(21)00224-1. doi: 10.1016&#x2F;j.jsxm.2021.01.178. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Little is known on how to address sexuality in clinical care for patients with multiple sclerosis (pwMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIM: To describe and contrast the perception of sexuality and associated aspects of communication in pwMS and their treating neurologists (&quot;MSologists&quot;) and provide a standard of care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients were surveyed using a 13-item questionnaire investigating perception on their own sexuality and opinions on communication about sexuality in context with MS. Certified MSologists in Austria received an 18-item survey regarding their approach to taking a sexual history of their patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OUTCOMES: We report the frequency of answers given in this survey and propose a possible standard of care how sexuality could be addressed in clinical routine.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Ninety-three pwMS (mean age 39 Â± 11 years, 57% female) and 75 MSologists (mean age 43 Â± 9 years, 63% male) completed this survey. Seventy-six percent of patients report their own sexuality as being (very) important to them and 95% think that sexual dysfunction would influence their quality of life. 84% would like to be asked about their sexuality by their MSologist. In contrast, only 15% of MSologists reported discussing sexuality with every patient. The most common reason for not doing so was a fear of crossing personal borders (34%). There is a strong desire for further medical education on this subject (76%).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLINICAL IMPLICATIONS: Discussing sexuality is important to pwMS and MSologists should consider their patients&#39; wishes and needs to talk about it.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STRENGTHS &amp; LIMITATIONS: This is the largest survey contrasting the views of patients and their treating physicians on the topic of communication about sexuality. The use of an empirical unvalidated questionnaire may have introduced bias. Moreover, patients that are open to talk about their sexuality may be potentially overrepresented in this study.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: MSologists should offer their patients an open opportunity and appropriate framework to discuss their sexuality during a consultation. Altmann P, Leithner K, Leutmezer F, et al. Sexuality and Multiple Sclerosis: Patient and Doctor Perspectives. J Sex Med 2021;XX:XXX-XXX.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744180&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33744180&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jsxm.2021.01.178&gt;10.1016&#x2F;j.jsxm.2021.01.178&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744180&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":668,"discovery_date":"2021-03-22T06:16:05","title":"Recommendations for the coordination of Neurology and Neuroradiology Departments in the management of patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurologia. 2021 Mar 17:S0213-4853(21)00029-3. doi: 10.1016&#x2F;j.nrl.2021.01.012. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Magnetic resonance imaging (MRI) is widely used for the diagnosis and follow-up of patients with multiple sclerosis (MS). Coordination between Neurology and Neuroradiology departments is crucial for performing and interpreting radiological studies as efficiently and as accurately as possible. However, improvements can be made in the communication between these departments in many Spanish hospitals.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A panel of 17 neurologists and neuroradiologists from 8 Spanish hospitals held in-person and online meetings to draft a series of good practice guidelines for the coordinated management of MS. The drafting process included 4 phases: 1) establishing the scope of the guidelines and the methodology of the study; 2) literature review on good practices or recommendations on the use of MRI in MS; 3) discussion and consensus between experts; and 4) validation of the contents.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The expert panel agreed a total of 9 recommendations for improving coordination between neurology and neuroradiology departments. The recommendations revolve around 4 main pillars: 1) standardising the process for requesting and scheduling MRI studies and reports; 2) designing common protocols for MRI studies; 3) establishing multidisciplinary committees and coordination meetings; and 4) creating formal communication channels between both departments.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These consensus recommendations are intended to optimise coordination between neurologists and neuroradiologists, with the ultimate goal of improving the diagnosis and follow-up of patients with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744061&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33744061&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nrl.2021.01.012&gt;10.1016&#x2F;j.nrl.2021.01.012&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744061&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":667,"discovery_date":"2021-03-22T06:16:05","title":"Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Feb 24;30:102606. doi: 10.1016&#x2F;j.nicl.2021.102606. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple Sclerosis (MS) patients often suffer from significant cognitive impairment. Earlier research has shown relationships between regional cortical atrophy and cognitive deterioration. However, due to a large number of neuropsychological assessments and a heterogenous pattern of cognitive deficits in MS patients, reported associations patterns are also heterogenous. Using an extensive neuropsychological battery of 23 different tasks, we explored domain (attention&#x2F;information processing, memory, spatial processing, executive functioning) and task-specific associations with regional cortical thickness in a representative sample of MS patients (N &#x3D; 97). Cortical regions associated with multiple cognitive tasks in the left hemisphere were predominantly located in the inferior insula (attention p &amp;lt; 0.001, memory p &#x3D; 0.047, spatial processing p &#x3D; 0.004, executive functioning p &#x3D; 0.037), the gyrus frontalis superior (attention p &#x3D; 0.015, memory p &#x3D; 0.037, spatial processing p &#x3D; 0.033, executive functioning p &#x3D; 0.017) and temporal medial (attention p &amp;lt; 0.001, memory two clusters p &#x3D; 0.016 and p &amp;lt; 0.001, executive functioning p &#x3D; 0.016). In the right hemisphere, we detected the strongest association in the sulcus interparietalis with five cluster (attention SDMT p &#x3D; 0.003 and TAP_DA p &amp;lt; 0.001; memory Rey recall p &#x3D; 0.013 and VLMT verbal learning p &#x3D; 0.016; spatial processing Rey copy p &amp;lt; 0.001). We replicated parts of our results in an independent sample of 30 mildly disabled MS patients. Moreover, comparisons to 29 healthy controls showed that the regional associations seemed to represent rather pathophysiological dependency than a physiological one. We believe that our results may prove useful in diagnosis and rehabilitation of cognitive impairments and may serve as guidance in future magnetic resonance imaging (MRI) studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744503&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33744503&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nicl.2021.102606&gt;10.1016&#x2F;j.nicl.2021.102606&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744503&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":666,"discovery_date":"2021-03-22T06:16:05","title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 7;51:102886. doi: 10.1016&#x2F;j.msard.2021.102886. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion criteria to the registry were either: (1) a biologically confirmed COVID-19 diagnosis based on a positive result of a COVID-19 polymerase chain reaction (PCR) test on a nasopharyngeal swab; or (2) COVID-19-typical symptoms (triad of cough, fever, and asthenia) in an epidemic zone of COVID-19. Descriptive statistics were performed on demographic and clinical variables. The cohort was later stratified for MS and NMOSD and univariate and multivariate logistic regression analysis was performed to identify variables associated with hospitalizations&#x2F;intensive critical units (ICU) admission.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 145 patients were included in the registry from 15 countries and 51 treating physicians. A total of 129 (89%) were MS patients and 16 (11%) NMOSD. 81.4% patients had confirmed COVID-19 and 18.6% were suspected cases. 23 (15.8%) patients were hospitalized, 9 (6.2%) required ICU and 5 (3.4 %) died due to COVID-19. In MS patients, greater age (OR 1.17, 95% CI 1.05 - 1.25) and disease duration (OR 1.39, 95%CI 1.14-1.69) were associated with hospitalization&#x2F;ICU. In NMOSD patients, a greater age (54.3 vs. 36 years, p&#x3D;&amp;lt;0.001), increased EDSS (5.5 vs 2.9, p&#x3D;0.0012) and disease duration (18.5 vs. 10.3 years, p&#x3D;0.001) were significantly associated with hospitalization&#x2F;ICU.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: we found that in MS patients, age and disease duration was associated with hospitalization and ICU admission requirement, while age, disease duration and EDSS was associated in NMOSD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744758&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33744758&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102886&gt;10.1016&#x2F;j.msard.2021.102886&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744758&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":665,"discovery_date":"2021-03-22T06:16:05","title":"Staufen1 in human neurodegeneration","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Neurol. 2021 Mar 21. doi: 10.1002&#x2F;ana.26069. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Mutant expansions of DNA CAG â¥32 repeats in ATXN2 can be a rare cause of Parkinson disease and Amyotrophic lateral sclerosis (ALS). We recently reported that the stress granule (SG) protein Staufen1 (STAU1) was overabundant in neurodegenerative disorder SCA2 patient cells, animal models, and ALS-TDP-43 fibroblasts and provided a link between SG formation and autophagy. We aimed to test if STAU1 overabundance has role in the pathogenesis of other neurodegenerative diseases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: With multiple neurodegenerative patient-derived cell models, animal models, and human postmortem ALS tissue, we evaluate STAU1 function using biochemical and immunohistological analyses.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We demonstrate STAU1 overabundance and increased total and phosphorylated mammalian target of rapamycin (mTOR) in fibroblast cells from ALS patients with mutations in TDP-43, dementia patients with PSEN1 mutations, a parkinsonism patient with MAPT mutation, Huntington disease (HD) mutations, and SCA2 mutations. Increased STAU1 levels and mTOR activity were seen in human ALS spinal cord tissues as well as in animal models. Changes in STAU1 and mTOR protein levels were post-transcriptional. Exogenous expression of STAU1 in wildtype cells was sufficient to activate mTOR and downstream targets and form SGs. Targeting STAU1 by RNAi normalized mTOR, suggesting a potential role for therapy in diseases associated with STAU1 overabundance.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: STAU1 overabundance in neurodegeneration is a common phenomenon associated with hyperactive mTOR. Targeting STAU1 with ASOs or miRNA viral vectors may represent a novel, efficacious therapy for neurodegenerative diseases characterized by overabundant STAU1. This article is protected by copyright. All rights reserved.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33745139&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33745139&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;ana.26069&gt;10.1002&#x2F;ana.26069&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33745139&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":664,"discovery_date":"2021-03-22T06:16:05","title":"ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rheumatology (Oxford). 2021 Mar 21:keab278. doi: 10.1093&#x2F;rheumatology&#x2F;keab278. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In patients with systemic sclerosis (SSc), the coexistence of ANCA-associated vasculitis (SSc-AAV) has been reported to be associated with a severe disease course, including significant pulmonary and renal involvement. The presence of ANCA is not uncommon in patients with SSc and therefore clinicians must maintain a high index of clinical suspicion about SSc-AAV. p-ANCA and anti-MPO antibodies are the most common antibodies observed. Patients typically present with clinical features of microscopic polyangiitis or renal-limited vasculitis There are multiple areas of potential interaction in the pathogenesis of SSc and AAV which can exacerbate&#x2F;compound vascular disease. In addition, similar patterns of major internal organ involvement (e.g., lung and kidneys) are seen in both conditions. We highlight a diagnostic approach to SSc-AAV and the paucity of data to inform management. As such, SSc-AAV is typically treated as per isolated AAV which can potentially be hazardous in patients with SSc (e.g., the association between high-dose steroid and scleroderma renal crisis). We propose that this rare clinical entity warrants rigorous investigation including definition of a therapeutic strategy to ameliorate the potentially devastating combination of pathologies in SSc-AAV.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744916&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33744916&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;rheumatology&#x2F;keab278&gt;10.1093&#x2F;rheumatology&#x2F;keab278&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744916&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":663,"discovery_date":"2021-03-22T06:16:05","title":"The Potential Preventive Effect of Pregnancy and Breastfeeding on Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur Neurol. 2021 Mar 19:1-14. doi: 10.1159&#x2F;000514432. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an inflammatory demyelinating chronic neurological disease that affects the central nervous system of young adults and their quality of life. Several studies have investigated the effects of pregnancy and breastfeeding on MS. However, the evidence regarding the influence of pregnancy and breastfeeding on MS is still accumulating. This review aimed to summarize the current evidence regarding the effects of pregnancy and breastfeeding on MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: A systematic electronic literature search of the PubMed and Embase databases was conducted to determine relevant published articles. The eligible studies were summarized and evaluated in tables. Key Messages: The majority of the studies indicated that pregnancy appears to lower the rate of MS relapses, particularly in the third trimester. The evidence regarding the effect of breastfeeding on MS remains inconsistent. Despite reports of negative obstetric outcomes in some pregnant women with MS, pregnancies in women with MS should not be categorized as high-risk pregnancies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744881&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33744881&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000514432&gt;10.1159&#x2F;000514432&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33744881&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":662,"discovery_date":"2021-03-22T06:16:05","title":"Visual Dysfunction in Multiple Sclerosis and its Animal Model, Experimental Autoimmune Encephalomyelitis: a Review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Neurobiol. 2021 Mar 20. doi: 10.1007&#x2F;s12035-021-02355-4. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Visual disabilities in central nervous system autoimmune diseases such as multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are important symptoms. Past studies have focused on neuro-inflammatory changes and demyelination in the white matter of the brain and spinal cord. In MS, neuro-inflammatory lesions have been diagnosed in the visual pathway; the lesions may perturb visual function. Similarly, neuropathological changes in the retina and optic nerves have been found in animals with chronic EAE. Although the retina and optic nerves are immunologically privileged sites via the blood-retina barrier and blood-brain barrier, respectively, inflammation can occur via other routes, such as the uvea (e.g., iris and choroid) and cerebrospinal fluid in the meninges. This review primarily addresses the direct involvement of the blood-retina barrier and the blood-brain barrier in the development of retinitis and optic neuritis in EAE models. Additional routes, including pro-inflammatory mediator-filled choroidal and subarachnoid spaces, are also discussed with respect to their roles in EAE-induced visual disability and as analogues of MS in humans.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33745114&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33745114&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s12035-021-02355-4&gt;10.1007&#x2F;s12035-021-02355-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33745114&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":661,"discovery_date":"2021-03-22T06:16:05","title":"BMP&#x2F;TGF-Î² signaling as a modulator of neurodegeneration in ALS","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Dev Dyn. 2021 Mar 21. doi: 10.1002&#x2F;dvdy.333. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;This commentary focuses on the emerging intersection between BMP&#x2F;TGF-Î² signaling roles in nervous system function and the amyotrophic lateral sclerosis (ALS) disease state. Future research is critical to elucidate the molecular underpinnings of this intersection of the cellular processes disrupted in ALS and those influenced by BMP&#x2F;TGF-Î² signaling, including synapse structure, neurotransmission, plasticity, and neuroinflammation. Such knowledge promises to inform us of ideal entry points for the targeted modulation of dysfunctional cellular processes in an effort to abrogate ALS pathologies. It is likely that different interventions are required, either at discrete points in disease progression, or across multiple dysfunctional processes which together lead to motor neuron degeneration and death. We discuss the challenging, but intriguing idea that modulation of the pleiotropic nature of BMP&#x2F;TGF-Î² signaling could be advantageous, as a way to simultaneously treat defects in more than one cell process across different forms of ALS. This article is protected by copyright. All rights reserved.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33745185&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3&quot;&gt;33745185&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;dvdy.333&gt;10.1002&#x2F;dvdy.333&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33745185&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210322021603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":660,"discovery_date":"2021-03-21T14:16:34","title":"Clinical false positives resulting from recent intravenous immunoglobulin therapy: case report","summary":"Many clinicians are aware that certain therapies administered to their patients can have downstream consequences in the form of clinical laboratory test interferences. This is particularly true of laboratory t...","link":"https:&#x2F;&#x2F;bmcinfectdis.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12879-021-05986-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":659,"discovery_date":"2021-03-21T08:26:34","title":"Targeting chemokines for acute lymphoblastic leukemia therapy","summary":"Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cyt...","link":"https:&#x2F;&#x2F;jhoonline.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13045-021-01060-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":658,"discovery_date":"2021-03-21T05:31:34","title":"The catastrophic out-of-pocket health expenditure of multiple sclerosis patients in Iran","summary":"The present study was designed and conducted to evaluate multiple sclerosis (MS) treatment costs and the resulting economic impact imposed on MS patients in Iran.","link":"https:&#x2F;&#x2F;bmchealthservres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12913-021-06251-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":657,"discovery_date":"2021-03-20T23:36:05","title":"COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;CNS Drugs. 2021 Mar 20. doi: 10.1007&#x2F;s40263-021-00804-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed these risks in patients with MS (PwMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective of this study was to describe the overall risk of coronavirus disease 2019 (COVID-19) infection, severe disease course, and potential population-level predictors of COVID-19 infection in PwMS, and to provide a context using a cohort of patients with systemic lupus erythematosus (SLE). In addition, the association of different MS DMTs with the incidence and clinical course of COVID-19 was evaluated. Safety data from the Biogen Global Safety Database are also presented on reported cases of COVID-19 in patients treated with Biogen MS therapies.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The IBM&lt;sup&gt;Â®&lt;&#x2F;sup&gt; Explorys electronic health record database of &amp;gt; 72,000,000 patients from US healthcare networks identified patients with MS or SLE, with and without polymerase chain reaction-confirmed COVID-19. COVID-19 cumulative incidence, hospitalization, and deaths among DMT classes were compared using logistic regression (adjusted for age, sex, body mass index, comorbidities, and race&#x2F;ethnicity). As a secondary data source to assess safety data, COVID-19 reports for Biogen MS therapies were extracted and described from Biogen&#39;s Global Safety Database.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 30,478 PwMS with an open DMT prescription were identified within Explorys; 344 were COVID-19 positive. The most significant risk factors for acquiring COVID-19 were comorbidity score â¥ 1, body mass index â¥ 30, and Black&#x2F;African ancestry. Similar risk factors were also identified for patients with SLE. Patients with MS were less likely to develop COVID-19 when treated with interferons (0.61%) and glatiramer acetate (0.51%), vs all other MS DMTs (both p &amp;lt; 0.001); anti-CD20 therapy was associated with the highest risk (3.45%; p &amp;lt; 0.0001). In the Biogen Global Safety Database, we identified 1217 patients who were COVID-19 positive treated with intramuscular interferon beta-1a, peginterferon beta-1a, natalizumab, dimethyl fumarate, diroximel fumarate, or fampridine.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Comorbidities, obesity, and Black&#x2F;African ancestry, but not age, were associated with a higher risk of SARS-CoV-2 infection in PwMS. Interferons and glatiramer acetate were associated with a reduced COVID-19 risk, whereas anti-CD20 therapies were associated with an increased risk, within the treated MS cohort. COVID-19 safety reports for patients receiving Biogen MS therapies were consistent with the Explorys database and MS literature, illustrating the replicability and power of this approach.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33743151&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320193603&amp;v&#x3D;2.14.3&quot;&gt;33743151&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s40263-021-00804-1&gt;10.1007&#x2F;s40263-021-00804-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33743151&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":656,"discovery_date":"2021-03-20T23:36:05","title":"Depression in individuals with multiple sclerosis and social media use: are they interlinked?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Neurol Belg. 2021 Mar 20. doi: 10.1007&#x2F;s13760-021-01656-8. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33743162&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320193603&amp;v&#x3D;2.14.3&quot;&gt;33743162&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s13760-021-01656-8&gt;10.1007&#x2F;s13760-021-01656-8&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33743162&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":655,"discovery_date":"2021-03-20T20:56:04","title":"Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 19. doi: 10.1007/s10072-021-05182-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Spasticity is a common and disabling symptom in patients with multiple sclerosis (PwMS): as highlighted by many epidemiological studies, it is often a severe and not well treated. Despite the availability of evidence-based spasticity management guidelines, there is still great variability in everyday therapeutic approach, especially for the most complex cases.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In our single-centre study, we retrospectively evaluated PwMS-treated nabiximols and botulinum toxin injections (BTI) from July 2015 to April 2019. Clinical and demographic data were collected. The severity of spasticity and spasms was recorded by modified Ashworth Scale (mAS) and Penn Spasm Frequency Scale (PSFS) at baseline and after 1 month of treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: We evaluated 64 treatments for MS-related spasticity: 28 patients were treated with BTI and 36 patients with nabiximols. We found that both BTI and nabiximols are effective in reducing mAS (nabiximols, BTI: p &lt; 0.001), PSFS frequency (nabiximols: p = 0.001, BTI: p = 0.008) and intensity (nabiximols: p = 0.001, BTI p = 0.016). No differences were found when directly comparing the efficacy of the two treatments, except for a statistical trend favouring BTI on spasms intensity (p = 0.091). Eleven patients were treated with both BTI and nabiximols, and only four patients continued both treatments. All dropouts were due to inefficacy of at least one of the two therapies.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our single-centre experience highlights that both BTI and nabiximols are effective in treating multiple sclerosis-related spasticity; however, BTI treatment may be more effective on spasms intensity. Combined nabiximols and BTI treatment could represent a therapeutic option for severe spasticity.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33742336/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210320165603&amp;v=2.14.3&quot;&gt;33742336&lt;/a&gt; | DOI:&lt;a href=&quot;https://doi.org/10.1007/s10072-021-05182-6&quot;&gt;10.1007/s10072-021-05182-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33742336/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210320165603&v=2.14.3","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":654,"discovery_date":"2021-03-20T20:46:35","title":"Neural crest cell-derived pericytes act as pro-angiogenic cells in human neocortex development and gliomas","summary":"Central nervous system diseases involving the parenchymal microvessels are frequently associated with a âmicrovasculopathyâ, which includes different levels of neurovascular unit (NVU) dysfunction, including b...","link":"https:&#x2F;&#x2F;fluidsbarrierscns.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12987-021-00242-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":653,"discovery_date":"2021-03-20T20:46:35","title":"Early behavioral and physiological markers of social anxiety in infants with fragile X syndrome","summary":"Social anxiety is highly prevalent in neurotypical children and children with fragile X syndrome (FXS). FXS is a genetic syndrome that is characterized by intellectual disability and an increased risk for auti...","link":"https:&#x2F;&#x2F;jneurodevdisorders.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s11689-021-09356-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":652,"discovery_date":"2021-03-20T19:06:39","title":"Prevalence of multiple sclerosis in key cities of Brazil. A study in Joinville, Southern Brazil","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2021000200122&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":651,"discovery_date":"2021-03-20T19:06:39","title":"Roberto Melaragno&#39;s scientific contributions to Brazilian Neurology","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2021000200175&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":650,"discovery_date":"2021-03-20T12:01:34","title":"Health-related quality of life of multiple sclerosis patients: a European multi-country study","summary":"Inconsistent use of generic and disease-specific health-related quality of life (HRQOL) instruments in multiple sclerosis (MS) studies limits cross-country comparability. The objectives: 1) investigate real-wo...","link":"https:&#x2F;&#x2F;archpublichealth.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13690-021-00561-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":649,"discovery_date":"2021-03-20T10:16:05","title":"Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 5;51:102880. doi: 10.1016&#x2F;j.msard.2021.102880. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Little is known about MS patients&#39; acceptability of a COVID-19 vaccine.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE AND METHODS: An online survey was conducted among MS patients to study COVID-19 vaccine acceptability and its associated factors.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS AND CONCLUSION: Among 256 participants, 80.9% of the patients were either definitely or probably willing to receive a COVID-19 vaccine. Most hesitant patients would consider being vaccinated under physician recommendation. Older patients and those with comorbidities seem to be more willing to get vaccinated. Moreover, vaccine acceptability was associated with participants&#39; convictions and concerns about COVID-19, as well as previous vaccination practices.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33740481&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320061603&amp;v&#x3D;2.14.3&quot;&gt;33740481&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102880&gt;10.1016&#x2F;j.msard.2021.102880&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33740481&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320061603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":648,"discovery_date":"2021-03-20T10:16:05","title":"Gastrointestinal dysfunction in neuroinflammatory diseases: Multiple sclerosis, neuromyelitis optica, acute autonomic ganglionopathy and related conditions","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Auton Neurosci. 2021 Mar 13;232:102795. doi: 10.1016&#x2F;j.autneu.2021.102795. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Disorders of the nervous system can produce a variety of gastrointestinal (GI) dysfunctions. Among these, lesions in various brain structures can cause appetite loss (hypothalamus), decreased peristalsis (presumably the basal ganglia, pontine defecation center&#x2F;Barrington&#39;s nucleus), decreased abdominal strain (presumably parabrachial nucleus&#x2F;Kolliker-Fuse nucleus) and hiccupping and vomiting (area postrema&#x2F;dorsal vagal complex). In addition, decreased peristalsis with&#x2F;without loss of bowel sensation can be caused by lesions of the spinal long tracts and the intermediolateral nucleus or of the peripheral nerves and myenteric plexus. Recently, neural diseases of inflammatory etiology, particularly those affecting the PNS, are being recognized to contribute to GI dysfunction. Here, we review neuroinflammatory diseases that potentially cause GI dysfunction. Among such CNS diseases are multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein associated disorder, and autoimmune encephalitis. Peripheral nervous system diseases impacting the gut include Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, acute sensory-autonomic neuropathy&#x2F;acute motor-sensory-autonomic neuropathy, acute autonomic ganglionopathy, myasthenia gravis and acute autonomic neuropathy with paraneoplastic syndrome. Finally, collagen diseases, such as Sjogren syndrome and systemic sclerosis, and celiac disease affect both CNS and PNS. These neuro-associated GI dysfunctions may predate or present concurrently with brain, spinal cord or peripheral nerve dysfunction. Such patients may visit gastroenterologists or physicians first, before the neurological diagnosis is made. Therefore, awareness of these phenomena among general practitioners and collaboration between gastroenterologists and neurologists are highly recommended in order for their early diagnosis and optimal management, as well as for systematic documentation of their presentations and treatment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33740560&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320061603&amp;v&#x3D;2.14.3&quot;&gt;33740560&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autneu.2021.102795&gt;10.1016&#x2F;j.autneu.2021.102795&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33740560&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210320061603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":647,"discovery_date":"2021-03-20T03:16:35","title":"A narrative review of the ethnomedicinal usage of Cannabis sativa Linnaeus as traditional phytomedicine by folk medicine practitioners of Bangladesh","summary":"There is a worldwide interest in the use of Cannabis sativa for biomedicine purposes. Cannabis has ethnomedicinal usage as a natural medicine in Bangladesh and cultivated during the British Empire period for reve...","link":"https:&#x2F;&#x2F;jcannabisresearch.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s42238-021-00063-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":646,"discovery_date":"2021-03-20T03:16:34","title":"Giant Intrapericardial bronchogenic cyst associated with congestive heart failure and atrial fibrillation: a case report","summary":"Large intracardiac bronchogenic cysts are rare mediastinal masses. However, they must always be considered in the differential diagnosis of heart failure with abnormal chest X-ray.","link":"https:&#x2F;&#x2F;cardiothoracicsurgery.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13019-021-01412-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":645,"discovery_date":"2021-03-19T23:36:04","title":"The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Med Econ. 2021 Mar 19:1. doi: 10.1080&#x2F;13696998.2021.1906013. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIM: Multiple sclerosis (MS) poses a substantial employer burden in medically related absenteeism and disability costs due to the chronic and debilitating nature of the disease.Although previous studies have evaluated relapse, nonadherence, discontinuation, and switching individually, little is known about their overall collective prevalence and implications in employees with MS treated with disease-modifying therapies (DMTs). This study evaluated the proportion of employees with MS with suboptimal DMT year-1 outcomes and to quantify the clinical and economic burden of suboptimal year-1 outcomes from a US employer perspective.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIALS AND METHODS: Employees with MS were selected from the WorkPartners database. Eligibility criteria were: â¥2 MS diagnosis claims (ICD-9-CM 340.xx&#x2F;ICD-10-CM G35) from 1&#x2F;1&#x2F;2010-3&#x2F;31&#x2F;2019, â¥1 once-&#x2F;twice-daily oral or self-injectable DMT claim (first claim &#x3D; index), continuous eligibility 6-months pre-&#x2F;1-year post-index, no baseline DMT, and age 18-64 years. Suboptimal year-1 outcomes included: non-adherence (proportion of days covered &amp;lt;80%), discontinuation (gap &amp;gt;60 days), switch, or relapse (MS-related hospitalization, emergency room visit, or outpatient visit with corticosteroid). A two-part logistic-generalized linear model evaluated costs.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Of 488 eligible patients, half (n &#x3D; 247; 50.6%) had suboptimal year-1 outcomes (39.5% non-adherence, 9.8% discontinuation, 10.9% switching, 20.7% relapse; not mutually exclusive). Employees with suboptimal year-1 outcomes had higher all-cause medical ($12,730 vs. $6428; p &amp;lt; 0.0001), MS-related medical ($5444 vs. $2652; p &amp;lt; 0.0001), non-DMT pharmacy ($2920 vs. $2169; p &#x3D; 0.0199), sick leave ($1247 vs. $908; p &#x3D; 0.0274), and short-term disability ($934 vs. $146; p &#x3D; 0.0001) costs. Long-term disability ($751 vs. $0; p &#x3D; 0.1250) and Workers&#39; Compensation ($56 vs. $24; p &#x3D; 0.1276) did not significantly differ.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;LIMITATIONS: Administrative claims lack clinical information. Results may not be generalizable to other patients or care settings.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Half of the employees with MS in this sample had suboptimal year-1 outcomes (i.e., non-adherence, discontinuation, switching, or relapse). These suboptimal year-1 outcomes were associated with greater medical, sick leave, and short-term disability costs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739915&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319193603&amp;v&#x3D;2.14.3&quot;&gt;33739915&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;13696998.2021.1906013&gt;10.1080&#x2F;13696998.2021.1906013&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739915&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":644,"discovery_date":"2021-03-19T23:36:04","title":"Correction to: Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 19. doi: 10.1007&#x2F;s10072-021-05137-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33740152&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319193603&amp;v&#x3D;2.14.3&quot;&gt;33740152&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05137-x&gt;10.1007&#x2F;s10072-021-05137-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33740152&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319193603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":643,"discovery_date":"2021-03-19T19:36:06","title":"Enhanced insulin signalling ameliorates C9orf72 hexanucleotide repeat expansion toxicity in Drosophila","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Elife. 2021 Mar 19;10:e58565. doi: 10.7554&#x2F;eLife.58565. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;G4C2 repeat expansions within the &lt;i&gt;C9orf72&lt;&#x2F;i&gt; gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The repeats undergo repeat-associated non-ATG translation to generate toxic dipeptide repeat proteins. Here, we show that insulin&#x2F;Igf signalling is reduced in fly models of &lt;i&gt;C9orf72&lt;&#x2F;i&gt; repeat expansion using RNA-sequencing of adult brain. We further demonstrate that activation of insulin&#x2F;Igf signalling can mitigate multiple neurodegenerative phenotypes in flies expressing either expanded G4C2 repeats or the toxic dipeptide repeat protein poly-GR. Levels of poly-GR are reduced when components of the insulin&#x2F;Igf signalling pathway are genetically activated in the diseased flies, suggesting a mechanism of rescue. Modulating insulin signalling in mammalian cells also lowers poly-GR levels. Remarkably, systemic injection of insulin improves the survival of flies expressing G4C2 repeats. Overall, our data suggest that modulation of insulin&#x2F;Igf signalling could be an effective therapeutic approach against &lt;i&gt;C9orf72&lt;&#x2F;i&gt; ALS&#x2F;FTD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739284&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33739284&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7554&#x2F;eLife.58565&gt;10.7554&#x2F;eLife.58565&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739284&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":642,"discovery_date":"2021-03-19T19:36:06","title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;JAMA Neurol. 2021 Mar 19. doi: 10.1001&#x2F;jamaneurol.2021.0688. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;IMPORTANCE: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To examine outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN, SETTING, AND PARTICIPANTS: This analysis used deidentified, cross-sectional data on patients with MS and SARS-CoV-2 infection reported by health care professionals in North American academic and community practices between April 1, 2020, and December 12, 2020, in the COVID-19 Infections in MS Registry. Health care professionals were asked to report patients after a minimum of 7 days from initial symptom onset and after sufficient time had passed to observe the COVID-19 disease course through resolution of acute illness or death. Data collection began April 1, 2020, and is ongoing.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;EXPOSURES: Laboratory-positive SARS-CoV-2 infection or highly suspected COVID-19.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MAIN OUTCOMES AND MEASURES: Clinical outcome with 4 levels of increasing severity: not hospitalized, hospitalization only, admission to the intensive care unit and&#x2F;or required ventilator support, and death.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Of 1626 patients, most had laboratory-positive SARS-CoV-2 infection (1345 [82.7%]), were female (1202 [74.0%]), and had relapsing-remitting MS (1255 [80.4%]). A total of 996 patients (61.5%) were non-Hispanic White, 337 (20.8%) were Black, and 190 (11.7%) were Hispanic&#x2F;Latinx. The mean (SD) age was 47.7 (13.2) years, and 797 (49.5%) had 1 or more comorbidity. The overall mortality rate was 3.3% (95% CI, 2.5%-4.3%). Ambulatory disability and older age were each independently associated with increased odds of all clinical severity levels compared with those not hospitalized after adjusting for other risk factors (nonambulatory: hospitalization only, odds ratio [OR], 2.8 [95% CI, 1.6-4.8]; intensive care unit&#x2F;required ventilator support, OR, 3.5 [95% CI, 1.6-7.8]; death, OR, 25.4 [95% CI, 9.3-69.1]; age [every 10 years]: hospitalization only, OR, 1.3 [95% CI, 1.1-1.6]; intensive care unit&#x2F;required ventilator support, OR, 1.3 [95% CI, 0.99-1.7]; death, OR, 1.8 [95% CI, 1.2-2.6]).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS AND RELEVANCE: In this registry-based cross-sectional study, increased disability was independently associated with worse clinical severity including death from COVID-19. Other risk factors for worse outcomes included older age, Black race, cardiovascular comorbidities, and recent treatment with corticosteroids. Knowledge of these risk factors may improve the treatment of patients with MS and COVID-19 by helping clinicians identify patients requiring more intense monitoring or COVID-19 treatment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739362&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33739362&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1001&#x2F;jamaneurol.2021.0688&gt;10.1001&#x2F;jamaneurol.2021.0688&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739362&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":641,"discovery_date":"2021-03-19T19:36:06","title":"CRISPR-mediated rapid generation of neural cell-specific knockout mice facilitates research in neurophysiology and pathology","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Ther Methods Clin Dev. 2021 Feb 18;20:755-764. doi: 10.1016&#x2F;j.omtm.2021.02.012. eCollection 2021 Mar 12.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Inducible conditional knockout mice are important tools for studying gene function and disease therapy, but their generation is costly and time-consuming. We introduced clustered regularly interspaced short palindromic repeats (CRISPR) and &lt;i&gt;Cre&lt;&#x2F;i&gt; into an LSL-Cas9 transgene-carrying mouse line by using adeno-associated virus (AAV)-PHP.eB to rapidly knockout gene(s) specifically in central nervous system (CNS) cells of adult mice. &lt;i&gt;NeuN&lt;&#x2F;i&gt; in neurons and &lt;i&gt;GFAP&lt;&#x2F;i&gt; in astrocytes were knocked out 2 weeks after an intravenous injection of vector, with an efficiency comparable to that of inducible Cre-&lt;i&gt;loxP&lt;&#x2F;i&gt; conditional knockout. For functional testing, we generated astrocyte-specific &lt;i&gt;Act1&lt;&#x2F;i&gt; knockout mice, which exhibited a phenotype similar to mice with Cre-&lt;i&gt;loxP&lt;&#x2F;i&gt;-mediated &lt;i&gt;Act1&lt;&#x2F;i&gt; knockout, in an animal model of multiple sclerosis (MS), an autoimmune disorder of the CNS. With this novel technique, neural cell-specific knockout can be induced rapidly (few weeks) and cost-effectively. Our study provides a new approach to building inducible conditional knockout mice, which would greatly facilitate research on CNS biology and disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738329&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33738329&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7940702&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;PMC7940702&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.omtm.2021.02.012&gt;10.1016&#x2F;j.omtm.2021.02.012&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738329&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":640,"discovery_date":"2021-03-19T19:36:06","title":"Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 18:10.1212&#x2F;WNL.0000000000011700. doi: 10.1212&#x2F;WNL.0000000000011700. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To explore &lt;i&gt;in-vivo&lt;&#x2F;i&gt; innate immune cell activation as a function of the distance from ventricular CSF in patients with Multiple Sclerosis (MS) using [18F]-DPA714 PET, and to investigate its relationship with periventricular microstructural damage, evaluated by magnetization transfer ratio (MTR), and with trajectories of disability worsening.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Thirty-seven MS patients and nineteen healthy controls underwent MRI and [18F]-DPA714 TSPO dynamic PET, from which individual maps of voxels characterized by innate immune cell activation (DPA+) were generated. White matter (WM) was divided in 3mm-thick concentric rings radiating from the ventricular surface toward the cortex, and the percentage of DPA+ voxels and mean MTR were extracted from each ring. Two-year trajectories of disability worsening were collected to identify patients with and without recent disability worsening.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The percentage of DPA+ voxels was higher in patients compared to controls in the periventricular WM (p&#x3D;6.10e-6), and declined with increasing distance from ventricular surface, with a steeper gradient in patients compared to controls (p&#x3D;0.001). This gradient was found both in periventricular lesions and normal-appearing WM. In the total WM, it correlated with a gradient of microstructural tissue damage measured by MTR (r&lt;sub&gt;s&lt;&#x2F;sub&gt;&#x3D;-0.65, p&#x3D;1.0e-3). When compared to clinically stable patients, patients with disability worsening were characterized by a higher percentage of DPA+ voxels in the periventricular normal-appearing WM (p&#x3D;0.025).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our results demonstrate that in MS the innate immune cell activation predominates in periventricular regions and associates with microstructural damage and disability worsening. This could result from the diffusion of pro-inflammatory CSF-derived factors into surrounding tissues.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737372&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33737372&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011700&gt;10.1212&#x2F;WNL.0000000000011700&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737372&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":639,"discovery_date":"2021-03-19T19:36:06","title":"Epley manoeuvre for posterior semicircular canal benign paroxysmal positional vertigo in people with multiple sclerosis: protocol of a randomised controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Open. 2021 Mar 18;11(3):e046510. doi: 10.1136&#x2F;bmjopen-2020-046510.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Vestibular disorders in multiple sclerosis (MS) could have central or peripheral origin. Although the central aetiology is the most expected in MS, peripheral damage is also significant in this disease. The most prevalent effect of vestibular peripheral damage is benign paroxysmal positional vertigo (BPPV). Impairments of the posterior semicircular canals represent 60%-90% of cases of BPPV. The standard gold treatment for this syndrome is the Epley manoeuvre (EM), the effectiveness of which has been poorly studied in patients with MS. Only one retrospective research study and a case study have reported encouraging results for EM with regard to resolution of posterior semicircular canal BPPV. The aim of this future randomised controlled trial (RCT) is to assess the effectiveness of EM for BPPV in participants with MS compared with a sham manoeuvre.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS AND ANALYSIS: The current protocol describes an RCT with two-arm, parallel-group design. Randomisation, concealed allocation and double-blinding will be conducted to reduce possible bias. Participants and evaluators will be blinded to group allocation. At least 80 participants who meet all eligibility criteria will be recruited. Participants will have the EM or sham manoeuvre performed within the experimental or control group, respectively. The primary outcome of the study is changes in the Dix Hallpike test. The secondary outcome will be changes in self-perceived scales: Dizziness Handicap Inventory and Vestibular Disorders Activities of Daily Living Scale. The sample will be evaluated at baseline, immediately after the intervention and 48 hours postintervention.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;ETHICS AND DISSEMINATION: The study was approved by the Andalusian Review Board and Ethics Committee of Virgen Macarena-Virgen del Rocio Hospitals (ID 0107-N-20, 23 July 2020). The results of the research will be disseminated by the investigators to peer-reviewed journals.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION NUMBER: NCT04578262.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737443&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33737443&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjopen-2020-046510&gt;10.1136&#x2F;bmjopen-2020-046510&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737443&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":638,"discovery_date":"2021-03-19T19:36:06","title":"Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;NPJ Digit Med. 2020 Oct 16;3(1):135. doi: 10.1038&#x2F;s41746-020-00338-8.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The rate of disability accumulation varies across multiple sclerosis (MS) patients. Machine learning techniques may offer more powerful means to predict disease course in MS patients. In our study, 724 patients from the Comprehensive Longitudinal Investigation in MS at Brigham and Women&#39;s Hospital (CLIMB study) and 400 patients from the EPIC dataset, University of California, San Francisco, were included in the analysis. The primary outcome was an increase in Expanded Disability Status Scale (EDSS) â¥ 1.5 (worsening) or not (non-worsening) at up to 5 years after the baseline visit. Classification models were built using the CLIMB dataset with patients&#39; clinical and MRI longitudinal observations in first 2 years, and further validated using the EPIC dataset. We compared the performance of three popular machine learning algorithms (SVM, Logistic Regression, and Random Forest) and three ensemble learning approaches (XGBoost, LightGBM, and a Meta-learner L). A &quot;threshold&quot; was established to trade-off the performance between the two classes. Predictive features were identified and compared among different models. Machine learning models achieved 0.79 and 0.83 AUC scores for the CLIMB and EPIC datasets, respectively, shortly after disease onset. Ensemble learning methods were more effective and robust compared to standalone algorithms. Two ensemble models, XGBoost and LightGBM were superior to the other four models evaluated in our study. Of variables evaluated, EDSS, Pyramidal Function, and Ambulatory Index were the top common predictors in forecasting the MS disease course. Machine learning techniques, in particular ensemble methods offer increased accuracy for the prediction of MS disease course.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737720&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33737720&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41746-020-00338-8&gt;10.1038&#x2F;s41746-020-00338-8&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737720&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":637,"discovery_date":"2021-03-19T19:36:06","title":"Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eye Brain. 2021 Mar 12;13:59-69. doi: 10.2147&#x2F;EB.S295610. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Retinal layer thickness parameters measured by optical coherence tomography (OCT) are emerging biomarkers of neuroaxonal degeneration and inflammation in multiple sclerosis (MS). We aimed to evaluate the value of retinal layer thickness for prediction of disability worsening and relapse in a real-world MS cohort.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PATIENTS AND METHODS: For this longitudinal observational study, we included MS patients with spectral-domain OCT scans available and â¥1 year of clinical follow-up. The value of peripapillary retinal nerve fiber layer (pRNFL), macular ganglion-cell-and-inner-plexiform-layer (GCIPL) and inner nuclear layer (INL) thickness for prediction of disability worsening and relapse during the observation period was tested by multivariate models.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We analyzed 60 MS patients during a mean observation period of 2.9 years (SD 1.8). Lower baseline thickness of GCIPL (cut-off &amp;lt;77Âµm; HR 4.1, p&#x3D;0.001) and pRNFL (cut-off â¤88Âµm; HR 3.1, p&#x3D;0.019) were associated with an increased risk of disability worsening. Longitudinally, mean thinning rates were -0.8Âµm&#x2F;year (SD 1.6) for GCIPL, -0.6Âµm&#x2F;year (SD 3.5) for pRNFL. GCIPL thinning â¥1.0Âµm&#x2F;year and pRNFL &amp;gt;1.5Âµm&#x2F;year is associated with higher likelihood of disability worsening (HR 5.7, p&#x3D;0.009 and HR 6.8, p&#x3D;0.003, respectively). INL thickened in patients with relapse by a mean 0.9Âµm while thinning by 0.3Âµm in patients without relapse (p&#x3D;0.04). In multivariate analyses, INL thickening was associated with an increased probability of relapse (OR 17.8, p&#x3D;0.023).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Cross-sectional and longitudinal measurement of GCIPL and pRNFL thinning is reliable as a biomarker of disability worsening in a real-world setting. Change of INL thickness is a promising marker of relapse, i.e. inflammatory activity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737853&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33737853&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7966301&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;PMC7966301&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;EB.S295610&gt;10.2147&#x2F;EB.S295610&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737853&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":636,"discovery_date":"2021-03-19T19:36:06","title":"Radiological and Clinical Value of 7T MRI for Evaluating 3T-Visible Lesions in Pharmacoresistant Focal Epilepsies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Mar 2;12:591586. doi: 10.3389&#x2F;fneur.2021.591586. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Objective:&lt;&#x2F;b&gt; The recent FDA approval of the first 7T MRI scanner for clinical diagnostic use in October 2017 will likely increase the utilization of 7T for epilepsy presurgical evaluation. This study aims at accessing the radiological and clinical value of 7T in patients with pharmacoresistant focal epilepsy and 3T-visible lesions. &lt;b&gt;Methods:&lt;&#x2F;b&gt; Patients with pharmacoresistant focal epilepsy were included if they had a lesion on pre-operative standard-of-care 3T MRI and also a 7T research MRI. An epilepsy protocol was used for the acquisition of the 7T MRI. Prospective visual analysis of 7T MRI was performed by an experienced board-certified neuroradiologist and communicated to the patient management team. The clinical significance of the additional 7T findings was assessed by intracranial EEG (ICEEG) ictal onset, surgical resection, post-operative seizure outcome and histopathology. A subset of lesions were demarked with arrows for subsequent, retrospective comparison between 3T and 7T by 7 neuroradiologists using a set of quantitative scales: lesion presence, conspicuity, boundary, gray-white tissue contrast, artifacts, and the most helpful sequence for diagnosis. Conger&#39;s kappa for multiple raters was performed for chance-adjusted agreement statistics. &lt;b&gt;Results:&lt;&#x2F;b&gt; A total of 47 patients were included, with the main pathology types of focal cortical dysplasia (FCD), hippocampal sclerosis, periventricular nodular heterotopia (PVNH), tumor and polymicrogyria (PMG). 7T detected additional smaller lesions in 19% (9&#x2F;47) of patients, who had extensive abnormalities such as PMG and PVNH; however, these additional findings were not necessarily epileptogenic. 3T-7T comparison by the neuroradiologist team showed that lesion conspicuity and lesion boundary were significantly better at 7T (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001), particularly for FCD, PVNH and PMG. Chance-adjusted agreement was within the fair range for lesion presence, conspicuity and boundary. Gray-white contrast was significantly improved at 7T (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001). Significantly more artifacts were encountered at 7T (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001). &lt;b&gt;Significance:&lt;&#x2F;b&gt; For patients with 3T-visible lesions, 7T MRI may better elucidate the extent of multifocal abnormalities such as PVNH and PMG, providing potential targets to improve ICEEG implantation. Patients with FCD, PVNH and PMG would likely benefit the most from 7T due to improved lesion conspicuity and boundary. Pathologies in the antero-inferior temporal regions likely benefit less due to artifacts.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737901&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33737901&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7960771&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;PMC7960771&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.591586&gt;10.3389&#x2F;fneur.2021.591586&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737901&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":635,"discovery_date":"2021-03-19T19:36:06","title":"Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ther Adv Neurol Disord. 2021 Feb 26;14:1756286420987941. doi: 10.1177&#x2F;1756286420987941. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Eligible participants who received either daclizumab beta or interferon beta-1a in DECIDE received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years in EXTEND, followed by 24 weeks of post-dosing follow-up. Safety and tolerability were evaluated, as were clinical efficacy and magnetic resonance imaging (MRI). EXTEND was terminated ahead of schedule by the sponsors.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The total safety population (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 1203) received at least one dose of daclizumab beta in EXTEND. In the DECIDE and EXTEND combined periods, the median number of doses of daclizumab beta was 53; median time on treatment was 196 weeks. By 24 September 2018, the end of the study, 110&#x2F;1203 (9%) participants had completed the protocol-specified treatment period and 1101&#x2F;1203 (92%) had experienced an adverse event (AE). The most commonly reported AEs were MS relapse, nasopharyngitis, and upper respiratory tract infection. Hepatic events (18%), cutaneous events (45%), and infections (62%) were common treatment-related AEs. The incidence of serious AEs was 29%, most commonly MS relapse and infections. The incidence of immune-mediated disorders was 2%; three of seven were encephalitis. Two of six deaths were considered treatment related. In participants who received continuous daclizumab beta throughout DECIDE and EXTEND, the treatment effects on clinical and MRI outcomes were maintained for up to 6 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Results from the combined DECIDE-EXTEND study elucidate outcomes of longer-term treatment with daclizumab beta in the clinical trial setting and underscore the importance of pharmacovigilance with immunomodulatory therapies in the real-world setting.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33737954&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7934044&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;PMC7934044&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1756286420987941&gt;10.1177&#x2F;1756286420987941&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33737954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":634,"discovery_date":"2021-03-19T19:36:06","title":"Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 25;7(1):2055217321997467. doi: 10.1177&#x2F;2055217321997467. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Teleneurology for multiple sclerosis (MS) care was considered feasible, but utilization was limited.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To describe how the existing teleneurology populations at two academic MS Centers changed during the COVID-19 pandemic.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this cross-sectional study, we captured all in-person and teleneurology visits at two academic MS Centers between January 2019 and April 2020. We compared group differences between the Centers, and COVID-related changes using T-, chi-squared Kruskal-Wallis and Fisher exact tests.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 2268 patients completed 2579 teleneurology visits (mean age 48.3 Â± 13.3 years, 72.9% female). Pre-COVID, the Centers&#39; teleneurology populations were similar for age, sex, MS type, and disability level (all p &amp;gt; 0.1), but differed for race (96.5% vs 80.7% white, p â¤ 0.001), MS treatment (49.1% vs 32.1% infusible, p â¤ 0.001), and median distance from Center (72 vs 186 miles, p â¤ 0.001). Post-COVID, both Centers&#39; teleneurology populations had more black (12.7% vs 4.37%, p â¤ 0.001) and local (median 34.5 vs 102 miles, p â¤ 0.001) patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Teleneurology visits in 2019 reflected the organizational and local teleneurology reimbursement patterns of our Centers. Our post-COVID-19 changes illustrate the potential for payors and policy to change disparities in access to, or utilization of, remote care. Patients&#39; perception of care quality and value following this shift warrants study.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738110&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33738110&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7934057&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;PMC7934057&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055217321997467&gt;10.1177&#x2F;2055217321997467&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738110&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":633,"discovery_date":"2021-03-19T19:36:06","title":"Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Apr;27(5):767-777. doi: 10.1177&#x2F;1352458520929626. Epub 2020 Jun 17.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS)-related knowledge is an important evaluation metric for health education interventions. However, few MS knowledge assessment tools are currently available for use.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: This study aims to develop a reliable and valid Multiple Sclerosis Knowledge Assessment Scale (MSKAS) for use in the MS community and the general public.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The MSKAS was developed using a Delphi study methodology and was administered to participants in the first open enrolment of the Understanding Multiple Sclerosis (UMS) online course. Rasch analysis was used to examine its psychometric properties and develop the final scale.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Experts from across the MS community participated in the development of the MSKAS, resulting in an initial scale of 42 items. Five hundred and forty-three UMS participants completed the MSKAS; 89% were female and 30% were people with MS. The final unidimensional 22-item scale has a person separation index of 2.16, a person reliability index of 0.82, an item separation index of 11.19, and a Cronbach&#39;s alpha (kr-20) test reliability of 0.87.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The MSKAS is a unidimensional scale with good construct validity and internal consistency. The MSKAS has the potential to be useful for the assessment of MS knowledge in research and clinical practice.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739199&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33739199&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458520929626&gt;10.1177&#x2F;1352458520929626&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739199&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":632,"discovery_date":"2021-03-19T19:36:06","title":"The clinical and paraclinical manifestations of tuberous sclerosis complex in children","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Neurol Belg. 2021 Mar 18. doi: 10.1007&#x2F;s13760-021-01635-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Tuberous sclerosis complex (TSC) is an autosomal-dominant, multi-system, neurocutaneous disorder characterized by hamartomas in multiple organs. This study aimed to evaluate the clinical and paraclinical manifestations of children with TSC. The clinical and paraclinical characteristics of 79 children with TSC were evaluated and the possible correlations between the factors were calculated. Among the studied children which composed of 41 females (51.9%) and 38 males (48.1%), skin manifestations as hypopigmented macules as well as the brain involvement as cortical tubers in all (100%) cases, seizure in 74 (93.7%), and sub-ependymal nodules in 73 (92.4%) patients were the most common findings. The renal angiomyolipoma was diagnosed in 36 (70.6%) out of 51 patients. Subependymal giant cell astrocytoma in 25 (3&#x2F;54%) out of 46 patients, retinal hamartoma in 15 (42.9%) out of 35 patients, and cardiac rhabdomyoma in 17 (41.3%) out of 46 patients were diagnosed. Furthermore, 50 (63.3%) out of 79 patients had psychological disorders that had a significant correlation with the prevalence of seizures (p &#x3D; 0.002). Given the multi-systemic involvement of TSC, it is necessary that all organs of the patients even without any related clinical symptom or sign be examined regularly for proper therapeutic intervention and prevent disease progression. The growth of hamartomas in the brain and kidneys can be life-threatening; therefore, these organs have more importance to be regularly followed up and examined.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738777&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33738777&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s13760-021-01635-z&gt;10.1007&#x2F;s13760-021-01635-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738777&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":631,"discovery_date":"2021-03-19T19:36:06","title":"Synthesis and 15N NMR Signal Amplification by Reversible Exchange of [15N]Dalfampridine at Microtesla Magnetic Fields","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Chemphyschem. 2021 Mar 18. doi: 10.1002&#x2F;cphc.202100109. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Signal Amplification by Reversible Exchange (SABRE) technique enables nuclear spin hyperpolarization of wide range of compounds using parahydrogen. Here we present the synthetic approach to prepare 15 N-labeled [ 15 N]dalfampridine (4-amino[ 15 N]pyridine) utilized as a drug to reduce the symptoms of multiple sclerosis. The synthesized compound was hyperpolarized using SABRE at microtesla magnetic fields (SABRE-SHEATH technique) with up to 2.0% 15 N polarization. The 7-hour-long activation of SABRE pre-catalyst [Ir(IMes)(COD)Cl] in the presence of [ 15 N]dalfampridine can be remedied by the use of pyridine co-ligand for catalyst activation while retaining the 15 N polarization levels of [ 15 N]dalfampridine. The effects of experimental conditions such as polarization transfer magnetic field, temperature, concentration, parahydrogen flow rate and pressure on 15 N polarization levels of free and equatorial catalyst-bound [ 15 N]dalfampridine were investigated. Moreover, we studied 15 N polarization build-up and decay at magnetic field of less than 0.04 Î¼T as well as 15 N polarization decay at the Earth&#39;s magnetic field and at 1.4 T.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33738893&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;cphc.202100109&gt;10.1002&#x2F;cphc.202100109&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33738893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":630,"discovery_date":"2021-03-19T19:36:06","title":"Impact of aerobic exercise on clinical and magnetic resonance imaging biomarkers in persons with multiple sclerosis: An exploratory randomized controlled trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Rehabil Med. 2021 Mar 19. doi: 10.2340/16501977-2814. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: There is insufficient knowledge about how aerobic exercise impacts the disease process of multiple sclerosis, which is characterized by accumulation of white matter lesions and accelerated brain atrophy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To examine the effect of aerobic exercise on neuroinflammation and neurodegeneration by magnetic resonance imaging and clinical measures of disease activity and progression in persons with multiple sclerosis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PATIENTS AND METHODS: An exploratory 12-week randomized control trial including an intervention group (n = 14, 12 weeks of aerobic exercise twice weekly) and a control group (n = 14, continuation of usual lifestyle). Primary outcomes were magnetic resonance imaging measures (lesion load, brain structure volume change), while secondary outcomes included disability measures, blood cytokine levels, cognitive tests and patient-reported outcomes.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The effects of aerobic exercise on whole brain and grey matter atrophy were minor. Surprisingly, the observed effect on volume (atrophy) in selected brain substructures was heterogeneous. Putaminal and posterior cingulate volumes decreased, parahippocampal gyrus volume increased, thalamus and amygdala volume remained the same, and active lesion load and count decreased. However, apart from weak improvements in walking speed and brain-derived neurotrophic factor levels, there was no effect of aerobic exercise on other clinical, cognitive or patient-reported outcomes.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: These results suggest that aerobic exercise in persons with multiple sclerosis has a positive effect on the volume of some of the substructures of the brain, possibly indicating a slowing of the neurodegenerative process in these regions, but a negative impact on the volume of some other substructures, with unclear implications. Further research is needed to determine whether the slight decrease in active lesion volume and count implies an anti-inflammatory effect of aerobic exercise, and the exact significance of the heterogeneous results of volumetric assessments.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33739437/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210319153603&amp;v=2.14.3&quot;&gt;33739437&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2340/16501977-2814&gt;10.2340/16501977-2814&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33739437/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210319153603&v=2.14.3","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":629,"discovery_date":"2021-03-19T19:36:06","title":"PART 2: Mouse models for multiple sclerosis research","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurourol Urodyn. 2021 Mar 19. doi: 10.1002&#x2F;nau.24654. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Lower urinary tract symptoms and dysfunction (LUTS&#x2F;LUTD) contribute to loss of quality of life, morbidity, and need for medical intervention in most patients with multiple sclerosis (MS). Although MS is an inflammatory neurodegenerative disease, clinical manifestations including continence control disorders have traditionally been attributed to the loss of neural signaling due to neurodegeneration. Clinical approaches to MS-LUTS&#x2F;LUTD have focused on addressing symptoms in the context of urodynamic dysfunctions as pathophysiologic understandings are incomplete. The mouse model provides a useful research platform for discovery of more detailed molecular, cellular, and tissue-level knowledge of the disease and its clinical manifestations. The aim of this two-part review is to provide a state-of-the-art update on the use of the mouse model for MS research, with a focus on lower urinary tract symptoms. Part I presents a summary of current understanding of MS pathophysiology, the impact on lower urinary tract symptoms, and briefly introduces the types of mouse models available to study MS. Part II presents the common animal models that are currently available to study MS, their mechanism, relevance to MS-LUTS&#x2F;LUTD and their urinary pathophysiology, advantages and disadvantages.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739481&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3&quot;&gt;33739481&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;nau.24654&gt;10.1002&#x2F;nau.24654&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33739481&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319153603&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":628,"discovery_date":"2021-03-19T18:31:35","title":"Adipose-derived mesenchymal stem cells attenuate dialysis-induced peritoneal fibrosis by modulating macrophage polarization via interleukin-6","summary":"Life-long peritoneal dialysis (PD) as a renal replacement therapy is limited by peritoneal fibrosis. Previous studies showed immunomodulatory and antifibrotic effects of adipose-derived mesenchymal stem cells ...","link":"https:&#x2F;&#x2F;stemcellres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13287-021-02270-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":627,"discovery_date":"2021-03-19T18:31:35","title":"Diffusion tensor imaging revealed different pathological processes of white matter hyperintensities","summary":"Although increasing evidence showed the correlations between white matter hyperintensities (WMHs) and cognitive impairment, the relationship between them is still modest. Many researchers began to focus on the...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02140-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":626,"discovery_date":"2021-03-19T18:31:35","title":"Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS&#x2F;FTD","summary":"The most common genetic cause of familial and sporadic amyotrophic lateral sclerosis (ALS) is a GGGGCC hexanucleotide repeat expansion (HRE) in the C9orf72 gene. While direct molecular hallmarks of the C9orf72...","link":"https:&#x2F;&#x2F;actaneurocomms.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40478-021-01150-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":625,"discovery_date":"2021-03-19T18:31:35","title":"Hip pathologies in mucopolysaccharidosis type III","summary":"Mucopolysaccharidosis type III (MPS III) comprises a group of rare lysosomal storage diseases. Although musculoskeletal symptoms are less pronounced than in other MPS subtypes, pathologies of hip and spine hav...","link":"https:&#x2F;&#x2F;josr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13018-021-02340-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":624,"discovery_date":"2021-03-19T18:06:37","title":"&quot;Chasing the Dragon&quot;: A Fatal Case Report of Toxic LeucoencÃ©phalopathie Due to Inhaled Heroin","summary":"","link":"http:&#x2F;&#x2F;www.scielo.org.co&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0034-74502020000400289&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":623,"discovery_date":"2021-03-19T18:06:37","title":"Espasticidad","summary":"","link":"http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2011-08392021000100008&lang=en","published_date":"","source":"Scielo","relevant":1,"table_constraints":null},{"article_id":622,"discovery_date":"2021-03-19T15:36:35","title":"Qigong mind-body program for caregivers of cancer patients: design of a pilot three-arm randomized clinical trial","summary":"Informal caregivers, often family and friends, experience significant psychological and physical distress leading to reductions in health and quality of life (QOL). Mind-body interventions focused on caregiver...","link":"https:&#x2F;&#x2F;pilotfeasibilitystudies.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40814-021-00793-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":621,"discovery_date":"2021-03-19T11:44:21","title":"Upper Extremity Motor Fatigability as an Early Indicator in Pediatric Onset Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Child Neurol. 2021 Mar 19:883073821999889. doi: 10.1177&#x2F;0883073821999889. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIM: To adopt a computer-based protocol to assess grip fatigability in patients with pediatric-onset multiple sclerosis to provide detection of subtle motor involvement identifying those patients most at risk for future decline.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: Pediatric-onset multiple sclerosis patients were recruited during routine outpatient visits to complete a grip assessment and compared to a group of healthy age- and sex-matched controls. All participants completed a computer-based measurement of standard maximal grip strength and repetitive and sustained grip performance measured by dynamic and static fatigue indices.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 38 patients with pediatric-onset multiple sclerosis and 24 healthy controls completed the grip protocol (right-hand dominant). There were no significant group differences in maximal grip strength bilaterally (right: 21.8 vs 19.9 kg, &lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .25; left: 20.4 vs 18.7 kg, &lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .33), although males with pediatric-onset multiple sclerosis were significantly less strong than healthy controls (right: 26.53 vs 21.23 kg, &lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .009; left; 25.13 vs 19.63 kg, &lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .003). Both dynamic and static fatigue indices were significantly higher bilaterally in pediatric-onset multiple sclerosis compared with healthy control participants (left-hand dynamic fatigue index: 18.6% vs 26.7%, &lt;i&gt;P&lt;&#x2F;i&gt; &#x3D; .003; right-hand static fatigue index: 28.3% vs 41.3%, &lt;i&gt;P&lt;&#x2F;i&gt; &amp;lt; .001; left-hand static fatigue index: 31.9% vs 42.6%, &lt;i&gt;P&lt;&#x2F;i&gt; &amp;lt; .001).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Brief repeatable grip assessment including measures of dynamic and sustained static output can be a sensitive indicator of upper extremity motor involvement in pediatric-onset multiple sclerosis, potentially identifying those in need of intervention to prevent future disability.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33736529&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319074419&amp;v&#x3D;2.14.3&quot;&gt;33736529&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;0883073821999889&gt;10.1177&#x2F;0883073821999889&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33736529&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319074419&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":620,"discovery_date":"2021-03-19T06:24:20","title":"Cognitive Performance in Relapsing-Remitting Multiple Sclerosis: At Risk or Impaired?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Dement Geriatr Cogn Disord. 2021 Mar 18:1-5. doi: 10.1159&#x2F;000514674. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Since cognitive impairment (CI) occurs on average in 45% of multiple sclerosis (MS) patients, the early detection of patients &quot;at risk&quot; of CI is important in order to promptly apply preventive strategies. The aim of the present study was to investigate the prevalence and risk factors for CI in MS patients using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) as a screening test.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: During the 1-year period, CI was evaluated in 82 consecutives mild relapsing-remitting MS (EDSS â¤ 3.5) patients. Patients with 1 altered BICAMS test were defined &quot;at risk.&quot; Both &quot;at risk&quot; and CI patients underwent an extensive neuropsychological battery.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We found that: (i) 23% had CI, (ii), 25% were &quot;at risk&quot; of CI, and (iii) 76% of the &quot;at risk&quot; patients were already impaired at the NP assessment. In particular, the Symbol Digit Modalities Test was the most compromised (70% of &quot;at risk&quot; and 79% of CI patients). Patients with CI had more frequently an EDSS â¥ 2.5 (p &#x3D; 0.05), lower education (p &#x3D; 0.05), and relapses in the last 12 months (p &#x3D; 0.03).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: CI is a significant issue in MS and integration of a screening test, such as the SDMT, into routine clinical practice could be of worth to identify &quot;at risk&quot; patients and to promote an early therapeutic intervention.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33735893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319022419&amp;v&#x3D;2.14.3&quot;&gt;33735893&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000514674&gt;10.1159&#x2F;000514674&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33735893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210319022419&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":619,"discovery_date":"2021-03-19T02:40:51","title":"Mesenchymal stem&#x2F;stromal cells as a valuable source for the treatment of immune-mediated disorders","summary":"Over recent years, mesenchymal stem&#x2F;stromal cells (MSCs) and their potential biomedical applications have received much attention from the global scientific community in an increasing manner. Firstly, MSCs wer...","link":"https:&#x2F;&#x2F;stemcellres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13287-021-02265-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":618,"discovery_date":"2021-03-19T02:40:51","title":"Effect of âhand and foot acupuncture with twelve needlesâ on hemiplegia patients with âqi deficiency and blood stasisâ syndrome in the convalescent stage of Ischaemic stroke: study protocol for a randomised controlled trial","summary":"Hemiplegia is a common sequela after stroke, and acupuncture is one of the most common physical therapies used to treat hemiplegia during the recovery stage after ischaemic stroke. âHand and foot acupuncture w...","link":"https:&#x2F;&#x2F;trialsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13063-021-05128-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":617,"discovery_date":"2021-03-19T02:40:51","title":"Repair abilities of mouse autologous adipose-derived stem cells and ShakeGelâ¢3D complex local injection with intrauterine adhesion by BMP7-Smad5 signaling pathway activation","summary":"The objective was to explore the therapeutic effect of autologous adipose-derived stem cells (ADSCs) combined with ShakeGelâ¢3D transplantation to activate the BMP7-Smad5 signaling pathway to treat intrauterine...","link":"https:&#x2F;&#x2F;stemcellres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13287-021-02258-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":616,"discovery_date":"2021-03-19T02:40:51","title":"Bayesian approach for predicting responses to therapy from high-dimensional time-course gene expression profiles","summary":"Historical and updated information provided by time-course data collected during an entire treatment period proves to be more useful than information provided by single-point data. Accurate predictions made us...","link":"https:&#x2F;&#x2F;bmcbioinformatics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12859-021-04052-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":615,"discovery_date":"2021-03-19T02:40:51","title":"Alterations of mesenchymal stromal cells in cerebrospinal fluid: insights from transcriptomics and an ALS clinical trial","summary":"Mesenchymal stromal cells (MSCs) have been studied with increasing intensity as clinicians and researchers strive to understand the ability of MSCs to modulate disease progression and promote tissue regenerati...","link":"https:&#x2F;&#x2F;stemcellres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13287-021-02241-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":614,"discovery_date":"2021-03-19T02:40:51","title":"Generation of UCiPSC-derived neurospheres for cell therapy and its application","summary":"Neural stem cell (NSC) therapy remains one of the most potential approaches for the treatment of neurological disorders. The discovery of human induced pluripotent stem cells (hiPSCs) and the establishment of ...","link":"https:&#x2F;&#x2F;stemcellres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13287-021-02238-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":613,"discovery_date":"2021-03-19T02:40:51","title":"Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report","summary":"The concept of mixed connective tissue disease (MCTD) as a unique connective tissue disease has endured for half a century. Disease onset can be in adulthood (MCTD) or of juvenile onset (jMCTD) and is characte...","link":"https:&#x2F;&#x2F;bmcrheumatol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s41927-021-00179-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":612,"discovery_date":"2021-03-18T23:45:23","title":"Age of hypertension onset in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177&#x2F;13524585211003016. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND&#x2F;OBJECTIVE: Hypertension (HTN) is common in multiple sclerosis (MS), and it is associated with poorer outcomes. We sought to characterize HTN age at onset (AAO) by MS status.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS&#x2F;RESULTS: There were 130,050 incident HTN patients, among whom there were 892 MS patients. We conducted multivariable linear regression adjusting for patient attributes. Sex- and race-stratified models were conducted. HTN AAO did not differ in patients with and without MS (&lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.17). Similar null associations were observed in the sex- and race-specific analyses.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: While there are complex relationships between HTN and MS, there are no differences in HTN AAO by MS status.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33733922&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3&quot;&gt;33733922&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211003016&gt;10.1177&#x2F;13524585211003016&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33733922&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":611,"discovery_date":"2021-03-18T23:45:23","title":"Central neuropathic pain in multiple sclerosis is associated with impaired innocuous thermal pathways and neuronal hyperexcitability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Pain Med. 2021 Mar 18:pnab103. doi: 10.1093&#x2F;pm&#x2F;pnab103. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: About a third of patients with multiple sclerosis (MS) suffer from chronic and excruciating central neuropathic pain (CNP). The mechanism underlying CNP in MS is not clear, since previous studies are scarce and their results are inconsistent. Our aim was to determine whether CNP in MS is associated with impairment of the spinothalamic-thalamocortical pathways (STTCs) and&#x2F;or increased excitability of the pain system.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN: Cross sectional study.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: General hospital.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUBJECTS: 47 MS patients with CNP, 42 MS patients without CNP, and 32 healthy controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Sensory testing included the measurement of temperature, pain, and touch thresholds and the thermal grill illusion (TGI) for evaluating STTCs function, and hyperpathia and allodynia as indicators of hyperexcitability. CNP was characterized using interviews and questionnaires.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The CNP group had higher cold and warm thresholds (p &amp;lt; 0.01), as well as higher TGI perception thresholds (p &amp;lt; 0.05), especially in painful body regions compared to controls, whereas touch and pain thresholds values were normal. The CNP group also had a significantly greater prevalence of hyperpathia and allodynia. Regression analysis revealed that whereas presence of CNP was associated with a higher cold threshold, CNP intensity, and the number of painful body regions were associated with allodynia and hyperpathia, respectively.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: CNP in MS is characterized by a specific impairment of STTC function; the innocuous thermal pathways, and by pain hyperexcitability. Whereas CNP presence is associated with STTC impairment, its severity and extent are associated with pain hyperexcitability. Interventions that reduce excitability level may therefore mitigate CNP severity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33734398&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3&quot;&gt;33734398&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;pm&#x2F;pnab103&gt;10.1093&#x2F;pm&#x2F;pnab103&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33734398&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":610,"discovery_date":"2021-03-18T23:45:23","title":"CORNEAL SUBBASAL NERVE PLEXUS EVALUATION BY IN VIVO CONFOCAL MICROSCOPY IN MULTIPLE SCLEROSIS: A POTENTIAL NEW BIOMARKER","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Eye Res. 2021 Mar 18. doi: 10.1080&#x2F;02713683.2021.1904509. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Purpose&#x2F;Aim&lt;&#x2F;b&gt;: Our study aims to evaluate corneal subbasal nerve plexus morphology by &lt;i&gt;in vivo&lt;&#x2F;i&gt; corneal confocal microscopy (CCM) in Multiple Sclerosis (MS) patients, and to explore their potential ability to distinguish between MS patients and healthy subjects.&lt;b&gt;Materials and Methods&lt;&#x2F;b&gt;: Cross-sectional study, including sixty MS patients and twenty-two healthy subjects. Expanded Disability Status Scale (EDSS) was used to assess neurological disability. All participants underwent full ophthalmology evaluation, CCM and optical coherence tomography (OCT). Corneal nerve fibre density (CNFD), branch density (CNBD), fibre length (CNFL) and fibre tortuosity (CNFT) were analysed. Generalized additive regression models were used to analyse the data.&lt;b&gt;Results&lt;&#x2F;b&gt;: Compared to controls, MS patients had lower CNFD, CNBD and CNFL (p&amp;lt;0.001) and higher CNFT (p&#x3D;0.002). The area under the ROC curve to distinguish MS patients from healthy controls with CNFD and CNBD was 0.84 (95%CI: 0.75 to 0.93; 95%CI: 0.75 to 0.92, respectively). A nonlinear association between EDSS and CNFD was found, with an initial density increase followed by a significant decrease until more severe disability status. EDSS was associated with CNFL and CNBD, with values being significantly lower for patients with an EDSS&amp;gt;2.5 (-2.06 mm&#x2F;mm2; 95%CI: -3.84 to -0.28; p&#x3D;0.027 and -8.70 branches&#x2F;mm2; 95%CI: -14.69 to -2.71; p&#x3D;0.006, respectively). An optic neuritis (ON) history did not influence CCM parameters.&lt;b&gt;Conclusions&lt;&#x2F;b&gt;: Our results confirm CCM parameters&#39; potential to differentiate MS patients from healthy subjects, not being influenced by a previous ON history. A significant relationship between patient&#39;s disability and corneal nerves morphology was also found.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33734930&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3&quot;&gt;33734930&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;02713683.2021.1904509&gt;10.1080&#x2F;02713683.2021.1904509&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33734930&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":609,"discovery_date":"2021-03-18T23:45:23","title":"Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Med Res Opin. 2021 Mar 18:1. doi: 10.1080&#x2F;03007995.2021.1904860. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;&lt;i&gt;Objective:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; To identify evidence in the literature presenting the economic and humanistic (based on health state utility values [HSUVs]) burden of multiple sclerosis (MS) and report the incremental burden of secondary progressive MS (SPMS) compared with relapsing-remitting MS (RRMS).&lt;b&gt;&lt;i&gt;Methods:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Electronic databases (EmbaseÂ®, MEDLINE&lt;sup&gt;Â®&lt;&#x2F;sup&gt;, MEDLINE&lt;sup&gt;Â®&lt;&#x2F;sup&gt; In-Process, Cochrane Library) and other relevant repositories were systematically searched from the date of inception until November 2019 for evidence on the economic burden of MS, or HSUVs in patients with MS. Data were extracted from studies investigating cost data or HSUVs for patients with SPMS compared with RRMS.&lt;b&gt;&lt;i&gt;Results:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; In total, 25 studies were identified that reported data on the economic and HSUV burden of SPMS versus RRMS: 18 studies reported cost data and nine presented HSUVs. Overall, costs associated with SPMS were consistently higher than those for RRMS. Major cost drivers appeared to shift following transition from RRMS to SPMS, with higher direct medical costs associated with RRMS than with SPMS, while the opposite was true for direct non-medical costs and indirect costs. In all studies presenting HSUVs specifically in patients with SPMS, the disease burden was greater (indicated by lower HSUV scores or a negative regression coefficient vs RRMS) for patients with SPMS than for those with RRMS. Fatigue and psychological stress (including depression) were identified as key drivers of this reduced health-related quality of life (HRQoL).&lt;b&gt;&lt;i&gt;Conclusions:&lt;&#x2F;i&gt;&lt;&#x2F;b&gt; Our findings indicate that SPMS is associated with higher costs and more substantial HRQoL decrements than RRMS. These results highlight the substantial unmet need for effective treatments that can slow disease progression in patients with SPMS, which, in turn, would reduce the rate of HRQoL deterioration and increasing healthcare costs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33733976&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3&quot;&gt;33733976&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;03007995.2021.1904860&gt;10.1080&#x2F;03007995.2021.1904860&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33733976&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":608,"discovery_date":"2021-03-18T23:45:23","title":"Deletion of arginase 2 attenuates neuroinflammation in an experimental model of optic neuritis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;PLoS One. 2021 Mar 18;16(3):e0247901. doi: 10.1371&#x2F;journal.pone.0247901. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Vision impairment due to optic neuritis (ON) is one of the major clinical presentations in Multiple Sclerosis (MS) and is characterized by inflammation and degeneration of the optic nerve and retina. Currently available treatments are only partially effective and have a limited impact on the neuroinflammatory pathology of the disease. A recent study from our laboratory highlighted the beneficial effect of arginase 2 (A2) deletion in suppressing retinal neurodegeneration and inflammation in an experimental model of MS. Utilizing the same model, the present study investigated the impact of A2 deficiency on MS-induced optic neuritis. Experimental autoimmune encephalomyelitis (EAE) was induced in wild-type (WT) and A2 knockout (A2-&#x2F;-) mice. EAE-induced cellular infiltration, as well as activation of microglia and macrophages, were reduced in A2-&#x2F;- optic nerves. Axonal degeneration and demyelination seen in EAE optic nerves were observed to be reduced with A2 deletion. Further, the lack of A2 significantly ameliorated astrogliosis induced by EAE. In conclusion, our findings demonstrate a critical involvement of arginase 2 in mediating neuroinflammation in optic neuritis and suggest the potential of A2 blockade as a targeted therapy for MS-induced optic neuritis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33735314&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3&quot;&gt;33735314&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1371&#x2F;journal.pone.0247901&gt;10.1371&#x2F;journal.pone.0247901&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33735314&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":607,"discovery_date":"2021-03-18T23:45:23","title":"Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Mar 18. doi: 10.1111&#x2F;ene.14829. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell plus inner plexiform layer (GCIPL) thinning are markers of neuroaxonal degeneration in multiple sclerosis (MS), which is reduced by disease-modifying treatment (DMT). We aimed to investigate the potential of pRNFL and GCIPL thinning for prediction of DMT failure in relapsing MS (RMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this 4-year prospective observational study on 113 RMS patients, pRNFL and GCIPL were measured at DMT initiation and after 12 (M12) and 24 months (M24). Treatment failure was defined as 6-month-confirmed EDSS progression and&#x2F;or Symbol Digit Modalities Test (SDMT) worsening. Optimal cut-off values for predicting treatment failure were determined by receiver-operating-characteristic-(ROC)-analyses, and hazard ratios (HR) by multivariable Cox regression adjusting for age, sex, disease duration, EDSS&#x2F;SDMT and DMT class.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Thinning of GCIPL &amp;gt;0.5Î¼m&#x2F;year at M24 showed superior value for treatment failure prediction (HR 4.5; 95% confidence interval [CI]: 1.8 - 7.6; p&amp;lt;0.001; specificity 91%, sensitivity 81%) followed by GCIPL &amp;gt;0.5Î¼m at M12 (OR 3.9; 95% CI: 1.4 - 6.9; p&amp;lt;0.001; specificity 85%, sensitivity 78%), and pRNFL â¥2Î¼m&#x2F;year at M24 (OR 3.7; 95% CI: 1.1 - 6.5; p&#x3D;0.023; specificity 84%, sensitivity 69%), while pRNFL at M12 was not predictive.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: GCIPL - and to a lesser degree pRNFL - thinning predicts disability progression after DMT initiation and may be a useful and accessible biomarker of treatment failure in RMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33735479&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3&quot;&gt;33735479&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14829&gt;10.1111&#x2F;ene.14829&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33735479&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318194521&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":606,"discovery_date":"2021-03-18T18:05:57","title":"CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mucosal Immunol. 2021 Mar 17. doi: 10.1038&#x2F;s41385-021-00388-5. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Allergic asthma is a chronic inflammatory disorder associated with airway hyperreactivity (AHR) whose global prevalence is increasing at an alarming rate. Group 2 innate lymphoid cells (ILC2s) and T helper 2 (T&lt;sub&gt;H&lt;&#x2F;sub&gt;2) cells are producers of type 2 cytokines, which may contribute to development of AHR. In this study, we explore the potential of CD52-targeted depletion of type 2 immune cells for treating allergic AHR. Here we show that anti-CD52 therapy can prevent and remarkably reverse established IL-33-induced AHR by reducing airway resistance and alleviating lung inflammation. We further show that CD52 depletion prevents and treats allergic AHR induced by clinically relevant allergens such as Alternaria alternata and house dust mite. Importantly, we leverage various humanized mice models of AHR to show new therapeutic applications for Alemtuzumab, an anti-CD52 depleting antibody that is currently FDA approved for treatment of multiple sclerosis. Our results demonstrate that CD52 depletion is a viable therapeutic option for reduction of pulmonary inflammation, abrogation of eosinophilia, improvement of lung function, and thus treatment of allergic AHR. Taken together, our data suggest that anti-CD52 depleting monoclonal antibodies, such as Alemtuzumab, can serve as viable therapeutic drugs for amelioration of T&lt;sub&gt;H&lt;&#x2F;sub&gt;2- and ILC2-dependent AHR.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33731828&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318140555&amp;v&#x3D;2.14.3&quot;&gt;33731828&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41385-021-00388-5&gt;10.1038&#x2F;s41385-021-00388-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33731828&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318140555&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":605,"discovery_date":"2021-03-18T18:05:57","title":"Editorial: &quot;Inside-Out&quot; vs &quot;Outside-In&quot; Paradigms in Multiple Sclerosis Etiopathogenesis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Cell Neurosci. 2021 Mar 1;15:666529. doi: 10.3389&#x2F;fncel.2021.666529. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33732113&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318140555&amp;v&#x3D;2.14.3&quot;&gt;33732113&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7957074&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318140555&amp;v&#x3D;2.14.3&quot;&gt;PMC7957074&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fncel.2021.666529&gt;10.3389&#x2F;fncel.2021.666529&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33732113&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318140555&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":604,"discovery_date":"2021-03-18T11:45:54","title":"Shear wave elastography evaluation of brachial plexus in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Radiol. 2021 Mar 17:2841851211002828. doi: 10.1177&#x2F;02841851211002828. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a chronic neuroinflammatory disease characterized by inflammation involving the peripheral nerves. Shear wave elastography (SWE) is potentially a method of choice for detecting peripheral nerve involvement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: To compare the degree of thickening and nerve elasticity of brachial plexus (BP) nerve roots and evaluate the usefulness of sonoelastography in patients with clinically diagnosed MS without brachial plexopathy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIAL AND METHODS: Thirty-two patients with MS and 32 controls were included in the study. Bilateral C5, C6, and C7 mean nerve root diameters, and mean elasticity values in kiloPascal (kPa) were measured in the patient and control groups. The relationship between the age, height, and weight values and nerve diameter-elasticity values of the patient and control groups was compared.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The elasticity values of the C5 and C6 nerve roots were increased, and the nerve root thickness was decreased in the MS group compared to that in the control (&lt;i&gt;P&lt;&#x2F;i&gt; &amp;lt; 0.05). There was no difference between the C7 mean nerve root elasticity (kPa) and diameter measurements in the patient and control groups (&lt;i&gt;P&lt;&#x2F;i&gt; &amp;gt; 0.05).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our study showed an increase in the BP nerve root elasticity values (kPa) in patients with MS compared to that of the control group and a decrease in diameter values thought to be related to the possible chronic atrophic process. The results are consistent with the demyelinating process of the peripheral nervous system (PNS) due to MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33730859&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318074552&amp;v&#x3D;2.14.3&quot;&gt;33730859&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;02841851211002828&gt;10.1177&#x2F;02841851211002828&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33730859&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318074552&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":603,"discovery_date":"2021-03-18T05:45:53","title":"Underutilization of Contraception in Young Females with Demyelinating Disorders","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 9;51:102881. doi: 10.1016&#x2F;j.msard.2021.102881. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Demyelinating disorders in young females are frequently treated with immunomodulatory therapy which often have unknown risks to fetuses during pregnancy. In spite of this, there is no literature in this population about the use of contraception. Our objective was to determine the rate of use of contraception used in a real-world cohort of pediatric patients on immunotherapy for demyelinating diseases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A retrospective, multi-center, chart-based review was performed. Inclusion criteria was female gender, use of immunotherapy for a demyelinating disorder, and age &amp;gt;11 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Fifty-six female patients were identified with an average age of 15.4 years. The most common demyelinating disorders was multiple sclerosis (n &#x3D; 33, 59%). The most common treatments were rituximab (n &#x3D; 18, 32%), dimethyl fumarate (n &#x3D; 13, 23%), IVIg (n &#x3D; 11, 20%), and fingolimod (n &#x3D; 11, 20%). Overall, only 16% (n &#x3D; 9) of patients used contraception at any point during their immunotherapy regimen. Hispanic patients accounted for 41% of the cohort but were uniformly not on contraceptives (p &#x3D; 0. 02). Contraceptive use did not impact ARR in any disease (p &#x3D; 0.45).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Contraceptive use in young females with demyelinating disorders is less than 1&#x2F;3rd of the general population with particular discrepancies in persons of Hispanic&#x2F;Latino descent.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33730609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318014551&amp;v&#x3D;2.14.3&quot;&gt;33730609&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102881&gt;10.1016&#x2F;j.msard.2021.102881&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33730609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210318014551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":602,"discovery_date":"2021-03-18T00:06:22","title":"Uncovering sex differences of rodent microglia","summary":"There are inherent structural and functional differences in the central nervous systems (CNS) of females and males. It has been gradually established that these sex-specific differences are due to a spectrum o...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02124-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":601,"discovery_date":"2021-03-17T21:06:22","title":"Elevated levels of inflammatory plasma biomarkers are associated with risk of HIV infection","summary":"To determine if individuals, from HIV-1 serodiscordant couple cohorts from Rwanda and Zambia, who become HIV-positive have a distinct inflammatory biomarker profile compared to individuals who remain HIV-negat...","link":"https:&#x2F;&#x2F;retrovirology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12977-021-00552-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":600,"discovery_date":"2021-03-17T17:45:54","title":"From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 16. doi: 10.1007&#x2F;s00115-021-01098-w. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neuromyelitis optica spectrum disorder (NMOSD), derived from NMO or Devic&#39;s disease, is considered as a distinct disease since the discovery of a novel and pathogenic serum autoantibody targeting aquaporinâ4 (AQP4-IgG) and is distinguished from classical multiple sclerosis (MS). With the continuous extension of knowledge on the clinical manifestations, the previously narrow diagnostic term NMO became NMOSD, which has also been used in the diagnostic criteria since 2015. The current diagnostic criteria enable the early diagnosis of NMOSD in patients with and without AQP4-IgG. Typical clinical manifestations include involvement of the spinal cord, optic nerve and brainstem. Typically patients with the disease also present with neuropathic pain, painful tonic spasms and also other unusual manifestations in NMOSD. Especially in AQP4-IgG positive NMOSD patients, the coexistence with other autoimmune diseases is frequently observed. In most cases NMOSD follows a relapsing course with exacerbation-free periods sometimes lasting years and can be manifested first in advanced adulthood. A subset of AQP4-IgG negative NMOSD patients have been found to harbor autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG), which is considered as a distinct disease entity: these MOG antibody-associated disorders (MOGAD) can present with clinical syndromes resembling both NMOSD and MS and are currently the subject of intensive research.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728474&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728474&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01098-w&gt;10.1007&#x2F;s00115-021-01098-w&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728474&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":599,"discovery_date":"2021-03-17T17:45:54","title":"Compressive Cervical Myelopathy in Patients With Demyelinating Disease of the Central Nervous System: Improvement After Surgery Despite a Late Diagnosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cureus. 2021 Feb 5;13(2):e13161. doi: 10.7759&#x2F;cureus.13161.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Objective We aimed to assess the impact of surgical intervention on outcome in patients diagnosed with demyelinating disorders and cervical degenerative disease warranting surgical intervention. Methods The records of patients with a diagnosis of a demyelinating disorder of the central nervous system who underwent cervical spine surgery at a single institution from 2016 to 2020 were reviewed. Demyelinating disease included multiple sclerosis (MS), neuromyelitis optica, and transverse myelitis (TM). The dates of initial spine symptom onset, recognition of spinal pathology by the primary provider, referral to spine surgery, and spine surgery procedures were collected. Hospital length of stay (LOS) and postoperative outcomes and complications were recorded. Results A total of 19 patients with a diagnosis of demyelinating disorders underwent cervical spine surgery at our institution. Seventeen patients had MS. The average time interval between a documented diagnosis of myelopathy or radiculopathy and referral to the Spine clinic was 67.95 months (M&#x3D;40, SD&#x3D;64.87). Twelve patients had imaging studies depicting degenerative spine disease that would warrant surgical intervention at the time of examination by their primary physician. The average delay for referral to the Spine clinic for these patients was 16.5 months (M&#x3D;5; SD&#x3D;25.36). More than 89% of patients experienced significant neurologic improvement postoperatively. Conclusions There is a delay in the recognition of cervical spine disease amenable to a surgical resolution in patients with demyelinating disorders. Surgical treatment can lead to significant clinical improvement in this patient population even if delayed, and likely carries similar risk to that of the general population.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728163&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728163&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7935266&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;PMC7935266&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7759&#x2F;cureus.13161&gt;10.7759&#x2F;cureus.13161&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728163&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":598,"discovery_date":"2021-03-17T17:45:54","title":"Role of Monoclonal Antibody &quot;Alemtuzumab&quot; in the Treatment of Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cureus. 2021 Feb 9;13(2):e13246. doi: 10.7759&#x2F;cureus.13246.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;This article will review current treatment options for multiple sclerosis (MS) while keeping our primary focus on alemtuzumab, as it is now approved in more than 65 countries. From a pathophysiological point of view, MS is a disabling disease impacting a patient&#39;s life both physically and mentally, leading to devastating social and economic impact. This review will elaborate on alemtuzumab&#39;s role in treating relapsing-remitting MS (RRMS) by comparing its efficacy, side effects, and monitoring with other disease-modifying therapies (DMTs) available in the market. It is a point of great concern not only for physicians but also for neurologists, nephrologists, endocrinologists, dermatologists, and oncologists when encountering long-term effects of alemtuzumab in the life of treated MS patients. We hope that our review will not only benefit treating faculties but also those who are suffering from this devastating disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728194&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728194&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7948316&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;PMC7948316&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7759&#x2F;cureus.13246&gt;10.7759&#x2F;cureus.13246&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728194&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":597,"discovery_date":"2021-03-17T17:45:54","title":"The IL-27&#x2F;IL-27R axis is altered in CD4(+) and CD8(+) T lymphocytes from multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Transl Immunology. 2021 Mar 5;10(3):e1262. doi: 10.1002&#x2F;cti2.1262. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: Pro- and anti-inflammatory properties have been attributed to interleukin-27 (IL-27). Nevertheless, the impact of this cytokine on chronic inflammatory diseases such as multiple sclerosis (MS) remains ill-defined. We investigated the biology of IL-27 and its specific receptor IL-27RÎ± in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Levels of IL-27 and its natural antagonist (IL-27-RÎ±) were measured by ELISA in biological fluids. CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; and CD8&lt;sup&gt;+&lt;&#x2F;sup&gt; T lymphocytes were isolated from untreated relapsing-remitting MS patients and healthy donors. Transcriptome-wide analysis compared T-cell subsets stimulated or not with IL-27. Expression of the IL-27RÎ±, key immune factors, STAT phosphorylation and cytokine production was assessed by flow cytometry.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We observed elevated levels of IL-27 in the serum and cerebrospinal fluid of MS patients compared with controls. Moreover, we show that specific IL-27-mediated effects on T lymphocytes are reduced in MS patients including the induction of PD-L1. IL-27-triggered STAT3 signalling pathway is enhanced in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; and CD8&lt;sup&gt;+&lt;&#x2F;sup&gt; T lymphocytes from MS patients. Elevated IL-27RÎ± levels in serum from MS patients are sufficient to impair the capacity of IL-27 to act on immune cells. We demonstrate that shedding of IL-27RÎ± by activated CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T lymphocytes from MS patients contributes to the increased IL-27RÎ± peripheral levels and consequently can dampen the IL-27 responsiveness.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our work identifies several mechanisms that are altered in the IL-27&#x2F;IL-27R axis in MS patients, especially in T lymphocytes. Our results underline the importance of characterising the biology of cytokines in human patients prior to design new therapeutics.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728050&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728050&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7934284&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;PMC7934284&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;cti2.1262&gt;10.1002&#x2F;cti2.1262&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728050&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":596,"discovery_date":"2021-03-17T17:45:54","title":"Perceived social support, mental health, and marital satisfaction in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Perspect Psychiatr Care. 2021 Mar 17. doi: 10.1111&#x2F;ppc.12760. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: This study aimed to examine the patients&#39; perceived social support, mental health, and marital satisfaction.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN AND METHODS: Data were collected via Patient Information Form, Barthel Index of Activities of Daily Living, Marital Life Scale, Multidimensional Scale of Perceived Social Support, and General Health Questionnaire for 72 patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;FINDINGS: Multiple sclerosis (MS) patients had a moderate level of marital satisfaction. The perceived social support showed positive correlation with marital satisfaction and negative correlation with mental health disorders in MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PRACTICE IMPLICATIONS: These results will facilitate the perception of mental problems, marital satisfaction, and social support in MS patients by the nurses.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728706&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ppc.12760&gt;10.1111&#x2F;ppc.12760&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":595,"discovery_date":"2021-03-17T17:45:54","title":"Overview of Ocular Side Effect of Selinexor","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Oncologist. 2021 Mar 16. doi: 10.1002&#x2F;onco.13756. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND&#x2F;PURPOSE: The aim of this review is to elucidate the type and frequency of ocular adverse events associated with selinexor with a goal to quantify the occurrence of these events in our investigator-initiated trial.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We retrospectively reviewed medical records of 174 patients treated with at least one dose of selinexor in combination with multiple standard chemotherapy or immunotherapy agents between July 2015 and July 2020 at a comprehensive cancer center in the United States. All reported ocular adverse events were assessed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 174 patient medical records were reviewed. All patients received at least one dose of selinexor in combination with multiple standard chemotherapy or immunotherapy agents in our cohort of patients with advanced malignancies. A total of 34 (19.54%) patients experienced 37 ocular adverse events. The most frequently reported ocular symptom was blurred vision, which was reported in 22 (12.6 4%) patients. The most frequently reported treatment-related adverse event was mild age-related nuclear sclerosis (cataract) was reported in 29 (16.66%) patients the with progression reported in 7 (4.0%) patients and dry eye syndrome reported in 21 (12.1%) patients, and 19 (10.9%) of them were diagnosed with mild dry eye. The second most. None of the ocular adverse events required therapy discontinuation CONCLUSION: Our findings highlight that ocular adverse events associated with oral selinexor were mild. The most frequently reported ocular treatment-related adverse events were mild dry eye and progression of age-related nuclear sclerosis. None of the ocular adverse events required therapy discontinuation IMPLICATIONS FOR PRACTICE: Patients receiving selinexor in combination with multiple standard chemotherapy or immunotherapy agents were reviewed, with a total of 34 patients experiencing 37 ocular adverse events. Findings highlight that ocular adverse events associated with oral selinexor were mild. The most frequently reported ocular treatment-related adverse events were mild dry eye and progression of age-related nuclear sclerosis. None of the ocular adverse events required therapy discontinuation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728727&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728727&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;onco.13756&gt;10.1002&#x2F;onco.13756&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728727&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":594,"discovery_date":"2021-03-17T17:45:54","title":"The prospect of dopaminergic therapy in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(2):67-70. doi: 10.17116&#x2F;jnevro202112102167.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Dopamine is a direct mediator of neuroimmune interactions. Recent studies show that by acting on the dopaminergic receptors, it is possible to modulate Th17-immune response, which play a crucial role in the pathogenesis of multiple sclerosis. Dopamine can modulate Th17 cells function as well as dendritic cell-mediated Th17-immune response that allows considering dopaminergic receptors as a new therapeutic target in multiple sclerosis. In this short communication, the prospects of using dopaminergic therapy as a pathogenetic treatment for multiple sclerosis are discussed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728853&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3&quot;&gt;33728853&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.17116&#x2F;jnevro202112102167&gt;10.17116&#x2F;jnevro202112102167&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33728853&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317134551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":593,"discovery_date":"2021-03-17T15:06:22","title":"Comparing the diagnostic value of Echocardiography In Stroke (CEIS) â results of a prospective observatory cohort study","summary":"Echocardiography is one of the main diagnostic tools for the diagnostic workup of stroke and is already well integrated into the clinical workup. However, the value of transthoracic vs. transesophageal echocar...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02136-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":592,"discovery_date":"2021-03-17T15:06:22","title":"Immune-related genes of the larval Holotrichia parallela in response to entomopathogenic nematodes Heterorhabditis beicherriana LF","summary":"Entomopathogenic nematodes (EPNs) emerge as compatible alternatives to conventional insecticides in controlling Holotrichia parallela larvae (Coleoptera: Scarabaeidae). However, the immune responses of H. paralle...","link":"https:&#x2F;&#x2F;bmcgenomics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12864-021-07506-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":591,"discovery_date":"2021-03-17T11:25:53","title":"Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Mar 16;8(3):e979. doi: 10.1212&#x2F;NXI.0000000000000979. Print 2021 May.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remitting multiple sclerosis (RRMS), to describe the association between BVL and clinical measures, and to investigate an effect of treatment escalation on the rate of BVL.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Together, 1903 patients predominantly with RRMS from the Avonex-Steroids-Azathioprine cohort (N &#x3D; 166), the study of early IFN-Î²1a treatment cohort (N &#x3D; 180), and the quantitative MRI cohort (N &#x3D; 1,557) with â¥2 MRI scans and â¥1-year of follow-up were included. Brain MRI scans (N &#x3D; 7,203) were performed using a single 1.5-T machine. Relationships between age or disease duration and global and tissue-specific BVL rates were analyzed using mixed models.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Age was not associated with the rate of BVL (Î² &#x3D; -0.003; Cohen f2 &#x3D; 0.0005; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.39). Although disease duration was associated with the rate of BVL, its effect on the BVL rate was minimal (Î² &#x3D; -0.012; Cohen f2 &#x3D; 0.004; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 4 Ã 10&lt;sup&gt;-5&lt;&#x2F;sup&gt;). Analysis of association between tissue-specific brain volume changes and age (Î² &#x3D; -0.019 to -0.011; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.028-1.00) or disease duration (Î² &#x3D; -0.028 to -0.008; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.16-0.96) confirmed these results. Although increase in the relapse rate (Î² &#x3D; 0.10; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 9 Ã 10&lt;sup&gt;-9&lt;&#x2F;sup&gt;), Expanded Disability Status Scale (EDSS; Î² &#x3D; 0.17; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 8 Ã 10&lt;sup&gt;-5&lt;&#x2F;sup&gt;), and EDSS change (Î² &#x3D; 0.15; adjusted &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 2 Ã 10&lt;sup&gt;-5&lt;&#x2F;sup&gt;) were associated with accelerated rate of BVL, their effect on the rate of BVL was minimal (all Cohen f2 â¤ 0.007). In 94 patients who escalated therapy, the rate of BVL decreased following treatment escalation by 0.29% (Î² &#x3D; -0.29; Cohen f2 &#x3D; 0.133; &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 5.5 Ã 10&lt;sup&gt;-8&lt;&#x2F;sup&gt;).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The rate of BVL is relatively stable throughout the course of RRMS. The accelerated BVL is weakly associated with concurrent higher disease activity, and timely escalation to high-efficacy immunotherapy helps decrease the rate of BVL.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727311&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3&quot;&gt;33727311&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXI.0000000000000979&gt;10.1212&#x2F;NXI.0000000000000979&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727311&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":590,"discovery_date":"2021-03-17T11:25:53","title":"Web-based physical activity intervention for people with progressive multiple sclerosis: application of consensus-based intervention development guidance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Open. 2021 Mar 16;11(3):e045378. doi: 10.1136&#x2F;bmjopen-2020-045378.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: People with progressive multiple sclerosis (PwPMS) report that they recognise the benefits of activity on their physical and psychological health but need support to achieve their physical activity goals. We aimed to systematically develop a theoretically informed intervention that would enable PwPMS to more readily engage in regular physical activity.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN: We used an intervention mapping approach to inform intervention development.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: We conducted semistructured interviews with PwPMS and their families&#x2F;carers and physiotherapists recruited from secondary care settings.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PARTICIPANTS: Fourteen PwPMS with an Expanded Disability Status Scale score of between 6 and 8 and 7 of their families&#x2F;carers and 13 physiotherapists and 1 physiotherapy technician participated.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Interview data suggested that the development of supportive coaching relationships with physiotherapists could promote the ability of PwPMS to achieve a desirable and achievable physical activity plan. These interview data informed the prototype &#39;Lifestyle Exercise and Activity Package for Multiple Sclerosis&#39; (LEAP-MS) consisting of a secure multiuser web-based platform (with an education and activity suite, interactive components enabling selection of exercises, goal setting and activity logging), up to six flexible face-to-face or web-based physiotherapy coaching sessions and remote support via an embedded web-based messaging function that all together draw on specific theory-based methods to achieve physical activity behaviour change, namely active learning, reinforcement, modelling, feedback, facilitation, goal setting and guided practice. Implementation is within a multiuser platform accessible to participants, trained physiotherapists and researchers.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We have followed an inclusive, systematic and transparent process to develop the LEAP-MS intervention that enables detailed description of components, context and guiding principles to inform ongoing evaluation. Importantly, PwPMS expressed the need for autonomy in developing physical activity plans. This has been achieved through the embedding of self-management principles in the design and delivery of the LEAP-MS intervention.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727274&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3&quot;&gt;33727274&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjopen-2020-045378&gt;10.1136&#x2F;bmjopen-2020-045378&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727274&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":589,"discovery_date":"2021-03-17T11:25:53","title":"ILC in chronic inflammation, cancer and targeting with biologicals","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Aspects Med. 2021 Mar 14:100963. doi: 10.1016&#x2F;j.mam.2021.100963. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Since their discovery, Innate Lymphoid Cells (ILC) have emerged as important effector cells, serving multiple roles in maintaining tissue homeostasis and responding to tissue insults. As such, dysregulations of their function and distribution have been observed in a variety of immune-mediated diseases, suggesting a specific role for ILC in the pathophysiology of several disorders including chronic inflammation and cancer. Here, we provide an updated view on ILC biology dissecting their pathological or protective contribution in chronic inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, psoriasis, rheumatoid arthritis, asthma and COPD, atherosclerosis, also exploring ILC role in tumor surveillance and progression. Throughout the review, we will also highlight how the potential dual role of these cells for protective or pathogenic immunity in many inflammatory diseases makes them interesting targets for the development of novel therapeutic strategies, particularly promising.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33726947&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3&quot;&gt;33726947&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.mam.2021.100963&gt;10.1016&#x2F;j.mam.2021.100963&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33726947&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":588,"discovery_date":"2021-03-17T11:25:53","title":"The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Mar 13:102802. doi: 10.1016&#x2F;j.autrev.2021.102802. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727153&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3&quot;&gt;33727153&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autrev.2021.102802&gt;10.1016&#x2F;j.autrev.2021.102802&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727153&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":587,"discovery_date":"2021-03-17T11:25:53","title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurologia. 2021 Mar 13:S0213-4853(21)00026-8. doi: 10.1016&#x2F;j.nrl.2021.01.010. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Late-onset neutropaenia is defined as an absolute neutrophil count of &amp;lt;1.5Ã10&lt;sup&gt;3&lt;&#x2F;sup&gt;cells&#x2F;Î¼L starting&amp;gt;4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of&amp;gt;28 days. Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis. We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33726971&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3&quot;&gt;33726971&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nrl.2021.01.010&gt;10.1016&#x2F;j.nrl.2021.01.010&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33726971&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":586,"discovery_date":"2021-03-17T11:25:52","title":"Pediatric inflammatory demyelinating disorders and mimickers: How to differentiate with MRI?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Mar 13:102801. doi: 10.1016&#x2F;j.autrev.2021.102801. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative disorder of the central nervous system (CNS).While the clinical symptoms of MS most commonly manifest between 20 and 40 years of age, approximately 3 to 10% of all MS patients report that their first inaugural events can occur earlier in life, even in childhood, and thus include the pediatric population. The prevalence of MS onset in childhood&#x2F;adolescence varies between 2.0% and 4.0% of all MS cases according to several extensive studies. The main imaging patterns of pediatric inflammatory demyelinating disorders and mimicking entities, including multiple sclerosis, neuromyelitis optica spectrum disorders, acute disseminated encephalomyelitis, MOG (myelin oligodendrocyte glycoprotein) antibody disorder and differential diagnoses will be addressed in this article, highlighting key points to the differential diagnosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727154&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3&quot;&gt;33727154&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autrev.2021.102801&gt;10.1016&#x2F;j.autrev.2021.102801&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33727154&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317072551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":585,"discovery_date":"2021-03-17T06:05:58","title":"Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Mar 5;354:577541. doi: 10.1016&#x2F;j.jneuroim.2021.577541. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;This study examined the utility of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in primary progressive multiple sclerosis in context with clinical severity, progression, and treatment. Using a single-molecule array (Quanterix), serum protein concentrations were measured from twenty-five participants semiannually for five years. There was no association between levels of either biomarker and disease severity, disease duration, or treatment group. Enrollment sNfL level was not associated with future clinical worsening. Precedent clinical worsening was not associated with last sGFAP measurement. These results suggest a limited role for these biomarkers in primary progressive disease management.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33725477&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317020556&amp;v&#x3D;2.14.3&quot;&gt;33725477&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577541&gt;10.1016&#x2F;j.jneuroim.2021.577541&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33725477&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317020556&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":584,"discovery_date":"2021-03-17T05:05:54","title":"A short-term exercise program in patients with multiple sclerosis: is body mass index important?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Rehabil Res. 2021 Mar 12. doi: 10.1097&#x2F;MRR.0000000000000462. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Obesity is a health problem that can exacerbate the symptoms of multiple sclerosis (MS). In the current study, we aimed to investigate the effectiveness of a short-term exercise program on fatigue, depression, anxiety, and walking performance in normal-weight and overweight patients with MS (PwMS). Sixty-two PwMS were divided into groups according to their BMI (BMI normal&#x2F;BMI high). Also, they were all included in the exercise program. The participants took a moderate-intensity walking program 5 days a week for 4 weeks, including 30 min between 5 min of warm-up and 5 min of cooling periods. Also, patients underwent breathing, posture, flexibility, and stretching exercises for 4 weeks. Fatigue, depression, anxiety, 6-minute walking test (6MWT), and BMI were measured before and after the 4 weeks. After the exercise program, there were statistically significant improvements in fatigue, depression, anxiety, and the 6MWT. However, no relation could be detected between the examined variables and BMI. All patients participated effectively in the exercise program, regardless of BMI. The results obtained from this study support that a short-term exercise program is an effective therapeutic intervention, unrelated to BMI, in improving fatigue, depression, anxiety, and walking performance in PwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724971&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317010552&amp;v&#x3D;2.14.3&quot;&gt;33724971&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;MRR.0000000000000462&gt;10.1097&#x2F;MRR.0000000000000462&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724971&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317010552&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":583,"discovery_date":"2021-03-17T05:05:54","title":"Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Adv Exp Med Biol. 2021;1286:87-105. doi: 10.1007&#x2F;978-3-030-55035-6_6.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Gut microbiota has essential roles in the prevention and progression of multiple sclerosis (MS). The association between the gut microbiota and the central nervous system (CNS) or immune system response of MS patients has been documented in many studies. The composition of the gut microbiota could lead to sensitization or resistance against promotion and development of MS disease. Probiotics are the major part of gut microflorapopulation and could be substituted with tolerogenic probiotics that protect the CNS against autoimmune responses. Tolerogenic probiotics with anti-inflammatory and immuno-modulatory properties have effects on intestinal flora and can reestablish regulatory mucosal and systemic immune responses. Probiotics are able to prevent and restore excessive activation of inflammatory responses, especially autoreactive T cells and inflammatory cytokines. Tolerogenic probiotics, through induction of regulatory T cells and increase of anti-inflammatory cytokines, play a crucial role in controlling inflammation and maintaining tolerance and hemostasis. Therefore, probiotics can be considered as a preventive or therapeutic tool in MS. In the present review, we focus on the immunoregulatory effects of tolerogenic probiotics on the severity of disease, as well as Th1, Th2, and Treg populations in different experimental and human studies of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33725347&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317010552&amp;v&#x3D;2.14.3&quot;&gt;33725347&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;978-3-030-55035-6_6&gt;10.1007&#x2F;978-3-030-55035-6_6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33725347&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317010552&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":582,"discovery_date":"2021-03-17T05:05:54","title":"Significant higher-level C-C motif chemokine ligand 2&#x2F;3 and chemotactic power in cerebral white matter than grey matter in rat and human","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurosci. 2021 Mar 16. doi: 10.1111&#x2F;ejn.15187. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Recent observations indicate cerebral white matter (WM) exhibits a higher chemoattractant capability for immune cells. The C-C motif chemokine ligand 2 and 3 (CCL2, CCL3) are key chemokines for monocytes and T-cells. However, tissue differential of these chemokines is unclear, though the higher CCL2&#x2F;3 mRNA levels were found in rodent WM. It has been shown that more immune cells infiltrated to WM than to grey matter (GM) in multiple sclerosis (MS) and human&#x2F;simian immunodeficiency virus (HIV&#x2F;SIV) infected brains. More nodular lesions have also been identified in the WM of patients with MS or HIV&#x2F;SIV encephalitis. We hypothesize that higher levels of CCL2&#x2F;3 in the WM may associate with neuropathogenesis. To test this hypothesis, we compared CCL2 and CCL3 peptide levels in WM and GM of rat and human, and found both were significantly higher in the WM. Next, we tested the effect of CCL2 on primary rat microglia migration and observed a dose-dependent migratory pattern. Then we assessed effects of WM and GM homogenates on microglia chemotaxis and observed significant stronger effects of WM than GM in a concentration-dependent manner. The concentration-dependent pattern of tissue homogenates on chemotaxis was similar to the effect of CCL2. Finally, we found the chemoattractant effects of WM on microglia were significantly attenuated by addition of a CCL2 receptor blocker to culture medium and a neutralizing antibody against CCL3 functional motif in the WM homogenate. Taking together, these results suggest that CCL2&#x2F;3 played significant roles in the microglia chemotaxis towards WM homogenate.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33725384&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317010552&amp;v&#x3D;2.14.3&quot;&gt;33725384&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ejn.15187&gt;10.1111&#x2F;ejn.15187&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33725384&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210317010552&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":581,"discovery_date":"2021-03-16T18:25:53","title":"Time to walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Mar 16. doi: 10.1111&#x2F;ene.14823. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Requiring a walking aid is a fundamental milestone in MS, represented by Expanded Disability Status Scale (EDSS) score â¥6.0. Here we assess the effect of ocrelizumab on time to EDSSâ¥6.0 in relapsing MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Time to EDSSâ¥6.0 confirmed for â¥24 and â¥48 weeks was assessed over 6.5 years (336 weeks) in the double-blind and open-label extension periods of OPERA I (NCT01247324) and OPERA II (NCT01412333).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Time to reach EDSSâ¥6.0 was significantly delayed in those initially randomized to ocrelizumab versus interferon. Over 6.5 years, the risk of requiring a walking aid confirmed for â¥24 weeks was 34% lower among those who initiated ocrelizumab earlier vs. delayed treatment (average HR DBP+OLE [95%CI]: 0.66 [0.45-0.95]; P &#x3D; 0.024); the risk of requiring a walking aid confirmed for â¥48 weeks was 46% lower (average HR DBP+OLE [95%CI]: 0.54 [0.35-0.83]; P &#x3D; 0.004).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The reduced risk of requiring a walking aid in earlier initiators of ocrelizumab demonstrates the long-term implications of earlier highly effective treatment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724637&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33724637&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14823&gt;10.1111&#x2F;ene.14823&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724637&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":580,"discovery_date":"2021-03-16T18:25:53","title":"MSProDiscuss - Development of a digital anamnesis tool to identify disease progression in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Fortschr Neurol Psychiatr. 2021 Mar 15. doi: 10.1055&#x2F;a-1397-6851. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;During the course of Multiple Sclerosis (MS), most patients with relapsing remitting MS (RRMS) convert to secondary progressive MS (SPMS), an MS-phenotype associated with a steady deterioration of functional ability independent from relapses and worsened prognosis. Due to the heterogeneity of this conversion, SPMS-diagnosis is often challenging and made retrospectively with a delay of several years. In this review, we first discuss advantages and limitations of screening tools for early SPMS-detection such as the &lt;i&gt;SPMS nomogram&lt;&#x2F;i&gt;, the &lt;i&gt;MS prediction score&lt;&#x2F;i&gt;, and the &lt;i&gt;best SPMS definition&lt;&#x2F;i&gt; approach. These screening tools might help to shorten the phase of diagnostic uncertainty. We then focus on the development of &lt;i&gt;MSProDiscuss&lt;&#x2F;i&gt;, a novel web-based tool that helps the treating neurologist to systematically assesses parameters highly relevant for SPMS-conversion during routine anamnesis. These parameters involve disease activity, symptoms, and impacts of the patient&#39;s overall symptoms. In a recent validation study, &lt;i&gt;MSProDiscuss&lt;&#x2F;i&gt; demonstrated high sensitivity, specificity, and interrater reliability. &lt;i&gt;MSProDiscuss&lt;&#x2F;i&gt; does not impose an additional time burden on the treating neurologist and its results are easy to interpret by a simple traffic light system. In first usability tests, it was therefore assessed as a helpful tool for the clinical routine. The early detection of clinically significant progression by diagnostic tools such as &lt;i&gt;MSProDiscuss&lt;&#x2F;i&gt; could open a time-window for therapeutic interventions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723837&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33723837&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1055&#x2F;a-1397-6851&gt;10.1055&#x2F;a-1397-6851&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723837&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":579,"discovery_date":"2021-03-16T18:25:53","title":"Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 16:awab045. doi: 10.1093&#x2F;brain&#x2F;awab045. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Leptomeningeal inflammation in multiple sclerosis is associated with worse clinical outcomes and greater cortical pathology. Despite progress in identifying this process in multiple sclerosis patients using post-contrast fluid-attenuated inversion recovery imaging, early trials attempting to target meningeal inflammation have been unsuccessful. There is a lack of appropriate model systems to screen potential therapeutic agents targeting meningeal inflammation. We utilized ultra-high field (11.7 T) MRI to perform post-contrast imaging in SJL&#x2F;J mice with experimental autoimmune encephalomyelitis induced via immunization with proteolipid protein peptide (PLP139-151) and complete Freund&#39;s adjuvant. Imaging was performed in both a cross-sectional and longitudinal fashion at time points ranging from 2 to 14 weeks post-immunization. Following imaging, we euthanized animals and collected tissue for pathological evaluation, which revealed dense cellular infiltrates corresponding to areas of contrast enhancement involving the leptomeninges. These areas of meningeal inflammation contained B cells (B220+), T cells (CD3+) and myeloid cells (Mac2+). We also noted features consistent with tertiary lymphoid tissue within these areas, namely the presence of peripheral node addressin-positive structures, C-X-C motif chemokine ligand-13 (CXCL13)-producing cells and FDC-M1+ follicular dendritic cells. In the cortex adjacent to areas of meningeal inflammation we identified astrocytosis, microgliosis, demyelination and evidence of axonal stress&#x2F;damage. Since areas of meningeal contrast enhancement persisted over several weeks in longitudinal experiments, we utilized this model to test the effects of a therapeutic intervention on established meningeal inflammation. We randomized mice with evidence of meningeal contrast enhancement on MRI scans performed at 6 weeks post-immunization, to treatment with either vehicle or evobrutinib [a Bruton tyrosine kinase (BTK) inhibitor] for a period of 4 weeks. These mice underwent serial imaging; we examined the effect of treatment on the areas of meningeal contrast enhancement and noted a significant reduction in the evobrutinib group compared to vehicle (30% reduction versus 5% increase; P &#x3D; 0.003). We used ultra-high field MRI to identify areas of meningeal inflammation and to track them over time in SJL&#x2F;J mice with experimental autoimmune encephalomyelitis, and then used this model to identify BTK inhibition as a novel therapeutic approach to target meningeal inflammation. The results of this study provide support for future studies in multiple sclerosis patients with imaging evidence of meningeal inflammation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724342&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33724342&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab045&gt;10.1093&#x2F;brain&#x2F;awab045&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724342&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":578,"discovery_date":"2021-03-16T18:25:53","title":"Efficacy of fingolimod after switching from interferon beta-1a in an adolescent with multiple sclerosis: case report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 16. doi: 10.1007&#x2F;s10072-021-05170-w. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Pediatric-onset multiple sclerosis (POMS) accounts for approximately 2-10% of all cases of multiple sclerosis (MS) and is associated with higher levels of disease activity than adult-onset MS, including higher rates of clinical relapse and a greater incidence of new T2 lesions on magnetic resonance imaging (MRI). First-line therapy for POMS usually includes interferon Î² or glatiramer acetate; however, there is limited evidence from randomized trials regarding the safety and efficacy of these disease-modifying drugs in pediatric patients. Fingolimod represents a second-line therapy option for relapsing-remitting MS in pediatric patients. Here, we report the case of a 14-year-old girl with a diagnosis of POMS who started interferon Î²-1a as first-line therapy and then switched to fingolimod after 12 months due to radiologic progression and clinical relapse. The patient subsequently experienced clinical stability and showed minimal radiologic activity on follow-up MRI. Our case demonstrates the real-world clinical effectiveness and safety of fingolimod in pediatric MS and is in line with the results of previous randomized and observational studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723709&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33723709&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05170-w&gt;10.1007&#x2F;s10072-021-05170-w&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723709&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":577,"discovery_date":"2021-03-16T18:25:53","title":"The effects of Oxygen-Ozone therapy on regulatory T-cell responses in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Biol Int. 2021 Mar 16. doi: 10.1002&#x2F;cbin.11589. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a common degenerative disorder of the central nervous system. The decreased frequency and dysfunction of Treg cell cause inflammation and disease progression. Ozone autohemotherapy can be used as a potential therapeutic approach to regulate the immune system responses and inflammation in MS. For this purpose, 20 relapsing-remitting multiple sclerosis (RRMS) patients were under treatment with Ozone twice weekly for six months. The frequency of Treg cell, the expression levels of the Treg cell-related factors (FoxP3, IL-10, TGF-Î², miR-17, miR-27, and miR-146A), and the secretion levels of IL-10 and TGF-Î² were assessed. We found a significant increase in the number of Treg cell, expression levels of FoxP3, miRNAs (miR-17 and miR-27), IL-10, and TGF-Î² factors in patients after Oxygen-Ozone (O2-O3) therapy compared to before treatment. In contrast, Oxygen-Ozone therapy notably decreased the expression level of miR-146a in treated patients. Interestingly, the secretion levels of both IL-10 and TGF-Î² cytokines were considerably increased in both serum and supernatant of cultured PBMCs in post-treatment condition compared to pre-treatment condition. According to results, Oxygen-Ozone therapy raised the frequency of Treg cell and its relevant factors in treated MS patients. Oxygen-Ozone therapy would be contributed to improving the MS patients by elevating the Treg cell responses. This article is protected by copyright. All rights reserved.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724614&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33724614&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;cbin.11589&gt;10.1002&#x2F;cbin.11589&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724614&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":576,"discovery_date":"2021-03-16T18:25:53","title":"Serum Glial Fibrillary Acidic Protein: a Neuromyelitis Optica Spectrum Disorder Biomarker","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Neurol. 2021 Mar 16. doi: 10.1002&#x2F;ana.26067. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity and assessed the impact of inebilizumab treatment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: N-MOmentum was a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial, in adults with NMOSD. sGFAP levels were measured by single-molecule arrays (SIMOA) in 1260 serial and attack-related samples from 215 N-MOmentum participants (92% aquaporin 4-immunoglobulin G-seropositive) and in control samples (from healthy donors and patients with relapsing-remitting multiple sclerosis).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: At baseline, 62 participants (29%) exhibited high sGFAP concentrations (â¥170 pg&#x2F;mL; â¥2 standard deviations above healthy donor mean concentration) and were more likely to experience an adjudicated attack than participants with lower baseline concentrations (hazard ratio [95% confidence interval], 3.09 [1.6-6.1], p &#x3D; 0.001). Median (interquartile range [IQR]) concentrations increased within 1 week of an attack (baseline: 168.4 [128.9-449.7] pg&#x2F;mL; attack: 2160.1 [302.7-9455.0] pg&#x2F;mL; p &#x3D; 0.0015) and correlated with attack severity (median fold change from baseline (FC) [IQR], minor attacks: 1.06 [0.9-7.4]; major attacks: 34.32 [8.7-107.5]; p &#x3D; 0.023). This attack-related increase in sGFAP occurred primarily in placebo-treated participants (FC: 20.2 [4.4-98.3]; p &#x3D; 0.001) and was not observed in inebilizumab-treated participants (FC: 1.1 [0.8-24.6]; p &amp;gt; 0.05). Five participants (28%) with elevated baseline sGFAP reported neurological symptoms leading to non-adjudicated attack assessments.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: sGFAP may serve as a biomarker of NMOSD activity, attack risk, and treatment effects. ClinicalTrials.gov (NCT02200770). This article is protected by copyright. All rights reserved.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724534&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33724534&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;ana.26067&gt;10.1002&#x2F;ana.26067&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724534&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":575,"discovery_date":"2021-03-16T18:25:53","title":"Small compounds mimicking the adhesion molecule L1 improve recovery in a zebrafish demyelination model","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Mar 15;11(1):5878. doi: 10.1038&#x2F;s41598-021-85412-1.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Demyelination leads to a loss of neurons, which results in, among other consequences, a severe reduction in locomotor function, and underlies several diseases in humans including multiple sclerosis and polyneuropathies. Considerable clinical progress has been made in counteracting demyelination. However, there remains a need for novel methods that reduce demyelination while concomitantly achieving remyelination, thus complementing the currently available tools to ameliorate demyelinating diseases. In this study, we used an established zebrafish demyelination model to test selected compounds, following a screening in cell culture experiments and in a mouse model of spinal cord injury that was aimed at identifying beneficial functions of the neural cell adhesion molecule L1. In comparison to mammalian nervous system disease models, the zebrafish allows testing of potentially promotive compounds more easily than what is possible in mammals. We found that our selected compounds tacrine and duloxetine significantly improved remyelination in the peripheral and central nervous system of transgenic zebrafish following pharmacologically induced demyelination. Given that both molecules are known to positively affect functions other than those related to L1 and in other disease contexts, we propose that their combined beneficial function raises hope for the use of these compounds in clinical settings.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723325&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33723325&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-85412-1&gt;10.1038&#x2F;s41598-021-85412-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723325&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":574,"discovery_date":"2021-03-16T18:25:53","title":"Characterization of a natural variant of human NDP52 and its functional consequences on mitophagy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Death Differ. 2021 Mar 15. doi: 10.1038&#x2F;s41418-021-00766-3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The role of mitophagy, a process that allows the removal of damaged mitochondria from cells, remains unknown in multiple sclerosis (MS), a disease that is found associated with dysfunctional mitochondria. Here we have qualitatively and quantitatively studied the main players in PINK1-mediated mitophagy in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting MS. We found the variant c.491G&amp;gt;A (rs550510, p.G140E) of NDP52, one of the major mitophagy receptor genes, associated with a MS cohort. Through the characterization of this variant, we discovered that the residue 140 of human NDP52 is a crucial modulator of NDP52&#x2F;LC3C binding, promoting the formation of autophagosomes in order to drive efficient mitophagy. In addition, we found that in the PBMC population, NDP52 is mainly expressed in B cells and by ensuring efficient mitophagy, it is able to limit the production of the proinflammatory cytokine TNF-Î± following cell stimulation. In sum, our results contribute to a better understanding of the role of NDP52 in mitophagy and underline, for the first time, a possible role of NDP52 in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723372&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33723372&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41418-021-00766-3&gt;10.1038&#x2F;s41418-021-00766-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723372&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":573,"discovery_date":"2021-03-16T18:25:53","title":"The hedgehog pathway suppresses neuropathogenesis in CD4 T cell-driven inflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 16:awab083. doi: 10.1093&#x2F;brain&#x2F;awab083. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The concerted actions of the CNS and the immune system are essential to coordinate the outcome of neuroinflammatory responses. Yet, the precise mechanisms involved in this crosstalk and their contribution to the pathophysiology of neuroinflammatory diseases largely elude us. Here, we show that the CNS-endogenous hedgehog pathway, a signal triggered as part of the host response during the inflammatory phase of multiple sclerosis and experimental autoimmune encephalomyelitis, attenuates the pathogenicity of human and mouse effector CD4 T cells by regulating their production of inflammatory cytokines. Using a murine genetic model in which the hedgehog signaling is compromised in CD4 T cells, we show that the hedgehog pathway acts on CD4 T cells to suppress pathogenic hallmarks of autoimmune neuroinflammation, including demyelination and axonal damage, and thus mitigates the development of experimental autoimmune encephalomyelitis. Impairment of hedgehog signaling in CD4 T cells exacerbates brain-brainstem-cerebellum inflammation and leads to the development of atypical disease. Moreover, we present evidence that hedgehog signaling regulates the pathogenic profile of CD4 T cells by limiting their production of inflammatory cytokines GM-CSF and IFN-Î³ and by antagonizing their inflammatory program at the transcriptome level. Likewise, hedgehog signaling attenuates the inflammatory phenotype of human CD4 memory T cells. From a therapeutic point of view, our study underlines the potential of harnessing the hedgehog pathway to counteract ongoing excessive CNS inflammation as systemic administration of a hedgehog agonist after disease onset effectively halts disease progression and significantly reduces neuroinflammation and the underlying neuropathology. We thus unveil a previously unrecognized role for the hedgehog pathway in regulating pathogenic inflammation within the CNS, but also propose to exploit its ability to modulate this neuroimmune network as a strategy to limit the progression of ongoing neuroinflammation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33723591&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab083&gt;10.1093&#x2F;brain&#x2F;awab083&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":572,"discovery_date":"2021-03-16T18:25:53","title":"Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;JAMA Neurol. 2021 Mar 16. doi: 10.1001&#x2F;jamaneurol.2021.0627. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;IMPORTANCE: Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus that has no proven effective treatment. Although rare cases of PML have occurred with other anti-CD20 therapies, there had been no prior cases associated with ocrelizumab.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To report the first ever case of PML occurring with ocrelizumab monotherapy in a patient with progressive multiple sclerosis without prior immunomodulation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN, SETTING, AND PARTICIPANT: This case was reported from an academic medical center. The patient had multiple sclerosis while receiving ocrelizumab monotherapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;EXPOSURES: Ocrelizumab monotherapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A 78-year-old man with progressive multiple sclerosis treated with ocrelizumab monotherapy for 2 years presented with 2 weeks of progressive visual disturbance and confusion. Examination demonstrated a right homonymous hemianopia, and magnetic resonance imaging revealed an enlarging nonenhancing left parietal lesion without mass effect. Cerebrospinal fluid revealed 1000 copies&#x2F;mL of JC virus, confirming the diagnosis of PML. Blood work on diagnosis revealed grade 2 lymphopenia, with absolute lymphocyte count of 710&#x2F;Î¼L, CD4 of 294&#x2F;Î¼L (reference range, 325-1251&#x2F;Î¼L), CD8 of 85&#x2F;Î¼L (reference range, 90-775&#x2F;Î¼L), CD19 of 1&#x2F;Î¼L, preserved CD4&#x2F;CD8 ratio (3.45), and negative HIV serology. Retrospective absolute lymphocyte count revealed intermittent grade 1 lymphopenia that preceded ocrelizumab (absolute lymphocyte count range, 800-1200&#x2F;Î¼L). The patient&#39;s symptoms progressed over weeks to involve bilateral visual loss, right-sided facial droop, and dysphasia. Ocrelizumab was discontinued and off-label pembrolizumab treatment was initiated. The patient nevertheless declined rapidly and ultimately died. PML was confirmed at autopsy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS AND RELEVANCE: In this case report, PML occurrence was likely a result of the immunomodulatory function of ocrelizumab as well as age-related immunosenescence. This case report emphasizes the importance of a thorough discussion of the risks and benefits of ocrelizumab, especially in patients at higher risk for infections such as elderly patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724354&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33724354&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1001&#x2F;jamaneurol.2021.0627&gt;10.1001&#x2F;jamaneurol.2021.0627&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724354&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":571,"discovery_date":"2021-03-16T18:25:53","title":"Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Mar 16. doi: 10.1111&#x2F;ene.14824. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Reaching Expanded Disability Status Scale (EDSS) â¥7.0 represents the requirement for a wheelchair. Here we : (1) assess the effect of ocrelizumab on time to EDSS â¥7.0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP); (2) quantify likely long-term benefits by extrapolating results; (3) assess the plausibility of extrapolations, using an independent real-world cohort (MSBase registry; ACTRN12605000455662).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Post-hoc analyses assessing time to 24-week confirmed EDSS â¥7.0 in two cohorts of patients with PPMS (baseline EDSS 3.0-6.5) were investigated, in ORATORIO and MSBase.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In the ORATORIO DBP+ECP, ocrelizumab reduced the risk of 24-week confirmed EDSS â¥7.0 (hazard ratio&#x3D;0.54, 95%CI: 0.31-0.92, P &#x3D; 0.022). Extrapolated median time to 24-week confirmed EDSS â¥7.0 was 12.1 and 19.2 years for placebo and ocrelizumab, respectively (7.1-year delay [95%CI: -4.3-18.4]). In MSBase, the median time to 24-week confirmed EDSS â¥7.0 was 12.4 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Compared with placebo, ocrelizumab significantly delayed time to 24-week confirmed wheelchair requirement in ORATORIO. The plausibility of the extrapolated median time to reach this milestone in the placebo group was supported by observed real-world data from MSBase. Extrapolated benefits for ocrelizumab over placebo could represent a truly meaningful delay in loss of ambulation and independence.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724638&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3&quot;&gt;33724638&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14824&gt;10.1111&#x2F;ene.14824&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33724638&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316142551&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":570,"discovery_date":"2021-03-16T17:24:26","title":"BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS&#x2F;FTD model","summary":"An intronic GGGGCC (G4C2) hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), referred to as C9ALS&#x2F;FTD. No ...","link":"https:&#x2F;&#x2F;clinicalepigeneticsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13148-021-01039-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":569,"discovery_date":"2021-03-16T17:24:26","title":"Effects of a positive thinking program on hope and sleep quality in Iranian patients with thalassemia: a randomized clinical trial","summary":"Thalassemia have a negative impact on the patients&#39; psychological health and sleep quality. This study aimed to determine the effects of a positive thinking training program on hope and sleep quality of patien...","link":"https:&#x2F;&#x2F;bmcpsychology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40359-021-00547-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":568,"discovery_date":"2021-03-16T17:24:26","title":"Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models","summary":"Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no ...","link":"https:&#x2F;&#x2F;cancerandmetabolism.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40170-021-00249-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":567,"discovery_date":"2021-03-16T15:23:37","title":"Trait mindfulness is primarily associated with depression and not with fatigue in multiple sclerosis (MS): implications for mindfulness-based interventions","summary":"Persons with MS (PwMS) often display symptoms of depression and fatigue. Mindfulness-based interventions are known to counteract these symptoms. However, to-date the exact relations between trait mindfulness, ...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02120-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":566,"discovery_date":"2021-03-16T15:23:37","title":"Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study","summary":"The reports of neurological symptoms are increasing in cases with coronavirus disease 2019 (COVID-19). This multi-center prospective study was conducted to determine the incidence of neurological manifestation...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02152-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":565,"discovery_date":"2021-03-16T12:13:25","title":"Multiple ways to a dead end: diverse mechanisms by which ALS mutant genes induce cell death","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Cycle. 2021 Mar 15:1-16. doi: 10.1080&#x2F;15384101.2021.1886661. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Amyotrophic Lateral Sclerosis (ALS) is a deadly neuromuscular disorder caused by progressive motor neuron loss in the brain and spinal cord. Over the past decades, a number of genetic mutations have been identified that cause or are associated with ALS disease progression. Numerous genes harbor ALS mutations, and they encode proteins displaying a wide range of physiological functions, with limited overlap. Despite the divergent functions, mutations in these genes typically trigger protein aggregation, which can confer gain- and&#x2F;or loss-of-function to a number of essential cellular processes. Nuclear processes such as mRNA splicing and the response to DNA damage are significantly affected in ALS patients. Cytoplasmic organelles such as mitochondria are damaged by ALS mutant proteins. Processes that maintain cellular homeostasis such as autophagy, nonsense-mediated mRNA decay and nucleocytoplasmic transport, are also impaired by ALS mutations. Here, we review the multiple mechanisms by which mutations in major ALS-associated genes, such as &lt;i&gt;TARDBP, C9ORF72&lt;&#x2F;i&gt; and &lt;i&gt;FUS&lt;&#x2F;i&gt;, lead to impairment of essential cellular processes.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33722167&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3&quot;&gt;33722167&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;15384101.2021.1886661&gt;10.1080&#x2F;15384101.2021.1886661&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33722167&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":564,"discovery_date":"2021-03-16T12:13:25","title":"Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-beta therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurologia. 2021 Mar 12:S0213-4853(21)00011-6. doi: 10.1016&#x2F;j.nrl.2021.02.002. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33722454&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3&quot;&gt;33722454&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nrl.2021.02.002&gt;10.1016&#x2F;j.nrl.2021.02.002&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33722454&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":563,"discovery_date":"2021-03-16T12:13:25","title":"High-salt diet suppresses autoimmune demyelination by regulating the blood-brain barrier permeability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2025944118. doi: 10.1073&#x2F;pnas.2025944118.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Sodium chloride, &quot;salt,&quot; is an essential component of daily food and vitally contributes to the body&#39;s homeostasis. However, excessive salt intake has often been held responsible for numerous health risks associated with the cardiovascular system and kidney. Recent reports linked a high-salt diet (HSD) to the exacerbation of artificially induced central nervous system (CNS) autoimmune pathology through changes in microbiota and enhanced T&lt;sub&gt;H&lt;&#x2F;sub&gt;17 cell differentiation [M. Kleinewietfeld &lt;i&gt;et al.&lt;&#x2F;i&gt;, &lt;i&gt;Nature&lt;&#x2F;i&gt; 496, 518-522 (2013); C. Wu &lt;i&gt;et al.&lt;&#x2F;i&gt;, &lt;i&gt;Nature&lt;&#x2F;i&gt; 496, 513-517 (2013); N. Wilck &lt;i&gt;et al.&lt;&#x2F;i&gt;, &lt;i&gt;Nature&lt;&#x2F;i&gt; 551, 585-589 (2017)]. However, there is no evidence that dietary salt promotes or worsens a spontaneous autoimmune disease. Here we show that HSD suppresses autoimmune disease development in a mouse model of spontaneous CNS autoimmunity. We found that HSD consumption increased the circulating serum levels of the glucocorticoid hormone corticosterone. Corticosterone enhanced the expression of tight junction molecules on the brain endothelial cells and promoted the tightening of the blood-brain barrier (BBB) thereby controlling the entry of inflammatory T cells into the CNS. Our results demonstrate the multifaceted and potentially beneficial effects of moderately increased salt consumption in CNS autoimmunity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723078&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3&quot;&gt;33723078&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1073&#x2F;pnas.2025944118&gt;10.1073&#x2F;pnas.2025944118&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723078&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":562,"discovery_date":"2021-03-16T12:13:25","title":"Emerging role of cannabinoids and synthetic cannabinoid receptor 1&#x2F;cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Cancer Res Ther. 2021 Jan-Mar;17(1):1-9. doi: 10.4103&#x2F;jcrt.JCRT_488_18.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cannabis was extensively utilized for its medicinal properties till the 19&lt;sup&gt;th&lt;&#x2F;sup&gt; century. A steep decline in its medicinal usage was observed later due to its emergence as an illegal recreational drug. Advances in technology and scientific findings led to the discovery of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis, that further led to the discovery of endogenous cannabinoids system consisting of G-protein-coupled receptors - cannabinoid receptor 1 and cannabinoid receptor 2 along with their ligands, mainly anandamide and 2-arachidonoylglycerol. Endocannabinoid (EC) is shown to be a modulator not only for physiological functions but also for the immune system, endocrine network, and central nervous system. Medicinal research and meta-data analysis over the last few decades have shown a significant potential for both THC and cannabidiol (CBD) to exert palliative effects. People suffering from many forms of advanced stages of cancers undergo chemotherapy-induced nausea and vomiting followed by severe and chronic neuropathic pain and weight loss. THC and CBD exhibit effective analgesic, anxiolytic, and appetite-stimulating effect on patients suffering from cancer. Drugs currently available in the market to treat such chemotherapy-induced cancer-related ailments are Sativex (GW Pharmaceutical), Dronabinol (Unimed Pharmaceuticals), and Nabilone (Valeant Pharmaceuticals). Apart from exerting palliative effects, THC also shows promising role in the treatment of cancer growth, neurodegenerative diseases (multiple sclerosis and Alzheimer&#39;s disease), and alcohol addiction and hence should be exploited for potential benefits. The current review discusses the nature and role of CB receptors, specific applications of cannabinoids, and major studies that have assessed the role of cannabinoids in cancer management.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723124&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3&quot;&gt;33723124&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.4103&#x2F;jcrt.JCRT_488_18&gt;10.4103&#x2F;jcrt.JCRT_488_18&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33723124&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210316081323&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":561,"discovery_date":"2021-03-16T11:53:56","title":"Long nonâcoding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer","summary":"Bone metastasis is the leading cause of mortality and reduced quality of life in patients with metastatic prostate cancer (PCa). Long non-coding RNA activated by DNA damage (NORAD) has been observed to have an...","link":"https:&#x2F;&#x2F;jeccr.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13046-021-01891-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":560,"discovery_date":"2021-03-16T08:53:55","title":"Systemic lupus Erythematosus and geomagnetic disturbances: a time series analysis","summary":"To examine the influence of solar cycle and geomagnetic effects on SLE disease activity.","link":"https:&#x2F;&#x2F;ehjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12940-021-00692-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":559,"discovery_date":"2021-03-16T03:13:26","title":"Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 15:1352458521999970. doi: 10.1177&#x2F;1352458521999970. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: People with multiple sclerosis (MS) experience myriad symptoms that negatively affect their quality of life. Despite significant progress in rehabilitation strategies for people living with relapsing-remitting MS (RRMS), the development of similar strategies for people with progressive MS has received little attention.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To highlight key symptoms of importance to people with progressive MS and stimulate the design and implementation of high-quality studies focused on symptom management and rehabilitation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A group of international research experts, representatives from industry, and people affected by progressive MS was convened by the International Progressive MS Alliance to devise research priorities for addressing symptoms in progressive MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Based on information from the MS community, we outline a rationale for highlighting four symptoms of particular interest: fatigue, mobility and upper extremity impairment, pain, and cognitive impairment. Factors such as depression, resilience, comorbidities, and psychosocial support are described, as they affect treatment efficacy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: This coordinated call to action-to the research community to prioritize investigation of effective symptom management strategies, and to funders to support them-is an important step in addressing gaps in rehabilitation research for people affected by progressive MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33720795&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3&quot;&gt;33720795&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521999970&gt;10.1177&#x2F;1352458521999970&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33720795&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":558,"discovery_date":"2021-03-16T03:13:26","title":"Restless Legs Syndrome and Periodic Limb Movements in 86 patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sleep. 2021 Mar 15:zsab066. doi: 10.1093&#x2F;sleep&#x2F;zsab066. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STUDY OBJECTIVES: To assess the frequency of restless legs syndrome (RLS), periodic limb movements during sleep (PLMS) and their overlap in a large sample of patients with multiple sclerosis (MS). To compare clinical and paraclinical findings among four sub-groups of patients: RLS-&#x2F;PLMS- (patients without RLS and PLMS), RLS+&#x2F;PLMS- (patients with RLS and without PLMS), RLS-&#x2F;PLMS (patients without RLS and with PLMS), RLS+&#x2F;PLMS+ (patients with both RLS and PLMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this cross-sectional, observational, instrumental study, eighty-six patients (M&#x2F;F: 27&#x2F;59; mean age 48.0 Â± 10.8 years) with a diagnosis of MS underwent a telephone interview assessing the five standard diagnostic criteria for RLS. Seventy-six participants underwent polysomnography (PSG) and maintenance of wakefulness test. Instrumental and clinical findings were subsequently statistically compared to investigate their association with RLS and PLMS index (PLMSI).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: RLS and PLMS (PLMSI â¥15&#x2F;h) frequency in patients with MS was of 31.4% and 31.6% respectively. Among patients with RLS, 37.5% had a PLMSI â¥15&#x2F;h. RLS-&#x2F;PLMS+ group showed higher wake after sleep onset (p &#x3D; 0.01), stage shifts per hour (p &#x3D; 0.03), increased stage N1 (p &#x3D; 0.03) and reduction in stage N3 (p &#x3D; 0.01) compared to RLS-&#x2F;PLMS-. RLS had no influence on clinical and PSG parameters (p &#x3D; 0.45).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: RLS is highly frequent in patients with MS. The frequency of PLMS is comparable to the general population. The low percentage of patients with RLS having a high PLMSI, together with the absence of correlation between RLS and female gender and older age, support the existence of a distinct symptomatic form of RLS in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33720378&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3&quot;&gt;33720378&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;sleep&#x2F;zsab066&gt;10.1093&#x2F;sleep&#x2F;zsab066&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33720378&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":557,"discovery_date":"2021-03-16T03:13:26","title":"The brain 3beta-HSD up-regulation in response to deteriorating effects of background emotional stress: an animal model of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Metab Brain Dis. 2021 Mar 15. doi: 10.1007&#x2F;s11011-021-00708-5. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The brain 3Î²-hydroxysteroid dehydrogenase (3Î²-HSD), is the enzyme that catalyzes the biosynthesis of a neuroprotective factor, progesterone. The regulation of 3Î²-HSD in response to stress exposure in the cuprizone-induced model of Multiple Sclerosis was investigated and the reaction related to the demyelination extremity. 32 female Wistar rats divided into four groups (i.e., control group (Cont), non-stress cuprizone treated (N-CPZ), physical stress- cuprizone treated (P-CPZ) and emotional stress- cuprizone treated (E-CPZ). A witness foot-shock model used to induce background stress for 5 days. An elevated-plus maze applied to validate the stress induction. Followed by 6 weeks of cuprizone treatment, the Y-maze test performed to confirm brain demyelination. 3Î²-HSD gene expression as an indicator of progesterone synthesis examined. At the behavioral level, both stressed groups reflected more impaired spatial memory compared to the N-CPZ group (p &amp;lt; 0.01), with more severe results in the E-CPZ group (p &amp;lt; 0.01). The results of mRNA expression of 3Î²-HSD illustrated significant elevation in all cuprizone treated groups (p &amp;lt; 0.001) with a higher up-regulation (p &amp;lt; 0.001) in the E-CPZ group. Background stress -particularly emotional type- exacerbates the demyelination caused by cuprizone treatment. The brain up-regulates the 3Î²-HSD gene expression as a protective response relative to the myelin degradation extent.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33721183&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3&quot;&gt;33721183&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11011-021-00708-5&gt;10.1007&#x2F;s11011-021-00708-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33721183&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":556,"discovery_date":"2021-03-16T03:13:26","title":"Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Vis Exp. 2021 Feb 28;(168). doi: 10.3791&#x2F;62094.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a neuroinflammatory disease with expanding axonal and neuronal degeneration and demyelination in the central nervous system, leading to motor dysfunctions, psychical disability, and cognitive impairment during MS progression. Positron emission tomography (PET) is an imaging technique able to quantify in vivo cellular and molecular alterations. Radiotracers with affinity to intact myelin can be used for in vivo imaging of myelin content changes over time. It is possible to detect either an increase or decrease in myelin content, what means this imaging technique can detect demyelination and remyelination processes of the central nervous system. In this protocol we demonstrate how to use PET imaging to detect myelin changes in the lysolecithin rat model, which is a model of focal demyelination lesion (induced by stereotactic injection) (i.e., a model of multiple sclerosis disease). &lt;sup&gt;11&lt;&#x2F;sup&gt;C-PIB PET imaging was performed at baseline, and 1 week and 4 weeks after stereotaxic injection of lysolecithin 1% in the right striatum (4 ÂµL) and corpus callosum (3 ÂµL) of the rat brain, allowing quantification of focal demyelination (injection site after 1 week) and the remyelination process (injection site at 4 weeks). Myelin PET imaging is an interesting tool for monitoring in vivo changes in myelin content which could be useful for monitoring demyelinating disease progression and therapeutic response.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33720130&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3&quot;&gt;33720130&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3791&#x2F;62094&gt;10.3791&#x2F;62094&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33720130&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315225416&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":555,"discovery_date":"2021-03-15T19:59:51","title":"Redistributing ill-defined causes of death â a case study from the BURDEN 2020-project in Germany","summary":"The cause of death statistics in Germany include a relatively high share (26% in 2017) of ill-defined deaths (IDD). To make use of the cause of death statistics for Burden of Disease calculations we redistribu...","link":"https:&#x2F;&#x2F;archpublichealth.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13690-021-00535-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":554,"discovery_date":"2021-03-15T19:59:51","title":"Ultrasound and non-ultrasound imaging techniques in the assessment of diaphragmatic dysfunction","summary":"Diaphragm muscle dysfunction is increasingly recognized as an important element of several diseases including neuromuscular disease, chronic obstructive pulmonary disease and diaphragm dysfunction in criticall...","link":"https:&#x2F;&#x2F;bmcpulmmed.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12890-021-01441-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":553,"discovery_date":"2021-03-15T19:59:22","title":"Lateral Suboccipital Approach in Semisitting Position for Resection of Vagal Schwannoma: 2-Dimensional Operative Video","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Surg B Skull Base. 2021 Feb;82(Suppl 1):S51-S52. doi: 10.1055&#x2F;s-0040-1701656. Epub 2020 Sep 17.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We present a case of a sizeable vagal schwannoma that was resected through a lateral suboccipital approach in semisitting position. An extra-axial lesion, occupying the left cerebellomedullary cistern and extending from the pontomedullary junction to the jugular foramen was incidentally discovered in a 40-year-old woman afflicted with secondary progressive multiple sclerosis during repeated magnetic resonance imaging ( Fig. 1 ). On physical examination, a mild deviation of the uvula to the right and a diminished gag reflex were observed. The patient was referred to our department after considerable growth of the lesion was noted and a broad interdisciplinary consensus was reached to treat the lesion surgically. A gross total resection was achieved, histopathology confirmed a WHO I schwannoma with a low proliferation index. Postoperative dysphonia resolved completely within a few weeks, there was no collateral neurological deficit and especially no functional dysphagia. At 3-year follow-up, there was no indication of residual or recurrence. This 2-dimensional video demonstrates pre- and postoperative imaging, positioning and set-up of operating room, anatomical and surgical nuances of the skull base approach, and the operative technique for microdissection of the schwannoma from the critical neurovascular structures ( Fig. 2 ). In summary, the lateral suboccipital approach in semisitting position is a powerful tool in the armamentarium for the microsurgical management of various pathologies residing in the posterior cranial fossa, especially large and vascularized schwannomas. Provided the necessary anesthesiological precautions and intraoperative procedures the semisitting position is safe and effective. The link to the video can be found at: https:&#x2F;&#x2F;youtu.be&#x2F;-9o_qJGkQhg .&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717819&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33717819&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7936039&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7936039&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1055&#x2F;s-0040-1701656&gt;10.1055&#x2F;s-0040-1701656&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717819&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":552,"discovery_date":"2021-03-15T19:59:22","title":"Differential Gene Expression Patterns in Blood and Cerebrospinal Fluid of Multiple Sclerosis and Neuro-Behcet Disease","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Genet. 2021 Feb 26;12:638236. doi: 10.3389&#x2F;fgene.2021.638236. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Inflammatory demyelinating disorders of the central nervous system are debilitating conditions of the young adult, here we focus on multiple sclerosis (MS) and neuro-BehÃ§et disease (NBD). MS is an autoimmune disorder of the central nervous system. NBD, a neurological manifestation of an idiopathic chronic relapsing multisystem inflammatory disease, the behÃ§et disease. The diagnosis of MS and NBD relies on clinical symptoms, magnetic resonance imaging and laboratory tests. At first onset, clinical and imaging similarities between the two disorders may occur, making differential diagnosis challenging and delaying appropriate management. Aiming to identify additional discriminating biomarker patterns, we measured and compared gene expression of a broad panel of selected genes in blood and cerebrospinal fluid (CSF) cells of patients suffering from NBD, MS and non inflammatory neurological disorders (NIND). To reach this aim, bivariate and multivariate analysis were applied. The Principal Analysis Component (PCA) highlighted distinct profiles between NBD, MS, and controls. Transcription factors foxp3 in the blood along with IL-4, IL-10, and IL-17 expressions were the parameters that are the main contributor to the segregation between MS and NBD clustering. Moreover, parameters related to cellular activation and inflammatory cytokines within the CSF clearly differentiate between the two inflammatory diseases and the controls. We proceeded to ROC analysis in order to identify the most distinctive parameters between both inflammatory neurological disorders. The latter analysis suggested that IL-17, CD73 in the blood as well as IL-1Î² and IL-10 in the CSF were the most discriminating parameters between MS and NBD. We conclude that combined multi-dimensional analysis in blood and CSF suggests distinct mechanisms governing the pathophysiology of these two neuro-inflammatory disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33719347&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33719347&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7954360&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7954360&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fgene.2021.638236&gt;10.3389&#x2F;fgene.2021.638236&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33719347&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":551,"discovery_date":"2021-03-15T19:59:22","title":"Animal modeling of lower urinary tract dysfunction associated with multiple sclerosis: Part I: Justification of the mouse model for MS research","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurourol Urodyn. 2021 Mar 14. doi: 10.1002&#x2F;nau.24649. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Lower urinary tract symptoms and dysfunction (LUTS&#x2F;LUTD) contribute to loss of quality of life, morbidity, and need for medical intervention in most patients with multiple sclerosis (MS). Although MS is an inflammatory neurodegenerative disease, clinical manifestations including continence control disorders have traditionally been attributed to the loss of neural signaling due to neurodegeneration. Clinical approaches to MS-LUTS&#x2F;LUTD have focused on addressing symptoms in the context of urodynamic dysfunctions as pathophysiologic understandings are incomplete. The mouse model provides a useful research platform for the discovery of more detailed molecular, cellular, and tissue-level knowledge of the disease and its clinical manifestations. The aim of this two-part review is to provide a state-of-the-art update on the use of the mouse model for MS research, with a focus on lower urinary tract symptoms. Part I presents a summary of the current understanding of MS pathophysiology, the impact on lower urinary tract symptoms, and briefly introduces the types of mouse models available to study MS. Part II presents the common animal models that are currently available to study MS, their mechanism, relevance to MS-LUTS&#x2F;LUTD and their urinary pathophysiology, advantages, and disadvantages.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33719097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33719097&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;nau.24649&gt;10.1002&#x2F;nau.24649&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33719097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":550,"discovery_date":"2021-03-15T19:59:22","title":"Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT() Autoinjector: A Prospective Observational Cohort Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 24;12:643126. doi: 10.3389&#x2F;fneur.2021.643126. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; In patients with multiple sclerosis (MS), non-adherence to disease-modifying drug therapy is associated with an increased rate of MS relapses. Early identification of patients at risk of non-adherence would allow provision of timely and individualized support. The aim of the BETAPREDICT study was to investigate potential predictors of adherence in patients with MS in Germany treated with interferon Î²-1b (IFNÎ²-1b) using the BETACONNECTÂ® autoinjector. &lt;b&gt;Methods:&lt;&#x2F;b&gt; BETAPREDICT was a national, multi-center, prospective, non-interventional, single-arm, 24-month cohort study of patients with relapsing-remitting MS or clinically isolated syndrome receiving IFNÎ²-1b via the BETACONNECTÂ® autoinjector (ClinicalTrials.gov: NCT02486640). Injection data were captured by the autoinjector. The primary objective was to determine baseline predictors of compliance, persistence, and adherence to IFNÎ²-1b treatment after 12- and 24 months using multivariable-adjusted regression. Secondary objectives included evaluation of satisfaction with the autoinjector, injection site pain, vitamin and nutrient supplementation, clinical course, and patient-related outcome measures. &lt;b&gt;Results:&lt;&#x2F;b&gt; Of 165 patients enrolled, 153 were available for analysis (120 with autoinjector data). Seventy-two patients left the study prematurely. Compliance (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 120), persistence (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 153), and adherence (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 120) at 24 months were 89.1, 53.6, and 41.7%, respectively. Compliance at 12- and 24 months was predicted by intake of vitamin D supplements and absence of specific injection site reactions. Positive predictors of persistence included age (at 12- and 24 months) and previous duration of treatment (at 12 months), while intake of vitamins&#x2F;nutrients other than vitamin D was a negative predictor (at 12 months). Positive predictors of adherence at 24 months were age and being experienced with IFNÎ²-1b. Higher scores in specific SF-36 subscales were positive predictors of medication-taking behavior at 24 months. Satisfaction with the autoinjector was high at baseline and 24 months (median score: 9 out of 10). &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Compliance with IFNÎ²-1b treatment among participants still under observation remained high over a 24-month period, while persistence and adherence continuously declined. Multiple factors affected medication-taking behavior, including patient characteristics, treatment history, injection site reactions, patients&#39; perception of their health and support programs. The importance of these factors may differ among patients according to their individual situation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33716945&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33716945&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7943887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7943887&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.643126&gt;10.3389&#x2F;fneur.2021.643126&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33716945&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":549,"discovery_date":"2021-03-15T19:59:22","title":"The Role of Natural Killer Cells in Autoimmune Diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 25;12:622306. doi: 10.3389&#x2F;fimmu.2021.622306. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Natural killer (NK) cells, the large granular lymphocytes differentiated from the common lymphoid progenitors, were discovered in early 1970&#39;s. They are members of innate immunity and were initially defined by their strong cytotoxicity against virus-infected cells and by their important effector functions in anti-tumoral immune responses. Nowadays, NK cells are classified among the recently discovered innate lymphoid cell subsets and have capacity to influence both innate and adaptive immune responses. Therefore, they can be considered as innate immune cells that stands between the innate and adaptive arms of immunity. NK cells don&#39;t express T or B cell receptors and are recognized by absence of CD3. There are two major subgroups of NK cells according to their differential expression of CD16 and CD56. While CD16&lt;sup&gt;+&lt;&#x2F;sup&gt;CD56&lt;sup&gt;dim&lt;&#x2F;sup&gt; subset is best-known by their cytotoxic functions, CD16&lt;sup&gt;-&lt;&#x2F;sup&gt;CD56&lt;sup&gt;bright&lt;&#x2F;sup&gt; NK cell subset produces a bunch of cytokines comparable to CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T helper cell subsets. Another subset of NK cells with production of interleukin (IL)-10 was named as NK regulatory cells, which has suppressive properties and could take part in immune-regulatory responses. Activation of NK cells is determined by a delicate balance of cell-surface receptors that have either activating or inhibitory properties. On the other hand, a variety of cytokines including IL-2, IL-12, IL-15, and IL-18 influence NK cell activity. NK-derived cytokines and their cytotoxic functions through induction of apoptosis take part in regulation of the immune responses and could contribute to the pathogenesis of many immune mediated diseases including ankylosing spondylitis, BehÃ§et&#39;s disease, multiple sclerosis, rheumatoid arthritis, psoriasis, systemic lupus erythematosus and type-1 diabetes. Dysregulation of NK cells in autoimmune disorders may occur through multiple mechanisms. Thanks to the rapid developments in biotechnology, progressive research in immunology enables better characterization of cells and their delicate roles in the complex network of immunity. As NK cells stand in between innate and adaptive arms of immunity and &quot;bridge&quot; them, their contribution in inflammation and immune regulation deserves intense investigations. Better understanding of NK-cell biology and their contribution in both exacerbation and regulation of inflammatory disorders is a requisite for possible utilization of these multi-faceted cells in novel therapeutic interventions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717125&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33717125&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7947192&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7947192&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.622306&gt;10.3389&#x2F;fimmu.2021.622306&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717125&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":548,"discovery_date":"2021-03-15T19:59:22","title":"Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ther Adv Chronic Dis. 2021 Feb 27;12:2040622320983121. doi: 10.1177&#x2F;2040622320983121. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: We aimed to examine the frequency of polypharmacy in a large cohort of patients at the time of diagnosis of relapsing-remitting multiple sclerosis (RRMS) and to explore its effects on discontinuation of first disease-modifying treatment (DMT) using survival analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a cohort ambispective single-centre study. We enrolled RRMS patients starting their first DMT between 1st January 2013 and 31st December 2015. According to the number of medicines prescribed (except DMTs), we divided the patients into three groups: no-poly RRMS, minor-poly RRMS (from one to three medications), and major-poly RRMS (more than three medications).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 392 RRMS patients were enrolled (mean age 41.1). The minor-poly RRMS group included 61 patients (15.6%) and the major-poly RRMS group included 112 (28.6%). Individuals in these groups were older and had higher median body mass index (BMI) than patients in the no-poly RRMS group (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.05). Upon multinomial regression analysis, older age at onset was associated with minor and major polypharmacy (OR 1.050, CI 1.010-1.093, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.015 and OR 1.063, CI 1.026-1.101, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.001, respectively) and higher BMI was associated with major polypharmacy (OR 1.186, CI 1.18-1.29, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.001). The rates of discontinuation of first DMT were similar among the three groups (50.7% for no-Poly RRMS, 50.8% for minor-Poly RRMS, and 53.3% for major-Poly RRMS, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.264). At log-Rank test, there were no differences among the three groups (&lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.834).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Polypharmacy was more common in older RRMS patients with high BMI.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717425&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33717425&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7923988&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7923988&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2040622320983121&gt;10.1177&#x2F;2040622320983121&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717425&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":547,"discovery_date":"2021-03-15T19:59:22","title":"Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 24;7(1):2055217321990852. doi: 10.1177&#x2F;2055217321990852. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: In the Phase 3, 96-week ORACLE-MS study, cladribine tablets 10 mg (3.5 or 5.25 mg&#x2F;kg cumulative dosage over two years) significantly reduced lesions associated with multiple sclerosis versus placebo in participants following a first clinical demyelinating event (FCDE).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To determine the timing of effects of cladribine tablets on lesion activity assessed by magnetic resonance imaging (MRI).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This &lt;i&gt;post hoc&lt;&#x2F;i&gt; analysis assessed the effect of cladribine tablets versus placebo in ORACLE-MS on secondary MRI endpoints including T1 gadolinium-enhancing (Gd+), new or enlarging T2 lesions, and combined unique active lesions assessed on MRI scans performed at screening and every 3 months thereafter.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Compared to placebo, cladribine tablets 3.5 mg&#x2F;kg treatment appeared to lead to a trend of reductions in the mean number of T1 Gd+ lesions by Week 13 (first post-baseline scan: 0.37 vs. 1.00), new or enlarging T2 (0.20 vs. 1.01) and combined unique active (0.29 vs. 1.91) lesions by Week 24. Low lesion counts were maintained with cladribine tablets throughout 96 weeks. Similar results were observed with the 5.25 mg&#x2F;kg dosage.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: In participants with an FCDE, cladribine tablets appeared to reduce lesion numbers within 13 weeks (time of first evaluation).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717501&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33717501&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7925953&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7925953&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055217321990852&gt;10.1177&#x2F;2055217321990852&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717501&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":546,"discovery_date":"2021-03-15T19:59:22","title":"Effectiveness of film as a health communication tool to improve perceptions and attitudes in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 27;7(1):2055217321995947. doi: 10.1177&#x2F;2055217321995947. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Health communication tools like film are capable of reducing health disparities and could be effective in addressing negative illness perceptions of MS in Hispanics&#x2F;Latinx.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To test the feasibility of using a culturally appropriate short narrative film to examine illness perceptions overtime and attitudes in Hispanics&#x2F;Latinx affected with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Participants were assigned to view a short narrative film (n &#x3D; 130) or not (n &#x3D; 106). The Brief Illness Perception Questionnaire (BIPQ) was used to examine illness perceptions at baseline, one and three months. Focus groups were conducted at 6 months. Measures of sociocultural integration were obtained. Individual group BIPQ domains were evaluated over time using paired sample t-test. Multivariate linear regression was used to examine predictors of BIPQ change.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A more positive perception of &lt;i&gt;treatment&lt;&#x2F;i&gt; (p &amp;lt; 0.0001) and &lt;i&gt;understanding&lt;&#x2F;i&gt; (p &#x3D; 0.0003) were seen at 3 months for those exposed to film. Focus groups were effective in highlighting that the perceived disease prognosis, family support and awareness of MS contributes to attitudes. Exposure to film was found to be the strongest predictor (Beta:6.31, p &#x3D; 0.01) of BIPQ change at three months.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our results provide support that a short narrative film of MS in Hispanics&#x2F;Latinx is a feasible intervention to change perceptions of MS to a more positive view.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717502&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33717502&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7923991&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7923991&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055217321995947&gt;10.1177&#x2F;2055217321995947&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717502&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":545,"discovery_date":"2021-03-15T19:59:22","title":"Oxidative Stress and Vitamin D as Predictors in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Health Sci J. 2020 Oct-Dec;46(4):371-378. doi: 10.12865&#x2F;CHSJ.46.04.07. Epub 2020 Dec 31.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple Sclerosis (MS) is a multifactorial demyelinating diseases that affect mostly the young and active people. Here, is crucial to identify new strategies in order to slow down the diseases progression and maintain a good functional outcome. Our hypothesis was that the interconnection between anti-oxidant molecules and anti-inflammatory or neuroprotective molecules can act as predictors of diseases progression. In the study were included 36 patients with MS. Inclusion criteria were the following: patients over 18 years old were divided in three groups, 16 relapsing-remitting MS (RRMS) group, 10 secondary progressive MS (SPMS) group and 10 healthy control group. We showed that the vitamin D sufficiency did not improve de EDSS score in the later stage of diseases. Also, we showed that in the early stage (RRMS) the vitamin D status can significantly improve the EDSS and IADL score and may slow down the diseases progression. started with the early stage of diseases (RRMS) we found that catalase activity, an enzyme that act as anti-oxidant, is significantly decreased compare with healthy people, and can be associated with a low level of vitamin D. we concluded that a pro-oxidative and anti-oxidative balance is an important player in the multifactorial mechanism of MS diseases progression and additional prospective studies are needed to determine optimal vitamin D levels that lead to clinical and immunological benefits for patients with MS. Long-term follow-up studies using high-dose vitamin D supplementation are needed to confirm the preliminary results of the studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717511&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33717511&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7948027&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;PMC7948027&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.12865&#x2F;CHSJ.46.04.07&gt;10.12865&#x2F;CHSJ.46.04.07&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33717511&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":544,"discovery_date":"2021-03-15T19:59:22","title":"There is an impairment in time perception of patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Somatosens Mot Res. 2021 Mar 9:1-6. doi: 10.1080&#x2F;08990220.2021.1879777. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective of this study is to examine time perception impairment in multiple sclerosis (MS) patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: The study was performed with 60 MS patients and 60 age-matched healthy people. Estimation and Production Tests were carried out with a standard personal laptop computer and participants were aware to count the seconds by the &#39;start&#39; command and to stop by the &#39;stop&#39; command. The outcome measure was the ratio between the estimated duration and the target (7 s, 32 s, or 58 s) one for the Estimation Test and the Produced duration and the target (7 s, 32 s, or 58 s) one for the Production Test; and each time duration was repeated three times both for Production and Estimation Tests.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We found a significant difference in the Estimation Test (7 s, 32 s, 58 s), and the Production Test (7 s, 32 s, 58 s) between the MS group and healthy control group (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; .05). It was observed that patients with MS had a higher deviation from the target time compared to the control group. It was found that this difference was statistically significant (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; .05). There was a high and negative correlation between the Estimation and Production Tests in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: In conclusion, our data suggests that time estimation and production are disturbed in MS patients, and cognitive rehabilitation is required for most of them.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33719839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3&quot;&gt;33719839&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;08990220.2021.1879777&gt;10.1080&#x2F;08990220.2021.1879777&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33719839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315155920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":543,"discovery_date":"2021-03-15T16:59:51","title":"Post-COVID-19 encephalomyelitis","summary":"Since the outbreak of coronavirus disease 2019 (COVID-19), a growing number of cases of acute transverse myelitis associated with COVID-19 have been reported. Here, we present the case of a patient who develop...","link":"https:&#x2F;&#x2F;neurolrespract.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s42466-021-00113-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":542,"discovery_date":"2021-03-15T13:59:51","title":"Correlation of osteoarthritis or rheumatoid arthritis with bone mineral density in adults aged 20â59 years","summary":"It is reported that osteoporosis commonly occurs among patients with rheumatoid arthritis (RA), whereas the association between osteoporosis and osteoarthritis (OA) remains controversial. Our aim in this study...","link":"https:&#x2F;&#x2F;josr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13018-021-02338-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":541,"discovery_date":"2021-03-15T12:19:22","title":"Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases: Thematic Review Series: Biology of Lipid Rafts","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Lipid Res. 2020 May;61(5):636-654. doi: 10.1194&#x2F;jlr.TR119000427. Epub 2020 Nov 7.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Lipid rafts are small, dynamic membrane areas characterized by the clustering of selected membrane lipids as the result of the spontaneous separation of glycolipids, sphingolipids, and cholesterol in a liquid-ordered phase. The exact dynamics underlying phase separation of membrane lipids in the complex biological membranes are still not fully understood. Nevertheless, alterations in the membrane lipid composition affect the lateral organization of molecules belonging to lipid rafts. Neural lipid rafts are found in brain cells, including neurons, astrocytes, and microglia, and are characterized by a high enrichment of specific lipids depending on the cell type. These lipid rafts seem to organize and determine the function of multiprotein complexes involved in several aspects of signal transduction, thus regulating the homeostasis of the brain. The progressive decline of brain performance along with physiological aging is at least in part associated with alterations in the composition and structure of neural lipid rafts. In addition, neurodegenerative conditions, such as lysosomal storage disorders, multiple sclerosis, and Parkinson&#39;s, Huntington&#39;s, and Alzheimer&#39;s diseases, are frequently characterized by dysregulated lipid metabolism, which in turn affects the structure of lipid rafts. Several events underlying the pathogenesis of these diseases appear to depend on the altered composition of lipid rafts. Thus, the structure and function of lipid rafts play a central role in the pathogenesis of many common neurodegenerative diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33715812&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315081920&amp;v&#x3D;2.14.3&quot;&gt;33715812&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1194&#x2F;jlr.TR119000427&gt;10.1194&#x2F;jlr.TR119000427&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33715812&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315081920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":540,"discovery_date":"2021-03-15T12:19:22","title":"Sex Differences in Neurodegeneration: The Role of the Immune System in Humans","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Biol Psychiatry. 2021 Jan 8:S0006-3223(21)00039-1. doi: 10.1016&#x2F;j.biopsych.2021.01.002. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Growing evidence supports significant involvement of immune dysfunction in the etiology of neurodegenerative diseases, several of which also display prominent sex differences across prevalence, pathology, and symptomology. In this review, we summarize evidence from human studies of established and recent findings of sex differences in multiple sclerosis, Alzheimer&#39;s disease, Parkinson&#39;s disease, and amyotrophic lateral sclerosis and discuss how sex-specific central nervous system innate immune activity could contribute to downstream sex differences in these diseases. We examine human genomic and transcriptomics studies in each neurodegenerative disease through the lens of sex differences in the neuroimmune system and highlight the importance of stratifying sex in clinical and translational research studies. Finally, we discuss the limitations of the existing studies and outline recommendations for further advancing sex-based analyses to uncover novel disease mechanisms that could ultimately help treat both sexes.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33715827&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315081920&amp;v&#x3D;2.14.3&quot;&gt;33715827&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.biopsych.2021.01.002&gt;10.1016&#x2F;j.biopsych.2021.01.002&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33715827&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315081920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":539,"discovery_date":"2021-03-15T10:59:56","title":"Harnessing the benefits of neuroinflammation:Generation of macrophages&#x2F;microglia with prominent remyelinating properties","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;content&#x2F;early&#x2F;2021&#x2F;03&#x2F;11&#x2F;JNEUROSCI.1948-20.2021","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":538,"discovery_date":"2021-03-15T05:59:21","title":"Effect of twelve weeks pilates training on functional balance of male patients with multiple sclerosis: Randomized controlled trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Bodyw Mov Ther. 2021 Jan;25:41-45. doi: 10.1016/j.jbmt.2020.11.003. Epub 2020 Nov 7.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Pilates training has several well-known benefits for people with Multiple Sclerosis (MS). However, its effect on functional balance is unclear. The present study aimed to evaluate the effect of pilates exercises on the functional balance of male patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHOD: In the present parallel group randomized controlled trial, 30 men with MS were recruited from a local corrective exercise clinic in Tehran, Iran, and randomized into Pilates training group (N = 15), and control group (N = 15). At baseline, the age range was 25-40 years, and disability score index was 3-5.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTERVENTION: The intervention group received Pilates exercises including the extension of the thoracic spine, abdominal strengthening, core stabilizing exercises, upper and lower limb, and posture exercises for 12 weeks.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OUTCOMES: Functional balance assessments including Berg&#x27;s Balance Scale (BBS) test, Timed Up and Go (TUG) test, and Functional Reach Test (FRT) were measured at the baseline and after 12 weeks.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: At a 12-week follow-up, a significant between-group difference was observed in favor of the Pilates training group for the functional balance scores (P &amp;lt; 0.05), while no adverse or harmful events were reported in any group.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Pilates training increases the functional balance of MS patients, and decreases known risk factors for falls among the patients in this group, which may have the potential to reduce therapeutic costs and can be considered as a complementary therapeutic approach for physical therapists and corrective exercise experts.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33714509/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210315015920&amp;v=2.14.3&quot;&gt;33714509&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jbmt.2020.11.003&gt;10.1016/j.jbmt.2020.11.003&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33714509/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315015920&v=2.14.3","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":537,"discovery_date":"2021-03-15T05:59:21","title":"Familial coexistence of demyelinating diseases and familial Mediterranean fever","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rheumatol Int. 2021 Mar 13. doi: 10.1007&#x2F;s00296-021-04821-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disease characterized by fever and serositis attacks caused by mutations in the MEditerranean FeVer (MEFV) gene encoding the pyrin gene. Gain of the function mutations of the pyrin gene lead to stimulation of pro-inflammatory cytokines. Persistent pro-inflammatory situation in the course of FMF may play a role in the development of some other inflammatory diseases such as Behcet&#39;s disease, psoriasis, and vasculitis. Multiple sclerosis (MS), as a demyelinating disorder, is also more commonly seen in FMF patients compared to the general population. There are scarcely any research reporting that these two diseases coexist in more than one person in the same family. We have discovered cases of FMF and demyelinating disorders in five members of two different families. Besides the two families we are reporting, there are only four other families reported so far. Having combined the data of all these six families, we present a case-based review in this study. We aimed to draw attention of physicians to familial co-occurence of FMF and demyelinating disorders and also to discuss possible mechanisms of the coexistence of these two diseases in light of the literature.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33715072&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315015920&amp;v&#x3D;2.14.3&quot;&gt;33715072&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00296-021-04821-7&gt;10.1007&#x2F;s00296-021-04821-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33715072&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315015920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":536,"discovery_date":"2021-03-15T05:59:21","title":"Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Neurol Neurosurg. 2021 Feb 25;203:106576. doi: 10.1016&#x2F;j.clineuro.2021.106576. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: Evidence on the effectiveness and safety of fingolimod in real-world clinical practice in the Middle East and North African (MENA) region is limited. This study aimed to evaluate the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) in real-world setting in the MENA region.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PATIENTS AND METHODS: RRMS patients who had been treated with fingolimod for at least 12 months were retrospectively identified from the databases of 34 centers across the MENA region. Study outcomes included the annualized relapse rate (ARR), relapse-free rate (RFR), time to first and second relapses, mean change in Expanded Disability Status Scale (EDSS), proportion of patients with Magnetic Resonance Imaging (MRI) activity and no evidence of disease activity (NEDA)-3, retention of patients on treatment, as well as all safety measures.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 806 patients were included: 66.34 % female; mean age 32.97 Â± 9.62 years; mean disease duration 4.92 Â± 4.66 years; mean fingolimod use 37.2 Â± 16.7 months. Most patients had received previous disease-modifying therapy (79.65 %). Compared to the year preceding fingolimod initiation, RFR improved (33.00%-86.35%; p &amp;lt; 0.001), ARR decreased (0.84 Â± 0.73 to 0.16 Â± 0.45; p &#x3D; 0.005), EDSS decreased (2.69 Â± 1.74-2.01 Â± 1.66; p &amp;lt; 0.001), and the proportion of patients with Gadolinium-enhancing T1 lesions decreased (57.84 % to 12.93 %; p &amp;lt; 0.001), after 12 months of fingolimod treatment. NEDA-3 was achieved in 41.3 % of patients. Median time to first and second relapses was not reached since 86.35 % and 98.39 % of patients had not experienced relapses for the first time and second time, respectively. Eight-hundred one (99.38 %) patients continued fingolimod treatment beyond 12 months. One-hundred thirty patients (16.13 %) experienced adverse events, mainly lymphopenia (5.46 %) and leukopenia (2.11 %), while 13 patients (1.61 %) experienced serious adverse events.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: This study confirms the effectiveness and safety profile of fingolimod in real-world setting in the Middle East and North African (MENA) region.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33714799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315015920&amp;v&#x3D;2.14.3&quot;&gt;33714799&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.clineuro.2021.106576&gt;10.1016&#x2F;j.clineuro.2021.106576&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33714799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210315015920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":535,"discovery_date":"2021-03-15T01:59:51","title":"Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities","summary":"Bacteria, viruses, protozoa, and fungi establish a complex ecosystem in the gut. Like other microbiota, gut mycobiota plays an indispensable role in modulating intestinal physiology. Notably, the most striking...","link":"https:&#x2F;&#x2F;microbiomejournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40168-021-01024-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":534,"discovery_date":"2021-03-14T12:39:21","title":"Editorial for &quot;MRI Findings of Arachnoiditis, Revisited. Is Classification Needed?&quot;","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Magn Reson Imaging. 2021 Mar 13. doi: 10.1002&#x2F;jmri.27597. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713514&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33713514&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;jmri.27597&gt;10.1002&#x2F;jmri.27597&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713514&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":533,"discovery_date":"2021-03-14T12:39:21","title":"Conjugated Linoleic Acid-Curcumin Attenuates Cognitive Deficits and Oxidative Stress Parameters in the Ethidium Bromide-Induced Model of Demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurotox Res. 2021 Mar 13. doi: 10.1007&#x2F;s12640-020-00310-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Oxidative stress has been shown to play an important role in the pathogenesis of multiple sclerosis (MS). Curcumin (CUR), an antioxidant compound, can be a potent treatment for neurodegenerative diseases, such as MS. CUR has poor bioavailability; therefore, it is used in nanoforms to increase its bioavailability. In the present study, the effects of CUR and conjugated linoleic acid-CUR (Lino-CUR) on spatial memory and oxidative stress in a putative animal model of MS were investigated. Forty-nine adult male Wistar rats (250 Â± 50 g) were randomly divided into seven groups (n &#x3D; 7): control, sham, ethidium bromide (EB), CUR (20 and 40 Î¼g&#x2F;kg) + EB, and Lino-CUR (20 and 40 Î¼g&#x2F;kg) + EB groups. Following MS induction, the groups were treated for 5 consecutive days. Finally, spatial memory and levels of oxidative stress parameters were assessed. Treatment with CUR and Lino-CUR at two doses significantly improved spatial memory and reduced oxidative stress parameters in the experimental models of MS. Furthermore, the effects of high dose (40 Î¼g&#x2F;kg) of Lino-CUR were more remarkable. These findings suggest that the microinjection of CUR in its synthetic form Lino-CUR significantly ameliorated spatial memory, through the reduction of oxidative stress markers in the brain of studied animals as a rat model of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713300&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33713300&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s12640-020-00310-0&gt;10.1007&#x2F;s12640-020-00310-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713300&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":532,"discovery_date":"2021-03-14T12:39:21","title":"Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 12. doi: 10.1007&#x2F;s10072-020-05027-8. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Pediatric-onset multiple sclerosis (MS) has a highly active and aggressive course, which can have a devastating effect on the physical and cognitive functioning of a child if not treated appropriately with effective disease-modifying drugs. The optimal treatment strategy of pediatric MS is currently unknown and debate continues as to whether treatment escalation or initiation of a highly active therapy provides a better outcome. Here, we present the case of a 16-year-old female diagnosed with highly active relapsing-remitting MS (age at onset: 14 years) who received first-line treatment with fingolimod within 1 year of the first recorded symptom. Since starting fingolimod, the course of the disease has essentially been stable. No new or active lesions were observed in magnetic resonance imaging scans performed at 3 and 12 months after starting fingolimod, and treatment was well tolerated. These data suggest that, in this case, early treatment with first-line fingolimod was able to slow disease progression.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33712907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33712907&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-020-05027-8&gt;10.1007&#x2F;s10072-020-05027-8&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33712907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":531,"discovery_date":"2021-03-14T12:39:21","title":"Keeping the ageing brain wired: a role for purine signalling in regulating cellular metabolism in oligodendrocyte progenitors","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Pflugers Arch. 2021 Mar 13. doi: 10.1007&#x2F;s00424-021-02544-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;White matter (WM) is a highly prominent feature in the human cerebrum and is comprised of bundles of myelinated axons that form the connectome of the brain. Myelin is formed by oligodendrocytes and is essential for rapid neuronal electrical communication that underlies the massive computing power of the human brain. Oligodendrocytes are generated throughout life by oligodendrocyte precursor cells (OPCs), which are identified by expression of the chondroitin sulphate proteoglycan NG2 (Cspg4), and are often termed NG2-glia. Adult NG2+ OPCs are slowly proliferating cells that have the stem cell-like property of self-renewal and differentiation into a pool of &#39;late OPCs&#39; or &#39;differentiation committed&#39; OPCs(COPs) identified by specific expression of the G-protein-coupled receptor GPR17, which are capable of differentiation into myelinating oligodendrocytes. In the adult brain, these reservoirs of OPCs and COPs ensure rapid myelination of new neuronal connections formed in response to neuronal signalling, which underpins learning and cognitive function. However, there is an age-related decline in myelination that is associated with a loss of neuronal function and cognitive decline. The underlying causes of myelin loss in ageing are manifold, but a key factor is the decay in OPC &#39;stemness&#39; and a decline in their replenishment of COPs, which results in the ultimate failure of myelin regeneration. These changes in ageing OPCs are underpinned by dysregulation of neuronal signalling and OPC metabolic function. Here, we highlight the role of purine signalling in regulating OPC self-renewal and the potential importance of GPR17 and the P2X7 receptor subtype in age-related changes in OPC metabolism. Moreover, age is the main factor in the failure of myelination in chronic multiple sclerosis and myelin loss in Alzheimer&#39;s disease, hence understanding the importance of purine signalling in OPC regeneration and myelination is critical for developing new strategies for promoting repair in age-dependent neuropathology.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33712969&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33712969&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00424-021-02544-z&gt;10.1007&#x2F;s00424-021-02544-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33712969&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":530,"discovery_date":"2021-03-14T12:39:21","title":"Aberrant multimodal brain networks in patients with anti-NMDA receptor encephalitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;CNS Neurosci Ther. 2021 Mar 13. doi: 10.1111&#x2F;cns.13632. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: To explore large-scale brain network alterations and examine their clinical and neuropsychological relevance in patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Twenty-four patients with anti-NMDAR encephalitis and 26 matched healthy controls (HCs) were enrolled in our study. Based on the multimodal MRI dataset, individual morphological, structural, and functional brain networks were constructed and compared between the two groups at multiple levels. The associations with clinical&#x2F;neuropsychological variables and the discriminant ability of significant alterations were further studied.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Multimodal network analysis revealed that anti-NMDAR encephalitis mainly affected morphological and structural networks, but subtle alterations were observed in functional networks. Intriguingly, decreased network local efficiency was observed for both morphological and structural networks and increased nodal centrality in the lateral orbital gyrus was convergently observed among the three types of networks in the patients. Moreover, the alterations, particularly those from structural networks, accounted largely for cognitive deficits of the patients and could distinguish the diseased individuals from the HCs with excellent performance (area under the curve &#x3D;0.933).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The current study provides a comprehensive view of characteristic multimodal network dysfunction in anti-NMDAR encephalitis, which is crucial to establish new diagnostic biomarkers and promising therapeutic targets for the disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713553&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33713553&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;cns.13632&gt;10.1111&#x2F;cns.13632&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713553&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":529,"discovery_date":"2021-03-14T12:39:21","title":"Elevated cerebrospinal fluid Î²2-microglobulin levels in patients with neuromyelitis optica spectrum disorders","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 19;49:102774. doi: 10.1016&#x2F;j.msard.2021.102774. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cerebrospinal fluid (CSF) Î²2-microglobulin (Î²2-MG) levels elevated in patients with multiple sclerosis (MS). We examined the levels of Î²2-MG in serum and cerebrospinal fluid (CSF) from 46 patients with neuromyelitis optica spectrum disorders (NMOSD), in serum from 21 healthy controls (HC), in CSF from 25 disease controls with non-inflammatory neurological diseases (NIND) with normal CSF results. CSF Î²2-MG levels were significantly higher in patients with NMOSD than controls and with weak association with the number of white blood cells, protein and lactate levels in CSF. CSF Î²2-MG is thus one more, non-specific indicator of inflammation in NMOSD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713918&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33713918&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102774&gt;10.1016&#x2F;j.msard.2021.102774&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33713918&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":528,"discovery_date":"2021-03-14T12:39:21","title":"TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 24;51:102865. doi: 10.1016&#x2F;j.msard.2021.102865. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: A significant proportion of pediatric-onset multiple sclerosis (POMS) patients do not respond to first-line disease-modifying therapies. Clinical trials showed that natalizumab is effective and safe in adults, but there are limited clinical trial data for children. Natalizumab is currently prescribed off-label for POMS. We aimed to characterize the effectiveness, safety and tolerability of natalizumab in all POMS cases treated in Portugal (from 2007 to 2018).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Data from clinical records were retrospectively collected for all POMS cases treated with natalizumab in Portugal.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Twenty-one patients were included, 14 (67%) of which were female. The median age at POMS diagnosis was 13 years old. The median duration of treatment with natalizumab was 2 years and 3 months. Median Expanded Disability Status Scale score decreased from 1.5 to 1.0 after 24 months. The Annualized Relapse Rate decreased from 1.31 events&#x2F;patient&#x2F;year before treatment with natalizumab to 0 after 12 months of treatment and to 0.04 after 24 months. No gadolinium-enhancing lesions or new or enlarged T2 hyperintense lesions were observed in 8&#x2F;8 patients (100%) after 12 months, and 4&#x2F;5 (80%) after 24 months. There was one possible serious adverse event, which did not require dose adjustment. Five patients discontinued treatment due to positive anti-JCV (JC virus) antibody JC serostatus.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Natalizumab may be an effective and safe disease-modifying therapy for POMS. Our results are in line with data published for the adult population, as well as with similar observational studies in pediatric populations in other regions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33714125&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33714125&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102865&gt;10.1016&#x2F;j.msard.2021.102865&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33714125&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":527,"discovery_date":"2021-03-14T12:39:21","title":"Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 3;51:102879. doi: 10.1016&#x2F;j.msard.2021.102879. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Population-based clinical studies in neuromyelitis optica spectrum disorder (NMOSD) and epidemiological and clinical comparisons of White ethnicities are missing. In a large population-based international cohort, we extensively characterized aquaporin-4 antibody seropositive (AQP4-Ab+) NMOSD, and also compared the clinical, radiological and epidemiological features between two European populations residing in different areas.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Between self-reported Danish and Hungarian ethnicities, we compared the population-based clinical features, disability outcomes, and death of 134 AQP4-Ab+ NMOSD cases fulfilling the 2015 International Panel for NMO Diagnosis (IPND) criteria. For precise comparison of epidemiology, we conducted a population-based head-to-head comparative study of the age-standardized prevalence (January 1, 2014) and incidence (2007-2013) of AQP4-Ab+ NMO&#x2F;NMOSD among adults (â¥16 years) in Denmark (4.6 million) and Hungary (6.4 million) by applying 2015 IPND (NMOSD) criteria and 2006 Wingerchuk (NMO).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Danes were more likely to present with transverse myelitis and were more affected by spinal cord damage on long-term disability. Hungarians presented most often with optic neuritis, although visual outcome was similar in the groups. No differences were observed in sex, disease course, relapse rate, autoimmune comorbidity, mortality, brain MRI, and treatment strategies. The age-standardized prevalence estimates of AQP4-Ab+ NMOSD (2015 IPND criteria) in Denmark vs. Hungary were 0.66 vs. 1.43 (&#x2F;100,000) while incidence rates were 0.04 vs. 0.11 (&#x2F;100,000 person-years); similar differences were found based on the 2006 NMO criteria.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: This head-to-head comparative study indicates different disease characteristics and epidemiology among White populations in Europe, and substantiates the need for population-based genetic and environmental studies in NMOSD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33714126&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3&quot;&gt;33714126&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102879&gt;10.1016&#x2F;j.msard.2021.102879&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33714126&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210314083920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":526,"discovery_date":"2021-03-13T13:59:23","title":"MPRAGE to MP2RAGE UNI translation via generative adversarial network improves the automatic tissue and lesion segmentation in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Comput Biol Med. 2021 Feb 26;132:104297. doi: 10.1016&#x2F;j.compbiomed.2021.104297. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND OBJECTIVE: Compared to the conventional magnetization-prepared rapid gradient-echo imaging (MPRAGE) MRI sequence, the specialized magnetization prepared 2 rapid acquisition gradient echoes (MP2RAGE) shows a higher brain tissue and lesion contrast in multiple sclerosis (MS) patients. The goal of this work is to retrospectively generate realistic-looking MP2RAGE uniform images (UNI) from already acquired MPRAGE images in order to improve the automatic lesion and tissue segmentation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: For this task we propose a generative adversarial network (GAN). Multi-contrast MRI data of 12 healthy controls and 44 patients diagnosed with MS was retrospectively analyzed. Imaging was acquired at 3T using a SIEMENS scanner with MPRAGE, MP2RAGE, FLAIR, and DIR sequences. We train the GAN with both healthy controls and MS patients to generate synthetic MP2RAGE UNI images. These images were then compared to the real MP2RAGE UNI (considered as ground truth) analyzing the output of automatic brain tissue and lesion segmentation tools. Reference-based metrics as well as the lesion-wise true and false positives, Dice coefficient, and volume difference were considered for the evaluation. Statistical differences were assessed with the Wilcoxon signed-rank test.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The synthetic MP2RAGE UNI significantly improves the lesion and tissue segmentation masks in terms of Dice coefficient and volume difference (p-values &amp;lt; 0.001) compared to the MPRAGE. For the segmentation metrics analyzed no statistically significant differences are found between the synthetic and acquired MP2RAGE UNI.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Synthesized MP2RAGE UNI images are visually realistic and improve the output of automatic segmentation tools.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33711559&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210313085921&amp;v&#x3D;2.14.3&quot;&gt;33711559&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.compbiomed.2021.104297&gt;10.1016&#x2F;j.compbiomed.2021.104297&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33711559&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210313085921&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":525,"discovery_date":"2021-03-13T13:59:23","title":"The concurrence of multiple sclerosis and glioblastoma","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 2;50:102877. doi: 10.1016&#x2F;j.msard.2021.102877. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Glioblastoma rarely coincides with multiple sclerosis. Although registries have reported a higher proportion of brain tumors-most of which are glial-these events appear to be underreported. The relative contribution of JC virus (an oncogenic virus) and disease modifying therapies that may facilitate JC virus neurotropism and tumor-specific immune evasion remain unknown.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CASE REPORT: We present the case of a 64-year-old woman who developed a primary glioblastoma eight years after diagnosis of multiple sclerosis while on dimethyl fumarate.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Systematic reporting may help answer whether JC virus seropositivity and certain disease modifying therapies confer higher risk for glioblastoma in patients with multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33711579&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210313085921&amp;v&#x3D;2.14.3&quot;&gt;33711579&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102877&gt;10.1016&#x2F;j.msard.2021.102877&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33711579&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210313085921&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":524,"discovery_date":"2021-03-13T13:59:23","title":"Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 12:jnnp-2020-325304. doi: 10.1136/jnnp-2020-325304. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: Alemtuzumab is effective in patients with active multiple sclerosis but has a complex safety profile, including the development of secondary autoimmunity. Most of patients enrolled in randomised clinical trials with alemtuzumab were either treatment naÃ¯ve or pretreated with injectable substances. Other previous disease-modifying treatments (DMTs) were not used in the study cohorts, and therefore, associated risks might yet remain unidentified.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We retrospectively evaluated a prospective dual-centre alemtuzumab cohort of 170 patients. We examined the baseline characteristics as well as safety and effectiveness outcomes, including the time to first relapse, the time to 3 months confirmed disability worsening and the time to secondary autoimmunity.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The regression analysis showed that, among all previously used DMTs, the pretreatment with fingolimod (n=33 HRs for the time to first relapse (HR 5.420, 95% CI 2.520 to 11.660; p&amp;lt;0.001)) and for the time to worsening of disability (HR 7.676, 95% CI 2.870 to 20.534; p&amp;lt;0.001). Additionally, patients pretreated with fingolimod were more likely to experience spinal relapses (55% vs 10% among previously naÃ¯ve patients; p&amp;lt;0.001) and had an increased risk of secondary autoimmunity (HR 5.875, 95% CI 2.126 to 16.27; p&amp;lt;0.001).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: In the real-world setting, we demonstrated suboptimal disease control and increased risk of secondary autoimmunity following alemtuzumab, among patients previously treated with fingolimod. These data can provide guidance for improving MS therapeutic management.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33712515/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210313085921&amp;v=2.14.3&quot;&gt;33712515&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/jnnp-2020-325304&gt;10.1136/jnnp-2020-325304&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33712515/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210313085921&v=2.14.3","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":523,"discovery_date":"2021-03-13T00:59:21","title":"Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Metab Brain Dis. 2021 Mar 12. doi: 10.1007&#x2F;s11011-021-00712-9. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In Part I of this Review we evaluated the scientific evidence for a Metabolic Model of multiple sclerosis (MS). Part II outlines the implementation of an adaptive pathology-supported genetic testing (PSGT) algorithm aimed at preventing&#x2F;reversing disability in two illustrative MS cases, starting with a questionnaire-based risk assessment, including family history and lifestyle factors. Measurement of iron, vitamin B12, vitamin D, cholesterol and homocysteine levels identified biochemical deficits in both cases. Case 1, after following the PSGT program for 15 years, had an expanded disability status scale (EDSS) of 2.0 (no neurological sequelae) together with preserved brain volume on magnetic resonance imaging (MRI). A novel form of iron deficiency was identified in Case 1, as biochemical testing at each hospital submission due to MS symptoms showed low serum iron, ferritin and transferrin saturation, while hematological status and erythrocyte sedimentation rate measurement of systemic inflammation remained normal. Case 2 was unable to walk unaided until her EDSS improved from 6.5 to 4.0 over 12 months after implementation of the PSGT program, with amelioration of her suboptimal biochemical markers and changes to her diet and lifestyle, allowing her to regain independence. Genotype-phenotype correlation using a pathway panel of functional single nucleotide variants (SNVs) to facilitate clinical interpretation of whole exome sequencing (WES), elucidated the underlying metabolic pathways related to the biochemical deficits. A cure for MS will remain an elusive goal if separated from nutritional support required for production and maintenance of myelin, which can only be achieved by a lifelong investment in wellness.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33710528&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312195920&amp;v&#x3D;2.14.3&quot;&gt;33710528&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11011-021-00712-9&gt;10.1007&#x2F;s11011-021-00712-9&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33710528&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312195920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":522,"discovery_date":"2021-03-13T00:59:21","title":"How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Qual Life Res. 2021 Mar 12. doi: 10.1007&#x2F;s11136-021-02802-8. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Health fluctuations even within a single day are typical in multiple sclerosis (MS), but are not captured by widely used questionnaires like the EQ-5D-5L. This exploratory study aimed to develop an ambulatory assessment (AA) version of the EQ-5D-5L (EQ-5D-AA) where patients rate their health on mobile phones multiple times per day over several days, and to assess its feasibility and face validity.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: An initial EQ-5D-AA version was based on two patient focus groups. It was then tested and continuously developed in an iterative process: patients completed it over several days, followed by debriefing interviews. Findings were used to refine the EQ-5D-AA, with the resulting version being tested by the subsequent wave of patients until participants declared no need for changes anymore. Before and after the AA period, participants completed the standard paper-based EQ-5D-5L asking about &#39;today&#39;.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Focus group participants reported that their impairments often fluctuated between and within days. They regarded an AA with three assessments per day over seven days most appropriate; assessment should be retrospective to the previous assessment, but not all items should be assessed at each time point. Four waves of AA testing were conducted. Thirteen out of the 17 participants preferred the AA over standard assessment as they regarded it more informative, but not too burdensome.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The newly developed one-week AA of the EQ-5D-5L captures within-day and day-to-day health fluctuations in people with MS. From the patients&#39; perspective, it is a feasible and face valid way to provide important information beyond what is captured by the standard EQ-5D-5L.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33710593&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312195920&amp;v&#x3D;2.14.3&quot;&gt;33710593&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11136-021-02802-8&gt;10.1007&#x2F;s11136-021-02802-8&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33710593&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312195920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":521,"discovery_date":"2021-03-13T00:59:21","title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 12:awab102. doi: 10.1093&#x2F;brain&#x2F;awab102. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Aquaporin 4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) is an autoimmune astrocytopathic disease pathologically characterized by the massive destruction and regeneration of astrocytes with diverse types of tissue injury with or without complement deposition. However, it is unknown whether this diversity is derived from differences in pathological processes or temporal changes. Furthermore, unlike for the demyelinating lesions in multiple sclerosis, there has been no staging of astrocytopathy in AQP4-IgG+NMOSD based on astrocyte morphology. Therefore, we classified astrocytopathy of the disease by comparing the characteristic features, such as AQP4 loss, inflammatory cell infiltration, complement deposition and demyelination activity, with the clinical phase. We performed histopathological analyses in eight autopsied cases of AQP4-IgG+NMOSD. There were six women and two men, with a median age of 56.5 years (range, 46-71 years) and a median disease duration of 62.5 months (range, 0.6-252 months). Astrocytopathy in AQP4-IgG+NMOSD was classified into the following four stages defined by the astrocyte morphology and immunoreactivity for glial fibrillary acidic protein (GFAP): (a) astrocyte lysis: Extensive loss of astrocytes with fragmented and&#x2F;or dust-like particles; (b) progenitor recruitment: Loss of astrocytes except small nucleated cells with GFAP-positive fibre-forming foot processes; (c) protoplasmic gliosis: Presence of star-shaped astrocytes with abundant GFAP-reactive cytoplasm; and (d) fibrous gliosis: Lesions composed of densely packed mature astrocytes. The astrocyte lysis and progenitor recruitment stages dominated in clinically acute cases (within 2 months after the last recurrence). Findings common to both stages were the loss of AQP4, a decreased number of oligodendrocytes, the selective loss of myelin-associated glycoprotein and active demyelination with phagocytic macrophages. The infiltration of polymorphonuclear cells and T cells (CD4-dominant) and the deposition of activated complement (C9neo), which reflects the membrane attack complex, a hallmark of acute NMOSD lesions, were selectively observed in the astrocyte lysis stage (98.4% in astrocyte lysis, 1.6% in progenitor recruitment, and 0% in protoplasmic gliosis and fibrous gliosis). Although most of the protoplasmic gliosis and fibrous gliosis lesions were accompanied by inactive demyelinated lesions with a low amount of inflammatory cell infiltration, the deposition of complement degradation product (C3d) was observed in all four stages, even in fibrous gliosis lesions, suggesting the past or chronic occurrence of complement activation, which is a useful finding to distinguish chronic lesions in NMOSD from those in multiple sclerosis. Our staging of astrocytopathy is expected to be useful for understanding the unique temporal pathology of AQP4-IgG+NMOSD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33711152&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312195920&amp;v&#x3D;2.14.3&quot;&gt;33711152&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab102&gt;10.1093&#x2F;brain&#x2F;awab102&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33711152&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312195920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":520,"discovery_date":"2021-03-12T19:59:56","title":"Harnessing the benefits of neuroinflammation:Generation of macrophages/microglia with prominent remyelinating properties","summary":"","link":"https://www.jneurosci.org/content/early/2021/03/11/JNEUROSCI.1948-20.2021","published_date":"","source":"JNeuroSci","relevant":1,"table_constraints":null},{"article_id":519,"discovery_date":"2021-03-12T19:59:51","title":"Isolated thoracic intramedullary Erdheim-Chester disease presenting with paraplegia: a case report and literature review","summary":"Erdheim-Chester disease (ECD) is a rare, idiopathic, systemic non-Langerhans cell histiocytosis involving long bone and visceral organs. Central nervous system (CNS) involvement is uncommon and most cases deve...","link":"https:&#x2F;&#x2F;bmcmusculoskeletdisord.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12891-021-04061-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":518,"discovery_date":"2021-03-12T19:59:51","title":"Identification of lncRNAs associated with the pathogenesis of ankylosing spondylitis","summary":"Ankylosing spondylitis (AS) is a chronic autoimmune disease affecting the sacroiliac joint. To date, few studies have examined the association between long non-coding RNAs (lncRNAs) and AS pathogenesis. As suc...","link":"https:&#x2F;&#x2F;bmcmusculoskeletdisord.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12891-021-04119-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":517,"discovery_date":"2021-03-12T18:19:22","title":"Predicting disability worsening in relapsing and progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Opin Neurol. 2021 Mar 11. doi: 10.1097&#x2F;WCO.0000000000000928. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: Multiple sclerosis (MS) is a clinically heterogeneous disease, which complicates expectant management as well as treatment decisions. This review provides an overview of both well established and emerging predictors of disability worsening, including clinical factors, imaging factors, biomarkers and treatment strategies.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: In addition to well known clinical predictors (age, male sex, clinical presentation, relapse behaviour), smoking, obesity, vascular and psychiatric comorbidities are associated with subsequent disability worsening in persons with MS. A number of imaging features are predictive of disability worsening and are present to varying degrees in relapsing and progressive forms of MS. These include brain volumes, spinal cord atrophy, lesion volumes and optical coherence tomography features. Cerebrospinal and more recently blood biomarkers including neurofilament light show promise as more easily attainable biomarkers of future disability accumulation. Importantly, recent observational studies suggest that initiation of early-intensive therapy, as opposed to escalation based on breakthrough disease, is associated with decreased accumulation of disability overall, although randomized controlled trials investigating this question are underway.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: Understanding risk factors associated with disability progression can help to both counsel patients and enhance the clinician&#39;s availability to provide evidence-based treatment recommendations.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709974&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709974&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;WCO.0000000000000928&gt;10.1097&#x2F;WCO.0000000000000928&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709974&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":516,"discovery_date":"2021-03-12T18:19:22","title":"U-Fiber Leukoencephalopathy Due to a Novel Mutation in the TACO1 Gene","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Genet. 2021 Mar 9;7(2):e573. doi: 10.1212&#x2F;NXG.0000000000000573. eCollection 2021 Apr.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709035&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709035&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7943219&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;PMC7943219&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXG.0000000000000573&gt;10.1212&#x2F;NXG.0000000000000573&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709035&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":515,"discovery_date":"2021-03-12T18:19:22","title":"Clinical characteristics, inflammation and coagulation status in patients with immunological disease-related chronic cerebrospinal venous insufficiency","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Transl Med. 2021 Feb;9(3):236. doi: 10.21037&#x2F;atm-20-4201.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Immunological disease-related chronic cerebrospinal venous insufficiency (CCSVI) is rarely reported. This study aimed to analyze clinical characteristics, inflammation, and coagulation status in patients with immunological disease-related CCSVI.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients with CCSVI were enrolled from 2017 to 2019 and divided into three cohorts based on their immunological disease backgrounds, including groups with confirmed autoimmune disease, with suspected&#x2F;subclinical autoimmune disease, and with non-immunological etiology. Immunological, inflammatory, and thrombophilia biomarker assay in blood samples were obtained. Mann-Whitney U test or Fisher&#39;s exact test was used to compare continuous variables or categorical variables between the CCSVI patients with or without the immunological etiology. Spearman&#39;s correlation analysis was conducted among age, baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), interleukin-6 (IL-6), C-reactive protein (CRP), and neuron-specific enolase (NSE) in the three groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A total of 255 consecutive patients with CCSVI were enrolled, including three subgroups: CCSVI with confirmed autoimmune disease (n&#x3D;41), CCSVI with suspected&#x2F;subclinical autoimmune disease (n&#x3D;116) and CCSVI with non-immunological etiology (n&#x3D;98). In the first subgroup, a series of 41 cases was confirmed with eight different autoimmune diseases including antiphospholipid syndrome (n&#x3D;18), SjÃ¶gren&#39;s syndrome (n&#x3D;8), immunoglobulin G4-related disease (n&#x3D;7), BehÃ§et&#39;s disease (n&#x3D;2), autoimmune hepatitis (n&#x3D;2), Wegener&#39;s granulomatosis (n&#x3D;2), systemic sclerosis (n&#x3D;1) and AQP4 antibody-positive neuromyelitis optica spectrum disorder (n&#x3D;1). Groups with immunological etiology did not show a higher incidence of thrombophilia or increased pro-inflammatory biomarkers (e.g., neutrophil, IL-6). However, patients with non-immunological etiology had a higher baseline level of CRP. Additionally, baseline PLR was moderately correlated to NLR and CRP in CCSVI patients with non-immunological etiology and suspected&#x2F;subclinical autoimmune disease.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The formation of CCSVI may be based on the inflammatory process, facilitated by multiple risk factors, among which medical history of immunological diseases may play a significant role due to the intricate relationship between inflammation and coagulation. Moreover, CCSVI may also cause an independent inflammatory injury in venous walls, leading to focal stenosis or thrombus, without attacks from autoimmune antibodies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33708863&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33708863&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7940939&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;PMC7940939&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.21037&#x2F;atm-20-4201&gt;10.21037&#x2F;atm-20-4201&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33708863&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":514,"discovery_date":"2021-03-12T18:19:22","title":"Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;AIMS Neurosci. 2021 Feb 5;8(2):239-253. doi: 10.3934&#x2F;Neuroscience.2021013. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Association between the serum vitamin D level and disability of patients with multiple sclerosis (MS) has been investigated during several researches. However, these studies reported different results. The current study aims to estimate the correlation between the concentrations of 25 (OH) vitamin D and the level of disability among MS patients. Using Mesh and non-Mesh terms related to MS, disability level and vitamin D, different data banks were searched. Required information was extracted from the selected eligible primary articles. Stata version 11 software was applied for combining the primary correlation coefficients using random effect model. The effect of MS type and patients&#39; age was assessed using meta-regression models. Sensitivity analysis was performed to investigate the role of each primary study in the pooled estimate. Egger test was applied to find any publication bias. Of 14 eligible studies, the total correlation coefficient (95% confidence interval) between 25 (OH) vitamin D level and disability in both sexes as well as among female was estimated as of -0.29 (-0.40, -0.17) and -0.35 (-0.46, -0.24) respectively. Two articles carried out among male did not report significant results. Our meta-analysis showed a significant negative correlation between 25 (OH) vitamin D level and disability of MS patients so that the disability reduces with increasing the 25 (OH) vitamin D level.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709027&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709027&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7940116&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;PMC7940116&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3934&#x2F;Neuroscience.2021013&gt;10.3934&#x2F;Neuroscience.2021013&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709027&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":513,"discovery_date":"2021-03-12T18:19:22","title":"Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Mol Life Sci. 2021 Mar 11. doi: 10.1007&#x2F;s00018-021-03792-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Transactive response DNA-binding protein 43 kDa (TDP-43) encoded by the TARDBP gene is an evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) that regulates multiple steps of RNA metabolism, and its cytoplasmic aggregation characterizes degenerating motor neurons in amyotrophic lateral sclerosis (ALS). In most ALS cases, cytoplasmic TDP-43 aggregation occurs in the absence of mutations in the coding sequence of TARDBP. Thus, a major challenge in ALS research is to understand the nature of pathological changes occurring in wild-type TDP-43 and to explore upstream events in intracellular and extracellular milieu that promote the pathological transition of TDP-43. Despite the inherent obstacles to analyzing TDP-43 dynamics in in vivo motor neurons due to their anatomical complexity and inaccessibility, recent studies using cellular and animal models have provided important mechanistic insights into potential links between TDP-43 and motor neuron vulnerability in ALS. This review is intended to provide an overview of the current literature on the function and regulation of TDP-43-containing RNP granules or membraneless organelles, as revealed by various models, and to discuss the potential mechanisms by which TDP-43 can cause selective vulnerability of motor neurons in ALS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709256&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709256&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00018-021-03792-z&gt;10.1007&#x2F;s00018-021-03792-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709256&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":512,"discovery_date":"2021-03-12T18:19:22","title":"Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Farm Hosp. 2020 Dec 30;45(2):73-76. doi: 10.7399&#x2F;fh.11567.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Dimethyl fumarate is a medication approved for the treatment of relapsing-remitting multiple sclerosis. The purpose of the study was to evaluate the safety and persistence of dimethyl fumarate in clinical practice and analyze the occurrence of lymphopenia is patients treated with dimethyl fumarate over a period of at least 6 months.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: This is a retrospective longitudinal observational study carried out between August 2015 and March 2019. The study cohort was made up of patients who had been treated with dimethyl fumarate for at least 6 months. Lymphocyte counts were recorded at different points of time (pre-treatment, at 3, 6, 12 months, and at the end of the study period). The evolution of lymphopenia was evaluated by means of a logistic regression statistical model. An analysis was performed of the relationship between a decreased lymphocyte count over the first 6 months of treatment and the development, by the end of the study, of grade II-III lymphopenia necessitating discontinuation of dimethyl fumarate. Other safety indicators were also evaluated including adverse events and interruptions or discontinuations of treatment. Persistence was determined by measuring the time to discontinuation of treatment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The study included a total of 55 patients, of whom 80% were female. The most common adverse events were lymphopenia (27), rubefaction (16), digestive symptoms (11), fatigue (9), headache (3) and sleep disturbances (2). Eleven subjects interrupted&#x2F;discontinued their treatment during the study period; reasons were as follows: pregnancy (2), personal decision (2), John Cunningham virus infection (1), allergy to the drug (2), and lymphopenia (4). Median duration of treatment was 23 months (4-43 months). A statistically significant association was found between a lower lymphocyte count over the first 6 months of treatment and the development of severe lymphopenia by the end of the study [OR &#x3D; 1.34 (0.35-2.60); 95% CI (p &#x3D; 0.001)].&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The adverse events observed in the present study are in line with those reported in previous analyses. Lymphopenia was the most common adverse event. The persistence of the medication was similar to that found in pivotal trials. The significant association found between a decreased lymphocyte count over the first 6 months of treatment and the development of severe lymphopenia by the end of the study suggests a connection between both variables, which could be instrumental in being able to predict and even prevent the occurrence of such lymphopenias.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709887&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7399&#x2F;fh.11567&gt;10.7399&#x2F;fh.11567&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709887&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":511,"discovery_date":"2021-03-12T18:19:22","title":"The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 24;7(1):2055217321989767. doi: 10.1177&#x2F;2055217321989767. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RATIONALE: To determine the prevalence of epileptic seizures in multiple sclerosis (MS) at an Australian tertiary hospital and to define their clinical features.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We retrospectively analysed adult patients at the Royal Melbourne Hospital electronically identified to have ICD codes for MS and seizures and&#x2F;or epilepsy between 1996 to 2019, utilising paper and electronic-based records.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Of the 2,125 MS patients identified, 16 (0.75%) experienced epileptic seizures during a mean follow-up period of 12.9 years. Median age of MS diagnosis (SD) was 38 (9.3) years. Four patients had relapsing remitting MS (25%), 10 secondary progressive MS (63.5%), and 2 primary progressive MS (12.5%). More than two-thirds of patients had seizure onset following the diagnosis of MS, and the majority of these had advanced disease (approximate EDSS &amp;gt;6) at the time of seizure onset. Focal onset-seizures occurred in 87.5% of patients with seizures.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The estimated prevalence of seizures in our cohort was lower than in previous studies (0.75 vs 2-4%). In most cases, seizures occurred after the diagnosis of MS in the context of advanced disease. Further studies are required to determine if MS disease modifying treatments reduce the risk of seizures in this cohort.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33708413&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33708413&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7907940&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;PMC7907940&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055217321989767&gt;10.1177&#x2F;2055217321989767&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33708413&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":510,"discovery_date":"2021-03-12T18:19:22","title":"Quality of life in multiple sclerosis: The differential impact of motor and cognitive fatigue","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 24;7(1):2055217321996040. doi: 10.1177&#x2F;2055217321996040. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis is a chronic disease leading to reduced quality of life.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To investigate whether motor and cognitive fatigue impact differently on aspects of quality of life among patients with multiple sclerosis, independently from bodily disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: 79 patients with multiple sclerosis from Aalborg University Hospital, Denmark were included in an observational, cross-sectional study. Each subject completed two separate questionnaires regarding fatigue (Fatigue Scale for Motor and Cognitive Functions and Modified Fatigue Impact Scale) and one regarding quality of life (Short Form 36). Disability was measured with the Expanded Disability Status Scale (EDSS)-scores obtained from patient records.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: All fatigue scores were significantly correlated to all areas of quality of life (p &amp;lt; 0,05). This remained significant after adjustment for age, disease duration and EDSS-score. When looking at each type of fatigue separately, cognitive fatigue correlated mainly with mental health aspects of quality of life and motor fatigue with physical health areas of quality of life.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Increased motor and cognitive fatigue lead to a differential reduction in physical and mental quality of life, independently of bodily disability. This underlines the importance of proper assessment and treatment of fatigue among patients with multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33708414&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33708414&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7907948&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;PMC7907948&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055217321996040&gt;10.1177&#x2F;2055217321996040&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33708414&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":509,"discovery_date":"2021-03-12T18:19:22","title":"Spastic paresis of the arms and flaccid paralysis of the legs in secondary progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 12. doi: 10.1007&#x2F;s00115-021-01103-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709169&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709169&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01103-2&gt;10.1007&#x2F;s00115-021-01103-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709169&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":508,"discovery_date":"2021-03-12T18:19:22","title":"Neuroprotective Effects of Telmisartan and Nifedipine Against Cuprizone-Induced Demyelination and Behavioral Dysfunction in Mice: Roles of NF-ÎºB and Nrf2","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Inflammation. 2021 Mar 11. doi: 10.1007&#x2F;s10753-021-01447-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis is a chronic inflammatory neurodegenerative disease of the central nervous system which injures the myelin sheath. Telmisartan and nifedipine are antihypertensive drugs that recently showed neuroprotective properties against neurodegenerative diseases. This study evaluated the neuroprotective effect of telmisartan or nifedipine in cuprizone-induced demyelination in mice by examining the underlying mechanisms. C57BL&#x2F;6 mice received a diet containing 0.7% (w&#x2F;w) cuprizone for 7 days followed by 3 weeks on a 0.2% cuprizone diet. Telmisartan (5 mg&#x2F;kg&#x2F;day, p.o.) or nifedipine (5 mg&#x2F;kg&#x2F;day, p.o.) was administered for 3 weeks starting from the second week. Telmisartan or nifedipine improved locomotor activity and enhanced motor coordination as demonstrated by open field, rotarod, and grip strength tests. Furthermore, telmisartan or nifedipine restored myelin basic protein mRNA and protein expression and increased luxol fast blue-staining intensity. Telmisartan or nifedipine attenuated cuprizone-induced oxidative stress and apoptosis by decreasing brain malondialdehyde and caspase-3 along with restoring reduced glutathione and brain-derived neurotrophic factor levels. Telmisartan or nifedipine exerted an anti-inflammatory effect by reducing the expression of nuclear factor kappa B (NF-ÎºB p65) as well as pro-inflammatory cytokines and elevating the expression of IÎºB-Î±. In parallel, telmisartan or nifedipine upregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and the levels of heme oxygenase-1 and NADPH quinone oxidoreductase 1 enzymes. In conclusion, the current study provides evidence for the protective effect of telmisartan and nifedipine in cuprizone-induced demyelination and behavioral dysfunction in mice possibly by modulating NF-ÎºB and Nrf2 signaling pathways.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709265&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709265&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10753-021-01447-6&gt;10.1007&#x2F;s10753-021-01447-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709265&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":507,"discovery_date":"2021-03-12T18:19:22","title":"The Vagus Nerve Somatosensory-evoked Potential in Neural Disorders: Systematic Review and Illustrative Vignettes","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin EEG Neurosci. 2021 Mar 12:15500594211001221. doi: 10.1177&#x2F;15500594211001221. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;i&gt;Objective.&lt;&#x2F;i&gt; To review the scientific publications reporting vagal nerve somatosensory-evoked potential (VSEP) findings from individuals with brain disorders, and present novel physiological explanations on the VSEP origin. &lt;i&gt;Methods.&lt;&#x2F;i&gt; We did a systematic review on the papers reporting VSEP findings from individuals with brain disorders and their controls. We evaluated papers published from 2003 to date indexed in PubMed, Web of Science, and Scielo databases. We extracted the following information: number of patients and controls, type of neural disorder, age, gender, stimulating&#x2F;recording and grounding electrodes as well as stimulus side, intensity, duration, frequency, and polarity. Information about physiological parameters, neurobiological variables, and correlation studies was also reviewed. Representative vignettes were included to add support to our conclusions. &lt;i&gt;Results.&lt;&#x2F;i&gt; The VSEP was studied in 297 patients with neural disorders such as Parkinson&#39;s disease (PD), Alzheimer&#39;s disease, vascular dementia, mild cognitive impairment, subjective memory impairment, major depression, and multiple sclerosis. Scalp responses marked as the VSEP showed high variability, low validity, and poor reproducibility. VSEP latencies and amplitudes did not correlate with disease duration, unified PD rating scale score, or heart function in PD patients nor with cerebrospinal fluid Î² amyloid, phosphor-Ï, and cognitive tests from patients with mental disorders. Vignettes demonstrated that the VSEP was volume conduction propagating from muscles surrounding the scalp recording electrodes. &lt;i&gt;Conclusion.&lt;&#x2F;i&gt; The VSEP is not a brain-evoked potential of neural origin but muscle activity induced by electrical stimulation of the tragus region of the ear. This review and illustrative vignettes argue against assessing the parasympathetic system using the so-called VSEP.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709798&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709798&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;15500594211001221&gt;10.1177&#x2F;15500594211001221&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709798&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":506,"discovery_date":"2021-03-12T18:19:22","title":"Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177&#x2F;13524585211000616. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Data on fertility after autologous hematopoietic stem cell transplantation (aHSCT) in women with multiple sclerosis (MS) are inconclusive. This study aims to report on post-aHSCT menstrual resumption in a multi-center MS-women cohort. Out of 43 women, 30 (70%) recovered menses after a mean time of 6.8 months. Older age (odds ratio (OR) &#x3D; 0.5, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.0001) and previous pulsed cyclophosphamide (OR &#x3D; 0.44, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.005) were independently associated with a reduced menstrual recovery probability. Conditioning regimens&#39; intensity resulted not associated with post-procedure amenorrhea. Our results highlight younger age as significantly associated with menses recovery; proper fertility counseling for MS women candidated to aHSCT both prior- and post-transplantation is therefore warranted.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709839&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;13524585211000616&gt;10.1177&#x2F;13524585211000616&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":505,"discovery_date":"2021-03-12T18:19:22","title":"Real-life clinical practice studies in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Farm Hosp. 2021 Mar 8;45(2):51-52. doi: 10.7399&#x2F;fh.11663.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709885&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709885&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7399&#x2F;fh.11663&gt;10.7399&#x2F;fh.11663&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709885&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":504,"discovery_date":"2021-03-12T18:19:22","title":"Use of disease-modifying drugs during pregnancy and breastfeeding","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Opin Neurol. 2021 Mar 11. doi: 10.1097&#x2F;WCO.0000000000000922. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: The fact that multiple sclerosis (MS) predominantly affects women has been recognized for many years. As the age at diagnosis is decreasing, and treatment options are becoming more complex, increasing numbers of women are facing decisions about the use of disease modifying therapy (DMT) in and around pregnancy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: New data are rapidly becoming available, particularly regarding the safety of therapies in both pregnancy and breastfeeding. Effective treatment and suppression of relapses is key to ensuring good outcomes in the longer term for the woman, however this must be balanced against individual risk of relapse and risks to the fetus. Women should be advised that it is possible to breastfeed while taking selected DMT.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: In this review, we discuss evidence surrounding the safety of DMTs in both pregnancy and breastfeeding, and use this knowledge to suggest approaches to pregnancy and family planning in women with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709977&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709977&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;WCO.0000000000000922&gt;10.1097&#x2F;WCO.0000000000000922&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709977&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":503,"discovery_date":"2021-03-12T18:19:22","title":"Vaccinations in multiple sclerosis patients receiving disease-modifying drugs","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Opin Neurol. 2021 Mar 11. doi: 10.1097&#x2F;WCO.0000000000000929. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: This review focuses on new evidence supporting the global immunization strategy for multiple sclerosis (MS) patients receiving disease-modifying drugs (DMDs), including the recently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: New data strengthen the evidence against a causal link between MS and vaccination. Recent consensus statements agree on the need to start vaccination early. Timings for vaccine administration should be adjusted to ensure safety and optimize vaccine responses, given the potential interference of DMDs. Patients treated with Ocrelizumab (and potentially other B-cell depleting therapies) are at risk of diminished immunogenicity to vaccines. This has relevant implications for the upcoming vaccination against SARS-CoV-2.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: An early assessment and immunization of MS patients allows optimizing vaccine responses and avoiding potential interference with treatment plans. Vaccinations are safe and effective but some specific considerations should be followed when vaccinating before, during, and after receiving immunotherapy. A time-window for vaccination taking into account the kinetics of B cell repopulation could potentially improve vaccine responses. Further understanding of SARS-CoV-2 vaccine response dynamics in MS patients under specific therapies will be key for defining the best vaccination strategy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709979&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3&quot;&gt;33709979&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;WCO.0000000000000929&gt;10.1097&#x2F;WCO.0000000000000929&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33709979&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312131920&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":502,"discovery_date":"2021-03-12T13:59:52","title":"miR-21: a nonâspecific biomarker of all maladies","summary":"miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequ...","link":"https:&#x2F;&#x2F;biomarkerres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40364-021-00272-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":501,"discovery_date":"2021-03-12T13:59:52","title":"Genetic and molecular biology of autism spectrum disorder among Middle East population: a review","summary":"Autism spectrum disorder (ASD) is a neurodevelopmental disease, characterized by impaired social communication, executive dysfunction, and abnormal perceptual processing. It is more frequent among males. All o...","link":"https:&#x2F;&#x2F;humgenomics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40246-021-00319-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":500,"discovery_date":"2021-03-12T13:59:52","title":"Peritoneal dialysis-associated peritonitis caused by Mycobacteroides massiliense: the first case and review of the literature","summary":"Peritoneal dialysis (PD)-associated peritonitis caused by nontuberculous Mycobacterium is rare; however, the number of cases has increased over the past decades. Mycobacteroides massiliense is a subspecies of the...","link":"https:&#x2F;&#x2F;bmcnephrol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12882-021-02297-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":499,"discovery_date":"2021-03-12T13:07:55","title":"In Vivo Profiling of a Natural Alkaloid, Anatabine, in Rodents: Pharmacokinetics and Anti-Inflammatory Efficacy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Nat Prod. 2021 Mar 11. doi: 10.1021&#x2F;acs.jnatprod.0c01044. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Natural alkaloids, a large class of plant-derived substances, have attracted considerable interest because of their pharmacological activities. In this study, the &lt;i&gt;in vivo&lt;&#x2F;i&gt; pharmacokinetics and anti-inflammatory profile of anatabine, a naturally occurring alkaloid, were characterized in rodents. Anatabine was found to be bioavailable and brain-penetrant following systemic administration. Following intraperitoneal (i.p.) administration (1, 2, and 5 mg&#x2F;kg), anatabine caused a dose-dependent reduction in carrageenan-induced paw edema in rats; in mice, it inhibited the production of pro-inflammatory cytokines and simultaneously elevated the levels of an anti-inflammatory cytokine in a dose-dependent manner 2 h after lipopolysaccharide challenge. Furthermore, anatabine (â¼10 and â¼20 mg&#x2F;kg&#x2F;day for 4 weeks; inhalation exposure) had effects in a murine model of multiple sclerosis, reducing neurological deficits and bodyweight loss. Comparative studies of the pharmacokinetics and anti-inflammatory activity of anatabine demonstrated its bioequivalence in rats following i.p. administration and inhalation exposure. This study not only provides the first detailed profile of anatabine pharmacokinetics in rodents but also comprehensively characterizes the anti-inflammatory activities of anatabine in acute and chronic inflammatory models. These findings provide a basis for further characterizing and optimizing the anti-inflammatory properties of anatabine.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33706515&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312080752&amp;v&#x3D;2.14.3&quot;&gt;33706515&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1021&#x2F;acs.jnatprod.0c01044&gt;10.1021&#x2F;acs.jnatprod.0c01044&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33706515&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312080752&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":498,"discovery_date":"2021-03-12T13:07:55","title":"Mitochondrial associated ER membrane (MAM) compartment and its dysregulation in Amyotrophic lateral sclerosis (ALS)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Semin Cell Dev Biol. 2021 Mar 8:S1084-9521(21)00026-4. doi: 10.1016&#x2F;j.semcdb.2021.02.002. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The endoplasmic reticulum (ER) and mitochondria connect at multiple contact sites to form a unique cellular compartment, termed the &#39;mitochondria-associated ER membranes&#39; (MAMs). MAMs are hubs for signalling pathways that regulate cellular homeostasis and survival, metabolism, and sensitivity to apoptosis. MAMs are therefore involved in vital cellular functions, but they are dysregulated in several human diseases. Whilst MAM dysfunction is increasingly implicated in the pathogenesis of neurodegenerative diseases, its role in amyotrophic lateral sclerosis (ALS) is poorly understood. However, in ALS both ER and mitochondrial dysfunction are well documented pathophysiological events. Moreover, alterations to lipid metabolism in neurons regulate processes linked to neurodegenerative diseases, and a link between lipid metabolism dysfunction and ALS has also been proposed. In this review we discuss the structural and functional relevance of MAMs in ALS and how targeting MAM could be therapeutically beneficial in this disorder this disoefdisorder.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33707063&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312080752&amp;v&#x3D;2.14.3&quot;&gt;33707063&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.semcdb.2021.02.002&gt;10.1016&#x2F;j.semcdb.2021.02.002&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33707063&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312080752&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":497,"discovery_date":"2021-03-12T12:47:08","title":"SOCS6 promotes radiosensitivity and decreases cancer cell stemness in esophageal squamous cell carcinoma by regulating c-Kit ubiquitylation","summary":"Radiotherapy is a major treatment for esophageal squamous cell carcinoma (ESCC). However, HPV infection related radioresistance caused poor prognosis of ESCC. The function of SOCS6, which has been shown to be ...","link":"https:&#x2F;&#x2F;cancerci.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12935-021-01859-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":496,"discovery_date":"2021-03-12T12:05:32","title":"Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurosci Lett. 2021 Mar 8:135813. doi: 10.1016&#x2F;j.neulet.2021.135813. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DNA methylation has garnered much attention in recent years for its diagnostic potential in multiple conditions including cancer and neurodegenerative diseases. Conversely, advances regarding the potential diagnostic relevance of DNA methylation status have been sparse in the field of amyotrophic lateral sclerosis (ALS) even though patients diagnosed with this condition would significantly benefit from improved molecular assays aimed at furthering the current diagnostic and therapeutic options available. This review will provide an overview of the current diagnostic approaches available for ALS diagnosis and discuss the potential clinical usefulness of DNA methylation. We will also present examples of DNA methylation as a diagnostic tool in various types of cancer and neurodegenerative conditions and expand on how circulating cfDNA methylation may be leveraged for the early detection of ALS. In general, this article will reinforce the importance of cfDNA methylation as diagnostic tools and will further highlight its clinical relevance for persons diagnosed with ALS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33705931&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312070529&amp;v&#x3D;2.14.3&quot;&gt;33705931&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.neulet.2021.135813&gt;10.1016&#x2F;j.neulet.2021.135813&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33705931&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210312070529&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":495,"discovery_date":"2021-03-12T04:05:29","title":"The latitude gradient for multiple sclerosis prevalence is established in the early lifecourse","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 11:awab104. doi: 10.1093&#x2F;brain&#x2F;awab104. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The strongest epidemiological clue that the environment at the population level has a significant impact on the risk of developing multiple sclerosis (MS) is the well-established, and in many instances, increasing latitudinal gradient of prevalence, incidence and mortality globally, with prevalence increasing by up to 10-fold between the equator and 60 degrees North and South. The drivers of this gradient are thought to be environmental with latitude seen as a proxy for ultraviolet radiation and thus vitamin D production, however other factors may also play a role. However several important questions remain unanswered, particularly when in the life course is the gradient established, does lifetime migration mitigate or exacerbate previously reported latitude gradients at location of diagnosis, and do factors such as sex or MS disease phenotype influence the timing or significance of the gradient? Utilising life time residence calendars collected as part of the New Zealand national MS prevalence study, we constructed lifetime latitudinal gradients for MS from birth to prevalence day 2006 taking into account migration internally and externally and then analysed by sex and MS clinical course phenotype. 2127 of 2917 people living in NZ on prevalence day 7 March 2006 with MS completed the life course questionnaire and of these 1587 were born in NZ. All cohorts and sub cohorts were representative of the overall MS population in NZ on prevalence day. We found that the prevalence gradient was present at birth and was in fact stronger than at census day, and the slope of the gradient persisted until the age of 12 before gradually declining. We found that internal and external migration into NZ had little if any effect on the gradient except to decrease the significance of the gradient somewhat. Finally, we found as we had reported previously that the lifetime prevalence gradients were largely driven by females with relapse onset MS. These findings confirm for the first time the importance of early life environmental exposures in the risk of MS indicating strongly that exposures as early as in utero and at birth drive the latitudinal gradient. Consequently, prevention studies should be focussed on high risk individuals and populations from the earliest possible time points especially, when appropriate, on females.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704407&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704407&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab104&gt;10.1093&#x2F;brain&#x2F;awab104&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704407&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":494,"discovery_date":"2021-03-12T04:05:29","title":"Structural Basis of Tirasemtiv Activation of Fast Skeletal Muscle","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Med Chem. 2021 Mar 11. doi: 10.1021&#x2F;acs.jmedchem.0c01412. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Troponin regulates the calcium-mediated activation of skeletal muscle. Muscle weakness in diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy occurs from diminished neuromuscular output. The first direct fast skeletal troponin activator, &lt;i&gt;tirasemtiv&lt;&#x2F;i&gt;, amplifies the response of muscle to neuromuscular input. &lt;i&gt;Tirasemtiv&lt;&#x2F;i&gt; binds selectively and strongly to fast skeletal troponin, slowing the rate of calcium release and sensitizing muscle to calcium. We report the solution NMR structure of &lt;i&gt;tirasemtiv&lt;&#x2F;i&gt; bound to a fast skeletal troponin C-troponin I chimera. The structure reveals that &lt;i&gt;tirasemtiv&lt;&#x2F;i&gt; binds in a hydrophobic pocket between the regulatory domain of troponin C and the switch region of troponin I, which overlaps with that of Anapoe in the X-ray structure of skeletal troponin. Multiple interactions stabilize the troponin C-troponin I interface, increase the affinity of troponin C for the switch region of fast skeletal troponin I, and drive the equilibrium toward the active state.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33703886&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33703886&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1021&#x2F;acs.jmedchem.0c01412&gt;10.1021&#x2F;acs.jmedchem.0c01412&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33703886&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":493,"discovery_date":"2021-03-12T04:05:29","title":"Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurodegener Dis Manag. 2021 Mar 11. doi: 10.2217&#x2F;nmt-2020-0051. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background&#x2F;objective:&lt;&#x2F;b&gt; Intravenous methylprednisolone (IVMP) is previously given to secondary progressive multiple sclerosis (SPMS) patients. This study aimed to re-examine the effects of IVMP in SPMS. &lt;b&gt;Materials &amp;amp; methods:&lt;&#x2F;b&gt; Major electronic databases were searched for randomized controlled trials. &lt;b&gt;Results:&lt;&#x2F;b&gt; Four randomized controlled trials were included. IVMP may be inferior to mitoxantrone (MTX) in terms of expanded disability status scale (EDSS) improvement. There was no significant difference in terms of EDSS reduction and magnetic resonance imaging (MRI) plaque reduction when IVMP + MTX were compared with MTX. There is no significant difference between IVMP and cyclophosphamide based on EDSS progression and relapse reduction. &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; IVMP should not be routinely used as treatment for SPMS and is not recommended as an alternative treatment for SPMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33703936&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33703936&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2217&#x2F;nmt-2020-0051&gt;10.2217&#x2F;nmt-2020-0051&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33703936&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":492,"discovery_date":"2021-03-12T04:05:29","title":"Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Oncol. 2020 Dec 30;28(1):203-208. doi: 10.3390&#x2F;curroncol28010022.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Natalizumab is used as a second-line treatment for multiple sclerosis (MS). Some reports have linked natalizumab to primary central nervous system lymphoma (PCNSL), although few have described its management. A 45-year-old woman with Balo&#39;s Concentric Sclerosis presented dizziness, vertigo accompanied by dysarthria, weakness on the left side and blurred vision to the right eye after the fourth dose of natalizumab. Magnetic resonance imaging (MRI) and a brain biopsy confirmed the diagnosis of PCNSL. The patient received modified PCNSL chemotherapy (MATRix protocol) followed by high-dose chemotherapy (HDC) supported by an autologous hematopoietic stem cell transplant (ASCT) as a consolidation therapy. Thirty months later, she is still in complete remission of her PCNSL and MS. In this case, whole brain radiotherapy was excluded because it may be associated with an increased risk of neurotoxicity in MS. ASCT was preferred because it has been shown to prevent disability progression in less advanced MS stages. Our patient is the second to receive an ASCT in this context and this option of treatment should be the preferred if the patient is eligible.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704187&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;curroncol28010022&gt;10.3390&#x2F;curroncol28010022&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":491,"discovery_date":"2021-03-12T04:05:29","title":"Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 11. doi: 10.1007&#x2F;s10072-021-05168-4. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704600&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704600&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05168-4&gt;10.1007&#x2F;s10072-021-05168-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704600&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":490,"discovery_date":"2021-03-12T04:05:29","title":"MS is rare in EBV-seronegative children with CNS inflammatory demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Neurol. 2021 Mar 11. doi: 10.1002&#x2F;ana.26062. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Although Epstein-Barr virus (EBV) is hypothesized to be a prerequisite for multiple sclerosis (MS), up to 15% of children with a diagnosis of MS were reported to be EBV-seronegative. When re-evaluating 25 EBV-seronegative children out of 189 pediatric patients with a diagnosis of clinically isolated syndrome&#x2F;MS, we found anti-myelin oligodendrocyte glycoprotein (MOG) antibody in 11&#x2F;25 (44%) EBV-seronegative, but only 9&#x2F;164 (5.5%, p &amp;lt; 0.001) EBV-seropositive patients. After critical review, MS remained a plausible diagnosis in only four of 14 EBV-seronegative&#x2F;MOG antibody-negative patients. In children with an MS-like presentation, EBV seronegativity should alert clinicians to consider diagnoses other than MS, especially MOG-antibody disease. This article is protected by copyright. All rights reserved.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704815&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704815&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;ana.26062&gt;10.1002&#x2F;ana.26062&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704815&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":489,"discovery_date":"2021-03-12T04:05:29","title":"Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Pharmacol Drug Dev. 2021 Mar 11. doi: 10.1002&#x2F;cpdd.925. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formulations of edaravone in healthy subjects examined the pharmacokinetics (PK), safety, racial differences, and drug-drug interactions (DDIs) and investigated the dose of the oral formulation considered to be bioequivalent to the approved dose of the IV formulation. Study 1 was a placebo-controlled, randomized, single-blind study of single-ascending-dose oral edaravone with the dose range of 30 to 300 mg (n &#x3D; 56). Study 2 was conducted in 2 cohorts (n &#x3D; 84); the first assessed DDIs with multiple-dose edaravone 120 mg&#x2F;day given over 5 or 8 days (coadministered with single-dose rosuvastatin, sildenafil, or furosemide), and the second evaluated PK and racial (Japanese&#x2F;White) differences in PK parameters with doses of 100-mg edaravone. The oral formulation of edaravone was well absorbed, and plasma concentrations of unchanged edaravone increased more than dose proportionally within the dose range of 30 to 300 mg. No effect of race on oral edaravone PK and no notable DDI effects possibly caused by orally administered edaravone were observed. The oral edaravone formulations were safe and tolerable under the assessed conditions. Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of â100 mg, with an absolute bioavailability of â60%.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704925&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704925&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;cpdd.925&gt;10.1002&#x2F;cpdd.925&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704925&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":488,"discovery_date":"2021-03-12T04:05:29","title":"QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Mar 11. doi: 10.1002&#x2F;acn3.51338. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Inflammation in chronic active lesions occurs behind a closed blood-brain barrier and cannot be detected with MRI. Activated microglia are highly enriched for iron and can be visualized with quantitative susceptibility mapping (QSM), an MRI technique used to delineate iron.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To characterize the histopathological correlates of different QSM hyperintensity patterns in MS lesions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: MS brain slabs were imaged with MRI and QSM, and processed for histology. Immunolabeled cells were quantified in the lesion rim, center, and adjacent normal-appearing white matter (NAWM). Iron&lt;sup&gt;+&lt;&#x2F;sup&gt; myeloid cell densities at the rims were correlated with susceptibilities. Human-induced pluripotent stem cell (iPSC)-derived microglia were used to determine the effect of iron on the production of reactive oxygen species (ROS) and pro-inflammatory cytokines.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: QSM hyperintensity at the lesion perimeter correlated with activated iron&lt;sup&gt;+&lt;&#x2F;sup&gt; myeloid cells in the rim and NAWM. Lesions with high punctate or homogenous QSM signal contained no or minimally activated iron&lt;sup&gt;-&lt;&#x2F;sup&gt; myeloid cells. In vitro, iron accumulation was highest in M1-polarized human iPSC-derived microglia, but it did not enhance ROS or cytokine production.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: A high QSM signal outlining the lesion rim but not punctate signal in the center is a biomarker for chronic inflammation in white matter lesions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704933&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51338&gt;10.1002&#x2F;acn3.51338&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":487,"discovery_date":"2021-03-12T04:05:29","title":"The perceived impact of multiple sclerosis and self-management: The mediating role of coping strategies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;PLoS One. 2021 Mar 11;16(3):e0248135. doi: 10.1371&#x2F;journal.pone.0248135. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Low level of self-management in people with multiple sclerosis (MS) is considered to be a predominant factor that leads to poor rehabilitation efficacy. Studies focusing on the relationship between self-management and psychological variables that can be modified could contribute to expanding the knowledge needed to propose interventional programs aiming at patient activation. This study aimed to analyze whether coping strategies play a mediating role in the association between the perceived impact of MS and level of self-management in people with MS. The cross-sectional study included 382 people with MS. The participants completed the Multiple Sclerosis Self-Management Scale-Revised, Multiple Sclerosis Impact Scale-29, and Coping Inventory for Stressful Situations. The study hypothesis was evaluated using mediation analysis. The STROBE checklist specifically prepared for cross-sectional research was applied in this study for reporting. Results indicate that the emotion- and problem-focused strategies of coping can be treated as mediating the association between the MS impact and level of self-management in people with MS. A negative relationship was found between the perceived MS impact and problem-oriented coping, while a positive relationship was found between problem-oriented coping and self-management. Furthermore, a positive relationship was found between the MS impact and emotion-oriented coping, while a negative relationship was found between emotion-oriented coping and self-management. The indirect role of avoidance-oriented coping was not significant. Our study confirms the role played by coping strategies in individuals&#39; self-management. In MS, self-management determined by perceived MS impact can be controlled by decreasing emotional-coping while increasing problem-coping strategies. Our study imparts new knowledge regarding the potential interventions for improving the level of self-management in people with MS. It indicates that recognition of individuals&#39; illness perceptions as well as maladaptive coping strategies can help health professionals identify those who might be having lower level of self-management.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33705470&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33705470&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1371&#x2F;journal.pone.0248135&gt;10.1371&#x2F;journal.pone.0248135&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33705470&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":486,"discovery_date":"2021-03-12T04:05:29","title":"Genetic variation in WNT9B increases relapse hazard in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Neurol. 2021 Mar 11. doi: 10.1002&#x2F;ana.26061. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Many multiple sclerosis (MS) genetic susceptibility variants have been identified, but understanding disease heterogeneity remains a key challenge. Relapses are a core feature of MS and a common primary outcome of clinical trials, with prevention of relapses benefiting patients immediately and potentially limiting long-term disability accrual. We aim to identify genetic variation associated with relapse hazard in MS by analyzing the largest study population to date.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We performed a genome-wide association study (GWAS) in a discovery cohort and investigated the genome-wide significant variants in a replication cohort. Combining both cohorts, we captured a total of 2231 relapses occurring before the start of any immunomodulatory treatment in 991 patients. For assessing time to relapse, we applied a survival analysis utilizing Cox proportional hazards models. We also investigated the association between MS genetic risk scores and relapse hazard and performed a gene ontology pathway analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The low-frequency genetic variant rs11871306 within WNT9B reached genomewide significance in predicting relapse hazard and replicated (meta-analysis hazard ratio (HR) &#x3D; 2.15, 95% confidence interval (CI) &#x3D; 1.70-2.78, p &#x3D; 2.07 Ã 10&lt;sup&gt;-10&lt;&#x2F;sup&gt; ). A pathway analysis identified an association of the pathway &quot;response to vitamin D&quot; with relapse hazard (p &#x3D; 4.33 Ã 10&lt;sup&gt;-6&lt;&#x2F;sup&gt; ). The MS genetic risk scores, however, were not associated with relapse hazard.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: Genetic factors underlying disease heterogeneity differ from variants associated with MS susceptibility. Our findings imply that genetic variation within the Wnt signaling and vitamin D pathways contributes to differences in relapse occurrence. The present study highlights these cross-talking pathways as potential modulators of MS disease activity. This article is protected by copyright. All rights reserved.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704824&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33704824&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;ana.26061&gt;10.1002&#x2F;ana.26061&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33704824&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":485,"discovery_date":"2021-03-12T04:05:29","title":"Altered communication dynamics reflect cognitive deficits in temporal lobe epilepsy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Epilepsia. 2021 Mar 11. doi: 10.1111&#x2F;epi.16864. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Although temporal lobe epilepsy (TLE) is recognized as a system-level disorder, little work has investigated pathoconnectomics from a dynamic perspective. By leveraging computational simulations that quantify patterns of information flow across the connectome, we tested the hypothesis that network communication is abnormal in this condition, studied the interplay between hippocampal- and network-level disease effects, and assessed associations with cognition.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We simulated signal spreading via a linear threshold model that temporally evolves on a structural graph derived from diffusion-weighted magnetic resonance imaging (MRI), comparing a homogeneous group of 31 patients with histologically proven hippocampal sclerosis to 31 age- and sex-matched healthy controls. We evaluated the modulatory effects of structural alterations of the neocortex and hippocampus on network dynamics. Furthermore, multivariate statistics addressed the relationship with cognitive parameters.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We observed a slowing of in- and out-spreading times across multiple areas bilaterally, indexing delayed information flow, with the strongest effects in ipsilateral frontotemporal regions, thalamus, and hippocampus. Effects were markedly reduced when controlling for hippocampal volume but not cortical thickness, underscoring the central role of the hippocampus in whole-brain disease expression. Multivariate analysis associated slower spreading time in frontoparietal, limbic, default mode, and subcortical networks with impairment across tasks tapping into sensorimotor, executive, memory, and verbal abilities.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SIGNIFICANCE: Moving beyond descriptions of static topology toward the formulation of brain dynamics, our work provides novel insight into structurally mediated network dysfunction and demonstrates that altered whole-brain communication dynamics contribute to common cognitive difficulties in TLE.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33705572&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3&quot;&gt;33705572&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;epi.16864&gt;10.1111&#x2F;epi.16864&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33705572&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311230527&amp;v&#x3D;2.14.3","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":484,"discovery_date":"2021-03-12T00:25:58","title":"UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records","summary":"Characterising the size and distribution of the population at risk of severe COVID-19 is vital for effective policy and planning. Older age, and underlying health conditions, are associated with higher risk of...","link":"https:&#x2F;&#x2F;bmcpublichealth.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12889-021-10427-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":483,"discovery_date":"2021-03-11T18:45:29","title":"The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-Mexico Program: A Myriad of Experiences and Knowledge","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 22;12:647425. doi: 10.3389&#x2F;fneur.2021.647425. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;After gaining experience conducting both auto and allografts in persons with hematological diseases in the HSCT programs in Puebla and Monterrey, MÃ©xico, this study outlines subsequent program autografting patients with autoimmune conditions. The first transplant in multiple sclerosis was conducted in Puebla on July 5, 2006. From 2015 we increased activity autografting persons with autoimmune conditions in the two campuses of the HSCT-MÃ©xico program: Puebla and Monterrey. By December 6, 2020, patient number 1,000 in the program was autografted. In our experience, a significant reduction in the expanded disability status scale score was achieved in all of the three phenotypes of the disease (from a median of 5.1 to 4.5 points), whereas the response rate (defined as a decrease of at least 0.5 of EDSS score regardless of baseline EDSS, or unchanged EDSS) was 83, 78, and 73% after 12 months in the relapsing-remitting, primary-progressive and secondary-progressive forms of multiple sclerosis, respectively. In addition to analyzing the viability, safety, and efficacy of our method, this study contributes new knowledge to the field of both stem cell transplantation and multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692748&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33692748&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7937693&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;PMC7937693&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.647425&gt;10.3389&#x2F;fneur.2021.647425&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692748&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":482,"discovery_date":"2021-03-11T18:45:29","title":"Role of the IL-23&#x2F;IL-17 Pathway in Rheumatic Diseases: An Overview","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 22;12:637829. doi: 10.3389&#x2F;fimmu.2021.637829. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12&#x2F;23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced by macrophages and dendritic cells, in response to exogenous or endogenous signals, and drives the differentiation and activation of T helper 17 (Th17) cells with subsequent production of IL-17A, IL-17F, IL-6, IL-22, and tumor necrosis factor Î± (TNF-Î±). Although IL-23 plays a pivotal role in the protective immune response to bacterial and fungal infections, its dysregulation has been shown to exacerbate chronic immune-mediated inflammation. Well-established experimental data support the concept that IL-23&#x2F;IL-17 axis activation contributes to the development of several inflammatory diseases, such as PsA, Psoriasis, Psoriatic Arthritis; AS, Ankylosing Spondylitis; IBD, Inflammatory Bowel Disease; RA, Rheumatoid Arthritis; SS, Sjogren Syndrome; MS, Multiple Sclerosis. As a result, emerging clinical studies have focused on the blockade of this pathogenic axis as a promising therapeutic target in several autoimmune disorders; nevertheless, a greater understanding of its contribution still requires further investigation. This review aims to elucidate the most recent studies and literature data on the pathogenetic role of IL-23 and Th17 cells in inflammatory rheumatic diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692806&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33692806&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7937623&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;PMC7937623&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.637829&gt;10.3389&#x2F;fimmu.2021.637829&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692806&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":481,"discovery_date":"2021-03-11T18:45:29","title":"Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 9:awab088. doi: 10.1093&#x2F;brain&#x2F;awab088. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Damage to the myelin sheath and the neuroaxonal unit is a cardinal feature of multiple sclerosis; however, a detailed characterization of the interaction between myelin and axon damage in vivo remains challenging. We applied myelin water and multi-shell diffusion imaging to quantify the relative damage to myelin and axons (i) among different lesion types; (ii) in normal-appearing tissue; and (iii) across multiple sclerosis clinical subtypes and healthy controls. We also assessed the relation of focal myelin&#x2F;axon damage with disability and serum neurofilament light chain as a global biological measure of neuroaxonal damage. Ninety-one multiple sclerosis patients (62 relapsing-remitting, 29 progressive) and 72 healthy controls were enrolled in the study. Differences in myelin water fraction and neurite density index were substantial when lesions were compared to healthy controls and normal-appearing MS tissue: both white matter and cortical lesions exhibited a decreased myelin water fraction and neurite density index compared with healthy (P &amp;lt; 0.0001) and peri-plaque white matter (P &amp;lt; 0.0001). Periventricular lesions showed decreased myelin water fraction and neurite density index compared with lesions in the juxtacortical region (P &amp;lt; 0.0001 and P &amp;lt; 0.05). Similarly, lesions with paramagnetic rims showed decreased myelin water fraction and neurite density index relative to lesions without a rim (P &amp;lt; 0.0001). Also, in 75% of white matter lesions, the reduction in neurite density index was higher than the reduction in the myelin water fraction. Besides, normal-appearing white and grey matter revealed diffuse reduction of myelin water fraction and neurite density index in multiple sclerosis compared to healthy controls (P &amp;lt; 0.01). Further, a more extensive reduction in myelin water fraction and neurite density index in normal-appearing cortex was observed in progressive versus relapsing-remitting participants. Neurite density index in white matter lesions correlated with disability in patients with clinical deficits (P &amp;lt; 0.01, beta&#x3D;-10.00); and neurite density index and myelin water fraction in white matter lesions were associated to serum neurofilament light chain in the entire patients cohort (P &amp;lt; 0.01, beta&#x3D;-3.60 and P &amp;lt; 0.01, beta&#x3D;0.13, respectively). These findings suggest that (i) myelin and axon pathology in multiple sclerosis is extensive in both lesions and normal-appearing tissue; (ii) particular types of lesions exhibit more damage to myelin and axons than others; (iii) progressive patients differ from relapsing-remitting because of more extensive axon&#x2F;myelin damage in the cortex; and (iv) myelin and axon pathology in lesions is related to disability in patients with clinical deficits and global measures of neuroaxonal damage.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693571&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33693571&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab088&gt;10.1093&#x2F;brain&#x2F;awab088&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693571&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":480,"discovery_date":"2021-03-11T18:45:29","title":"Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 9:awab100. doi: 10.1093&#x2F;brain&#x2F;awab100. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The involvement of specific viral and bacterial infections as risk factors for multiple sclerosis has been studied extensively. However, whether this extends to infections in a broader sense is less clear and little is known about whether risk of a multiple sclerosis diagnosis is associated with other types and sites of infections, such as of the CNS. This study aims to assess if hospital-diagnosed infections by type and site before age 20 years are associated with risk of a subsequent multiple sclerosis diagnosis and whether this association is explained entirely by infectious mononucleosis, pneumonia, and CNS infections. Individuals born in Sweden between 1970-1994 were identified using the Swedish Total Population Register (n &#x3D; 2,422,969). Multiple sclerosis diagnoses from age 20 years and hospital-diagnosed infections before age 20 years were identified using the Swedish National Patient Register. Risk of a multiple sclerosis diagnosis associated with various infections in adolescence (11-19 years) and earlier childhood (birth-10 years) was estimated using Cox regression, with adjustment for sex, parental socioeconomic position, and infection type. None of the infections by age 10 years were associated with risk of a multiple sclerosis diagnosis. Any infection in adolescence increased the risk of a multiple sclerosis diagnosis (hazard ratio 1.33, 95% confidence interval 1.21-1.46) and remained statistically significant after exclusion of infectious mononucleosis, pneumonia, and CNS infection (hazard ratio 1.17, 95% confidence interval 1.06-1.30). CNS infection in adolescence (excluding encephalomyelitis to avoid including acute disseminated encephalitis) increased the risk of a multiple sclerosis diagnosis (hazard ratio 1.85, 95% confidence interval 1.11-3.07). The increased risk of a multiple sclerosis diagnosis associated with viral infection in adolescence was largely explained by infectious mononucleosis. Bacterial infections in adolescence increased risk of a multiple sclerosis diagnosis, but the magnitude of risk reduced after excluding infectious mononucleosis, pneumonia and CNS infection (hazard ratio 1.31, 95% confidence interval 1.13-1.51). Respiratory infection in adolescence also increased risk of a multiple sclerosis diagnosis (hazard ratio 1.51, 95% confidence interval 1.30-1.75), but was not statistically significant after excluding infectious mononucleosis and pneumonia. These findings suggest that a variety of serious infections in adolescence, including novel evidence for CNS infections, are risk factors for a subsequent multiple sclerosis diagnosis, further demonstrating adolescence is a critical period of susceptibility to environmental exposures that raise the risk of a multiple sclerosis diagnosis. Importantly, this increased risk cannot be entirely explained by infectious mononucleosis, pneumonia, or CNS infections.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693538&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33693538&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab100&gt;10.1093&#x2F;brain&#x2F;awab100&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693538&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":479,"discovery_date":"2021-03-11T18:45:29","title":"Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain. 2021 Mar 9:awab093. doi: 10.1093&#x2F;brain&#x2F;awab093. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Meningeal B lymphocyte aggregates have been described in autopsy material of patients with chronic Multiple Sclerosis. The presence of meningeal B cell aggregates has been correlated with worse disease. However, the functional role of these meningeal B cell aggregates is not understood. Here, we use a mouse model of Multiple Sclerosis, the spontaneous opticospinal encephalomyelitis model, which is built on the double transgenic expression of myelin oligodendrocyte glycoprotein-specific T cell- and B cell-receptors, to show that the formation of meningeal B cell aggregates is dependent on the expression of Î±4 integrins by antigen-specific T cells. T cell-conditional genetic ablation of Î±4 integrins in opticospinal encephalomyelitis mice impaired the formation of meningeal B cell aggregates, and surprisingly, led to a higher disease incidence as compared to opticospinal encephalomyelitis mice with Î±4 integrin-sufficient T cells. B cell-conditional ablation of Î±4 integrins in opticospinal encephalomyelitis mice resulted in the entire abrogation of the formation of meningeal B cell aggregates, and opticospinal encephalomyelitis mice with Î±4 integrin-deficient B cells suffered from a higher disease burden than regular opticospinal encephalomyelitis mice. While anti-CD20 antibody-mediated systemic depletion of B cells in opticospinal encephalomyelitis mice after onset of disease failed to efficiently decrease meningeal B cell aggregates without significantly modulating disease progression, treatment with anti-CD19 chimeric antigen receptor-T cells eliminated meningeal B cell aggregates and exacerbated clinical disease in opticospinal encephalomyelitis mice. Since about 20 percent of B cells in organised meningeal B cell aggregates produced either IL-10 or IL-35, we propose that meningeal B cell aggregates might also have an immunoregulatory function as to the immunopathology in adjacent spinal cord white matter. The immunoregulatory function of meningeal B cell aggregates needs to be considered when designing highly efficient therapies directed against meningeal B cell aggregates for clinical application in Multiple Sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693558&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33693558&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;brain&#x2F;awab093&gt;10.1093&#x2F;brain&#x2F;awab093&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693558&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":478,"discovery_date":"2021-03-11T18:45:29","title":"Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4-Positive Neuromyelitis optica Spectrum Disorder","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 22;12:608149. doi: 10.3389&#x2F;fneur.2021.608149. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; &lt;i&gt;Neuromyelitis optica&lt;&#x2F;i&gt; spectrum disorder (NMOSD) is a relapsing autoimmune-related neurological disorder of the central nervous system. Most patients with NMOSD have serum anti-aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). In addition to optic neuritis and myelitis, other insidious symptoms such as depressive state and chronic fatigue in NMOSD are gradually being recognized. &lt;b&gt;Methods:&lt;&#x2F;b&gt; To elucidate the impact of low- to medium-dose oral prednisolone (PSL) as a relapse prevention therapy for psychiatric disturbances and chronic fatigue in NMOSD, we evaluated clinical data from 39 patients with AQP4-IgG-positive NMOSD, along with the details of present and cumulative oral PSL dosage. &lt;b&gt;Results:&lt;&#x2F;b&gt; Thirty-six of the 39 patients were treated with low- to medium-dose oral PSL, and the mean and standard deviation of the present daily dose of oral PSL were 7.9 Â± 4.0 mg&#x2F;day. None of the patients were treated with a daily PSL dose of &amp;gt;15 mg. As a result, the disease duration and the untreated period before starting oral PSL showed weak to moderate correlations with the subsequent severities of psychiatric disturbance and fatigue level. Meanwhile, none of the other treatment-related variables evaluated, such as the present oral PSL daily dose, cumulative PSL dose, months of oral PSL administration, previous courses of steroid pulse therapy, and coadministered immunosuppressants, were correlated with these insidious symptoms. &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; Our results suggest that the use of long-term low- to medium-dose oral PSL â¤15 mg daily for relapse prevention in AQP4-IgG-positive NMOSD would not aggravate the psychiatric and fatigue conditions. On the contrary, early initiation of oral PSL for relapse prevention, together with significantly decreased relapse rate, alleviated the subsequent depressive state and fatigue from the disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692739&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33692739&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7938311&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;PMC7938311&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2021.608149&gt;10.3389&#x2F;fneur.2021.608149&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692739&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":477,"discovery_date":"2021-03-11T18:45:29","title":"Dimethyl Fumarate Induces Metabolic Crisie to Suppress Pancreatic Carcinoma","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Pharmacol. 2021 Feb 22;12:617714. doi: 10.3389&#x2F;fphar.2021.617714. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Dimethyl fumarate (DMF) is an approved drug used in the treatment of multiple sclerosis (MS) and psoriasis therapy. Multiple studies have demonstrated other pharmacological activities of DMF such as an anti-cancer agent. In particular, studies have shown that DMF can modulate the NRF2&#x2F;HO1&#x2F;NQO1 antioxidant signal pathway and inactivate NF-ÎºB to suppress the growth of colon and breast cancer cells, and induce cell death. In this study, we aimed to evaluate the anti-tumor activities of DMF in pancreatic cancer (PC) focusing on cell death as the predominant mechanism of response. We showed that both mitochondrial respiration and aerobic glycolysis were severely depressed following treatment with DMF and the effects could be abrogated by treatment with L-cysteine and N-acetyl-L-cysteine (NAC). Importantly, we verified that DMF induced metabolic crisis and that cell death was not related to alterations in ROS. Our data implied that MTHFD1 could be a potential downstream target of DMF identified by molecular docking analysis. Finally, we confirmed that MTHFD1 is up-regulated in PC and overexpression of MTHFD1 was negatively related to outcomes of PC patients. Our data indicate that DMF induces metabolic crisie to suppress cell growth and could be a potential novel therapy in the treatment of PC.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692690&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33692690&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7937954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;PMC7937954&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fphar.2021.617714&gt;10.3389&#x2F;fphar.2021.617714&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692690&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":476,"discovery_date":"2021-03-11T18:45:29","title":"Insights for Fostering Resilience in Young Adults With Multiple Sclerosis in the Aftermath of the COVID-19 Emergency: An Italian Survey","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Psychiatry. 2021 Feb 22;11:588275. doi: 10.3389&#x2F;fpsyt.2020.588275. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Objective:&lt;&#x2F;b&gt; Recent evidence has demonstrated that the COVID-19 pandemic is taking a toll on the mental health of the general population. The psychological consequences might be even more severe for patients with special healthcare needs and psychological vulnerabilities due to chronic diseases, such as multiple sclerosis (MS). Thus, we aimed to explore the psychological impact of this pandemic and of the subsequent healthcare service changes on young adults with MS living in Italy and to examine their coping strategies and preferences regarding psychological support in the aftermath of the pandemic. &lt;b&gt;Methods:&lt;&#x2F;b&gt; Data were collected using a cross-sectional, web-based survey advertised on social networks. We report both quantitative (descriptive statistics, &lt;i&gt;t&lt;&#x2F;i&gt;-tests, and one-way ANOVA) and qualitative data (inductive content analysis). &lt;b&gt;Results:&lt;&#x2F;b&gt; Two hundred and forty-seven respondents (mean age 32 Â± 7 years), mainly with relapsing-remitting MS, from all Italian regions participated. Participants felt more worried, confused, sad, and vulnerable because of the disease &quot;during&quot; the pandemic in comparison to their self-evaluation of the period &quot;before&quot; the COVID-19 outbreak. Similarly, their perception of control over MS decreased &quot;during&quot; the pandemic in comparison to the retrospective evaluation of the period &quot;before&quot; the COVID-19 outbreak (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.01). Canceled&#x2F;postponed visits&#x2F;exams were listed as the most frequent MS management changes, with modified&#x2F;postponed pharmacological treatment representing the most stressful change. Psychological support in dealing with pandemic-related fears and improving MS acceptance and well-being was considered extremely important by almost 40% of the respondents. Different coping strategies were mentioned in the qualitative section of the survey, with social support, hobbies, and keeping busy being the most frequent ones. &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Considering the enormous impact of the pandemic on young adults with MS, we urge MS clinical centers to implement psychological support programs that address the potentially long-lasting psychological negative impact, thus fostering the therapeutic alliance that is being threatened by the infection prevention measures imposed during the pandemic, and promoting psychological resources for adaptively managing future waves of COVID-19.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692703&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33692703&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7938709&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;PMC7938709&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fpsyt.2020.588275&gt;10.3389&#x2F;fpsyt.2020.588275&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692703&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":475,"discovery_date":"2021-03-11T18:45:29","title":"Common and rare genetic variants that could contribute to severe otitis media in an Australian Aboriginal population","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Infect Dis. 2021 Mar 9:ciab216. doi: 10.1093&#x2F;cid&#x2F;ciab216. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Our goal was to identify genetic risk factors for severe otitis media (OM) in Aboriginal Australians.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Illumina Â® Omni2.5 BeadChip and imputed data were compared between 21 children with severe OM (multiple episodes chronic suppurative OM and&#x2F;or perforations or tympanic sclerosis) and 370 individuals without this phenotype, followed by FUnctional Mapping and Annotation (FUMA). Exome data filtered for common (EXaC_allâ¥0.1) putative deleterious variants influencing protein coding (CADD-scaled scores â¥ 15) were used to compare 15 severe OM cases with 9 mild cases (single episode of acute OM recorded over â¥ 3 consecutive years). Rare (ExAC_allâ¤0.01) such variants were filtered for those present only in severe OM. Enrichr was used to determine enrichment of genes contributing to pathways&#x2F;processes relevant to OM.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: FUMA analysis identified two plausible genetic risk loci for severe OM: NR3C1 (Pimputed_1000G&#x3D;3.62x10 -6) encoding the glucocorticoid receptor, and NREP (Pimputed_1000G&#x3D;3.67x10 -6) encoding neuronal regeneration related protein. Exome analysis showed: (i) association of severe OM with variants influencing protein coding (CADD-scaled â¥ 15) in a gene-set (GRXCR1, CDH23, LRP2, FAT4, ARSA, EYA4) enriched for Mammalian Phenotype Level 4 abnormal hair cell stereociliary bundle morphology and related phenotypes; (ii) rare variants influencing protein coding only seen in severe OM provided gene-sets enriched for &quot;abnormal ear&quot; (LMNA, CDH23, LRP2, MYO7A, FGFR1), integrin interactions, transforming growth factor signalling, and cell projection phenotypes including hair cell stereociliary bundles and cilium assembly.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: This study highlights interacting genes and pathways related to cilium structure and function that may contribute to extreme susceptibility to OM in Aboriginal Australian children.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693626&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33693626&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;cid&#x2F;ciab216&gt;10.1093&#x2F;cid&#x2F;ciab216&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33693626&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":474,"discovery_date":"2021-03-11T18:45:29","title":"The pro-inflammatory microRNA miR-155 influences fibrillar Î²-Amyloid1 -42 catabolism by microglia","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Glia. 2021 Mar 10. doi: 10.1002&#x2F;glia.23988. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Microglia are the innate immune cells of the central nervous system that adopt rapid functional changes in response to Damage Associated Molecular Patterns, including aggregated Î²-Amyloid (AÎ²) found in Alzheimer&#39;s disease (AD). microRNAs (miRNAs) are post-transcriptional modulators that influence the timing and magnitude of microglia inflammatory responses by downregulating the expression of inflammatory effectors. Recent studies implicate miR-155, a miRNA known to regulate inflammatory responses, in the pathogenesis of neurodegenerative disorders including multiple sclerosis, ALS, familial Parkinson&#39;s disease, and AD. In this work, we asked if miR-155 expression in microglia modifies cellular behaviors in response to fibrillar AÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; (fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; ), in vitro. We hypothesized that in microglia, miR-155 expression would impact the internalization and catabolism of extracellular fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; . Primary microglia stimulated with lipopolysaccharide demonstrate fast upregulation of miR-155 followed by delayed upregulation of miR-146a, an anti-inflammatory miRNA. Conditional overexpression of miR-155 in microglia resulted in significant upregulation of miR-146a. Conditional deletion of miR-155 promoted transit of fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; to low-pH compartments where catabolism occurs, while miR-155 overexpression decreases fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; catabolism. Uptake of fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; across the plasma membrane increased with both up and downregulation of miR-155 expression. Taken together, our results support the hypothesis that inflammatory signaling influences the ability of microglia to catabolize fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; through interconnected mechanisms modulated by miR-155. Understanding how miRNAs modulate the ability of microglia to catabolize fAÎ²&lt;sub&gt;1-42&lt;&#x2F;sub&gt; will further elucidate the role of cellular players and molecular crosstalk in AD pathophysiology.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33694209&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2&quot;&gt;33694209&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;glia.23988&gt;10.1002&#x2F;glia.23988&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33694209&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311134527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":473,"discovery_date":"2021-03-11T13:25:28","title":"Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 10:10.1212&#x2F;WNL.0000000000011712. doi: 10.1212&#x2F;WNL.0000000000011712. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To determine whether there was an increase in payments for neurologist-prescribed drugs, we performed a retrospective analysis of prescription claims in the Medicare Part D Prescriber Public Use Files from 2013-2017.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We included claims prescribed by providers with the taxonomy &quot;Neurology&quot; and included drugs present in all five years. Drugs were designated in 2013 as generic (GEN), brand name only (BNO), and brand name prescribed even though a generic equivalent is available (BNGE). To observe payment trends, the percentage change in the per claim payment was compared between drug classes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We included 520 drugs, of which 322 were GEN, 61 BNO, and 137 BNGE, representing 90,716,536 claims and generating payments of $26,654,750,720. While the number of claims from 2013 to 2017 only increased 7.6%, the total payment increased 50.4%. Adjusted for inflation, claim payments for GEN drug increased 0.6%, compared to significant increases in BNO and BNGE drugs of 42.4% and 45.0% (p&lt;sub&gt;trend&lt;&#x2F;sub&gt;&amp;lt;0.001). The percentage of overall GEN claims increased from 81.9% to 88.0%, BNO increased from 4.9% to 6.2%, and BNGE decreased from 13.3% to 5.8%. Neuroimmunology&#x2F;multiple sclerosis drugs represented over 50% of the total payments despite being only 4.3% of claims.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Payments for neurologist-prescribed brand name, but not generic, drugs in Medicare Part D increased consistently and well above inflation from 2013-2017. Unless the overall trend stabilizes or is reversed, or high cost-to-claim drugs are addressed, this trend will place an increasing burden on the neurologic Medicare budget.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311082527&amp;v&#x3D;2.14.2&quot;&gt;33692164&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011712&gt;10.1212&#x2F;WNL.0000000000011712&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33692164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311082527&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":472,"discovery_date":"2021-03-11T12:25:59","title":"A meta-analysis of the epidemiology of giant cell arteritis across time and space","summary":"Giant cell arteritis (GCA) is a common large vessel vasculitis in those over age 50âyears. This meta-analysis examined the geographical and temporal distribution of the incidence, prevalence, and mortality of ...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02450-w","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":471,"discovery_date":"2021-03-11T06:58:12","title":"Potential Role of Trace Elements (Al, Cu, Zn, and Se) in Multiple Sclerosis Physiopathology","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroimmunomodulation. 2021 Mar 10:1-15. doi: 10.1159&#x2F;000511308. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is an unpredictable disease of the central nervous system. The cause of MS is not known completely, and pathology is specified by involved demyelinated areas in the white and gray matter of the brain and spinal cord. Inflammation and peripheral tolerance breakdown due to Treg cell defects and&#x2F;or effector cell resistance are present at all stages of the disease. Several invading peripheral immune cells are included in the process of the disease such as macrophages, CD8+ T cells, CD4+ T cells, B cells, and plasma cells. Trace elements are known as elements found in soil, plants, and living organisms in small quantities. Some of them (e.g., Al, Cu, Zn, Mn, and Se) are essential for the body&#39;s functions like catalysts in enzyme systems, energy metabolism, etc. Al toxicity and Cu, Zn, and Se toxicity and deficiency can affect the immune system and following neuron inflammation and degeneration. These processes may result in MS pathology. Of course, factors such as lifestyle, environment, and industrialization can affect levels of trace elements in the human body.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691322&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33691322&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000511308&gt;10.1159&#x2F;000511308&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691322&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":470,"discovery_date":"2021-03-11T06:58:12","title":"Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Rep. 2021 Mar 9;34(10):108835. doi: 10.1016&#x2F;j.celrep.2021.108835.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In multiple sclerosis (MS) and other neurological diseases, the failure to repair demyelinated lesions contributes to axonal damage and clinical disability. Here, we provide evidence that Mertk, a gene highly expressed by microglia that alters MS risk, is required for efficient remyelination. Compared to wild-type (WT) mice, Mertk-knockout (KO) mice show impaired clearance of myelin debris and remyelination following demyelination. Using single-cell RNA sequencing, we characterize Mertk-influenced responses to cuprizone-mediated demyelination and remyelination across different cell types. Mertk-KO brains show an attenuated microglial response to demyelination but an elevated proportion of interferon (IFN)-responsive microglia. In addition, we identify a transcriptionally distinct subtype of surviving oligodendrocytes specific to demyelinated lesions. The inhibitory effect of myelin debris on remyelination is mediated in part by IFNÎ³, which further impedes microglial clearance of myelin debris and inhibits oligodendrocyte differentiation. Together, our work establishes a role for Mertk in microglia activation, phagocytosis, and migration during remyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691116&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33691116&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.celrep.2021.108835&gt;10.1016&#x2F;j.celrep.2021.108835&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691116&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":469,"discovery_date":"2021-03-11T06:58:12","title":"No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Mar 2;51:102875. doi: 10.1016&#x2F;j.msard.2021.102875. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: No evidence of disease activity (NEDA) is a composite surrogate assessing the responsiveness to various disease-modifying treatments (DMTs) in patients with relapsing and remitting multiple sclerosis (RRMS), addressing clinical as well as radiological disease activity. Despite the rising prevalence of multiple sclerosis in Saudi Arabia (SA), there is a lack of evidence focusing on this important aspect in the management of RRMS. This study aimed to identify the prevalence of NEDA-3 status achievement in patients with RRMS on DMTs (mainly the interferon) and to describe the factors affecting its attainment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHOD: This was a retrospective, cross-sectional study carried out at King Fahd University Hospital after obtaining institutional ethical approval. The electronic records of 119 patients diagnosed with RRMS were reviewed. Clinical manifestations at initial presentation, relapse after starting treatment, disability progression, and development of new lesions on follow-up magnetic resonance imaging were all documented to assess NEDA-3 status. Data were analyzed using Statistical Package for Social Sciences, version 22.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: NEDA-3 status was achieved in 41 (33.6%) patients. The female-to-male ratio for all patients was 1.5:1. Interferon (IFN) was the most commonly prescribed DMT. NEDA-3 status was achieved in 30.9% of patients receiving IFN. Mean baseline Expanded Disability Status Scale in patients who did not achieve NEDA-3 was 2.8Â±1.8. Patients with ataxia (P &#x3D; &amp;lt;0.001), sphincter disturbances (P&#x3D;0.002) and infra-tentorial brain lesions (P&#x3D;0.03) were less likely to achieve NEDA-3 status. Involvement of pyramidal, cerebellar and more than one system at initial presentation was more frequent in patients who could not achieve NEDA-3 status (P&#x3D;0.002) CONCLUSION: Less than one third of total patients on IFN as DMT could achieve NEDA-3 status in our cohort of patients which is in agreement with the literature published in the West. We could not properly asses NEDA-3 status for other DMTs in our center due to the very small sample size of patients on these DMTs, and recommend future studies including larger number of patients on DMTs other than IFN. Significant differences were identified between the two groups of patients with respect to attainment of NEDA-3 status, which requires further verification by multicenter prospective studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691260&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33691260&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102875&gt;10.1016&#x2F;j.msard.2021.102875&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691260&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":468,"discovery_date":"2021-03-11T06:58:12","title":"Retention of Physical Gains in the Community Following Physical Training for Multiple Sclerosis: A Systematic Review and Implications","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Semin Neurol. 2021 Mar 9. doi: 10.1055&#x2F;s-0041-1725139. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a progressive neurological illness whose typically young adult onset results in a nearly entire lifetime of worsening disability. But despite being an unrelenting neurodegenerative disease, numerous clinical trials over the past 40 years for MS have vigorously attempted to improve or at least stabilize declining physical function. Although the vast majority of the studies assessed training effects only within controlled laboratory or clinic settings, in recent years a growing interest has emerged to test whether newer therapies can instead benefit real-life activities in the community. Nonetheless, comparatively little attention has been paid to whether the training gains can be retained for meaningful periods. This review discusses the comparative success of various physical training methods to benefit within-community activities in MS, and whether the gains can be retained long afterward. This review will suggest future research directions toward establishing efficacious treatments that can allow persons with MS to reclaim their physical abilities and maximize functionality for meaningful periods.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33690875&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33690875&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1055&#x2F;s-0041-1725139&gt;10.1055&#x2F;s-0041-1725139&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33690875&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":467,"discovery_date":"2021-03-11T06:58:12","title":"Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Adv Healthc Mater. 2021 Mar 9:e2002214. doi: 10.1002&#x2F;adhm.202002214. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cytokine signaling is critical to a range of biological processes including cell development, tissue repair, aging, and immunity. In addition to acting as key signal mediators of the immune system, cytokines can also serve as potent immunotherapies with more than 20 recombinant products currently Food and Drug Administration (FDA)-approved to treat conditions including hepatitis, multiple sclerosis, arthritis, and various cancers. Yet despite their biological importance and clinical utility, cytokine immunotherapies suffer from intrinsic challenges that limit their therapeutic potential including poor circulation, systemic toxicity, and low tissue- or cell-specificity. In the past decade in particular, methods have been devised to engineer cytokines in order to overcome such challenges and here, the myriad strategies are reviewed that may be employed in order to improve the therapeutic potential of cytokine and chemokine immunotherapies with applications in cancer and autoimmune disease therapy, as well as tissue engineering and regenerative medicine. For clarity, these strategies are collected and presented as they vary across size scales, ranging from single amino acid substitutions, to larger protein-polymer conjugates, nano&#x2F;micrometer-scale particles, and macroscale implants. Together, this work aims to provide readers with a timely view of the field of cytokine engineering with an emphasis on early-stage therapeutic approaches.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33690997&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33690997&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;adhm.202002214&gt;10.1002&#x2F;adhm.202002214&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33690997&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":466,"discovery_date":"2021-03-11T06:58:12","title":"Itaconate confers tolerance to late NLRP3 inflammasome activation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Rep. 2021 Mar 9;34(10):108756. doi: 10.1016&#x2F;j.celrep.2021.108756.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Itaconate is a unique regulatory metabolite that is induced upon Toll-like receptor (TLR) stimulation in myeloid cells. Here, we demonstrate major inflammatory tolerance and cell death phenotypes associated with itaconate production in activated macrophages. We show that endogenous itaconate is a key regulator of the signal 2 of NLR family pyrin domain containing 3 (NLRP3) inflammasome activation after long lipopolysaccharide (LPS) priming, which establishes tolerance to late NLRP3 inflammasome activation. We show that itaconate acts synergistically with inducible nitric oxide synthase (iNOS) and that the ability of various TLR ligands to establish NLRP3 inflammasome tolerance depends on the pattern of co-expression of IRG1 and iNOS. Mechanistically, itaconate accumulation upon prolonged inflammatory stimulation prevents full caspase-1 activation and processing of gasdermin D, which we demonstrate to be post-translationally modified by endogenous itaconate. Altogether, our data demonstrate that metabolic rewiring in inflammatory macrophages establishes tolerance to NLRP3 inflammasome activation that, if uncontrolled, can result in pyroptotic cell death and tissue damage.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33691097&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.celrep.2021.108756&gt;10.1016&#x2F;j.celrep.2021.108756&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":465,"discovery_date":"2021-03-11T06:58:12","title":"Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Rep. 2021 Mar 9;34(10):108833. doi: 10.1016&#x2F;j.celrep.2021.108833.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Sex differences in multiple sclerosis (MS) incidence and severity have long been recognized. However, the underlying cellular and molecular mechanisms for why male sex is associated with more aggressive disease remain poorly defined. Using a T cell adoptive transfer model of chronic experimental autoimmune encephalomyelitis (EAE), we find that male Th17 cells induce disease of increased severity relative to female Th17 cells, irrespective of whether transferred to male or female recipients. Throughout the disease course, a greater frequency of male Th17 cells produce IFNÎ³, a hallmark of pathogenic Th17 responses. Intriguingly, XY chromosomal complement increases the pathogenicity of male Th17 cells. An X-linked immune regulator, Jarid1c, is downregulated in pathogenic male murine Th17 cells, and functional experiments reveal that it represses the severity of Th17-mediated EAE. Furthermore, Jarid1c expression is downregulated in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells from MS-affected individuals. Our data indicate that male sex chromosomal complement critically regulates Th17 cell pathogenicity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33691111&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.celrep.2021.108833&gt;10.1016&#x2F;j.celrep.2021.108833&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":464,"discovery_date":"2021-03-11T06:58:12","title":"Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroepidemiology. 2021 Mar 10:1-7. doi: 10.1159&#x2F;000513763. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Italy is considered a high-risk country for multiple sclerosis (MS). Exploiting electronic health archives (EHAs) is highly useful to continuously monitoring the prevalence of the disease, as well as the care delivered to patients and its outcomes. The aim of this study was to validate an EHA-based algorithm to identify MS patients, suitable for epidemiological purposes, and to estimate MS prevalence in Piedmont (North Italy).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: MS cases were identified, in the period between January 1, 2012 and December 31, 2017, linking data from 4 different sources: hospital discharges, drug prescriptions, exemptions from co-payment to health care, and long-term care facilities. Sensitivity of the algorithm was tested through record linkage with a cohort of 656 neurologist-confirmed MS cases; specificity was tested with a cohort of 2,966,293 residents presumably not affected by MS. Undercount was estimated by a capture-recapture method. We calculated crude, and age- and gender-specific prevalence. We also calculated age-adjusted prevalence by level of urbanization of the municipality of residence.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: On December 31, 2017, the algorithm identified 8,850 MS cases. Sensitivity was 95.9%, specificity was 99.97%, and the estimated completeness of ascertainment was 91.9%. The overall prevalence, adjusted for undercount, was 152 per 100,000 among men and 286 among women; it increased with increasing age and reached its peak value in the 45- to 54-year class, followed by a progressive reduction. The age-adjusted prevalence of residents in cities was 15% higher than in those living in the countryside.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DISCUSSION&#x2F;CONCLUSION: We validated an algorithm based on EHAs to identify cases of MS for epidemiological use. The prevalence of MS, adjusted for undercount, was among the highest in Italy. We also found that the prevalence was higher in highly urbanized areas.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691323&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2&quot;&gt;33691323&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000513763&gt;10.1159&#x2F;000513763&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33691323&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210311015810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":463,"discovery_date":"2021-03-11T04:18:11","title":"TDP-43 maximizes nerve conduction velocity by repressing a cryptic exon for paranodal junction assembly in Schwann cells","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Elife. 2021 Mar 10;10:e64456. doi: 10.7554&#x2F;eLife.64456.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TDP-43 is extensively studied in neurons in physiological and pathological contexts. However, emerging evidence indicates that glial cells are also reliant on TDP-43 function. We demonstrate that deletion of TDP-43 in Schwann cells results in a dramatic delay in peripheral nerve conduction causing significant motor deficits in mice, which is directly attributed to the absence of paranodal axoglial junctions. By contrast, paranodes in the central nervous system are unaltered in oligodendrocytes lacking TDP-43. Mechanistically, TDP-43 binds directly to &lt;i&gt;Neurofascin&lt;&#x2F;i&gt; mRNA, encoding the cell adhesion molecule essential for paranode assembly and maintenance. Loss of TDP-43 triggers the retention of a previously unidentified cryptic exon, which targets &lt;i&gt;Neurofascin&lt;&#x2F;i&gt; mRNA for nonsense-mediated decay. Thus, TDP-43 is required for neurofascin expression, proper assembly and maintenance of paranodes, and rapid saltatory conduction. Our findings provide a framework and mechanism for how Schwann cell-autonomous dysfunction in nerve conduction is directly caused by TDP-43 loss-of-function.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33689679&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310231810&amp;v&#x3D;2.14.2&quot;&gt;33689679&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7554&#x2F;eLife.64456&gt;10.7554&#x2F;eLife.64456&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33689679&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310231810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":462,"discovery_date":"2021-03-11T04:18:11","title":"Challenges in multiple sclerosis care: Results from an international mixed-methods study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102854. doi: 10.1016&#x2F;j.msard.2021.102854. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Disease-modifying treatment (DMT) selection for people with multiple sclerosis (MS) is challenging. Neurologists and advanced practice nurses (APNs) in MS care may be facing knowledge and confidence gaps when screening patients to initiate or switch between DMTs, assessing the safety of new DMTs and monitoring for adverse events. Healthcare providers are required to demonstrate enhanced patient communication skills, to share treatment decisions and assess treatment adherence. To better inform educational interventions, there is a need to better understand these challenges and uncover their causalities. We undertook an international study across seven countries to identify challenges for neurologists and APNs that may impact DMT choices and optimum care for people with MS (pwMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This mixed methods study involved two concurrent data collection phases, a qualitative phase with semi-structured interviews and a quantitative phase using an online survey. Neurologists (n&#x3D;333) and APNs (n&#x3D;135) were recruited from Canada, France, Germany, Italy, Spain, United Kingdom and the United States. All participants had to have a minimum of two years&#39; experience in the care of pwMS and be currently active in clinical practice.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A triangulated analysis of qualitative and quantitative data identified multiple challenges. For APNs, these mainly related to diagnosing MS, integrating new agents in their practice, sequential DMT selection, treatment monitoring and providing personalized care. Specifically, two-thirds of APNs reported no or basic knowledge of the 2017 McDonald criteria and over half reported a knowledge gap of new DMTs available (51%) and a skill gap when integrating them into practice (58%). APNs expressed a knowledge gap of treatment sequencing (46%) and a skill gap in making decisions about sequencing (62%). Forty-four percent of APNs reported a gap in their skills of integrating patient&#39;s goals into treatment recommendations. For neurologists, the main challenges included managing side effects, aligning care to their patient&#39;s personal goals and quality of life (QoL). Specifically, over a third of neurologists reported no or basic knowledge of the characteristics of treatment failure (35%), and 32% reported no or basic skills identifying treatment failure. Skills needed to integrate patient&#39;s individual goals into treatment recommendations were reported as none or low by 39% of neurologists. In addition, there were significant differences according to years of practice in the majority (9 out of 14) of confidence items with respect to discussing specific MS-related topics with patients. Significant differences between countries were also identified.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The complexity of diagnosing MS and the variety of available DMTs for pwMS lead to uncertainties, even among specialized healthcare professionals. These should be addressed through focused education and training to optimize care for pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33690086&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310231810&amp;v&#x3D;2.14.2&quot;&gt;33690086&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102854&gt;10.1016&#x2F;j.msard.2021.102854&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33690086&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310231810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":461,"discovery_date":"2021-03-11T00:58:42","title":"Reducing posttraumatic stress in parents of patients with a rare inherited metabolic disorder using eye movement desensitization and reprocessing therapy: a case study","summary":"Parents of children with severe inborn errors of metabolism frequently face stressful events related to the disease of their child and are consequently at high risk for developing parental posttraumatic stress...","link":"https:&#x2F;&#x2F;ojrd.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13023-021-01768-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":460,"discovery_date":"2021-03-10T21:38:12","title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 9:jnnp-2020-324826. doi: 10.1136&#x2F;jnnp-2020-324826. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Brain structural alterations and their clinical significance of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) have not been determined.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We recruited 35 MOGAD, 38 aquaporin 4 antibody positive neuromyelitis optica spectrum diseases (AQP4+ NMOSD), 37 multiple sclerosis (MS) and 60 healthy controls (HC) who underwent multimodal brain MRI from two centres. Brain lesions, volumes of the whole brain parenchyma, cortical and subcortical grey matter (GM), brainstem, cerebellum and cerebral white matter (WM) and diffusion measures (fractional anisotropy, FA and mean diffusivity, MD) were compared among the groups. Associations between the MRI measurements and the clinical variables were assessed by partial correlations. Logistic regression was performed to differentiate MOGAD from AQP4+ NMOSD and MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In MOGAD, 19 (54%) patients had lesions on MRI, with cortical&#x2F;juxtacortical (68%) as the most common location. MOGAD and MS showed lower cortical and subcortical GM volumes than HC, while AQP4+ NMOSD only demonstrated a decreased cortical GM volume. MS demonstrated a lower cerebellar volume, a lower FA and an increased MD than MOGAD and HC. The subcortical GM volume was negatively correlated with Expanded Disability Status Scale in MOGAD (R&#x3D;-0.51; p&#x3D;0.004). A combination of MRI and clinical measures could achieve an accuracy of 85% and 93% for the classification of MOGAD versus AQP4+ NMOSD and MOGAD versus MS, respectively.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: MOGAD demonstrated cortical and subcortical atrophy without severe WM rarefaction. The subcortical GM volume correlated with clinical disability and a combination of MRI and clinical measures could separate MOGAD from AQP4+ NMOSD and MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687975&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;33687975&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-324826&gt;10.1136&#x2F;jnnp-2020-324826&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687975&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":459,"discovery_date":"2021-03-10T21:38:12","title":"DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 9:jnnp-2020-325676. doi: 10.1136&#x2F;jnnp-2020-325676. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: We aimed to investigate the influence of environmental risk factors for multiple sclerosis (MS) in different genetic contexts, and study if interactions between environmental factors and human leucocyte antigen (HLA) genes differ in magnitude according to heterozygocity and homozygocity for &lt;i&gt;HLA-DRB1*15:01&lt;&#x2F;i&gt;.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Using population-based case-control studies (6985 cases, 6569 controls), subjects with different genotypes and smoking, EBNA-1 status and adolescent Body Mass status, were compared regarding MS risk, by calculating OR with 95% CI employing logistic regression. The interaction between different genotypes and each environmental factor was evaluated on the additive scale.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The effect of each &lt;i&gt;DRB1*15:01&lt;&#x2F;i&gt; allele on MS risk was additive on the log-odds scale for each additional allele. Interaction between &lt;i&gt;DRB1*15:01&lt;&#x2F;i&gt; and each assessed environmental factor was of similar magnitude regardless of the number of &lt;i&gt;DRB1*15:01&lt;&#x2F;i&gt; alleles, although ORs were affected. When any of the environmental factors were present in &lt;i&gt;DRB1*15:01&lt;&#x2F;i&gt; carriers without the protective &lt;i&gt;A*02:01&lt;&#x2F;i&gt; allele, a three-way interaction occurred and rendered high ORs, especially among &lt;i&gt;DRB1*15:01&lt;&#x2F;i&gt; homozygotes (OR 20.0, 95% CI 13.1 to 30.5 among smokers, OR 21.9, 95% CI 15.0 to 31.8 among those with elevated EBNA-1 antibody levels, and OR 44.3, 95% CI 13.5 to 145 among those who reported adolescent overweight&#x2F;obesity).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The strikingly increased MS risk among &lt;i&gt;DRB*15:01&lt;&#x2F;i&gt; homozygotes exposed to any of the environmental factors is a further argument in favour of these factors acting on immune-related mechanisms. The data further reinforce the importance of preventive measures, in particular for those with a genetic susceptibility to MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687974&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;33687974&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-325676&gt;10.1136&#x2F;jnnp-2020-325676&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687974&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":458,"discovery_date":"2021-03-10T21:38:12","title":"Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 9:jnnp-2020-325274. doi: 10.1136&#x2F;jnnp-2020-325274. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To identify early clinical and paraclinical factors that may help predict later conversion to multiple sclerosis (MS) in patients presenting with isolated myelitis (ie, &#39;transverse myelitis&#39; without clinical or radiological evidence of inflammation&#x2F;demyelination elsewhere in the central nervous system).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this retrospective cohort study, we included patients with isolated myelitis who were followed clinically and radiologically at our specialised myelopathy clinic. We excluded patients with MS at the onset, aquaporin-4-IgG seropositivity, myelin oligodendrocyte glycoprotein-IgG seropositivity or other identified aetiology. Logistic regression was used to identify factors predictive of conversion to MS (defined by the 2017 McDonald criteria).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We included 100 patients, followed for a median of 4.3 years. Conversion to MS occurred in 25 of 77 patients (32%) with short-segment myelitis (longest lesion spanning &amp;lt;3 vertebral segments on MRI) as compared with 0 of 23 patients (0%) with longitudinally extensive myelitis (p&#x3D;0.002). Among patients with short-segment myelitis, factors identified as highly predictive of conversion to MS using multivariate logistic regression included cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCB) (OR (OR) 9.2, 95% CI 2.1 to 41.0, p&#x3D;0.004), younger age (OR 1.1 for each year younger, 95% CI 1.0 to 1.1, p&#x3D;0.04) and longer follow-up (OR 1.3 for each year longer, 95% CI 1.0 to 1.6, p&#x3D;0.04). Conversion to MS occurred at a median of 2.8 years after myelitis onset.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Short-segment MRI cord lesion(s), CSF-restricted OCB, younger age and longer follow-up are all factors predictive of conversion to MS in patients presenting with isolated myelitis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687973&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;33687973&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-325274&gt;10.1136&#x2F;jnnp-2020-325274&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687973&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":457,"discovery_date":"2021-03-10T21:38:12","title":"Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Biologics. 2021 Mar 2;15:53-59. doi: 10.2147&#x2F;BTT.S267277. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Autologous hematopoietic stem cell transplantation (AHSCT) is considered as the novel approach to improve multiple sclerosis (MS) patients with disease-modifying therapies (DMTs)-resistance. The results obtained from different studies indicate that AHSCT increases the life quality of MS patients. Several factors are known to be influenced on the successful rate of AHSCT in patients with MS. The individuals aged &amp;lt;40 years with a short duration of MS disease have been demonstrated to show a better response to AHSCT administration. Furthermore, this treatment approach was more effective in relapsing remitting MS (RRMS) patients than progressive MS (PMS). Different clinical trials revealed that AHSCT with a low density conditioning regimen could be suggested as a suitable candidate approach in the management of MS. Several molecular and cellular mechanisms are known to be involved in the resetting of the immune system following the AHSCT infusion in MS patients. These mechanisms play a role in the depletion of auto-reactive lymphocytes and immune system renewal. In the present review, we discuss different clinical and molecular aspects of AHSCT application in the alleviation of MS symptoms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33688164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;33688164&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7936693&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;PMC7936693&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;BTT.S267277&gt;10.2147&#x2F;BTT.S267277&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33688164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":456,"discovery_date":"2021-03-10T21:38:12","title":"Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review on SIRTUIN Activators as Potential Immunomodulators and Influences on other Dysfunctions","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Endocr Metab Immune Disord Drug Targets. 2021 Mar 8. doi: 10.2174&#x2F;1871530321666210309112234. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Immune dysregulation, neuronal inflammation, and oligodendrocyte degradation are key causes for autoimmune disorders like multiple sclerosis (MS) and various otherimmune dysregulated neurodegenerative complications responsible for CNS-mediated immune responses.Sirtuins (SIRT-1) is nicotinamide adenosine dinucleotide (NAD)-dependent transcriptional protein thatdeacetylases and removes acetyl groups from its transcription factors like P53, FOXO, NF-Îb, PGC-1Î±. SIRT-1 mediates a wide range of physiological functions,including gene transcription, metabolism, neuronal apoptosis, and glucose production.SIRT-1 dysregulation targets transcription factors,and other molecular alterations such as gene expression modification influence neuronal plasticity, inhibits Th17 cells, and interleukin-1Î² can aggravate brain diseases.Preclinical and clinical findings show that the upregulation of SIRT-1 reduces autoimmunity, neurodegeneration, and neuroexcitation. Even though drugs are being developed for symptomatic therapies in clinical trials, there are particular pharmacological implications for improving post-operative conditions in neurodegenerativepatients where intensive care is required.Understanding the SIRT-1 signaling and identifying immune-mediated neuron deterioration can detect major therapeutic interventions that could prevent neurocomplications.Thus, in the current review, we have addressed the manifestations of disease by the downregulation of SIRT-1 that could potentially cause MS and other neurodegenerative disorders and provided data on existing available and effective drug therapies and disease management strategies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;33687904&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1871530321666210309112234&gt;10.2174&#x2F;1871530321666210309112234&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33687904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":455,"discovery_date":"2021-03-10T21:38:12","title":"Driving errors that predict simulated rear-end collisions in drivers with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Traffic Inj Prev. 2021 Mar 10:1-6. doi: 10.1080&#x2F;15389588.2021.1883008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Drivers with Multiple Sclerosis (MS) may have an increased crash risk. However, the driving performance deficits that contribute to crashes are not fully understood. Based on the extant literature, adjustment to stimuli errors indicate failing an on-road assessment. This study examines whether adjustment to stimuli errors can detect the occurrence of collisions in a driving simulator in drivers with MS.&lt;&#x2F;p&gt;&lt;p xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: As part of a quasi-experiment, 38 participants with MS and 21 participants without MS completed visual-cognitive and driving simulator assessments, which also recorded their adjustment to stimuli maneuvers. We quantified participants&#39; adjustment to stimuli maneuvers via initial pedal reaction time (seconds), time to collision (seconds), mean speed (meters per second), and the occurrence of rear-end collisions (collide vs. did not collide) when a simulated vehicle cut across the lane in front of them.&lt;&#x2F;p&gt;&lt;p xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Logistic regression analyses indicated that, compared to drivers without MS, those with MS had a shorter time to collision (OR&#x3D; .04, &lt;i&gt;p&lt;&#x2F;i&gt;&#x3D; .001, 95% CI&#x3D; [.006, .27]) and a faster mean speed (OR&#x3D; 1.32, &lt;i&gt;p&lt;&#x2F;i&gt;&#x3D; .04, 95% CI&#x3D; [1.01, 1.74]) which increased the odds of experiencing a rear-end collision. Receiver operating characteristic curve analyses indicated that, for MS and control groups, time to collision (MS group &#x3D; AUC&#x3D; .94, &lt;i&gt;p&lt;&#x2F;i&gt;&amp;lt;.0001, Control group &#x3D; AUC&#x3D; .86, &lt;i&gt;p&lt;&#x2F;i&gt;&amp;lt;.0001) and mean speed (MS group &#x3D; AUC&#x3D; .76, &lt;i&gt;p&lt;&#x2F;i&gt;&#x3D;.005, Control group &#x3D; AUC &#x3D; .78, &lt;i&gt;p&lt;&#x2F;i&gt;&#x3D; .005) differentiated between participants who collided vs. did not collide. For drivers with MS, a time to collision of &lt;mml:math&gt;&lt;mml:mo&gt;â¤&lt;&#x2F;mml:mo&gt;&lt;&#x2F;mml:math&gt;1.81 seconds (85% sensitivity, 100% specificity, 15% error rate), and a mean speed of &lt;mml:math&gt;&lt;mml:mo&gt;â¥&lt;&#x2F;mml:mo&gt;&lt;&#x2F;mml:math&gt;7.83 meters per second (77% sensitivity, 76% specificity, 47% error rate) predicted the occurrence of collisions with the lowest error rate.&lt;&#x2F;p&gt;&lt;p xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: During a driving simulator assessment, adjustment to stimuli errors predicted the occurrence of rear-end collisions in drivers with MS (vs. without MS). Driving assessors may target scenarios that measure participants&#39; adjustment to stimuli, via time to collision and mean speed, to make decisions about their visual-cognitive deficits and driving performance.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33688770&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2&quot;&gt;33688770&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;15389588.2021.1883008&gt;10.1080&#x2F;15389588.2021.1883008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33688770&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210310163810&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":454,"discovery_date":"2021-03-10T18:58:47","title":"Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00069-4/fulltext","published_date":"","source":"The Lancet","relevant":1,"table_constraints":null},{"article_id":453,"discovery_date":"2021-03-10T18:58:42","title":"Insomnia in neurological diseases","summary":"Insomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime pe...","link":"https:&#x2F;&#x2F;neurolrespract.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s42466-021-00106-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":452,"discovery_date":"2021-03-10T18:58:42","title":"Exploratory factor analysis of PROMIS-29 V1.0, PROMIS Global Health and the RAND SF-36 from chiropractic responders attending care in a practice-based research network","summary":"The SF-36 questionnaire is perhaps the most widely used quality of life instrument in the world today, while the PROMIS instruments continue to gain popularity. Given their continued use in chiropractic resear...","link":"https:&#x2F;&#x2F;hqlo.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12955-021-01725-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":451,"discovery_date":"2021-03-10T18:58:42","title":"IL-17 deficiency aggravates the streptozotocinâinduced diabetic nephropathy through the reduction of autophagosome formation in mice","summary":"Diabetic nephropathy (DN) is one of the most important medical complications of diabetes mellitus. Autophagy is an important mediator of pathological response and plays a critical role in inflammation during t...","link":"https:&#x2F;&#x2F;molmed.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s10020-021-00285-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":450,"discovery_date":"2021-03-10T18:06:27","title":"Heparanome-Mediated Rescue of Oligodendrocyte Progenitor Quiescence following Inflammatory Demyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;content&#x2F;41&#x2F;10&#x2F;2245","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":449,"discovery_date":"2021-03-10T15:06:24","title":"Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis","summary":"The influence of the gut microbiota on traumatic brain injury (TBI) is presently unknown. This knowledge gap is of paramount clinical significance as TBI patients are highly susceptible to alterations in the g...","link":"https:&#x2F;&#x2F;actaneurocomms.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40478-021-01137-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":448,"discovery_date":"2021-03-10T15:06:24","title":"Normal levels of KIF5 but reduced KLC1 levels in both Alzheimer disease and Alzheimer disease in Down syndrome: evidence suggesting defects in anterograde transport","summary":"Impaired axonal transport may contribute to the pathogenesis of neurodegenerative diseases, including Alzheimerâs disease (AD) and Down syndrome (DS). Axonal transport is a complex process in which specific mo...","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00796-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":447,"discovery_date":"2021-03-10T15:06:23","title":"Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis","summary":"The incidence and mortality of lung cancer are the highest among all cancers. Patients with systemic sclerosis show a four-fold greater risk of lung cancer than the general population. However, the underlying ...","link":"https:&#x2F;&#x2F;bmccancer.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12885-021-07959-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":446,"discovery_date":"2021-03-09T21:06:28","title":"Altered iron and myelin in premanifest Huntington&#39;s Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study","summary":"","link":"https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;ebiom&#x2F;article&#x2F;PIIS2352-3964(21)00059-1&#x2F;fulltext","published_date":"","source":"The Lancet","relevant":null,"table_constraints":null},{"article_id":445,"discovery_date":"2021-03-09T18:06:23","title":"Early prediction of putamen imaging features in HIV-associated neurocognitive impairment syndrome","summary":"ToÂ explore the correlation between the volume of putamen and brain cognitive impairment in patients with HIV and to predict the feasibility of early-stage HIV brain cognitive impairment through radiomics.","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02114-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":444,"discovery_date":"2021-03-09T18:06:23","title":"Assessing the measurement invariance of the 10-item Centre for Epidemiological Studies Depression Scale and Beck Anxiety Inventory questionnaires across people living with HIV&#x2F;AIDS and healthy people","summary":"Recently, extensive research has been reported the higher rate of depression and anxiety among people living with HIV&#x2F;AIDS (PLWHAs) as compared to the general population. However, no single study has been carr...","link":"https:&#x2F;&#x2F;bmcpsychology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40359-021-00546-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":443,"discovery_date":"2021-03-09T18:06:23","title":"Alterations in the gut microbiota and metabolite profiles in the context of neuropathic pain","summary":"The aim of this study was to explore the relationships among gut microbiota disturbances and serum and spinal cord metabolic disorders in neuropathic pain. 16S rDNA amplicon sequencing and serum and spinal cor...","link":"https:&#x2F;&#x2F;molecularbrain.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13041-021-00765-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":442,"discovery_date":"2021-03-09T18:06:23","title":"Identification of 11 candidate structured noncoding RNA motifs in humans by comparative genomics","summary":"Only 1.5% of the human genome encodes proteins, while large part of the remaining encodes noncoding RNAs (ncRNA). Many ncRNAs form structures and perform many important functions. Accurately identifying struct...","link":"https:&#x2F;&#x2F;bmcgenomics.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12864-021-07474-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":441,"discovery_date":"2021-03-09T13:25:54","title":"Correction to: Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)-study protocol for a randomised controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Trials. 2021 Mar 8;22(1):196. doi: 10.1186&#x2F;s13063-021-05152-5.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33685464&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309082552&amp;v&#x3D;2.14.2&quot;&gt;33685464&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s13063-021-05152-5&gt;10.1186&#x2F;s13063-021-05152-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33685464&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309082552&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":440,"discovery_date":"2021-03-09T13:25:54","title":"Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Mar 8;11(1):5402. doi: 10.1038&#x2F;s41598-021-84751-3.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Most multiple sclerosis (MS) patients given currently available disease-modifying drugs (DMDs) experience progressive disability. Accordingly, there is a need for new treatments that can limit the generation of new waves T cell autoreactivity that drive disease progression. Notably, immune cells express GABA&lt;sub&gt;A&lt;&#x2F;sub&gt;-receptors (GABA&lt;sub&gt;A&lt;&#x2F;sub&gt;-Rs) whose activation has anti-inflammatory effects such that GABA administration can ameliorate disease in models of type 1 diabetes, rheumatoid arthritis, and COVID-19. Here, we show that oral GABA, which cannot cross the blood-brain barrier (BBB), does not affect the course of murine experimental autoimmune encephalomyelitis (EAE). In contrast, oral administration of the BBB-permeable GABA&lt;sub&gt;A&lt;&#x2F;sub&gt;-R-specific agonist homotaurine ameliorates monophasic EAE, as well as advanced-stage relapsing-remitting EAE (RR-EAE). Homotaurine treatment beginning after the first peak of paralysis reduced the spreading of Th17 and Th1 responses from the priming immunogen to a new myelin T cell epitope within the CNS. Antigen-presenting cells (APC) isolated from homotaurine-treated mice displayed an attenuated ability to promote autoantigen-specific T cell proliferation. The ability of homotaurine treatment to limit epitope spreading within the CNS, along with its safety record, makes it an excellent candidate to help treat MS and other inflammatory disorders of the CNS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33686135&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309082552&amp;v&#x3D;2.14.2&quot;&gt;33686135&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-84751-3&gt;10.1038&#x2F;s41598-021-84751-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33686135&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309082552&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":439,"discovery_date":"2021-03-09T06:56:46","title":"Barriers and facilitators to employment: A comparison of participants with multiple sclerosis and spinal cord injury","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arch Phys Med Rehabil. 2021 Mar 5:S0003-9993(21)00222-7. doi: 10.1016&#x2F;j.apmr.2021.02.015. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To compare self-reported barriers and facilitators to employment among employed and unemployed participants with multiple sclerosis (MS) and spinal cord injury (SCI).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN: Cross-sectional using self-report assessment obtained by mail or online.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: Medical university in the Southeastern USA.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PARTICIPANTS: There was a total of 2,624 participants, including 1,234 with MS and 1,390 with SCI, identified from either a specialty hospital or a state-based surveillance system in the Southeastern USA. All were under the age of 65 at the time of assessment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERVENTIONS: N&#x2F;A MAIN OUTCOME MEASURES: Self-reported barriers and facilitators to employment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Overall, the MS participants reported more barriers, particularly stress, cognition, and fatigue, whereas those with SCI were more likely to report not having the proper education and training, resources, transportation, and attendant care. Follow-up analyses broken down by employment status indicated several barriers and facilitators were significantly related to diagnosis for either employed or unemployed participants, but not both. Among those employed, those with SCI were more likely to report they could not do the same types of jobs as they could pre-SCI and those with MS were more likely to state that they did not know much about jobs for people with disabilities (no differences were noted for these variables among those unemployed). Unemployed individuals with SCI were more likely to report the jobs for which they were trained were not accessible.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The primary barriers for people with MS revolve around the condition itself, whereas those for SCI appear more related to modifiable factors. Vocational rehabilitation specialists need to identify diagnostic specific barriers to promote employment outcomes.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684369&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2&quot;&gt;33684369&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.apmr.2021.02.015&gt;10.1016&#x2F;j.apmr.2021.02.015&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684369&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":438,"discovery_date":"2021-03-09T06:56:46","title":"Oxysterols and Multiple Sclerosis: physiopathology, evolutive biomarkers and therapeutic strategy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Steroid Biochem Mol Biol. 2021 Mar 5:105870. doi: 10.1016&#x2F;j.jsbmb.2021.105870. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis is an autoimmune disease that affects the central nervous system. Dysfunction of the immune system leads to lesions that cause motor, sensory, cognitive, visual and&#x2F;or sphincter disturbances. In the long term, these disorders can progress towards an irreversible handicap. The diagnosis takes time because there are no specific criteria to diagnose multiple sclerosis. To realize the diagnosis, a combination of clinical, biological, and radiological arguments is therefore required. Hence, there is a need to identify multiple sclerosis biomarkers. Some biomarkers target immunity through the detection of oligoclonal bands, the measurement of the IgG index and cytokines. During the physiopathological process, the blood-brain barrier can be broken, and this event can be identified by measuring metalloproteinase activity and diffusion of gadolinium in the brain by magnetic resonance imaging. Markers of demyelination and of astrocyte and microglial activity may also be of interest as well as markers of neuronal damage and mitochondrial status. The measurement of different lipids in the plasma and cerebrospinal fluid can also provide suitable information. These different lipids include fatty acids, fatty acid peroxidation products, phospholipids as well as oxidized derivatives of cholesterol (oxysterols). Oxysterols could constitute new biomarkers providing information on the form of multiple sclerosis, the outcome of the disease and the answer to treatment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684483&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2&quot;&gt;33684483&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jsbmb.2021.105870&gt;10.1016&#x2F;j.jsbmb.2021.105870&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684483&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":437,"discovery_date":"2021-03-09T06:56:46","title":"The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 27;354:577520. doi: 10.1016&#x2F;j.jneuroim.2021.577520. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Regulatory B cells are a rare B-cell subset widely known to exert their immunosuppressive function via the production of interleukin-10 (IL-10) and other mechanisms. B10 cells are a special subset of regulatory B cells with immunoregulatory function that is fully attributed to IL-10. Their unique roles in the animal model of multiple sclerosis (MS) have been described, as well as their relevance in MS patients. This review specifically focuses on the identification and development of B10 cells, the signals that promote IL-10 production in B cells, the roles of B10 cells in MS, and the potential and major challenges of the application of B10-based therapies for MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684831&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2&quot;&gt;33684831&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577520&gt;10.1016&#x2F;j.jneuroim.2021.577520&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33684831&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210309015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":436,"discovery_date":"2021-03-09T00:16:46","title":"Regulation of the expression of human endogenous retroviruses (HERVs): elements in fetal development and a possible role in the development of cancer and neurological diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;APMIS. 2021 Mar 8. doi: 10.1111&#x2F;apm.13130. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Human endogenous retroviruses (HERVs) are remnants of ancient retroviral germline infections. Most HERV sequences are silenced in somatic cells, but interest is emerging on the involvement of HERV derived transcripts and proteins in human physiology and disease. A HERV-W encoded protein, syncytin-1, has been co-opted into fetal physiology, where it plays a role in trophoblast formation. Altered HERV transcription and expression of HERV derived proteins are associated with various cancer types and neurological diseases such as multiple sclerosis (MS). The implication of HERVs as potential mediators of both health and disease suggests important roles of regulatory mechanisms and alterations of these in physiological and pathological processes. The regulation of HERV sequences is mediated by a wide variety of mechanisms, and the focus of this review is on selected aspects of these, including epigenetic mechanisms such as CpG methylation and histone modifications of the HP1-H3K9me axis, viral transactivation events, and regulatory perspectives of transient stimuli in the microenvironment. Increasing knowledge of the regulation of HERV sequences will not only contribute to the understanding of complex pathogeneses, but may pinpoint potential targets for better diagnosis and treatment in complex diseases as MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683784&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308191644&amp;v&#x3D;2.14.2&quot;&gt;33683784&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;apm.13130&gt;10.1111&#x2F;apm.13130&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683784&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308191644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":435,"discovery_date":"2021-03-08T21:43:30","title":"Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimerâs disease","summary":"Emerging evidence indicates that impaired mitophagy-mediated clearance of defective mitochondria is a critical event in Alzheimerâs disease (AD) pathogenesis. Amyloid-beta (AÎ²) metabolism and the microtubule-a...","link":"https:&#x2F;&#x2F;molecularneurodegeneration.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13024-021-00435-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":434,"discovery_date":"2021-03-08T21:43:30","title":"Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes","summary":"Alexander disease (AxD) is a rare neurodegenerative disorder that is caused by dominant mutations in the gene encoding glial fibrillary acidic protein (GFAP), an intermediate filament that is primarily express...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02118-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":433,"discovery_date":"2021-03-08T21:43:30","title":"Correction to: Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)âstudy protocol for a randomised controlled trial","summary":"An amendment to this paper has been published and can be accessed via the original article.","link":"https:&#x2F;&#x2F;trialsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13063-021-05152-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":432,"discovery_date":"2021-03-08T18:56:46","title":"Synergic use of botulinum toxin injection and radial extracorporeal shockwave therapy in Multiple Sclerosis spasticity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Biomed. 2021 Jan 28;92(1):e2021076. doi: 10.23750&#x2F;abm.v92i1.11101.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND AIM: In Multiple Sclerosis (MS) spasticity worsen patient&#39;s quality of life. Botulinum NeuroToxin TypeA (BoNT-A) is extensively used in focal spasticity, frequently combined with physical therapies. Radial extracorporeal shock waves (rESW) were already used in association with BoNT-A. Considering that loss of efficacy and adverse events are determinants of BoNT-A treatment interruption, this study aimed to evaluate the possibility to prolong BoNT-A&#39;s effect by using rESW in MS focal spasticity.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Sixteen MS patients with spasticity of triceps surae muscles were first subjected to BoNT-A therapy and, four months later, to 4 sections of rESWT. Patients were evaluated before, 30, 90 days after the end of the treatments, by using Modified Ashworth Scale (MAS), Modified Tardieu Scale (MTS) and kinematic analysis of passive and active ankle ROM. Results: BoNT-A determined a significant reduction of spasticity evaluated by MAS with a reduction of positive effects after 4months (p&amp;lt;0.05); MTS highlighted the efficacy only 90 days after injection (p&amp;lt;0.05). rESWT decreased MAS values at the end and 30 days later the treatment (p&amp;lt;0.01); MTS values showed instead a prolonged effect (p&amp;lt;0.01). BoNT-A determined a gain of passive and active ankle ROM, persisting along with treatment and peaking the maximum value after rESWT (p&amp;lt;0.05). Conclusions: rESWT can prolong BoNT-A effect inducing significant reduction of spasticity and improvement in passive and active ankle ROM in MS patients. The use of rESWT following BoNT-A injection is useful to avoid some limitations and to prolong the therapeutic effects of BoNT-A therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682833&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2&quot;&gt;33682833&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.23750&#x2F;abm.v92i1.11101&gt;10.23750&#x2F;abm.v92i1.11101&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682833&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":431,"discovery_date":"2021-03-08T18:56:46","title":"Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Vis Exp. 2021 Feb 19;(168). doi: 10.3791&#x2F;62142.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The overall goal of this article is to demonstrate a state-of-the-art ultrahigh field (UHF) magnetic resonance (MR) protocol of the brain at 7.0 Tesla in multiple sclerosis (MS) patients. MS is a chronic inflammatory, demyelinating, neurodegenerative disease that is characterized by white and gray matter lesions. Detection of spatially and temporally disseminated T2-hyperintense lesions by the use of MRI at 1.5 T and 3 T represents a crucial diagnostic tool in clinical practice to establish accurate diagnosis of MS based on the current version of the 2017 McDonald criteria. However, the differentiation of MS lesions from brain white matter lesions of other origins can sometimes be challenging due to their resembling morphology at lower magnetic field strengths (typically 3 T). Ultrahigh field MR (UHF-MR) benefits from increased signal-to-noise ratio and enhanced spatial resolution, both key to superior imaging for more accurate and definitive diagnoses of subtle lesions. Hence, MRI at 7.0 T has shown encouraging results to overcome the challenges of MS differential diagnosis by providing MS-specific neuroimaging markers (e.g., central vein sign, hypointense rim structures and differentiation of MS grey matter lesions). These markers and others can be identified by other MR contrasts other than T1 and T2 (T2*, phase, diffusion) and substantially improve the differentiation of MS lesions from those occurring in other neuroinflammatory conditions such as neuromyelitis optica and Susac syndrome. In this article, we describe our current technical approach to study cerebral white and grey matter lesions in MS patients at 7.0 T using different MR acquisition methods. The up-to-date protocol includes the preparation of the MR setup including the radio-frequency coils customized for UHF-MR, standardized screening, safety and interview procedures with MS patients, patient positioning in the MR scanner and acquisition of dedicated brain scans tailored for examining MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682856&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2&quot;&gt;33682856&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3791&#x2F;62142&gt;10.3791&#x2F;62142&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682856&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":430,"discovery_date":"2021-03-08T18:56:46","title":"The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177&#x2F;1352458521999274. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The impact of cerebellar damage and (dys)function on cognition remains understudied in multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess the cognitive relevance of cerebellar structural damage and functional connectivity (FC) in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This study included 149 patients with early RRMS, 81 late RRMS, 48 SPMS and 82 controls. Cerebellar cortical imaging included fractional anisotropy, grey matter volume and resting-state functional magnetic resonance imaging (MRI). Cerebellar FC was assessed with literature-based resting-state networks, using static connectivity (that is, conventional correlations), and dynamic connectivity (that is, fluctuations in FC strength). Measures were compared between groups and related to disability and cognition.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Cognitive impairment (CI) and cerebellar damage were worst in SPMS. Only SPMS showed cerebellar connectivity changes, compared to early RRMS and controls. Lower static FC was seen in fronto-parietal and default-mode networks. Higher dynamic FC was seen in dorsal and ventral attention, default-mode and deep grey matter networks. Cerebellar atrophy and higher dynamic FC together explained 32% of disability and 24% of cognitive variance. Higher dynamic FC was related to working and verbal memory and to information processing speed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Cerebellar damage and cerebellar connectivity changes were most prominent in SPMS and related to worse CI.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683158&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2&quot;&gt;33683158&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521999274&gt;10.1177&#x2F;1352458521999274&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33683158&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":429,"discovery_date":"2021-03-08T18:43:30","title":"A pilot study of the impact of an exercise intervention on brain structure, cognition, and psychosocial symptoms in individuals with relapsing-remitting multiple sclerosis","summary":"Despite pharmacological treatment, many individuals with multiple sclerosis (MS) continue to experience symptoms and medication side effects. Exercise holds promise for MS, but changes in brain structure follo...","link":"https:&#x2F;&#x2F;pilotfeasibilitystudies.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40814-021-00806-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":428,"discovery_date":"2021-03-08T18:43:30","title":"An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases","summary":"PIWI-interacting RNAs (piRNAs) are small non-coding transcripts that are highly conserved across species and regulate gene expression through pre- and post-transcriptional processes. piRNAs were originally dis...","link":"https:&#x2F;&#x2F;translationalneurodegeneration.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40035-021-00233-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":427,"discovery_date":"2021-03-08T18:43:30","title":"Thyroid hormone: sex-dependent role in nervous system regulation and disease","summary":"Thyroid hormone (TH) regulates many functions including metabolism, cell differentiation, and nervous system development. Alteration of thyroid hormone level in the body can lead to nervous system-related prob...","link":"https:&#x2F;&#x2F;bsd.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13293-021-00367-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":426,"discovery_date":"2021-03-08T18:43:30","title":"The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): translation, adaptation and validation of the Polish version for patients with multiple sclerosis and spinal cord injury","summary":"Polish physicians and researchers lack an extensive and precise instrument in their native language for evaluating sexual dysfunction in individuals with neurogenic disorders. The aim of this study was to crea...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02132-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":425,"discovery_date":"2021-03-08T12:36:46","title":"Constructing and validating a diagnostic nomogram for multiple sclerosis via bioinformatic analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;3 Biotech. 2021 Mar;11(3):127. doi: 10.1007&#x2F;s13205-021-02675-1. Epub 2021 Feb 16.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The purpose of this study was to identify biomarkers and construct a diagnostic prediction model for multiple sclerosis (MS). Microarray datasets in the Gene Expression Omnibus (GEO) were downloaded. Weighted gene coexpression analysis (WGCNA) was used to search for hub modules and biomarkers related to MS. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to roughly define their biological functions and pathways. Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analysis were used to identify the diagnostic biomarkers and construct a nomogram. The calibration curve and receiver operating characteristic (ROC) curve were used to judge the diagnostic predictive ability. In addition, cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm was used to calculate the proportion of 22 kinds of immune cells. GSE41850 was used as the training set, and GSE17048 was used as the test set. WGCNA revealed one hub module containing 165 hub genes. Most of their biological functions and pathways are related to cell metabolism and immune cell activation. The diagnostic nomogram contained &lt;i&gt;ARPC5&lt;&#x2F;i&gt;, &lt;i&gt;ROD1&lt;&#x2F;i&gt;, &lt;i&gt;UBQLN2&lt;&#x2F;i&gt;, &lt;i&gt;ZNF281&lt;&#x2F;i&gt;, &lt;i&gt;ABCA1&lt;&#x2F;i&gt; and &lt;i&gt;FAS&lt;&#x2F;i&gt;. The ROC curve and the calibration curve of the training set and test set confirmed that the nomogram had great prediction ability. In addition, monocytes and M0 macrophages were significantly different between MS patients and healthy people. The expression of &lt;i&gt;ARPC5, ZNF281&lt;&#x2F;i&gt; and &lt;i&gt;ABCA1&lt;&#x2F;i&gt; is correlated with M0 macrophages. The nomogram provides new insights and contributes to the accurate diagnosis of MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007&#x2F;s13205-021-02675-1.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680693&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33680693&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7886954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7886954&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s13205-021-02675-1&gt;10.1007&#x2F;s13205-021-02675-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680693&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":424,"discovery_date":"2021-03-08T12:36:46","title":"Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Mar 23;2(1):e000022. doi: 10.1136&#x2F;bmjno-2019-000022. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Remote ischaemic preconditioning (RIPC) is the exposure of body parts to brief periods of circulatory occlusion and reperfusion. Recent studies have also shown that RIPC can improve exercise performance in healthy individuals.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: This study aimed to assess the effect of RIPC on walking in people with multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a double-blind randomised controlled clinical trial. We used three cycles of RIPC delivered by occluding the upper arm with a blood pressure (BP) cuff inflated to a pressure of 30 mm Hg above the systolic BP. In patients in the sham intervention group, the BP cuff was inflated only to 30 mm Hg below diastolic BP. Outcome measures included the Six-Minute Walk Test (6MWT), gait speed, the Borg rate of perceived exertion (RPE) scale, the tolerability of the RIPC using a Numerical Rating Scale for discomfort from 0 to 10, and adverse events. We identified responders meeting the minimal clinically important difference (MCID) established in the literature in each group.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Seventy-five participants completed the study (RIPC: 38 and Sham: 37). The distance walked during the 6MWT improved by 1.9% in the sham group and 5.7% in the RIPC group (p&#x3D;0.012). The number of responders meeting MCID criteria in the RIPC group was significantly greater compared with the sham intervention group. No serious adverse events occurred.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Single cycle of RIPC resulted in immediate improvement in walking distances during 6MWT in people with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION NUMBERS: NCT03153553.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681776&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681776&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7903187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7903187&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2019-000022&gt;10.1136&#x2F;bmjno-2019-000022&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681776&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":423,"discovery_date":"2021-03-08T12:36:46","title":"Development of a Multi-Study Repository to Support Research on Veteran Health: The VA Cooperative Studies Program Epidemiology Center-Durham (CSPEC-Durham) Data and Specimen Repository","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Public Health. 2021 Feb 17;9:612806. doi: 10.3389&#x2F;fpubh.2021.612806. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Federal agencies, including the Department of Veterans Affairs (VA), have prioritized improved access to scientific data and results collected through federally funded research. Our VA Cooperative Studies Program Epidemiology Center in Durham, North Carolina (CSPEC-Durham) assembled a repository of data and specimens collected through multiple studies on Veteran health issues to facilitate future research in these areas. We developed a single protocol, request process that includes scientific and ethical review of all applications, and a database architecture using metadata (common variable descriptors) to securely store and share data across diverse studies. In addition, we created a mechanism to allow data and specimens collected through older studies in which re-use was not addressed in the study protocol or consent forms to be shared if the future research is within the scope of the original consent. Our CSPEC-Durham Data and Specimen Repository currently includes research data, genomic data, and study specimens (e.g., DNA, blood) for three content areas: colorectal cancer, amyotrophic lateral sclerosis, and Gulf War research. The linking of the study specimens and research data can support additional genetic analyses and related research to improve Veterans&#39; health.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681131&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681131&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7925406&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7925406&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fpubh.2021.612806&gt;10.3389&#x2F;fpubh.2021.612806&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681131&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":422,"discovery_date":"2021-03-08T12:36:46","title":"Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer&#39;s Disease","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:639369. doi: 10.3389&#x2F;fimmu.2021.639369. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegenerative diseases are closely related to inflammatory and autoimmune events, suggesting that the dysregulation of the immune system is a key pathological factor. Both multiple sclerosis (MS) and Alzheimer&#39;s disease (AD) are characterized by infiltrating immune cells, activated microglia, astrocyte proliferation, and neuronal damage. Moreover, MS and AD share a common pro-inflammatory signature, characterized by peripheral leukocyte activation and transmigration to the central nervous system (CNS). MS and AD are both characterized by the accumulation of activated neutrophils in the blood, leading to progressive impairment of the blood-brain barrier. Having migrated to the CNS during the early phases of MS and AD, neutrophils promote local inflammation that contributes to pathogenesis and clinical progression. The role of circulating T cells in MS is well-established, whereas the contribution of adaptive immunity to AD pathogenesis and progression is a more recent discovery. Even so, blocking the transmigration of T cells to the CNS can benefit both MS and AD patients, suggesting that common adaptive immunity mechanisms play a detrimental role in each disease. There is also growing evidence that regulatory T cells are beneficial during the initial stages of MS and AD, supporting the link between the modulatory immune compartments and these neurodegenerative disorders. The number of resting regulatory T cells declines in both diseases, indicating a common pathogenic mechanism involving the dysregulation of these cells, although their precise role in the control of neuroinflammation remains unclear. The modulation of leukocyte functions can benefit MS patients, so more insight into the role of peripheral immune cells may reveal new targets for pharmacological intervention in other neuroinflammatory and neurodegenerative diseases, including AD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679799&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933037&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933037&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.639369&gt;10.3389&#x2F;fimmu.2021.639369&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":421,"discovery_date":"2021-03-08T12:36:46","title":"Protective Effects of a Nano-Formulation of Curcumin against Cuprizone-Induced Demyelination in the Mouse Corpus Callosum","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Iran J Pharm Res. 2020 Summer;19(3):310-320. doi: 10.22037&#x2F;ijpr.2020.112952.14033.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), characterized by neuroinflammation, oligodendrocytes (OLs) loss, and demyelination Curcumin, a natural phenolic substance, has been shown to have significant therapeutic properties in various neurodegenerative diseases, including MS. In our laboratory by loading curcumin in dendrosome nanoparticles we improved its solubility and bioavailability. Our previous study showed anti-inflammatory and anti-oxidative effects of dendrosomal nano-curcumin (DNC) in experimental autoimmune encephalomyelitis (EAE) model of MS. Here, by using a toxic demyelination model, induced by cuprizone (CPZ), we investigated the protective effect of DNC on oligodendroglial lineage cells (OLLC) and myelin preservation in context of acute demyelination. CPZ is a copper chelator, thus its intake reduces the mitochondrial activity, activates oxidative stress response, leading to specific OLs death, due to their high-energy consumption. We also evaluated DNC effect on activation of astrocytes and microglia, which are enriched in both MS and CPZ demyelinated lesions. Our results demonstrated that DNC treatment protected Oligodendrocyte lineage cells (OLLCs) against CPZ toxin. Besides DNC treatment suppressed accumulation of astrocytes and microglia in CC of CPZ-fed mice, compared to PBS treated onse. Moreover, DNC treatment lead to higher index of luxol fast bluefast blue (LFB) and myelin-specific proteins, myelin basic protein (MBP) intensity in the corpus callosum (CC), as indicators of myelin content. These results suggest a potent pleiotropic therapeutic efficiency for DNC for protection of myelinating cells, possibly via suppression of astrocytes and microglia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680032&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33680032&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7758014&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7758014&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.22037&#x2F;ijpr.2020.112952.14033&gt;10.22037&#x2F;ijpr.2020.112952.14033&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680032&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":420,"discovery_date":"2021-03-08T12:36:46","title":"Delayed phases of contrast MRI, can it be valuable in multiple sclerosis active phase diagnosis?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Caspian J Intern Med. 2020 Fall;11(4):432-436. doi: 10.22088&#x2F;cjim.11.4.432.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Observing the enhancing plaques in magnetic resonance imaging (MRI) is one of the most valuable diagnostic modalities in confirming the diagnosis of multiple sclerosis (MS), its recurrence and for better detection of active disease. Since active lesions discovery can improve designating diffusion in time diagnosis of MS and controlling disease activity, and there is not any definite time for delay image acquisition, therefore, the aim of the current study was to evaluate the enhancement of MS plaques in different delayed phases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this interventional study, after receiving written consent, 40 MS patients with at least one enhancing plaque in a previous MRI were evaluated in Babol Ayatollah Rouhani Hospital. Gadolinium was injected to all patients at the dose of 0.1 mg&#x2F;kg, and MRI was taken at 5 and 15 minutes. The results were analyzed using SPSS 23. A p&amp;lt;0.05 was considered as significant level.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The mean of plaque signal intensity was 1190.20 and 1349.60 at 5 and 15 min, respectively, and this difference was significant (p&amp;lt;0.001). Moreover, the mean of plaque total size was 5.16 cm and 7.04 cm at 5 and 15 min with significant difference, respectively (p&amp;lt;0.001). The mean of plaque number was 1.92 and 2.58 at 5 and 15 min, respectively, which was significantly different (P&amp;lt;0.001).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The results indicated improvement in detection of MS plaques in images taken in the delayed phase compared to those in the early phase. The plaque intensity, size and number were significantly higher in the delayed phase (15 min), than early phase (5 min).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680386&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33680386&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7911766&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7911766&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.22088&#x2F;cjim.11.4.432&gt;10.22088&#x2F;cjim.11.4.432&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33680386&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":419,"discovery_date":"2021-03-08T12:36:46","title":"Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:620963. doi: 10.3389&#x2F;fimmu.2021.620963. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Platelets are clearly central to thrombosis and hemostasis. In addition, more recently, evidence has emerged for non-hemostatic roles of platelets including inflammatory and immune reactions&#x2F;responses. Platelets express immunologically relevant ligands and receptors, demonstrate adhesive interactions with endothelial cells, monocytes and neutrophils, and toll-like receptor (TLR) mediated responses. These properties make platelets central to innate and adaptive immunity and potential candidate key mediators of autoimmune disorders. Multiple sclerosis (MS) is the most common chronic autoimmune central nervous system (CNS) disease. An association between platelets and MS was first indicated by the increased adhesion of platelets to endothelial cells. This was followed by reports identifying structural and functional changes of platelets, their chronic activation in the peripheral blood of MS patients, platelet presence in MS lesions and the more recent revelation that these structural and functional abnormalities are associated with all MS forms and stages. Investigations based on the murine experimental autoimmune encephalomyelitis (EAE) MS model first revealed a contribution to EAE pathogenesis by exacerbation of CNS inflammation and an early role for platelets in EAE development via platelet-neuron and platelet-astrocyte associations, through sialated gangliosides in lipid rafts. Our own studies refined and extended these findings by identifying the critical timing of platelet accumulation in pre-clinical EAE and establishing an initiating and central rather than merely exacerbating role for platelets in disease development. Furthermore, we demonstrated platelet-neuron associations in EAE, coincident with behavioral changes, but preceding the earliest detectable autoreactive T cell accumulation. In combination, these findings establish a new paradigm by asserting that platelets play a neurodegenerative as well as a neuroinflammatory role in MS and therefore, that these two pathological processes are causally linked. This review will discuss the implications of these findings for our understanding of MS, for future applications for imaging toward early detection of MS, and for novel strategies for platelet-targeted treatment of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679764&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679764&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933211&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933211&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.620963&gt;10.3389&#x2F;fimmu.2021.620963&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679764&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":418,"discovery_date":"2021-03-08T12:36:46","title":"Lactobacillus acidipiscis Induced Regulatory Gamma Delta T Cells and Attenuated Experimental Autoimmune Encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:623451. doi: 10.3389&#x2F;fimmu.2021.623451. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis is a chronic autoimmune disease involving the central nervous system, and shows a high disability rate. Its pathogenesis is complicated, and there is no good treatment. In recent years, with in-depth studies on the regulation of gastrointestinal flora, the relationship between the mammalian immune system and the intestinal flora has been extensively explored. Changes in the composition and structure of the gastrointestinal flora can affect the characteristics and development of the host immune system and even induce a series of central nervous system inflammation events. The occurrence and development of multiple sclerosis are closely related to the continuous destruction of the intestinal barrier caused by intestinal dysbacteriosis. In this study, we analyzed &lt;i&gt;Lactobacillus acidipiscis&lt;&#x2F;i&gt; in a mouse model of experimental autoimmune encephalomyelitis (EAE). We found that the amount of &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; in the intestinal tract was inversely proportional to the progress of EAE development. In addition, the number of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; FOXP3&lt;sup&gt;+&lt;&#x2F;sup&gt; regulatory T cells in the mesenteric lymph nodes of mice increased significantly after the mice were fed with &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt;, and the differentiation of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells to Th1 and Th17 cells was inhibited. However, the protective effect of &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; was lost in Î³Î´ T cell-deficient mice and hence was concluded to depend on the presence of regulatory Î³Î´ T cells in the intestinal epithelium. Moreover, including &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; enhanced the development of VÎ³1&lt;sup&gt;+&lt;&#x2F;sup&gt;Î³Î´ T cells but suppressed that of VÎ³4&lt;sup&gt;+&lt;&#x2F;sup&gt;Î³Î´ T cells. In summary, our results demonstrated the ability of &lt;i&gt;L. acidipiscis&lt;&#x2F;i&gt; to induce generation of regulatory Î³Î´ T cells that suppress the development of the encephalomyelitic Th1 and Th17 cells and the progress of EAE.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679767&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679767&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933195&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933195&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.623451&gt;10.3389&#x2F;fimmu.2021.623451&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679767&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":417,"discovery_date":"2021-03-08T12:36:46","title":"Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 19;12:624685. doi: 10.3389&#x2F;fimmu.2021.624685. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Antigen-specific therapy for multiple sclerosis may lead to a more effective therapy by induction of tolerance to a wide range of myelin-derived antigens without hampering the normal surveillance and effector function of the immune system. Numerous attempts to restore tolerance toward myelin-derived antigens have been made over the past decades, both in animal models of multiple sclerosis and in clinical trials for multiple sclerosis patients. In this review, we will give an overview of the current approaches for antigen-specific therapy that are in clinical development for multiple sclerosis as well provide an insight into the challenges for future antigen-specific treatment strategies for multiple sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679769&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679769&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7933447&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7933447&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.624685&gt;10.3389&#x2F;fimmu.2021.624685&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679769&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":416,"discovery_date":"2021-03-08T12:36:46","title":"Asymptomatic Herpes Simplex Virus Type 1 Infection Causes an Earlier Onset and More Severe Experimental Autoimmune Encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 15;12:635257. doi: 10.3389&#x2F;fimmu.2021.635257. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is an increasingly prevalent progressive autoimmune and debilitating chronic disease that involves the detrimental recognition of central nervous system (CNS) antigens by the immune system. Although significant progress has been made in the last decades on the biology of MS and the identification of novel therapies to treat its symptoms, the etiology of this disease remains unknown. However, recent studies have suggested that viral infections may contribute to disease onset. Interestingly, a potential association between herpes simplex virus type 1 (HSV-1) infection and MS has been reported, yet a direct relationship among both has not been conclusively demonstrated. Experimental autoimmune encephalomyelitis (EAE) recapitulates several aspects of MS in humans and is widely used to study this disease. Here, we evaluated the effect of asymptomatic brain infection by HSV-1 on the onset and severity of EAE in C57BL&#x2F;6 mice. We also evaluated the effect of infection with an HSV-1-mutant that is attenuated in neurovirulence and does not cause encephalitis. Importantly, we observed more severe EAE in mice previously infected either, with the wild-type (WT) or the mutant HSV-1, as compared to uninfected control mice. Also, earlier EAE onset was seen after WT virus inoculation. These findings support the notion that a previous exposure to HSV-1 can accelerate and enhance EAE, which suggests a potential contribution of asymptomatic HSV-1 to the onset and severity of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33679788&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7928309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7928309&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.635257&gt;10.3389&#x2F;fimmu.2021.635257&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33679788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":415,"discovery_date":"2021-03-08T12:36:46","title":"Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Jul 9;2(1):e000060. doi: 10.1136&#x2F;bmjno-2020-000060. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Because clozapine and risperidone have been shown to reduce neuroinflammation in humans and mice, the Clozapine and Risperidone in Progressive Multiple Sclerosis (CRISP) trial was conducted to determine whether clozapine and risperidone are suitable for progressive multiple sclerosis (pMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The CRISP trial (ACTRN12616000178448) was a blinded, randomised, placebo-controlled trial with three parallel arms (n&#x3D;12&#x2F;arm). Participants with pMS were randomised to clozapine (100-150 mg&#x2F;day), risperidone (2.0-3.5 mg&#x2F;day) or placebo for 6 months. The primary outcome measures were safety (adverse events (AEs)&#x2F;serious adverse events (SAE)) and acceptability (Treatment Satisfaction Questionnaire for Medication-9).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: An interim analysis (n&#x3D;9) revealed significant differences in the time-on-trial between treatment groups and placebo (p&#x3D;0.030 and 0.025, clozapine and risperidone, respectively) with all participants receiving clozapine being withdrawn during the titration period (mean dose&#x3D;35Â±15 mg&#x2F;day). Participants receiving clozapine or risperidone reported a significantly higher rate of AEs than placebo (p&#x3D;0.00001) but not SAEs. Specifically, low doses of clozapine appeared to cause an acute and dose-related intoxicant effect in patients with pMS who had fairly severe chronic spastic ataxic gait and worsening over all mobility, which resolved on drug cessation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: The CRISP trial results suggest that patients with pMS may experience increased sensitivity to clozapine and risperidone and indicate that the dose and&#x2F;or titration schedule developed for schizophrenia may not be suitable for pMS. While these findings do not negate the potential of these drugs to reduce multiple sclerosis-associated neuroinflammation, they highlight the need for further research to understand the pharmacodynamic profile and effect of clozapine and risperidone in patients with pMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION NUMBER: ACTRN12616000178448.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681788&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7903182&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7903182&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000060&gt;10.1136&#x2F;bmjno-2020-000060&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681788&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":414,"discovery_date":"2021-03-08T12:36:46","title":"Comparison of neurofilament light chain results between two independent facilities","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Oct 19;2(2):e000063. doi: 10.1136&#x2F;bmjno-2020-000063. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To examine levels of neurofilament light chain (NFL) in identical cerebrospinal fluid (CSF) and blood samples at two different facilities, and how differences affect interpretation of levels within and above the normal range.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: CSF and plasma from patients with multiple sclerosis (MS) and healthy controls (HCs) were analysed by Simoa (Quanterix) for levels of NFL providing a total of 165 CSF samples (119 from MS) and 225 plasma samples (180 from MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: CSF and plasma concentrations highly correlated between NFL laboratory facilities (R: 0.92 and 0.84, &amp;lt;0.0001, respectively), and there were no differences between facilities. A bias between the two sites for plasma was -0.95 pg&#x2F;mL and for CSF -73.53 pg&#x2F;mL. The cut-offs for CSF were 807.5 and 571.0 pg&#x2F;mL at site 1 and site 2, respectively; the cut-offs for plasma were 13.0 and 11.8 pg&#x2F;mL, respectively. Seven out of 180 plasma samples (3.9%) and 3 out of 119 CSF samples (2.5%) from MS patients could be reclassified as normal&#x2F;abnormal, that is, below&#x2F;above cut-off, when measured at different facilities.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our study demonstrates that results of NFL in CSF and blood measured with SIMOA are comparable between facilities. Nevertheless, healthcare practitioners should consider reference values at different laboratories, since different sensitivity&#x2F;specificity can affect interpretation when low values are adjacent to cut-offs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681796&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7871722&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7871722&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000063&gt;10.1136&#x2F;bmjno-2020-000063&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":413,"discovery_date":"2021-03-08T12:36:46","title":"Hospital diagnosed pneumonia before age 20 years and multiple sclerosis risk","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2020 Jun 16;2(1):e000044. doi: 10.1136&#x2F;bmjno-2020-000044. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Respiratory inflammation has been proposed as a risk factor for MS. This study aims to determine if hospital-diagnosed pneumonia in adolescence (before age 20 years) is associated with subsequent multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This case-control study included incident MS cases after age 20 years identified using the Swedish national registers. Cases were matched with 10 general population controls by age, sex and region. Pneumonia diagnoses were identified between 0-5, 6-10, 11-15 and 16-20 years of age. Conditional logistic regression models adjusted for infectious mononucleosis (IM) and education calculated ORs with 95% CIs. Urinary tract infections (UTIs), a common complication of MS, before age 20 years were included as a control diagnosis for reverse causation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were 6109 cases and 49 479 controls included. Pneumonia diagnosed between age 11-15 years was associated with subsequent MS (adj OR 2.00, 95% CI 1.22 to 3.27). Although not statistically significant, sensitivity analyses showed similar magnitude associations of pneumonia between age 11-15 years and MS. No statistically significant associations with MS for pneumonia at other age groups were observed. Adjustment for IM had no notable effect on associations, but was statistically significantly associated with MS. UTIs were not associated with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Pneumonia at 11-15 years of age was associated with MS, suggesting a possible role for inflammation of the respiratory system in the aetiology of MS during a period of susceptibility in adolescence. Further research on respiratory infections prior to MS onset should be conducted to replicate this finding and determine explanatory causal mechanisms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681783&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681783&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7903180&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7903180&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000044&gt;10.1136&#x2F;bmjno-2020-000044&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681783&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":412,"discovery_date":"2021-03-08T12:36:46","title":"Two case reports of acquired haemophilia A as complications of alemtuzumab treatment for multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;BMJ Neurol Open. 2021 Jan 18;3(1):e000095. doi: 10.1136&#x2F;bmjno-2020-000095. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To describe the case histories of two patients who developed acquired haemophilia A following treatment with alemtuzumab for multiple sclerosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Two patients, a 48-year-old woman and a 31-year-old woman, developed acquired haemophilia A 21 months after their second doses of alemtuzumab. Both presented with spontaneous bruising, and the second case reported menorrhagia. One patient required treatment to control bleeding. Both patients responded to treatment with prednisolone and cyclophosphamide to eliminate the inhibitor.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Acquired haemophilia A is a rare complication following treatment with alemtuzumab. Activated partial thromboplastin time and prothrombin time should be performed in cases of abnormal bleeding in which the platelet count is normal, to facilitate timely diagnosis and prevention of major bleeding complications.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33681807&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7871705&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7871705&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;bmjno-2020-000095&gt;10.1136&#x2F;bmjno-2020-000095&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33681807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":411,"discovery_date":"2021-03-08T12:36:46","title":"Serum vasohibin-1 levels: a potential marker of dermal and pulmonary fibrosis in systemic sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Exp Dermatol. 2021 Mar 8. doi: 10.1111&#x2F;exd.14321. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Vasohibin-1 (VASH-1) is a potent anti-angiogenic factor mainly produced by endothelial cells. In addition, VASH-1 prevents TGF-Î²-dependent activation of renal fibroblasts. Since systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy and fibrosis of multiple organs, VASH-1 may be involved in the development of this disease. In this study, we investigated the potential role of VASH-1 in SSc by evaluating the clinical correlation of serum VASH-1 levels and the expression of VASH-1 in SSc-involved skin. Serum VASH-1 levels were higher in SSc patients, especially those with diffuse cutaneous involvement, than in healthy controls and positively correlated with skin score. Furthermore, SSc patients with interstitial lung disease had significantly elevated levels of serum VASH-1 as compared to those without. Importantly, serum VASH-1 levels correlated inversely with both the percentage of predicted vital capacity and the percentage of predicted diffusion lung capacity for carbon monoxide and positively with serum KL-6 levels, but not serum surfactant protein-D levels. In SSc-involved skin, VASH1 mRNA was remarkably upregulated compared with healthy control skin, but the major source of VASH-1 was not clear. Fli1 deficiency, a predisposing factor inducing SSc-like endothelial properties, did not affect VASH-1 expression in human dermal microvascular endothelial cells. Collectively, these results suggest that VASH-1 upregulation in the skin and sera is linked to dermal and pulmonary fibrotic changes in SSc, while the contribution of VASH-1 to SSc vasculopathy seems to be limited.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682189&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2&quot;&gt;33682189&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;exd.14321&gt;10.1111&#x2F;exd.14321&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33682189&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":410,"discovery_date":"2021-03-08T09:56:46","title":"Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Semin Arthritis Rheum. 2021 Feb 19;51(2):425-429. doi: 10.1016&#x2F;j.semarthrit.2021.02.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION&#x2F;BACKGROUND: Skin ulcers are a complex array of clinical manifestations of systemic sclerosis (SSc) and are often difficult to treat. However, the definition of SSc-skin ulcers has to date not been promising, demonstrating poor reliability and accuracy. There are emerging data that ultrasound has significant potential to evaluate SSc-skin ulcers.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To perform a systematic literature review (SLR) to understand the degree to which ultrasound of SSc skin ulcers has been validated according to OMERACT criteria.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In a SLR, we investigated the Cochrane Library, Web of Science and Pubmed databases for manuscripts from inception to 1st April 2020. Inclusion and exclusion criteria included manuscripts on SSc patients aged over 16 years, performing SSc-related skin ulcer evaluation with ultrasound machines. Papers on animal model, diseases other than SSc, venous ulcers were excluded. Data extraction used a uniform case report form which collected data on patient demographics, disease activity, description of the ultrasound machine and procedures and the degree to which domains of validity were fulfilled. Manuscript evaluation and extraction was performed by two independent assessors, with a third author being consulted in case of disagreement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: amongst 308 manuscripts that were identified, 6 published manuscripts&#x2F; posters fulfilled the inclusion&#x2F;exclusion criteria and were extracted. Face validity was found. Three studies developed an US definition of SSc-ulcers across patients (content validity); one study evaluated the concordance between US image and clinical assessment. Criterion validity was shown by one study and ultrasound detected improvement (sensitivity to change) of SSc-skin ulcer in response to therapy. Feasibility was demonstrated by US use for skin ulcers in multiple settings (the 6 manuuscripts&#x2F;posters).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: This systematic literature review shows that ultrasound for skin ulcers in SSc has been partially validated. It has face, content, criterion validity, responsiveness and reasonable feasibility. Further validation for construct validity, reliability and discrimination is required.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677309&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.semarthrit.2021.02.008&gt;10.1016&#x2F;j.semarthrit.2021.02.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":409,"discovery_date":"2021-03-08T09:56:46","title":"Developing a clinical pathway to identify and manage cognitive problems in Multiple Sclerosis: Qualitative findings from patients, family members, charity volunteers, clinicians and healthcare commissioners","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2020 Oct 4;49:102563. doi: 10.1016&#x2F;j.msard.2020.102563. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Cognitive problems are a common and debilitating symptom of multiple sclerosis (MS). Screening and treatment for cognitive problems are recommended, however these are not routinely delivered in UK clinics. We collected and synthesised stakeholder perspectives to develop a care pathway for cognitive problems in MS and produce a logic model, illustrating how this pathway might operate.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Forty-nine stakeholders, including people with MS and care providers, participated in semi-structured interviews and focus groups. Participants viewed information that illustrated how the pathway might work and provided feedback. Data, transcribed verbatim and analysed using Framework Analysis, were mapped onto a preliminary logic model and accompanying thematic framework.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The proposed pathway was perceived as helpful in providing standardised support for a neglected MS symptom. Training packages, online cognitive screening, and triaging decisions were viewed as crucial activities. Shared responsibility, a person-centred approach, and addressing the complexity of cognitive problems were important engagement mechanisms. Allocating time during clinic appointments and within staff workloads were essential resources for implementation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our co-constructed MS cognitive screening and management pathway will be evaluated for clinical and cost-effectiveness in a trial. However, in the interim, clinicians can adapt and implement this pathway in their own services and evaluate it locally.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677366&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677366&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2020.102563&gt;10.1016&#x2F;j.msard.2020.102563&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677366&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":408,"discovery_date":"2021-03-08T09:56:46","title":"beta-endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 27;50:102868. doi: 10.1016&#x2F;j.msard.2021.102868. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an autoimmune-mediated degenerative disorder with increased peripheral inflammation disrupting the blood brain barrier. With increasing MS-related healthcare costs, the requirement to validate minimally invasive biomarkers has become imperative.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Relapsing-remitting MS patients on disease modifying therapies were consented at the Penn State Health MS Clinic to provide blood samples for analyses of serum cytokines and endogenous opioid peptides, as well as to complete the MSQOL-54 survey.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Serum OGF levels in MS patients on glatiramer acetate (mean &#x3D; 326 pg&#x2F;ml), dimethyl fumarate (mean &#x3D; 193.3 pg&#x2F;ml) and natalizumab (mean &#x3D; 393.4 pg&#x2F;ml) were significantly elevated (p &amp;lt; 0.01) compared to healthy controls (mean &#x3D; 98.46 pg&#x2F;ml). Individuals with elevated OGF levels also had increased levels of TNFÎ± (r &#x3D; 0.78) and IL-17A (r &#x3D; 0.81). Only patients treated with glatiramer acetate had significant (p &amp;lt; 0.01) elevations in serum Î²-endorphin levels. Analyses of MS-QoL 54 data showed no significant differences in physical or mental composite scores between treatment groups. However, serum levels of Î²-endorphin had a direct correlation with physical health composite score (r &#x3D; 0.70) in all treatments. Serum vitamin D levels had an indirect relationship with 25-foot walk test times (r &#x3D; 0.47).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Both regression and cohort data suggest that serum levels of OGF, Î²-endorphin, and vitamin D are potential biomarkers for physical disease status in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677409&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102868&gt;10.1016&#x2F;j.msard.2021.102868&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":407,"discovery_date":"2021-03-08T09:56:46","title":"A randomized pilot trial of oral prednisone taper vs placebo following iv methylprednisolone for multiple sclerosis relapses: Effects on adrenal function and clinical efficacy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 24;50:102867. doi: 10.1016&#x2F;j.msard.2021.102867. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We performed a pilot trial investigating the effect of a steroid taper on adrenal function and safety measures after acute MS relapses. Twenty-five patients were randomized to either prednisone taper (n&#x3D;12) or placebo (n&#x3D;13) after 3 days of intravenous methylprednisolone. No patient showed signs of adrenal insufficiency at any time by cortisol response to ACTH. This significantly increased between baseline and 6 months in both groups. Patients remained clinically and radiologically stable, but those under prednisone taper experienced more frequently mood disorders, hyperglycaemia and weight increase. If confirmed by sufficiently powered studies, these results would question the need of a steroid taper following short-term intravenous methylprednisolone.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677411&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102867&gt;10.1016&#x2F;j.msard.2021.102867&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":406,"discovery_date":"2021-03-08T09:56:46","title":"The cholesterol autoxidation products, 7-ketocholesterol and 7beta-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 26;50:102864. doi: 10.1016&#x2F;j.msard.2021.102864. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Serum neurofilament light chain (sNfL) is an established marker of neuroaxonal injury in multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To investigate if oxysterols produced from non-enzymatic and enzymatic cholesterol oxidation are differentially associated with sNfL measurements in MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This longitudinal study included 62 relapsing-remitting (RR-MS) and 36 progressive MS (PMS) patients with baseline and 5-year follow-up measures of serum levels of 6 oxysterols, sNfL and lipids. The oxysterols, 24-hydroxycholesterol (24HC), 25HC, 27HC, 7Î±HC, 7Î²HC and 7-ketocholesterol (7KC), were measured using liquid chromatography-mass spectrometry. sNfL was measured using single molecular array assay. Serum high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were obtained from a lipid profile.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The enzymatically produced oxysterols 24HC, 25HC, 27HC and 7Î±HC were not associated with sNfL. However, baseline levels of reactive oxygen species (ROS) produced oxysterols, 7KC (p &#x3D; 0.032) and 7Î²HC (p &#x3D; 0.0025), were positively associated with sNfL levels at follow-up. Follow-up 7KC (p &#x3D; 0.038) levels were also associated with follow-up sNfL levels. The associations of 7KC or 7Î²HC with sNfL remained significant after adjusting for LDL-C or HDL-C.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: 7KC and 7Î²HC, produced by ROS-mediated cholesterol oxidation are associated with neuroaxonal injury as assessed by sNfL in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677412&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677412&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102864&gt;10.1016&#x2F;j.msard.2021.102864&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677412&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":405,"discovery_date":"2021-03-08T09:56:46","title":"Synergistic neuroprotective effects of Fingolimod and Mesenchymal Stem Cells (MSC) in Experimental Autoimmune Encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Lett. 2021 Mar 4:S0165-2478(21)00033-X. doi: 10.1016&#x2F;j.imlet.2021.03.003. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Fingolimod (Gilenyaâ¢) is an effective oral medication approved for relapsing-remitting multiple sclerosis (MS), albeit less effective in chronic disease. Its main mechanism of action is through peripheral immunomodulation but neuroprotective effects may also be involved. Mesenchymal stem cells (MSC) were shown to exert immunomodulatory and neurotrophic effects in the model of multiple sclerosis (experimental autoimmune encephalomyelitis-EAE). The use of combination treatments in chronic diseases such as MS, has long been advocated and may result in improvement of the beneficial effects of each one of them. We tested the in vitro effects of Fingolimod on MSC and the in vivo effect of such combination treatment in the model of EAE. Fingolimod did not affect in any detrimental way the basic features of MSCs and it promoted their migration ability and neurotrophic factors&#39; secretion and suppressed the production of pro-inflammatory cytokines from astrocytes, in vitro. In vivo, the combined treatment of FTY720 and MSC (either by the intravenous or the intra-cerebroventricular route of administration) resulted in synergistic clinical beneficial effects compared to FTY720 or MSC alone, paralleled by a significant reduction of inflammatory CNS infiltrations and of axonal loss. These data may indicate a synergism of fingolimod with MSC and may support future combinations of immunomodulatory drugs with cellular therapies for the improvement of the benefits in progressive forms of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676976&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33676976&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.imlet.2021.03.003&gt;10.1016&#x2F;j.imlet.2021.03.003&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676976&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":404,"discovery_date":"2021-03-08T09:56:46","title":"Late-onset MS is associated with an increased rate of reaching disability milestones","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Mar 7. doi: 10.1007&#x2F;s00415-021-10490-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To describe patient characteristics and assess the risk of disability worsening in patients of different age groups with focus on late-onset multiple sclerosis (LOMS) defined as disease onset after the age of 50 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The nationwide population-based Danish Multiple Sclerosis Registry served as data source. We described baseline characteristics and analyzed rates of reaching Expanded Disability Status Scale (EDSS) milestones.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We identified 28,232 patients with MS with a known year of clinical onset, of which 2661 had LOMS. The LOMS group had a higher proportion of males and patients with primary progressive disease course, and they were less likely to receive disease-modifying therapy. The initial rate of reaching EDSS milestone 6 after diagnosis was higher in LOMS [hazard ratio (HR) 1.53; 95% confidence interval (CI) 1.14-2.06]; however, when assessing the risk of reaching EDSS 6 according to age, the HR was significantly lower for the LOMS group (HR 0.307; 95% CI 0.221-0.426).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The clinical characteristics and treatment approaches for patients with LOMS differ from their younger counterparts. Following diagnosis, patients with LOMS initially have an increased rate of reaching EDSS score 6; however, the risk of reaching EDSS score 6 at any given age is higher in patients with non-LOMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677675&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10490-0&gt;10.1007&#x2F;s00415-021-10490-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":403,"discovery_date":"2021-03-08T09:56:46","title":"Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 6. doi: 10.1007&#x2F;s10072-021-05127-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Comparative effectiveness of natalizumab and fingolimod over a follow-up longer than 2 years has been not addressed yet.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To compare the effect on no evidence of disease activity (NEDA-3) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab or fingolimod for at least 4 years.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We included RRMS patients switched from first-line agents to natalizumab or fingolimod. Patients were propensity score (PS)-matched on a 1-to-1 basis. Percentages of patients reaching NEDA-3 status at 2 and 4 years of follow-up were compared using the chi-square test. The risk of not achieving NEDA-3 at 4 years was explored in matched samples by Cox regression models.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We evaluated 174 PS-matched patients. Patients receiving natalizumab reached a NEDA-3 status at 2 and 4 years more frequently than those exposed to fingolimod (63% vs 44%, p&#x3D;0.037; 45.7% vs 25.8%, p&#x3D;0.015, respectively). Patients receiving natalizumab were at a significant lower risk of not achieving the NEDA-3 status at 4 years compared to those exposed to fingolimod (hazard ratio (95% confidence interval): 0.54 (0.36-0.80), p&#x3D;0.002).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Although both medications were effective in patients non-responding to first-line agents, natalizumab seems to be superior to fingolimod in RRMS in obtaining NEDA-3 status at 4 years.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677753&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2&quot;&gt;33677753&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05127-z&gt;10.1007&#x2F;s10072-021-05127-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33677753&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210308045644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":402,"discovery_date":"2021-03-08T06:43:30","title":"Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension","summary":"In pulmonary arterial hypertension (PAH), progressive right ventricular (RV) dysfunction is believed to be largely secondary to RV ischaemia. A recent pilot study has demonstrated the feasibility of Oxygen-sen...","link":"https:&#x2F;&#x2F;jcmr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12968-020-00694-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":401,"discovery_date":"2021-03-07T18:43:30","title":"Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury","summary":"Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide....","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00793-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":400,"discovery_date":"2021-03-07T15:43:30","title":"Effect of fecal microbiota transplantation on neurological restoration in a spinal cord injury mouse model: involvement of brain-gut axis","summary":"Spinal cord injury (SCI) patients display disruption of gut microbiome, and gut dysbiosis exacerbate neurological impairment in SCI models. Cumulative data support an important role of gut microbiome in SCI. H...","link":"https:&#x2F;&#x2F;microbiomejournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40168-021-01007-y","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":399,"discovery_date":"2021-03-07T12:16:46","title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 20;50:102849. doi: 10.1016&#x2F;j.msard.2021.102849. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Background Eculizumab, a terminal complement inhibitor, significantly reduced the risk of relapse compared with placebo in patients with anti-aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the PREVENT trial. We report efficacy and safety analyses in Asian patients in PREVENT and its open-label extension (OLE). Methods PREVENT was a double-blind, randomized, phase 3 trial. Patients with AQP4+ NMOSD were randomly assigned (2:1) to receive intravenous eculizumab (maintenance dose, 1200 mg&#x2F;2 weeks) or placebo. Patients who completed PREVENT could receive eculizumab in an OLE. Analyses were performed in a prespecified subgroup of Asian patients. Results Of 143 patients enrolled, 52 (36.4%) were included in the Asian subgroup (eculizumab, n &#x3D; 37; placebo, n &#x3D; 15); 45 Asian patients received eculizumab in the OLE. Most Asian patients (86.5%) received concomitant immunosuppressive therapy. During PREVENT, one adjudicated relapse occurred in patients receiving eculizumab and six occurred in patients receiving placebo in the Asian subgroup (hazard ratio, 0.05; 95% confidence interval: 0.01-0.35; p &#x3D; 0.0002). An estimated 95.2% of Asian patients remained relapse-free after 144 weeks of eculizumab treatment. Upper respiratory tract infections, headache, and nasopharyngitis were the most common adverse events with eculizumab in the Asian subgroup. Conclusion Eculizumab reduces the risk of relapse in Asian patients with AQP4+ NMOSD, with a benefit-risk profile similar to the overall PREVENT population. The benefits of eculizumab were maintained during long-term therapy. Clinical trial registration ClinicalTrials.gov identifiers: NCT01892345 (PREVENT); NCT02003144 (open-label extension).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676197&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210307071644&amp;v&#x3D;2.14.2&quot;&gt;33676197&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102849&gt;10.1016&#x2F;j.msard.2021.102849&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33676197&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210307071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":398,"discovery_date":"2021-03-07T04:16:45","title":"Whole Brain Adiabatic T(1rho) and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Magn Reson Imaging. 2021 Mar 6. doi: 10.1002&#x2F;jmri.27586. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: In preclinical models of multiple sclerosis (MS), both adiabatic T&lt;sub&gt;1rho&lt;&#x2F;sub&gt; (T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; ) and relaxation along a fictitious field (RAFF) imaging have demonstrated potential to noninvasively characterize MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: To evaluate the feasibility of whole brain T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and RAFF imaging in healthy volunteers and patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STUDY TYPE: Single institutional clinical trial.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUBJECTS: About 38 healthy volunteers (24-69 years) and 21 patients (26-59 years) with MS. Five healthy volunteers underwent a second MR examination performed within 8 days. Clinical disease severity (The Expanded Disability Status Scale [EDSS] and The Multiple Sclerosis Severity Score [MSSS]) was evaluated at baseline and 1-year follow-up (FU).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;FIELD STRENGTH&#x2F;SEQUENCE: RAFF in second rotating frame of reference (RAFF2) was performed at 3 T using 3D-fast-field echo with magnetization preparation, RF amplitude of 11.74 Î¼T while the corresponding value for T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; was 13.50 Î¼T. T&lt;sub&gt;1&lt;&#x2F;sub&gt; -, T&lt;sub&gt;2&lt;&#x2F;sub&gt; -, and FLAIR-weighted images were acquired with reconstruction voxel size 1.0 Ã 1.0 Ã 1.0 mm&lt;sup&gt;3&lt;&#x2F;sup&gt; .&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;ASSESSMENT: The parametric maps of T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and RAFF2 (T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; ) were calculated using a monoexponential model. Semi-automatic segmentation of MS lesions, white matter (WM), and gray matter (GM), and WM tracks was performed using T&lt;sub&gt;1&lt;&#x2F;sub&gt; -, T&lt;sub&gt;2&lt;&#x2F;sub&gt; -, and FLAIR-weighted images.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;STATISTICAL TESTS: Regression analysis was used to evaluated correlation of T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; with age and disease severity while a Friedman test followed by Wilcoxon Signed Rank test for differences between tissue types. Short-term repeatability was evaluated on voxel level.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Both T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; demonstrated good short-term repeatability with relative differences on voxel level in the range of 6.1%-11.9%. Differences in T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; between the tissue types in MS patients were significant (P &amp;lt; 0.05). T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; correlated (P &amp;lt; 0.001) with baseline EDSS&#x2F;MSSM and disease progression at FU (P &amp;lt; 0.001).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DATA CONCLUSION: Whole brain T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; at 3 T was feasible with significant differences in T&lt;sub&gt;1Ïadiab&lt;&#x2F;sub&gt; and T&lt;sub&gt;RAFF2&lt;&#x2F;sub&gt; values between tissues time and correlation with disease severity.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;EVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 1.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675564&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306231644&amp;v&#x3D;2.14.2&quot;&gt;33675564&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;jmri.27586&gt;10.1002&#x2F;jmri.27586&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675564&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306231644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":397,"discovery_date":"2021-03-07T00:43:30","title":"Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimerâs disease","summary":"Regenerative therapies to mitigate Alzheimerâs disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells h...","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00791-x","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":396,"discovery_date":"2021-03-06T21:43:30","title":"Blockage of NLRP3 inflammasome activation ameliorates acute inflammatory injury and long-term cognitive impairment induced by necrotizing enterocolitis in mice","summary":"Necrotizing enterocolitis (NEC) is an inflammatory gastrointestinal disease in premature neonates with high mortality and morbidity, while the underlining mechanism of intestinal injury and profound neurologic...","link":"https:&#x2F;&#x2F;jneuroinflammation.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12974-021-02111-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":395,"discovery_date":"2021-03-06T14:16:46","title":"The Role of the Inflammasome in Neurodegenerative Diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Molecules. 2021 Feb 11;26(4):953. doi: 10.3390&#x2F;molecules26040953.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegenerative diseases are chronic, progressive disorders that occur in the central nervous system (CNS). They are characterized by the loss of neuronal structure and function and are associated with inflammation. Inflammation of the CNS is called neuroinflammation, which has been implicated in most neurodegenerative diseases, including Alzheimer&#39;s disease (AD), Parkinson&#39;s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Much evidence indicates that these different conditions share a common inflammatory mechanism: the activation of the inflammasome complex in peripheral monocytes and in microglia, with the consequent production of high quantities of the pro-inflammatory cytokines IL-1Î² and IL-18. Inflammasomes are a group of multimeric signaling complexes that include a sensor Nod-like receptor (NLR) molecule, the adaptor protein ASC, and caspase-1. The NLRP3 inflammasome is currently the best-characterized inflammasome. Multiple signals, which are potentially provided in combination and include endogenous danger signals and pathogens, trigger the formation of an active inflammasome, which, in turn, will stimulate the cleavage and the release of bioactive cytokines including IL-1Î² and IL-18. In this review, we will summarize results implicating the inflammasome as a pivotal player in the pathogenesis of neurodegenerative diseases and discuss how compounds that hamper the activation of the NLRP3 inflammasome could offer novel therapeutic avenues for these diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33670164&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;molecules26040953&gt;10.3390&#x2F;molecules26040953&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670164&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":394,"discovery_date":"2021-03-06T14:16:46","title":"Functional genomic analyses highlight a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells and underlying myelin dysregulation in the aged mouse cerebrum","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Aging Cell. 2021 Mar 5:e13335. doi: 10.1111&#x2F;acel.13335. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Brain ageing is characterised by a decline in neuronal function and associated cognitive deficits. There is increasing evidence that myelin disruption is an important factor that contributes to the age-related loss of brain plasticity and repair responses. In the brain, myelin is produced by oligodendrocytes, which are generated throughout life by oligodendrocyte progenitor cells (OPCs). Currently, a leading hypothesis points to ageing as a major reason for the ultimate breakdown of remyelination in Multiple Sclerosis (MS). However, an incomplete understanding of the cellular and molecular processes underlying brain ageing hinders the development of regenerative strategies. Here, our combined systems biology and neurobiological approach demonstrate that oligodendroglial and myelin genes are amongst the most altered in the ageing mouse cerebrum. This was underscored by the identification of causal links between signalling pathways and their downstream transcriptional networks that define oligodendroglial disruption in ageing. The results highlighted that the G-protein coupled receptor Gpr17 is central to the disruption of OPCs in ageing and this was confirmed by genetic fate-mapping and cellular analyses. Finally, we used systems biology strategies to identify therapeutic agents that rejuvenate OPCs and restore myelination in age-related neuropathological contexts.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675110&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33675110&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;acel.13335&gt;10.1111&#x2F;acel.13335&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675110&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":393,"discovery_date":"2021-03-06T14:16:46","title":"Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Agonist","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Drug Metab Dispos. 2021 Mar 4:DMD-AR-2020-000220. doi: 10.1124&#x2F;dmd.120.000220. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Ozanimod is approved for the treatment of relapsing forms of multiple sclerosis. Absorption, metabolism and excretion of ozanimod was investigated following a single oral dose of 1.0 mg &lt;sup&gt;14&lt;&#x2F;sup&gt;C-ozanimod hydrochloride to six healthy subjects. In vitro experiments were conducted to understand the metabolic pathways and enzyme involved in the metabolism of ozanimod and its active metabolites. The total mean recovery of the administered radioactivity was ~63%, with ~26% and ~37% recovered from urine and feces, respectively. Based on exposure, the major circulating components were active metabolite CC112273 and inactive metabolite RP101124 and together accounted for 50% of the circulating total radioactivity exposure while ozanimod accounted for 6.7% of the total radioactive exposure. Ozanimod was extensively metabolized, with 13 metabolites identified including 2 major active metabolites (CC112273 and CC1084037) and 1 major inactive metabolite (RP101124) in circulation. Ozanimod is metabolized by three primary pathways including aldehyde dehydrogenase and alcohol dehydrogenase, cytochrome P450 (CYP) isoforms 3A4, 1A1, and reductive metabolism by gut microflora. The primary metabolite RP101075 is further metabolized to form major active metabolite CC112273 by monoamine oxidase B which further undergoes reduction by carbonyl reductases (CBR) to form CC1084037 or CYP2C8 mediated oxidation to form RP101509. CC1084037 is oxidized rapidly to form CC112273 by aldo-keto reductase (AKR) 1C1&#x2F;1C2, and&#x2F;or 3Î²- and 11Î²-hydroxysteroid dehydrogenase (HSD) and this reversible oxido-reduction between two active metabolites favors CC112273. Ozanimod example illustrates the need for conducting timely radiolabeled human ADME studies for characterization of disproportionate metabolites and assessment of exposure coverage during drug development. &lt;b&gt;Significance Statement&lt;&#x2F;b&gt; Absorption, metabolism, and excretion of ozanimod was characterized in humans and the enzymes involved in complex metabolism were elucidated. Disproportionate metabolites were identified, and the activity of these metabolites were determined.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33674268&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33674268&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1124&#x2F;dmd.120.000220&gt;10.1124&#x2F;dmd.120.000220&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33674268&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":392,"discovery_date":"2021-03-06T14:16:46","title":"Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Med. 2021 Feb 19;10(4):868. doi: 10.3390&#x2F;jcm10040868.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing&#x2F;remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33669799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33669799&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;jcm10040868&gt;10.3390&#x2F;jcm10040868&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33669799&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":391,"discovery_date":"2021-03-06T14:16:46","title":"Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 22;22(4):2182. doi: 10.3390&#x2F;ijms22042182.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The effect of the inflammatory response on regenerative processes in the brain is complex. This complexity is even greater when the cause of the tissue damage is an autoimmune response. Multiple sclerosis (MS) is an immune-mediated disease in which demyelination foci are formed in the central nervous system. The degree of repair through oligodendrocyte regeneration and remyelination is insufficient. Ephrins are membrane-bound ligands activating tyrosine kinase signaling proteins that are known to have an inhibitory effect on oligodendrocyte regeneration. In this study, we examined the expression of ephrins on immune cells of 43 patients with relapsing-remitting (RR) MS compared to 27 matched healthy controls (HC). We found an increased expression of ephrin-A2, -A3 and -B3, especially on T cell subpopulations. We also showed overexpression of ephrins on immune cells of patients with RR-MS that increases the forward signaling pathway and that expression of ephrins on immune cells has an inhibitory effect on the differentiation of oligodendrocyte precursor cells (OPCs) in vitro. Our study findings support the concept that the immune activity of T cells in patients with RR-MS has an inhibitory effect on the differentiation capacity of OPCs through the expression and forward signaling of ephrins.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671716&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671716&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22042182&gt;10.3390&#x2F;ijms22042182&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671716&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":390,"discovery_date":"2021-03-06T14:16:46","title":"The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 11;22(4):1804. doi: 10.3390&#x2F;ijms22041804.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Currently, there is some information on the consequences of COVID-19 infection in multiple sclerosis (MS) patients, as it is a newly discovered coronavirus, but its far-reaching effects on participation in neurodegenerative diseases seem to be significant. Recent cases reports showed that SARS-CoV-2 may be responsible for initiating the demyelination process in people who previously had no symptoms associated with any nervous system disorders. It is presently known that infection of SARS-CoV-2 evokes cytokine storm syndrome, which may be one of the factors leading to the acute cerebrovascular disease. One of the substantial problems is the coexistence of cerebrovascular disease and MS in an individual&#39;s life span. Epidemiological studies showed an enhanced risk of death rate from vascular disabilities in MS patients of approximately 30%. It has been demonstrated that patients with severe SARS-CoV-2 infection usually show increased levels of D-dimer, fibrinogen, C-reactive protein (CRP), and overactivation of blood platelets, which are essential elements of prothrombotic events. In this review, the latest knowledge gathered during an ongoing pandemic of SARS-CoV-2 infection on the neurodegeneration processes in MS is discussed.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670394&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33670394&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22041804&gt;10.3390&#x2F;ijms22041804&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33670394&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":389,"discovery_date":"2021-03-06T14:16:46","title":"Pharmacological Management of Neurogenic Bowel Dysfunction after Spinal Cord Injury and Multiple Sclerosis: A Systematic Review and Clinical Implications","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Med. 2021 Feb 22;10(4):882. doi: 10.3390&#x2F;jcm10040882.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurogenic bowel dysfunction (NBD) is a common problem for people with spinal cord injury (SCI) and multiple sclerosis (MS), which seriously impacts quality of life. Pharmacological management is an important component of conservative bowel management. The objective of this study was to first assemble a list of pharmacological agents (medications and medicated suppositories) used in current practice. Second, we systematically examined the current literature on pharmacological agents to manage neurogenic bowel dysfunction of individuals specifically with SCI or MS. We searched Medline, EMBASE and CINAHL databases up to June 2020. We used the GRADE System to provide a systematic approach for evaluating the evidence. Twenty-eight studies were included in the review. We found a stark discrepancy between the large number of agents currently prescribed and a very limited amount of literature. While there was a small amount of literature in SCI, there was little to no literature available for MS. There was low-quality evidence supporting rectal medications, which are a key component of conservative bowel care in SCI. Based on the findings of the literature and the clinical experience of the authors, we have provided clinical insights on proposed treatments and medications in the form of three case study examples on patients with SCI or MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671492&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671492&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;jcm10040882&gt;10.3390&#x2F;jcm10040882&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671492&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":388,"discovery_date":"2021-03-06T14:16:46","title":"Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 28;22(5):2440. doi: 10.3390&#x2F;ijms22052440.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The need for remyelinating drugs is essential for healing disabling diseases such as multiple sclerosis (MS). One of the reasons for the lack of this class of therapies is the impossibility to monitor remyelination in vivo, which is of utmost importance to perform effective clinical trials. Here, we show how optical coherence tomography (OCT), a cheap and non-invasive technique commonly used in ophthalmology, may be used to assess remyelination in vivo in MS patients. Our pioneer approach validates OCT as a technique to study remyelination of the optic nerve and reflects what is occurring in non-accessible central nervous system (CNS) structures, like the spinal cord. In this study we used the orally bioavailable small molecule VP3.15, confirming its therapeutical potential as a neuroprotective, anti-inflammatory, and probably remyelinating drug for MS. Altogether, our results confirm the usefulness of OCT to monitor the efficacy of remyelinating therapies in vivo and underscore the relevance of VP3.15 as a potential disease modifying drug for MS therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671012&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671012&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22052440&gt;10.3390&#x2F;ijms22052440&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671012&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":387,"discovery_date":"2021-03-06T14:16:46","title":"Methylxanthines and Neurodegenerative Diseases: An Update","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nutrients. 2021 Feb 28;13(3):803. doi: 10.3390&#x2F;nu13030803.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Methylxanthines (MTX) are purine derived xanthine derivatives. Whereas naturally occurring methylxanthines like caffeine, theophylline or theobromine are widely consumed in food, several synthetic but also non-synthetic methylxanthines are used as pharmaceuticals, in particular in treating airway constrictions. Besides the well-established bronchoprotective effects, methylxanthines are also known to have anti-inflammatory and anti-oxidative properties, mediate changes in lipid homeostasis and have neuroprotective effects. Known molecular mechanisms include adenosine receptor antagonism, phosphodiesterase inhibition, effects on the cholinergic system, wnt signaling, histone deacetylase activation and gene regulation. By affecting several pathways associated with neurodegenerative diseases via different pleiotropic mechanisms and due to its moderate side effects, intake of methylxanthines have been suggested to be an interesting approach in dealing with neurodegeneration. Especially in the past years, the impact of methylxanthines in neurodegenerative diseases has been extensively studied and several new aspects have been elucidated. In this review we summarize the findings of methylxanthines linked to AlzheimerÂ´s disease, Parkinson&#39;s disease and Multiple Sclerosis since 2017, focusing on epidemiological and clinical studies and addressing the underlying molecular mechanisms in cell culture experiments and animal studies in order to assess the neuroprotective potential of methylxanthines in these diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671099&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671099&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;nu13030803&gt;10.3390&#x2F;nu13030803&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671099&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":386,"discovery_date":"2021-03-06T14:16:46","title":"Measuring Aqueduct of Sylvius Cerebrospinal Fluid Flow in Multiple Sclerosis Using Different Software","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Diagnostics (Basel). 2021 Feb 17;11(2):325. doi: 10.3390&#x2F;diagnostics11020325.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Aqueduct of Sylvius (AoS) cerebrospinal fluid flow can be quantified using phase-contrast (PC) Magnetic Resonance Imaging. The software used for AoS segmentation might affect the PC-derived measures. We analyzed AoS PC data of 30 people with multiple sclerosis and 19 normal controls using three software packages, and estimated cross-sectional area (CSA), average and highest AoS velocity (Vmean and Vmax), flow rate and volume. Our aims were to assess the repeatability and reproducibility of each PC-derived measure obtained with the various software packages, including in terms of group differentiation. All the variables had good repeatability, except the average Vmean, flow rate and volume obtained with one software package. Substantial to perfect agreement was seen when evaluating the overlap between the AoS segmentations obtained with different software packages. No variable was significantly different between software packages, with the exception of Vmean diastolic peak and CSA. Vmax diastolic peak differentiated groups, regardless of the software package. In conclusion, a clinical study should preliminarily evaluate the repeatability in order to interpret its findings. Vmax seemed to be a repeatable and reproducible measure, since the pixel with its value is usually located in the center of the AoS, and is thus unlikely be affected by ROI size.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671219&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671219&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;diagnostics11020325&gt;10.3390&#x2F;diagnostics11020325&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671219&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":385,"discovery_date":"2021-03-06T14:16:46","title":"Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Molecules. 2021 Feb 23;26(4):1188. doi: 10.3390&#x2F;molecules26041188.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Alzheimer&#39;s, Parkinson&#39;s, and multiple sclerosis are neurodegenerative diseases related by neuronal degeneration and death in specific areas of the central nervous system. These pathologies are associated with neuroinflammation, which is involved in disease progression, and halting this process represents a potential therapeutic strategy. Evidence suggests that microglia function is regulated by A&lt;sub&gt;1&lt;&#x2F;sub&gt; and A&lt;sub&gt;2A&lt;&#x2F;sub&gt; adenosine receptors (AR), which are considered as neuroprotective and neurodegenerative receptors, respectively. The manuscript&#39;s aim is to elucidate the role of these receptors in neuroinflammation modulation through potent and selective A&lt;sub&gt;1&lt;&#x2F;sub&gt;AR agonists (N&lt;sup&gt;6&lt;&#x2F;sup&gt;-cyclopentyl-2&#39;- or 3&#39;-deoxyadenosine substituted or unsubstituted in 2 position) and A&lt;sub&gt;2A&lt;&#x2F;sub&gt;AR antagonists (9-ethyl-adenine substituted in 8 and&#x2F;or in 2 position), synthesized in house, using N13 microglial cells. In addition, the combined therapy of A&lt;sub&gt;1&lt;&#x2F;sub&gt;AR agonists and A&lt;sub&gt;2A&lt;&#x2F;sub&gt;AR antagonists to modulate neuroinflammation was evaluated. Results showed that A&lt;sub&gt;1&lt;&#x2F;sub&gt;AR agonists were able, to varying degrees, to prevent the inflammatory effect induced by cytokine cocktail (tumor necrosis factor (TNF)-Î±, interleukin (IL)-1Î², and interferon (IFN)-Î³), while A&lt;sub&gt;2A&lt;&#x2F;sub&gt;AR antagonists showed a good ability to counteract neuroinflammation. Moreover, the effect achieved by combining the two most effective compounds (&lt;b&gt;1&lt;&#x2F;b&gt; and &lt;b&gt;6&lt;&#x2F;b&gt;) in doses previously found to be non-effective was greater than the treatment effect of each of the two compounds used separately at maximal dose.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33672225&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33672225&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;molecules26041188&gt;10.3390&#x2F;molecules26041188&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33672225&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":384,"discovery_date":"2021-03-06T14:16:46","title":"Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Sci. 2021 Feb 22;11(2):272. doi: 10.3390&#x2F;brainsci11020272.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Suitable in vivo and in vitro models are instrumental for the development of new drugs aimed at improving symptoms or progression of multiple sclerosis (MS). The cuprizone (CPZ)-induced murine model has gained momentum in recent decades, aiming to address the demyelination component of the disease. This work aims at assessing the differential cytotoxicity of CPZ in cells of different types and from different species: human oligodendroglial (HOG), human neuroblastoma (SH-SY5Y), human glioblastoma (T-98), and mouse microglial (N-9) cell lines. Moreover, the effect of CPZ was investigated in primary rat brain cells. Cell viability was assayed by oxygen rate consumption and by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based (MTT) method. Our results demonstrated that CPZ did not cause death in any of the assayed cell models but affected mitochondrial function and aerobic cell respiration, thus compromising cell metabolism in neural cells and neuron-glia co-cultures. In this sense, we found differential vulnerability between glial cells and neurons as is the case of the CPZ-induced mouse model of MS. In addition, our findings demonstrated that reduced viability was spontaneous reverted in a time-dependent manner by treatment discontinuation. This reversible cell-based model may help to further investigate the role of mitochondria in the disease, and study the molecular intricacies underlying the pathophysiology of the MS and other demyelinating diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671675&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;brainsci11020272&gt;10.3390&#x2F;brainsci11020272&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671675&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":383,"discovery_date":"2021-03-06T14:16:46","title":"The Dying Forward Hypothesis of ALS: Tracing Its History","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Sci. 2021 Feb 27;11(3):300. doi: 10.3390&#x2F;brainsci11030300.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The site of origin of amyotrophic lateral sclerosis (ALS), although unsettled, is increasingly recognized as being cortico-fugal, which is a dying-forward process primarily starting in the corticomotoneuronal system. A variety of iterations of this concept date back to over 150 years. Recently, the hallmark TAR DNA-binding protein 43 (TDP-43) pathology, seen in &amp;gt;95% of patients with ALS, has been shown to be largely restricted to corticofugal projecting neurons (&quot;dying forward&quot;). Possibly, soluble but toxic cytoplasmic TDP-43 could enter the axoplasm of Betz cells, subsequently causing dysregulation of nuclear protein in the lower brainstem and spinal cord anterior horn cells. As the disease progresses, cortical involvement in ALS becomes widespread, including or starting with frontotemporal dementia, implying a broader view of ALS as a brain disease. The onset at the motor and premotor cortices should be considered a nidus at the edge of multiple cortical networks which eventually become disrupted, causing failure of a widespread cortical connectome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33673524&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33673524&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;brainsci11030300&gt;10.3390&#x2F;brainsci11030300&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33673524&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":382,"discovery_date":"2021-03-06T14:16:46","title":"Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J Mol Sci. 2021 Feb 15;22(4):1914. doi: 10.3390&#x2F;ijms22041914.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). MS and its animal model called experimental autoimmune encephalomyelitis (EAE) immunopathogenesis involve a plethora of immune cells whose activation releases a variety of proinflammatory mediators and free radicals. Vitamin D3 (VitD) is endowed with immunomodulatory and antioxidant properties that we demonstrated to control EAE development. However, this protective effect triggered hypercalcemia. As such, we compared the therapeutic potential of VitD and paricalcitol (Pari), which is a non-hypercalcemic vitamin D analog, to control EAE. From the seventh day on after EAE induction, mice were injected with VitD or Pari every other day. VitD, but not Pari, displayed downmodulatory ability being able to reduce the recruitment of inflammatory cells, the mRNA expression of inflammatory parameters, and demyelination at the CNS. Lower production of proinflammatory cytokines by lymph node-derived cells and IL-17 by gut explants, and reduced intestinal inflammation were detected in the EAE&#x2F;VitD group compared to the EAE untreated or Pari groups. Dendritic cells (DCs) differentiated in the presence of VitD developed a more tolerogenic phenotype than in the presence of Pari. These findings suggest that VitD, but not Pari, has the potential to be used as a preventive therapy to control MS severity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671896&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33671896&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;ijms22041914&gt;10.3390&#x2F;ijms22041914&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33671896&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":381,"discovery_date":"2021-03-06T14:16:46","title":"A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Mar 6. doi: 10.1002&#x2F;acn3.51325. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To assess feasibility, tolerability, and safety of N-acetyl cysteine (NAC) for fatigue in progressive MS. Secondary objectives evaluated changes in fatigue and oxidative pathway biomarkers on NAC versus placebo.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Individuals with progressive MS with Modified Fatigue Impact Scale (MFIS) &amp;gt; t38 were randomized 2:1 to NAC 1250mg TID or placebo for 4 weeks. The primary outcome was tolerability and safety. The secondary outcome to evaluate efficacy was MFIS change from baseline to week 4 between groups. Exploratory biomarker outcomes included change in blood GSH&#x2F;GSSG ratio (reduced-to-oxidized glutathione (GSH)) and in vivo relative GSH using 7T MR spectroscopy (MRS) between groups. Fisher exact test was used for categorical and rank sum for continuous outcomes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Fifiteen were randomized (10 NAC, 5 placebo; mean age 56.1 years, 80% female, median EDSS 6.0). At least one adverse event (AE) occurred in 60% on NAC versus 80% on placebo (p &#x3D; 0.75). There were two AEs attributed to NAC in one patient (abdominal pain and constipation), with 94% adherence to NAC. MFIS decreased in both groups at week 4, with the mean improvement of 11-points on NAC versus 18-points on placebo (p &#x3D; 0.33). GSH&#x2F;GSSG ratio decreased on placebo (-0.6) and NAC (-0.1) (p &#x3D; 0.18). Change in GSH levels to total creatine in anterior and posterior cingulate cortex, insula, caudate, putamen, and thalamus did not differ between groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTERPRETATION: NAC was well-tolerated in progressive MS, although reduction in fatigue on NAC was similar to placebo. Antioxidant blood and MRS biomarkers were not significantly altered by NAC, which could be due to dose, route of administration, time of sample collection, short half-life, or lack of effect. REGISTERED: clinicaltrials.gov NCT02804594.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675156&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2&quot;&gt;33675156&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51325&gt;10.1002&#x2F;acn3.51325&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33675156&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306091644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":380,"discovery_date":"2021-03-06T12:35:19","title":"Dorsal Hippocampal Actin Polymerization Is Necessary for Activation of G-Protein-Coupled Estrogen Receptor (GPER) to Increase CA1 Dendritic Spine Density and Enhance Memory Consolidation","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;48&#x2F;9598","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":379,"discovery_date":"2021-03-06T12:35:19","title":"White Matter Stroke Induces a Unique Oligo-Astrocyte Niche That Inhibits Recovery","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;47&#x2F;9343","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":378,"discovery_date":"2021-03-06T12:35:19","title":"Autophagy in Myelinating Glia","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2019&#x2F;11&#x2F;19&#x2F;JNEUROSCI.1066-19.2019","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":377,"discovery_date":"2021-03-06T12:35:19","title":"NeuroEVs: Characterizing Extracellular Vesicles Generated in the Neural Domain","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;47&#x2F;9262","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":376,"discovery_date":"2021-03-06T12:35:19","title":"Blocking the Thrombin Receptor Promotes Repair of Demyelinated Lesions in the Adult Brain","summary":"","link":"https://www.jneurosci.org//content/40/7/1483","published_date":"","source":"JNeuroSci","relevant":1,"table_constraints":null},{"article_id":375,"discovery_date":"2021-03-06T12:35:19","title":"Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer&#39;s Disease","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;48&#x2F;9645","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":374,"discovery_date":"2021-03-06T12:35:19","title":"Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;6&#x2F;1176","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":373,"discovery_date":"2021-03-06T12:35:19","title":"Distinct P2Y Receptors Mediate Extension and Retraction of Microglial Processes in Epileptic and Peritumoral Human Tissue","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;7&#x2F;1373","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":372,"discovery_date":"2021-03-06T12:35:19","title":"Meningeal Lymphangiogenesis and Enhanced Glymphatic Activity in Mice with Chronically Implanted EEG Electrodes","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;11&#x2F;2371","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":371,"discovery_date":"2021-03-06T12:35:19","title":"p75NTR and DR6 Regulate Distinct Phases of Axon Degeneration Demarcated by Spheroid Rupture","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;39&#x2F;48&#x2F;9503","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":370,"discovery_date":"2021-03-06T12:35:19","title":"Activated CX3CL1&#x2F;Smad2 signals prevent neuronal loss and Alzheimer&#39;s tau pathology-mediated cognitive dysfunction","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2019&#x2F;12&#x2F;10&#x2F;JNEUROSCI.1333-19.2019","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":369,"discovery_date":"2021-03-06T12:35:19","title":"The Next 50 Years of Neuroscience","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;1&#x2F;101","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":368,"discovery_date":"2021-03-06T12:35:19","title":"Aberrant ER Stress Induced Neuronal-IFNÎ² Elicits White Matter Injury Due to Microglial Activation and T-Cell Infiltration after TBI","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;2&#x2F;424","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":367,"discovery_date":"2021-03-06T12:35:19","title":"Attenuating Neurogenic Sympathetic Hyperreflexia Robustly Improves Antibacterial Immunity After Chronic Spinal Cord Injury","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;2&#x2F;478","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":366,"discovery_date":"2021-03-06T12:35:19","title":"Hippocampal Neurogenesis and Neural Circuit Formation in a Cuprizone-Induced Multiple Sclerosis Mouse Model","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;2&#x2F;447","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":365,"discovery_date":"2021-03-06T12:35:19","title":"Convergence between Microglia and Peripheral Macrophages Phenotype during Development and Neuroinflammation","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;4&#x2F;784","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":364,"discovery_date":"2021-03-06T12:35:19","title":"Short-Chain Fatty Acids Improve Poststroke Recovery via Immunological Mechanisms","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;5&#x2F;1162","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":363,"discovery_date":"2021-03-06T12:35:19","title":"Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;26&#x2F;5105","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":362,"discovery_date":"2021-03-06T12:35:19","title":"Idebenone Has Distinct Effects on Mitochondrial Respiration in Cortical Astrocytes Compared to Cortical Neurons Due to Differential NQO1 Activity","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;23&#x2F;4609","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":361,"discovery_date":"2021-03-06T12:35:19","title":"Actin-Binding Protein Cortactin Promotes Pathogenesis of Experimental Autoimmune Encephalomyelitis by Supporting Leukocyte Infiltration into the Central Nervous System","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;7&#x2F;1389","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":360,"discovery_date":"2021-03-06T12:35:19","title":"Nonionotropic Action of Endothelial NMDA Receptors on BloodâBrain Barrier Permeability via Rho&#x2F;ROCK-Mediated Phosphorylation of Myosin","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;8&#x2F;1778","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":359,"discovery_date":"2021-03-06T12:35:19","title":"Fingolimod rescues demyelination in a mouse model of Krabbe&#39;s disease","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2020&#x2F;02&#x2F;27&#x2F;JNEUROSCI.2346-19.2020","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":358,"discovery_date":"2021-03-06T12:35:19","title":"Granulocyte-Macrophage Colony Stimulating Factor As an Indirect Mediator of Nociceptor Activation and Pain","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;11&#x2F;2189","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":357,"discovery_date":"2021-03-06T12:35:19","title":"Behavioral and Neural Signatures of Working Memory in Childhood","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;26&#x2F;5090","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":356,"discovery_date":"2021-03-06T12:35:19","title":"Interferon-Î² Plays a Detrimental Role in Experimental Traumatic Brain Injury by Enhancing Neuroinflammation That Drives Chronic Neurodegeneration","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;11&#x2F;2357","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":355,"discovery_date":"2021-03-06T12:35:19","title":"Colocalized White Matter Plasticity and Increased Cerebral Blood Flow Mediate the Beneficial Effect of Cardiovascular Exercise on Long-Term Motor Learning","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;12&#x2F;2416","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":354,"discovery_date":"2021-03-06T12:35:19","title":"Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;14&#x2F;2960","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":353,"discovery_date":"2021-03-06T12:35:19","title":"Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during Myelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;15&#x2F;2993","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":352,"discovery_date":"2021-03-06T12:35:19","title":"Deletion of Voltage-Gated Calcium Channels in Astrocytes during Demyelination Reduces Brain Inflammation and Promotes Myelin Regeneration in Mice","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;17&#x2F;3332","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":351,"discovery_date":"2021-03-06T12:35:19","title":"Neonatal Stroke and TLR1&#x2F;2 Ligand Recruit Myeloid Cells through the Choroid Plexus in a CX3CR1-CCR2- and Context-Specific Manner","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;19&#x2F;3849","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":350,"discovery_date":"2021-03-06T12:35:19","title":"Mouse Î³-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;20&#x2F;3896","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":349,"discovery_date":"2021-03-06T12:35:19","title":"Dendritic Spine Dynamics after Peripheral Nerve Injury: An Intravital Structural Study","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;22&#x2F;4297","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":348,"discovery_date":"2021-03-06T12:35:19","title":"Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;23&#x2F;4596","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":347,"discovery_date":"2021-03-06T12:35:19","title":"N-Wasp Regulates Oligodendrocyte Myelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;32&#x2F;6103","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":346,"discovery_date":"2021-03-06T12:35:19","title":"Differential Contribution of Cadm1âCadm3 Cell Adhesion Molecules to Peripheral Myelinated Axons","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;7&#x2F;1393","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":345,"discovery_date":"2021-03-06T12:35:19","title":"The Neuroimmunology of Chronic Pain: From Rodents to Humans","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;5&#x2F;855","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":344,"discovery_date":"2021-03-06T12:35:19","title":"How to Interpret Resting-State fMRI: Ask Your Participants","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;6&#x2F;1130","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":343,"discovery_date":"2021-03-06T12:35:19","title":"NF-ÎºB Activation Accounts for the Cytoprotective Effects of PERK Activation on Oligodendrocytes during EAE","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;33&#x2F;6444","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":342,"discovery_date":"2021-03-06T12:35:19","title":"A Developmental Analysis of Juxtavascular Microglia Dynamics and Interactions with the Vasculature","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;34&#x2F;6503","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":341,"discovery_date":"2021-03-06T12:35:19","title":"Spinal Wnt5a Plays a Key Role in Spinal Dendritic Spine Remodeling in Neuropathic and Inflammatory Pain Models and in the Proalgesic Effects of Peripheral Wnt3a","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;35&#x2F;6664","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":340,"discovery_date":"2021-03-06T12:35:19","title":"The Secreted Glycoprotein Reelin Suppresses the Proliferation and Regulates the Distribution of Oligodendrocyte Progenitor Cells in the Embryonic Neocortex","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;40&#x2F;7625","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":339,"discovery_date":"2021-03-06T12:35:19","title":"Impaired Postnatal Myelination in a Conditional Knockout Mouse for the Ferritin Heavy Chain in Oligodendroglial Cells","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;40&#x2F;7609","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":338,"discovery_date":"2021-03-06T12:35:19","title":"Corticocortical and Thalamocortical Changes in Functional Connectivity and White Matter Structural Integrity after Reward-Guided Learning of Visuospatial Discriminations in Rhesus Monkeys","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;41&#x2F;7887","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":337,"discovery_date":"2021-03-06T12:35:19","title":"Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;44&#x2F;8587","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":336,"discovery_date":"2021-03-06T12:35:19","title":"Ferroptosis Mediates Cuprizone-Induced Loss of Oligodendrocytes and Demyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;48&#x2F;9327","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":335,"discovery_date":"2021-03-06T12:35:19","title":"CREB Coactivator CRTC2 Plays a Crucial Role in Endothelial Function","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;40&#x2F;49&#x2F;9533","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":334,"discovery_date":"2021-03-06T12:35:19","title":"Chronic Pharmacological Increase of Neuronal Activity Improves Sensory-Motor Dysfunction in Spinal Muscular Atrophy Mice","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;2&#x2F;376","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":333,"discovery_date":"2021-03-06T12:35:19","title":"Heparanome-mediated rescue of oligodendrocyte progenitor quiescence following inflammatory demyelination","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;early&#x2F;2021&#x2F;01&#x2F;14&#x2F;JNEUROSCI.0580-20.2021","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":332,"discovery_date":"2021-03-06T12:35:19","title":"Disruption of Conscious Access in Psychosis Is Associated with Altered Structural Brain Connectivity","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;3&#x2F;513","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":331,"discovery_date":"2021-03-06T12:35:19","title":"The Wnt Effector TCF7l2 Promotes Oligodendroglial Differentiation by Repressing Autocrine BMP4-Mediated Signaling","summary":"","link":"https:&#x2F;&#x2F;www.jneurosci.org&#x2F;&#x2F;content&#x2F;41&#x2F;8&#x2F;1650","published_date":"","source":"JNeuroSci","relevant":null,"table_constraints":null},{"article_id":330,"discovery_date":"2021-03-06T12:14:20","title":"CXCL13&#x2F;CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis","summary":"","link":"https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;ebiom&#x2F;article&#x2F;PIIS2352-3964(20)30473-4&#x2F;fulltext","published_date":"","source":"The Lancet","relevant":null,"table_constraints":null},{"article_id":329,"discovery_date":"2021-03-06T11:22:22","title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30342-2/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":328,"discovery_date":"2021-03-06T11:22:22","title":"Incidence of multiple sclerosis in China: A nationwide hospital-based study","summary":"","link":"https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(20)30010-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":327,"discovery_date":"2021-03-06T11:22:22","title":"Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30247-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":326,"discovery_date":"2021-03-06T11:22:22","title":"Catherine Lubetzkiâexpert on remyelination in multiple sclerosis","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30241-6/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":325,"discovery_date":"2021-03-06T11:22:21","title":"hESC-derived immune suppressive dendritic cells induce immune tolerance of parental hESC-derived allografts","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30496-5/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":324,"discovery_date":"2021-03-06T11:22:21","title":"CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30473-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":323,"discovery_date":"2021-03-06T11:22:21","title":"Remyelination in multiple sclerosis: from basic science to clinical translation","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30140-X/fulltext","published_date":"","source":"The Lancet","relevant":1,"table_constraints":null},{"article_id":322,"discovery_date":"2021-03-06T11:22:21","title":"Tolerance-inducing medicines in autoimmunity: rheumatology and beyond","summary":"","link":"https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30100-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":321,"discovery_date":"2021-03-06T11:22:21","title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30432-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":320,"discovery_date":"2021-03-06T11:22:21","title":"Regional and global perspectives on the incidence of multiple sclerosis and neuromyelitis optica and its spectrum disorders from Asia with emphasis on China","summary":"","link":"https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(20)30039-0/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":319,"discovery_date":"2021-03-06T11:22:21","title":"The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017","summary":"","link":"https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30190-0/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":318,"discovery_date":"2021-03-06T11:22:21","title":"Cognition in multiple sclerosis: Charcot was right","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30306-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":317,"discovery_date":"2021-03-06T11:22:21","title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30277-5/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":316,"discovery_date":"2021-03-06T11:22:21","title":"Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?","summary":"","link":"https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30340-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":315,"discovery_date":"2021-03-06T11:22:21","title":"High-dose biotin in multiple sclerosis: the end of the road","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30353-7/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":314,"discovery_date":"2021-03-06T11:22:21","title":"Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30347-1/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":313,"discovery_date":"2021-03-06T11:22:21","title":"Long-term ocrelizumab in progressive multiple sclerosis","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30399-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":312,"discovery_date":"2021-03-06T11:22:21","title":"Are drugs for multiple sclerosis fatigue just placebos?","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30415-4/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":311,"discovery_date":"2021-03-06T11:22:21","title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30354-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":310,"discovery_date":"2021-03-06T11:22:21","title":"Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study","summary":"","link":"https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30362-X/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":309,"discovery_date":"2021-03-06T11:22:21","title":"Multiple sclerosis in 2020: un bon cru","summary":"","link":"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30441-5/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":308,"discovery_date":"2021-03-06T11:22:21","title":"Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00004-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":307,"discovery_date":"2021-03-06T11:22:21","title":"Serum markers of multiple sclerosis - a new approach","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00022-0/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":306,"discovery_date":"2021-03-06T11:22:21","title":"Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor","summary":"","link":"https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00020-7/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":305,"discovery_date":"2021-03-06T11:22:21","title":"Established and novel therapeutic options for autoimmune hepatitis","summary":"","link":"https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30328-9/fulltext","published_date":"","source":"The Lancet","relevant":"","table_constraints":null},{"article_id":304,"discovery_date":"2021-03-06T11:06:13","title":"Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction?","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S1677-55382020000600891&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":303,"discovery_date":"2021-03-06T11:06:13","title":"Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001100741&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":302,"discovery_date":"2021-03-06T11:06:13","title":"Telemedicine in neurology: current evidence","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001200818&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":301,"discovery_date":"2021-03-06T11:06:13","title":"Neurobiology of COVID-19: how can the virus affect the brain?","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S1516-44462021005003203&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":300,"discovery_date":"2021-03-06T11:06:13","title":"Decreased levels of interleukin 27 in the serum of vitiligo patients,","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0365-05962020000500570&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":299,"discovery_date":"2021-03-06T11:06:13","title":"Qualitative and Quantitative Ultrastructural Analysis of the Mitochondria from Adrenal Gland Cortex Under the Action of Viperidae family Snake Venoms","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022020000501271&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":298,"discovery_date":"2021-03-06T11:06:13","title":"The Modified Method of Luxol Fast Blue for Paraffin-Embedded Myelin Sheath Staining","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022020000501197&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":297,"discovery_date":"2021-03-06T11:06:13","title":"Altered Oligodendrocytes in Spinal Enlargements of Streptozotocin Diabetic Rats","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022020000601606&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":296,"discovery_date":"2021-03-06T11:06:13","title":"Cobalt deficiency in cattle and its impact on production","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0100-736X2020001100837&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":295,"discovery_date":"2021-03-06T11:06:13","title":"Restless legs syndrome&#x2F;Willis-Ekbom disease in multiple sclerosis: a contributing factor for anxiety, disability, sleep disorder, and quality of life","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001100708&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":294,"discovery_date":"2021-03-06T11:06:13","title":"Differentiation of relapsing-remitting and secondary progressive multiple sclerosis: a magnetic resonance spectroscopy study based on machine learning","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001200789&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":293,"discovery_date":"2021-03-06T11:06:13","title":"Acute Disseminated Encephalomyelitis in COVID-19: presentation of two cases and review of the literature","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0004-282X2020001200805&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":292,"discovery_date":"2021-03-06T11:06:13","title":"Probabilistic Multiple Sclerosis Lesion Detection using Superpixels and Markov Random Fields","summary":"","link":"http:&#x2F;&#x2F;www.scielo.org.mx&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0188-95322020000300102&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":291,"discovery_date":"2021-03-06T11:06:13","title":"Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments","summary":"","link":"http:&#x2F;&#x2F;www.scielo.br&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0100-879X2021000300602&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":290,"discovery_date":"2021-03-06T11:06:13","title":"Ultrastructural Clarification of the Peripherally Located Actin Network in the Myelinated Axons","summary":"","link":"http:&#x2F;&#x2F;www.scielo.cl&#x2F;scielo.php?script&#x3D;sci_arttext&amp;pid&#x3D;S0717-95022021000100179&amp;lang&#x3D;en","published_date":"","source":"Scielo","relevant":null,"table_constraints":null},{"article_id":289,"discovery_date":"2021-03-06T10:52:00","title":"Exercise therapy for multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;14622","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":288,"discovery_date":"2021-03-06T10:52:00","title":"Identification and management of depression in multiple sclerosisSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;46271","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":287,"discovery_date":"2021-03-06T10:52:00","title":"Multiple sclerosis: management of multiple sclerosis in primary and secondary care: full guideline (CG186)Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;42404","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":286,"discovery_date":"2021-03-06T10:52:00","title":"Effectiveness of physical therapy interventions in reducing fear of falling among individuals with neurological diseases: a systematic review and meta-analysisSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;61919","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":285,"discovery_date":"2021-03-06T10:52:00","title":"Which behavioural and exercise interventions targeting fatigue show the most promise in multiple sclerosis? A systematic review with narrative synthesis and meta-analysis [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;59262","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":284,"discovery_date":"2021-03-06T10:52:00","title":"Occupational therapy for multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;9626","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":283,"discovery_date":"2021-03-06T10:52:00","title":"Treatment for ataxia in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;17698","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":282,"discovery_date":"2021-03-06T10:52:00","title":"Multidisciplinary rehabilitation for adults with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;18223","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":281,"discovery_date":"2021-03-06T10:52:00","title":"Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;22189","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":280,"discovery_date":"2021-03-06T10:52:00","title":"Whole-body vibration training for patients with neurodegenerative disease (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;30992","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":279,"discovery_date":"2021-03-06T10:52:00","title":"Non pharmacological interventions for spasticity in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;34946","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":278,"discovery_date":"2021-03-06T10:52:00","title":"Exercise therapy for fatigue in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;43790","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":277,"discovery_date":"2021-03-06T10:52:00","title":"Telerehabilitation for persons with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;42483","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":276,"discovery_date":"2021-03-06T10:52:00","title":"Respiratory muscle training for multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;52008","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":275,"discovery_date":"2021-03-06T10:52:00","title":"Non-pharmacological interventions for chronic pain in multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;55880","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":274,"discovery_date":"2021-03-06T10:52:00","title":"Interventions for preventing falls in people with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;59246","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":273,"discovery_date":"2021-03-06T10:52:00","title":"Palliative care interventions for people with multiple sclerosis (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;58944","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":272,"discovery_date":"2021-03-06T10:52:00","title":"Rehabilitation for people with multiple sclerosis: an overview of Cochrane reviews (Cochrane review) [with consumer summary]Select","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;56062","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":271,"discovery_date":"2021-03-06T10:52:00","title":"EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;25074","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":270,"discovery_date":"2021-03-06T10:52:00","title":"Nursing management of the patient with multiple sclerosisSelect","summary":"","link":"https:&#x2F;&#x2F;search.pedro.org.au&#x2F;search-results&#x2F;record-detail&#x2F;33859","published_date":"","source":"PEDro","relevant":null,"table_constraints":null},{"article_id":269,"discovery_date":"2021-03-06T10:36:00","title":"18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study","summary":"Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting tha...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02460-8","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":268,"discovery_date":"2021-03-06T10:36:00","title":"Zygomatic implant penetration to the central portion of orbit: a case report","summary":"Zygomatic implants have been proposed in literature for atrophic maxillary fixed oral rehabilitations. The aim of the present research was to evaluate, by a clinical and tomography assessment, a surgical compl...","link":"https:&#x2F;&#x2F;bmcophthalmol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12886-021-01846-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":267,"discovery_date":"2021-03-06T10:18:24","title":"Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016â2020","summary":"Little attention has been paid to customising fatigue questionnaires for patients with Substance Use Disorders (SUDs). The present study aims to validate and shorten the nine-item Fatigue Severity Scale (FSS-9...","link":"https:&#x2F;&#x2F;hqlo.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12955-021-01708-w","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":266,"discovery_date":"2021-03-06T10:18:24","title":"","summary":"","link":"https:","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":265,"discovery_date":"2021-03-06T10:18:24","title":"Juvenile primary Fibromyalgia Syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis","summary":"Juvenile primary fibromyalgia syndrome (JPFS) is a chronic, musculoskeletal pain syndrome affecting children and adolescents, most commonly adolescent girls. The syndrome has a multifactorial etiology, with al...","link":"https:&#x2F;&#x2F;ped-rheum.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12969-021-00493-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":264,"discovery_date":"2021-03-06T10:18:24","title":"Consistency and applicability of different brief screen instrument of cognitive function in elderly population","summary":"Screening for cognitive impairment (CI) is often hampered by lack of consensus as to which screening instrument to use. The aim is to assess the consistence and applicability of different CI screening tools.","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02048-4","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":263,"discovery_date":"2021-03-06T10:18:24","title":"Outcomes of intra-articular calcaneal fractures: surgical treatment of 114 consecutive cases at a maximum care trauma center","summary":"The aim of this retrospective monocentric study was to investigate the outcomes of surgically treated intra-articular calcaneus fractures in a maximum care trauma center.","link":"https:&#x2F;&#x2F;bmcmusculoskeletdisord.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12891-021-04088-w","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":262,"discovery_date":"2021-03-06T10:18:24","title":"Association of CSF proteins with tau and amyloid Î² levels in asymptomatic 70-year-olds","summary":"Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimerâs disease (AD) is important for the understanding of disease pathophysiology and also crucial to be ab...","link":"https:&#x2F;&#x2F;alzres.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13195-021-00789-5","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":261,"discovery_date":"2021-03-06T10:18:24","title":"Knockdown of Circ_SLC39A8 protects against the progression of osteoarthritis by regulating miR-591&#x2F;IRAK3 axis","summary":"The dysregulation of circular RNAs (circRNAs) has been identified in various human diseases, including osteoarthritis (OA). The purpose of this study was to identify the role and mechanism of circ_SLC39A8 in r...","link":"https:&#x2F;&#x2F;josr-online.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13018-021-02323-7","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":260,"discovery_date":"2021-03-06T10:18:24","title":"Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction","summary":"Physiological disturbances in cortical network excitability and plasticity are established and widespread in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those harb...","link":"https:&#x2F;&#x2F;molecularneurodegeneration.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13024-021-00433-8","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":259,"discovery_date":"2021-03-06T10:18:24","title":"An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer","summary":"Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1&#x2F;2 (gBRCA1&#x2F;2) mutations, and efforts to expand the utility of PARPi beyond BRCA1&#x2F;2 are ongoing. In preclin...","link":"https:&#x2F;&#x2F;breast-cancer-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13058-021-01408-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":258,"discovery_date":"2021-03-06T10:18:24","title":"Case report: exome sequencing achieved a definite diagnosis in a Chinese family with muscle atrophy","summary":"Due to large genetic and phenotypic heterogeneity, the conventional workup for Charcot-Marie-Tooth (CMT) diagnosis is often underpowered, leading to diagnostic delay or even lack of diagnosis. In the present s...","link":"https:&#x2F;&#x2F;bmcneurol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12883-021-02093-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":257,"discovery_date":"2021-03-06T10:18:24","title":"The effects of vitamin D3 supplementation on TGF-Î² and IL-17 serum levels in migraineurs: post hoc analysis of a randomized clinical trial","summary":"Although the exact mechanism involved in migraine pathogenesis remained uncertain, and different researches have been developed to address the role of neuroinflammation and immune dysfunction. Therefore, consi...","link":"https:&#x2F;&#x2F;jphcs.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40780-021-00192-0","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":256,"discovery_date":"2021-03-06T10:18:24","title":"Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)","summary":"Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a sho...","link":"https:&#x2F;&#x2F;arthritis-research.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13075-021-02454-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":255,"discovery_date":"2021-03-06T10:18:24","title":"Pien Tze Huang (PZH) as a Multifunction Medicinal Agent in Traditional Chinese Medicine (TCM): a review on cellular, molecular and physiological mechanisms","summary":"Pien Tze Huang (PZH) is a well-known Traditional Chinese Medicine (TCM), characterized by a multitude of pharmacological effects, such as hepatoprotection and inhibition of inflammation and cell proliferative ...","link":"https:&#x2F;&#x2F;cancerci.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12935-021-01785-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":254,"discovery_date":"2021-03-06T10:18:24","title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?","summary":"Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, ...","link":"https:&#x2F;&#x2F;ojrd.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13023-021-01758-9","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":253,"discovery_date":"2021-03-06T10:18:23","title":"seqQscorer: automated quality control of next-generation sequencing data using machine learning","summary":"Controlling quality of next-generation sequencing (NGS) data files is a necessary but complex task. To address this problem, we statistically characterize common NGS quality features and develop a novel qualit...","link":"https:&#x2F;&#x2F;genomebiology.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13059-021-02294-2","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":252,"discovery_date":"2021-03-06T10:18:23","title":"Pre-implantation exogenous progesterone and pregnancy in sheep: I. polyamines, nutrient transport, and progestamedins","summary":"Administration of exogenous progesterone (P4) to ewes during the pre-implantation period advances conceptus development and implantation. This study determined effects of exogenous P4 on transport of select nu...","link":"https:&#x2F;&#x2F;jasbsci.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s40104-021-00554-6","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":251,"discovery_date":"2021-03-06T10:18:23","title":"Eye Movement Desensitization (EMD) to reduce posttraumatic stress disorder-related stress reactivity in Indonesia PTSD patients: a study protocol for a randomized controlled trial","summary":"Posttraumatic stress disorder (PTSD) may develop after exposure to a traumatic event. Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based psychological treatment for PTSD. It is yet uncle...","link":"https:&#x2F;&#x2F;trialsjournal.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s13063-021-05100-3","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":250,"discovery_date":"2021-03-06T10:18:23","title":"Clinical utility of cerebrospinal fluid vitamin D-binding protein as a novel biomarker for the diagnosis of viral and bacterial CNS infections","summary":"Rapid and accurate diagnosis of central nervous system (CNS) infections is important, and laboratory tests help diagnose CNS infections. Even when the patient has symptoms, laboratory tests often do not reveal...","link":"https:&#x2F;&#x2F;bmcinfectdis.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12879-021-05924-z","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":249,"discovery_date":"2021-03-06T10:18:23","title":"Renal transplantation outcomes in obese patients: a French cohort-based study","summary":"Whilst there are a number of publications comparing the relationship between body mass index (BMI) of kidney transplant recipients and graft&#x2F;patient survival, no study has assessed this for a French patient co...","link":"https:&#x2F;&#x2F;bmcnephrol.biomedcentral.com&#x2F;articles&#x2F;10.1186&#x2F;s12882-021-02278-1","published_date":"","source":"BioMedCentral","relevant":null,"table_constraints":null},{"article_id":248,"discovery_date":"2021-03-06T10:16:45","title":"The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Biomed Pharmacother. 2021 Mar 2;138:111428. doi: 10.1016&#x2F;j.biopha.2021.111428. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In an ageing society, neurodegenerative diseases have attracted attention because of their high incidence worldwide. Despite extensive research, there is a lack of conclusive insights into the pathogenesis of neurodegenerative diseases, which limit the strategies for symptomatic treatment. Therefore, better elucidation of the molecular mechanisms involved in neurodegenerative diseases can provide an important theoretical basis for the discovery of new and effective prevention and treatment methods. The innate immune system is activated during the ageing process and in response to neurodegenerative diseases. Inflammasomes are multiprotein complexes that play an important role in the activation of the innate immune system. They mediate inflammatory reactions and pyroptosis, which are closely involved in neurodegeneration. There are different types of inflammasomes, although the nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is the most common inflammasome; NLRP3 plays an important role in the pathogenesis of neurodegenerative diseases. In this review, we will discuss the mechanisms that are involved in the activation of the NLRP3 inflammasome and its crucial role in the pathology of neurodegenerative disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis and multiple sclerosis. We will also review various treatments that target the NLRP3 inflammasome pathway and alleviate neuroinflammation. Finally, we will summarize the novel treatment strategies for neurodegenerative disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33667787&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306051644&amp;v&#x3D;2.14.2&quot;&gt;33667787&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.biopha.2021.111428&gt;10.1016&#x2F;j.biopha.2021.111428&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33667787&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210306051644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":247,"discovery_date":"2021-03-06T00:56:45","title":"Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurovirol. 2021 Mar 5. doi: 10.1007&#x2F;s13365-021-00951-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Given the complexity of immune complex diseases including multiple sclerosis (MS) and the plausible interactions between different risk factors, delineating the interplay between them would be imperative. The current study aimed to evaluate the in vitro effects of Epstein-Barr virus (EBV) and vitamin D on immune response in MS patients and healthy controls. The status of vitamin D and EBV load was evaluated using multiple techniques. In vitro EBV-infected peripheral blood mononuclear cells (PBMCs), in the presence or absence of vitamin D, were checked for IL-10, IFN-Î³, and vitamin D receptor. MS patients showed significantly higher plasma levels of 1,25-(OH)2D but not 25-OHD, increased EBV load, and lower levels of vitamin D receptor (VDR) expression compared with healthy controls. Interestingly, an inverse correlation was observed between VDR expression and EBV load in PBMCs. Indeed, the levels of IFN-Î³ and IL-10 production were significantly higher in supernatant collected from in vitro EBV-infected PBMCs in MS patients compared with controls. While all vitamin D-treated PBMCs showed reduced levels of IFN-Î³ production, in vitro treatment of vitamin D showed no influence in IL-10 production. EBV and vitamin D were found to exert opposite in vitro effects on immune dysregulation in these patients. Our results highlight the complex interactions of different risk factors with immune system.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2&quot;&gt;33666884&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s13365-021-00951-7&gt;10.1007&#x2F;s13365-021-00951-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666884&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":246,"discovery_date":"2021-03-06T00:56:45","title":"Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Drug Saf. 2021 Mar 5. doi: 10.1007&#x2F;s40264-021-01057-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions; however, safety concerns have arisen.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective of this systematic review was to investigate the safety profile of S1P modulators in patients with multiple sclerosis, ulcerative colitis, Crohn&#39;s disease, psoriasis, and systemic lupus erythematosus.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1 January, 1990 through 1 April, 2020. We also performed a manual review of conference databases from 2017 through 2020. The primary outcome was the occurrence of adverse events and serious adverse events. We also estimated the occurrence of serious infections, herpes zoster infection, malignancy, bradycardia, atrio-ventricular block, and macular edema. We performed a meta-analysis of controlled studies to assess the risks of such events.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We identified 3843 citations; of these, 26 studies were finally included, comprising 9604 patients who were exposed to a sphingosine-1-phosphate modulator. A meta-analysis of randomized controlled trials showed an increased risk in herpes zoster infection [risk ratio, 1.75 (95% confidence interval 1.09-2.80)], bradycardia [2.64 (1.77-3.96)], and atrio-ventricular block [1.73 (1.03-2.91)] among subjects exposed to sphingosine-1-phosphate modulators as compared with a placebo or an active comparator.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLINICAL TRIAL REGISTRATION: PROSPERO CRD42020172575.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2&quot;&gt;33666900&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s40264-021-01057-z&gt;10.1007&#x2F;s40264-021-01057-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305195644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":245,"discovery_date":"2021-03-05T23:50:03","title":"Berg Balance Scale (BBS) for Multiple Sclerosis (MS)","summary":"Berg Balance Scale for Multiple Sclerosis","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/berg-balance-scale-bbs-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":244,"discovery_date":"2021-03-05T23:50:03","title":"Multiple Sclerosis (MS) Functional Composite (MSFC) ","summary":"Measures limitations and unidimensionality of prior existing functional status outcomes such as the Expanded Disability Status Scale (EDSS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/multiple-sclerosis-ms-functional-composite-msfc-","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":243,"discovery_date":"2021-03-05T23:50:03","title":"Expanded Disability Status Scale (EDSS) for Multiple Sclerosis (MS)","summary":"Measures neurologic evaluation of multiple sclerosis (MS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/expanded-disability-status-scale-edss-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":242,"discovery_date":"2021-03-05T23:50:03","title":"Rivermead Mobility Index for Multiple Sclerosis (MS)","summary":"Target population: People with multiple sclerosis (MS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/rivermead-mobility-index-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":241,"discovery_date":"2021-03-05T23:50:03","title":"Multiple Sclerosis (MS) Quality of Life Inventory ","summary":"Measures fatigue, pain, gait, quality of life, role function, social function.","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/multiple-sclerosis-ms-quality-of-life-inventory-","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":240,"discovery_date":"2021-03-05T23:50:03","title":"Hauser Ambulation Index for Multiple Sclerosis","summary":"Target population: People with multiple sclerosis (MS).","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/hauser-ambulation-index-for-multiple-sclerosis","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":239,"discovery_date":"2021-03-05T23:50:03","title":"Functional Reach Test for Multiple Sclerosis (MS)","summary":"Functional Reach Test for Multiple Sclerosis (MS)","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/functional-reach-test-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":238,"discovery_date":"2021-03-05T23:50:03","title":"Activities-specific Balance Confidence (ABC) Scale for Multiple Sclerosis (MS) ","summary":"A 16-item self-report measure in which patients rate their balance confidence in performing several activities.","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/activities-specific-balance-confidence-abc-scale-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":237,"discovery_date":"2021-03-05T23:50:03","title":"Four Square Step Test (FSST) for Multiple Sclerosis (MS)","summary":"Four Square Step Test (FSST) for Multiple Sclerosis (MS)","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/four-square-step-test-fsst-for-multiple-sclerosis-ms","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":236,"discovery_date":"2021-03-05T23:50:03","title":"Multiple Sclerosis in Adults: Management [NICE CG186]","summary":"This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over and aims to improve the quality of life for adults with multiple sclerosis.","link":"https://www.apta.org/patient-care/evidence-based-practice-resources/cpgs/multiple-sclerosis-in-adults-management-nice-cg186","published_date":"","source":"APTA","relevant":"","table_constraints":null},{"article_id":235,"discovery_date":"2021-03-05T18:56:46","title":"What is the evidence that mycobacteria are associated with the pathogenesis of Sjogren&#39;s syndrome?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Transl Autoimmun. 2021 Feb 5;4:100085. doi: 10.1016&#x2F;j.jtauto.2021.100085. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Sjogren&#39;s syndrome (SS) is a common, systemic autoimmune disorder primarily affecting the exocrine glands resulting in xerostomia and xerophthalmia. SS may also manifest with polyarthralgia, polyarthritis, polymyalgia, cutaneous&#x2F;other organ vasculitis, interstitial lung disease, and&#x2F;or various other disorders. The primary autoantibodies associated with SS and used as adjuncts to diagnosis are anti-Ro (SSA) and anti-La (SSB). The pathogenesis of SS is considered to involve genetic susceptibility and environmental triggers. An identified genetic susceptibility for SS lies in variants of the tumor necrosis factor alpha inducible protein 3 (&lt;i&gt;TNFAIP3&lt;&#x2F;i&gt;) gene, the product of which is known as A20. Deficiency or dysfunction of A20 is known to induce macrophage inflammatory response to mycobacteria, potentially increasing the repertoire of mycobacterial antigens available and predisposing to autoimmunity &lt;i&gt;via&lt;&#x2F;i&gt; the paradigm of molecular mimicry; &lt;i&gt;i.e.&lt;&#x2F;i&gt;, providing a mechanistic link between genetic susceptibility to SS and exposure to environmental non-tuberculous mycobacteria (NTM). &lt;i&gt;Mycobacterium avium&lt;&#x2F;i&gt; ss. &lt;i&gt;paratuberculosis&lt;&#x2F;i&gt; (&lt;i&gt;MAP&lt;&#x2F;i&gt;) is an NTM that causes Johne&#39;s disease, an enteritis of ruminant animals. Humans are broadly exposed to &lt;i&gt;MAP&lt;&#x2F;i&gt; or its antigens in the environment and in food products from infected animals. &lt;i&gt;MAP&lt;&#x2F;i&gt; has also been implicated as an environmental trigger for a number of autoimmune diseases &lt;i&gt;via&lt;&#x2F;i&gt; cross reactivity of its heat shock protein 65 (hsp65) with host-specific proteins. In the context of SS, mycobacterial hsp65 shares epitope homology with the Ro and La proteins. A recent study showed a strong association between SS and antibodies to mycobacterial hsp65. If and when this association is validated, it would be important to determine whether bacillus Calmette-Guerin (BCG) vaccination (known to be protective against NTM likely through epigenetic alteration of innate and adaptive immunity) and anti-mycobacterial drugs (to decrease mycobacterial antigenic load) may have a preventive or therapeutic role against SS. Evidence to support this concept is that BCG has shown benefit in type 1 diabetes mellitus and multiple sclerosis, autoimmune diseases that have been linked to &lt;i&gt;MAP via&lt;&#x2F;i&gt; hsp65 and disease-specific autoantibodies. In conclusion, a number of factors lend credence to the notion of a pathogenic link between environmental mycobacteria and SS, including the presence of antibodies to mycobacterial hsp65 in SS, the homology of hsp65 with SS autoantigens, and the beneficial effects seen with BCG vaccination against certain autoimmune diseases. Furthermore, given that BCG may protect against NTM, has immune modifying effects, and has a strong safety record of billions of doses given, BCG and&#x2F;or anti-mycobacterial therapeutics should be studied in SS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665595&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33665595&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7902540&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;PMC7902540&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jtauto.2021.100085&gt;10.1016&#x2F;j.jtauto.2021.100085&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665595&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":234,"discovery_date":"2021-03-05T18:56:46","title":"Cardiac autonomic function in patients with early multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Auton Res. 2021 Mar 4. doi: 10.1007&#x2F;s10286-021-00790-w. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Cardiac autonomic dysfunction has been reported in patients with long-standing multiple sclerosis (MS); however, data in early disease are limited. The present study was aimed at evaluating cardiac autonomic function in patients with early MS in the context of white matter metabolic status, which could potentially affect functions of the autonomic brain centers.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Cardiac sympathetic and baroreflex cardiovagal responses to the Valsalva maneuver, orthostatic test, and the Stroop test were evaluated in 16 early, treatment-naÃ¯ve patients with relapsing-remitting MS, and in 14 healthy participants. Proton magnetic resonance spectroscopic imaging (MRSI) of the brain was performed in eight of these MS patients and in eight controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Valsalva maneuver outcomes were comparable between patients and controls. At baseline, norepinephrine levels were lower (p &#x3D; 0.027) in MS patients compared to controls. The patients had higher heart rate (p &#x3D; 0.034) and lower stroke volume (p &#x3D; 0.008), but similar blood pressure, cardiac output and norepinephrine increments from baseline to 2 min of the orthostatic test compared to controls. MS patients and controls did not differ in responses to the Stroop test. MRSI showed lower total N-acetylaspartate&#x2F;total creatine (p &#x3D; 0.038) and higher myo-inositol&#x2F;total creatine (p &#x3D; 0.013) in MS lesions compared to non-lesional white matter.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our results show normal cardiac sympathetic and baroreflex cardiovagal function in MS patients with relapsing-remitting MS with lesions at the post-acute&#x2F;early resolving stage.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov under the Identifier: NCT03052595 and complies with the STROBE checklist for cohort, case-control, and cross-sectional studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665745&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33665745&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10286-021-00790-w&gt;10.1007&#x2F;s10286-021-00790-w&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33665745&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":233,"discovery_date":"2021-03-05T18:56:46","title":"Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177&#x2F;1352458521993070. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rarely recognized hyperinflammatory condition of high death risk.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The objective was to describe a case of HLH in a patient with multiple sclerosis (MS) treated with ocrelizumab.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Clinical observation, laboratory testing, and use of HLH-2004 criteria for HLH diagnosis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A 32-year-old Caucasian female developed HLH during ocrelizumab treatment. She met six of the eight HLH criteria including fever, splenomegaly, cytopenia, hypertriglyceridemia and hypofibrinogenemia, high serum ferritin level, and low natural killer (NK) cells.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: HLH should be considered in the differential diagnosis in MS patients displaying a fever and malaise syndrome following administration of ocrelizumab.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33666121&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521993070&gt;10.1177&#x2F;1352458521993070&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666121&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":232,"discovery_date":"2021-03-05T18:56:46","title":"Functional correlates of motor control impairments in multiple sclerosis: A 7 Tesla task functional MRI study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Hum Brain Mapp. 2021 Mar 5. doi: 10.1002&#x2F;hbm.25389. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Upper and lower limb impairments are common in people with multiple sclerosis (pwMS), yet difficult to clinically identify in early stages of disease progression. Tasks involving complex motor control can potentially reveal more subtle deficits in early stages, and can be performed during functional MRI (fMRI) acquisition, to investigate underlying neural mechanisms, providing markers for early motor progression. We investigated brain activation during visually guided force matching of hand or foot in 28 minimally disabled pwMS (Expanded Disability Status Scale (EDSS) &amp;lt; 4 and pyramidal and cerebellar Kurtzke Functional Systems Scores â¤ 2) and 17 healthy controls (HC) using ultra-high field 7-Tesla fMRI, allowing us to visualise sensorimotor network activity in high detail. Task activations and performance (tracking lag and error) were compared between groups, and correlations were performed. PwMS showed delayed (+124 s, p &#x3D; .002) and more erroneous (+0.15 N, p &#x3D; .001) lower limb tracking, together with lower cerebellar, occipital and superior parietal cortical activation compared to HC. Lower activity within these regions correlated with worse EDSS (p &#x3D; .034), lower force error (p &#x3D; .006) and higher lesion load (p &amp;lt; .05). Despite no differences in upper limb task performance, pwMS displayed lower inferior occipital cortical activation. These results demonstrate that ultra-high field fMRI during complex hand and foot tracking can identify subtle impairments in lower limb movements and upper and lower limb brain activity, and differentiates upper and lower limb impairments in minimally disabled pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666314&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2&quot;&gt;33666314&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;hbm.25389&gt;10.1002&#x2F;hbm.25389&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33666314&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":231,"discovery_date":"2021-03-05T13:36:45","title":"Multiple sclerosis, B cell therapy, and the COVID-19 vaccine","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;eNeurologicalSci. 2021 Mar;22:100319. doi: 10.1016&#x2F;j.ensci.2021.100319. Epub 2021 Jan 21.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33521339&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305083644&amp;v&#x3D;2.14.2&quot;&gt;33521339&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7826102&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305083644&amp;v&#x3D;2.14.2&quot;&gt;PMC7826102&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.ensci.2021.100319&gt;10.1016&#x2F;j.ensci.2021.100319&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33521339&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305083644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":230,"discovery_date":"2021-03-05T12:16:45","title":"Imperative role of glycosylation in human MOG-HLA interaction: molecular insights of MOG-Ab associated demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Biomol Struct Dyn. 2021 Mar 4:1-11. doi: 10.1080&#x2F;07391102.2021.1893816. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Myelin oligodendrocyte glycoprotein is a transmembrane protein found on the outer lamella of the myelin sheath. The autoimmune attack on the MOG leads to demyelination which differs from normal multiple sclerosis. MOG has three epitope regions MOG&lt;sub&gt;1-22&lt;&#x2F;sub&gt;, MOG&lt;sub&gt;35-55&lt;&#x2F;sub&gt;, and MOG&lt;sub&gt;92-106&lt;&#x2F;sub&gt; in the extracellular region, and the crucial MOG&lt;sub&gt;35-55&lt;&#x2F;sub&gt; epitope and Human Leukocyte Antigen (HLA) interaction is the initial step for autoantibody generation. To study the effective role of glycosylation in MOG-HLA interaction, we performed molecular dynamics simulations of the complex where HLA interacts with three MOG epitopes both in the absence and presence of glycan. The results projected that the epitope MOG&lt;sub&gt;1-22&lt;&#x2F;sub&gt; is decisive for the HLA interaction in the absence of glycan and HLA interacts with the epitope MOG&lt;sub&gt;35-55&lt;&#x2F;sub&gt; irrespective of glycan existence. The residues Arg9, Arg46, and Arg66 were found to interact strongly with HLA even in the presence of glycan. The glycan increased the flexibility of hMOG and enhanced the interaction of MOG with water molecules.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33663341&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2&quot;&gt;33663341&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;07391102.2021.1893816&gt;10.1080&#x2F;07391102.2021.1893816&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33663341&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":229,"discovery_date":"2021-03-05T12:16:45","title":"Associations of serum short-chain fatty acids with circulating immune cells and serum biomarkers in patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Mar 4;11(1):5244. doi: 10.1038&#x2F;s41598-021-84881-8.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Altered composition of gut bacteria and changes to the production of their bioactive metabolites, the short-chain fatty acids (SCFAs), have been implicated in the development of multiple sclerosis (MS). However, the immunomodulatory actions of SCFAs and intermediaries in their ability to influence MS pathogenesis are uncertain. In this study, levels of serum SCFAs were correlated with immune cell abundance and phenotype as well as with other relevant serum factors in blood samples taken at first presentation of Clinically Isolated Syndrome (CIS; an early form of MS) or MS and compared to healthy controls. There was a small but significant reduction in propionate levels in the serum of patients with CIS or MS compared with healthy controls. The frequencies of circulating T follicular regulatory cells and T follicular helper cells were significantly positively correlated with serum levels of propionate. Levels of butyrate associated positively with frequencies of IL-10-producing B-cells and negatively with frequencies of class-switched memory B-cells. TNF production by polyclonally-activated B-cells correlated negatively with acetate levels. Levels of serum SCFAs associated with changes in circulating immune cells and biomarkers implicated in the development of MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33664396&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2&quot;&gt;33664396&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-84881-8&gt;10.1038&#x2F;s41598-021-84881-8&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33664396&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":228,"discovery_date":"2021-03-05T06:56:45","title":"The distinct roles of monoamines in multiple sclerosis: a bridge between the immune and nervous systems?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Behav Immun. 2021 Mar 1:S0889-1591(21)00095-7. doi: 10.1016&#x2F;j.bbi.2021.02.030. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The monoaminergic neurotransmitters dopamine, noradrenaline, and serotonin are pivotal actors of the interplay between the nervous and the immune system due to their ability of binding to cell-receptors of both systems, crucially regulating their function within the central nervous system and the periphery. As monoamines are dysfunctional in many neurological and psychiatric diseases, they have been successfully used as pharmacological targets. Multiple sclerosis (MS) is one of the best examples of neurological disease caused by an altered interaction between the nervous and immune system and emerging evidence supports a dysregulation of monoaminergic systems in the pathogenesis of MS, secondary to both inflammation-induced reduction of monoamines&#39; synthesis and structural damage to monoaminergic pathways within the brain. Here we review the evidence for monoamines being key mediators of neuroimmune interaction, affecting MS pathogenesis and course. Moreover, we discuss how the reduction&#x2F;dysfunction of monoamines in MS may contribute to some clinical features typical of the disease, particularly fatigue and depression. Finally, we summarize different drugs targeting monoamines that are currently under evaluation for their potential efficacy to treat MS, as well as to alleviate fatigue and depression in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662501&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662501&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.bbi.2021.02.030&gt;10.1016&#x2F;j.bbi.2021.02.030&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662501&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":227,"discovery_date":"2021-03-05T06:56:45","title":"Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102856. doi: 10.1016&#x2F;j.msard.2021.102856. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The COVID-19 pandemic has raised concerns for increased risk of infection in patients with multiple sclerosis (MS) and disrupted their routine MS care. The aim of this study is to characterize the extent of MS patients&#39; perceptions of risk and adherence to care during the pandemic.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A survey was emailed to patients from a large MS center in New York City during the local peak of the pandemic to assess perceptions of infection risk and adherence to MS care including appointments, laboratory studies, MRIs, and taking disease-modifying therapies (DMT).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 529 patients from the MS center responded to the survey during two weeks in April 2020. Patients collectively showed concern about becoming infected with COVID-19 (88%) and perceived a higher infection risk due of having MS (70%) and taking DMTs (68%). Patients frequently postponed appointments (41%), laboratory studies (46%), and MRIs (41%). Noncompliance with DMTs was less common (13%). Decisions to alter usual recommendations for care were made by the patient more often than by the provider regarding adherence to appointments (68%), laboratory studies (70%), MRI (67%), and DMT (65%). Degree of concern for infection was associated with adherence to appointments (p&#x3D;0.020) and laboratory studies (p&#x3D;0.016) but not with adherence to MRI and DMTs. Thirty-five patients reported being tested for COVID-19, of whom fourteen reported a positive test.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients with MS were highly concerned about becoming infected during the local peak of the COVID-19 pandemic. Behaviors that deviated from originally recommended MS care were common and often self-initiated, but patients were overall compliant with continuing DMTs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662858&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662858&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102856&gt;10.1016&#x2F;j.msard.2021.102856&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662858&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":226,"discovery_date":"2021-03-05T06:56:45","title":"COVID-19 in a temporal relation to the onset of multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 24;50:102863. doi: 10.1016&#x2F;j.msard.2021.102863. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurological complications of COVID-19 have been described. We present the case of a 27-year-old woman who developed COVID-19 in April 2020. She continued to present anosmia and ageusia eight months later. Six months after contracting COVID-19, she developed dysesthesia, hypoesthesia and hyperreflexia. Her magnetic resonance imaging showed demyelinating lesions, of which two were enhanced by gadolinium. She was positive for oligoclonal bands in her spinal fluid. This patient developed multiple sclerosis with a temporal relationship to COVID-19. We believe that SARS-CoV-2 led to her autoimmune disease through a virus-induced neuroimmunopathological condition.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662859&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662859&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102863&gt;10.1016&#x2F;j.msard.2021.102863&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662859&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":225,"discovery_date":"2021-03-05T06:56:45","title":"Multiple Sclerosis and Incidence of Urinary and Fecal Incontinence in Almost 9,000 Patients Followed Up for up to 10 Years in Germany","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroepidemiology. 2021 Mar 4:1-8. doi: 10.1159&#x2F;000513234. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: There is a lack of large studies on urinary (UI) and fecal incontinence (FI) following multiple sclerosis (MS) diagnosis. Thus, our goal was to investigate the association between MS and the incidence of UI and FI in patients followed up for up to 10 years in Germany.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This study included patients who received an initial documentation of MS diagnosis in general practices in Germany during 2005-2018 (index date). Patients without MS were matched (1:1) to those with MS using propensity scores based on sex, age, index year, follow-up time (in years), general practice, and the Charlson Comorbidity Index score (index date: a randomly selected visit date).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: This retrospective study included 4,461 patients with MS and 4,461 patients without MS (69.9% women; mean [SD] age 44.2 [12.7] years). Within 10 years of index date, a higher proportion of patients with MS were diagnosed with UI (11.7 vs. 3.2%) and FI (2.3 vs. 0.5%; p values &amp;lt;0.001) than those without MS. MS was further found to be associated with both UI (hazard ratio [HR] &#x3D; 3.85) and FI (HR &#x3D; 5.38; p values &amp;lt;0.001) in the Cox regressions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: UI and FI are frequent complications of MS, and the presence of these complications should be regularly assessed in primary care practices.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2&quot;&gt;33662954&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000513234&gt;10.1159&#x2F;000513234&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33662954&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210305015644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":224,"discovery_date":"2021-03-05T02:56:45","title":"Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Opin Neurol. 2021 Mar 1. doi: 10.1097&#x2F;WCO.0000000000000921. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: With the introduction of new diagnostic criteria, the sensibility for multiple sclerosis (MS) diagnosis increased and the number of cases with the clinically isolated syndrome (CIS) decreased. Nevertheless, a misdiagnosis might always be around the corner, and the exclusion of a &#39;better explanation&#39; is mandatory.There is a pressing need to provide an update on the main prognostic factors that increase the risk of conversion from CIS or from radiologically isolated syndrome (RIS) to MS, and on the potential &#39;red flags&#39; to consider during the diagnostic workup.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: We discuss diagnostic challenges when facing patients presenting with a first demyelinating attack or with a RIS, with a focus on recently revised diagnostic criteria, on other neuroinflammatory conditions to be considered in the differential diagnosis and on factors distinguishing patients at risk of developing MS.A correct definition of a &#39;typical&#39; demyelinating attack, as well as a correct interpretation of MRI findings, remains crucial in the diagnostic process. The cerebrospinal fluid examination is warmly recommended to confirm the dissemination in time of the demyelinating process and to increase the diagnostic accuracy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: An early and accurate diagnosis of MS requires careful consideration of all clinical, paraclinical and radiological data, as well the reliable exclusion of other mimicking pathological conditions. This is advocated to promptly initiate an appropriate disease-modifying therapy, which can impact positively on the long-term outcome of the disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661162&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661162&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;WCO.0000000000000921&gt;10.1097&#x2F;WCO.0000000000000921&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661162&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":223,"discovery_date":"2021-03-05T02:56:45","title":"Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Exp Med. 2021 May 3;218(5):e20201290. doi: 10.1084&#x2F;jem.20201290.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with continuous neuronal loss. Treatment of clinical progression remains challenging due to lack of insights into inflammation-induced neurodegenerative pathways. Here, we show that an imbalance in the neuronal receptor interactome is driving glutamate excitotoxicity in neurons of MS patients and identify the MS risk-associated metabotropic glutamate receptor 8 (GRM8) as a decisive modulator. Mechanistically, GRM8 activation counteracted neuronal cAMP accumulation, thereby directly desensitizing the inositol 1,4,5-trisphosphate receptor (IP3R). This profoundly limited glutamate-induced calcium release from the endoplasmic reticulum and subsequent cell death. Notably, we found Grm8-deficient neurons to be more prone to glutamate excitotoxicity, whereas pharmacological activation of GRM8 augmented neuroprotection in mouse and human neurons as well as in a preclinical mouse model of MS. Thus, we demonstrate that GRM8 conveys neuronal resilience to CNS inflammation and is a promising neuroprotective target with broad therapeutic implications.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661276&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661276&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1084&#x2F;jem.20201290&gt;10.1084&#x2F;jem.20201290&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661276&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":222,"discovery_date":"2021-03-05T02:56:45","title":"Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Cell Biochem. 2021 Mar 4. doi: 10.1007&#x2F;s11010-021-04103-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), can be clinically heterogeneous which may be explained by the co-inheritance of multiple genetic variants that modify the clinical course. In this study we examine variants in three genes in a family with one individual presenting with ALS and lipodystrophy. Sequencing revealed a p.Gly602Ser variant in LMNA, and two additional variants, one each in SETX (g.intron10-13delCTT) and FUS (p.Gly167_Gly168del). These latter genes have been linked to ALS. All family members were genotyped and each variant, and each combination of variants detected, were functionally evaluated in vitro regarding effects on cell survival, expression patterns and cellular phenotype. Muscle biopsy retrieved from the individual with ALS showed leakage of chromatin from the nucleus, a phenotype that was recapitulated in vitro with expression of all three variants simultaneously. Individually expressed variants gave cellular phenotypes there were unremarkable. Interestingly the FUS variant appears to be protective against the effects of the SETX and the LMNA variants on cell viability and may indicate loss of interaction of FUS with SETX and&#x2F;or R-loops. We conclude that these findings support genetic modifications as an explanation of the clinical heterogeneity observed in human disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661429&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661429&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11010-021-04103-7&gt;10.1007&#x2F;s11010-021-04103-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661429&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":221,"discovery_date":"2021-03-05T02:56:45","title":"Prevalence of pain in amyotrophic lateral sclerosis: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Amyotroph Lateral Scler Frontotemporal Degener. 2021 Mar 4:1-10. doi: 10.1080&#x2F;21678421.2021.1892765. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;i&gt;Objectives:&lt;&#x2F;i&gt; Physical pain is a known symptom in amyotrophic lateral sclerosis (ALS), but no systematically derived prevalence estimate is available. The aim of this study was to determine the pooled prevalence of pain in ALS, relative to its method of measurement and pain characteristics. &lt;i&gt;Methods&lt;&#x2F;i&gt;: A systematic search across multiple databases was conducted on January 16, 2020. Random-effects meta-analyses of single proportions were performed on prevalence data. Heterogeneity was determined using the &lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; statistic. Where available, pain location, intensity, and type or source were compared. &lt;i&gt;Results:&lt;&#x2F;i&gt; 2552 articles were identified. Twenty-one eligible studies were included. All studies used observational designs (14 cross-sectional, 6 cohort, 1 case-control). Pooled prevalence of pain in ALS across all studies was 60% (95% CI &#x3D; 50-69%), with a high degree of heterogeneity (&lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 94%, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; .001). Studies that used only validated measures had lower heterogeneity (&lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 82%, &lt;i&gt;p&lt;&#x2F;i&gt; &#x3D; 0.002), compared to those that used tailored measures, or tailored supplemented with validated measures (&lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 90%, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001 and &lt;i&gt;I&lt;&#x2F;i&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt; &#x3D; 83%, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001, respectively). In a subset of studies (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 9), the most commonly reported pain location was the upper limbs including shoulders&#x2F;extremities (41.5%). A further study subset (&lt;i&gt;N&lt;&#x2F;i&gt; &#x3D; 7) showed moderate-severe intensity pain was most frequently reported. Type of pain was commonly related to cramp or spasm. &lt;i&gt;Conclusions:&lt;&#x2F;i&gt; Experiencing physical pain in ALS occurs with high prevalence. Deriving consensus on which specific tools should be used to assess, monitor and compare symptoms of pain in this population will reduce current heterogeneity in approaches and increase the likelihood of ameliorating distressing experiences more effectively.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661072&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661072&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;21678421.2021.1892765&gt;10.1080&#x2F;21678421.2021.1892765&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661072&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":220,"discovery_date":"2021-03-05T02:56:45","title":"The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Mar 4. doi: 10.1007&#x2F;s00415-021-10489-7. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: High Temperature Requirement Serine Protease A1 (HTRA1) degrades extracellular matrix molecules (ECMs) and growth factors. It interacts with several proteins implicated in multiple sclerosis (MS), but has not previously been linked to the disease.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Investigate the levels of HTRA1 in cerebrospinal fluid (CSF) in different subtypes of MS and brain tissue.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Using ELISA, HTRA1 levels were compared in CSF from untreated patients with relapsing-remitting MS (RRMS, n &#x3D; 23), secondary progressive MS (SPMS, n &#x3D; 26) and healthy controls (HCs, n &#x3D; 26). The effect of disease modifying therapies (DMTs) were examined in both patient groups. Cellular distribution in human brain was studied using immunochemistry and the oligointernode database, based on a single-nuclei RNA expression map.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: HTRA1 increased in RRMS and SPMS compared to HCs. DMT decreased HTRA1 levels in both types of MS. Using ROC analysis, HTRA1 cut-offs could discriminate HCs from RRMS patients with 100% specificity and 82.6% sensitivity. In the brain, HTRA1 was expressed in glia and neurons.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: HTRA1 is a promising CSF biomarker for MS correlating with disease- and disability progression. Most cell species of the normal and diseased CNS express HTRA1 and the expression pattern could reflect pathological processes involved in MS pathogenesis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661357&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661357&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10489-7&gt;10.1007&#x2F;s00415-021-10489-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661357&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":219,"discovery_date":"2021-03-05T02:56:45","title":"The role of prolactin in central nervous system inflammation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rev Neurosci. 2021 Jan 1. doi: 10.1515&#x2F;revneuro-2020-0082. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Prolactin has been shown to favor both the activation and suppression of the microglia and astrocytes, as well as the release of inflammatory and anti-inflammatory cytokines. Prolactin has also been associated with neuronal damage in diseases such as multiple sclerosis, epilepsy, and in experimental models of these diseases. However, studies show that prolactin has neuroprotective effects in conditions of neuronal damage and inflammation and may be used as neuroprotector factor. In this review, we first discuss general information about prolactin, then we summarize recent findings of prolactin function in inflammatory and anti-inflammatory processes and factors involved in the possible dual role of prolactin are described. Finally, we review the function of prolactin specifically in the central nervous system and how it promotes a neuroprotective effect, or that of neuronal damage, particularly in experimental autoimmune encephalomyelitis and during excitotoxicity. The overall studies indicated that prolactin may be a promising molecule for the treatment of some neurological diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661585&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2&quot;&gt;33661585&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1515&#x2F;revneuro-2020-0082&gt;10.1515&#x2F;revneuro-2020-0082&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33661585&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304215644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":218,"discovery_date":"2021-03-04T18:56:45","title":"The relationship between vitamin D levels and cognitive impairment in patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2021-2030. doi: 10.26355&#x2F;eurrev_202102_25105.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Neurocognitive impairment is one of the most common manifestations of multiple sclerosis (MS). However, the pathophysiology of this issue is still poorly understood. The objective of this study is to investigate the relationship between vitamin D levels and cognitive function in patients with MS as assessed by the Cambridge Neuropsychological Test Automated Battery (CANTAB).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PATIENTS AND METHODS: This was a cross-sectional, case-control study; the subjects were 39 Saudi patients diagnosed with MS. For all participants, demographic information, including age, sex, and educational level, was collected. Participants were also evaluated using the disease steps scale and the PHQ-9 scale. Their vitamin D levels were assessed, and the participants completed a computerized cognitive assessment using the CANTAB.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: From the total sample of 39 patients with MS, 31 (79.5%) were female. Physical disability due to MS was insignificant in 25 (64.1%) of the subjects and significant in 14 (35.9%). Seventeen (43.6%) of the participants had normal vitamin D levels; 22 (56.4%) had low vitamin D levels. The MS patients had lower MOT mean errors than the control group, and this difference was statistically significant (t &#x3D; -4.313, p &amp;lt; 0.01). Moreover, the scores of the two groups for all subcategories of the memory domain were different at statistically significant levels. Furthermore, the control group had higher PAL total errors (adjusted), PAL total errors (6 shapes, adjusted), and PRM percent correct than the MS patients (p &amp;lt; 0.01). The control group also achieved lower scores on SWM between errors and SWM strategy than the MS patients (p &amp;lt; 0.01). The MOT mean error was found to correlate with the disease steps score (r &#x3D; 0.394, p &amp;lt; 0.05) and with significant physical disability (r &#x3D; 0.457, p&amp;lt; 0.01). In the memory domain, PAL total errors (adjusted) correlated with age (r &#x3D; 0.381, p &amp;lt; 0.05), SWM between errors correlated with age at onset of disease (r &#x3D; 0.345, p &amp;lt; 0.05), and vitamin D level (r &#x3D; 0.335, p &amp;lt; 0.05) and SWM strategy correlated with the number of relapses in the past 12 months (r &#x3D; -0.355, p &amp;lt; 0.05).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Cognitive performance was impaired in patients with MS. Vitamin D deficiency, a potentially modifiable risk factor, independently predicted cognitive impairment in MS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660814&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2&quot;&gt;33660814&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.26355&#x2F;eurrev_202102_25105&gt;10.26355&#x2F;eurrev_202102_25105&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660814&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":217,"discovery_date":"2021-03-04T18:56:45","title":"Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Invest. 2021 Mar 4:1-16. doi: 10.1080&#x2F;08820139.2021.1887888. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;This systematic review and meta-analysis aimed to identify deferentially expressed serum miRNAs in multiple sclerosis patients and to evaluate their diagnostic value in multiple sclerosis diagnosis. Studies were identified on PubMed, Google scholar and Saudi digital library up to 30 September 2019. Articles that examined miRNA expression level in MS patients compared to healthy control group were included in the review and the data were extracted by three independent author. The comprehensive Meta-Analysis version 3 software was used for meta-analysis and heterogeneity of studies was identified according to I2 value. Our literatures search identified 9 eligible articles concerning the serum miRNA as a diagnostic biomarker for multiple sclerosis in comparison to healthy control group. 19 serum miRNAs differentially expressed in MS patients were identified (8 downregulated, 11 upregulated and 1 with discordant result). In publications that provided information on specific miRNA diagnostic value, the pooled AUC was 72% (95% CI 0.65-0.78, &lt;i&gt;p&lt;&#x2F;i&gt;-value 0.00) for the overall multiple sclerosis patients and primary progressive MS (PPMS) (95% CI 0.66-0.78 &lt;i&gt;p&lt;&#x2F;i&gt;-value 0.00). A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing multiple sclerosis from control groups. When using single miRNA (miR-145), the sensitivity increased to 79% and the specificity to 87%. The available data from the literature and this meta-analysis suggests the potential use of serum miRNA as biomarkers for early diagnosis of MS with high sensitivity and specificity in distinguishing multiple sclerosis subtypes from healthy controls.&lt;b&gt;Abbreviation&lt;&#x2F;b&gt;: MS: Multiple sclerosis; IDD: inflammatory demyelinating diseases; RRMS: relapsing-remitting Multiple sclerosis; PPMS: primary progressive Multiple sclerosis; SPMS: secondary progressive Multiple sclerosis; NMO: Neuromyelitis optica; miRNA: microRNA; ECmiRNA: extracellular microRNA; AUC: Area Under the Curve; ROC: Receiver Operator Characteristic.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660581&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2&quot;&gt;33660581&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;08820139.2021.1887888&gt;10.1080&#x2F;08820139.2021.1887888&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660581&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":216,"discovery_date":"2021-03-04T18:56:45","title":"The gelsolin level in patients with primary Sjogren&#39;s syndrome","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2072-2078. doi: 10.26355&#x2F;eurrev_202102_25112.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Gelsolin (GSN) is a multifunctional protein that can regulate cell proliferation, apoptosis, inflammation and infection. GSN has been reported to be involved in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS) and many other diseases. The role of GSN in primary Sjogren&#39;s syndrome (pSS) remains still unclear. The aim of this study is to investigate the changes of GSN level in serum and whole blood cells of pSS patients and evaluate the relationship between GSN and fatigue or other clinical indicators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PATIENTS AND METHODS: The cross-sectional study included 47 pSS patients (1 male and 46 females, average age: 52.83Â±12.63 years) and 51 healthy controls (all females, average age: 50.61Â±9.86 years). The patients were collected from the Second Affiliated Hospital of Harbin Medical University, China, without the age and sex differences. The levels of GSN in serum of pSS patients and the healthy controls were measured by Western blotting. The sequencing gene expression omnibus (GEO) data from National Center for Biotechnology Information (NCBI) about GSN levels in the whole blood cells of pSS patients and the healthy controls were analyzed by R language.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Compared with healthy controls, the level of GSN was significantly decreased in the serum of pSS patients (98.89 Â± 28.94 vs. 131.6 Â± 37.1 Âµg&#x2F;ml, p&amp;lt;0.001). The expression of GSN in the whole blood cells of pSS patients was significantly lower than that in the healthy controls (6.4 Â± 0.19 vs. 6.6 Â± 0.17, p&amp;lt;0.01). Compared to non-fatigued pSS patients, the level of GSN was down-regulated in serum (85.69 Â± 27.08 vs. 111.52 Â± 24.71 Âµg&#x2F;ml, p&amp;lt;0.01) and whole blood cells (6.43 Â± 0.18 vs. 6.58 Â± 0.21, p&amp;lt;0.001) in fatigue pSS patients. However, there was no significant correlation between the level of GSN and EULAR Sjogrens syndrome disease activity index (ESSDAI) in pSS patients (p&#x3D;0.73).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: GSN is decreased in serum and whole blood cells of pSS patients, and it is much lower in fatigue patients than that in non-fatigue patients. The correlation between the level of GSN and ESSDAI was not significant in pSS patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660820&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2&quot;&gt;33660820&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.26355&#x2F;eurrev_202102_25112&gt;10.26355&#x2F;eurrev_202102_25112&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660820&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":215,"discovery_date":"2021-03-04T12:16:45","title":"New methods of posturographic data analysis may improve the diagnostic value of static posturography in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Heliyon. 2021 Feb 11;7(2):e06190. doi: 10.1016&#x2F;j.heliyon.2021.e06190. eCollection 2021 Feb.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Early and accurate diagnosis of multiple sclerosis (MS) is crucial for its effective treatment. In MS diagnostic, neuronal networks that control posture and movement are of particular importance, which performance can be assessed using static posturography. Unfortunately, most of the commercially available posturographic platforms are not equipped with the appropriate procedures.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: To solve this problem, the postural sway trajectories have been recorded in 55 MS patients while standing quiet with eyes open (EO), and then with eyes closed (EC). The trajectories were analyzed using our novel methods of postural sway parametrization, including sway stability vector (SV), anteroposterior and mediolateral sway indices (DIAP and DIML).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The results exhibited unique postural sway patterns that may be attributed to MS. Our novel parametrization methods of postural sway showed pathology specific increase of the postural sway velocity in EC tests. Additionally, we documented the abnormal alterations of the anteroposterior (AP) and the mediolateral (ML) sway indices that were also uniquely dependent on visual input. In EC tests, patients exhibited a characteristic pattern of sway increase in both AP and ML directions that correlated with the advance of the disease as measured by the EDSS Kurtzke scale and Functional System Scores.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The applied in the present study our novel posturographic metrics give the assessment a diagnostic value. It allows us to recommend the static posturography test as a simple and safe supplementary clinical tool in the diagnosis of MS. In the assessment of MS pathology or the effects of its treatment, the impact of vision on the sway stability vector seems the most important factor.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659736&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33659736&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7892908&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7892908&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.heliyon.2021.e06190&gt;10.1016&#x2F;j.heliyon.2021.e06190&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659736&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":214,"discovery_date":"2021-03-04T12:16:45","title":"Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Immunol. 2021 Feb 15;12:625465. doi: 10.3389&#x2F;fimmu.2021.625465. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659007&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33659007&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7917254&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7917254&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fimmu.2021.625465&gt;10.3389&#x2F;fimmu.2021.625465&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659007&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":213,"discovery_date":"2021-03-04T12:16:45","title":"Poster Abstracts from the 10th International Symposium on Gait and Balance in Multiple Sclerosis: The Role of Fatigue and Fatigability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):45-46. doi: 10.7224&#x2F;1537-2073-23.1.45. Epub 2021 Feb 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658906&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658906&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906032&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906032&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073-23.1.45&gt;10.7224&#x2F;1537-2073-23.1.45&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658906&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":212,"discovery_date":"2021-03-04T12:16:45","title":"Editorial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):iv. doi: 10.7224&#x2F;1537-2073-23.1.iv. Epub 2021 Feb 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658907&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906026&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906026&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073-23.1.iv&gt;10.7224&#x2F;1537-2073-23.1.iv&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658907&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":211,"discovery_date":"2021-03-04T12:16:45","title":"Safety, Feasibility, and Efficacy of an Eccentric Exercise Intervention in People with Multiple Sclerosis with Ankle Contractures","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):31-36. doi: 10.7224&#x2F;1537-2073.2019-022. Epub 2020 Mar 6.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The primary aim of this study was to investigate the safety and feasibility of an eccentric exercise program for people with multiple sclerosis (MS) who have ankle contractures, ie, reduced ankle range of motion (ROM). Secondary aims were to explore the efficacy of this eccentric exercise on ankle joint ROM and functional mobility.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Five adults with MS with ankle contractures (three women and two men; mean Â± SD age, 50.8 Â± 9.4; MS duration, 7.6 Â± 5.6 years) completed two eccentric exercise training sessions (10-45 minutes) per week for 12 weeks. The training involved walking backward downhill on an inclined treadmill (gradient, 10Â°-14Â°) at a self-selected pace. The intervention was assessed for safety (adverse events), feasibility (recruitment rates, adherence rates, enjoyment levels, difficulty, and discomfort), and clinical outcomes, including passive&#x2F;active ankle ROM and distance walked in 6 minutes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were no adverse events during or after the eccentric exercise training. There was a 100% adherence rate. All participants enjoyed the training and experienced low levels of muscle soreness&#x2F;discomfort. The training program improved passive&#x2F;active ankle ROM in all participants; however, improvements did not translate to improvements in walking for all participants.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Walking backward and downhill is a safe and feasible training modality for people with MS with ankle contractures. Clinical outcomes (greater passive&#x2F;active ankle ROM) after this eccentric exercise training were evident. However, translation to clinically meaningful changes in walking function requires further examination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658904&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906030&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906030&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-022&gt;10.7224&#x2F;1537-2073.2019-022&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":210,"discovery_date":"2021-03-04T12:16:45","title":"Identifying Barriers to and Facilitators of Health Service Access Encountered by Individuals with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):37-44. doi: 10.7224&#x2F;1537-2073.2020-026. Epub 2021 Feb 23.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The symptoms of multiple sclerosis (MS) can be diverse, complex, and progressive, creating a need for frequent and long-standing health care services. The purpose of this scoping review was to identify the barriers people with MS encounter when attempting to access multidisciplinary health services and the reported facilitators for better access to health services.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The MEDLINE, Embase, and CINAHL databases were searched, without date or geographic restrictions, using the following terms: &lt;i&gt;multiple sclerosis, health services accessibility, health care access, health care delivery,&lt;&#x2F;i&gt; and &lt;i&gt;delivery of health care&lt;&#x2F;i&gt;. After screening based on exclusion criteria, 23 articles were included in the final review.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Five main themes were identified as barriers and facilitators to accessing health services: 1) information (information available to people with MS, health care provider knowledge of and familiarity with MS), 2) interactions (interactions between health care providers and people with MS, social networks and support of people with MS, collaboration among health care providers), 3) beliefs and skills (personal values and beliefs, perceived time to travel to and attend appointments, and self-assessment of symptoms and needs of people with MS), 4) practical considerations (wait times, physical barriers, affordability of services), and 5) nature of MS (complexity and unpredictability of disease symptoms).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: People with MS and their health care providers may benefit from structured and comprehensive MS-specific education to address barriers to accessing health care services. The education can ultimately facilitate the process of addressing unmet health care needs and contribute to a greater quality of life for people with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658905&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658905&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906029&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906029&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2020-026&gt;10.7224&#x2F;1537-2073.2020-026&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658905&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":209,"discovery_date":"2021-03-04T12:16:45","title":"Modeling the Multiple Sclerosis Specialist Nurse Workforce by Determination of Optimum Caseloads in the United Kingdom","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):1-7. doi: 10.7224&#x2F;1537-2073.2019-058. Epub 2020 Jan 13.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: It is estimated that there are more than 100,000 people in the United Kingdom who have multiple sclerosis (MS). Patient experience and outcome are improved by access to a specialist nursing service. The aim of this study was to perform demand modeling to understand the need for MS nursing interventions, and thus inform modeling of the future UK MS nursing workforce.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Existing national data and specific workload and service data were collected from 163 MS specialist nurses who completed a questionnaire on activity and complexity of work both done and left undone.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Data were received from across all of the United Kingdom. Twenty-nine percent of respondents were specialist nurses in the field for 3 years or less. Unpaid overtime was regularly performed by 83.4% of respondents. The MS specialist nurse was part of all areas of the patient journey. Areas of work left undone were psychological interventions, physical assessments, social interventions&#x2F;benefits, and recommending or prescribing medications.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The current recommended caseload of 358 people with MS per full-time equivalent seems to be too high, with a considerable amount of work left undone, particularly psychosocial care. Factors such as travel time, complexity of caseload, changing drug therapies, and societal issues such as the benefits system contributed to driving demand&#x2F;workload.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658899&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906027&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906027&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-058&gt;10.7224&#x2F;1537-2073.2019-058&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":208,"discovery_date":"2021-03-04T12:16:45","title":"Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):8-15. doi: 10.7224&#x2F;1537-2073.2019-051. Epub 2020 Feb 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Fatigue is the most disabling symptom in patients with multiple sclerosis (MS). Although there is no standard tool to evaluate fatigue in clinical settings, the Fatigue Impact Scale (FIS), Fatigue Severity Scale (FSS), and Multidimensional Assessment of Fatigue (MAF) scale are popular instruments for this purpose. The aim of this study was to compare the psychometric properties of the Persian versions of these scales.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: One hundred thirty adult patients with MS and 60 controls participated in this study. They completed the scales on two occasions 3 days apart. Reproducibility and internal consistency were evaluated as intraclass correlation coefficients (ICCs) and Cronbach Î±. Convergent validity was assessed by evaluating the association of the fatigue scales with age, sex, Expanded Disability Status Scale (EDSS) score, disease duration, and sleep quality. Dimensionality was evaluated using confirmatory factor analysis. Acceptability and known-group validity were investigated. The effect size of each scale was computed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The ICC of all instruments was 0.99. Internal consistency was 0.97 for the MAF scale, 0.93 for FSS, and 0.83 for FIS. The instruments showed moderate-to-good correlations with Pittsburgh Sleep Quality Index, EDSS score, and disease duration. Acceptability was acceptable. The FIS had three dimensions, and the FSS and MAF scale were unidimensional. All scales were able to discriminate patients with MS from controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The Persian version of the MAF scale seems to be the most suitable instrument to evaluate fatigue in patients with MS based on its time efficiency, effect size, and detailed data about various aspects of fatigue.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658900&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906033&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906033&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-051&gt;10.7224&#x2F;1537-2073.2019-051&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658900&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":207,"discovery_date":"2021-03-04T12:16:45","title":"Incorporation and Impact of a Clinical Pharmacist in a Hospital-Based Neurology Clinic Treating Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):16-20. doi: 10.7224&#x2F;1537-2073.2019-032. Epub 2020 Feb 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Clinical pharmacists are uniquely positioned to assist with the complexities of medication management for patients with multiple sclerosis (MS). The objective was to describe clinical pharmacy services provided, as well as provider satisfaction with and perceived impact of incorporating a clinical pharmacist in MS patient care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The study consisted of a retrospective medical record review and a provider survey conducted in an outpatient neurology clinic at an academic medical center. Between April 2017 and June 2018, electronic medical records of patients with documented interventions by a pharmacist were reviewed to describe clinical pharmacy services provided to patients with MS. A voluntary, anonymous survey was distributed to neurology providers to evaluate provider satisfaction with and perceived impact of clinical pharmacist involvement in MS patient care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There were 64 patients identified with 378 documented interventions made by clinical pharmacists. Pharmacist interventions were mostly related to facilitating medication access (n &#x3D; 208), pretreatment screening (n &#x3D; 57), patient counseling (n &#x3D; 51), and providing drug information (n &#x3D; 43). All nine providers surveyed indicated that facilitating medication access, counseling patients, and managing drug interactions were moderately or very important clinical pharmacy services. Furthermore, all providers surveyed strongly agreed that pharmacist involvement decreased time to therapy initiation and provider time spent on medication management.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Clinical pharmacists play an integral role in MS patient care, particularly with facilitating medication access. Prospective studies are needed to further evaluate the contribution of clinical pharmacists in MS patient care.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658901&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658901&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906034&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906034&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-032&gt;10.7224&#x2F;1537-2073.2019-032&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658901&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":206,"discovery_date":"2021-03-04T12:16:45","title":"Social Cognitive Theory and Physical Activity in Older Adults with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):21-25. doi: 10.7224&#x2F;1537-2073.2019-071. Epub 2020 Feb 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The expanding population of older adults with multiple sclerosis (MS) likely experiences many of the same benefits of physical activity (PA) as younger and middle-aged adults with MS. However, participation in PA is exceedingly low in this segment of the MS population. This study examined variables from social cognitive theory (SCT) as correlates of PA in older adults with MS to inform the subsequent development of behavioral interventions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Older adults with MS (â¥60 years of age, N &#x3D; 180) completed an online survey including demographic and clinical characteristics, SCT variables (exercise self-efficacy, exercise goal setting, social support, and outcome expectations), and PA (total PA [TPA] and moderate-to-vigorous PA [MVPA]).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Bivariate correlation analyses indicated that all SCT variables were significantly associated with TPA and MVPA (all &lt;i&gt;P&lt;&#x2F;i&gt; â¤ .001). Hierarchical linear regression analyses indicated that disability status was a significant correlate of TPA (&lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.48, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.23) and MVPA (&lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.44, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.19) in step 1; disability and self-efficacy were significant correlates of TPA (disability &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.20, self-efficacy &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; 0.59, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.50) and MVPA (disability &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.16, self-efficacy &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; 0.60, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.47) in step 2; and disability, self-efficacy, and exercise goal setting were significant correlates of TPA (disability &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.21, self-efficacy &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; 0.50, exercise goal setting &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; 0.14, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.55) and MVPA (disability &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; -0.17, self-efficacy &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; 0.51, exercise goal setting &lt;i&gt;Î²&lt;&#x2F;i&gt; &#x3D; 0.15, &lt;i&gt;R&lt;sup&gt;2&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; &#x3D; 0.51) in step 3.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These results suggest that behavioral interventions focusing on self-efficacy and exercise goal setting as targets from SCT may be appropriate for increasing PA in older adults with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658902&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658902&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906028&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906028&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-071&gt;10.7224&#x2F;1537-2073.2019-071&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658902&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":205,"discovery_date":"2021-03-04T12:16:45","title":"Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int J MS Care. 2021 Jan-Feb;23(1):26-30. doi: 10.7224&#x2F;1537-2073.2019-015. Epub 2020 Apr 14.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection. Multiple sclerosis (MS) therapies may put individuals with LTBI at higher risk of TB.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients at the Beth Israel Deaconess Medical Center MS Clinic were screened for TB as part of routine testing with the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Ltd) from 2013 to 2017. Patients were tested either before or during immunomodulatory therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Four of 222 patients (1.8%; 95% CI, 0.1%-3.6%) had positive QFT-GIT results; three patients had risk factors for TB, having emigrated from TB-endemic countries or worked in the health care industry. Twenty-eight of 222 patients (12.6%) had an indeterminate assay result, and 75.0% of these occurred in patients taking dimethyl fumarate. Fingolimod, natalizumab, or anti-CD20 treatments showed 0% to 7.7% indeterminate results.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The prevalence of LTBI was 1.8% in the Beth Israel Deaconess Medical Center MS Clinic. Not all LTBI cases were associated with known risk factors for TB. Screening for LTBI before starting immunosuppressive agents for MS could help prevent activation of TB. Dimethyl fumarate use is associated with indeterminate QFT-GIT results, possibly due to functional effects on lymphocytes and levels of cytokines, such as interferon gamma. In contrast, fingolimod use was rarely associated with indeterminate QFT-GIT results despite a high rate of lymphopenia in virtually all patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658903&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7906031&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7906031&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7224&#x2F;1537-2073.2019-015&gt;10.7224&#x2F;1537-2073.2019-015&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":204,"discovery_date":"2021-03-04T12:16:45","title":"Minimally Invasive Oral Surgery Induction of the FRICT-ION Chronic Neuropathic Pain Model","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Bio Protoc. 2020 Apr 20;10(8):e3591. doi: 10.21769&#x2F;BioProtoc.3591. eCollection 2020 Apr 20.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;An easily induced preclinical trigeminal neuropathic nerve injury model is described here for the study of chronic pain, the model acronym &lt;b&gt;FRICT-ION (F&lt;&#x2F;b&gt;oramen &lt;b&gt;R&lt;&#x2F;b&gt;otundum &lt;b&gt;I&lt;&#x2F;b&gt;nflammatory &lt;b&gt;C&lt;&#x2F;b&gt;onstriction &lt;b&gt;T&lt;&#x2F;b&gt;rigeminal &lt;b&gt;I&lt;&#x2F;b&gt;nfra&lt;b&gt;O&lt;&#x2F;b&gt;rbital &lt;b&gt;N&lt;&#x2F;b&gt;erve). In patients, neuropathic pain is thought to be related to vascular alignment or multiple sclerosis along this small trigeminal nerve branch (V2) innervating the maxillary teeth and middle third of the face. With no detectable outward physical signs, the FRICT-ION model is ideal for blinded studies. The acronym FRICT-ION applied relates to the persistence of the trigeminal neuropathic pain model likely due to sliding irritation with normal chewing in the mice. A step-by-step method to induce the mild chronic rodent neuropathic pain model is described here. The surgery is performed orally through a tiny surgical slit inside the cheek crease to align a chromic gut suture irritant along the nerve as it passes into the skull. The model allows testing of non-evoked subjective measures and evoked quantitative mechanical hypersensitivity (allodynia) testing with von Frey filaments through at least 10-14 weeks (100 days). Anxiety and depression behaviors develop within 3-6 weeks relevant to the affective component of chronic pain. While many pain drugs have failed based on testing performed in the acute animal models available, the more stable and easily replicated trigeminal inflammatory compression model is the better suited for understanding both mechanistic and affective components of nerve injury-induced chronic neuropathic pain states as well as the more ideal for preclinical trials of novel non-opioid pain relief therapies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659557&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33659557&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7842532&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7842532&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.21769&#x2F;BioProtoc.3591&gt;10.21769&#x2F;BioProtoc.3591&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33659557&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":203,"discovery_date":"2021-03-04T12:16:45","title":"Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Pharmacol. 2020 Nov 20;11:589146. doi: 10.3389&#x2F;fphar.2020.589146. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P&lt;sub&gt;3&lt;&#x2F;sub&gt; receptor activation. &lt;b&gt;Methods:&lt;&#x2F;b&gt; e systematically searched PUBMED, EMBASE database, and Cochrane Library database to identify randomized controlled trials (RCTs) from inception to June 28, 2020. Trials were considered eligible if they 1) were randomized clinical trials (RCTs); 2) enrolled adult participants diagnosed with Relapsing-remitting MS; 3) compared ozanimod with placebo or any other approved DMDs that evaluated in phase III or phase II clinical trials; 4) enrolled over 100 participants; 5) provided any available information for predefined primary or secondary outcomes. &lt;b&gt;Results:&lt;&#x2F;b&gt; 2917 participants from three high-quality, multi-centered randomized clinical trials were pooled in our analysis. We found that using ozanimod was significantly associated with the reduction of the annualized relapse rate during the treatment period (RR, -0.10 [95% CI, -0.15, -0.06]). Also, the decreased number of gadolinium-enhancing lesions at the end of the trial was relative to the treatment of ozanimod (ozanimod, 0.29; control, 0.65; RR, -0.20 [95% CI, -0.34, -0.06]). Compared with patients in the control group, the number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod (ozanimod, 1.82; control, 3.55; RR, -1.12 [95% CI, -1.52, -0.71]). As to the safety endpoints, patients in the ozanimod group reported a lower rate of adverse events (ozanimod, 66.03%; control, 77.07%; RR, 0.64 [95% CI, 0.43, 0.95]). Similar incidence of infection-related TEAEs was found across treatment groups (nasopharyngitis: ozanimod, 11.19%; control, 9.83%; RR, 1.10 [95% CI, 0.77-1.57]; urinary-tract infection: ozanimod, 3.81%; control, 2.97%; RR, 1.29 [95% CI, 0.83-2.00]). No case of macular edema was noted as well as second-degree, type 2, or third-degree atrioventricular block. As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). No significant difference in causing adverse events between 1 and 0.5 mg was found. &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Our meta-analysis found that, with favorable safety performance, the use of ozanimod as a treatment of relapsing-remitting multiple sclerosis in adults was associated with a significant reduction of the annualized relapse rate during the treatment period, decreased number of gadolinium-enhancing lesions at the end of the trial, and lowered number of new or enlarging T2 lesions over the treatment period. Ozanimod 1 mg outperformed 0.5 mg dose in efficacy without increasing the risk of adverse events.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658933&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7919188&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7919188&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fphar.2020.589146&gt;10.3389&#x2F;fphar.2020.589146&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658933&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":202,"discovery_date":"2021-03-04T12:16:45","title":"Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 15;11:574748. doi: 10.3389&#x2F;fneur.2020.574748. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; Multiple sclerosis (MS), a disabling demyelinating disease of the central nervous system, is associated with cognitive impairment, spasticity, and fatigue. There are still no established guidelines on the management of MS-related sequela. Memantine has the potential to reduce glutamate toxicity, thereby reducing consequent cognitive impairment, spasticity, and fatigue. &lt;b&gt;Objectives:&lt;&#x2F;b&gt; This study aims to determine the efficacy and safety of memantine in preventing cognitive impairment, reducing spasticity and fatigue, and controlling disability in MS patients through a review of relevant randomized trials. &lt;b&gt;Methods:&lt;&#x2F;b&gt; MEDLINE, CENTRAL, Scopus, Embase, LILACS, ClinicalTrials.gov, and HERDIN were searched from inception to May 2020 for relevant trials. &lt;b&gt;Results:&lt;&#x2F;b&gt; The search yielded 203 articles; four studies were included in the analysis. Pooled evidence shows that memantine compared with placebo does not significantly improve PASAT, ASS, MFIS, and EDSS scores of patients with MS. Memantine is associated with mild adverse drug events such as dizziness, fatigue, and anxiety. &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; There is not enough evidence to support the efficacy of memantine in preventing cognitive decline, controlling spasticity, reducing fatigue, and preventing disability. Future researches should consider the different MS subtypes, effect of co-administration of disease-modifying therapies, longer duration of administration, and more sensitive outcome measures to evaluate the potential benefit of memantine in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33658967&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7917060&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;PMC7917060&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fneur.2020.574748&gt;10.3389&#x2F;fneur.2020.574748&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33658967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":201,"discovery_date":"2021-03-04T12:16:45","title":"Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 3. doi: 10.1007&#x2F;s10072-021-05145-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: So far, a limited number of real-world evidence studies about the effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients. We aimed to study the efficacy and safety of ALM in real-world clinical practice in two MS centers in Slovenia and Croatia.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a retrospective chart review of 71 consecutive patients with relapsing-remitting MS who were treated with ALM from 2015 till 2018. The following data were collected: gender, age at disease onset, disease duration at ALM initiation, previous disease modifying therapy, number of relapses, active MRI lesions, and EDSS in the year prior to ALM initiation and every year of follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: All patients completed the standard dosing schedule and were followed for a mean time of 3.2Â±1.1 years after the initiation of treatment. Complete data for the 2 years after treatment (relapses, EDSS, and MRI) were available for 48 patients, of which 14 (29.2%) achieved NEDA. Clinical NEDA was achieved in 38 out of 63 participants (60.3%). In year 1, 24 out of 57 (42.1%) patients achieved NEDA. In year 2, 26 out of 41 (63.4%) patients achieved NEDA. Lower EDSS prior to starting ALM was the only independent predictor of NEDA in a multivariable model. Adverse events occurred in 58 participants (84.1%), with no new safety signals identified.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: According to the data from our cohort of early active RRMS patients we conclude ALM efficacy remains high in the real-world clinical practice.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660157&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2&quot;&gt;33660157&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05145-x&gt;10.1007&#x2F;s10072-021-05145-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33660157&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210304071644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":200,"discovery_date":"2021-03-04T00:16:45","title":"Correction for: Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Aging (Albany NY). 2021 Mar 3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33657013&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303191644&amp;v&#x3D;2.14.2&quot;&gt;33657013&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33657013&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303191644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":199,"discovery_date":"2021-03-03T18:56:45","title":"Disease-modifying treatment of secondary progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 3. doi: 10.1007&#x2F;s00115-021-01080-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a disease continuum from a clinically isolated syndrome through relapsing remitting MS to secondary progressive MS (SPMS). There are numerous therapeutic approaches with proven efficacy on relapse and focal inflammatory disease aspects, whereas treatment of secondary progression and associated neuropathological aspects continues to be a challenge.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Overview of the current options for disease-modifying treatment of SPMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIAL AND METHODS: Results of randomized clinical trials are presented and evaluated on a substance-specific basis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Randomized SPMS trials showed inconsistent results regarding disability progression for beta interferons and negative results for natalizumab. Oral cladribine and ocrelizumab reduced disability progression in relapsing MS but have not been specifically studied in an SPMS population. Positive results for mitoxantrone are only partially applicable to current SPMS patients. For siponimod, a substance that crosses the blood-brain barrier, the EXPAND trial demonstrated a significant reduction in the risk of disability progression in typical SPMS. Subgroup analyses suggest a higher efficacy of siponimod in younger patients with active SPMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: There is limited evidence for the use of previously available disease-modifying treatment in SPMS. Siponimod represents a new therapeutic option for active SPMS, defined by relapses or focal inflammatory MRI activity. To establish the therapeutic indications for siponimod, early detection of relapse-independent progression as well as differentiation of active SPMS from inactive disease are of critical importance.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656569&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656569&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01080-6&gt;10.1007&#x2F;s00115-021-01080-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656569&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":198,"discovery_date":"2021-03-03T18:56:45","title":"Blood-cerebrospinal fluid (CSF) barrier dysfunction means reduced CSF flow not barrier leakage - conclusions from CSF protein data","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arq Neuropsiquiatr. 2021 Jan;79(1):56-67. doi: 10.1590&#x2F;0004-282X-anp-2020-0094.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Increased concentrations of serum proteins in cerebrospinal fluid (CSF) are interpreted as blood-CSF barrier dysfunction. Frequently used interpretations such as barrier leakage, disruption or breakdown contradict CSF protein data, which suggest a reduced CSF flow rate as the cause.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Even the severest barrier dysfunctions do not change the molecular size-dependent selectivity or the interindividual variation of the protein transfer across barriers. Serum protein concentrations in lumbar CSF increase with hyperbolic functions, but the levels of proteins that do not pass the barrier remain constant (brain proteins) or increase linearly (leptomeningal proteins). All CSF protein dynamics above and below a lumbar blockade can also be explained, independent of their barrier passage, by a reduced caudally directed flow. Local accumulation of gadolinium in multiple sclerosis (MS) is now understood as due to reduced bulk flow elimination by interstitial fluid (ISF). Nonlinear change of the steady state in barrier dysfunction and along normal rostro-caudal gradients supports the diffusion&#x2F;flow model and contradicts obstructions of diffusion pathways. Regardless of the cause of the disease, pathophysiological flow blockages are found in bacterial meningitis, leukemia, meningeal carcinomatosis, Guillain-BarrÃ© syndrome, MS and experimental allergic encephalomyelitis. In humans, the fortyfold higher albumin concentrations in early fetal development decrease later with maturation of the arachnoid villi, i.e., with beginning CSF outflow, which contradicts a relevant outflow to the lymphatic system. Respiration- and heartbeat-dependent oscillations do not disturb net direction of CSF flow.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Blood-CSF and blood-brain barrier dysfunctions are an expression of reduced CSF or ISF flow rate.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656113&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656113&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1590&#x2F;0004-282X-anp-2020-0094&gt;10.1590&#x2F;0004-282X-anp-2020-0094&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656113&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":197,"discovery_date":"2021-03-03T18:56:45","title":"Change in Learning and Memory Partially Mediates Effects of Compensatory Cognitive Training on Self-Reported Cognitive Symptoms","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Head Trauma Rehabil. 2021 Feb 22. doi: 10.1097&#x2F;HTR.0000000000000662. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To examine associations among compensatory cognitive training (CCT), objective cognitive functioning, and self-reported cognitive symptoms. We examined whether change in objective cognitive functioning associated with participation in CCT at 10-week follow-up mediates change in self-reported cognitive symptoms associated with CCT at 15-week follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SETTING: Three VA outpatient mental health clinics.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PARTICIPANTS: Veterans with a history of mild traumatic brain injury who reported cognitive deficits.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DESIGN: Randomized controlled trial post hoc causal mediation analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MAIN MEASURES: Self-reported cognitive symptoms were measured by the Prospective-Retrospective Memory Questionnaire and the Multiple Sclerosis Neuropsychological Screening Questionnaire. Objective cognitive functioning was measured using a battery of neuropsychological tests.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Improvement on the Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall test mediated the association between participation in CCT and decrease in the Prospective-Retrospective Memory Questionnaire total score. Improvement on the HVLT-R Total Recall and HVLT-R Delayed Recall tests both meditated the association between participation in CCT and decrease in the Multiple Sclerosis Neuropsychological Screening Questionnaire total score. No other measures of objective cognitive functioning were significant mediators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients&#39; perceptions of cognitive symptom improvement due to CCT are partially mediated by learning and memory, though these subjective improvements occur regardless of other changes in objective cognitive functioning associated with CCT.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656484&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656484&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;HTR.0000000000000662&gt;10.1097&#x2F;HTR.0000000000000662&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656484&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":196,"discovery_date":"2021-03-03T18:56:45","title":"The effects of PDE inhibitors on multiple sclerosis: a review of in vitro and in vivo models","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Pharm Des. 2021 Mar 3. doi: 10.2174&#x2F;1381612827666210303142356. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory and immune-mediated disease, whose current therapeutic means are mostly effective in the relapsing-remitting form of MS, where inflammation is still prominent, but fall short of preventing long term impairment. However, apart from inflammation-mediated demyelination, autoimmune mechanisms play a major role in MS pathophysiology, constituting a promising pharmacological target. Phosphodiesterase (PDE) inhibitors have been approved for clinical use in psoriasis and have undergone trials suggesting their neuroprotective effects, rendering them eligible as an option for accessory MS therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: In this review, we discuss the potential role of PDE inhibitors as a complementary MS therapy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We conducted a literature search through which we screened and comparatively assessed papers on the effects of PDE inhibitor use, both in vitro and in animal models of MS, taking into account a number of inclusion and exclusion criteria.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In vitro studies indicated that PDE inhibitors promote remyelination and axonal sustenance, while curbing inflammatory cell infiltration, hindering oligodendrocyte and neuronal loss and suppressing cytokine production. In vivo studies underlined that these agents alleviate symptoms and reduce disease scores in MS animal models.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: PDE inhibitors proved to be effective in addressing various aspects of MS pathogenesis both in vitro and in vivo models. Given the latest clinical trials proving that the PDE4 inhibitor Ibudilast exerts neuroprotective effects in patients with progressive MS, research on this field should be intensified and selective PDE4 inhibitors with enhanced safety features should be seriously considered as prospective complementary MS therapy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655851&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33655851&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1381612827666210303142356&gt;10.2174&#x2F;1381612827666210303142356&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655851&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":195,"discovery_date":"2021-03-03T18:56:45","title":"Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Stem Cell Res Ther. 2021 Mar 3. doi: 10.2174&#x2F;1574888X16666210303151237. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Mesenchymal stem cells (MSCs) have shown promising therapeutic effects in a wide variety of medical conditions including neurodegenerative disorders and cardiovascular diseases. Although preliminary research has emphasized the ability of MSCs to engraft at sites of injury, several studies have revealed that MSCs mediate their effects through release of various paracrine factors, and through their antioxidant, anti-inflammatory, immunomodulatory, and anti-apoptotic effects. However, the clinical implications of MSCs application are limited due to their low survival rate in conditions of inflammation, oxidative stress, and nutrient restriction in damaged areas. Furthermore, the function of isolated MSCs is usually affected by the patient&#39;s health. Therefore, it is necessary to develop new methods to enhance the therapeutic efficacy of MSCs under pathophysiological conditions. This review provides an overview of the general properties of MSCs, their therapeutic potential in neurodegenerative disorders such as Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease, as well as cardiovascular diseases such as myocardial infarction, diabetic cardiomyopathy, and dilated cardiomyopathy, and their related mechanisms. In addition, this review also discusses potential problems and side effects, as well as current and future directions for improvement of MSCs therapy and their implications and applications.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655876&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33655876&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1574888X16666210303151237&gt;10.2174&#x2F;1574888X16666210303151237&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655876&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":194,"discovery_date":"2021-03-03T18:56:45","title":"What gait features influence the amount and intensity of physical activity in people with multiple sclerosis?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Medicine (Baltimore). 2021 Mar 5;100(9):e24931. doi: 10.1097&#x2F;MD.0000000000024931.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Although the mutual relationship between ambulation and physical activity (PA) in people with multiple sclerosis (pwMS) has been described in several studies, there is still a lack of detailed information about the way in which specific aspects of the gait cycle are associated with amount and intensity of PA. This study aimed to verify the existence of possible relationships among PA parameters and the spatio-temporal parameters of gait when both are instrumentally assessed.Thirty-one pwMS (17F, 14 M, mean age 52.5, mean Expanded Disability Status Scale (EDSS) score 3.1) were requested to wear a tri-axial accelerometer 24 hours&#x2F;day for 7 consecutive days and underwent an instrumental gait analysis, performed using an inertial sensor located on the low back, immediately before the PA assessment period. Main spatio-temporal parameters of gait (i.e., gait speed, stride length, cadence and duration of stance, swing, and double support phase) were extracted by processing trunk accelerations. PA was quantified using average number of daily steps and percentage of time spent at different PA intensity, the latter calculated using cut-point sets previously validated for MS. The existence of possible relationships between PA and gait parameters was assessed using Spearman rank correlation coefficient rho.Gait speed and stride length were the parameters with the highest number of significant correlations with PA features. In particular, they were found moderately to largely correlated with number of daily steps (rho 0.62, P&amp;lt; .001), percentage of sedentary activity (rho &#x3D; -0.44, P &amp;lt; .001) and percentage of moderate-to-vigorous activity (rho &#x3D; 0.48, P &amp;lt; .001). Small to moderate significant correlations were observed between PA intensity and duration of stance, swing and double support phases.The data obtained suggest that the most relevant determinants associated with higher and more intense levels of PA in free-living conditions are gait speed and stride length. The simultaneous quantitative assessment of gait parameters and PA levels might represent a useful support for physical therapists in tailoring optimized rehabilitative and training interventions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33655958&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;MD.0000000000024931&gt;10.1097&#x2F;MD.0000000000024931&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":193,"discovery_date":"2021-03-03T18:56:45","title":"The impact of physical functions on depressive symptoms in people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Arq Neuropsiquiatr. 2021 Jan;79(1):44-50. doi: 10.1590&#x2F;0004-282X20200099.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive symptoms during their lifetime and depressive symptoms may predict impairment of physical functions. However, prediction of depressive symptoms based on objective measures of physical functions is still necessary.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To compare physical functions between people with MS presenting depressive symptoms or not and to identify predictors of depressive symptoms using objective measures of physical functions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Cross-sectional study including 26 people with MS. Anxiety and&#x2F;or depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) and by the Hospital Anxiety and Depression Scale (HADS). Outcomes of physical functions included: the Nnnine-hole Ppeg Ttest (NHPT), knee muscle strength, balance control, the Timed Up and Go Test (TUG), and the 6-minute walk test (6MWT). Perceived exertion was measured using the Borg scale.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The frequency of depressive symptoms was 42% in people with MS. Balance control during a more challenging task was impaired in people with MS who presented depressive symptoms. Balance could explain 21-24% of the variance in depressive symptoms. 6MWT and TUG presented a trend of significance explaining 16% of the variance in the BDI-II score.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Impairment in physical functions consists in a potential predictor of depressive symptoms in people with MS. Exercise interventions aiming at the improvement of physical functions, together with the treatment of depressive symptoms and conventional medical treatment, are suggested.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656111&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1590&#x2F;0004-282X20200099&gt;10.1590&#x2F;0004-282X20200099&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656111&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":192,"discovery_date":"2021-03-03T18:56:45","title":"Effects on Motor Control of Personalized Neuromodulation Against Multiple Sclerosis Fatigue","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Topogr. 2021 Mar 3. doi: 10.1007&#x2F;s10548-021-00820-w. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Fatigue is a hidden symptom of Multiple Sclerosis (MS) disease that nevertheless impacts severely on patients&#39; everyday life. Evidence indicates the involvement of the sensorimotor network and its inter-nodes communication at the basis of this symptom. Two randomized controlled trials (RCTs) showed that the personalized neuromodulation called Fatigue Relief in Multiple Sclerosis (FaReMuS) efficaciously fights multiple sclerosis (MS) fatigue. By this Proof of Concept study, we tested whether FaReMuS reverts the alteration of the brain-muscular synchronization previously observed occurring with fatigue. The cortico muscular coherence (CMC) was studied in 11 patients before and after FaReMuS, a 5-day tDCS (1.5 mA, 15 min per day) anodal over the whole body&#39;s somatosensory representation (S1) via a personalized MRI-based electrode (35 cm&lt;sup&gt;2&lt;&#x2F;sup&gt;) against the occipital cathode (70 cm&lt;sup&gt;2&lt;&#x2F;sup&gt;). Before FaReMuS, the CMC was observed at a mean frequency of 31.5 Â± 1.6 Hz (gamma-band) and positively correlated with the level of fatigue (p &#x3D; .027). After FaReMuS, fatigue reduced in average of 28% Â± 33% the baseline level, and the CMC frequency reduced to 26.6 Â± 1.5 Hz (p &#x3D; .022), thus forthcoming the physiological beta-band as observed in healthy people. The personalized S1 neuromodulation treatment, ameliorating the central-peripheral communication that subtends simple everyday movements, supports the appropriateness of neuromodulations aiming at increasing the parietal excitability in fighting MS fatigue. The relationship between central-peripheral features and fatigue profile strengthens a central more than peripheral origin of the symptom.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656622&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2&quot;&gt;33656622&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10548-021-00820-w&gt;10.1007&#x2F;s10548-021-00820-w&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33656622&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303135644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":191,"discovery_date":"2021-03-03T12:36:46","title":"The Seaweed Diet in Prevention and Treatment of the Neurodegenerative Diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mar Drugs. 2021 Feb 26;19(3):128. doi: 10.3390&#x2F;md19030128.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Edible marine algae are rich in bioactive compounds and are, therefore, a source of bioavailable proteins, long chain polysaccharides that behave as low-calorie soluble fibers, metabolically necessary minerals, vitamins, polyunsaturated fatty acids, and antioxidants. Marine algae were used primarily as gelling agents and thickeners (phycocolloids) in food and pharmaceutical industries in the last century, but recent research has revealed their potential as a source of useful compounds for the pharmaceutical, medical, and cosmetic industries. The green, red, and brown algae have been shown to have useful therapeutic properties in the prevention and treatment of neurodegenerative diseases: Parkinson, Alzheimer&#39;s, and Multiple Sclerosis, and other chronic diseases. In this review are listed and described the main components of a suitable diet for patients with these diseases. In addition, compounds derived from macroalgae and their neurophysiological activities are described.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652930&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33652930&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;md19030128&gt;10.3390&#x2F;md19030128&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652930&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":190,"discovery_date":"2021-03-03T12:36:46","title":"Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 2:10.1212&#x2F;WNL.0000000000011788. doi: 10.1212&#x2F;WNL.0000000000011788. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To evaluate whether a retinal spectral-domain optical coherence tomography (SD-OCT) assessment at baseline is associated with long-term disability worsening in people with multiple sclerosis (PwMS), we performed SD-OCT and Expanded Disability Status Scale (EDSS) assessments among 132 PwMS at baseline and at a median of 10 years later.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: In this prospective, longitudinal study, participants underwent SD-OCT, EDSS, and visual acuity (VA) assessments at baseline and at follow-up. Statistical analyses were performed using generalized linear regression models, adjusted for age, sex, race, MS subtype, and baseline disability. We defined clinically meaningful EDSS worsening as an increase of â¥2.0 if baseline EDSS score was &amp;lt;6.0, or an increase of â¥1.0 if baseline EDSS score was â¥6.0.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 132 PwMS (mean age: 43 years; n&#x3D;106 patients with relapsing remitting MS) were included in analyses. Median duration of follow-up was 10.4 years. In multivariable models excluding eyes with prior optic neuritis, relative to patients with an average baseline ganglion cell+inner plexiform layer (GCIPL) thickness â¥70Âµm (the mean GCIPL thickness of all eyes at baseline), an average baseline GCIPL thickness &amp;lt;70Âµm was associated with a 4-fold increased odds of meaningful EDSS worsening (adjusted odds ratio: 3.97; 95% CI: 1.24-12.70; p&#x3D;0.02), and an almost 3-fold increased odds of low-contrast VA worsening (adjusted odds ratio: 2.93; 95% CI: 1.40-6.13; p&#x3D;0.04).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS. Accordingly, SD-OCT at a single time-point may help to guide therapeutic decision making among individual PwMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653904&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011788&gt;10.1212&#x2F;WNL.0000000000011788&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":189,"discovery_date":"2021-03-03T12:36:46","title":"Brain Activation Changes While Walking in Adults with and without Neurological Disease: Systematic Review and Meta-Analysis of Functional Near-Infrared Spectroscopy Studies","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Sci. 2021 Feb 26;11(3):291. doi: 10.3390&#x2F;brainsci11030291.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;(1) Functional near-infrared spectroscopy (fNIRS) provides a useful tool for monitoring brain activation changes while walking in adults with neurological disorders. When combined with dual task walking paradigms, fNIRS allows for changes in brain activation to be monitored when individuals concurrently attend to multiple tasks. However, differences in dual task paradigms, baseline, and coverage of cortical areas, presents uncertainty in the interpretation of the overarching findings. (2) Methods: By conducting a systematic review of 35 studies and meta-analysis of 75 effect sizes from 17 studies on adults with or without neurological disorders, we show that the performance of obstacle walking, serial subtraction and letter generation tasks while walking result in significant increases in brain activation in the prefrontal cortex relative to standing or walking baselines. (3) Results: Overall, we find that letter generation tasks have the largest brain activation effect sizes relative to walking, and that significant differences between dual task and single task gait are seen in persons with multiple sclerosis and stroke. (4) Conclusions: Older adults with neurological disease generally showed increased brain activation suggesting use of more attentional resources during dual task walking, which could lead to increased fall risk and mobility impairments. PROSPERO ID: 235228.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33652706&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3390&#x2F;brainsci11030291&gt;10.3390&#x2F;brainsci11030291&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":188,"discovery_date":"2021-03-03T12:36:46","title":"Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 2:10.1212&#x2F;WNL.0000000000011796. doi: 10.1212&#x2F;WNL.0000000000011796. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653899&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011796&gt;10.1212&#x2F;WNL.0000000000011796&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653899&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":187,"discovery_date":"2021-03-03T12:36:46","title":"Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Mar 2:10.1212&#x2F;WNL.0000000000011793. doi: 10.1212&#x2F;WNL.0000000000011793. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653903&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011793&gt;10.1212&#x2F;WNL.0000000000011793&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653903&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":186,"discovery_date":"2021-03-03T12:36:46","title":"Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Mar 2;8(3):e975. doi: 10.1212&#x2F;NXI.0000000000000975. Print 2021 May.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but within the unique microenvironment of the brain, type II antibodies may be more beneficial, as type II antibodies exhibit reduced complement-dependent cytotoxicity and they have an increased capacity to induce direct cell death that is independent of the host immune response.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We compared the effect of type I with type II anti-CD20 therapy in a new rodent model of secondary progressive MS (SPMS), which recapitulates the principal histopathologic features of MS including meningeal B-cell aggregates. Focal MS-like lesions were induced by injecting heat-killed &lt;i&gt;Mycobacterium tuberculosis&lt;&#x2F;i&gt; into the piriform cortex of MOG-immunized mice. Groups of mice were treated with anti-CD20 antibodies (type I [rituxumab, 10 mg&#x2F;kg] or type II [GA101, 10 mg&#x2F;kg]) 4 weeks after lesion initiation, and outcomes were evaluated by immunohistochemistry.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Anti-CD20 therapy decreased the extent of glial activation, significantly decreased the number of B and T lymphocytes in the lesion, and resulted in disruption of the meningeal aggregates. Moreover, at the given dose, the type II anti-CD20 therapy was more efficacious than the type I and also protected against neuronal death.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These results indicate that anti-CD20 may be an effective therapy for SPMS with B-cell aggregates and that the elimination of CD20&lt;sup&gt;+&lt;&#x2F;sup&gt; B cells alone is sufficient to cause disruption of aggregates in the brain.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653962&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33653962&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXI.0000000000000975&gt;10.1212&#x2F;NXI.0000000000000975&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33653962&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":185,"discovery_date":"2021-03-03T12:36:46","title":"Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Rev Neurosci. 2021 Mar 2. doi: 10.1038&#x2F;s41583-021-00431-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP43; also known as TARDBP or TDP-43) is a key pathological feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP43 typically resides in the nucleus but can shuttle between the nucleus and the cytoplasm to exert its multiple functions, which include regulation of the splicing, trafficking and stabilization of RNA. Cytoplasmic mislocalization and nuclear loss of TDP43 have both been associated with ALS and FTD, suggesting that calibrated levels and correct localization of TDP43 - achieved through an autoregulatory loop and tightly controlled nucleocytoplasmic transport - safeguard its normal function. Furthermore, TDP43 can undergo phase transitions, including its dispersion into liquid droplets and its accumulation into irreversible cytoplasmic aggregates. Thus, autoregulation, nucleocytoplasmic transport and phase transition are all part of an intrinsic control system regulating the physiological levels and localization of TDP43, and together are essential for the cellular homeostasis that is affected in neurodegenerative disease.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654312&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33654312&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41583-021-00431-1&gt;10.1038&#x2F;s41583-021-00431-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654312&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":184,"discovery_date":"2021-03-03T12:36:46","title":"Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuropsychiatr Dis Treat. 2021 Feb 22;17:587-604. doi: 10.2147&#x2F;NDT.S268360. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is a demyelinating disease that can damage neurons in the brain and spinal cord and is associated with several psychiatric disorders. However, few studies have evaluated the risk of psychiatric disorders in patients with MS by using a nationwide database. This study investigated the association between MS and the risk of psychiatric disorders.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Using data from the Taiwan National Health Insurance Research Database from 2000 to 2015, we identified 1066 patients with MS. After adjustment for confounding factors, Fine and Gray&#39;s competing risk model was used to compare the risk of psychiatric disorders during 15 years of follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Of the patients with MS, 531 (4622.86 per 10&lt;sup&gt;5&lt;&#x2F;sup&gt; person years) developed psychiatric disorders; by contrast, 891 of the 3198 controls (2485.31 per 10&lt;sup&gt;5&lt;&#x2F;sup&gt; person years) developed psychiatric disorders. Fine and Gray&#39;s competing risk model revealed an adjusted hazard ratio (HR) of 5.044 (95% confidence interval &#x3D; 4.448-5.870, &lt;i&gt;p&lt;&#x2F;i&gt; &amp;lt; 0.001) after adjustment for all the covariates. MS was associated with depression, anxiety, bipolar disorder, sleep disorders, schizophrenia, schizophreniform disorder, and other psychotic disorders (adjusted HR: 12.464, 4.650, 6.987, 9.103, 2.552, 2.600, 2.441, and 2.574, respectively; all p &amp;lt; 0.001). Some disease-modifying drugs were associated with a lower risk of anxiety or depression.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients with MS were determined to have a higher risk of developing a wide range of psychiatric disorders.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654401&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33654401&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7910105&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;PMC7910105&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;NDT.S268360&gt;10.2147&#x2F;NDT.S268360&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33654401&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":183,"discovery_date":"2021-03-03T12:36:46","title":"The emerging role of the chondroitin sulfate proteoglycan family in neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rev Neurosci. 2021 Mar 1. doi: 10.1515&#x2F;revneuro-2020-0146. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Chondroitin sulfate (CS) is a kind of linear polysaccharide that is covalently linked to proteins to form proteoglycans. Chondroitin sulfate proteoglycans (CSPGs) consist of a core protein, with one or more CS chains covalently attached. CSPGs are precisely regulated and they exert a variety of physiological functions by binding to adhesion molecules and growth factors. Widely distributed in the nervous system in human body, CSPGs contribute to the major component of extracellular matrix (ECM), where they play an important role in the development and maturation of the nervous system, as well as in the pathophysiological response to damage to the central nervous system (CNS). While there are more than 30 types of CSPGs, this review covers the roles of the most important ones, including versican, aggrecan, neurocan and NG2 in the pathogenesis of neurodegenerative diseases, including Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis and multiple sclerosis. The updated reports of the treatment of neurodegenerative diseases are involving CSPGs.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655733&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2&quot;&gt;33655733&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1515&#x2F;revneuro-2020-0146&gt;10.1515&#x2F;revneuro-2020-0146&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33655733&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303073644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":182,"discovery_date":"2021-03-03T07:16:46","title":"Roles of leptin on the key effector cells of rheumatoid arthritis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunol Lett. 2021 Feb 27:S0165-2478(21)00029-8. doi: 10.1016&#x2F;j.imlet.2021.02.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Leptin, an adipokine sharing structural characteristics of the long-chain helical cytokine family with the crucial role as a regulator in energy homeostasis, has been paid more and more attention on its immunoregulatory function. Emerging evidence has indicated the roles of leptin on autoimmune diseases such as systemic lupus erythematous (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA) and psoriasis, implying that leptin might be involved in autoimmune disorders. It is very definite that there exists immunocyte dysfunction in RA patients. Growing data has manifested that leptin was increased in both serum and synovial fluid of RA patients compared to healthy controls, suggesting leptin might take part in the pathogenesis of RA. The aim of this review is to discuss about what we currently know with regard to the role of leptin in immune system and its effects on RA crucial cells. To clarify the role of leptin in the pathogenesis of RA is beneficial to both the treatment and medical study.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652029&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652029&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.imlet.2021.02.008&gt;10.1016&#x2F;j.imlet.2021.02.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652029&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":181,"discovery_date":"2021-03-03T07:16:46","title":"Exercise training and cognition in multiple sclerosis: The GET Smart trial protocol","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Contemp Clin Trials. 2021 Feb 27:106331. doi: 10.1016&#x2F;j.cct.2021.106331. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) causes cognitive impairment in approximately 50% of cases. Disease modifying medications and cognitive rehabilitation produce only small positive effects on cognition in MS. Converging animal and human research suggests that aerobic exercise may improve cognition in people with MS, but definitive trials are lacking. We describe the design of the GET Smart study, a randomized controlled trial comparing the effects of aerobic exercise versus stretching and toning on cognition in MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The study is a single-blind, parallel group randomized (1:1) controlled trial that compares aerobic exercise training with an active control group consisting of stretching and toning exercises for improving cognition. Participants are nondepressed, ambulatory, non-exercising adults with MS aged 18-54 years who have below average cognitive processing speed. Both treatments were designed to generate equivalent outcome expectancies and entailed supervised, progressive exercise programs, 3 times per week for up to 40 min over a 6 month period.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PROJECTED PATIENT OUTCOMES: The primary hypothesis is that the aerobic training group will demonstrate significantly greater cognitive processing speed compared with the control group at the end of the treatment phase (6 months) as measured by a composite of the Paced Auditory Serial Additon Test and the oral Symbol-Digit Modalities Test using intent-to treat analyses. Secondary outcomes are neuropsychological functioning and cardiorespiratory fitness as well as participant reported outcomes such as depression, sleep, and fatigue. Study findings will inform future research, patient education, clinical care and policymaking.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02106052.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652128&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652128&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.cct.2021.106331&gt;10.1016&#x2F;j.cct.2021.106331&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652128&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":180,"discovery_date":"2021-03-03T07:16:46","title":"Accuracy of the Brazilian version of the DYMUS questionnaire for the screening of oropharyngeal dysphagia in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 19;50:102772. doi: 10.1016&#x2F;j.msard.2021.102772. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Oropharyngeal dysphagia is a common symptom of many neurological diseases, including Multiple Sclerosis (MS). Early identification of the risk of dysphagia in neurological patients is very important for early referral for specialized evaluations of oropharyngeal swallowing and treatments. The Dysphagia in Multiple Sclerosis (DYMUS) questionnaire has been translated and validated in different countries over the last 10 years. We aimed to analyze the accuracy of the Brazilian Portuguese version of the DYMUS (DYMUS-BR) questionnaire in identifying dysphagia in patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The DYMUS questionnaire and a videofluorographic swallowing study (VFSS) were conducted in 30 patients with MS. Dysphagia was identified by at least one abnormal response and was considered alarming when the DYMUS scores were equal to or higher than 3. Patients were considered to have dysphagia in the VFSS when one or more signs of impairment in the efficiency and&#x2F;or safety of swallowing were detected.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: According to the initial self-assessment, 37% (N &#x3D; 11) of patients with MS self-reported with dysphagia. According to the DYMUS-BR scores, 53% (N &#x3D; 16) of the patients with MS were classified as having dysphagia. The sensitivity, specificity, and positive and negative predictive values of the DYMUS-BR questionnaire for the detection of dysphagia as measured by the VFSS were 50% [95% confidence interval (CI) 29-71], 78% (95% CI 61-90), 60% (95% CI 42-76), and 70% (95% CI 60-78), respectively. The area under the receiver-operating characteristic curve for detecting dysphagia was 64% (95% CI 49-79).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The accuracy of the DYMUS-BR questionnaire is poor to detect mild swallowing impairment in patients with MS. However, we suggest longitudinal follow-up in patients with low DYMUS-BR scores for early detection of oropharyngeal dysphagia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652231&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652231&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102772&gt;10.1016&#x2F;j.msard.2021.102772&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652231&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":179,"discovery_date":"2021-03-03T07:16:46","title":"Seroconversion rate following HBV vaccination in clinical practice: The role of age and DMT treatment","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102859. doi: 10.1016&#x2F;j.msard.2021.102859. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;HBV screening and immunization is recommended in all MS patients and is mandatory before the start of some DMT. However, studies evaluating the immune response to HBV vaccine in MS patients are scarce. We aimed to evaluate the seroprotection rate following HBV immunization in MS patients and to assess if older age and DMT-treatment influenced seroprotection. We conducted a cohort study between 2016 and 2020 and compared the immune response to HBV vaccine in MS patients under different DMTs and in patients 50 years old or younger and older than 50. We found that patients under non-injectable DMT presented lower rates of seroprotection comparing to patients under injectable DMT&#39;s or without treatment. In patients older than 50, although the seroprotection rate was similar to the remaining patients, the antibody anti-HBV surface antigen titers following HBV immunization were lower and patients were more likely to require a 4th dose of the vaccine to achieve seroprotection. Our findings highlight to need to consider HBV immunization in MS patients early in the disease course, in order to ensure a proper immune response to the vaccine.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652232&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652232&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102859&gt;10.1016&#x2F;j.msard.2021.102859&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652232&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":178,"discovery_date":"2021-03-03T07:16:46","title":"Efficacy of core stability versus task oriented trainings on balance in ataxic persons with multiple sclerosis. A single blinded randomized controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102866. doi: 10.1016&#x2F;j.msard.2021.102866. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Balance and ataxic symptoms are commonly encountered in people with multiple sclerosis (PwMS). Many intervention approaches have been proposed to address balance in PwMS. The purpose of this study was to investigate the efficacy of adding core stability versus task oriented trainings on traditional approaches on balance in ataxic PwMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Forty five ataxic relapsing-remitting PwMS from both sexes were randomly assigned into three identical groups. Control group (CG) treated with conventional balance exercise program; study groups I (GI) and II (GII) received respectively additional training using core stability exercises and task oriented trainings. Outcome measures recorded pre and post study period included stability index (SI), anterior posterior stability index (APSI), and mediolateral stability index (MLSI) using Biodex stability system in addition to the Berg balance scale (BBS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Post treatment, the results indicated significant improvement in (SI) and (APSI) (p&amp;lt;0.05), and non-significant improvement (p&amp;gt;0.05) in (MLSI) and BBS in CG. In GI and GII there was a significant improvement in all balance measures (p&amp;lt;0.05). Comparison of post treatment results between groups indicated a significant improvement of GII compared to CG in all study measures, GI showed non- significant difference in all balance measures compared to the CG(P&amp;gt;0.05).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: In PwMS balance rehabilitation should be multimodal; core stability exercises and task-oriented training in addition to conventional balance training are effective to improve balance and should be considered as an essential part of the training program for balance rehabilitation in ataxic PwMS. Task-oriented training in addition to conventional balance rehabilitation seem to be a favorable approach.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652233&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2&quot;&gt;33652233&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102866&gt;10.1016&#x2F;j.msard.2021.102866&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33652233&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210303021644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":177,"discovery_date":"2021-03-03T00:36:46","title":"Validity of the Italian multiple sclerosis neuropsychological screening questionnaire","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Mar 2. doi: 10.1007&#x2F;s10072-021-05141-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is a brief questionnaire useful for screening patients with multiple sclerosis (MS) at risk for cognitive impairment. It includes a patient self-assessment (MSNQ-p) and a section for the caregiver (informant) (MSNQ-i). This study&#39;s aim was to validate the Italian version of MSNQ and to compare MSNQ scores with Symbol Digit Modality Test (SDMT), Beck Depression Inventory (BDI), and Expanded Disability Status Scale (EDSS) score, measuring cognitive skills, mood status, and physical disability respectively. We enrolled 122 MS patients (and related caregivers) at MS center of Tor Vergata University Hospital of Rome. The final study sample consisted of 122 patients with MS (90 relapsing-remitting, 24 secondary progressive, and 8 primary progressive). Our results highlighted that MSNQ has a unidimensional factor structure. Correlational analyses found a good correlation between both versions (MSNQ-p and MSNQ-i) of the questionnaire. Both MSNQ-p and MSNQ-i were correlated with clinical variables, specifically with cognitive impairment, mood disorder, and with disability. The Italian version of MSNQ is reliable and useful as screening tool to identify MS patients at high risk of cognitive impairment.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651198&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2&quot;&gt;33651198&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10072-021-05141-1&gt;10.1007&#x2F;s10072-021-05141-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651198&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":176,"discovery_date":"2021-03-03T00:36:46","title":"A man with erythematosquamous plaques","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ned Tijdschr Geneeskd. 2021 Feb 18;165:D5795.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;A 43-year-old male visited our dermatology department with a skin eruption diagnosed as psoriasis. It began 1 month after starting peg-interferon-Î±-1a therapy for multiple sclerosis. Peg-interferon is known to be able to induce psoriasis, as well as other medication, while the pathophysiology remains unclear.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651510&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2&quot;&gt;33651510&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651510&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302193644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":175,"discovery_date":"2021-03-02T23:16:45","title":"Benign monomelic amyotrophy of lower limb in a cohort of chinese patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Behav. 2021 Mar 2:e02073. doi: 10.1002&#x2F;brb3.2073. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Benign monomelic amyotrophy of lower limb (BMALL) is a neurogenic syndrome representing an unclear field. Further studies might be helpful to elucidate uncertainties regarding causation, outcome, and the risk of progression to amyotrophic lateral sclerosis (ALS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: According to the inclusion and exclusion criteria, 37 patients with BMALL were retrospectively collected in three neuromuscular centers from January 2012 to October 2018. The detailed medical data were summarized. Multiple laboratory tests were examined. Routine electrophysiological examinations, muscle MRI of lower limbs, and muscle biopsy were conducted.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The cohort included 24 male and 13 female cases with median age of onset 47 years. Muscle MRI revealed that the distribution of involved muscles matched with the extent of fat infiltration, so the pattern muscle atrophy can be divided into the following four types: six patients with thigh atrophy (type I), 14 patients with leg atrophy (type II); 10 patients with disproportionate atrophy in both thigh and leg (type III); and seven patients with well-proportionate atrophy in both thigh and leg (type IV). Electrophysiological findings showed neurogenic pattern, spontaneous activity, and abnormal H reflex, which suggested a disorder of spinal anterior horn cell in the patients with types I-III. However, no electrophysiological abnormalities were found in the patients with type IV. Muscle pathology varied from almost normal pattern to advanced neurogenic pattern in nine biopsied patients. Follow-up showed that two patients with type II developed to ALS four years later, and all patients with type IV were in stable condition without any complaints.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Muscle MRI was useful to exactly localize the distribution of involved muscles in BMALL patients. The distribution of atrophic muscles can be roughly divided into four types based on the MRI features. The classification of distributing types might be as an indicator for the prognosis of BMALL.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650811&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650811&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;brb3.2073&gt;10.1002&#x2F;brb3.2073&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650811&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":174,"discovery_date":"2021-03-02T23:16:45","title":"Untreated patients with multiple sclerosis: a study of French expert centers","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Mar 1. doi: 10.1111&#x2F;ene.14790. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Disease modifying therapies (DMTs), have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (pwMS) remain untreated. The objective of the present study was to determine the proportion of untreated patients with multiple sclerosis (pwMS) followed in expert centers in France and determine the predictive factors of non-treatment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Retrospective cohort study. Data were extracted from the 38 centers participating in the European Database for Multiple Sclerosis (EDMUS) on 12&#x2F;15&#x2F;2018 and pwMS seen at least once during the study period (from June 15, 2016 to June 14, 2017) were included. Results Among the 21,189 pwMS (age 47.1Â±13.1; EDSS 3.4Â±2.4), 6,631 (31.3%; 95%CI&#x3D;30.7-31.9) of the patients were not receiving any DMT. Although patients with a relapsing-remitting course (n &#x3D; 11,693) were the most likely to receive DMT, 14.8% (95%CI &#x3D; 14.2-15.4) were still untreated (6.8% never treated). After multivariate analysis among relapsing-remitting pwMS, the main factors explaining never having been treated were not having â¥9 lesions on brain MRI (OR &#x3D; 0.52 [0.44-0.61]) and lower EDSS (OR &#x3D; 0.78 [0.74-0.82]). Most patients with progressive MS (50.4% for secondary and 64.2% for primary progressive MS) did not receive any DMT during the study period, 11.6% for secondary and 34.0% for primary progressive MS had never received any DMT.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: A significant proportion of pwMS did not receive any DMT, even though such treatments are reimbursed by the healthcare system for French patients. This result highlights the unmet need for current DMTs for a large subgroup of pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650261&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650261&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14790&gt;10.1111&#x2F;ene.14790&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650261&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":173,"discovery_date":"2021-03-02T23:16:45","title":"Development of a Web-Based Mindfulness Program for People With Multiple Sclerosis: Qualitative Co-Design Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Med Internet Res. 2021 Mar 2;23(3):e19309. doi: 10.2196&#x2F;19309.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Mindfulness-based stress reduction is an efficacious treatment for people with chronic health problems; however, it is highly intensive and time-consuming, which is a barrier for service provision.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: This study aims to develop an internet-delivered adapted version of mindfulness-based stress reduction for people with multiple sclerosis to make the intervention more accessible.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We co-designed a web-based mindfulness program with end users, that is, people with multiple sclerosis (N&#x3D;19). Iterative feedback was also collected from a subsample of the initial group of end users (n&#x3D;11), and the program was reviewed by experts (n&#x3D;8).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: We identified three main themes common to people with multiple sclerosis: dealing with uncertainty and fears for the future, grief and loss, and social isolation. These themes were incorporated into narratives throughout the program. People with multiple sclerosis who reviewed the program gave feedback that the program was relatable, feasible, and acceptable. Experts agreed that the program appropriately represented the main tenets of mindfulness. Iterative feedback was used to further refine the program.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The web-based mindfulness program that we developed was viewed positively by both experts and end users. The program reflects common concerns for people with multiple sclerosis and has the potential to meet important unmet psychological needs. A randomized controlled trial was planned to determine the efficacy of the program.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650980&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650980&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2196&#x2F;19309&gt;10.2196&#x2F;19309&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650980&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":172,"discovery_date":"2021-03-02T23:16:45","title":"Metformin Protects Myelin from Degeneration in A Mouse Model of Iysophosphatidylcholine-Induced Demyelination in The Optic Chiasm","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell J. 2021 Apr;23(1):119-128. doi: 10.22074&#x2F;cellj.2021.7174. Epub 2021 Mar 1.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. The autoimmune pathology and long-term inflammation lead to substantial demyelination. These events lead to a substantial loss of oligodendrocytes (OLs), which in a longer period, results in axonal loss and long-term disabilities. Neural cells protection approaches decelerate or inhibit the disease progress to avoid further disability. Previous studies showed that metformin has beneficial effects against neurodegenerative conditions. In this study, we examined possible protective effects of metformin on toxin-induced myelin destruction in adult mice brains.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIALS AND METHODS: In this experimental study, lysophosphatidylcholine (LPC) was used to induce demyelination in mice optic chiasm. We examined the extent of demyelination at different time points post LPC injection using myelin staining and evaluated the severity of inflammation. Functional state of optic pathway was evaluated by visual evoked potential (VEP) recording.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Metformin attenuated LPC-induced demyelination (P&amp;lt;0.05) and inflammation (P&amp;lt;0.05) and protected against significant decrease (P&amp;lt;0.05) in functional conductivity of optic tract. These data indicated that metformin administration attenuates the myelin degeneration following LPC injection which led to functional enhancement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our findings suggest metformin for combination therapy for patients suffering from the myelin degenerative diseases, especially multiple sclerosis; however, additional mechanistic studies are required.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650828&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33650828&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.22074&#x2F;cellj.2021.7174&gt;10.22074&#x2F;cellj.2021.7174&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33650828&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":171,"discovery_date":"2021-03-02T23:16:45","title":"Neuroimmunology of COVID-19","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nervenarzt. 2021 Mar 2. doi: 10.1007&#x2F;s00115-021-01077-1. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Many neuroimmunological diseases, such as encephalopathy, encephalitis, myelitis and acute disseminated encephalomyelitis (ADEM) have occurred more frequently after infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which indicates a parainfectious or postinfectious association. The most likely underlying mechanisms include virus-triggered overactivation of the immune system with hyperinflammation and cytokine storm but potentially also the development of specific autoantibodies against central nervous system (CNS) tissue. These were predominantly detected in the cerebrospinal fluid of severely ill coronavirus disease 2019 (COVID-19) patients. In contrast, direct damage after invasion of SARS-CoVâ2 into the brain and spinal cord does not seem to play a relevant role. Susceptibility to infection with SARS-CoVâ2 in patients with multiple sclerosis, myasthenia or other neuroimmunological diseases including the risk for severe disease courses, is not determined by the administered immunotherapy but by known risk factors, such as age, comorbidities and the disease-related degree of disability. Therefore, immunotherapy in these patients should not be delayed or discontinued. The contribution of neuroimmunological mechanisms to long-term sequelae after survival of a COVID-19 illness, such as fatigue, impairment of memory, sleep dysfunction or anxiety, will require long-term clinical follow-up, preferentially in COVID-19 register studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651117&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2&quot;&gt;33651117&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00115-021-01077-1&gt;10.1007&#x2F;s00115-021-01077-1&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33651117&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302181644&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":170,"discovery_date":"2021-03-02T13:09:11","title":"Neuronal hibernation following hippocampal demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Neuropathol Commun. 2021 Mar 1;9(1):34. doi: 10.1186&#x2F;s40478-021-01130-9.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cognitive dysfunction occurs in greater than 50% of individuals with multiple sclerosis (MS). Hippocampal demyelination is a prominent feature of postmortem MS brains and hippocampal atrophy correlates with cognitive decline in MS patients. Cellular and molecular mechanisms responsible for neuronal dysfunction in demyelinated hippocampi are not fully understood. Here we investigate a mouse model of hippocampal demyelination where twelve weeks of treatment with the oligodendrocyte toxin, cuprizone, demyelinates over 90% of the hippocampus and causes decreased memory&#x2F;learning. Long-term potentiation (LTP) of hippocampal CA1 pyramidal neurons is considered to be a major cellular readout of learning and memory in the mammalian brain. In acute slices, we establish that hippocampal demyelination abolishes LTP and excitatory post-synaptic potentials of CA1 neurons, while pre-synaptic function of Schaeffer collateral fibers is preserved. Demyelination also reduced Ca&lt;sup&gt;2+&lt;&#x2F;sup&gt;-mediated firing of hippocampal neurons in vivo. Using three-dimensional electron microscopy, we investigated the number, shape (mushroom, stubby, thin), and post-synaptic densities (PSDs) of dendritic spines that facilitate LTP. Hippocampal demyelination did not alter the number of dendritic spines. Surprisingly, dendritic spines appeared to be more mature in demyelinated hippocampi, with a significant increase in mushroom-shaped spines, more perforated PSDs, and more astrocyte participation in the tripartite synapse. RNA sequencing experiments identified 400 altered transcripts in demyelinated hippocampi. Gene transcripts that regulate myelination, synaptic signaling, astrocyte function, and innate immunity were altered in demyelinated hippocampi. Hippocampal remyelination rescued synaptic transmission, LTP, and the majority of gene transcript changes. We establish that CA1 neurons projecting demyelinated axons silence their dendritic spines and hibernate in a state that may protect the demyelinated axon and facilitates functional recovery following remyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33648591&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s40478-021-01130-9&gt;10.1186&#x2F;s40478-021-01130-9&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":169,"discovery_date":"2021-03-02T13:09:11","title":"Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Genome Med. 2021 Feb 28;13(1):35. doi: 10.1186&#x2F;s13073-021-00853-7.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Immunoglobulin G4-related disease (IgG4-RD) and systemic sclerosis (SSc) are rare autoimmune diseases characterized by the presence of CD4+ cytotoxic T cells in the blood as well as inflammation and fibrosis in various organs, but they have no established etiologies. Similar to other autoimmune diseases, the gut microbiome might encode disease-triggering or disease-sustaining factors.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The gut microbiomes from IgG4-RD and SSc patients as well as healthy individuals with no recent antibiotic treatment were studied by metagenomic sequencing of stool DNA. De novo assembly-based taxonomic and functional characterization, followed by association and accessory gene set enrichment analysis, were applied to describe microbiome changes associated with both diseases.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Microbiomes of IgG4-RD and SSc patients distinctly separated from those of healthy controls: numerous opportunistic pathogenic Clostridium and typically oral Streptococcus species were significantly overabundant, while Alistipes, Bacteroides, and butyrate-producing species were depleted in the two diseases compared to healthy controls. Accessory gene content analysis in these species revealed an enrichment of Th17-activating Eggerthella lenta strains in IgG4-RD and SSc and a preferential colonization of a homocysteine-producing strain of Clostridium bolteae in SSc. Overabundance of the classical mevalonate pathway, hydroxyproline dehydratase, and fibronectin-binding protein in disease microbiomes reflects potential functional differences in host immune recognition and extracellular matrix utilization associated with fibrosis. Strikingly, the majority of species that were differentially abundant in IgG4-RD and SSc compared to controls showed the same directionality in both diseases. Compared with multiple sclerosis and rheumatoid arthritis, the gut microbiomes of IgG4-RD and SSc showed similar signatures; in contrast, the most differentially abundant taxa were not the facultative anaerobes consistently identified in inflammatory bowel diseases, suggesting the microbial signatures of IgG4-RD and SSc do not result from mucosal inflammation and decreased anaerobism.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: These results provide an initial characterization of gut microbiome ecology in fibrosis-prone IgG4-RD and SSc and reveal microbial functions that offer insights into the pathophysiology of these rare diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648559&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33648559&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s13073-021-00853-7&gt;10.1186&#x2F;s13073-021-00853-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648559&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":168,"discovery_date":"2021-03-02T13:09:11","title":"Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Immunol. 2021 Mar 1:ji1900656. doi: 10.4049&#x2F;jimmunol.1900656. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;IL-17A and IL-22 derived from Th17 cells play a significant role in mucosal immunity and inflammation. TGF-Î² and IL-6 promote Th17 differentiation; however, these cytokines have multiple targets. The identification and screening of additional molecules that regulate IL-17A and IL-22 responses in certain inflammatory conditions is of great clinical significance. In this study, we show that CDDO-Im, a specific Nrf2 activator, promotes IL-17A and IL-22 responses in murine Th17 cells. In contrast, CDDO-Im inhibits IL-17A response in multiple sclerosis patient-derived PBMCs. However, Nrf2 specifically regulates IL-22 response in vivo. Nrf2 acts through the regulation of antioxidant response element (ARE) binding motifs in target genes to induce or repress transcription. Promoter analysis revealed that &lt;i&gt;Il17a&lt;&#x2F;i&gt;, &lt;i&gt;Rorc&lt;&#x2F;i&gt;, and &lt;i&gt;Ahr&lt;&#x2F;i&gt; genes have several ARE motifs. We showed that Nrf2 bound to ARE repressor (ARE-R2) of &lt;i&gt;Rorc&lt;&#x2F;i&gt; and inhibited &lt;i&gt;Rorc&lt;&#x2F;i&gt;-dependent IL-17A transactivation. The luciferase reporter assay data showed that CDDO-Im regulated &lt;i&gt;Ahr&lt;&#x2F;i&gt; promoter activity. Chromatin immunoprecipitation quantitative PCR data showed that Nrf2 bound to ARE of AhR. Finally, we confirmed that the CDDO-Im-mediated induction of IL-22 production in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells was abrogated in CD4-specific &lt;i&gt;Ahr&lt;&#x2F;i&gt; knockout mice (&lt;i&gt;Ahr&lt;sup&gt;CD4&lt;&#x2F;sup&gt;&lt;&#x2F;i&gt; ). CH-223191, a specific AhR antagonist, inhibits CDDO-Im-induced IL-22 production in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells, which further confirmed the AhR-dependent regulation. Collectively, our data showed that Nrf2 via AhR pathways regulated IL-22 response in CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648937&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33648937&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.4049&#x2F;jimmunol.1900656&gt;10.4049&#x2F;jimmunol.1900656&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33648937&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":167,"discovery_date":"2021-03-02T13:09:11","title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 1:jnnp-2020-325302. doi: 10.1136&#x2F;jnnp-2020-325302. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. The most popular bridging therapy was oral prednisone taper chosen by 38% of responders while rituximab was the most popular maintenance therapy chosen by 46%. Most responders considered maintenance immunosuppression after a second relapse in patients with neuronal surface antibodies (70%) or seronegative autoimmune encephalitis (61%) as opposed to those with onconeuronal antibodies (29%). Most responders opted to cancer screening for 4 years in patients with neuronal surface antibodies (49%) or limbic encephalitis (46%) as opposed to non-limbic seronegative autoimmune encephalitis (36%). Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649021&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33649021&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-325302&gt;10.1136&#x2F;jnnp-2020-325302&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649021&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":166,"discovery_date":"2021-03-02T13:09:11","title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol Neurosurg Psychiatry. 2021 Mar 1:jnnp-2020-325300. doi: 10.1136&#x2F;jnnp-2020-325300. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. Corticosteroids alone or combined with other agents (intravenous IG or plasmapheresis) were selected as a first-line therapy by 84% of responders for patients with a general presentation, 74% for patients presenting with faciobrachial dystonic seizures, 63% for NMDAR-IgG encephalitis and 48.5% for classical paraneoplastic encephalitis. Half the responders indicated they would add a second-line agent only if there was no response to more than one first-line agent, 32% indicated adding a second-line agent if there was no response to one first-line agent, while only 15% indicated using a second-line agent in all patients. As for the preferred second-line agent, 80% of responders chose rituximab while only 10% chose cyclophosphamide in a clinical scenario with unknown antibodies. Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649022&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2&quot;&gt;33649022&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;jnnp-2020-325300&gt;10.1136&#x2F;jnnp-2020-325300&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33649022&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302080909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":165,"discovery_date":"2021-03-02T11:49:12","title":"Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 23;50:102860. doi: 10.1016&#x2F;j.msard.2021.102860. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Primary progressive multiple sclerosis (PPMS) has long been defined by progressive disability accrual in the absence of initial relapses. However, its underlying neurodegenerative process seems to be accompanied by central nervous system inflammation. A new classification defined multiple sclerosis courses according to clinical&#x2F;radiological activity and progression. We provide further insight into PPMS activity according to this classification and other daily living aspects.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This was a multicentre, prospective, cohort study including 55 adult patients with PPMS according to 2010 McDonald criteria, within ten years from neurologic symptom onset and not receiving disease-modifying therapies during the past six months, who were followed up for 12 months. The primary study endpoint was the percentage of patients with active disease based on clinical relapses and&#x2F;or magnetic resonance activity. Disability progression, cognitive function, physical&#x2F;psychological impact, depression symptoms, stigma and employment were secondary endpoints.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Eleven (25.6%) patients exhibited multiple sclerosis activity throughout the 12-month study follow-up. Fourteen showed non-active multiple sclerosis without progression, 11 non-active multiple sclerosis with progression, 6 active multiple sclerosis without progression and 4 active multiple sclerosis with progression; one patient with disease activity was not assessable for progression. Cognitive function scores remained unchanged or increased, disease physical impact was maintained and disease psychological impact significantly decreased. The proportion of patients with depression symptoms or stigma remained without significant changes as well as employment outcomes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: This study shows that one-fourth of PPMS patients may exhibit disease activity over one year, with disability progression in approximately one-third but without worsening of cognitive function, disease impact, depression, stigma or employment outcomes.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2&quot;&gt;33647591&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102860&gt;10.1016&#x2F;j.msard.2021.102860&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647591&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":164,"discovery_date":"2021-03-02T11:49:12","title":"Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 20;353:577525. doi: 10.1016&#x2F;j.jneuroim.2021.577525. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Tumour Necrosis Factor alpha (TNFÎ±) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFÎ± blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFÎ± blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFÎ± blockers-associated Multiple Sclerosis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647875&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2&quot;&gt;33647875&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577525&gt;10.1016&#x2F;j.jneuroim.2021.577525&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647875&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":163,"discovery_date":"2021-03-02T11:49:12","title":"Kidney Imaging Surveillance in Commercially Insured Patients With Tuberous Sclerosis Complex","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Pediatr Neurol. 2020 Dec 26;117:21-26. doi: 10.1016&#x2F;j.pediatrneurol.2020.12.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Kidney disease has historically been the primary source of early mortality in adults with tuberous sclerosis complex (TSC). Kidney imaging surveillance promotes early detection of lesions requiring intervention. We describe kidney imaging frequency in relationship to patient-level characteristics for commercially insured patients with TSC in the United States.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: This retrospective observational study used 2003 to 2016 enrollment and claims data from a de-identified fully insured commercial health insurer. Patients with TSC less than 65 years were included. The patient-level kidney imaging rate was calculated as the number of kidney imaging procedures divided by length of continuous enrollment. A multiple linear regression model was used to determine the relationship between imaging rate and progression of TSC-associated kidney disease, number of specialists seen, and nephrologist care.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: At least half of the 70 patients with TSC included in the study were aged 16 years or younger. Over a follow-up period of up to 14 years, the median kidney imaging rate was 0.13 procedures per year with 43% (N &#x3D; 30) of patients lacking evidence of kidney imaging during the observation period. Imaging frequency increased with progression of TSC-associated kidney disease, more specialists, and nephrologist care (P &amp;lt; 0.05 for all three in regression model).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: A substantial percentage of patients with TSC in the United States are at risk for delayed detection of kidney manifestations due to infrequent kidney imaging surveillance. Multispecialty care, including neurologists, may positively affect kidney surveillance rates.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647778&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2&quot;&gt;33647778&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.pediatrneurol.2020.12.008&gt;10.1016&#x2F;j.pediatrneurol.2020.12.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33647778&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210302064909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":162,"discovery_date":"2021-03-02T01:29:12","title":"Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Diagn Ther. 2021 Mar 1. doi: 10.1007&#x2F;s40291-021-00513-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cerebrospinal fluid (CSF) is a clear and paucicellular fluid that circulates within the ventricular system and the subarachnoid space of the central nervous system (CNS), and diverse CNS disorders can impact its composition, volume, and flow. As conventional CSF testing suffers from suboptimal sensitivity, this review aimed to evaluate the role of next-generation sequencing (NGS) in the work-up of infectious, neoplastic, neuroimmunological, and neurodegenerative CNS diseases. Metagenomic NGS showed improved sensitivity-compared to traditional methods-to detect bacterial, viral, parasitic, and fungal infections, while the overall performance was maximized in some studies when all diagnostic modalities were used. In patients with primary CNS cancer, NGS findings in the CSF were largely concordant with the molecular signatures derived from tissue-based molecular analysis; of interest, additional mutations were identified in the CSF in some glioma studies, reflecting intratumoral heterogeneity. In patients with metastasis to the CNS, NGS facilitated diagnosis, prognosis, therapeutic management, and monitoring, exhibiting higher sensitivity than neuroimaging, cytology, and plasma-based molecular analysis. Although evidence is still rudimentary, NGS could enhance the diagnosis and pathogenetic understanding of multiple sclerosis in addition to Alzheimer and Parkinson disease. To conclude, NGS has shown potential to aid the research, facilitate the diagnostic approach, and improve the management outcomes of all the aforementioned CNS diseases. However, to establish its role in clinical practice, the clinical validity and utility of each NGS protocol should be determined. Lastly, as most evidence has been derived from small and retrospective studies, results from randomized control trials could be of significant value.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646562&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646562&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s40291-021-00513-x&gt;10.1007&#x2F;s40291-021-00513-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646562&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":161,"discovery_date":"2021-03-02T01:29:12","title":"Neurologic Features Associated With SARS-CoV-2 Infection in Children: A Case Series Report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Child Neurol. 2021 Mar 1:883073821989164. doi: 10.1177&#x2F;0883073821989164. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Although multiple neurologic manifestations associated with SARS-CoV-2 infection have been described in adults, there is little information about those presented in children. Here, we described neurologic manifestations associated with COVID-19 in the pediatric population.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Retrospective case series report. We included patients younger than 18 years, admitted with confirmed SARS-CoV-2 infection and neurologic manifestations at our hospital in Santiago, Chile. Demographics, clinical presentations, laboratory results, radiologic and neurophysiological studies, treatment, and outcome features were described. Cases were described based on whether they presented with predominantly central or peripheral neurologic involvement.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Thirteen of 90 (14.4%) patients admitted with confirmed infection presented with new-onset neurologic symptoms and 4 patients showed epilepsy exacerbation. Neurologic manifestations ranged from mild (headache, muscle weakness, anosmia, ageusia), to severe (status epilepticus, Guillain-BarrÃ© syndrome, encephalopathy, demyelinating events).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We found a wide range of neurologic manifestations in children with confirmed SARS-CoV-2 infection. In general, neurologic symptoms were resolved as the systemic presentation subsided. It is essential to recognize and report the main neurologic manifestations related to this new infectious disease in the pediatric population. More evidence is needed to establish the specific causality of nervous system involvement.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646895&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646895&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;0883073821989164&gt;10.1177&#x2F;0883073821989164&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646895&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":160,"discovery_date":"2021-03-02T01:29:12","title":"Impact of complement activation on clinical outcomes in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Mar 1. doi: 10.1002&#x2F;acn3.51334. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We determined activation profiles of the classical and alternative complement pathway in 39 treatment-naÃ¯ve patients with early relapse-onset MS. Plasma concentrations of complement fragments were unchanged in MS compared to 32 patients with non-inflammatory neurological diseases. Profiles in patients experiencing clinical exacerbations did not differ from patients with stable disease and did not correlate with baseline EDSS, numbers of T2 lesions and time to second relapse. Long-term EDSS outcomes 4 years after diagnosis did not significantly correlate with baseline complement levels. These data do not support the use of complement activation products as biomarkers for disease activity in early MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646629&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646629&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51334&gt;10.1002&#x2F;acn3.51334&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646629&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":159,"discovery_date":"2021-03-02T01:29:12","title":"DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Elife. 2021 Feb 26;10:e58430. doi: 10.7554&#x2F;eLife.58430. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;We performed a systematic analysis of blood DNA methylation profiles from 4,483 participants from seven independent cohorts identifying differentially methylated positions (DMPs) associated with psychosis, schizophrenia and treatment-resistant schizophrenia. Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNA methylation data, with the largest differences seen in treatment-resistant schizophrenia patients. We implemented a stringent pipeline to meta-analyze epigenome-wide association study (EWAS) results across datasets, identifying 95 DMPs associated with psychosis and 1,048 DMPs associated with schizophrenia, with evidence of colocalization to regions nominated by genetic association studies of disease. Many schizophrenia-associated DNA methylation differences were only present in patients with treatment-resistant schizophrenia, potentially reflecting exposure to the atypical antipsychotic clozapine. Our results highlight how DNA methylation data can be leveraged to identify physiological (e.g., differential cell counts) and environmental (e.g., smoking) factors associated with psychosis and molecular biomarkers of treatment-resistant schizophrenia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646943&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2&quot;&gt;33646943&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7554&#x2F;eLife.58430&gt;10.7554&#x2F;eLife.58430&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646943&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301202911&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":158,"discovery_date":"2021-03-01T18:49:10","title":"Fingolimod-associated macular edema: A case report of late onset","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Ophthalmol. 2021 Mar 1:1120672121999632. doi: 10.1177&#x2F;1120672121999632. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: The authors present a case of a male with Multiple Sclerosis (MS) who developed unilateral Fingolimod-Associated Macular Edema (FAME) 10 years after initiating fingolimod therapy. By reporting this case study, the authors present a comprehensive review on FAME, its current incidence, and therapy options in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CASE DESCRIPTION: A 58-year-old Caucasian male patient was referred to the hospital with a history of MS. He was on fingolimod treatment for 10 years. The patient presented with a referring second episode of blurred vision in his left eye (OS). His best corrected visual acuity (BCVA) was 20&#x2F;20 (right eye - OD) and 20&#x2F;30 (OS). Dilated fundus examination of the OS revealed dull foveal reflex with retinal thickening. Spectral domain optical coherence tomography (SD-OCT) scan demonstrated increased central macular thickness of 459 Î¼m, foveal cysts and subretinal fluid. Neurologists decided to discontinue fingolimod treatment based on the ophthalmological findings. Three months post fingolimod discontinuation, macular edema resolved and BCVA was 20&#x2F;20 (OD) and 20&#x2F;25 (OS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: The authors report a case of late onset FAME. FAME may occur several years after starting fingolimod treatment and it should be part of differential diagnosis of blurred vision in patients receiving fingolimod. Both Microcystic Macular Edema secondary to MS and Macular Edema Associated with MS-induced Uveitis should always be excluded. Those two conditions, secondary to MS, might show the lack of drug effectiveness and the possible need for changing the existing therapy in order to prevent further disease progress.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645300&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645300&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1120672121999632&gt;10.1177&#x2F;1120672121999632&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645300&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":157,"discovery_date":"2021-03-01T18:49:10","title":"Translation, cross-cultural adaptation, and reliability and validity of the Turkish version of the SF-Qualiveen in people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurourol Urodyn. 2021 Mar 1. doi: 10.1002&#x2F;nau.24645. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: The short form Qualiveen (SF-Qualiveen) is a simple, easy to understand, and valid scale used to evaluate the effect of urologic problems on quality of life in neurological patients. The aim of this study was to translate, culturally adapt, and validate the Turkish version of the SF-Qualiveen in people with multiple sclerosis (pwMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Translation and cultural adaptation of the questionnaire was carried out after obtaining the necessary permissions. To decide on the final Turkish version of SF-Qualiveen, ten pwMS with urologic problems were pre-tested. Patients included in the study were asked to complete the Turkish SF-Qualiveen and urinary distress inventory-short form (UDI-6) questionnaires. The validity and reliability of the scale were determined after the retest 2 weeks later.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Sixty-three pwMS with urologic problems were enrolled. Internal consistency (Cronbach&#39;s Î± &#x3D; 0.87) and reproducibility intraclass correlation coefficient [ICC] &#x3D; 0.97) were good for the total SF-Qualiveen. The Cronbach&#39;s Î± and ICC values ranged from 0.43 to 0.77 and 0.88-0.98 for SF-Qualiveen subscales, respectively. Content validity of the questionnaire was appropriate. A moderate correlation was founded between the SF-Qualiveen and the UDI-6 (r &#x3D; 0.62; p &amp;lt; 0.001). There were no floor or ceiling effects in our study.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The Turkish version of the SF-Qualiveen is a valid and reliable questionnaire for pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645839&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;nau.24645&gt;10.1002&#x2F;nau.24645&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645839&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":156,"discovery_date":"2021-03-01T18:49:10","title":"Plasma Creatinine Level Does Not Predict Respiratory Function in Amyotrophic Lateral Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuromuscul Dis. 2021 Feb 23. doi: 10.3233&#x2F;JND-200583. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In amyotrophic lateral sclerosis (ALS) lower plasma creatinine level has been associated with shorter survival and faster functional decline. It has not been clear if creatinine is associated with respiratory outcome. We analyzed retrospectively a population of unselected ALS patients. Multiple-regression and Cox-regression analyses were performed. We included 233 patients, mean age 62.8, mean disease duration of 18.6 months. At baseline, creatinine was significantly associated with ALSFRS-R, but not with its decline rate. No predictive value was disclosed for FVC, or their decline rate, or with survival. We did not confirm that creatinine is a marker of respiratory outcome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646173&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33646173&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3233&#x2F;JND-200583&gt;10.3233&#x2F;JND-200583&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646173&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":155,"discovery_date":"2021-03-01T18:49:10","title":"Exploiting Rational Assembly to Map Distinct Roles of Regulatory Cues during Autoimmune Therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;ACS Nano. 2021 Mar 1. doi: 10.1021&#x2F;acsnano.0c07440. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Autoimmune diseases like multiple sclerosis (MS), type 1 diabetes, and lupus occur when the immune system attacks host tissue. Immunotherapies that promote selective tolerance without suppressing normal immune function are of tremendous interest. Here, nanotechnology was used for rational assembly of peptides and modulatory immune cues into immune complexes. Complexes containing self-peptides and regulatory nucleic acids reverse established paralysis in a preclinical MS model. Importantly, mice responding to immunotherapy maintain healthy, antigen-specific B and T cell responses during a foreign antigen challenge. A therapeutic library isolating specific components reveals that regulatory nucleic acids suppress inflammatory genes in innate immune cells, while disease-matched peptide sequences control specificity of tolerance. Distinct gene expression profiles in cells and animals are associated with the immune signals administered in particulate and soluble forms, highlighting the impact of biophysical presentation of signals. This work provides insight into the rational manipulation of immune signaling to drive tolerance.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645967&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1021&#x2F;acsnano.0c07440&gt;10.1021&#x2F;acsnano.0c07440&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645967&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":154,"discovery_date":"2021-03-01T18:49:10","title":"Connection between JAK&#x2F;STAT and PPARgamma signaling during the progression of multiple sclerosis: Insights into the modulation of T-cells and immune responses in the brain","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Mol Pharmacol. 2021 Mar 1. doi: 10.2174&#x2F;1874467214666210301121432. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple Sclerosis (MS) is a severe brain and spinal cord condition with a diverse autoimmune response and a wide variety of demyelination symptoms that primarily affect young adults. The primary reason for this disease is inflammation of white and grey matter caused by increased production of proinflammatory cytokines, which further damages the progenitor oligodendrocytes and appears to induce hypertrophy of the astrocytes and gliosis. Overexpression of the JAK&#x2F;STAT signaling pathway contributes directly to physiological and pathological results in motor neuron diseases. Cytokines such as IL-17, IL-6, IL-12, TNF-Î±, and INF-Ï use JAK&#x2F;STAT signaling to trigger self-reactive CD4+ T-cells differentiate them into Th1 phenotypes that over-activate immune reactions in the brain. Similarly, PPARÎ³ plays a critical role in regulating the immune response by providing an anti-inflammatory effect by inhibiting macrophage and cytokine production activation. PPARÎ³ also mediates the intrinsic molecular process of the T-cell, which selectively regulates the differentiation of Th17. Various studies indicate the neuroprotective function of PPARÎ³ agonists by attenuating the JAK&#x2F;STAT mediated activation of glial cells, inhibiting interleukin, and the differentiation of Th1 cells. Therefore, to maintain the brain&#39;s immune system, both PPARÎ³,and JAK&#x2F;STAT oppositely regulate each other. Dysregulation in JAK&#x2F;STAT and PPARÎ³ signaling contributes to several physiological changes leading to neurological disorders, including MS. Based on the above view; we summarized the combined role of JAK&#x2F;STAT-PPARÎ³signaling in MS and explored potential therapeutic strategies for disease improvement by the use of pathway modulators.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645493&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645493&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2174&#x2F;1874467214666210301121432&gt;10.2174&#x2F;1874467214666210301121432&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645493&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":153,"discovery_date":"2021-03-01T18:49:10","title":"Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Invest. 2021 Mar 1;131(5):141694. doi: 10.1172&#x2F;JCI141694.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Approximately 80% of neuromyelitis optica spectrum disorder (NMOSD) patients harbor serum anti-aquaporin-4 autoantibodies targeting astrocytes in the CNS. Crucial for NMOSD lesion initiation is disruption of the blood-brain barrier (BBB), which allows the entrance of Abs and serum complement into the CNS and which is a target for new NMOSD therapies. Astrocytes have important functions in BBB maintenance; however, the influence of their loss and the role of immune cell infiltration on BBB permeability in NMOSD have not yet been investigated. Using an experimental model of targeted NMOSD lesions in rats, we demonstrate that astrocyte destruction coincides with a transient disruption of the BBB and a selective loss of occludin from tight junctions. It is noteworthy that BBB integrity is reestablished before astrocytes repopulate. Rather than persistent astrocyte loss, polymorphonuclear leukocytes (PMNs) are the main mediators of BBB disruption, and their depletion preserves BBB integrity and prevents astrocyte loss. Inhibition of PMN chemoattraction, activation, and proteolytic function reduces lesion size. In summary, our data support a crucial role for PMNs in BBB disruption and NMOSD lesion development, rendering their recruitment and activation promising therapeutic targets.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645550&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33645550&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1172&#x2F;JCI141694&gt;10.1172&#x2F;JCI141694&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33645550&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":152,"discovery_date":"2021-03-01T18:49:10","title":"Telehealth in Multiple Sclerosis Clinical Care and Research","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Curr Neurol Neurosci Rep. 2021 Feb 28;21(4):14. doi: 10.1007&#x2F;s11910-021-01103-4.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: The COVID-19 pandemic has provided us with a unique opportunity to experiment with telehealth and evaluate its benefits and limitations. This review discusses the impact of telehealth on multiple sclerosis (MS) care and research in adults and children.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: Telehealth visits for MS patients have been shown to reduce missed workdays and costs for patients. Brief telephone-based counseling may be associated with better adherence to disease-modifying therapy, although results of multiple home-based tele-rehabilitation for people with MS have been equivocal. Overall, patients and providers have reported high levels of satisfactions with telehealth. Several remote disability measures and numerous other technological tools have emerged for use in remote MS research and care. Major challenges of telehealth include limitations to performing a complete neurologic exam and disparities in access to telehealth amongst vulnerable populations with limited access to virtual platforms. Following the rapid expansion of telehealth during the pandemic, it is highly likely that we will continue to embrace the benefits of this valuable tool. Future directions for improving telehealth should include more evidence-based research on the diagnostic accuracy in neuroimmunology and reducing disparities in the access to telehealth.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2&quot;&gt;33646409&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11910-021-01103-4&gt;10.1007&#x2F;s11910-021-01103-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33646409&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210301134909&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":151,"discovery_date":"2021-03-01T11:11:00","title":"Recent developments on PET radiotracers for TSPO and their applications in neuroimaging","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Acta Pharm Sin B. 2021 Feb;11(2):373-393. doi: 10.1016/j.apsb.2020.08.006. Epub 2020 Aug 25.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The 18 kDa translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor, is predominately localized to the outer mitochondrial membrane in steroidogenic cells. Brain TSPO expression is relatively low under physiological conditions, but is upregulated in response to glial cell activation. As the primary index of neuroinflammation, TSPO is implicated in the pathogenesis and progression of numerous neuropsychiatric disorders and neurodegenerative diseases, including Alzheimer&#x27;s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson&#x27;s disease (PD), multiple sclerosis (MS), major depressive disorder (MDD) and obsessive compulsive disorder (OCD). In this context, numerous TSPO-targeted positron emission tomography (PET) tracers have been developed. Among them, several radioligands have advanced to clinical research studies. In this review, we will overview the recent development of TSPO PET tracers, focusing on the radioligand design, radioisotope labeling, pharmacokinetics, and PET imaging evaluation. Additionally, we will consider current limitations, as well as translational potential for future application of TSPO radiopharmaceuticals. This review aims to not only present the challenges in current TSPO PET imaging, but to also provide a new perspective on TSPO targeted PET tracer discovery efforts. Addressing these challenges will facilitate the translation of TSPO in clinical studies of neuroinflammation associated with central nervous system diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643818/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643818&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7893127/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7893127&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.apsb.2020.08.006&gt;10.1016/j.apsb.2020.08.006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643818/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":150,"discovery_date":"2021-03-01T11:11:00","title":"Impact of Excipients on Stability of Polymer Microparticles for Autoimmune Therapy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Bioeng Biotechnol. 2021 Feb 11;8:609577. doi: 10.3389/fbioe.2020.609577. eCollection 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Therapies for autoimmune diseases such as multiple sclerosis and diabetes are not curative and cause significant challenges for patients. These include frequent, continued treatments required throughout the lifetime of the patient, as well as increased vulnerability to infection due to the non-specific action of therapies. Biomaterials have enabled progress in antigen-specific immunotherapies as carriers and delivery vehicles for immunomodulatory cargo. However, most of this work is in the preclinical stage, where small dosing requirements allow for on-demand preparation of immunotherapies. For clinical translation of these potential immunotherapies, manufacturing, preservation, storage, and stability are critical parameters that require greater attention. Here, we tested the stabilizing effects of excipients on the lyophilization of polymeric microparticles (MPs) designed for autoimmune therapy; these MPs are loaded with peptide self-antigen and a small molecule immunomodulator. We synthesized and lyophilized particles with three clinically relevant excipients: mannitol, trehalose, and sucrose. The biophysical properties of the formulations were assessed as a function of excipient formulation and stage of addition, then formulations were evaluated in primary immune cell culture. From a manufacturing perspective, excipients improved caking of lyophilized product, enabled more complete resuspension, increased product recovery, and led to smaller changes in MP size and size distribution over time. Cocultures of antigen-presenting cells and self-reactive T cells revealed that MPs lyophilized with excipients maintained tolerance-inducing function, even after significant storage times without refrigeration. These data demonstrate that excipients can be selected to drive favorable manufacturing properties without impacting the immunologic properties of the tolerogenic MPs.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33644005/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33644005&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7906284/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7906284&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fbioe.2020.609577&gt;10.3389/fbioe.2020.609577&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33644005/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":149,"discovery_date":"2021-03-01T11:11:00","title":"Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;ERJ Open Res. 2021 Feb 22;7(1):00235-2020. doi: 10.1183/23120541.00235-2020. eCollection 2021 Jan.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;This systematic review summarises current evidence to help guide treatment decisions for patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD). A systematic search of the literature (January 2012 to April 2018), including grey literature (searched between 1992 and 2011), was conducted using multiple electronic databases. Guidelines, meta-analyses, randomised controlled trials and observational studies reporting on risk stratification, screening, diagnosis, treatment and management outcomes for patients with SSc-ILD were included. A quality assessment of the included evidence was undertaken. In total, 2464 publications were identified and 280 included. Multiple independent risk factors for ILD in patients with SSc were identified, including older age, male sex and baseline pulmonary function. High-resolution computed tomography (HRCT) has been used for characterising ILD in patients with SSc, and pulmonary function tests are a key adjunctive component in the diagnostic and monitoring pathway. The clinical value of biomarkers relating to SSc-ILD diagnosis or assessment for disease progression is unknown at present. Immunosuppressive therapy (monotherapy or combined therapy) is the current standard of care for SSc-ILD; long-term evidence for effective and safe treatment of SSc-ILD is limited. Identification of patients at risk for SSc-ILD remains challenging. HRCT and pulmonary function tests are key to diagnosing and monitoring for disease progression. Although immunosuppressive therapy is considered current first-line treatment, it is partly associated with adverse effects and long-term follow-up evidence is limited. Novel therapies and biomarkers should be further explored in well-controlled clinical studies.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33644224/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33644224&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7897846/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7897846&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1183/23120541.00235-2020&gt;10.1183/23120541.00235-2020&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33644224/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":148,"discovery_date":"2021-03-01T11:11:00","title":"Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinsons Disease","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol India. 2021 Jan-Feb;69(1):115-118. doi: 10.4103/0028-3886.310102.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONTEXT: A host of microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, microRNA changes are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues of central nervous system diseases, including glioma, Alzheimer&#x27;s disease (AD), Parkinson&#x27;s disease (PD), multiple sclerosis, and depression. Compared with other body fluids, CSF can reflect the brain pathological processes more accurately.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;AIMS: To understand whether microRNA expression may be misregulated in patients with PD, and further discover potential diagnostic biomarkers and promising therapeutic targets for PD.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: Here, through real-time reverse-transcription polymerase chain reaction (RT-PCR), we compared CSF microRNA from 15 PD patients, 11 AD patients, and 16 controls with other neurologic disorders, such as encephalitis and Guillain-Barre syndrome.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Finally, we identified hsa-miR-626 changes in the CSF of PD patients. The mean expression level of hsa-miR-626 was significantly reduced in the CSF of PD patients compared with AD patients and controls.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our approach provides a preliminary research for identifying biomarkers in the CSF that could be used for the detection, diagnosis, and monitoring of PD.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642281/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642281&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.4103/0028-3886.310102&gt;10.4103/0028-3886.310102&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642281/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":147,"discovery_date":"2021-03-01T11:11:00","title":"Pharmacological interventions targeting nuclear factor-kappa B signaling in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neural Regen Res. 2021 Oct;16(10):2023-2025. doi: 10.4103/1673-5374.308088.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642388/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642388&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.4103/1673-5374.308088&gt;10.4103/1673-5374.308088&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642388/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":146,"discovery_date":"2021-03-01T11:11:00","title":"Astrocytic and Oligodendrocytic P2X7 Receptors Determine Neuronal Functions in the CNS","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Mol Neurosci. 2021 Feb 9;14:641570. doi: 10.3389/fnmol.2021.641570. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;P2X7 receptors are members of the ATP-gated cationic channel family with a preferential localization at the microglial cells, the resident macrophages of the brain. However, these receptors are also present at neuroglia (astrocytes, oligodendrocytes) although at a considerably lower density. They mediate necrosis/apoptosis by the release of pro-inflammatory cytokines/chemokines, reactive oxygen species (ROS) as well as the excitotoxic (glio)transmitters glutamate and ATP. Besides mediating cell damage i.e., superimposed upon chronic neurodegenerative processes in Alzheimer&#x27;s Disease, Parkinson&#x27;s Disease, multiple sclerosis, and amyotrophic lateral sclerosis, they may also participate in neuroglial signaling to neurons under conditions of high ATP concentrations during any other form of neuroinflammation/neurodegeneration. It is a pertinent open question whether P2X7Rs are localized on neurons, or whether only neuroglia/microglia possess this receptor-type causing indirect effects by releasing the above-mentioned signaling molecules. We suggest as based on molecular biology and functional evidence that neurons are devoid of P2X7Rs although the existence of neuronal P2X7Rs cannot be excluded with absolute certainty.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642994/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642994&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7906075/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7906075&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fnmol.2021.641570&gt;10.3389/fnmol.2021.641570&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642994/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":145,"discovery_date":"2021-03-01T11:11:00","title":"Engine Failure in Axo-Myelinic Signaling: A Potential Key Player in the Pathogenesis of Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Cell Neurosci. 2021 Feb 10;15:610295. doi: 10.3389/fncel.2021.610295. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple Sclerosis (MS) is a complex and chronic disease of the central nervous system (CNS), characterized by both degenerative and inflammatory processes leading to axonal damage, demyelination, and neuronal loss. In the last decade, the traditional &lt;i&gt;outside-in&lt;/i&gt; standpoint on MS pathogenesis, which identifies a primary autoimmune inflammatory etiology, has been challenged by a complementary &lt;i&gt;inside-out&lt;/i&gt; theory. By focusing on the degenerative processes of MS, the axo-myelinic system may reveal new insights into the disease triggering mechanisms. Oxidative stress (OS) has been widely described as one of the means driving tissue injury in neurodegenerative disorders, including MS. Axonal mitochondria constitute the main energy source for electrically active axons and neurons and are largely vulnerable to oxidative injury. Consequently, axonal mitochondrial dysfunction might impair efficient axo-glial communication, which could, in turn, affect axonal integrity and the maintenance of axonal, neuronal, and synaptic signaling. In this review article, we argue that OS-derived mitochondrial impairment may underline the dysfunctional relationship between axons and their supportive glia cells, specifically oligodendrocytes and that this mechanism is implicated in the development of a primary cytodegeneration and a secondary pro-inflammatory response (&lt;i&gt;inside-out&lt;/i&gt;), which in turn, together with a variably primed host&#x27;s immune system, may lead to the onset of MS and its different subtypes.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33642995/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33642995&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7902503/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7902503&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fncel.2021.610295&gt;10.3389/fncel.2021.610295&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33642995/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":144,"discovery_date":"2021-03-01T11:11:00","title":"A Neurodisparity Index of Nationwide Access to Neurological Health Care in Northern Ireland","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 12;12:608070. doi: 10.3389/fneur.2021.608070. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Nationwide disparities in managing neurological patients have rarely been reported. We compared neurological health care between the population who reside in a Health and Social Care Trust with a tertiary neuroscience center and those living in the four non-tertiary center Trusts in Northern Ireland. Using the tertiary center Trust population as reference, neurodisparity indices (NDIs) defined as the number of treated patients resident in each Trust per 100,000 residents compared to the same ratio in the tertiary center Trust for a fixed time period. NDIs were calculated for four neurological pathways-intravenous thrombolysis (iv-tPA) and mechanical thrombectomy (MT) for acute ischemic stroke (AIS), disease modifying treatment (DMT) in multiple sclerosis (MS) and admissions to a tertiary neurology ward. Neurological management was recorded in 3,026 patients. Patients resident in the tertiary center Trust were more likely to receive AIS treatments (iv-tPA and MT) and access to the neurology ward (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) than patients residing in other Trusts. DMT use for patients with MS was higher in two non-tertiary center Trusts than in the tertiary center Trust. There was a geographical gradient for MT for AIS patients and ward admissions. Averaged NDIs for non-tertiary center Trusts were: 0.48 (95%CI 0.32-0.71) for patient admissions to the tertiary neurology ward, 0.50 (95%CI 0.38-0.66) for MT in AIS patients, 0.78 (95%CI 0.67-0.92) for iv-tPA in AIS patients, and 1.11 (95%CI 0.99-1.26) for DMT use in MS patients. There are important neurodisparities in Northern Ireland, particularly for MT and tertiary ward admissions. Neurologists and health service planners should be aware that geography and time-dependent management of neurological patients worsen neurodisparities.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643193/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643193&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7907594/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7907594&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.608070&gt;10.3389/fneur.2021.608070&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643193/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":143,"discovery_date":"2021-03-01T11:11:00","title":"An Interview-Based Assessment of the Experience of Cognitive Impairment in Multiple Sclerosis: The Cognitive Assessment Interview (CAI)","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 11;12:637895. doi: 10.3389/fneur.2021.637895. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; Cognitive impairment is a common feature of multiple sclerosis (MS). A semi-structured interview, including informant input, can characterize the experience of individuals living with MS and cognitive involvement. &lt;b&gt;Objective:&lt;/b&gt; We administered the Cognitive Assessment Interview (CAI), a patient- and informant-based semi-structured interview, to characterize the experience of cognitive impairments in those living with MS. &lt;b&gt;Methods:&lt;/b&gt; Trained raters administered the CAI to a sample of MS participants and their informants enrolled for a trial of cognitive remediation. Cognitive impairments on the CAI were characterized and compared to those captured by neuropsychological and self-report measures. &lt;b&gt;Results:&lt;/b&gt; A total of &lt;i&gt;n&lt;/i&gt; = 109 MS participants (mean age = 50.3 Â± 12.2) and their available informants (&lt;i&gt;n&lt;/i&gt; = 71) were interviewed. Participants reported experiencing processing speed (90/106, 85%), working memory (87/109, 80%), and learning and memory (79/109, 72%) problems most commonly. CAI-based ratings were moderately correlated with a self-report measure (Multiple Sclerosis Neuropsychological Screening Questionnaire, &lt;i&gt;r&lt;/i&gt; &lt;sub&gt;s&lt;/sub&gt; = 0.52, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) and only mildly correlated with objective neuropsychological measures specific to executive functions (&lt;i&gt;r&lt;/i&gt; &lt;sub&gt;&lt;i&gt;s&lt;/i&gt;&lt;/sub&gt; = 0.21, &lt;i&gt;p&lt;/i&gt; = 0.029). For those with informant interviews, ratings were overall consistent, suggesting that the CAI is valid even in cases in which an informant is unavailable and the interview is conducted with the patient alone (as is often the case in clinical and research settings). &lt;b&gt;Conclusions:&lt;/b&gt; The CAI provides a semi-structured interview to characterize the experience of cognitive impairment in MS, with findings representing real-world functioning, adding valuable information to both self-report measures and neuropsychological assessment.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643211/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643211&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7905222/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7905222&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.637895&gt;10.3389/fneur.2021.637895&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643211/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":142,"discovery_date":"2021-03-01T11:11:00","title":"Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 12;12:645298. doi: 10.3389/fneur.2021.645298. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Borrelia-specific antibodies in serum did not contribute to the diagnosis of Borrelia arthritis or Borrelia-associated dermatitis in a young woman with ongoing treatment with rituximab due to multiple sclerosis. The diagnosis was confirmed by the detection of Borrelia-DNA in a skin punch biopsy. The patient history did not reveal any tick exposure. She had suffered for several months from fluctuating pain and swelling of the right knee as well as skin involvement with redness and oedema around the ankle of the same leg. Monoarthritis was confirmed by a rheumatologist. Knee puncture was performed but the synovial fluid was only sufficient for microscopic examination of crystals. Neither monosodium urate crystals nor calcium pyrophosphate crystals were found. Borrelia serology in blood revealed borderline levels of immunoglobulin (Ig)M and IgG, respectively. Treatment with doxycycline resulted in resolution of the joint and skin manifestations within a month. This case highlights that Borrelia-specific antibody levels cannot be reliably interpreted in patients who have received B-cell depleting therapy. Under these circumstances, detection of the bacterial genome in different body fluids, such as in the skin, can be a useful complement to the diagnosis of Lyme disease. In this young female, the diagnosis would certainly have been further delayed without the detection of Borrelia-DNA in the skin.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643217/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643217&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7907593/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7907593&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.645298&gt;10.3389/fneur.2021.645298&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643217/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":141,"discovery_date":"2021-03-01T11:11:00","title":"Health economics of disease-modifying therapy for multiple sclerosis in the United States","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ther Adv Neurol Disord. 2021 Feb 17;14:1756286420987031. doi: 10.1177/1756286420987031. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price increases for most DMTs have surpassed 10% annually. Currently, many MS DMTs exceed US$90,000 a year and their economic value is widely debated. In addition to creating a financial burden for the healthcare system, high DMT costs negatively impact patients through unaffordable out-of-pocket costs and excessive restrictions by insurance companies. The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643441/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643441&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7894590/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7894590&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1756286420987031&gt;10.1177/1756286420987031&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643441/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":140,"discovery_date":"2021-03-01T11:11:00","title":"Health Promoting Self-care Behaviors in Patients With Multiple Sclerosis in the Southeast of Iran: Developing a Model for Practice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Basic Clin Neurosci. 2020 Sep-Oct;11(5):687-699. doi: 10.32598/bcn.11.5.1670.1. Epub 2020 Sep 1.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Promoting self-care practice, as a critical strategy for enhancing the quality of life in patients with Multiple Sclerosis (MS) is a challenging issue. This study aimed to propose a model of health-promoting self-care behaviors in MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In this cross-sectional study, 200 patients with MS, who had referred to the Hospital for Special Diseases in Kerman City, Iran, were chosen. The main data collection instruments were the multiple sclerosis knowledge questionnaire, the Rosenberg self-esteem scale, multiple sclerosis self-efficacy scale, questionnaire of perceived barriers and benefits of self-care behaviors, social support, the health promotion lifestyle profile II, and resilience and sense of coherence scale. Data analysis was conducted in SPSS V. 22 and AMOS18 software. The Structural Equation Modeling (SEM) was also used for further analysis of data.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The model explained 82% of variance in Health-Promoting self-care Behavior (HPB). The results of the final model obtained from the SEM showed that self-efficacy (Î²=0.53, SE=0.04, P= 0.007), self-esteem (Î²=0.39, SE=0.04, P=0.005), social support (Î²=0.36, SE=0.04, P=0.009), sense of coherence (Î²=0.34, SE=0.07, P=0.006), resilience (Î²=0.33, SE=0.07, P=0.018), and perceived benefits (Î²=0.25, SE=0.05, P=0.009) had a positive and significant relationship with HPB.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The self-care empowerment model in patients with MS presented in this study can be used as a framework for designing health promotion interventions to improve the quality of life of patients with MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643561/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643561&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7878060/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7878060&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.32598/bcn.11.5.1670.1&gt;10.32598/bcn.11.5.1670.1&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643561/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":139,"discovery_date":"2021-03-01T11:11:00","title":"Personalised inpatient multidisciplinary rehabilitation elicits clinically relevant improvements in physical function in patients with multiple sclerosis - The Danish MS Hospitals Rehabilitation Study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 17;7(1):2055217321989384. doi: 10.1177/2055217321989384. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Evidence of the effects of inpatient multidisciplinary rehabilitation (MDR) on physical function in patients with multiple sclerosis (MS) is limited, particularly whether clinically relevant improvements can be achieved. The aim of this study, therefore, was to investigate the effects of personalised inpatient MDR on the physical function of MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Embedded in the Danish MS Hospitals Rehabilitation Study, a pragmatic study was performed in MS patients undergoing four weeks of inpatient MDR specifically targeting physical function. Outcomes were assessed at baseline (n = 142), at discharge (n = 137) and at six months follow-up (n = 126) using the six-minute walk test (6MWT), six-spot step test (SSST), five times sit to stand test (5STS), nine-hole peg test (NHPT), dynamic gait index (DGI) and 12-item MS walking scale (MSWS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: From Baseline-to-Discharge, significant and clinically relevant improvements were found in all measures of walking capacity (6MWT, SSST, 5STS, DGI and MSWS; p &amp;lt; 0.05) along with significant (but not clinically relevant) improvements in upper extremity function (NHPT; p &amp;lt; 0.05). Whilst comparable improvements were observed within subgroups of MS phenotype (relapsing-remitting [RR] vs. secondary + primary progressive [SP + PP]), disease severity (moderate [EDSS&lt;sub&gt;2.5-5.5&lt;/sub&gt;] vs. severe [EDSS&lt;sub&gt;6.0-7.5&lt;/sub&gt;]) and age (young/middle-aged [Age&lt;sub&gt;24-59&lt;/sub&gt;] vs. old [Age&lt;sub&gt;60-65&lt;/sub&gt;]), an attenuated adaptation was nevertheless observed for 6MWT in the most affected and vulnerable subgroups (i.e. SP + PP, EDSS&lt;sub&gt;6.0-7.5&lt;/sub&gt; and Age&lt;sub&gt;60-65&lt;/sub&gt;). The significant improvements in walking capacity and upper extremity function persisted at six months follow-up but did not exceed anymore the thresholds regarded as clinically relevant.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The results provide novel evidence that personalised inpatient MDR targeting physical function in MS patients elicits significant and clinically relevant improvements in physical function.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643662/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643662&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7894699/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7894699&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217321989384&gt;10.1177/2055217321989384&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643662/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":138,"discovery_date":"2021-03-01T11:11:00","title":"Remote administration of the symbol digit modalities test to individuals with multiple sclerosis is reliable: A short report","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 14;7(1):2055217321994853. doi: 10.1177/2055217321994853. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The Symbol Digit Modalities Test (SDMT) is the gold standard for cognitive screening in multiple sclerosis (MS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Due to the recent COVID-19 pandemic and the increased need for virtual clinical visits, we examined the reliability of remote administration of the SDMT vs. standard in-person administration to individuals with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Pearson&#x27;s correlation analysis was performed between SDMT scores on the in-person and remote administrations.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: For n = 132 participants, remote and in-person SDMT scores were strongly correlated (r = .80, &lt;i&gt;p&lt;/i&gt; = .000).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Remote administration of the SDMT is a reliable cognitive screening approach in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33643663/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33643663&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7890734/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;PMC7890734&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217321994853&gt;10.1177/2055217321994853&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33643663/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":137,"discovery_date":"2021-03-01T11:11:00","title":"Research progress of effect of Rhei Radix et Rhizoma and its anthraquinone in treatment of autoimmune diseases","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Zhongguo Zhong Yao Za Zhi. 2021 Jan;46(1):15-23. doi: 10.19540/j.cnki.cjcmm.20201012.601.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Rhei Radix et Rhizoma was first recorded in Shennong Ben Cao Jing, with a wide range of pharmacological activities. Autoimmune disease is a kind of disease that damages the tissue structure and function of immune cells and their components due to the impairment of immune tolerance function, including atherosclerosis, multiple sclerosis, gout, rheumatoid arthritis, autoimmune thyroiditis, ulcerative colitis, type 1 diabetes and IgA nephropathy. In recent years, clinical and experimental studies show that Rhei Radix et Rhizoma has potential therapeutic effects on autoimmune diseases. Under the guidance of the theory of traditional Chinese medicine, this paper reviews therapeutic and intervening effects of Rhei Radix et Rhizoma and its main active ingredient anthraquinone on autoimmune diseases. It also puts forward new study directions in view of the existing problems in studies of rhubarb and its anthraquinone, with the aim to provide reference for clinical treatment and scientific studies of effect of Rhei Radix et Rhizomaon autoimmune diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33645046/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301072909&amp;v=2.14.2&quot;&gt;33645046&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.19540/j.cnki.cjcmm.20201012.601&gt;10.19540/j.cnki.cjcmm.20201012.601&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33645046/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301072909&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":136,"discovery_date":"2021-03-01T11:11:00","title":"Acute myelopathies associated to SARS-CoV-2 infection: viral or immune-mediated damage?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Travel Med Infect Dis. 2021 Feb 25:102000. doi: 10.1016/j.tmaid.2021.102000. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33640477/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33640477&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.tmaid.2021.102000&gt;10.1016/j.tmaid.2021.102000&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33640477/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":135,"discovery_date":"2021-03-01T11:11:00","title":"Gamma Knife radiosurgery for the treatment of trigeminal neuralgia in patients with multiple sclerosis: A single-center retrospective study and literature review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;World Neurosurg. 2021 Feb 25:S1878-8750(21)00267-9. doi: 10.1016/j.wneu.2021.02.074. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Trigeminal neuralgia (TN) in patients with multiple sclerosis (MS) is a challenging condition to manage that is treated with Gamma Knife radiosurgery (GKRS). The aim of this report is to assess the safety, efficacy, and durability of GKRS for the treatment of TN in patients with MS. Our findings are compared with those of the existing literature and discussed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We retrospectively reviewed all patients at our institution who underwent GKRS for the treatment of TN secondary to MS and had one or more years of follow-up. Pre-operative and post-operative pain intensities and facial numbness were evaluated with the Barrow Neurological Institute (BNI) scores. Durability of successful pain relief was statistically evaluated with Kaplan-Meier analysis. The prognostic role of perioperative factors was investigated and analyzed using Cox proportional hazards regression.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: There were 29 patients with MS-TN who underwent GKRS at our institution. Two patients underwent bilateral treatment. Four patients underwent repeat GKRS for pain recurrence. The median period of follow-up assessment was 33 months. Rates of reasonable pain reduction at 1, 3, and 5 years were 70%, 57%, and 57% respectively. All patients who underwent repeat GKRS had durable pain reduction. No prognostic factor for successful pain reduction was found.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our study shows that GKRS for the treatment of TN secondary to MS is a safe and effective procedure in controlling pain in the short term, but often fails to provide long-term pain control. GKRS can be safely repeated to prolong the time of pain reduction.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33640527/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33640527&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.wneu.2021.02.074&gt;10.1016/j.wneu.2021.02.074&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33640527/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":134,"discovery_date":"2021-03-01T11:11:00","title":"Comparative treatment effectiveness of oral fingolimod and conventional injectable disease modifying agents in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Pharmacotherapy. 2021 Feb 28. doi: 10.1002/phar.2517. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Fingolimod was the first approved oral Disease Modifying Agent (DMA) to reduce relapses in Multiple Sclerosis (MS). Previous observational studies assessed the effectiveness of DMAs only through relapse and did not consider the treatment switch.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To compare the effectiveness of oral fingolimod and conventional injectable DMAs using the composite endpoint of relapse or treatment switch in patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: This retrospective longitudinal study utilized the IBM MarketScan Commercial Claims and Encounters Database from 2010-2012. Adults (â¥18 years) with MS diagnosis (ICD-9-CM:340) and newly initiated with a DMA were included. Cox Proportional Hazards (PH) regression model weighted for stabilized Inverse Probability Treatment Weights (IPTW) with robust sandwich estimator was used to evaluate the composite endpoint (time to relapse/treatment switch) between oral fingolimod and injectable DMA users during the one-year follow-up after the treatment initiation. Additional analyses were performed on patients who were adherent (proportion of days covered [PDC]â¥0.8) to DMAs during the first three months.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The incident study cohort consisted of 1,997 MS patients who initiated oral fingolimod (15.6%) or injectable (84.4%) DMAs. The proportion of patients who had a composite endpoint (relapse/DMA treatment switch) in oral fingolimod and injectable DMA users was found to be 16.72% and 27.16%, respectively. The Cox PH regression model with stabilized IPTW revealed that fingolimod is equally effective as injectable DMAs in reducing the risk of experiencing the composite endpoint of relapse or DMA switch (adjusted Hazards Ratio [aHR]: 0.67, 95% CI: 0.43-1.03). Additional analysis among patients who were adherent also found no significant difference in the composite endpoint (aHR: 0.70, 95% CI 0.49-1.15) between oral fingolimod and injectable DMA users.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Oral fingolimod has similar effectiveness as injectable DMAs in reducing the risk of experiencing the composite endpoint (relapse or treatment switch). In addition, when assessed independently, oral fingolimod showed no difference in reducing the time to relapse or DMA treatment switch compared to injectable DMA users.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33641232/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33641232&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/phar.2517&gt;10.1002/phar.2517&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33641232/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":133,"discovery_date":"2021-03-01T11:11:00","title":"Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Rev Neurosci. 2021 Feb 25. doi: 10.1515/revneuro-2020-0140. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is the most well-known autoimmune disorder of the central nervous system, and constitutes a major cause of disability, especially in young individuals. A wide array of pharmacological treatments is available, but they have often been proven to be ineffective in ameliorating disease symptomatology or slowing disease progress. As such, non-invasive and non-pharmacological techniques have been gaining more ground. Transcranial magnetic stimulation (TMS) utilizes the electric field generated by a magnetic coil to stimulate neurons and has been applied, usually paired with electroencephalography, to study the underlying pathophysiology of MS, and in repetitive trains, in the form of repetitive transcranial magnetic stimulation (rTMS), to induce long-lasting changes in neuronal circuits. In this review, we present the available literature on the application of TMS and rTMS in the context of MS, with an emphasis on its therapeutic potential on various clinical aspects, while also naming the ongoing trials, whose results are anticipated in the future.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33641274/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210301022914&amp;v=2.14.2&quot;&gt;33641274&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1515/revneuro-2020-0140&gt;10.1515/revneuro-2020-0140&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33641274/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210301022914&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":132,"discovery_date":"2021-02-28T11:11:00","title":"Mitochondrial Dysfunction and Traffic Jams in Amyotrophic Lateral Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mitochondrion. 2021 Feb 24:S1567-7249(21)00015-5. doi: 10.1016/j.mito.2021.02.008. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neurodegenerative diseases are characterized by progressive neuronal loss anatomically or physiologically and accumulation of protein in the cells. Mitochondria provide energy to these neuronal cells consuming 20% of the body&#x27;s oxygen. Mitochondria are the dynamic membrane-bound cell organelles that function to generate ATP, regulate calcium homeostasis, and produce reactive oxygen species. Because of alterations in the electron transport chain, mutation, and environmental toxins, there is reduced ATP production, calcium dyshomeostasis, and increased oxidative stress, resulting in mitochondrial dysfunction, leading to the pathogenesis of neurodegenerative diseases such as ALS. ALS is described as the loss of upper and lower motor neurons resulting in progressive muscle denervation and loss of voluntary movements. There are multiple shreds of evidence in the literature regarding the mechanism involved in mitochondrial dysfunction and possible therapeutic targets to treat the condition. Moreover, different studies reported the role of different gene mutations and malfunctions in transport system responsible for the accumulation and aggregation of the proteins inside the brain cells. This accumulation and/or aggregation of proteins in the neuronal cells is known as neuronal traffic jam, which also plays the leading role in the progressive neurodegenerative diseases. In this review, we have elucidated the critical insights into mitochondrial dysfunction and neuronal traffic jam; and its role in the initiation and progression of ALS. Moreover, the pharmacological targets and possible conducts to this scenario are also brought together.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33639271/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210228052230&amp;v=2.14.2&quot;&gt;33639271&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.mito.2021.02.008&gt;10.1016/j.mito.2021.02.008&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33639271/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210228052230&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":131,"discovery_date":"2021-02-28T11:11:00","title":"Early neuropsychological markers of cognitive involvement in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol Sci. 2021 Feb 17;423:117349. doi: 10.1016/j.jns.2021.117349. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Cognitive impairment due to multiple sclerosis (MS) is common and often limits occupational functioning, contributes to disability, and reduces quality of life. Early detection of cognitive involvement in MS is critical for treatment planning and intervention, and frequent, regular cognitive monitoring may provide insight into subtle changes in disease progression.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To compare the sensitivity and specificity of clinical, computer-based and experimental measures to early cognitive involvement in MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Cognitive functioning was compared in MS participants early in the disease course to matched healthy controls using conventional, computer-based and functional assessments: the Brief International Cognitive Assessment in MS (BICAMS); the computer-based Cogstate Brief Battery (CBB); the Attention Network Test-Interaction (ANT-I), including intra-individual variability; and the Test of Everyday Cognitive Ability (TECA), a functional measure of instrumental activities of daily living.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: MS participants (n = 25, mean disease duration= 5.82 Â± 3.65 years) and demographically matched healthy controls (n = 29) completed the cognitive assessments. The Cogstate measure of choice reaction time (AUC = 0.73, p = .004), intra-individual variability on the ANT-I (AUC = 0.79, p = .001), and TECA (AUC = 0.78, p = .001) scores were the most sensitive and specific markers of cognitive involvement in MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Brief, repeatable, computer-based measures of reaction time and variability detect early MS associated cognitive involvement.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33639421/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210228052230&amp;v=2.14.2&quot;&gt;33639421&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jns.2021.117349&gt;10.1016/j.jns.2021.117349&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33639421/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210228052230&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":130,"discovery_date":"2021-02-28T11:11:00","title":"Fall Prevention Education FOR People WITH Multiple Sclerosis: A Randomized Clinical Trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Int J Qual Health Care. 2021 Feb 26:mzab035. doi: 10.1093/intqhc/mzab035. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Online spaced education (OSE) is a method recognized for promoting long-term knowledge retention, changing behaviors, and improving outcomes for students and healthcare professionals. However, there is little evidence about the impacts on patient education. The aim of this research was to compare knowledge retention using educational brochure and OSE on individuals with multiple sclerosis (MS); to verify the impact of educational methods on fall outcome.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Individuals with MS (n=230) were randomly assigned for two types of patient education - educational brochure (control) and OSE (intervention). During 12 weeks, the intervention group received multiple choice tests on fall prevention. Knowledge retention, behavior change, and fall incidence were assessed before intervention and after three and six months. The participants&#x27; satisfaction with the education method was also evaluated.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Knowledge retention was similar between groups and behavior change was observed in both groups. There was a significant reduction in fall rate in the intervention group, from 0.60 to 0.27 at six months (p&amp;lt;0.001). Participants&#x27; satisfaction achieved an average of 8.75, with no differences between groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Individuals demonstrated significant improvement in fall rate outcome in both groups with no significant difference. On regard to test scores and satisfaction, results were similar between groups.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33638988/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227222934&amp;v=2.14.2&quot;&gt;33638988&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1093/intqhc/mzab035&gt;10.1093/intqhc/mzab035&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33638988/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227222934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":129,"discovery_date":"2021-02-27T11:11:00","title":"Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Breathe (Sheff). 2020 Dec;16(4):200203. doi: 10.1183/20734735.0203-2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Systemic inflammatory diseases are a heterogeneous family of autoimmune chronic inflammatory disorders that affect multiple systems within the human body. Connective tissue disease (CTD) is a large group within this family characterised by immune-mediated inflammation of the connective tissue. This group of disorders are often associated with pleural manifestations. CTD-induced pleuritis exhibits a wide variety of symptoms and signs including exudative pleural effusions and chest pain. Accurate estimation of prevalence for CTD-related pleuritis is challenging as small effusions are asymptomatic and remain undetected. Rheumatoid arthritis and systemic lupus erythematosus are frequent CTDs and present with pleural pathology in approximately 5-20% and 17-60% of cases, respectively. By contrast, pleural involvement in systemic sclerosis, eosinophilia-myalgia syndrome, mixed connective tissue disease, ankylosing spondylitis, polymyositis and dermatomyositis syndrome is rare. Clinical management depends on the severity of symptoms; however, most effusions resolve spontaneously. In this review we discuss the pathophysiological mechanisms and the clinical considerations of CTD-induced pleuritis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33447289/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227172937&amp;v=2.14.2&quot;&gt;33447289&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7792825/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227172937&amp;v=2.14.2&quot;&gt;PMC7792825&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1183/20734735.0203-2020&gt;10.1183/20734735.0203-2020&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33447289/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227172937&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":128,"discovery_date":"2021-02-27T11:11:00","title":"Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;BMJ Case Rep. 2021 Feb 26;14(2):e238167. doi: 10.1136/bcr-2020-238167.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;We present a case of 48-year-old woman with relapsing remitting multiple sclerosis (MS), who switched disease modifying therapy from Copaxone to Fingolimod due to her clinical and radiological MS disease progression. Unexpectedly after 2.5 years of stable MS symptoms and liver function tests (LFTs), we noted deranged LFTs during routine testing. Additional investigations showed hepatitis C positivity, genotype 3. It is likely a case of hepatitis C reactivation secondary to prolonged immunosuppressive effects of Fingolimod. Although the increased risk of viral reactivation related to varicella zoster virus is known to occur with Fingolimod treatment, to our knowledge, this is only the second case of hepatitis C disease activity reported with Fingolimod treatment. We would like to raise the awareness of hepatitis C viral reactivation as a possible complication of prolonged immunosuppression with Fingolimod.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637491/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637491&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/bcr-2020-238167&gt;10.1136/bcr-2020-238167&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637491/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":127,"discovery_date":"2021-02-27T11:11:00","title":"Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Actas Urol Esp. 2021 Feb 23:S0210-4806(20)30258-8. doi: 10.1016/j.acuro.2020.11.004. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Renal angiomyolipoma is a frequent manifestation of Tuberous Sclerosis Complex (TSC), for which everolimus therapy has been recently established as a novel non-invasive therapeutic option. As there are limited real life and long-term data, the analysis of our experience provides added value in terms of safety and efficacy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIAL AND METHODS: Descriptive analysis of our experience in patients with giant bilateral renal angiomyolipomas, in the context of TSC, treated with 10 mg oral everolimus daily, during a median of 71.5 months. We evaluated the following parameters: response rate and duration, reduction of kidney size and lesions, prevention of complications and presentation of toxicity and its cause.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: We confirm the effectiveness of treatment in 4 young patients, with multiple, bilateral angiomyolipomas of a median of 12 (5-19) cm maximum diameter, from June 2013 to date, after continuous reduction in lesion size, a decrease of 30% of the volume in 75% at six months and 50% in half of the subjects at two years, still showing drug response. Absence of complications such as bleeding or glomerular filtration rate decline in the long term, with a favorable safety profile, without interruptions and with mild-moderate, non-cumulative adverse effects, mostly within the first year of treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Everolimus is a safe and effective therapeutic option for renal angiomyolipoma and various manifestations of TSC, which has been reproduced in real life with six years of follow-up.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637375/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637375&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.acuro.2020.11.004&gt;10.1016/j.acuro.2020.11.004&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637375/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":126,"discovery_date":"2021-02-27T11:11:00","title":"Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 26;11(1):4735. doi: 10.1038/s41598-021-84023-0.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Early innate education of hematopoietic progenitors within the bone marrow (BM) stably primes them for either trained immunity or instead immunoregulatory functions. We herein demonstrate that in vivo or in vitro activation within the BM via Toll-like receptor-9 generates a population of plasmacytoid dendritic cell (pDC) precursors (CpG-pre-pDCs) that, unlike pDC precursors isolated from PBS-incubated BM (PBS-pre-pDCs), are endowed with the capacity to halt progression of ongoing experimental autoimmune encephalomyelitis. CpG activation enhances the selective migration of pDC precursors to the inflamed spinal cord, induces their immediate production of TGF-Î², and after migration, of enhanced levels of IL-27. CpG-pre-pDC derived TGF-Î² and IL-27 ensure protection at early and late phases of the disease, respectively. Spinal cords of CpG-pre-pDC-protected recipient mice display enhanced percentages of host-derived pDCs expressing TGF-Î² as well as an accumulation of IL-10 producing B cells and of CD11c&lt;sup&gt;+&lt;/sup&gt; CD11b&lt;sup&gt;+&lt;/sup&gt; dendritic cells. These results reveal that pDC precursors are conferred stable therapeutic properties by early innate activation within the BM. They further extend to the pDC lineage promising perspectives for cell therapy of autoimmune diseases with innate activated hematopoietic precursor cells.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637789/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637789&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41598-021-84023-0&gt;10.1038/s41598-021-84023-0&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637789/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":125,"discovery_date":"2021-02-27T11:11:00","title":"Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a \"common\" first line treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Rev Neurol (Paris). 2021 Feb 23:S0035-3787(21)00040-0. doi: 10.1016/j.neurol.2020.11.009. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: In countries where fingolimod is available as first-line therapy without restrictions, we have an opportunity to observe long-term efficacy profile of this drug in treatment-naive patients according to their initial disease activity.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We retrospectively analysed the data of RRMS patients treated with FTY, focusing on 2 groups: 17 highly active patients (HA) defined as follows: â¥2 relapses in the year before treatment initiation and eitherâ¥1 Gd-enhancing T1 lesion or a significant increase in T2 lesion load from a baseline MRI; and 37 &quot;not highly active&quot; (NHA). We reviewed treatment efficacy (defined as NEDA-3), reasons for discontinuation and treatment tolerance in both groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Mean follow-up duration was 48.2 months, SD 18.4. Fingolimod efficiently reduced relapses (NHA 90.3% reduction, P&amp;lt;0.001, HA 84.9%, P&amp;lt;0.001), and new Gd enhancing lesions (NHA 85.4% reduction, P=0.019, HA 92.3%, P=0.043). The proportion of patients reaching NEDA-3 status was higher in the NHA group (NHA: 80% at 2 years and 66% at 4 years, HA: 58% at 2 years and 38% at 4 years, P=0.042). Fingolimod was discontinued in 20 cases, mainly because of lack of efficacy (n=15).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: FTY is efficient in reducing relapses and new Gd enhancing lesions in both HA and NHA patients although the probability of achieving NEDA-3 over time is higher in early-treated treatment-naive NHA patients.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33637293/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33637293&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.neurol.2020.11.009&gt;10.1016/j.neurol.2020.11.009&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33637293/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227092934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":124,"discovery_date":"2021-02-27T11:11:00","title":"Low Field Magnetic Stimulation Promotes Myelin Repair and Cognitive Recovery in Chronic Cuprizone Mouse Model","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Exp Pharmacol Physiol. 2021 Feb 26. doi: 10.1111/1440-1681.13490. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an inflammatory demyelinating disease featured with neuroinflammation, demyelination, and the loss of oligodendrocytes. Cognitive impairment and depression are common neuropsychiatric symptoms in MS that are poorly managed with the present interventions.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: This study aimed to investigate the effects of low field magnetic stimulation (LFMS), a novel non-invasive neuromodulation technology, on cognitive impairment and depressive symptoms associated with MS using a mouse model of demyelination.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: C57BL female mice were fed with a 0.2% cuprizone diet for twelve weeks to induce a chronic demyelinating model followed by four weeks of cuprizone withdrawal with either sham or LFMS treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Improved cognition and depression-like behavior and restored weight gain were observed in mice with LFMS treatment. Immunohistochemical and immunoblotting data showed enhanced myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein expressions (MOG) in the prefrontal cortex of mice with LFMS treatment, supporting that myelin repair was promoted. LFMS also increased the protein expressions of mature oligodendrocyte biomarker glutathione-S-transferase (GST-Ï).In addition, expression of TGF-Î² and associated receptors were elevated with LFMS treatment, implicating this pathway in the response.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Results from the present study revealed LFMS to have neuroprotective effects, suggesting that LFMS has potential therapeutic value for treating cognitive impairment and depression related to demyelination disorders.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33638234/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227092934&amp;v=2.14.2&quot;&gt;33638234&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/1440-1681.13490&gt;10.1111/1440-1681.13490&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://onlinelibrary.wiley.com/doi/10.1111/1440-1681.13490","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":123,"discovery_date":"2021-02-27T11:11:00","title":"Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102845. doi: 10.1016/j.msard.2021.102845. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system (CNS) that affects both white and gray matter. Although it has been traditionally considered as a T cell mediated disease, the role of B cell in MS pathology has become a topic of great research interest. Cortical lesions, key feature of the progressive forms of MS, are involved in cognitive impairment and worsening of the patients&#x27; outcome. These lesions present pathognomonic hallmarks, such as: absence of blood-brain barrier (BBB) disruption, limited inflammatory events, reactive microglia, neurodegeneration, demyelination and meningeal inflammation. B cells located in the meninges, either as part of diffuse inflammation or as part of follicle-like structures, are strongly associated with cortical damage. The function of CD20-expressing B cells in MS is further highlighted by the success of specific therapies using anti-CD20 antibodies. The possible roles of B cells in pathology go beyond their ability to produce antibodies, as they also present antigens to T cells, secrete cytokines (both pathogenic and protective) within the CNS to modulate T and myeloid cell functions, and are involved in meningeal inflammation. Here, we will review the contributions of B cells to the pathogenesis of meningeal inflammation and cortical lesions in MS patients as well as in preclinical animal models.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636613/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636613&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102845&gt;10.1016/j.msard.2021.102845&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636613/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":122,"discovery_date":"2021-02-27T11:11:00","title":"Patterns of Medical Cannabis Use among Patients Diagnosed with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102830. doi: 10.1016/j.msard.2021.102830. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To survey the pattern and benefits of medical cannabis use (MCU) in a cross section of persons with multiple sclerosis (PWMS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: One hundred and fifteen subjects completed a 36-question survey online or on paper which queried aspects of their use of cannabis, including frequency of use, effect on symptoms, and changes in their use of prescription medications, as well asa number of key demographic variables such as age, gender, disease duration and clinical course, etc. All subjects were treated at a multiple sclerosis (MS) clinic in Connecticut and enrolled in the Connecticut Medical Marijuana Program (CTMMP).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Self-reported benefit from cannabis use for two or more symptoms of MS was associated with relapsing remitting MS (RRMS) vs progressive (PMS) (OR 3.043, 95% CI 1.026-9.028, p=0.038) and less benefit for two or more symptoms for those who required a wheelchair vs. those who ambulated without assistance (OR .246, 95% CI .195-.797, p=0.016). General benefit from cannabis use was reported for mood disorders (p&amp;lt;0.001), insomnia (p&amp;lt;0.001), sensory symptoms, including pain (p&amp;lt;0.001), and muscle cramps and spasms (p&amp;lt;0.001). Furthermore, benefit was also significantly associated with symptom severity in the case of insomnia (OR 9.735, 95% CI 2.751-34.445, p&amp;lt;0.001), and cramps and spasms (OR 5.234, 95% CI 1.261-21.729, p=0.014). A significant proportion of respondents had stopped or reduced prescription medications (86% vs. 55%, p&amp;lt;0.001) as a function of finding cannabis more effective than prescription medications. These included opioids, benzodiazepines, muscle relaxers and other pain medications.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: MCU among PWMS can lead to the reduction or discontinuation of several categories of prescription medications for symptoms of MS. Persons reporting the most benefit from MCU tended to have a milder form of MS with less disability, in contrast to previous studies. This study confirms the benefit of cannabis in several common MS symptoms, extending these findings to show that benefit can be related to baseline severity of some symptoms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636612/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636612&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102830&gt;10.1016/j.msard.2021.102830&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636612/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":121,"discovery_date":"2021-02-27T11:11:00","title":"Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102837. doi: 10.1016/j.msard.2021.102837. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Background Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) have been recently reevaluated as a biomarker of acquired demyelinating syndromes (ADS) of the central nervous system (CNS). Here, we describe the clinical and neuroimaging features, and the long-term outcome of children with ADS of the CNS associated with MOG-IgG. Methods All patients underwent brain and spinal cord magnetic resonance imaging (MRI), lumbar puncture for cerebrospinal fluid (CSF) analysis and MOG-IgG and aquaporin-4 IgG (AQP4-IgG) testing. Results Forty-eight pediatric patients were recruited. MOG-IgG were detected in 11/48 (25%) patients with the following clinical presentations: encephalomyelitis (EM), 8/11 (73%); optic neuritis (ON), 2/11 (18%); transverse myelitis (TM), 1/11 (9%). Patients negative for MOG-IgG were diagnosed with Multiple Sclerosis (MS) (n=15), EM (n=7), ON (n=7), neuromyelitis optica spectrum disorders (NMOSD) (n=5), TM (n=2) and encephalitis (n=1). MOG-IgG positive patients were younger at disease onset and they more frequently experienced encephalopathy and epileptic seizures compared with negative patients. EM and inflammatory lesions involving optic nerves on MRI imaging were more frequent in MOG-IgG positive patients. None of the patients with MOG-IgG became persistently seronegative during the follow-up, although a decrease in MOG-IgG titer was observed. Patients with MOG-IgG showed a good response to therapy and only two patients presented relapses during follow-up. Conclusion This study supports the distinction of MOG autoimmune oligodendrocytopathy as a unique disease entity, with clinical features different from those of MS and AQP4-IgG-positive NMOSD.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636614/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636614&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102837&gt;10.1016/j.msard.2021.102837&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636614/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":120,"discovery_date":"2021-02-27T11:11:00","title":"Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Cell Chem Biol. 2021 Feb 16:S2451-9456(21)00051-9. doi: 10.1016/j.chembiol.2021.01.025. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Small molecules that promote the formation of new myelinating oligodendrocytes from oligodendrocyte progenitor cells (OPCs) are potential therapeutics for demyelinating diseases. We recently established inhibition of specific cholesterol biosynthesis enzymes and resulting accumulation of 8,9-unsaturated sterols as a unifying mechanism through which many such molecules act. To identify more potent sterol enhancers of oligodendrocyte formation, we synthesized a collection of 8,9-unsaturated sterol derivatives and found that 24,25-epoxylanosterol potently promoted oligodendrocyte formation. In OPCs, 24,25-epoxylanosterol was metabolized to 24,25-epoxycholesterol via the epoxycholesterol shunt pathway. Increasing flux through the epoxycholesterol shunt using genetic manipulation or small-molecule inhibition of lanosterol synthase (LSS) increased endogenous 24,25-epoxycholesterol levels and OPC differentiation. Notably, exogenously supplied 24,25-epoxycholesterol promoted oligodendrocyte formation despite lacking an 8,9-unsaturation. This work highlights epoxycholesterol shunt usage, controlled by inhibitors of LSS, as a target to promote oligodendrocyte formation. Additionally, sterols beyond the 8,9-unsaturated sterols, including 24,25-epoxycholesterol, drive oligodendrocyte formation.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636107/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636107&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.chembiol.2021.01.025&gt;10.1016/j.chembiol.2021.01.025&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636107/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":119,"discovery_date":"2021-02-27T11:11:00","title":"Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 21;50:102851. doi: 10.1016/j.msard.2021.102851. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636615/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636615&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102851&gt;10.1016/j.msard.2021.102851&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636615/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":118,"discovery_date":"2021-02-27T11:11:00","title":"Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 20;50:102850. doi: 10.1016/j.msard.2021.102850. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: Depression, anxiety, stress, and physical disabilities are a common complaint in people with multiple sclerosis (MS), and monitoring of these symptoms are based on self-report questionnaires. The objective of this study was to determine psychometric properties of the Croatian version of the Depression, Anxiety, and Stress Scale-21 (DASS-21) and Multiple Sclerosis Impact Scale-29 (MSIS-29) in people with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: We included data on 163 people with MS registered in the Association of multiple sclerosis societies of Croatia (AMSSC). Patients&#x27; demographic information, education level, and disease-related variables were ascertained. DASS-21 was applied for assessing depression, anxiety, and stress, while MSIS-29 scale was used for assessment of the physical and psychological impact of MS disease. Psychometric properties were examined by estimating the validity and reliability of the DASS-21 and MSIS-29 scale. Predictive validity of DASS-21 subscales and relevant demographic and disease-related variables was examined by the hierarchical regression model.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The Croatian version of the three DASS-21 subscales and two MSIS-29 subscales had excellent internal consistencies (Cronbach&#x27;s alpha coefficients 0.88-0.93) and good convergent validity, as expressed by inter-correlations between DASS-21 and MSIS-29 subscales. Hierarchical regression analysis using MSIS-29 subscales as criterion variables showed consistent evidence for the predictive validity of depression, anxiety, and stress on psychological impact, and predictive validity of age, EDSS, and anxiety on physical impact.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: The Croatian versions of DASS-21 and MSIS-29 are reliable and valid scales in people with MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636617/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636617&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102850&gt;10.1016/j.msard.2021.102850&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636617/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":117,"discovery_date":"2021-02-27T11:11:00","title":"Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 28;50:102801. doi: 10.1016/j.msard.2021.102801. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains unclear. Therefore, we explored whether these modifiable lifestyle factors were associated with 10-year clinical disability progression in patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In this prospective study, a cohort of 88 patients with relapsing-remitting MS completed a randomized controlled study on Ï-3 fatty acids between 2004 and 2008. During 24 months, serum 25-hydroxyvitamin D (25(OH)D), serum cotinine (nicotine metabolite), and BMI were repeatedly measured. In 2017, a follow-up study was conducted among 80 of the participants, including disability assessment by the Expanded Disability Status Scale (EDSS). Linear regression was used to explore associations between the lifestyle factors and the EDSS change over 10 years.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Higher seasonally adjusted 25(OH)D levels were associated with lower 10-year EDSS progression (change in EDSS per 1 SD increase in 25(OH)D in a model adjusted for sex, age and baseline EDSS: -0.45 point, 95% CI: -0.75 to -0.16, p=0.003). Further adjustments for potential confounders related to lifestyle and disease status gave similar results. The association was mainly driven by low 25(OH)D levels during spring, as well as seasonally adjusted levels below 80 nmol/L. No clear association was found for BMI and cotinine.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Lower 25(OH)D levels, but apparently not tobacco use or higher BMI, were significantly associated with worse long-term disability progression in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33636616/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210227052934&amp;v=2.14.2&quot;&gt;33636616&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102801&gt;10.1016/j.msard.2021.102801&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33636616/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210227052934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":116,"discovery_date":"2021-02-26T11:11:00","title":"Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The research is focused on sensitive biomarkers in multiple sclerosis (MS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA (no evident disease activity), including brain volumetry, in a cohort of MS patients treated with disease-modifying treatment (DMT).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Levels of pNfL (Single Molecule Array (SIMOA) technology) were examined in 95 RRMS (relapsing-remitting multiple sclerosis) patients and analyzed in relationship to NEDA-3 status and NEDA-BVL (brain volume loss; NEDA-3 extended by brain volumetry) during the last 12 months. The statistical model was developed using logistic regression analysis, including the independent variables: demographic, clinical, and magnetic resonance imaging (MRI) data. Dependent variables were NEDA-3 and NEDA-BVL status.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The mean age of the study participants (&lt;i&gt;n&lt;/i&gt; = 95, 62% females) was 37.85 years (standard deviation (SD) = 9.62) and the median disability score was 3.5 (2.5-4.1). Receiver operating characteristics (ROC) analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 92% and 78%, respectively, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) and NEDA-BVL status (the sensitivity and specificity were 80% and 65%, respectively, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-BVL status, including brain MRI-volumetry in patients with RRMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635154/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635154&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521998039&gt;10.1177/1352458521998039&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635154/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":115,"discovery_date":"2021-02-26T11:11:00","title":"Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Sci. 2021 Feb 26. doi: 10.1007/s10072-021-05086-5. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Fingolimod is currently approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of pediatric patients with relapsing-remitting multiple sclerosis (RRMS). However, transient asymptomatic bradycardia with treatment initiation has been reported in a small population of predisposed patients, which may be a result of short-term activation and internalization/desensitization of the G-protein-gated potassium channel IKACh on the atrial myocyte membrane. Asymptomatic bradycardia, with or without atrioventricular block, is generally self-limiting and has been reported within the first 6 h of administration of the first oral dose of fingolimod. Therefore, patients initiating fingolimod treatment are monitored for this initial period to identify any changes in their electrocardiogram and heart rate that may require further treatment. Here, we report a case of a 17-year-old female with RRMS who received her first fingolimod dose and showed asymptomatic bradycardia that resolved without treatment.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635428/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635428&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10072-021-05086-5&gt;10.1007/s10072-021-05086-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635428/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":114,"discovery_date":"2021-02-26T11:11:00","title":"Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 26:1352458521994259. doi: 10.1177/1352458521994259. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory demyelinating disorder of the central nervous system (CNS). Aquaporin-4 (AQP4) antibodies in the serum are highly specific for the diagnosis of NMOSD, but the sensitivity remains under 90% allowing for diagnosis of AQP4 IgG seronegative disease. It remains of crucial importance to identify seronegative NMOSD myelitis as early as the first attack to initiate long-term treatment that will reduce future relapses and disability and to avoid potentially harmful treatments such as those of multiple sclerosis (MS). Over the years, many spinal imaging features have been reported to favour the diagnosis of NMOSD, but only longitudinally extensive transverse myelitis (LETM) was specific enough to make the diagnostic criteria in the AQP4 IgG seronegative cases. Bright spotty lesions (BSLs), which are defined as hyperintense lesions on axial T2-weighted images and sometimes associated with T1 low signal, are now reported to have a higher specificity and sensitivity compared to LETM in predicting a diagnosis of NMOSD against other causes of myelitis. In the review, we aim to highlight the position of BSLs in diagnosing NMOSD as well as its possible role as a prognostic factor for the clinical outcome.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635151/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635151&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521994259&gt;10.1177/1352458521994259&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635151/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":113,"discovery_date":"2021-02-26T11:11:00","title":"Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autophagy. 2021 Feb 8:1-382. doi: 10.1080/15548627.2020.1797280. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for &lt;i&gt;bona fide&lt;/i&gt; autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33634751/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33634751&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/15548627.2020.1797280&gt;10.1080/15548627.2020.1797280&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33634751/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":112,"discovery_date":"2021-02-26T11:11:00","title":"Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To evaluate whether ibudilast 100 mg/day alters serum and cerebrospinal fluid (CSF) levels of NfL in progressive MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In a protocol-defined exploratory analysis from a 2-year, phase 2 clinical trial of ibudilast in progressive MS (NCT01982942), serum samples were collected from 239 subjects and a subset contributed CSF and assayed using single-molecule assay (SIMOA) immunoassay. A mixed model for repeated measurements yielded log(NfL) as the response variable.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The geometric mean baseline serum NfL was 31.9 and 28.8 pg/mL in placebo and ibudilast groups, respectively. The geometric mean baseline CSF NfL was 1150.8 and 1290.3 pg/mL in placebo and ibudilast groups, respectively. Serum and CSF NfL correlations were &lt;i&gt;r&lt;/i&gt; = 0.52 and &lt;i&gt;r&lt;/i&gt; = 0.78 at weeks 48 and 96, respectively. Over 96 weeks, there was no between-group difference in NfL in either serum (&lt;i&gt;p&lt;/i&gt; = 0.76) or CSF (&lt;i&gt;p&lt;/i&gt; = 0.46). After controlling for factors that may affect NfL, no effect of ibudilast on NfL in either serum or CSF was observed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Ibudilast treatment was not associated with a change in either serum or CSF NfL.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635141/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635141&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458520986956&gt;10.1177/1352458520986956&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635141/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":111,"discovery_date":"2021-02-26T11:11:00","title":"Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Metab Brain Dis. 2021 Feb 26. doi: 10.1007/s11011-021-00691-x. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple Sclerosis (MS) is a progressive neurodegenerative disease with clinical signs of neuroinflammation and the central nervous system&#x27;s demyelination. Numerous studies have identified the role of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) overexpression and the low level of peroxisome proliferator-activated receptor-gamma (PPAR-Î³) in MS pathogenesis. Guggulsterone (GST), an active component derived from &#x27;Commiphora Mukul,&#x27; has been used to treat various diseases. Traditional uses indicate that GST is a suitable agent for anti-inflammatory action. Therefore, we assessed the therapeutic potential of GST (30 and 60 mg/kg) in ethidium bromide (EB) induced demyelination in experimental rats and investigated the molecular mechanism by modulating the JAK/STAT and PPAR-Î³ receptor signaling. Wistar rats were randomly divided into six groups (n = 6). EB (0.1%/10 Î¼l) was injected selectively in the intracerebropeduncle (ICP) region for seven days to cause MS-like manifestations. The present study reveals that long-term administration of GST for 28 days has a neuroprotective effect by improving behavioral deficits (spatial cognition memory, grip, and motor coordination) associated with lower STAT-3 levels. While elevating PPAR-Î³ and myelin basic protein levels in rat brains are consistent with the functioning of both signaling pathways. Also, GST modulates the neurotransmitter level by increasing Ach, dopamine, serotonin and by reducing glutamate. Moreover, GST ameliorates inflammatory cytokines (TNF, IL-1Î²), and oxidative stress markers (AchE, SOD, catalase, MDA, GSH, nitrite). In addition, GST prevented apoptosis, as demonstrated by the reduction of caspase-3 and Bax. Simultaneously, Bcl-2 elevation and the restoration of gross morphology alterations are also recovered by long-term GST treatment. Therefore, it can be concluded that GST may be a potential alternative drug candidate for MS-related motor neuron dysfunctions.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33635478/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226132934&amp;v=2.14.2&quot;&gt;33635478&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s11011-021-00691-x&gt;10.1007/s11011-021-00691-x&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33635478/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226132934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":110,"discovery_date":"2021-02-26T11:11:00","title":"C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autophagy. 2021 Feb 26:1-17. doi: 10.1080/15548627.2021.1872189. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two clinically distinct classes of neurodegenerative disorders. Yet, they share a range of genetic, cellular, and molecular features. Hexanucleotide repeat expansions (HREs) in the &lt;i&gt;C9orf72&lt;/i&gt; gene and the accumulation of toxic protein aggregates in the nervous systems of the affected individuals are among such common features. Though the mechanisms by which HREs cause toxicity is not clear, the toxic gain of function due to transcribed HRE RNA or dipeptide repeat proteins (DPRs) produced by repeat-associated non-AUG translation together with a reduction in C9orf72 expression are proposed as the contributing factors for disease pathogenesis in ALS and FTD. In addition, several recent studies point toward alterations in protein homeostasis as one of the root causes of the disease pathogenesis. In this review, we discuss the effects of the C9orf72 HRE in the autophagy-lysosome pathway based on various recent findings. We suggest that dysfunction of the autophagy-lysosome pathway synergizes with toxicity from C9orf72 repeat RNA and DPRs to drive disease pathogenesis.&lt;b&gt;Abbreviation:&lt;/b&gt; ALP: autophagy-lysosome pathway; ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ASO: antisense oligonucleotide; C9orf72: C9orf72-SMCR8 complex subunit; DENN: differentially expressed in normal and neoplastic cells; DPR: dipeptide repeat protein; EIF2A/eIF2Î±: eukaryotic translation initiation factor 2A; ER: endoplasmic reticulum; FTD: frontotemporal dementia; GAP: GTPase-activating protein; GEF: guanine nucleotide exchange factor; HRE: hexanucleotide repeat expansion; iPSC: induced pluripotent stem cell; ISR: integrated stress response; M6PR: mannose-6-phosphate receptor, cation dependent; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MN: motor neuron; MTORC1: mechanistic target of rapamycin kinase complex 1; ND: neurodegenerative disorder; RAN: repeat-associated non-ATG; RB1CC1/FIP200: RB1 inducible coiled-coil 1; SLC66A1/PQLC2: solute carrier family 66 member 1; SMCR8: SMCR8-C9orf72 complex subunit; SQSTM1/p62: sequestosome 1; STX17: syntaxin 17; TARDBP/TDP-43: TAR DNA binding protein; TBK1: TANK binding kinase 1; TFEB: transcription factor EB; ULK1: unc-51 like autophagy activating kinase 1; UPS: ubiquitin-proteasome system; WDR41: WD repeat domain 41.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632058/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632058&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/15548627.2021.1872189&gt;10.1080/15548627.2021.1872189&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632058/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":109,"discovery_date":"2021-02-26T11:11:00","title":"Overview of stem cells therapy in amyotrophic lateral sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Res. 2021 Feb 25:1-17. doi: 10.1080/01616412.2021.1893564. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons with high burden on society. Despite tremendous efforts over the last several decades, there is still no definite cure for ALS. Up to now, only two disease-modifying agents, riluzole and edaravone, are approved by U.S. Food and Drug Administration (FDA) for ALS treatment, which only modestly improves survival and disease progression. Major challenging issues to find an effective therapy are heterogeneity in the pathogenesis and genetic variability of ALS. As such, stem cell therapy has been recently a focus of both preclinical and clinical investigations of ALS. This is because stem cells have multifaceted features that can potentially target multiple pathogenic mechanisms in ALS even though its underlying mechanisms are not completely elucidated. &lt;b&gt;Methods &amp;amp; Results:&lt;/b&gt; Here, we will have an overview of stem cell therapy in ALS, including their therapeutic mechanisms, the results of recent clinical trials as well as ongoing clinical trials. In addition, we will further discuss complications and limitations of stem cell therapy in ALS. &lt;b&gt;Conclusion:&lt;/b&gt; The determination of whether stem cells offer a viable treatment strategy for ALS rests on well-designed and appropriately powered future clinical trials. Randomized, double-blinded, and sham-controlled studies would be valuable.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632084/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632084&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/01616412.2021.1893564&gt;10.1080/01616412.2021.1893564&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632084/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":108,"discovery_date":"2021-02-26T11:11:00","title":"Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on \"Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function\"","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Fluids Barriers CNS. 2021 Feb 25;18(1):9. doi: 10.1186/s12987-021-00244-5.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Pilz et al. (Fluids Barriers CNS 17:7; 2020) investigated how CSF CXCL13 concentrations are influenced by CXCL13 serum concentrations and blood-CSF barrier (BCSFB) function, comparing the impact of serum CXCL13 levels and Q&lt;sub&gt;albumin&lt;/sub&gt; (CSF albumin/serum albumin) on CSF CXCL13 among patients with CNS inflammation categorized as CXCL13 negative, low, medium, or high. Among all CXCL13 groups, their results showed no correlation between CSF CXCL13 concentrations and serum CXCL13 or Q&lt;sub&gt;albumin&lt;/sub&gt;. The authors argue that, in contrast to other proteins, CXCL13 passage across the BCSFB does not occur, regardless of BCSFB function, and is instead solely influenced by intrathecal production. In contrast to the authors&#x27; findings, in our studies including both non-inflammatory neurological disorders (NIND; n = 62) and multiple sclerosis (MS) patients we observed a significant correlation between serum CXCL13 concentrations and CSF CXCL13 concentrations. We review several observations which may underlie these contrasting results, including (1) the impact of serum CXCL13 concentrations on CSF CXCL13 in patients with lower intrathecal CXCL13 production and thus lower CXCL13 concentrations (i.e. NIND and MS), (2) the proposed diffusion dynamics of the small molecule CXCL13 across the BCSFB, and (3) differing definitions of negative versus elevated CSF CXCL13 concentrations determined by an assay&#x27;s relative sensitivity. In conclusion, we argue that for patients with moderately elevated CSF CXCL13 concentrations, serum CXCL13 concentrations influence CSF CXCL13 levels, and thus the appropriate corrections including incorporation of CSF/serum ratios and Q&lt;sub&gt;albumin&lt;/sub&gt; values should be utilized.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632258/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632258&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1186/s12987-021-00244-5&gt;10.1186/s12987-021-00244-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632258/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":107,"discovery_date":"2021-02-26T11:11:00","title":"Optic neuropathy by ethambutol in a patient with multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Arch Soc Esp Oftalmol. 2021 Feb 22:S0365-6691(21)00019-8. doi: 10.1016/j.oftal.2020.12.009. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;We present the clinical case of a patient who developed a toxic optic neuropathy due to ethambutol in the context of a tuberculosis reactivation and who also had a personal history of multiple sclerosis. The objective is to highlight the importance of making a good differential diagnosis of this adverse effect and of knowing its main clinical, campimetric and tomographic manifestations and characteristics. Furthermore, since the reversibility of damage is still discussed in the literature, early diagnosis is essential. For this purpose, it is important to inform the patient of the possible symptoms and to carry out an ophthalmological examination and colour tests before starting treatment to assess whether there is progression.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632567/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632567&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.oftal.2020.12.009&gt;10.1016/j.oftal.2020.12.009&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632567/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":106,"discovery_date":"2021-02-26T11:11:00","title":"Symptom management of patients with multiple sclerosis in primary care: focus on overlooked symptoms","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Br J Gen Pract. 2021 Feb 25;71(704):139-141. doi: 10.3399/bjgp21X715193. Print 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33632695/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33632695&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3399/bjgp21X715193&gt;10.3399/bjgp21X715193&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33632695/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":105,"discovery_date":"2021-02-26T11:11:00","title":"Cognitive Impairment Impacts Exercise Effects on Cognition in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Jan 28;11:619500. doi: 10.3389/fneur.2020.619500. eCollection 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Purpose:&lt;/b&gt; Exercise training reveals high potential to beneficially impact cognitive performance in persons with multiple sclerosis (pwMS). Research indicates that high-intensity interval training (HIIT) has potentially higher effects on physical fitness and cognition compared to moderate continuous exercise. This study (i) compares the effects of a 3-week HIIT and moderate continuous exercise training on cognitive performance and cardiorespiratory fitness of pwMS in an overall analysis and (ii) investigates potential effects based on baseline cognitive status in a subgroup analysis. &lt;b&gt;Methods:&lt;/b&gt; Seventy-five pwMS were randomly assigned to an intervention (HIIT: 5 Ã 1.5-min intervals at 95-100% HR&lt;sub&gt;max&lt;/sub&gt;, 3 Ã/week) or active control group (CG: 24 min continuous exercise at 65% HR&lt;sub&gt;max&lt;/sub&gt;, 3 Ã/week). Cognitive performance was assessed pre- and post-intervention with the Brief International Cognitive Assessment for MS (BICAMS). (I) To examine potential within (time) and interaction (time Ã group) effects in the overall analysis, separate analyses of covariance (ANCOVA) were conducted. (II) For the subgroup analysis, participants were divided into two groups [intact cognition or impaired cognition (&amp;gt;1.5 standard deviation (SD) compared to healthy, age-matched norm data in at least one of the three tests of the BICAMS]. Potential impacts of cognitive status and intervention were investigated with multivariate analyses of variance (MANOVA). &lt;b&gt;Results:&lt;/b&gt; Overall analysis revealed significant time effects for processing speed, verbal learning, rel. VO2peak, and rel. power output. A time&lt;sup&gt;*&lt;/sup&gt;group interaction effect was observed for rel. power output. Subgroup analysis indicated a significant main effect for cognition (impaired cognition vs. intact cognition). Subsequent &lt;i&gt;post-hoc&lt;/i&gt; analysis showed significant larger effects on verbal learning in pwMS with impaired cognition. &lt;b&gt;Conclusion:&lt;/b&gt; Current results need to be confirmed in a powered randomized controlled trial with cognitive performance as primary endpoint and eligibility based on cognitive performance that is assessed prior to study inclusion.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33633658/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33633658&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7902024/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;PMC7902024&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2020.619500&gt;10.3389/fneur.2020.619500&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33633658/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":104,"discovery_date":"2021-02-26T11:11:00","title":"Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Neurol. 2021 Feb 9;12:618370. doi: 10.3389/fneur.2021.618370. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Sexual dysfunction (SD) in people with multiple sclerosis (pwMS) has a detrimental impact on individual health-related quality of life (HRQoL). It is not clear whether SD in multiple sclerosis (MS) is an independent symptom or merely a byproduct of other symptoms such as depression or anxiety. This cross-sectional study of 93 pwMS determines risk factors for SD in MS based on prevalence, HRQoL, and associated disease outcomes. Diagnosis of SD was determined based on the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19) and correlated with physical disability (measured by Expanded Disability Status scale, EDSS), depression and anxiety [Hospital Anxiety and Depression Scale (HADS)], and HRQoL [Multiple Sclerosis Quality of Life-54 (MSQoL-54)]. Multivariate regression models were performed to determine independent risk factors for SD in pwMS. Almost half of the participants in this study (46%) reported SD. HRQoL was significantly poorer in patients with MS suffering from SD (median [IQR] MSQoL-54 scores: physical subscale 52 [41-68] vs. 81 [69-89], &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001; mental subscale 50 [38-82] vs. 86 [70-89], &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001). In the multivariate model, EDSS was the only independent risk factor for SD (OR 18.1 for EDSS â¥4 [95% CI 3.3-31.4, &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001]), while depression and anxiety were not. We conclude that the risk for SD is growing with increasing EDSS and is independent of depression or anxiety. Screening for SD becomes particularly relevant in patients with growing disability.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33633671/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33633671&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7900565/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;PMC7900565&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fneur.2021.618370&gt;10.3389/fneur.2021.618370&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33633671/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":103,"discovery_date":"2021-02-26T11:11:00","title":"Coping strategies: Seeking personalized care in relapsing-remitting multiple sclerosis. A patient reported measure-coping responses inventory","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 11;7(1):2055217320987588. doi: 10.1177/2055217320987588. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Coping is defined as a set of cognitive and behavioral efforts made to master stressful specific demands. Adaptation to chronic diseases, such as Multiple Sclerosis (MS), depends on the effectiveness of coping. &lt;b&gt;Objective:&lt;/b&gt; To assess the psychometric properties of the Coping Responses Inventory (CRI-A) in persons with MS (PwMS), verifying the transferability of the measure, already validated in the Argentine general population, and to describe the types of coping strategies available for PwMS. &lt;b&gt;Methods:&lt;/b&gt; 90 PwMS were included. &lt;b&gt;Outcome measures:&lt;/b&gt; CRI-A Inventory, Expanded Disability Status Scale (EDSS), Beck Depression Inventory, Fatigue Severity Scale and MS International Quality of Life questionnaire. &lt;b&gt;Results:&lt;/b&gt; Descriptive data is as follows: mean age (years): 40.97 Â± 12.85; years of education: 13.46 Â± 3.93; EDSS: 2.48 Â± 1.79; disease evolution (years): 10.76 Â± 9.72; depression: 13.92 Â± 10.45; fatigue 3.77 Â± 1.72. The psychometric properties of the CRI-A Inventory observed in the Argentine general population are present in the MS sample as well, with adequate validity and reliability. The respondents most frequently utilized a problem-focused coping style. &lt;b&gt;Conclusions:&lt;/b&gt; Results showed the CRI-A has good transferability properties from the Argentine general population to the MS population.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33633866/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;33633866&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7887687/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226082934&amp;v=2.14.2&quot;&gt;PMC7887687&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217320987588&gt;10.1177/2055217320987588&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33633866/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226082934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":102,"discovery_date":"2021-02-26T11:11:00","title":"Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Psychosom Res. 2021 Feb 16;144:110402. doi: 10.1016/j.jpsychores.2021.110402. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To compare and characterize major depressive disorder (MDD) subtypes (i.e., pure atypical, pure melancholic and mixed atypical-melancholic) and depression symptoms in persons with multiple sclerosis (PwMS) with persons without MS (Pw/oMS) fulfilling the DSM-5 criteria for a past 12-month MDD.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: MDD in PwMS (n = 92) from the Swiss Multiple Sclerosis Registry was compared with Pw/oMS (n = 277) from a Swiss community-based study. Epidemiological MDD diagnoses were based on the Mini-SPIKE (shortened form of the Structured Psychopathological Interview and Rating of the Social Consequences for Epidemiology). Logistic and multinomial regression analyses (adjusted for sex, age, civil status, depression and severity) were computed for comparisons and characterization. Latent class analysis (LCA) was conducted to empirically identify depression subtypes in PwMS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: PwMS had a higher risk for the mixed atypical-melancholic MDD subtype (OR = 2.22, 95% CI = 1.03-4.80) compared to Pw/oMS. MDD in PwMS was specifically characterized by a higher risk of the two somatic atypical depression symptoms &#x27;weight gain&#x27; (OR = 6.91, 95% CI = 2.20-21.70) and &#x27;leaden paralysis&#x27; (OR = 3.03, 95% CI = 1.35-6.82) and the symptom &#x27;irritable/angry&#x27; (OR = 3.18, 95% CI = 1.08-9.39).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: MDD in PwMS was characterized by a higher risk for specific somatic atypical depression symptoms and the mixed atypical-melancholic MDD subtype. The pure atypical MDD subtype, however, did not differentiate between PwMS and Pw/oMS. Given the high phenomenological overlap with MS symptoms, the mixed atypical-melancholic MDD subtype represents a particular diagnostic challenge.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33631437/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226014934&amp;v=2.14.2&quot;&gt;33631437&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jpsychores.2021.110402&gt;10.1016/j.jpsychores.2021.110402&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33631437/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226014934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":101,"discovery_date":"2021-02-26T11:11:00","title":"Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Neurol Neurosurg. 2021 Feb 15;203:106563. doi: 10.1016/j.clineuro.2021.106563. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Iran is one of the countries with a high prevalence of multiple sclerosis (MS) and COVID-19.MS patients receiving the immunomodulatory or immunosuppressive therapy have a higher risk of infection. Due to the significance of determining the risk factors for getting COVID-19 among MS patients, the present study was designed to assess the risk of infection following the pulse steroid therapy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: This cross-sectional study included all MS patients that received corticosteroids in Tehran from December 2019 to August 2020 during the COVID-19 pandemic spread. The subjects&#x27; clinical records including their sex, age, the type of MS, the type of medication, the number of days using corticosteroids, the status of prednisolone intake, and the number of days receiving prednisolone after the corticosteroid therapy were obtained. Moreover, main outcomes such as COVID-19 infection and the occurrence of death were recorded by patient&#x27;s visits and follow-up phone calls. COVID-19 infection was confirmed by physicians according to the clinical performance of RT-PCR, chest CT scan, and antibody tests.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Totally, 133 MS cases participated in the study, and the pulse therapy was completed for 104 (78.2%) patients up to 5-7 days. 89 (66.9%) cases used the prednisolone tablet following the pulse therapy. Overall, the infection by Covid-19 was observed in 8 (6%) cases, among whom 5 (71.4%) cases received the pulse therapy for 5-7 days and 4 (57.1%) cases had a history of taking the prednisolone tablet. The age of less than 40 years (OR = 1.03; 95% CI (0.23-4.51)), male sex (OR = 0.35; 95% CI (0.03-3.34)), and the RRMS type (OR = 2.87; 95% CI (0.52-15.72)) had no effect on the risk of Covid-19 infection. In addition, there was not statistically significant difference between subjects with the short-term pulse therapy duration (3-4 days) (OR 0.68 (0.12-3.74) and those with the long-term pulse therapy duration (5-7 days). Similarly, no statistically significant difference was observed between subjects taking prednisolone (OR = 1.62 (0.34-7.61) and those not taking prednisolone. Furthermore, there was no significant association between different medication groups and the risk of Covid-19 infection (p &amp;lt; 0.05). No death occurred due to Covid-19 infection among the subjects.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: COVID-19 infection was more common among female and younger patients as well as patients with a longer duration of the pulse therapy and prednisolone intake. There was no significant association between the pulse steroid therapy in MS patients and the risk of infection by COVID-19 in the Iranian population.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33631509/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226014934&amp;v=2.14.2&quot;&gt;33631509&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.clineuro.2021.106563&gt;10.1016/j.clineuro.2021.106563&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33631509/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226014934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":100,"discovery_date":"2021-02-26T11:11:00","title":"Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neuroepidemiology. 2021 Feb 25:1-10. doi: 10.1159/000513647. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: COVID-19 can be accompanied by acute neurological complications of both central and peripheral nervous systems (CNS and PNS). In this study, we estimate the frequency of such complications among hospital inpatients with COVID-19 in Assiut and Aswan university hospitals.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: We screened all patients with suspected COVID-19 admitted from 1 June to 10 August 2020 to the university hospitals of Assiut and Aswan in Upper Egypt. Clinical and laboratory tests, CT/MRI of the chest and brain, and neurophysiology study were performed for each patient if indicated.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 439 patients had confirmed/probable COVID-19; neurological manifestations occurred in 222. Of these, 117 had acute neurological disease and the remainder had nonspecific neuropsychiatric symptoms such as headache, vertigo, and depression. The CNS was affected in 75 patients: 55 had stroke and the others had convulsions (5), encephalitis (6), hypoxic encephalopathy (4), cord myelopathy (2), relapse of multiple sclerosis (2), and meningoencephalitis (1). The PNS was affected in 42 patients: the majority had anosmia and ageusia (31) and the others had Guillain-BarrÃ© syndrome (4), peripheral neuropathy (3), myasthenia gravis (MG, 2), or myositis (2). Fever, respiratory symptoms, and headache were the most common general symptoms. Hypertension, diabetes mellitus, and ischemic heart disease were the most common comorbidities in patients with CNS affection.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: In COVID-19, both the CNS and PNS are affected. Stroke was the most common complication for CNS, and anosmia and/or ageusia were common for PNS diseases. However, there were 6 cases of encephalitis, 2 cases of spinal cord myelopathy, 2 cases of MG, and 2 cases of myositis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33631765/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210226014934&amp;v=2.14.2&quot;&gt;33631765&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1159/000513647&gt;10.1159/000513647&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33631765/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210226014934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":99,"discovery_date":"2021-02-26T11:11:00","title":"Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter : Effect of Several Administrations of Gadoterate Meglumine in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Neuroradiol. 2021 Feb 25. doi: 10.1007/s00062-021-00995-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Several studies reported gadolinium deposition in the dentate nuclei (DN) and the globus pallidus (GP) that was associated to linear GBCA administrations rather than macrocyclic. It is therefore imperative to evaluate and assess the safety of cumulative administration of gadoterate meglumine (macrocyclic). Thus, T1-weighted images (T1WI) of multiple sclerosis (MS) patients longitudinally followed for 4 years were retrospectively analyzed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: In this study 44 patients, 10 with clinically isolated syndrome (CIS), 24 relapsing-remitting MS (RRMS) and 10 primary-progressive MS (PPMS) were examined every 6 months (first four scans) and then with a 1-year interval (last two scans). Image processing consisted in reorienting unenhanced T1WI to standard space, followed by B1 inhomogeneity correction. A patient-specific template was then generated to normalize T1WI signal intensity (SI) and segment the DN and subcortical GM structures. All structures were then transformed to each patient space in order to measure the SI in each region. The cerebellar peduncles (CP) and semi-oval (SO) white matter were then manually delineated and used as reference to calculate SI ratios in the DN and subcortical GM structures. A linear mixed-effect model was finally applied to longitudinally analyze SI variations.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The SI measurements performed in all structures showed no significant increases with the cumulative GBCA administration.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: This study showed no significant SI increases within the DN and subcortical GM structures of longitudinally followed MS patients even with the cumulative administration of the macrocyclic GBCA gadoterate meglumine.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33630120/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225202934&amp;v=2.14.2&quot;&gt;33630120&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00062-021-00995-6&gt;10.1007/s00062-021-00995-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33630120/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225202934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":98,"discovery_date":"2021-02-25T11:11:00","title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 25:1352458521991433. doi: 10.1177/1352458521991433. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33629615/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225134934&amp;v=2.14.2&quot;&gt;33629615&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521991433&gt;10.1177/1352458521991433&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33629615/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225134934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":97,"discovery_date":"2021-02-25T11:11:00","title":"Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Food Funct. 2021 Feb 25. doi: 10.1039/d0fo03203d. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Preliminary evidence shows the potential role of probiotics in ameliorating multiple sclerosis (MS); however, the effects of probiotics on MS remain unclear. Therefore, the aim of this study was to evaluate the efficacy of probiotics on multiple sclerosis by systematically reviewing the preclinical trials (animal trials) and performing meta-analysis of randomized controlled trials. PubMed, Web of Science, Cochrane central of randomized clinical trials, EMBASE, Clinical Trials, and a search engine Google Scholar were systematically searched and manually screened updated to November 2020, resulting in eligible 3 randomized controlled trials (RCTs) and 22 preclinical studies. Meta-analysis of RCTs enrolling 173 patients with MS receiving probiotics revealed significant beneficial effects of probiotic supplementation on mental health (expanded disability status scale scores: standardized mean difference [SMD] = -1.22; I2 = 92%; 95% CI, -2.40 to -0.03, P = 0.04; Beck depression inventory total scores: SMD = -1.58; I2 = 94%; 95% CI, -3.03 to -0.12; P = 0.03; general health questionnaire scores: SMD = -0.71; I2 = 0%; 95% CI, -1.02 to -0.40; P &amp;lt; 0.00001; depression anxiety and stress scale scores: SMD = -0.72; I2 = 0%; 95% CI, -1.12 to -0.33; P = 0.0003), with very low certainty of evidence. In addition, probiotic intake markedly improved insulin resistance and inflammatory and oxidative stress markers. Preclinical studies have shown that probiotic consumption reduces the incidence and severity of MS, delays MS progression (15 studies), and improves motor impairment (3 studies) with favorable alterations of immune and inflammatory markers (20 studies) and intestinal microbiome compositions (4 studies) in MS. These results indicated that probiotics may have beneficial effects on the prevention and treatment of multiple sclerosis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33629669/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225134934&amp;v=2.14.2&quot;&gt;33629669&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1039/d0fo03203d&gt;10.1039/d0fo03203d&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33629669/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225134934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":96,"discovery_date":"2021-02-25T11:11:00","title":"Effects of mindfulness-and acceptance-based interventions on quality of life, coping, cognition, and mindfulness of people with multiple sclerosis: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Psychol Health Med. 2021 Feb 25:1-18. doi: 10.1080/13548506.2021.1894345. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;This systematic review and meta-analysis of randomized controlled trials (RCTs) examined effects of mindfulness- and acceptance-based interventions (MABIs) on quality of life (QoL), coping, cognition, and mindfulness among people with multiple sclerosis (MS). Four electronic databases were searched to 3 July 2020. Data was combined in a random-effects meta-analysis model. Eighteen RCTs met the eligibility criteria. Meta-analyses at the immediate posttest found: moderate effects of MABIs on QoL, coping, and attention; and a large effect on memory. A large effect of MABIs on QoL was found at follow-up. There was no significant effect of MABIs on mindfulness. Relatively fewer studies in outcomes other than QoL were found, and the overall risk of bias across the included 18 RCTs was unclear. Future high-quality studies with follow-up evaluations are needed to support effects of MABIs on QoL, coping, cognition, and mindfulness in people with MS and examine intervention features that increase and maintain effects.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33629885/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225134934&amp;v=2.14.2&quot;&gt;33629885&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/13548506.2021.1894345&gt;10.1080/13548506.2021.1894345&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33629885/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225134934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":95,"discovery_date":"2021-02-25T11:11:00","title":"RXRÎ± Blocks Nerve Regeneration after Spinal Cord Injury by Targeting p66shc","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Oxid Med Cell Longev. 2021 Feb 10;2021:8253742. doi: 10.1155/2021/8253742. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Nerve regeneration after spinal cord injury is regulated by many factors. Studies have found that the expression of retinoid X receptor &lt;i&gt;Î±&lt;/i&gt; (RXR&lt;i&gt;Î±&lt;/i&gt;) does not change significantly after spinal cord injury but that the distribution of RXR&lt;i&gt;Î±&lt;/i&gt; in cells changes significantly. In undamaged tissues, RXR&lt;i&gt;Î±&lt;/i&gt; is distributed in motor neurons and the cytoplasm of glial cells. RXR&lt;i&gt;Î±&lt;/i&gt; migrates to the nucleus of surviving neurons after injury, indicating that RXR&lt;i&gt;Î±&lt;/i&gt; is involved in the regulation of gene expression after spinal cord injury. p66shc is an important protein that regulates cell senescence and oxidative stress. It can induce the apoptosis and necrosis of many cell types, promoting body aging. The absence of p66shc enhances the resistance of cells to reactive oxygen species (ROS) and thus prolongs life. It has been found that p66shc deletion can promote hippocampal neurogenesis and play a neuroprotective role in mice with multiple sclerosis. To verify the function of RXR&lt;i&gt;Î±&lt;/i&gt; after spinal cord injury, we established a rat T9 spinal cord transection model. After RXR&lt;i&gt;Î±&lt;/i&gt; agonist or antagonist administration, we found that RXR&lt;i&gt;Î±&lt;/i&gt; agonists inhibited nerve regeneration after spinal cord injury, while RXR&lt;i&gt;Î±&lt;/i&gt; antagonists promoted the regeneration of injured neurites and the recovery of motor function in rats. The results showed that RXR&lt;i&gt;Î±&lt;/i&gt; played an impeding role in repair after spinal cord injury. Immunofluorescence staining showed that p66shc expression was upregulated in neurons after spinal cord injury (&lt;i&gt;in vivo&lt;/i&gt; and &lt;i&gt;in vitro&lt;/i&gt;) and colocalized with RXR&lt;i&gt;Î±&lt;/i&gt;. RXR&lt;i&gt;Î±&lt;/i&gt; overexpression in cultured neurons promoted the expression of p66shc, while RXR&lt;i&gt;Î±&lt;/i&gt; interference inhibited the expression of p66shc. Using a luciferase assay, we found that RXR&lt;i&gt;Î±&lt;/i&gt; could bind to the promoter region of p66shc and regulate the expression of p66shc, thereby regulating nerve regeneration after spinal cord injury. The above results showed that RXR&lt;i&gt;Î±&lt;/i&gt; inhibited nerve regeneration after spinal cord injury by promoting p66shc expression, and interference with RXR&lt;i&gt;Î±&lt;/i&gt; or p66shc promoted functional recovery after spinal cord injury.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628383/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628383&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7889345/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7889345&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/8253742&gt;10.1155/2021/8253742&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://www.hindawi.com/journals/omcl/2021/8253742/","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":94,"discovery_date":"2021-02-25T11:11:00","title":"Beneficial Metabolic Effects of TREM2 in Obesity are Uncoupled from its Expression on Macrophages","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Diabetes. 2021 Feb 24:db200572. doi: 10.2337/db20-0572. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Obesity-induced white adipose tissue (WAT) hypertrophy is associated with elevated adipose tissue macrophage (ATM) content. Overexpression of the triggering receptor expressed on myeloid cells 2 (TREM2) reportedly increases adiposity, worsening health. Paradoxically, using insulin resistance, elevated fat mass and hypercholesterolemia as hallmarks of unhealthy obesity, a recent report demonstrated ATM-expressed TREM2 promoted health. Here, we identified that in mice TREM2 deficiency aggravated diet-induced insulin resistance and hepatic steatosis independently of fat and cholesterol levels. Metabolomics linked TREM2 deficiency with elevated obesity-instigated serum ceramides that correlated with impaired insulin sensitivity. Remarkably, while inhibiting ceramide synthesis exerted no influences on TREM2-dependent ATM remodeling, inflammation or lipid load, it restored insulin tolerance, reversing adipose hypertrophy and secondary hepatic steatosis of TREM2-deficient animals. Bone marrow transplantation experiments revealed unremarkable influences of immune cell-expressed TREM2 on health instead demonstrating that WAT-intrinsic mechanisms impinging on sphingolipid metabolism dominate in TREM2&#x27;s systemic protective effects on metabolic health.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627323/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627323&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2337/db20-0572&gt;10.2337/db20-0572&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627323/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":93,"discovery_date":"2021-02-25T11:11:00","title":"Amyloidoma mimicking multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Pract Neurol. 2021 Feb 24:practneurol-2020-002855. doi: 10.1136/practneurol-2020-002855. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627491/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627491&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/practneurol-2020-002855&gt;10.1136/practneurol-2020-002855&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627491/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":92,"discovery_date":"2021-02-25T11:11:00","title":"The tumor therapy landscape of synthetic lethality","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Commun. 2021 Feb 24;12(1):1275. doi: 10.1038/s41467-021-21544-2.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the computational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627666/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627666&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41467-021-21544-2&gt;10.1038/s41467-021-21544-2&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627666/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":91,"discovery_date":"2021-02-25T11:11:00","title":"1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Acta Pharmacol Sin. 2021 Feb 24. doi: 10.1038/s41401-021-00613-8. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;NOD-like receptor (NLR) family pyrin domain-containing-3 (NLRP3) inflammasome is implicated in inflammation-associated diseases such as multiple sclerosis, Parkinson&#x27;s disease, and stroke. Targeting the NLRP3 inflammasome is beneficial to these diseases, but few NLRP3 inflammasome-selective inhibitors are identified to date. Essential oils (EOs) are liquid mixtures of volatile and low molecular-weight organic compounds extracted from aromatic plants, which show various pharmacological activities, including antibacterial, antifungal, antiviral, antioxidant, and anti-inflammatory properties. In this study we screened active ingredients from essential oils, and identified 1,2,4-trimethoxybenzene (1,2,4-TTB) as a selective NLRP3 inflammasome inhibitor. We showed that 1,2,4-TTB (1 mM) markedly suppressed nigericin- or ATP-induced NLRP3 inflammasome activation, thus decreased caspase-1 activation and IL-1Î² secretion in immortalized murine bone marrow-derived macrophages (iBMDMs) and in primary mouse microglia. Moreover, 1,2,4-TTB specifically inhibited the activation of NLRP3 inflammasome without affecting absent in melanoma 2 (AIM2) inflammasome activation. We further demonstrated that 1,2,4-TTB inhibited oligomerization of the apoptosis-associated speck-like protein containing a CARD (ASC) and protein-protein interaction between NLRP3 and ASC, thus blocking NLRP3 inflammasome assembly in iBMDMs and in primary mouse macrophages. In mice with experimental autoimmune encephalomyelitis (EAE), administration of 1,2,4-TTB (200 mg Â· kg&lt;sup&gt;-1&lt;/sup&gt; Â· d&lt;sup&gt;-1&lt;/sup&gt;, i.g. for 17 days) significantly ameliorated EAE progression and demyelination. In conclusion, our results demonstrate that 1,2,4-TTB is an NLRP3 inflammasome inhibitor and attenuates the clinical symptom and inflammation of EAE, suggesting that 1,2,4-TTB is a potential candidate compound for treating NLRP3 inflammasome-driven diseases, such as multiple sclerosis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627802/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627802&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41401-021-00613-8&gt;10.1038/s41401-021-00613-8&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627802/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":90,"discovery_date":"2021-02-25T11:11:00","title":"Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ther Adv Neurol Disord. 2021 Jan 22;14:1756286420975227. doi: 10.1177/1756286420975227. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Peginterferon beta-1a administered every 2 weeks &lt;i&gt;via&lt;/i&gt; subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated injection site reactions (ISRs) can lead to treatment discontinuation. Prior studies with interferon beta-1a reported a lower frequency of ISRs with intramuscular (IM) administration than with SC administration. IM administration of peginterferon beta-1a may therefore represent a useful alternative treatment option.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: A phase I, open-label, two-period crossover study randomized healthy volunteers to receive a single dose of peginterferon beta-1a 125 mcg administered IM followed by a single 125 mcg dose administered SC after a 28-day washout or vice versa. Blood samples were collected up to 504 h post dose to determine pharmacokinetic (PK) and pharmacodynamic (PD) profiles. The primary endpoint was assessment of bioequivalence based on maximum serum concentration (C&lt;sub&gt;max&lt;/sub&gt;) and area under the curve from time zero extrapolated to infinity (AUC&lt;sub&gt;inf&lt;/sub&gt;). Other PK parameters, as well as PD (serum neopterin) and safety profiles, were also evaluated.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The study enrolled 136 participants. Bioequivalence of IM and SC peginterferon beta-1a was established for both C&lt;sub&gt;max&lt;/sub&gt; ([least squares (LS)] mean IM/SC ratio: 1.083 [90% confidence interval (CI), 0.975-1.203]) and AUC&lt;sub&gt;inf&lt;/sub&gt; (LS mean IM/SC ratio: 1.089 [90% CI, 1.020-1.162]). Other PK and PD parameters were similar between administration routes, although moderate to high inter-subject variability was observed for IM and SC. Safety profiles were generally balanced between IM and SC administration. ISRs occurred at a lower frequency with IM [14.4% (95% CI, 8.89-21.56%)] than with SC [32.1% (95% CI, 24.29-40.70%)] administration (&lt;i&gt;p&lt;/i&gt; = 0.0005).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: These results demonstrate bioequivalence between peginterferon beta-1a IM and SC and support the consideration of IM injection of peginterferon beta-1a as a viable treatment option in patients with RRMS and RMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628334/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628334&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7883310/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7883310&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1756286420975227&gt;10.1177/1756286420975227&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628334/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":89,"discovery_date":"2021-02-25T11:11:00","title":"Reelin Depletion Protects Against Atherosclerosis by Decreasing Vascular Adhesion of Leukocytes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Arterioscler Thromb Vasc Biol. 2021 Feb 25:ATVBAHA121316000. doi: 10.1161/ATVBAHA.121.316000. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Reelin and its receptor Apoer2 (apolipoprotein E receptor 2) play a prominent role in endothelial cell dysfunction by promoting leukocyte-endothelial cell adhesion, an important component of the inflammatory process underlying atherosclerosis. We, therefore, hypothesized that pharmacological depletion of circulating reelin represents a novel therapeutic strategy to impede the progression of atherosclerosis. Approach and Results: In vitro studies demonstrated that human plasma induced monocyte adhesion to endothelial cells, while reelin-depleted plasma had no effect on monocyte adhesion. Signaling analysis revealed that reelin activated Dab2, PI3K, Akt, and NF-ÎºB (nuclear factor ÎºB) cascade to promote the expression of adhesion markers (E-selectin, ICAM-1 [intercellular adhesion molecule 1], and VCAM-1 [vascular cell adhesion molecule 1]). Intravital microscopy confirmed decreased leukocyte-endothelial adhesion in mice treated with reelin antisense oligonucleotide. In vascular smooth muscle cells, reelin induced Stat3 phosphorylation to promote cell proliferation, which is another hallmark of atherosclerotic plaque progression. To investigate if reelin pharmaceutical depletion protects against atherosclerosis, low-density lipoprotein receptor-deficient (&lt;i&gt;Ldlr&lt;/i&gt;&lt;sup&gt;-/-&lt;/sup&gt;) mice fed with high-cholesterol diet were treated with either reelin antisense oligonucleotide or neutralizing antibody (CR-50) to systemically deplete circulating reelin. In both treatments, atherosclerotic plaque progression was markedly attenuated. These in vivo results suggest that reelin depletion decreases vascular adhesion and inhibits the recruitment of monocytes and consequently prevents plaque progression.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: These findings suggest that reelin inhibition may provide a novel therapeutic approach to counteract leukocyte or monocyte adhesion as well as extravasation and inhibit the progression of atherosclerosis. This strategy may also be relevant for other diseases that involve leukocyte or monocyte extravasation as a central pathological mechanism, such as multiple sclerosis or arthritis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626909/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33626909&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1161/ATVBAHA.121.316000&gt;10.1161/ATVBAHA.121.316000&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626909/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":88,"discovery_date":"2021-02-25T11:11:00","title":"Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;NPJ Digit Med. 2021 Feb 24;4(1):36. doi: 10.1038/s41746-021-00401-y.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;As the burden of neurodegenerative diseases increases, time-limited clinic encounters do not allow quantification of complex neurological functions. Patient-collected digital biomarkers may remedy this, if they provide reliable information. However, psychometric properties of digital tools remain largely un-assessed. We developed a smartphone adaptation of the cognitive test, the Symbol-Digit Modalities Test (SDMT) by randomizing the test&#x27;s symbol-number codes and testing sequences. The smartphone SDMT showed comparable psychometric properties in 154 multiple sclerosis (MS) patients and 39 healthy volunteers (HV). E.g., smartphone SDMT achieved slightly higher correlations with cognitive subscores of neurological examinations and with brain injury measured by MRI (R&lt;sup&gt;2&lt;/sup&gt; = 0.75, Rho = 0.83, p &amp;lt; 0.0001) than traditional SDMT. Mathematical adjustment for motoric disability of the dominant hand, measured by another smartphone test, compensates for the disadvantage of touch-based test. Averaging granular home measurements of the digital biomarker also increases accuracy of identifying true neurological decline.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33627777/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33627777&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41746-021-00401-y&gt;10.1038/s41746-021-00401-y&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33627777/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":87,"discovery_date":"2021-02-25T11:11:00","title":"The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Int. 2021 Feb 5;2021:6611897. doi: 10.1155/2021/6611897. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Multiple studies have reported that cannabis administration in multiple sclerosis patients is associated with decreased symptom severity. This study was conducted to evaluate the prevalence of cannabis abuse in multiple sclerosis cases and to evaluate the effect of cannabis on serum cytokines in such cases. &lt;i&gt;Patients and Methods&lt;/i&gt;. A total of 150 multiple sclerosis cases along with 150 healthy controls were included during the study period. All cases were subjected to history taking, neurological examination, and routine investigations. Cases were asked about cannabis intake which was confirmed by a urine test. Serum cytokines including IL-1, IL-2, IL-4, IL-10, IL-12, IL-17, IL-22, IFN-&lt;i&gt;Î³&lt;/i&gt;, IFN-&lt;i&gt;Î²&lt;/i&gt;1, and TNF-&lt;i&gt;Î±&lt;/i&gt; were ordered for all cases and controls.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Twenty-eight cases were cannabis abusers (MS/cannabis group, 18.67%). The remaining 122 cases represented the MS group. There was no significant difference between the three groups regarding age, disease duration, or MS type. Male gender was more predominant in the MS/cannabis group, and the number of relapses was significantly lower in the same group. Fifteen cases (53.6%) reported that their symptoms were improved by cannabis. Proinflammatory cytokines were significantly elevated in the MS group compared to the MS/cannabis and control groups. Additionally, anti-inflammatory cytokines had significantly lower values in the MS group compared to the MS/cannabis and control groups. Most clinical symptoms were significantly improved in the MS/cannabis group compared to the MS group apart from sexual dysfunction, bladder symptoms, and visual disturbances. Mild side effects of cannabis were also reported.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Cannabis may have a positive impact on the cytokine and clinical profiles in cases with multiple sclerosis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628507/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628507&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7884151/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7884151&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/6611897&gt;10.1155/2021/6611897&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628507/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":86,"discovery_date":"2021-02-25T11:11:00","title":"Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Int. 2021 Feb 15;2021:6667006. doi: 10.1155/2021/6667006. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;More than half of all patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) are women of childbearing age. Raising a family is an important life goal for women in our region of the world. However, fears and misconceptions about the clinical course of relapsing-remitting MS (RRMS) and the effects of disease-modifying drugs (DMDs) on the foetus have led many women to reduce their expectations of raising a family, sometimes even to the point of avoiding pregnancy altogether. The increase in the number of DMDs available to manage RRMS and recent studies on their effects in pregnancy have broadened management options for these women. Interferon beta now has an indication in Europe for use during pregnancy (according to clinical need) and can be used during breastfeeding. Glatiramer acetate is a further possible option for women with lower levels of RRMS disease activity who are, or about to become, pregnant; natalizumab may be used up to 30 weeks in patients with higher levels of disease activity. Where possible, physicians need to support and encourage women to pursue their dream of a fulfilling family life, supported where necessary by active interventions for RRMS that are increasingly evidence based.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628508/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628508&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7899766/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7899766&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/6667006&gt;10.1155/2021/6667006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628508/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":85,"discovery_date":"2021-02-25T11:11:00","title":"Systemic Sclerosis: Current State and Survival After Lung Transplantation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Cureus. 2021 Jan 20;13(1):e12797. doi: 10.7759/cureus.12797.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Systemic sclerosis (SSc) is an autoimmune disorder characterized by the involvement of skin and internal organs. With the introduction of angiotensin-converting enzyme inhibitors (ACEIs), scleroderma renal crisis (SRC) is no longer considered a leading cause of death in affected patients. In fact, pulmonary manifestations [interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH)] are currently the major cause of death in patients with SSc. Historically, many centers have been reluctant to offer lung transplantation to patients with SSc due to multiple extrapulmonary manifestations and the assumption of poor post-transplant survival. The purpose of this review is to highlight the recent advances in the evaluation and management of patients with pulmonary manifestations of SSc. We also engage in a systematic literature review to assess all the available data on the survival of patients with SSc after lung transplantation.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628666/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;33628666&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7893677/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225072936&amp;v=2.14.2&quot;&gt;PMC7893677&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.7759/cureus.12797&gt;10.7759/cureus.12797&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33628666/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225072936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":84,"discovery_date":"2021-02-25T11:11:00","title":"Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102840. doi: 10.1016/j.msard.2021.102840. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Neurofilament heavy (NfH) is a promising biomarker for neuro-axonal damage in Multiple Sclerosis (MS). We compared the performance of high-sensitivity serum-NfH immunoassays, with as aim to investigate the value of serum-NfH as biomarker for MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We measured serum-NfH in 76 MS patients with Simoa (one commercial, one in-house) or Luminex assays. Serum-NfH measured by the immunoassay with greatest sensitivity was related to clinical and radiological outcomes with age and sex-adjusted linear regression analysis, and to biological outcomes cerebrospinal fluid (CSF)-NfH, serum neurofilament light (NfL) and CSF-NfL with Spearman&#x27;s correlation analysis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: With the commercial Simoa assay, we obtained 100% serum-NfH detectability (in-house Simoa: 70%, Luminex: 61%), with lowest coefficient of variation (CV) between duplicates of 11%CV (in-house Simoa: 22%CV, Luminex: 30%CV). Serum-NfH quantified with the commercial Simoa assay was associated with disease duration (standardized beta (sÎ²) = 0.28, p = 0.034), T2 lesion volume (sÎ² = 0.23, p = 0.041), and tended to associate with black hole count (sÎ² = 0.21, p = 0.084) but not with Expanded Disease Disability Score (EDSS) or normalized brain volume (all: p&amp;gt;0.10). Furthermore, serum-NfH showed correlations with CSF-NfH (rho = 0.27, p = 0.018) and serum-NfL (rho=0.44, p &amp;lt; 0.001), but not with CSF-NfL.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Serum-NfH can be quantified with high-sensitivity technology. Cross-sectionally, we observed some weak correlations of serum-NfH with MS disease burden parameters, suggesting there might be some utility for serum-NfH as biomarker for MS disease burden.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626430/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626430&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102840&gt;10.1016/j.msard.2021.102840&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626430/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":83,"discovery_date":"2021-02-25T11:11:00","title":"The CYP2R1 Enzyme: Structure, Function, Enzymatic Properties and Genetic Polymorphism","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Pharm Pharm Sci. 2021;24:94-112. doi: 10.18433/jpps31305.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Since the discovery of its role in vitamin D metabolism, significant progress has been made in the understanding of gene organisation, protein structure, catalytic function, and genetic polymorphism of cytochrome P450 2R1 (CYP2R1). Located on chromosome 11p15.2, CYP2R1 possesses five exons, unlike most other CYP isoforms that carry nine exons. CYP2R1 crystal structure displays a fold pattern typical of a CYP protein, with 12 a-helices as its structural core, and b-sheets mostly arranged on one side, and the heme buried in the interior part of the protein. Overall, CYP2R1 structure adopts a closed conformation with the B&#x27; helix serving as a gate covering the substrate access channel, with the substrate vitamin D3 occupying a position with the side chain pointing toward the heme group. In liver, CYP2R1 25-hydroxylates vitamin D and serves as an important determinant of 25(OH)D level in the tissue and in circulation. While substrate profile has been well studied, inhibitor specificity for CYP2R1 requires further investigation. Both exonic and non-exonic single nucleotide polymorphisms (SNPs) have been reported in CYP2R1, including the CYP2R1*2 carrying Leu99Pro exchange, and a number of non-exonic SNPs with variable functional consequences in gene regulation. A non-exonic SNP, rs10741657, has its causal relationship with diseases established, including that of rickets, ovarian cancer, and multiple sclerosis. The role of other CYP2R1 SNPs in vitamin D deficiency and their causal link to other traits however remain uncertain currently and more studies are warranted to help identify possible physiological mechanisms underlying those complex traits.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626316/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626316&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.18433/jpps31305&gt;10.18433/jpps31305&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626316/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":82,"discovery_date":"2021-02-25T11:11:00","title":"The role of language ability in verbal fluency of individuals with multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102846. doi: 10.1016/j.msard.2021.102846. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: While cognitive deficits in memory and processing speed have been well-documented in individuals with multiple sclerosis (MS), language is largely considered to be intact. Verbal fluency deficits observed in MS are often attributed to impaired processing speed and executive functions rather than language ability. The current study evaluates the contribution of various cognitive factors to verbal fluency including language ability, oral-motor speed, processing speed, and executive functions.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We analyzed pre-existing data from seventy-four (74) individuals with MS who completed a battery of neuropsychological tests designed to assess individual ability for various cognitive factors. We conducted linear multiple regression analyses with letter and category verbal fluency as outcome variables and performance on other cognitive domains (e.g., processing speed, executive functioning) as predictors.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Both vocabulary and processing speed predicted letter fluency while only vocabulary predicted category fluency. These findings suggest that the observed verbal fluency deficits in MS may reflect both impaired language ability and processing speed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: We propose that further research on language ability in MS is needed to determine if comprehensive neuropsychological test batteries for persons with MS should include tests of language ability to fully understand the cognitive profile of any given patient. Given the importance of language ability, it may be necessary to conduct a more thorough assessment of language in individuals with MS who experience a deficit in this domain.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626431/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626431&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102846&gt;10.1016/j.msard.2021.102846&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626431/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":81,"discovery_date":"2021-02-25T11:11:00","title":"Idiopathic Intracranial Hypertension and Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102829. doi: 10.1016/j.msard.2021.102829. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Unexplained elevated intracranial pressure occasionally develops in individuals with Multiple Sclerosis (MS). Visual symptoms and signs are common to both conditions. An awareness of this association is particularly relevant due to the increased incidence of headache in MS and the frequent overlap of symptoms and signs in both conditions.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626432/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210225020934&amp;v=2.14.2&quot;&gt;33626432&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102829&gt;10.1016/j.msard.2021.102829&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626432/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210225020934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":80,"discovery_date":"2021-02-25T11:11:00","title":"A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different Disability Levels","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;IEEE Trans Biomed Eng. 2021 Feb 24;PP. doi: 10.1109/TBME.2021.3061998. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: Mobility assessment is critical in the clinical management of people with Multiple Sclerosis (pwMS). Instrumented gait analysis provides a plethora of metrics for quantifying concurrent factors contributing to gait deterioration. However, a gait model discriminating underlying features contributing to this deterioration is lacking in pwMS. This study aimed at developing and validating such a model.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: The gait of 24 healthy controls and 114 pwMS with mild, moderate, or severe disability was measured with inertial sensors on the shanks and lower trunk while walking for 6 minutes along a hospital corridor. Twenty out of thirty-six initially explored metrics computed from the sensor data met the quality criteria for exploratory factor analysis. This analysis provided the sought model, which underwent a confirmatory factor analysis before being used to characterize gait impairment across the three disability groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: A gait model consisting of five domains (rhythm/variability, pace, asymmetry, and forward and lateral dynamic balance) was revealed by the factor analysis, which was able to highlight gait abnormalities across the disability groups: significant alterations in rhythm/variability-, asymmetry-, and pace-based features were present in the mild group, but these were more profound in the moderate and severe groups. Deterioration in dynamic balance-based features was only noted in pwMS with a moderate and severe disability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: A conceptual model of gait for disease-specific mobility assessment in pwMS was successfully developed and tested.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;SIGNIFICANCE: The new model, built with metrics that represent gait impairment in pwMS, highlighted clinically relevant changes across different disability levels, including those with no clinically observable walking disability. This shows the clear potential as a monitoring biomarker in pwMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625975/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33625975&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1109/TBME.2021.3061998&gt;10.1109/TBME.2021.3061998&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625975/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":79,"discovery_date":"2021-02-25T11:11:00","title":"Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-Î² treatment","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Acta Neurol Scand. 2021 Feb 24. doi: 10.1111/ane.13400. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To identify serum proteins associated with MS and affected by interferon beta treatment.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Plasma samples from 29 untreated relapsing-remitting MS patients and 15 healthy controls were investigated with a multiplexed panel containing 92 proteins related to inflammation. Follow-up samples were available from 13 patients at 1 and 3 months after initiation of treatment with interferon beta-1a.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Ten proteins were differentially expressed in MS patients. Five of these were altered by treatment with IFN-Î² 1a: uPA, CX3CL1, CCL2, TRAIL and IL18.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: CCL2 and TRAIL were confirmed to be modulated with interferon beta treatment in MS. As novel findings, we now report that uPA and CX3CL1 were differentially expressed in MS and increased after IFN-beta-1a treatment. Conflicting results have been reported on how interferon beta affects IL-18.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626181/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33626181&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/ane.13400&gt;10.1111/ane.13400&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626181/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":78,"discovery_date":"2021-02-25T11:11:00","title":"Leveraging electronic health records data to predict multiple sclerosis disease activity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Feb 24. doi: 10.1002/acn3.51324. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: No relapse risk prediction tool is currently available to guide treatment selection for multiple sclerosis (MS). Leveraging electronic health record (EHR) data readily available at the point of care, we developed a clinical tool for predicting MS relapse risk.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Using data from a clinic-based research registry and linked EHR system between 2006 and 2016, we developed models predicting relapse events from the registry in a training set (n = 1435) and tested the model performance in an independent validation set of MS patients (n = 186). This iterative process identified prior 1-year relapse history as a key predictor of future relapse but ascertaining relapse history through the labor-intensive chart review is impractical. We pursued two-stage algorithm development: (1) L&lt;sub&gt;1&lt;/sub&gt; -regularized logistic regression (LASSO) to phenotype past 1-year relapse status from contemporaneous EHR data, (2) LASSO to predict future 1-year relapse risk using imputed prior 1-year relapse status and other algorithm-selected features.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The final model, comprising age, disease duration, and imputed prior 1-year relapse history, achieved a predictive AUC and F score of 0.707 and 0.307, respectively. The performance was significantly better than the baseline model (age, sex, race/ethnicity, and disease duration) and noninferior to a model containing actual prior 1-year relapse history. The predicted risk probability declined with disease duration and age.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Our novel machine-learning algorithm predicts 1-year MS relapse with accuracy comparable to other clinical prediction tools and has applicability at the point of care. This EHR-based two-stage approach of outcome prediction may have application to neurological disease beyond MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626237/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33626237&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/acn3.51324&gt;10.1002/acn3.51324&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626237/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":77,"discovery_date":"2021-02-24T11:11:00","title":"Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625275/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625275&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521996699&gt;10.1177/1352458521996699&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625275/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":76,"discovery_date":"2021-02-24T11:11:00","title":"Machine and deep learning in MS research are just powerful statistics - Yes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458520981309. doi: 10.1177/1352458520981309. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625280/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625280&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458520981309&gt;10.1177/1352458520981309&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625280/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":75,"discovery_date":"2021-02-24T11:11:00","title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Manag Care Spec Pharm. 2021 Feb 24:1-11. doi: 10.18553/jmcp.2021.20413. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;BACKGROUND:&lt;/b&gt; Ocrelizumab (OCR) is the only disease-modifying therapy (DMT) for both relapsing and primary progressive forms of multiple sclerosis (MS). OCR is given by intravenous (IV) infusion twice a year, which may improve adherence to the dosing schedule relative to other MS DMTs that require more frequent administration. Real-world evidence on the persistence and adherence of patients with MS to OCR compared with other DMTs is limited. &lt;b&gt;OBJECTIVE:&lt;/b&gt; To examine the persistence and adherence to OCR compared with other DMTs for MS in the United States. &lt;b&gt;METHODS:&lt;/b&gt; This analysis was conducted in the PharMetrics Plus commercial claims database and included patients with MS who initiated a new DMT between April 2017 and September 2018. Patients were required to have health plan enrollment for â¥ 1 year before and after DMT initiation (a subgroup analysis was performed for those with â¥ 18 months&#x27; continuous enrollment after DMT initiation). Persistence was defined as not switching to another DMT and having no gap in coverage of the initiated DMT for â¥ 60 days during the postinitiation period. The proportion of days covered (PDC) was calculated as the total days covered by the DMT during the postinitiation period divided by the length of the time period (12 or 18 months); PDC â¥ 0.8 was considered adherent. Multivariable Poisson regression models compared discontinuation (nonpersistence) and nonadherence between OCR users and users of other DMTs grouped by administration route. &lt;b&gt;RESULTS:&lt;/b&gt; A total of 4,587 patients (OCR, 1,319; injectable, 1,051; oral, 1,876; other IV, 341) were included. The OCR group had the lowest proportion of patients discontinuing at 12 months (8% vs. 28%, 32%, and 43% for other IV, oral, and injectable, respectively) and the highest mean PDC (93% vs. 76%, 74%, and 69%, respectively). Compared with patients initiating OCR, adjusted relative risks (RR) of 12-month discontinuation were 3.3 (95% CI = 2.3-4.6), 3.8 (95% CI = 3.0-4.9), and 5.5 (95% CI = 4.1-7.5) for patients initiating other IV, oral, and injectable DMTs, respectively. Similarly, patients initiating other IV, oral, and injectable DMTs had RRs of 4.9 (95% CI = 3.6-6.8), 5.1 (95% CI = 3.9-6.6), and 6.8 (95% CI = 5.0-9.3) for 12-month nonadherence compared with OCR. A subgroup of 2,913 patients with 18 months of continuous enrollment had similar trends, with 17% in the OCR group discontinuing compared with 40%, 41%, and 55% in the other IV, oral, and injectable groups, respectively. Trends over 18 months were consistent with the 12-month analysis in adjusted models. &lt;b&gt;CONCLUSIONS:&lt;/b&gt; Patients initiating OCR had superior persistence and adherence at 12 and 18 months of follow-up compared with patients initiating other MS DMTs. Long-term persistence and adherence should be monitored as OCR experience accrues in a real-world setting. &lt;b&gt;DISCLOSURES:&lt;/b&gt; This study was funded by Genentech (South San Francisco, CA), a member of the Roche Group. Engmann, Sheinson, Bawa, and Ng are employees of Genentech and shareholders of F. Hoffman-La Roche (Basel, Switzerland).&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624535/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33624535&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.18553/jmcp.2021.20413&gt;10.18553/jmcp.2021.20413&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624535/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":74,"discovery_date":"2021-02-24T11:11:00","title":"A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Phytother Res. 2021 Feb 24. doi: 10.1002/ptr.7050. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple Sclerosis (MS) is a demyelinating disease affecting the central nervous system, with no curative medicine available. The use of herbal drugs and dietary supplements is increasing among people with MS (PwMS), raising a need for knowledge about potential interactions between conventional MS medicine and herbal drugs/dietary supplements. This systematic review provides information about the safety of simultaneous use of conventional MS-drugs and herbal drugs frequently used by PwMS. The study included 14 selected disease-modifying treatments and drugs frequently used for symptom-alleviation. A total of 129 published papers found via PubMed and Web of Science were reviewed according to defined inclusion- and exclusion criteria. Findings suggested that daily recommended doses of Panax ginseng and Ginkgo biloba should not be exceeded, and herbal preparations differing from standardized products should be avoided, especially when combined with anticoagulants or substrates of certain cytochrome P450 isoforms. Further studies are required regarding ginseng&#x27;s ability to increase aspirin bioavailability. Combinations between chronic cannabis use and selective serotonin reuptake inhibitors or non-steroidal antiinflammatory drugs should be carefully monitored, whereas no significant evidence for drug-interactions between conventional MS-drugs and ginger, cranberry, vitamin D, fatty acids, turmeric, probiotics or glucosamine was found.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624893/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33624893&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/ptr.7050&gt;10.1002/ptr.7050&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624893/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":73,"discovery_date":"2021-02-24T11:11:00","title":"Machine and deep learning in MS research are just powerful statistics - No","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458520978648. doi: 10.1177/1352458520978648. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625302/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625302&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458520978648&gt;10.1177/1352458520978648&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625302/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":72,"discovery_date":"2021-02-24T11:11:00","title":"Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Cell Mol Neurobiol. 2021 Feb 24. doi: 10.1007/s10571-021-01059-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Antibodies and oxidative stress are hallmarks of multiple sclerosis (MS) lesions. We aimed to clarify the relation between them, their role in MS patients and to investigate their specificity, comparing MS with classical neurodegenerative diseases (ND). Brain samples from 14 MS cases, 6 with ND and 9 controls (without neurological diseases). Immunohistochemistry assays were used to detect oxidized lipids (EO6), IgG and IgM, oligodendrocytes (Olig2), axons (NF, neurofilament) and cellular (TUNEL) and axonal damage (APP, amyloid precursor protein). We did not observe EO6 in controls. All samples from MS patients showed EO6 in oligodendrocytes and axons within lesions. We did not detect co-localization between EO6 and antibodies. Neither did we between EO6 and TUNEL or APP. 94.4% of TUNEL-positive cells in normal appearing white matter were also stained for IgG and 75.5% for IgM. IgM, but not IgG, co-localized with APP. EO6 was associated with axonal damage in amyotrophic lateral sclerosis (ALS). We did not observe association between antibodies and cellular or axonal damage in ND patients. MS patients showed a higher number of B cells and plasma cells in the lesions and meninges than controls. The number of B cells and plasma cells was associated with the presence of antibodies and with the activity of the lesions. We observed a main role of B lymphocytes in the development of MS lesions. Antibodies contribute to the oligodendrocyte and axonal damage in MS. Oxidative stress was associated with axonal damage in ALS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33625628/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224152934&amp;v=2.14.2&quot;&gt;33625628&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10571-021-01059-6&gt;10.1007/s10571-021-01059-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33625628/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224152934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":71,"discovery_date":"2021-02-24T11:11:00","title":"Single-cell immune repertoire and transcriptome sequencing reveals that clonally expanded and transcriptionally distinct lymphocytes populate the aged central nervous system in mice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Proc Biol Sci. 2021 Feb 24;288(1945):20202793. doi: 10.1098/rspb.2020.2793. Epub 2021 Feb 24.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neuroinflammation plays a crucial role during ageing and various neurological conditions, including Alzheimer&#x27;s disease, multiple sclerosis and infection. Technical limitations, however, have prevented an integrative analysis of how lymphocyte immune receptor repertoires and their accompanying transcriptional states change with age in the central nervous system. Here, we leveraged single-cell sequencing to simultaneously profile B cell receptor and T cell receptor repertoires and accompanying gene expression profiles in young and old mouse brains. We observed the presence of clonally expanded B and T cells in the central nervous system of aged male mice. Furthermore, many of these B cells were of the IgM and IgD isotypes, and had low levels of somatic hypermutation. Integrating gene expression information additionally revealed distinct transcriptional profiles of these clonally expanded lymphocytes. Our findings implicate that clonally related T and B cells in the CNS of elderly mice may contribute to neuroinflammation accompanying homeostatic ageing.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622131/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622131&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1098/rspb.2020.2793&gt;10.1098/rspb.2020.2793&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622131/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":70,"discovery_date":"2021-02-24T11:11:00","title":"Effects of diminished positive mood and depressed mood upon verbal learning and memory among people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Clin Exp Neuropsychol. 2021 Feb 23:1-12. doi: 10.1080/13803395.2020.1853066. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Objective&lt;/b&gt;: Cognitive impairment affects as many as 65% of people with multiple sclerosis (PWMS), and memory impairment confers greater severity of disability and functional impairment. Depression is also common among PWMS, and lifetime prevalence rates are as high as 50%. Research has yet to clearly define the relationship between memory dysfunction and depression among PWMS, and may reflect incomplete assessment of depressive symptoms. The present study examined different aspects of depressive symptoms including anhedonia (i.e., diminished positive mood) and their relationships with verbal learning and memory among PWMS.&lt;b&gt;Method&lt;/b&gt;: Participants were 48 healthy individuals and 96 PWMS. They were primarily Caucasian (90.3%) and female (75.0%). Participants completed the California Verbal Learning Test-2 (CVLT-2) to assess verbal learning and memory and the Chicago Multiscale Depression inventory to assess depressed mood (CMDI-Mood) and diminished positive mood (CMDI-DPM).&lt;b&gt;Results&lt;/b&gt;: Linear regression revealed that the main effect of CMDI-DPM and the interaction of CMDI-DPM and CMDI-Mood significantly explained variance across learning, recall, and recognition CVLT-2 indices. Follow-up analyses indicated that CMDI-DPM was only significant in the absence of high CMDI-Mood scores. CMDI-Mood explained variance in only CVLT-2 Trial B.&lt;b&gt;Conclusions&lt;/b&gt;: Depressed mood had little direct effect upon memory performance in PWMS. In the absence of severe depressed mood, higher levels of positive mood corresponded to better memory performance. However, the impact of diminished positive mood was rendered null among those endorsing high levels of depressed mood. These data may imply that anhedonia corresponds with poorer memory function among PWMS, and suggests that investigators and clinicians should assess multiple mood dimensions among PWMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622171/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622171&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/13803395.2020.1853066&gt;10.1080/13803395.2020.1853066&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622171/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":69,"discovery_date":"2021-02-24T11:11:00","title":"Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(3):e964. doi: 10.1212/NXI.0000000000000964. Print 2021 May.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in patients with progressive multiple sclerosis (PMS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We enrolled 61 patients with primary or secondary PMS in a randomized double-blind, parallel-group, phase II trial on oral EGCG (up to 1,200 mg daily) or placebo for 36 months with an optional open-label EGCG treatment extension (OE) of 12-month duration. The primary end point was the rate of brain atrophy, quantified as brain parenchymal fraction (BPF). The secondary end points were radiologic and clinical disease parameters and safety assessments.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: In our cohort, 30 patients were randomized to EGCG treatment and 31 to placebo. Thirty-eight patients (19 from each group) completed the study. The primary endpoint was not met, as in 36 months the rate of decrease in BPF was 0.0092 Â± 0.0152 in the treatment group and -0.0078 Â± 0.0159 in placebo-treated patients. None of the secondary MRI and clinical end points revealed group differences. Adverse events of EGCG were mostly mild and occurred with a similar incidence in the placebo group. One patient in the EGCG group had to stop treatment due to elevated aminotransferases (&amp;gt;3.5 times above normal limit).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: In a phase II trial including patients with multiple sclerosis (MS) with progressive disease course, we were unable to demonstrate a treatment effect of EGCG on the primary and secondary radiologic and clinical disease parameters while confirming on overall beneficial safety profile.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CLINICALTRIALGOV IDENTIFIER: NCT00799890.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This phase II trial provides Class II evidence that for patients with PMS, EGCG was safe, well tolerated, and did not significantly reduce the rate of brain atrophy.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622766/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622766&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1212/NXI.0000000000000964&gt;10.1212/NXI.0000000000000964&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622766/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":68,"discovery_date":"2021-02-24T11:11:00","title":"Correlation of Dietary Intake and Helicobacter pylori Infection with Multiple Sclerosis, a Case-Control Study in Rafsanjan, Iran, 2017-18","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Qatar Med J. 2021 Feb 5;2020(3):45. doi: 10.5339/qmj.2020.45. eCollection 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Some environmental factors, such as &lt;i&gt;Helicobacter pylori&lt;/i&gt; infection (HPI), are likely to be considered a protective factor in MS. Dietary intake may provide exposure to or have protective effects for MS. The present study aimed to determine the relationship between serum anti-H. pylori IgG antibody (HPIA) level and dietary intake in patients with MS referred to the MS Clinic in Rafsanjan city, Iran.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: The present case-control study was conducted on 97 patients with MS and 95 controls. The two groups had no significant difference in age and gender (&lt;i&gt;p&lt;/i&gt; &amp;gt; 0.05). HPIA was checked, and the food frequency questionnaire was completed in both groups to measure nutritional intake. All data were analyzed by the SPSS 20 software using independent t-test, Chi-Square, Mann-Whitney U test, and correlation.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The median serum HPIA level was significantly lower in MS cases than in controls. Furthermore, the median consumption of glutamic acid, arginine, serine, aspartic acid, alanine, proline, and caffeine was significantly lower in MS cases than in controls. A significant positive correlation was found between the levels of linoleic acid, lactose, Ca, molybdenum, galactose, leucine, and valine, and the level of HPIA in controls.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Our study results demonstrated that some dietary nutrients had correlations with MS and HPI. Therefore, professionals from multiple disciplines must find which foods contain these dietary nutrients in future studies.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623753/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623753&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7878158/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;PMC7878158&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.5339/qmj.2020.45&gt;10.5339/qmj.2020.45&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623753/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":67,"discovery_date":"2021-02-24T11:11:00","title":"Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neural Transm (Vienna). 2021 Feb 23. doi: 10.1007/s00702-021-02306-2. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson&#x27;s disease symptoms and viral infections. Considering amantadine&#x27;s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington&#x27;s disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine&#x27;s therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database http://www.clinicaltrials.gov reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624170/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33624170&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00702-021-02306-2&gt;10.1007/s00702-021-02306-2&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624170/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":66,"discovery_date":"2021-02-24T11:11:00","title":"Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Sci Sleep. 2021 Feb 16;13:201-207. doi: 10.2147/NSS.S256676. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The prevalence of sleep disorders in individuals with multiple sclerosis (MS) is 3-5 times higher compared to the general population. Insomnia Disorder, defined as difficulty falling asleep, maintaining sleep or waking up too early, can lead to significant fatigue, the most common and disabling symptom of MS. In addition, fatigue and insomnia in patients with MS also can overlap with and exacerbate other psychological and physical symptoms. Cognitive behavioral therapy for insomnia (CBT-I) has been shown as an effective treatment for chronic insomnia and burgeoning research has demonstrated the effectiveness of this treatment for insomnia in individuals with a variety of comorbid medical conditions including MS. The purpose of the current review will explore the literature surrounding the prevalence and impact of sleep disorders and fatigue in MS. Additionally, this review will address practical ways to help individuals with MS manage fatigue as well as how to modify typical standard behavioral treatments for insomnia to take into account special considerations for individuals with MS based on the level of disability and other comorbid issues that impact sleep.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623461/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623461&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7896778/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;PMC7896778&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2147/NSS.S256676&gt;10.2147/NSS.S256676&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623461/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":65,"discovery_date":"2021-02-24T11:11:00","title":"Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 23;11(1):4358. doi: 10.1038/s41598-021-83991-7.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The improvement of life quality and medical advances has resulted in increased life expectancy. Despite this, health status commonly worsens in the last years of life. Frailty is an intermediate and reversible state that often precedes dependency and therefore, its identification may be essential to prevent dependency. However, there is no consensus on the best tools to identify frailty. In this sense, diverse molecules have been proposed as potential biomarkers. Some investigations pointed to an increased chronic inflammation or inflammaging with frailty, while others did not report such differences. In this work, we evaluated the circulating concentration of the inflammaging markers in adults and older adults (aged over 70 years) by ELISA and Luminex techniques. The Barthel Index was applied for the evaluation of dependency and Timed up-and-go, Gait Speed, Short Physical Performance Battery, Tilburg Frailty Indicator and Gerontopole Frailty Screening Tool were used for the identification of frailty. CRP, TNF-Î±, IL-6 and albumin concentrations were measured, and we found that elevated inflammation is present in older adults, while no differences with frailty and dependency were reported. Our results were consistent for all the evaluated frailty scales, highlighting the need to reconsider increased inflammation as a biomarker of frailty.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623057/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623057&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41598-021-83991-7&gt;10.1038/s41598-021-83991-7&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623057/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":64,"discovery_date":"2021-02-24T11:11:00","title":"Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 8;7(1):2055217321992394. doi: 10.1177/2055217321992394. eCollection 2021 Jan-Mar.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: To identify Magnetic Resonance Imaging (MRI), clinical and demographic biomarkers predictive of worsening information processing speed (IPS) as measured by Symbol Digit Modalities Test (SDMT).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Demographic, clinical data and 1.5 T MRI scans were collected in 76 patients at time of inclusion, and after 5 and 10 years. Global and tissue-specific volumes were calculated at each time point. For the primary outcome of analysis, SDMT was used.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Worsening SDMT at 5-year follow-up was predicted by baseline age, Expanded Disability Status Scale (EDSS), SDMT, whole brain volume (WBV) and T2 lesion volume (LV), explaining 30.2% of the variance of SDMT. At 10-year follow-up, age, EDSS, grey matter volume (GMV) and T1 LV explained 39.4% of the variance of SDMT change.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: This longitudinal study shows that baseline MRI-markers, demographic and clinical data can help predict worsening IPS. Identification of patients at risk of IPS decline is of importance as follow-up, treatment and rehabilitation can be optimized.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33623706/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33623706&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7876764/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;PMC7876764&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055217321992394&gt;10.1177/2055217321992394&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33623706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":63,"discovery_date":"2021-02-24T11:11:00","title":"Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Hum Brain Mapp. 2021 Feb 24. doi: 10.1002/hbm.25375. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;There is evidence that multiple sclerosis (MS) pathology leads to distinct patterns of volume loss over time (VLOT) in different central nervous system (CNS) structures. We aimed to use such patterns to identify patient subgroups. MS patients of all classical disease phenotypes underwent annual clinical, blood, and MRI examinations over 6 years. Spinal, striatal, pallidal, thalamic, cortical, white matter, and T2-weighted lesion volumes as well as serum neurofilament light chain (sNfL) were quantified. CNS VLOT patterns were identified using principal component analysis and patients were classified using hierarchical cluster analysis. 225 MS patients were classified into four distinct Groups A, B, C, and D including 14, 59, 141, and 11 patients, respectively). These groups did not differ in baseline demographics, disease duration, disease phenotype distribution, and lesion-load expansion. Interestingly, Group A showed pronounced spinothalamic VLOT, Group B marked pallidal VLOT, Group C small between-structure VLOT differences, and Group D myelocortical volume increase and pronounced white matter VLOT. Neurologic deficits were more severe and progressed faster in Group A that also had higher mean sNfL levels than all other groups. Group B experienced more frequent relapses than Group C. In conclusion, there are distinct patterns of VLOT across the CNS in MS patients, which do not overlap with clinical MS subtypes and are independent of disease duration and lesion-load but are partially associated to sNfL levels, relapse rates, and clinical worsening. Our findings support the need for a more biologic classification of MS subtypes including volumetric and body-fluid markers.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33624390/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33624390&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/hbm.25375&gt;10.1002/hbm.25375&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33624390/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":62,"discovery_date":"2021-02-24T11:11:00","title":"miRNA-467b inhibits Th17 differentiation by targeting eIF4E in experimental autoimmune encephalomyelitis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mol Immunol. 2021 Feb 20;133:23-33. doi: 10.1016/j.molimm.2021.02.008. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are neuroinflammatory autoimmune diseases characterized by the axonal loss, demyelination, and neurodegeneration of the central nervous system. Overactivation of CD4&lt;sup&gt;+&lt;/sup&gt; T cells, especially the migration of the Th1 and Th17 subsets into the central nervous system (CNS), leads to the secretion of inflammatory mediators and destruction of the contact between neurons and activated macrophages, which can then result in a series of neurocognitive and motor deficits. In this study, we intended to explore the role of miRNA-467b in regulating Th cell development in EAE. We found that the level of miRNA-467b was decreased and eukaryotic initiation factor 4 F (eIF4E) was increased in lymph nodes and the CNS at EAE peak. eIF4E was confirmed as the direct target of miRNA467b. Overexpression of miRNA-467b could suppress a percentage of CD4&lt;sup&gt;+&lt;/sup&gt; IL-17&lt;sup&gt;+&lt;/sup&gt; cells in EAE CD4 + T cells in vitro. In addition, we also identified miRNA-467b, which could suppress Th17 cell differentiation by targeting eIF4E in vitro. Furthermore, injecting miRNA-467b mimics into the caudal vein of EAE mice contributed to less inflammation in the peripheral lymphoid organs and CNS and alleviated disease severity. Taken together, our findings imply that miRNA-467b inhibits the differentiation and function of Th17 cells by targeting eIF4E, thereby alleviating EAE.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621940/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224012934&amp;v=2.14.2&quot;&gt;33621940&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.molimm.2021.02.008&gt;10.1016/j.molimm.2021.02.008&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621940/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224012934&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":61,"discovery_date":"2021-02-24T11:11:00","title":"Is maximal muscle strength and fatigability of three lower limb muscle groups associated with walking capacity and fatigability in multiple sclerosis? An exploratory study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102841. doi: 10.1016/j.msard.2021.102841. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Both muscle fatigability and walking fatigability are prevalent in persons with MS (pwMS), but their associations remains unclear. The aim of this study was to examine the association of muscle strength and fatigability from both isometric and concentric protocols of three different muscle groups, and their association to walking capacity and walking fatigability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Twenty-seven pwMS and 13 Healthy Controls (HC) were included in this exploratory study. All participants performed a six-minute walking test (6MWT), where the distance walked index (DWI) was calculated to measure walking fatigability with a cut-off score of -10%. In three different muscle groups (knee extensors (KE), knee flexors (KF), ankle dorsiflexors (DF)), isometric and concentric muscle fatigability protocols (FI&lt;sub&gt;isometric&lt;/sub&gt; or FI&lt;sub&gt;concentric&lt;/sub&gt;) were used to quantify maximal voluntary contraction (MVC) and muscle fatigability. Pearson or Spearman correlation coefficients and linear regression models were calculated to establish the association between muscle strength/fatigability and walking capacity/fatigability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Higher MVCs values for all muscle groups were found in HC compared to pwMS (mainly those having walking fatigability) (p &amp;lt; 0.05). FI&lt;sub&gt;isometric&lt;/sub&gt; of DF was lower in pwMS having walking fatigability compared to no walking fatigability. MVC of KE, KF and DF had a low to moderate association with walking capacity (range r = 0.52-0.56; p &amp;lt; 0.05) and walking fatigability in pwMS (range r-r&lt;sub&gt;s&lt;/sub&gt;: 0.39-0.50; p&amp;lt;0.05). FI&lt;sub&gt;concentric&lt;/sub&gt; of KF and DF, but not of KE, were associated with walking fatigability (r = 0.39 and r&lt;sub&gt;s&lt;/sub&gt; = 0.47, respectively; p &amp;lt; 0.05). In contrast, FI&lt;sub&gt;isometric&lt;/sub&gt; for all muscle groups were not related to walking capacity or walking fatigability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: MVC of KE, KF and DF are associated with walking capacity and walking fatigability, while concentric (but not isometric) muscle fatigability of KF and DF are associated with walking fatigability.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621946/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224012934&amp;v=2.14.2&quot;&gt;33621946&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102841&gt;10.1016/j.msard.2021.102841&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621946/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224012934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":60,"discovery_date":"2021-02-24T11:11:00","title":"Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Radiology. 2021 Feb 23:203071. doi: 10.1148/radiol.2021203071. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Susceptibility-weighted imaging (SWI) evolved from simple two-dimensional T2*-weighted sequences to three-dimensional sequences with improved spatial resolution and enhanced susceptibility contrast. SWI is an MRI sequence sensitive to compounds that distort the local magnetic field (eg, calcium and iron), in which the phase information can differentiate. But the term &lt;i&gt;SWI&lt;/i&gt; is colloquially used to denote high-spatial-resolution susceptibility-enhanced sequences across different MRI vendors and sequences even when phase information is not used. The imaging appearance of SWI and related sequences strongly depends on the acquisition technique. Initially, SWI and related sequences were mostly used to improve the depiction of findings already known from standard two-dimensional T2*-weighted neuroimaging: more microbleeds in patients who are aging or with dementia or mild brain trauma; increased conspicuity of superficial siderosis in Alzheimer disease and amyloid angiopathy; and iron deposition in neurodegenerative diseases or abnormal vascular structures, such as capillary telangiectasia. But SWI also helps to identify findings not visible on standard T2*-weighted images: the nigrosome 1 in Parkinson disease and dementia with Lewy bodies, the central vein and peripheral rim signs in multiple sclerosis, the peripheral rim sign in abscesses, arterial signal loss related to thrombus, asymmetrically prominent cortical veins in stroke, and intratumoral susceptibility signals in brain neoplasms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620291/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620291&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1148/radiol.2021203071&gt;10.1148/radiol.2021203071&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620291/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":59,"discovery_date":"2021-02-24T11:11:00","title":"The impact of neurological disability and sensory loss on mindfulness practice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Disabil Rehabil. 2021 Feb 23:1-9. doi: 10.1080/09638288.2021.1887946. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVES: Mindfulness-based approaches are increasingly recommended in the management of medical conditions associated with sensory loss and absence, such as Spinal Cord Injury (SCI), Multiple Sclerosis (MS) and Functional Neurological Disorder (FND). Yet the implications of undertaking practices such as body scanning when living with sensory loss have not been considered. This study aimed to explore the impact of sensory loss on the practice and experience of mindfulness in qualified mindfulness teachers with SCI/FND/MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Eight mindfulness teachers (5 females, 3 males) with SCI/FND/MS, sensory loss and wheelchair use were recruited from mindfulness teacher databases. In-depth, semi-structured interviews were undertaken, lasting between 50 and 93 min. Interviews were transcribed verbatim and analysed using Interpretative Phenomenological Analysis. Idiographic analyses for descriptive, linguistic and conceptual themes were completed before cross-case analyses.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Analyses resulted in two superordinate themes: (1) Adopting your Body; and (2) Sensation without Loss. These themes reflected the challenge of overcoming initial resistance to areas of the body with sensory disruption, building a relationship with the whole body, such that sensory awareness could be visualised and experienced without proprioception.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Mindfulness offers a unique approach to accepting and working with the body after paralysis or sensory loss. Fundamental to the use of mindfulness with such populations, is the prioritisation of inclusive sensory language and exploring sensory absence as well as sensory presence. The cognitive and emotional outcomes of body scanning may be uniquely elevated in populations with neurophysiological disorders, highlighting the benefits of mindfulness for adaptive and protective self-management.IMPLICATIONS FOR REHABILITATIONMindfulness-based practices which focus on the body and sensation are accessible to people with neurological limitations.Mindfulness techniques can be extended through the use of visualisation strategies to encourage (non-proprioceptive) awareness of paralysed limbs or areas of the body with sensory loss.The language used in mindfulness-based interventions may need adapted by practitioners so that it remains inclusive for people with sensory loss as well as sensory presence.Additional care needs to be taken when using body scans during mindfulness as they have the potential to exacerbate psychological distress in people with reduced sensory awareness.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621135/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33621135&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/09638288.2021.1887946&gt;10.1080/09638288.2021.1887946&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621135/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":58,"discovery_date":"2021-02-24T11:11:00","title":"Efficacy classification of modern therapies in multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Comp Eff Res. 2021 Feb 23. doi: 10.2217/cer-2020-0267. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. &lt;b&gt;Materials &amp;amp; methods:&lt;/b&gt; Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. &lt;b&gt;Results:&lt;/b&gt; For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. &lt;b&gt;Conclusion:&lt;/b&gt; Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620251/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620251&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2217/cer-2020-0267&gt;10.2217/cer-2020-0267&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620251/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":57,"discovery_date":"2021-02-24T11:11:00","title":"The effect of pelvic floor exercise program on incontinence and sexual dysfunction in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Int Urol Nephrol. 2021 Feb 23. doi: 10.1007/s11255-021-02804-y. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that involves different neurological areas. In addition to lower urinary tract symptoms (LUTS), sexual dysfunction (SD), and psychopathological effects, MS sometimes seriously impairs the quality of life (QoL). We hypothesize that the pelvic floor exercise program (PFEP) could improve bladder, sexual function, depression, and QoL in MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Patients diagnosed with MS completed the Incontinence Questionnaire Short Form (ICIQ-SF), the Beck Depression Inventory (BDI), the Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire, and either the Female Sexual Function Index (FSFI) or the Sexual Health Inventory for Men (SHIM). Maximum bladder volumes (MBV) and post-voiding residual (PVR) volumes were measured using ultrasonography. The patients who regularly completed the PFEP for 12 weeks were asked to fill out the questionnaires again, and their MBV and PVR were remeasured.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Seventy-two patients with relapsing-remitting multiple sclerosis (RRMS) were included in the study. Forty-two (58.3%) RRMS patients reached the end of the study. The patients&#x27; post-PFEP average MBV statistically increased (p = 0.01). In contrast, no statistically significant difference was found in the PVR (p = 0.2). After exercise, the FSFI values in women increased (p = 0.02), and ICIQ-SF and BDI values in all the RRMS patients statistically decreased (p = 0.004, p = 0.01, respectively), but there was no improvement in the MSQoL-54 score (p &amp;gt; 0.05).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: PFEP, which causes a reduction in LUTS by enhancing the MBV of RRMS patients, can be seen as an investment in the future in terms of reducing depression in MS patients and preventing or delaying SD in women.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620664/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620664&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s11255-021-02804-y&gt;10.1007/s11255-021-02804-y&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620664/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":56,"discovery_date":"2021-02-24T11:11:00","title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;IMPORTANCE: Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease of the central nervous system characterized by inflammatory demyelination with axonal transection. MS affects an estimated 900 000 people in the US. MS typically presents in young adults (mean age of onset, 20-30 years) and can lead to physical disability, cognitive impairment, and decreased quality of life. This review summarizes current evidence regarding diagnosis and treatment of MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBSERVATIONS: MS typically presents in young adults aged 20 to 30 years with unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes such as internuclear ophthalmoplegia developing over several days. The prevalence of MS worldwide ranges from 5 to 300 per 100 000 people and increases at higher latitudes. Overall life expectancy is less than in the general population (75.9 vs 83.4 years), and MS more commonly affects women (female to male sex distribution of nearly 3:1). Diagnosis is made based on a combination of signs and symptoms, radiographic findings (eg, magnetic resonance imaging [MRI] T2 lesions), and laboratory findings (eg, cerebrospinal fluid-specific oligoclonal bands), which are components of the 2017 McDonald Criteria. Nine classes of disease-modifying therapies (DMTs), with varying mechanisms of action and routes of administration, are available for relapsing-remitting MS, defined as relapses at onset with stable neurologic disability between episodes, and secondary progressive MS with activity, defined as steadily increasing neurologic disability following a relapsing course with evidence of ongoing inflammatory activity. These drugs include interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. One additional DMT, ocrelizumab, is approved for primary progressive MS. These DMTs reduce clinical relapses and MRI lesions (new T2 lesions, gadolinium-enhancing lesions). Efficacy rates of current DMTs, defined by reduction in annualized relapse rates compared with placebo or active comparators, range from 29%-68%. Adverse effects include infections, bradycardia, heart blocks, macular edema, infusion reactions, injection-site reactions, and secondary autoimmune adverse effects, such as autoimmune thyroid disease.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS AND RELEVANCE: MS is characterized by physical disability, cognitive impairment, and other symptoms that affect quality of life. Treatment with DMT can reduce the annual relapse rate by 29% to 68% compared with placebo or active comparator.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620411/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33620411&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1001/jama.2020.26858&gt;10.1001/jama.2020.26858&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620411/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":55,"discovery_date":"2021-02-24T11:11:00","title":"The Efficacy of Ketogenic Therapies in the Clinical Management of People with Neurodegenerative Disease: A Systematic Review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Adv Nutr. 2021 Feb 23:nmaa180. doi: 10.1093/advances/nmaa180. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Ketone bodies have potential disease-modifying activity that represent a novel therapeutic approach for neurodegenerative diseases (NDD). The aim of this systematic review was to summarize and evaluate the evidence for the application of ketogenic therapies (dietary or exogenous ketogenic agents) for NDD and provide recommendations for future research. Eight databases were electronically searched for articles reporting on controlled trials (â¥4 wk duration) that induced ketosis or elevated serum ketone concentrations in people with NDD. Of 4498 records identified, 17 articles met the inclusion criteria with a total of 979 participants including studies on mild cognitive impairment (MCI; n = 6), multiple sclerosis (n = 4), Alzheimer&#x27;s disease (n = 5), Parkinson&#x27;s disease (n = 1), and MCI secondary to Parkinson&#x27;s disease (n = 1). Of 17 studies, 7 were randomized double-blind placebo-controlled trials. Most studies used dietary interventions (n = 9), followed by medium-chain triglycerides (n = 7) and a fasting protocol (n = 1). Generally, trials were 6 wk in duration and assessed cognition as the primary outcome. Studies were heterogeneous in type and severity of NDD, interventions used, and outcomes assessed. Overall, 3/17 studies carried a low risk of bias. Based on available evidence, exogenous ketogenic agents may be more feasible than dietary interventions in NDD from a compliance and adherence perspective; more research is required to confirm this. Recommendations for future research include improving exogenous formulations to reduce adverse effects, exploring interindividual factors affecting response-to-treatment, and establishing a &quot;minimum required dose&quot; for clinically meaningful improvements in disease-specific symptoms, such as cognition or motor function.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621313/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33621313&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1093/advances/nmaa180&gt;10.1093/advances/nmaa180&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621313/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":54,"discovery_date":"2021-02-24T11:11:00","title":"Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Feb 23. doi: 10.1002/acn3.51310. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to previous disease-modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing four doses of OCR per initial US prescribing recommendations in the main study, participants in the substudy (N = 129) received a fifth dose over a 2-h duration (vs. 3.5 h). Infusion-related reactions occurred in 12.4% of patients. None were severe, life-threatening or led to treatment discontinuation. Shorter infusion time did not change the safety profile of OCR. Clinicaltrials.gov (NCT0237856).&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33621404/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223200936&amp;v=2.14.2&quot;&gt;33621404&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/acn3.51310&gt;10.1002/acn3.51310&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33621404/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223200936&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":53,"discovery_date":"2021-02-23T11:11:00","title":"Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: A case report","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Rev Neurol (Paris). 2021 Feb 19:S0035-3787(21)00032-1. doi: 10.1016/j.neurol.2020.11.003. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618890&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.neurol.2020.11.003&gt;10.1016/j.neurol.2020.11.003&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":52,"discovery_date":"2021-02-23T11:11:00","title":"Diet-dependent regulation of TGFÎ² impairs reparative innate immune responses after demyelination","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Metab. 2021 Feb;3(2):211-227. doi: 10.1038/s42255-021-00341-7. Epub 2021 Feb 18.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Proregenerative responses are required for the restoration of nervous-system functionality in demyelinating diseases such as multiple sclerosis (MS). Yet, the limiting factors responsible for poor CNS repair are only partially understood. Here, we test the impact of a Western diet (WD) on phagocyte function in a mouse model of demyelinating injury that requires microglial innate immune function for a regenerative response to occur. We find that WD feeding triggers an ageing-related, dysfunctional metabolic response that is associated with impaired myelin-debris clearance in microglia, thereby impairing lesion recovery after demyelination. Mechanistically, we detect enhanced transforming growth factor beta (TGFÎ²) signalling, which suppresses the activation of the liver X receptor (LXR)-regulated genes involved in cholesterol efflux, thereby inhibiting phagocytic clearance of myelin and cholesterol. Blocking TGFÎ² or promoting triggering receptor expressed on myeloid cells 2 (TREM2) activity restores microglia responsiveness and myelin-debris clearance after demyelinating injury. Thus, we have identified a druggable microglial immune checkpoint mechanism regulating the microglial response to injury that promotes remyelination.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33619376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33619376&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s42255-021-00341-7&gt;10.1038/s42255-021-00341-7&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33619376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":51,"discovery_date":"2021-02-23T11:11:00","title":"Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Elife. 2021 Feb 22;10:e57417. doi: 10.7554/eLife.57417.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Cells exist within complex milieus of communicating factors, such as cytokines, that combine to generate context-specific responses, yet nearly all knowledge about the function of each cytokine and the signaling propagated downstream of their recognition is based on the response to individual cytokines. Here, we found that regulatory T cells (Tregs) integrate concurrent signaling initiated by IL-2 and IL-4 to generate a response divergent from the sum of the two pathways in isolation. IL-4 stimulation of STAT6 phosphorylation was blocked by IL-2, while IL-2 and IL-4 synergized to enhance STAT5 phosphorylation, IL-10 production, and the selective proliferation of IL-10-producing Tregs, leading to increased inhibition of conventional T cell activation and the reversal of asthma and multiple sclerosis in mice. These data define a mechanism of combinatorial cytokine signaling and lay the foundation upon which to better understand the origins of cytokine pleiotropy while informing improved the clinical use of cytokines.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33617447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33617447&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.7554/eLife.57417&gt;10.7554/eLife.57417&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33617447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":50,"discovery_date":"2021-02-23T11:11:00","title":"Quantifying upper limb tremor in people with multiple sclerosis using Fast Fourier Transform based analysis of wrist accelerometer signals","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Rehabil Assist Technol Eng. 2021 Feb 3;8:2055668320966955. doi: 10.1177/2055668320966955. eCollection 2021 Jan-Dec.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Tremor is a disabling symptom of Multiple Sclerosis (MS). The development of objective methods of tremor characterisation to assess intervention efficacy and disease progression is therefore important. The possibility of using a Fast Fourier Transform (FFT) method for tremor detection was explored.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Acceleration from a wrist-worn device was analysed using FFTs to identify and characterise tremor magnitude and frequency. Processing parameters were explored to provide insight into the optimal algorithm. Participants wore a wrist tri-axial accelerometer during 9 tasks. The FAHN clinical assessment of tremor was used as the reference standard.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Five people with MS and tremor (57.6 Â± 15.3 years, 3 F/2M) and ten disease-free controls (42.4 Â± 10.9 years, 5 M/5F) took part. Using specific algorithm settings tremor identification was possible (peak frequency 3-15Hz; magnitude greater than 0.06 g; 2 s windows with 50% overlap; using 2 of 3 axes of acceleration), giving sensitivity 0.974 and specificity 0.971 (38 tremor occurrences out of 108 tasks, 1 false positive, 2 false negatives). Tremor had frequency 3.5-13.0 Hz and amplitude 0.07-2.60g.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Upper limb tremor in people with MS can be detected using a FFT approach based on acceleration recorded at the wrist, demonstrating the possibility of using this minimally encumbering technique within clinical practice.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614109&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7869147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7869147&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/2055668320966955&gt;10.1177/2055668320966955&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":49,"discovery_date":"2021-02-23T11:11:00","title":"Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Immunometabolism. 2021;3(1):e210006. doi: 10.20900/immunometab20210006. Epub 2021 Jan 22.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Targeting glycolysis in T helper 17 (Th17) cells presents an attractive opportunity to treat Th17 cell-mediated autoimmune diseases such as multiple sclerosis (MS). Pyruvate kinase isoform 2 (PKM2) is a glycolytic enzyme expressed in T cells infiltrating the central nervous system in a mouse model of MS, suggesting PKM2 modulation could provide a new avenue for MS therapeutics. In a recent article in &lt;i&gt;Science Signaling&lt;/i&gt;, Seki et al. show that pharmacological modulation of PKM2 alters but does not ameliorate disease in a mouse model of MS. These results warrant further consideration of PKM2 modulators to treat Th17 cell-mediated autoimmunity.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614166&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7894650/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7894650&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.20900/immunometab20210006&gt;10.20900/immunometab20210006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":48,"discovery_date":"2021-02-23T11:11:00","title":"Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102831. doi: 10.1016/j.msard.2021.102831. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Spasticity is a common problematic symptom in Multiple Sclerosis with over one third of patients failing first line therapies. Intrathecal baclofen is a safe and efficacious option for treatment resistant spasticity. Anecdotally patients report improved concentration/cognitive performance when switching to intrathecal baclofen (ITB) from systemic medications.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;AIM: To explore whether subjects who proceed with ITB pump implantation for spasticity management and reduce oral anti-spasticity agents will have improved cognitive function.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Subjects were admitted for trial of ITB via lumbar puncture and subsequent pump implantation. Spasticity and cognitive measures before ITB trial and 3 months post implant were recorded. Paired t-test or Wilcoxon Signed Ranks test was used for within subject change and effect sizes (Cohen&#x27;s d&lt;sub&gt;z&lt;/sub&gt;) were calculated. Subgroup analysis of those on â¥2, or â¤ 1 spasticity medications at baseline was performed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 27 subjects with MS completed per protocol. Mean age 46 years [26 - 56], disease duration 15 years [6 - 26], RRMS = 3, SPMS = 17 and PPMS=7. The majority were on multiple spasticity medications. Spasticity scores significantly improved post pump implant. Mean ITB dose at 3 months was 143 mcg / day and 19 discontinued all other treatments for spasticity. There was no deterioration on any cognitive or mood measure. An improvement of moderate effect size was found in Backwards Digit Span (d=0.41, p=0.059) and HADS - anxiety (d=0.37, p=0.097). Fatigue Severity Scale score decreased substantially (d=0.81, p=0.005). Small improvements in Symbol Digit Modalities Test score (d=0.24) and Sustained Attention to Response Task response time (d=0.23) were non-significant. Performance on other measures did not change. Effect sizes were larger in subgroup on â¥2 oral spasticity medications at baseline, compared to the group on â¤1 medication (SDMT, d=0.42 vs d=0.07; Backwards digit span 0.45 vs 0.28; HADS-anxiety 0.39 vs 0.32; HADS-depression d=0.32 vs 0.05 and FSS, d= 1.14 vs 0.42).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: In a pilot study exploring the impact of ITB on cognition, spasticity scores improved universally and beneficial effects on some measures of fatigue, anxiety, auditory attention and verbal working memory were found. Improvement of speed of processing in those withdrawing higher doses of oral medication was also demonstrated suggesting that switching to ITB has added cognitive and psychological benefits for people with MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618123&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102831&gt;10.1016/j.msard.2021.102831&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":47,"discovery_date":"2021-02-23T11:11:00","title":"Feasibility and efficacy of a physical activity intervention for managing restless legs syndrome in multiple sclerosis: Results of a pilot randomized controlled trial","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102836. doi: 10.1016/j.msard.2021.102836. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: This pilot randomized controlled trial examined the feasibility and efficacy of a physical activity behavior change intervention for improving restless legs syndrome (RLS) severity and secondary sleep outcomes among a sample of adults with multiple sclerosis (MS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Participants with MS(N=15) were randomly assigned into intervention(n=8) or waitlist control(n=7) conditions. The physical activity intervention was delivered over a 16-week period and outcomes were assessed at baseline and immediately following the 16-week period in both conditions.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: There was a significant, positive effect of the intervention on overall RLS severity (p=.01;Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.43), severity during the night(p=.03,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.35), severity during the day while resting(p=.01,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.44), and severity during the day while active(p&amp;lt;.01,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.61), and non-significant improvements in RLS severity while falling asleep (p=.33,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.09). There were significant positive effects on sleep satisfaction(p&amp;lt;.01,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.49) and non-significant improvements in self-reported global sleep quality(p=.35,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.08). There was a significant intervention effect on self-reported time in bed(p=.03,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.37) and total sleep time(p=.03,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.36), and non-significant improvements in self-reported sleep latency (p=.08,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.25), sleep efficiency(p=.27,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.11), and daytime sleepiness (p=.52,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.04;p=.35,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.08;p=.51,Î·&lt;sub&gt;Ï&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;=.04). There was no significant effect of the intervention on device-measured sleep quality.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: We provide preliminary evidence for the feasibility and efficacy of a physical activity intervention for reducing RLS severity and potentially improving self-reported sleep outcomes in adults with MS. CLINICALTRIALS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;GOV IDENTIFICATION NUMBER: NCT04061681.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618120/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618120&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102836&gt;10.1016/j.msard.2021.102836&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618120/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":46,"discovery_date":"2021-02-23T11:11:00","title":"Design considerations for a multiple sclerosis fatigue mobile app MS Energize: A pragmatic iterative approach using usability testing and resonance checks","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Internet Interv. 2021 Feb 2;24:100371. doi: 10.1016/j.invent.2021.100371. eCollection 2021 Apr.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic neurological condition affecting around 2.2 million people worldwide. The illness includes a range of symptoms, with fatigue considered to be one of the most disabling. This paper describes how a pragmatic and iterative approach, supported by usability and resonance testing, was used to build a minimum viable product of MS Energize-or MS Energise in UK English regions. MS Energise is a mobile application focused on self-management of fatigue for people with MS. The iterative approach included various stages of testing, during which user feedback including comments about interface, navigation and content, was sought to inform incremental app development and continual improvement. Usability testing was conducted with 11 people with longstanding multiple sclerosis in New Zealand and the United Kingdom, and focused on particular sections of the app as well as the accessibility of the app to users with MS. Two participants contributed to further resonance testing post-release to ensure the app was perceived as relevant and useful to the user. The usability testing and resonance testing phases suggested that user experience of MS Energise was mostly positive. Participants provided a number of suggestions for improvements to aspects of content and design; some of which we implemented during our app development process. Findings will also contribute to future planning and design iteration to enhance the user experience. The next step is further improvement of MS Energise prior to a trial of its clinical and cost effectiveness.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614414&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7878181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7878181&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.invent.2021.100371&gt;10.1016/j.invent.2021.100371&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":45,"discovery_date":"2021-02-23T11:11:00","title":"Multiple Koenen Tumors, a Rare Entity: Combination Treatment with 1% Topical Sirolimus Electrofulguration and Excision","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Skin Appendage Disord. 2021 Jan;7(1):66-70. doi: 10.1159/000511743. Epub 2020 Dec 16.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Koenen tumors are benign, cutaneous manifestations of tuberous sclerosis. These are disfiguring, painful, and challenging to treat as they frequently recur. We report a case of long-standing, multiple Koenen tumors affecting all twenty nails in an elderly female who was successfully treated with a combination of topical sirolimus 1%, surgical excision, and electrofulguration.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CASE REPORT: A 57-year-old lady presented with multiple, asymptomatic periungual, and subungual tumors affecting all twenty nails since 27 years. Cutaneous examination revealed confetti macules, ash-leaf macule, and shagreen patch over trunk. Nail biopsy was compatible with Koenen&#x27;s tumor. Computerized tomography of brain showed diffuse patchy sclerosis. The tumors were treated with topical sirolimus 1% ointment for 10 months with excellent regression. Electro-fulguration for both great toenails and surgical excision of right thumbnail periungual fibroma was done. 1% sirolimus was advised after the surgical treatment. There were no adverse effects or recurrence of tumors over a 2-year follow-up.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;DISCUSSION: Topical sirolimus 1% was effective in tumor regression and preventing new tumor formation. Larger tumors that interfered in daily chores were treated with excision and electrofulguration. Thus, a combination treatment for this rare presentation of tuberous sclerosis provided optimum results.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33614724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33614724&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7879313/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7879313&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1159/000511743&gt;10.1159/000511743&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33614724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":44,"discovery_date":"2021-02-23T11:11:00","title":"Management strategies for neurogenic lower urinary tract dysfunction: a qualitative study of the experiences of people with multiple sclerosis and healthcare professionals","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Disabil Rehabil. 2021 Feb 22:1-11. doi: 10.1080/09638288.2021.1887378. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Urinary symptoms are highly prevalent among people with MS. This study aimed to explore the experiences of people with MS and HCPs in managing urinary symptoms and explore their views on using TTNS to treat urinary symptoms.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;MATERIALS AND METHODS: Audio-recorded semi-structured, interviews were employed with people with MS and HCPs. All transcribed interviews were exported to NVivo software (Version 12) and analyzed using a reflexive approach to thematic analysis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Four main themes were identified; The wide-ranging negative impacts of urinary symptoms (&quot;It&#x27;s limited everything else&quot;), Gaps in urinary services (&quot;Is there somebody like that, sort of specialized in that area?&quot;), Management strategies (&quot;I don&#x27;t go too far from the toilet in case I need to use one&quot;), and optimism about TTNS (&quot;Are you giving Me Hope?&quot;).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Urinary symptoms are common and very troublesome for people with MS. Despite their prevalence, many people with MS continue to suffer in silence. People with MS require skilled multidisciplinary services guided by clinical care pathways to improve service provision and to address urinary symptoms. HCP&#x27;s and people with MS are open to the use of TTNS for urinary symptoms and have clear preferences for location and duration of intervention delivery. Implications for rehabilitation Urinary symptoms are very common and troublesome for people with multiple sclerosis, yet many continue to suffer in silence. People with multiple sclerosis lack knowledge about treatment options for urinary symptoms. There is an on-going need for healthcare provider education on guidelines for screening and managing urinary symptoms in people with MS and the role of specialist urinary service providers. HCP&#x27;s and people with MS are open to the use of TTNS for urinary symptoms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33617371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33617371&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1080/09638288.2021.1887378&gt;10.1080/09638288.2021.1887378&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33617371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":43,"discovery_date":"2021-02-23T11:11:00","title":"Physician Compensation in the United States - Through the Lens of the MS Neurologist","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 17;50:102847. doi: 10.1016/j.msard.2021.102847. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE OF REVIEW: To explore the elements that are typically considered when determining physician compensation in the United States and to examine if the compensation of neurologists with expertise in multiple sclerosis (MS) care is commensurate with that for other neurological specialists and medical specialists that also employ complex therapies, e.g., oncology.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RECENT FINDINGS: The complexity in the diagnosis and management of MS requires increasing specialization. Additionally, changing models for the delivery of MS care has resulted in the MS neurologist generating significant contribution margins. In fact, the revenue to compensation ratio for the MS neurologist may be significantly higher than that of any other discipline in neuroscience service lines. However, while the contribution margin is often a key justification of compensation of interventional and intensive care practitioners in neuroscience service lines, it is generally not considered in the MS neurologist&#x27;s compensation. Compensation models for MS neurologists typically depend heavily on the absolute number of relative value units associated with evaluation and management (E&amp;amp;M) codes making other fields of neurology financially more attractive to trainees.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;SUMMARY: In considering the shortage of MS specialists, the demands of their discipline, and the revenue to compensation ratios, the MS neurologist is significantly undercompensated relative to other neurological specialists and to physicians in other disciplines. Compensating the MS neurologist appropriately and supporting the necessary infrastructure for MS care will likely attract more trainees to this discipline and help reverse the current scarcity of MS neurologists in the United States.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618121/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618121&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102847&gt;10.1016/j.msard.2021.102847&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618121/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":42,"discovery_date":"2021-02-23T11:11:00","title":"Role of extracellular vesicles in neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Prog Neurobiol. 2021 Feb 19:102022. doi: 10.1016/j.pneurobio.2021.102022. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Extracellular vesicles (EVs) are heterogeneous cell-derived membranous structures that arise from the endosome system or directly detach from the plasma membrane. In recent years, many advances have been made in the understanding of the clinical definition and pathogenesis of neurodegenerative diseases, but translation into effective treatments is hampered by several factors. Current research indicates that EVs are involved in the pathology of diseases such as Alzheimer&#x27;s disease (AD), Parkinson&#x27;s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington&#x27;s disease (HD). Besides, EVs are also involved in the process of myelin formation, and can also cross the blood-brain barrier to reach the sites of CNS injury. It is suggested that EVs have great potential as a novel therapy for the treatment of neurodegenerative diseases. Here, we reviewed the advances in understanding the role of EVs in neurodegenerative diseases and addressed the critical function of EVs in the CNS. We have also outlined the physiological mechanisms of EVs in myelin regeneration and highlighted the therapeutic potential of EVs in neurodegenerative diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33617919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33617919&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.pneurobio.2021.102022&gt;10.1016/j.pneurobio.2021.102022&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33617919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":41,"discovery_date":"2021-02-23T11:11:00","title":"Emerging Therapeutic Applications for Fumarates","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Trends Pharmacol Sci. 2021 Feb 19:S0165-6147(21)00007-9. doi: 10.1016/j.tips.2021.01.004. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Fumarates are successfully used for the treatment of psoriasis and multiple sclerosis. Their antioxidative, immunomodulatory, and neuroprotective properties make fumarates attractive therapeutic candidates for other pathologies. The exact working mechanisms of fumarates are, however, not fully understood. Further elucidation of the mechanisms is required if these drugs are to be successfully repurposed for other diseases. Towards this, administration route, dosage, and treatment timing, frequency, and duration are important parameters to consider and optimize with clinical paradigms in mind. Here, we summarize the rapidly expanding literature on the pharmacokinetics and pharmacodynamics of fumarates, including a discussion on two recently FDA-approved fumarates Vumerity&lt;sup&gt;TM&lt;/sup&gt; and Bafiertam&lt;sup&gt;TM&lt;/sup&gt;. We review emerging applications of fumarates, focusing on neurological and cardiovascular diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33618840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33618840&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.tips.2021.01.004&gt;10.1016/j.tips.2021.01.004&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33618840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":40,"discovery_date":"2021-02-23T11:11:00","title":"The Novel Coronavirus Infection (COVID-19) and Nervous System Involvement: Mechanisms of Neurological Disorders, Clinical Manifestations, and the Organization of Neurological Care","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurosci Behav Physiol. 2021 Feb 18:1-8. doi: 10.1007/s11055-021-01050-0. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The new coronavirus SARS-CoV-2 and the disease it causes COVID-19 involves not only respiratory system damage, but can also lead to disorders of the central and peripheral nervous system, as well as the muscular system. This article presents published data and our own observations on the course of neurological disorders in COVID-19 patients. There is a relationship between the severity of COVID-19 and the severity and frequency of neurological manifestations. Severe neurological disorders are mostly seen in severe cases of COVID-19 and include acute cerebrovascular accidents (aCVA), acute necrotizing encephalopathy, and Guillain-BarrÃ© syndrome. Factors potentially complicating the course of COVID-19 and increasing the development of neurological complications include arterial hypertension, diabetes mellitus, and chronic cardiac and respiratory system diseases. Questions of the possible effects of human coronaviruses on the course of chronic progressive neurological diseases are addressed using multiple sclerosis (MS) as an example. We discuss the management of patients with aCVA and MS depending on the risk of developing coronavirus infection.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33619413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33619413&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7889305/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;PMC7889305&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s11055-021-01050-0&gt;10.1007/s11055-021-01050-0&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33619413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":39,"discovery_date":"2021-02-23T11:11:00","title":"Activated microglia drive demyelination via CSF1R signaling","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Glia. 2021 Feb 23. doi: 10.1002/glia.23980. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Microgliosis is a prominent pathological feature in many neurological diseases including multiple sclerosis (MS), a progressive auto-immune demyelinating disorder. The precise role of microglia, parenchymal central nervous system (CNS) macrophages, during demyelination, and the relative contributions of peripheral macrophages are incompletely understood. Classical markers used to identify microglia do not reliably discriminate between microglia and peripheral macrophages, confounding analyses. Here, we use a genetic fate mapping strategy to identify microglia as predominant responders and key effectors of demyelination in the cuprizone (CUP) model. Colony-stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF) - a secreted cytokine that regulates microglia development and survival-is upregulated in demyelinated white matter lesions. Depletion of microglia with the CSF1R inhibitor PLX3397 greatly abrogates the demyelination, loss of oligodendrocytes, and reactive astrocytosis that results from CUP treatment. Electron microscopy (EM) and serial block face imaging show myelin sheaths remain intact in CUP treated mice depleted of microglia. However, these CUP-damaged myelin sheaths are lost and robustly phagocytosed upon-repopulation of microglia. Direct injection of CSF1 into CNS white matter induces focal microgliosis and demyelination indicating active CSF1 signaling can promote demyelination. Finally, mice defective in adopting a toxic astrocyte phenotype that is driven by microglia nevertheless demyelinate normally upon CUP treatment implicating microglia rather than astrocytes as the primary drivers of CUP-mediated demyelination. Together, these studies indicate activated microglia are required for and can drive demyelination directly and implicate CSF1 signaling in these events.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33620118/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210223163220&amp;v=2.14.2&quot;&gt;33620118&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/glia.23980&gt;10.1002/glia.23980&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33620118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210223163220&v=2.14.2","published_date":"","source":"","relevant":"","table_constraints":null},{"article_id":38,"discovery_date":"2021-02-23T11:11:00","title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 11;50:102842. doi: 10.1016/j.msard.2021.102842. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Natalizumab (NTZ) treatment of multiple sclerosis (MS) has been associated with increased risk of progressive multifocal leukoencephalopathy (PML). The aim of the present study was to evaluate the impact of PML risk assessment on PML incidence in NTZ treated MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: By using information from the population-based Swedish MS registry a retrospective cohort was established of patients treated with NTZ between 2006-2018. The effect on PML incidence before and after utilizing a risk management plan, including JC virus (JCV) serology, was analyzed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: In December 2018, 804 PML cases associated with NTZ therapy of MS had been reported globally, including 9 cases from Sweden. The estimated PML incidence 2018 in Sweden and globally was 0.7 (0.3-1.4) and 4.15 (3.9-4.4) per 1,000 person years, respectively. In Sweden, JCV serology was introduced 2012 for PML risk assessment and the cumulative risk of PML was significantly lower 2012-2018 compared to the period 2006-2011 (p=0.042). The mean NTZ exposure time was 60.1 months (SD 37.2) in the first period (2006-2011) and 32.6 months (SD 22.0) in the second period (2012-2018). The number of patients treated with NTZ decreased, and the number of patients at increased risk of PML was 1.9 % at the end of the study period.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Since 2006 the incidence of PML associated with NTZ treatment of MS has decreased in Sweden. Our findings suggest that this reduction is due to an effective adoptation and adherence to the established risk management plan that implies switching patients at increased PML risk from NTZ to other highly efficacious therapies. A less pronounced decline in PML incidence has recently been observed in France, but not globally.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610957/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33610957&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102842&gt;10.1016/j.msard.2021.102842&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610957/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":37,"discovery_date":"2021-02-23T11:11:00","title":"Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neuroinflammation. 2021 Feb 20;18(1):52. doi: 10.1186/s12974-021-02102-5.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Tissue plasminogen activator (tPA) is a serine protease involved in fibrinolysis. It is released by endothelial cells, but also expressed by neurons and glial cells in the central nervous system (CNS). Interestingly, this enzyme also contributes to pathological processes in the CNS such as neuroinflammation by activating microglia and increasing blood-brain barrier permeability. Nevertheless, its role in the control of adaptive and innate immune response remains poorly understood.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: tPA effects on myeloid and lymphoid cell response were studied in vivo in the mouse model of multiple sclerosis experimental autoimmune encephalomyelitis and in vitro in splenocytes.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: tPA&lt;sup&gt;-/-&lt;/sup&gt; animals exhibited less severe experimental autoimmune encephalomyelitis than their wild-type counterparts. This was accompanied by a reduction in both lymphoid and myeloid cell populations in the spinal cord parenchyma. In parallel, tPA increased T cell activation and proliferation, as well as cytokine production by a protease-dependent mechanism and via plasmin generation. In addition, tPA directly raised the expression of MHC-II and the co-stimulatory molecules CD80 and CD86 at the surface of dendritic cells and macrophages by a direct action dependent of the activation of epidermal growth factor receptor.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our study provides new insights into the mechanisms responsible for the harmful functions of tPA in multiple sclerosis and its animal models: tPA promotes the proliferation and activation of both lymphoid and myeloid populations by distinct, though complementary, mechanisms.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610187/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33610187&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1186/s12974-021-02102-5&gt;10.1186/s12974-021-02102-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610187/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":36,"discovery_date":"2021-02-23T11:11:00","title":"Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007/s00415-021-10460-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Previous studies have reported an association between anti-tumor necrosis factor alpha (anti-TNFÎ±) treatment and central nervous system (CNS) events. We described eight patients presenting with demyelinating CNS events while on treatment with anti-TNFÎ± for autoimmune diseases and followed up for a medium period of 4 years. Four patients presented with isolated demyelinating events, three patients fulfilled the criteria for multiple sclerosis (MS), and one patient showed worsening of pre-existing MS after anti-TNF therapy initiation. All patients except one, showed a good medium-term prognosis. Our observation supports an association between anti-TNFÎ± treatment and demyelinating events and suggests that a prompt discontinuation of the drug may lead to a favorable demyelinating disease outcome.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611609/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611609&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10460-6&gt;10.1007/s00415-021-10460-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611609/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":35,"discovery_date":"2021-02-23T11:11:00","title":"Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 21. doi: 10.1007/s00415-021-10436-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Multiple sclerosis (MS) and functional neurological disorder (FND) are both diagnostically challenging conditions which can present with similar symptoms. We systematically reviewed the literature to identify patients with MS who were misdiagnosed with FND, patients with FND who were misdiagnosed with MS, and reports of patients with both conditions. In addition to FND, we included studies of patients with other functional and psychiatric disorders where these caused symptoms leading to investigation for or a diagnosis of MS, which in a different context would likely have been labeled as FND. Our review suggests that MS is one of the most common causes of misdiagnosis of FND and vice versa. We discuss the clinical errors that appear to result in misdiagnoses, such as over-reliance on psychiatric comorbidity when making a diagnosis of FND or over-reliance on neuroimaging for the diagnosis of MS, and practical ways to avoid them. Comorbidity between these two conditions is also likely common, has been poorly studied, and adds complexity to diagnosis and treatment in patients with both MS and FND. Misdiagnosis and comorbidity in a landscape of emerging evidence-based treatments for both MS and FND are issues not only of clinical importance to the care of these patients, but also to treatment trials, especially of MS, where FND could be a hidden confounder.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611631/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611631&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10436-6&gt;10.1007/s00415-021-10436-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611631/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":34,"discovery_date":"2021-02-23T11:11:00","title":"COVID-19 in multiple sclerosis patients treated with dimethyl fumarate","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007/s00415-021-10446-4. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611610/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611610&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10446-4&gt;10.1007/s00415-021-10446-4&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611610/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":33,"discovery_date":"2021-02-23T11:11:00","title":"Efficacy of Gamma Knife radiosurgery in the management of multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurosurg Rev. 2021 Feb 20. doi: 10.1007/s10143-021-01507-3. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Trigeminal neuralgia (TN) is the most frequent craniofacial pain condition, which commonly affects patients suffering from multiple sclerosis (MS). Stereotactic radiosurgery, especially Gamma Knife radiosurgery (GKRS), represents a safe and effective treatment for TN, and it has been adopted also for MS-TN, with a lower success rate. Therefore, we aimed to analyze the outcome of GKRS for MS-TN. PubMed, Web of Science, and Google Scholar and the reference list of relevant articles were searched for GKRS in MS-TN. Two investigators independently identified the articles, assessed the study quality, and extracted the data. Endpoints of interest were initial pain responders, successful treatments at the end of follow-up, and factors influencing the outcome. Data analyses were performed using R software. Twelve articles involving 646 patients met our inclusion criteria. Pooled proportion of patients who experienced an initial response to GKRS treatment was 83% (CI 74-90%). The cumulative proportion of successful treatments at the end of follow-up was 47% (CI 33-60%). No variables were found to have a significant contribution to heterogeneity regarding the initial response outcome. The only variable significantly explaining the heterogeneity found in the proportion of successful treatments was the length of the follow-up, with a negative b coefficient (- 0.0051, p value = 0.0047). Regarding the efficacy of GKRS in MS-TN, the initial pain response rate was 83%, which dramatically decreases to 47% during follow-up. GKRS still represents a valuable option for MS-TN; however, its long-term efficacy should be always considered.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611721/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611721&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10143-021-01507-3&gt;10.1007/s10143-021-01507-3&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611721/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":32,"discovery_date":"2021-02-23T11:11:00","title":"Blood Trace Element Status in Multiple Sclerosis: a Systematic Review and Meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Biol Trace Elem Res. 2021 Feb 21. doi: 10.1007/s12011-021-02621-5. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The aim of this meta-analysis was to investigate whether the blood concentrations of patients with multiple sclerosis (MS) are associated with those of the healthy control group in terms of trace elements including zinc (Zn), iron (Fe), manganese (Mn), magnesium (Mg), selenium (Se), and copper (Cu). A comprehensive search was performed in online databases including PubMed, Scopus, Embase, and Web of Science for studies, which have addressed trace elements in MS up to July 23, 2020. The chi-square test and I&lt;sup&gt;2&lt;/sup&gt; statistic were utilized to evaluate inter-study heterogeneity across the included studies. Weighted mean differences (WMDs) and corresponding 95% CI were considered as a pooled effect size (ES). Twenty-seven articles (or 32 studies) with a total sample comprised of 2895 participants (MS patients (n = 1567) and controls (n = 1328)) were included. Pooled results using random-effects model indicated that the levels of Zn (WMD = - 7.83 mcg/dl, 95% CI = - 12.78 to - 2.87, Z = 3.09, P = 0.002), and Fe (WMD = - 13.66 mcg/dl, 95% CI = - 23.13 to - 4.19, Z = 2.83, P = 0.005) were significantly lower in MS patients than in controls. However, it was found that levels of Mn (WMD = 0.03 mcg/dl, 95% CI = 0.01 to 0.04, Z = 2.89, P = 0.004) were significantly higher in MS patients. Yet, no significant differences were observed in the levels of Mg, Se, and Cu between both groups. This meta-analysis revealed that the circulating levels of Zn and Fe were significantly lower in MS patients and that Mn level was significantly higher than those in the control group. However, it was found that there was no significant difference between MS patients and controls with regard to levels of Mg, Se, and Cu.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33611740/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210222032229&amp;v=2.14.2&quot;&gt;33611740&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s12011-021-02621-5&gt;10.1007/s12011-021-02621-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33611740/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210222032229&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":31,"discovery_date":"2021-02-23T11:11:00","title":"Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Feb 19:10.1212/WNL.0000000000011630. doi: 10.1212/WNL.0000000000011630. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a two-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statistics.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Genetic variants in the vicinity of &lt;i&gt;TNFRSF1A&lt;/i&gt;, the gene encoding TNF receptor 1 (TNFR1), were identified as predictive of pharmacologic blockade of TNFR1 signaling by anti-TNF therapy, based on genetic associations with lower circulating C-reactive protein (CRP; GWAS N = 204,402). The effects of TNF-TNFR1 inhibition were estimated for PD risk (N&lt;sub&gt;cases&lt;/sub&gt;/&lt;sub&gt;controls&lt;/sub&gt; = 37,688/981,372) and age at PD onset (N = 28,568) using GWAS data from the International Parkinson&#x27;s Disease Genomics Consortium and 23andMe, Inc. To validate variants as proxies of long-term anti-TNF treatment, we also assessed whether variant associations reflected anticipated effects of TNFR1 inhibition on Crohn disease, ulcerative colitis and multiple sclerosis risk (N = 38,589-45,975).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: TNF-TNFR1 signaling inhibition was not estimated to affect PD risk (odds ratio/OR per 10% lower circulating CRP = 0.99; 95% CI: 0.91-1.08) or age at onset (0.13 years later onset; 95% CI: -0.66 to 0.92). In contrast, genetically-indexed TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease (OR = 0.75; 95% CI: 0.65-0.86) and ulcerative colitis (OR = 0.84; 95% CI: 0.74-0.97) and increased multiple sclerosis risk (OR = 1.57; 95% CI: 1.36-1.81). Findings were consistent across models using different genetic instruments and MR estimators.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our findings do not imply that TNF-TNFR1 signaling inhibition will prevent or delay PD onset.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that TNF-TNFR1 signaling inhibition is not associated with the risk or age at onset of PD.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33608417/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33608417&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1212/WNL.0000000000011630&gt;10.1212/WNL.0000000000011630&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33608417/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":30,"discovery_date":"2021-02-23T11:11:00","title":"Sexual dimorphism in immunometabolism and autoimmunity: Impact on personalized medicine","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102775. doi: 10.1016/j.autrev.2021.102775. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Immune cells play essential roles in metabolic homeostasis and thus, undergo analogous changes in normal physiology (e.g., puberty and pregnancy) and in various metabolic and immune diseases. An essential component of this close relationship between the two is sex differences. Many autoimmune diseases, such as systemic lupus erythematous and multiple sclerosis, feature strikingly increased prevalence in females, whereas in contrast, infectious diseases, such as Ebola and Middle East Respiratory Syndrome, affect more men than women. Therefore, there are fundamental aspects of metabolic homeostasis and immune functions that are regulated differently in males and females. This can be observed in sex hormone-immune interaction where androgens, such as testosterone, have shown immunosuppressive effects whilst estrogen is on the opposite side of the spectrum with immunoenhancing facilitation of mechanisms. In addition, the two sexes exhibit significant differences in metabolic regulation, with estrous cycles in females known to induce variability in traits and more pronounced metabolic disease phenotype exhibited by males. It is likely that these differences underlie both the development of metabolic and autoimmune diseases and the response to current treatment options. Sexual dimorphism in immunometabolism has emerged to become an area of intense research, aiming to uncover sex-biased effector molecules in the various metabolic tissues and immune cell types, identify sex-biased cell-type-specific functions of common effector molecules, and understand whether the sex differences in metabolic and immune functions influence each other during autoimmune pathogenesis. In this review, we will summarize recent findings that address these critical questions of sexual dimorphism in immunometabolism as well as their translational implications for the clinical management of autoimmune diseases.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609790/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609790&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.autrev.2021.102775&gt;10.1016/j.autrev.2021.102775&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609790/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":29,"discovery_date":"2021-02-23T11:11:00","title":"Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007/s00415-021-10466-0. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609155/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609155&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10466-0&gt;10.1007/s00415-021-10466-0&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609155/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":28,"discovery_date":"2021-02-23T11:11:00","title":"Menopause does not modify disability trajectories in a longitudinal cohort of women with CIS and MS followed from disease onset","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Feb 20. doi: 10.1111/ene.14782. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: to evaluate the effect of menopause on disability accumulation in women followed from their clinically isolated syndrome (CIS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We examined the longitudinal changes in EDSS from CIS until the last follow-up in women belonging to the Barcelona CIS prospective cohort, followed through their menopausal transition. The analysis is based on 13,718 EDSS measurements with an average of 28 EDSS per patient. Differences in EDSS trajectories between menopausal and non-menopausal women, controlling for age and disease duration were evaluated. We performed two sensitivity analyses, in women with confirmed MS and in those experiencing and early menopause.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: from 764 eligible women, 496 (65%) responded to the questionnaire and 74 (14.9%) reached menopause over follow-up. We did not find a significant inflection point in EDSS trajectories around menopause (slope change -0.009 (95%CI -0.066; 0.046). The annual increase in EDSS over the complete course of the disease was significantly higher in menopausal women (0.049 IC 95% 0.026 - 0.074) versus non-menopausal (0.019 IC 95% 0.008 - 0.031, interaction p-value 0.025). This difference was lost once controlling for age and disease duration (EDSS annual increase of 0.059 95% CI 0.025- 0.094 vs 0.038 IC 95% 0.021 - 0.057 respectively, interaction p-value 0.321). No inflection point was detected when the analysis was restricted to women with confirmed MS or with earlier menopause.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: menopause is not associated with an increased risk of disability in a CIS population, considering EDSS trajectories throughout the course of the disease, together with age and disease duration.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609298/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609298&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/ene.14782&gt;10.1111/ene.14782&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609298/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":27,"discovery_date":"2021-02-23T11:11:00","title":"Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Eur J Hosp Pharm. 2021 Mar;28(2):112-114. doi: 10.1136/ejhpharm-2019-002048. Epub 2019 Oct 16.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: A descriptive retrospective observational study including all patients with RRMS treated with natalizumab followed-up after 10 years.The likelihood of developing PML was estimated based on three risk factors: anti-John Cunningham virus antibody index, previous immunosuppressive therapy, and duration of treatment. Patients were classified into five categories: minimum probability (&amp;lt;0.1/1000); low (0.1/1000); medium-low (0.2-0.6/1000); medium-high (0.8-3/1000); high probability (3-10/1000).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 34 patients were included. The probability of PML in the last cycle was: 55.9% minimum, 8.8% low, 11.8% medium-low, 3% medium-high, and 20.5% high. 12 patients continue with active treatment with natalizumab. No cases of PML have been confirmed. Adverse effects were detected in 50% of patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Quantifying risk factors allows us to estimate the probability of PML appearance, thus assessing the maintenance or suspension of natalizumab.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33608441/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33608441&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1136/ejhpharm-2019-002048&gt;10.1136/ejhpharm-2019-002048&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33608441/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":26,"discovery_date":"2021-02-23T11:11:00","title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurochem. 2021 Feb 20. doi: 10.1111/jnc.15327. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;There is growing evidence that excessive microglial phagocytosis of neurons and synapses contributes to multiple brain pathologies. RNA-seq and genome wide association (GWAS) studies have linked multiple phagocytic genes to neurodegenerative diseases, and knock-out of phagocytic genes has been found to protect against neurodegeneration in animal models, suggesting that excessive microglial phagocytosis contributes to neurodegeneration. Here, we review recent evidence that microglial phagocytosis of live neurons and synapses causes neurodegeneration in animal models of Alzheimer&#x27;s disease and other tauopathies, Parkinson&#x27;s disease, frontotemporal dementias, multiple sclerosis, retinal degeneration, and neurodegeneration induced by ischaemia, infection or ageing. We also review factors regulating microglial phagocytosis of neurons, including: nucleotides, frackalkine, phosphatidylserine, calreticulin, UDP, CD47, sialylation, complement, galectin-3, Apolipoprotein E, phagocytic receptors, Siglec receptors, cytokines, microglial epigenetics and expression profile. Some of these factors may be potential treatment targets to prevent neurodegeneration mediated by excessive microglial phagocytosis of live neurons and synapses.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33608912/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33608912&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/jnc.15327&gt;10.1111/jnc.15327&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33608912/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":25,"discovery_date":"2021-02-23T11:11:00","title":"B lymphocytes, the gastrointestinal tract and autoimmunity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102777. doi: 10.1016/j.autrev.2021.102777. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Under homeostatic conditions, bidirectional interactions between the gastrointestinal and the immune system allow production of both inflammatory and anti-inflammatory responses designed to prevent undesirable inflammation and to respond efficiently to potential insults. This balanced regulation can be disrupted in disorders that affect tissues remote to the gastrointestinal tract, as seen in autoimmune diseases. Recent reports have described a variety of B lymphocyte-mediated functions that likely contribute to gastrointestinal homeostasis to a greater extent than previously thought. Studies have shown that early B cell development takes place within the intestine, and that self-reactive B cells are rendered tolerant using mechanisms known to occur in the bone marrow, indicating that the gastrointestinal tract contributes to maintaining immune tolerance to self. Relatedly, continuous bacterial stimulation is essential for maintaining regulatory B cell functions and for mediating mucosal homeostasis. In studies of neuro-inflammation, intestinal IgA+ B cells, which constitute a prominent source of lymphocytes in the organism, can migrate to inflamed tissues and exert regulatory functions that attenuate inflammation in the central nervous system, indicating that, in addition to its local effects in the intestin, gut microbiota-B cell crosstalk can exert long-range beneficial effects. At the translational level, metabolites produced by gut microbiota can act as B cell-intrinsic epigenetic modulators, reducing inflammation in the skin and kidneys of mice suffering from experimental lupus. Given the significant impact of B cell-intestinal microbiota interactions, there is a momentum for improving our understanding of these pathways in autoinflammatory diseases and for designing novel therapeutic strategies for systemic autoimmune diseases where B cells play key roles.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609796/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609796&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.autrev.2021.102777&gt;10.1016/j.autrev.2021.102777&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609796/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":24,"discovery_date":"2021-02-23T11:11:00","title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 3;50:102807. doi: 10.1016/j.msard.2021.102807. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Studies on the prevalence of neuromyelitis optica spectrum disorder (NMOSD) are still scarce. The aim of the current study was to determine the prevalence rate of NMOSD in Belo Horizonte, southeast Brazil, where the prevalence rate of multiple sclerosis (MS) has already been established.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: For this observational study, eligible patients had to meet the 2015 International Panel for Neuromyelitis Optica Diagnosis, be seen at the study center between January 2000 and February 2019 and live in Belo Horizonte. The prevalence rate of NMOSD was estimated based on the number of MS and NMOSD patients seen at same Center during the same period, and the previously established prevalence of MS in Belo Horizonte.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: During the study period, there were 69 patients with NMOSD, 60 (87.0%) of whom were females, and 44 (63.8%) non-whites. The median age at disease onset was 36.7 (4-72) years, the mean EDSS score 4.78Â±2.36, and the mean ARR 0.57Â±0.43. Anti-aquaporin-4 immunoglobulin testing was available for 61 (88.4%) patients, of whom 41 (67.2%) had a positive result. During the same period, 280 MS patients were seen. Considering the local known prevalence rate of MS of 18.1/100,000 inhabitants, the estimated NMOSD prevalence rate in Belo Horizonte was 4.52/100,000 (95% CI 3.72-5.43) inhabitants.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The prevalence rate of NMOSD in Belo Horizonte is high as compared with those found in most of the studies reported to date.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609926/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609926&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102807&gt;10.1016/j.msard.2021.102807&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609926/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":23,"discovery_date":"2021-02-23T11:11:00","title":"Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102834. doi: 10.1016/j.msard.2021.102834. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disorder; and leads to the uncontrolled production of interleukin (IL)-1Î². Multiple sclerosis (MS) is an inflammatory disease of the central nervous system; and its development seems to be partly correlated with IL-1Î² levels. It is hypothesized that FMF could be associated with MS. We aim to describe the features of patients displaying both diseases and to investigate the MEFV mutation rate in MS patients.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Patients with definite MS were retrieved from the cohort of FMF patients in the Reference Center for Rare Auto-inflammatory Diseases and Amyloidosis (CEREMAIA). We also performed a systematic literature review of articles from PubMed that were published from 1990 to 2020.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Twenty-four patients were included in the case series: five patients (1.3%) from our cohort of 364 and 19 patients from the literature. The sex ratio was 2:1. The mean age at diagnosis of FMF was 19 years old; and that for MS was 29 years old. Seven studies investigating the MEFV mutation rate in MS patients were included. Three studies found a higher mutation rate in MS patients than in the control group.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: FMF and MS features were comparable to those of patients with unrelated diseases; and MEFV mutation carriage was not positively correlated with MS. However; MS prevalence in FMF patients was higher than was expected in a healthy population. To a lesser extent; FMF prevalence in MS patients was higher than expected in a healthy population and the difference might not be significant. These data suggest that FMF could be associated with MS; and further studies are needed to investigate a potential causal association.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609923/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609923&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102834&gt;10.1016/j.msard.2021.102834&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609923/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":22,"discovery_date":"2021-02-23T11:11:00","title":"Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 13;49:102754. doi: 10.1016/j.msard.2021.102754. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Coronavirus disease 2019 (COVID-19) raises particular concerns for people with multiple sclerosis (PwMS) on disease-modifying treatments (DMTs), and for physicians caring for them. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on PwMS receiving DMTs that inhibit immune cell trafficking, such as natalizumab (NTZ) and fingolimod (FTY), remains to be determined, as do the possible effects of these drugs on both the infection and the related disease.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;AIMS: To describe self-reported COVID-19 symptoms and disease severity in PwMS on NTZ or FTY who received serology confirmation of SARS-CoV-2 infection.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: From 27th April to 3rd May 2020, telephone interviews were conducted with 140 PwMS under treatment with NTZ or FTY in order to collect structured data on multiple sclerosis (MS) and COVID-19. The patients, all followed at our center, were classified as symptomatic, paucisymptomatic or asymptomatic on the basis of their self-reported clinical characteristics. COVID-19 severity was rated on a 7-point ordinal scale. In addition, in the period 4th May to 3rd June 2020 SARS-CoV-2 serology testing, using the Roche SARS-CoV-2 IgG assay (Elecsys&lt;sup&gt;â&lt;/sup&gt;), was performed in 104/140 (74.2%) of the interviewed PwMS (50 treated with NTZ and 54 with FTY).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: 14/104 (13.4%) PwMS on NTZ or FTY had anti-SARS-CoV-2 antibodies: 8 met the criteria for asymptomatic, 3 for paucisymptomatic and 3 for symptomatic COVID-19 (COVID-19 severity score lower than 3). None of them required hospitalization or showed severe COVID-19 complications.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Despite the relatively high SARS CoV-2 seroprevalence found in this sample of PwMS, all the positive cases showed either no or only mild COVID-19 symptoms. These reassuring findings indicate a lack of COVID-19 complications in PwMS on DMTs and support the hypothesis that it is safe to maintain ongoing treatment with these drugs in the current setting.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609958/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609958&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102754&gt;10.1016/j.msard.2021.102754&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609958/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":21,"discovery_date":"2021-02-23T11:11:00","title":"Generation of six induced pluripotent stem cell lines from patients with amyotrophic lateral sclerosis with associated genetic mutations in either FUS or ANXA11","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Stem Cell Res. 2021 Feb 12;52:102246. doi: 10.1016/j.scr.2021.102246. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of upper and lower motor neurons, causing gradual paralysis, and resulting in death 3-5 years from diagnosis. ALS causative mutations have been identified in multiple genes, including Fused in sarcoma (FUS), and recently characterized Annexin A11 (ANXA11). We have derived induced pluripotent stem cell (iPSC) lines from six ALS patient lymphoblastoid cell lines, three with mutations in FUS (Q519E, R521H, R522G), and three with mutations in ANXA11 (G38R, D40G, R235Q). These lines have been characterized and provide a novel resource for investigation into ALS pathology.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610019/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33610019&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.scr.2021.102246&gt;10.1016/j.scr.2021.102246&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610019/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":20,"discovery_date":"2021-02-23T11:11:00","title":"Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102838. doi: 10.1016/j.msard.2021.102838. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;There is not much awareness of varicella zoster virus (VZV) associated central nervous system (CNS) infections under treatment with natalizumab. Here we describe two natalizumab treated MS patients who developed acute retinal necrosis combined with CNS vasculitis caused by VZV. In natalizumab treated patients, visual symptoms atypical of optic neuritis should be promptly evaluated by an ophthalmologist. Currently, a total of 12 cases of natalizumab-associated VZV CNS or retinal infections are reported in literature. Our two cases and overview of currently available data provide information on prognosis and treatment decisions of this rare but devastating complication.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609925/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609925&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102838&gt;10.1016/j.msard.2021.102838&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609925/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":19,"discovery_date":"2021-02-23T11:11:00","title":"Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2020 Dec 28;49:102724. doi: 10.1016/j.msard.2020.102724. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The Expanded Disability Status Scale (EDSS) measures disease progression in Multiple Sclerosis (MS). EDSS changes are assumed to be due to worsening MS-related disability. Strict interpretation of this premise may include some normal findings as abnormal, inflating the disability score. Further, determining the cause of neurologic symptoms can be difficult in an older population with comorbid illness and polypharmacy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To examine the association between EDSS, age, comorbidities and polypharmacy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: 106 people, 55 years and older, with and without MS were administered the EDSS and a validated comorbidity questionnaire. Polypharmacy was also assessed.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Median EDSS scores were 6.0 in people with MS and 3.0 in people without MS. No participant in our cohort had an EDSS of 0. Higher EDSS scores were associated with older age and more polypharmacy. Pyramidal and cerebellar functional systems accounted for the largest percentage of unique variance between groups.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Older individuals with and without MS demonstrated significant disability on the EDSS. These findings indicate that EDSS scores may be partially due to factors other than MS. Our understanding of disease course and disability may benefit from the development of normative EDSS scores to correct for these factors.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609959/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609959&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2020.102724&gt;10.1016/j.msard.2020.102724&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609959/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":18,"discovery_date":"2021-02-23T11:11:00","title":"Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 5;49:102738. doi: 10.1016/j.msard.2021.102738. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Axonal injury is the primary source of irreversible neurological decline in persons with multiple sclerosis (pwMS). Identifying and quantifying myelin and axonal loss in lesional and perilesional tissue in vivo is fundamental for a better understanding of multiple sclerosis (MS) outcomes and patient impairment. Using advanced magnetic resonance imaging (MRI) methods, consisting of selective inversion recovery quantitative magnetization transfer imaging (SIR-qMT) and multi-compartment diffusion MRI with the spherical mean technique (SMT), we conducted a cross-sectional pilot study to assess myelin and axonal damage in the normal appearing white matter (NAWM) surrounding chronic black holes (cBHs) and how this pathology correlates with disability in vivo. We hypothesized that lesional axonal transection propagates tissue injury in the surrounding NAWM and that the degree of this injury is related to patient disability.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Eighteen pwMS underwent a 3.0 Tesla conventional clinical MRI, inclusive of T1 and T2 weighted protocols, as well as SIR-qMT and SMT. Regions of interests (ROIs) were manually delineated in cBHs, NAWM neighboring cBHs (perilesional NAWM), distant ipsilateral NAWM and contra-lateral distant NAWM. SIR-qMT-derived macromolecular-to-free pool size ratio (PSR) and SMT-derived apparent axonal volume fraction (V&lt;sub&gt;ax&lt;/sub&gt;) were extracted to infer on myelin and axonal content, respectively. Group differences were assessed using mixed-effects regression models and correlation analyses were obtained by bootstrapping 95% confidence interval.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: In comparison to perilesional NAWM, both PSR and V&lt;sub&gt;ax&lt;/sub&gt; values were reduced in cBHs (p &amp;lt; 0.0001) and increased in distant contra-lateral NAWM ROIs (p &amp;lt; 0.001 for PSR and p &amp;lt; 0.0001 for V&lt;sub&gt;ax&lt;/sub&gt;) but not ipsilateral NAWM (p = 0.176 for PSR and p = 0.549 for V&lt;sub&gt;ax&lt;/sub&gt;). V&lt;sub&gt;ax&lt;/sub&gt; values measured in cBHs correlated with those in perilesional NAWM (Pearson rho = 0.63, p &amp;lt; 0.001). No statistically relevant associations were seen between PSR/V&lt;sub&gt;ax&lt;/sub&gt; values and clinical and/or MRI metrics of the disease with the exception of cBH PSR values, which correlated with the Expanded Disability Status Scale (Pearson rho = -0.63, p = 0.03).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: Our results show that myelin and axonal content, detected by PSR and V&lt;sub&gt;ax&lt;/sub&gt;, are reduced in perilesional NAWM, as a function of the degree of focal cBH axonal injury. This finding is indicative of an ongoing anterograde/retrograde degeneration and suggests that treatment prevention of cBH development is a key factor for preserving NAWM integrity in surrounding tissue. It also suggests that measuring changes in perilesional areas over time may be a useful measure of outcome for proof-of-concept clinical trials on neuroprotection and repair. PSR and V&lt;sub&gt;ax&lt;/sub&gt; largely failed to capture associations with clinical and MRI characteristics, likely as a result of the small sample size and cross-sectional design, however, longitudinal assessment of a larger cohort may unravel the impact of this pathology on disease progression.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33609957/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33609957&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.msard.2021.102738&gt;10.1016/j.msard.2021.102738&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33609957/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":17,"discovery_date":"2021-02-23T11:11:00","title":"Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Feb 12;30:102587. doi: 10.1016/j.nicl.2021.102587. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;In multiple sclerosis (MS), monoaminergic systems are altered as a result of both inflammation-dependent reduced synthesis and direct structural damage. Aberrant monoaminergic neurotransmission is increasingly considered a major contributor to fatigue pathophysiology. In this study, we aimed to compare the integrity of the monoaminergic white matter fibre tracts projecting from brainstem nuclei in a group of patients with MS (n = 68) and healthy controls (n = 34), and to investigate its association with fatigue. Fibre tracts integrity was assessed with the novel fixel-based analysis that simultaneously estimates axonal density, by means of &#x27;fibre density&#x27;, and white matter atrophy, by means of fibre &#x27;cross section&#x27;. We focused on ventral tegmental area, locus coeruleus, and raphe nuclei as the main source of dopaminergic, noradrenergic, and serotoninergic fibres within the brainstem, respectively. Fourteen tracts of interest projecting from these brainstem nuclei were reconstructed using diffusion tractography, and compared by means of the product of fibre-density and cross-section (FDC). Finally, correlations of monoaminergic axonal damage with the modified fatigue impact scale scores were evaluated in MS. Fixel-based analysis revealed significant axonal damage - as measured by FDC reduction - within selective monoaminergic fibre-tracts projecting from brainstem nuclei in MS patients, in comparison to healthy controls; particularly within the dopaminergic-mesolimbic pathway, the noradrenergic-projections to prefrontal cortex, and serotoninergic-projections to cerebellum. Moreover, we observed significant correlations between severity of cognitive fatigue and axonal damage within the mesocorticolimbic tracts projecting from ventral tegmental area, as well as within the locus coeruleus projections to prefrontal cortex, suggesting a potential contribution of dopaminergic and noradrenergic pathways to central fatigue in MS. Our findings support the hypothesis that axonal damage along monoaminergic pathways contributes to the reduction/dysfunction of monoamines in MS and add new information on the mechanisms by which monoaminergic systems contribute to MS pathogenesis and fatigue. This supports the need for further research into monoamines as therapeutic targets aiming to combat and alleviate fatigue in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33610097/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210221121510&amp;v=2.14.2&quot;&gt;33610097&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.nicl.2021.102587&gt;10.1016/j.nicl.2021.102587&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33610097/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210221121510&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":16,"discovery_date":"2021-02-20T00:00:00.000Z","title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases - PubMed","summary":"Current strategies for the treatment of demyelinating diseases such as multiple sclerosis (MS) are based on anti-inflammatory or immunomodulatory drugs. Those drugs have the potential to reduce the frequency of new lesions but do not directly promote remyelination in the damaged central nervous system (CNS). Targeting CXCR7 (ACKR3) has been postulated as a potential therapeutic approach in demyelinating diseases, leading to both immunomodulation by reducing leukocyte infiltrates and promyelination by enhancing myelin repair. ACT-1004-1239 is a potent, selective, insurmountable, and orally available first-in-class CXCR7 receptor antagonist. The effect of ACT-1004-1239 was evaluated in the myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) and the cuprizone-induced demyelination mouse models. In addition, ACT-1004-1239 was assessed in a rat oligodendrocyte precursor cell (OPC) differentiation assay in vitro. In the MOG-induced EAE model, ACT-1004-1239 treatment (10-100 mg/kg, twice daily, orally) showed a significant dose-dependent reduction in disease clinical scores, resulting in increased survival. At the highest dose tested (100 mg/kg, twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltrates into the CNS and plasma neurofilament light chain concentration. Treatment with ACT-1004-1239 dose-dependently increased plasma CXCL12 concentration, which correlated with a reduction of the cumulative disease score. Furthermore, in the cuprizone model, ACT-1004-1239 treatment significantly increased the number of mature myelinating oligodendrocytes and enhanced myelination in vivo. In vitro, ACT-1004-1239 promoted the maturation of OPCs into myelinating oligodendrocytes. These results provide evidence that ACT-1004-1239 both reduces neuroinflammation and enhances myelin repair substantiating the rationale to explore its therapeutic potential in a clinical setting.","link":"https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202002465R","published_date":"2021-02-20T00:00:00.000Z","source":"FASEB","relevant":1,"table_constraints":null},{"article_id":15,"discovery_date":"2021-02-23T11:11:00","title":"First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 19. doi: 10.1007/s00415-021-10469-x. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Peripapillary retinal nerve fiber layer thickness correlates with radiological and clinical parameters in patients with MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: The aim of this study is to investigate the use of the first measured pRNFL thickness as a predictor of disease course in patients with RRMS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: One hundred and thirty seven RRMS patients were enrolled in the study within the first 5 years of illness. Patients were followed for 34.1 months and the EDSS was used to assess disability status to determine whether the first measured pRNFL thickness, using proportional hazards models, predicts the risk of disability worsening.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The mean disease duration was 26.1 months. Disability worsening was detected in 36 patients. In tertile-based groups formed according to pRNFL thickness, the group with the lowest pRNFL thickness had a 2.8-fold increase in the risk of disability worsening compared to the group with the highest. The risk was higher in the first 2 years of the study (HR = 3.48; p = 0.008).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The first measured pRNFL thickness in RRMS patients can predict the risk of disability worsening, and the risk of disability worsening in the early period was higher in the group with the lowest pRNFL value.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33606071/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33606071&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s00415-021-10469-x&gt;10.1007/s00415-021-10469-x&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33606071/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":14,"discovery_date":"2021-02-23T11:11:00","title":"Healthcare access experiences of persons with MS explored through the Candidacy Framework","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Health Soc Care Community. 2021 Feb 19. doi: 10.1111/hsc.13320. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Canada has one of the highest rates of multiple sclerosis (MS) in the world, affecting 1 in every 385 individuals. This neurodegenerative condition is unpredictable and variable in symptom profile and disease course making it difficult to manage. Canadians with MS are high users of healthcare services; however, they report multiple unmet needs, high disease burden, and low satisfaction with healthcare. Access to healthcare is vital to health maintenance and may explain these poor experiences. Access is often measured using utilisation as a proxy, which may fail to capture the complexities of access experiences that this population faces. The Candidacy Framework offers an alternative to utilisation measures, by examining the process of accessing care, while considering the impact of social patterning and health system environments on this process. The aim of the current study is to align the experiences of persons with MS in accessing healthcare services with the stages of the Candidacy Framework. Forty-eight individuals with MS living across Ontario were recruited to participate in one of five focus groups or ten individual interviews. Analysis included a first inductive phase, using constant comparative methods, followed by a deductive phase, using content analysis. The Candidacy Framework was not able to capture all experiences shared by persons with MS, including patient-centred care, past experiences and outcome expectation, and care outcomes. We propose these concepts be included as refinements to the current Framework, providing a more thorough explanation of the experiences of persons with MS in accessing care to manage their condition.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33606904/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33606904&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1111/hsc.13320&gt;10.1111/hsc.13320&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33606904/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":13,"discovery_date":"2021-02-23T11:11:00","title":"Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Med Hypotheses. 2021 Feb 10;149:110530. doi: 10.1016/j.mehy.2021.110530. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Hidradenitis Suppurativa (HS) is a chronic, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. The pathophysiology of the disease remains elusive, with newer therapies targeting various aspects of the dysregulated immune system. This presents a useful opportunity to look at the cytokine profile in HS and other inflammatory conditions that share similar patterns with the aim of teasing out less considered explanations for HS pathogenesis. It has been observed that IL-17 appears to be the most common denominator linking HS with other immune mediated diseases like Crohn, ulcerative colitis, multiple sclerosis and psoriasis. Given that IL-17 plays an important role in antifungal immunity, evidenced by the cytokine pattern in fungal disease and the bulk of data citing their potential involvement in Crohn, ulcerative colitis, multiple sclerosis and psoriasis; it is fair to suggest the need to explore the role that fungi play in the setting of HS going forward. The aryl hydrocarbon receptor (ahr) is a ubiquitous and largely conserved entity that is gaining interest in inflammatory conditions such as psoriasis and atopic dermatitis. It is well known to modulate autoimmune states. Its activation by both exogenous and endogenous agents result in secretion of IL-17 by Th17 cells. One of such agents is the tryptophan metabolite 6-formylindolo [3,2-b] carbazole (FICZ)-which can be produced by microorganisms such as fungi. It will be interesting to explore its usefulness in HS pathogenesis.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33607406/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33607406&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.mehy.2021.110530&gt;10.1016/j.mehy.2021.110530&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33607406/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":12,"discovery_date":"2021-02-23T11:11:00","title":"Depression and multiple sclerosis: A bidirectional Mendelian randomisation study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Depression is common in multiple sclerosis (MS); however, the underlying mechanism for the relationship remains unknown. In this study, we examined a putative causal relationship between depression and MS using a bidirectional Mendelian randomisation (MR) framework. Using the latest genome-wide association study data available, 168 non-major histocompatibility complex (MHC) independent variants associated with MS and 96 independent genetic variants associated with depression susceptibility were used. Maximum likelihood, weighted median, inverse variance weighted method and MR-Egger regression analyses were performed. There was no significant risk for the development of MS in persons carrying variants associated with depression or for risk of depression in individuals who are genetically susceptible to MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33605804/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33605804&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521996601&gt;10.1177/1352458521996601&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33605804/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":11,"discovery_date":"2021-02-23T11:11:00","title":"The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Obesity is associated with increased risk of multiple sclerosis (MS); however, the underlying mechanisms remain unclear.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: To determine the extent to which decreased vitamin D bioavailability and altered levels of adiponectin and leptin mediate the association between obesity and MS.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: We performed Mendelian randomization (MR) analyses to estimate the effects on MS of body mass index (BMI), 25-hydroxyvitamin D (25OHD), adiponectin, and leptin levels in a cohort of 14,802 MS cases and 26,703 controls. We then estimated the proportion of the effect of obesity on MS explained by these potential mediators.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: Genetic predisposition to higher BMI was associated with increased MS risk (odds ratio (OR) = 1.33 per standard deviation (SD), 95% confidence interval (CI) = 1.09-1.63), while higher 25OHD levels reduced odds of MS (OR = 0.72 per SD, 95% CI = 0.60-0.87). In contrast, we observed no effect of adiponectin or leptin. In MR mediation analysis, 5.2% of the association between BMI and MS was attributed to obesity lowering 25OHD levels (95% CI = 0.3%-31.0%).&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSIONS: This study found that a minority of the increased risk of MS conferred by obesity is mediated by lowered vitamin D levels, while leptin and adiponectin had no effect. Consequently, vitamin D supplementation would only modestly reverse the effect of obesity on MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33605807/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33605807&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1177/1352458521995484&gt;10.1177/1352458521995484&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33605807/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":10,"discovery_date":"2021-02-23T11:11:00","title":"N-Acetyl-Lysyltyrosylcysteine Amide, a Novel Systems Pharmacology Agent, Reduces Bronchopulmonary Dysplasia in Hyperoxic Neonatal Rat Pups","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Free Radic Biol Med. 2021 Feb 16:S0891-5849(21)00079-4. doi: 10.1016/j.freeradbiomed.2021.02.006. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Bronchopulmonary dysplasia (BPD) is caused primarily by oxidative stress and inflammation. To induce BPD, neonatal rat pups were raised in hyperoxic (&amp;gt;90% O&lt;sub&gt;2&lt;/sub&gt;) environments from day one (P1) until day ten (P10) and treated with N-acetyl-lysyltyrosylcysteine amide (KYC). In vivo studies showed that KYC improved lung complexity, reduced myeloperoxidase (MPO) positive (+) myeloid cell counts, MPO protein, chlorotyrosine formation, increased endothelial cell CD31 expression, decreased 8-OH-dG and Cox-1/Cox-2, HMGB1, RAGE, TLR4, increased weight gain and improved survival in hyperoxic pups. EPR studies confirmed that MPO reaction mixtures oxidized KYC to a KYC thiyl radical. Adding recombinant HMGB1 to the MPO reaction mixture containing KYC resulted in KYC thiylation of HMGB1. In rat lung microvascular endothelial cell (RLMVEC) cultures, KYC thiylation of RLMVEC proteins was increased the most in RLMVEC cultures treated with MPO+H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;, followed by H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;, and then KYC alone. KYC treatment of hyperoxic pups decreased total HMGB1 in lung lysates, increased KYC thiylation of HMGB1, terminal HMGB1 thiol oxidation, decreased HMGB1 association with TLR4 and RAGE, and shifted HMGB1 in lung lysates from a non-acetylated to a lysyl-acetylated isoform, suggesting that KYC reduced lung cell death and that recruited immune cells had become the primary source of HMGB1 released into the hyperoxic lungs. MPO-dependent and independent KYC-thiylation of Keap1 were both increased in RLMVEC cultures. Treating hyperoxic pups with KYC increased KYC thiylation and S-glutathionylation of Keap1, and Nrf2 activation. These data suggest that KYC is a novel system pharmacological agent that exploits MPO to inhibit toxic oxidant production and is oxidized into a thiyl radical that inactivates HMGB1, activates Nrf2, and increases antioxidant enzyme expression to improve lung complexity and reduce BPD in hyperoxic rat pups.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33607217/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33607217&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.freeradbiomed.2021.02.006&gt;10.1016/j.freeradbiomed.2021.02.006&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33607217/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":9,"discovery_date":"2021-02-23T11:11:00","title":"CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 18;11(1):4132. doi: 10.1038/s41598-021-83591-5.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;To identify markers in the CSF of multiple sclerosis (MS) subtypes, we used a two-step proteomic approach: (i) Discovery proteomics compared 169 pooled CSF from MS subtypes and inflammatory/degenerative CNS diseases (NMO spectrum and Alzheimer disease) and healthy controls. (ii) Next, 299 proteins selected by comprehensive statistics were quantified in 170 individual CSF samples. (iii) Genes of the identified proteins were also screened among transcripts in 73 MS brain lesions compared to 25 control brains. F-test based feature selection resulted in 8 proteins differentiating the MS subtypes, and secondary progressive (SP)MS was the most different also from controls. Genes of 7 out these 8 proteins were present in MS brain lesions: GOLM was significantly differentially expressed in active, chronic active, inactive and remyelinating lesions, FRZB in active and chronic active lesions, and SELENBP1 in inactive lesions. Volcano maps of normalized proteins in the different disease groups also indicated the highest amount of altered proteins in SPMS. Apolipoprotein C-I, apolipoprotein A-II, augurin, receptor-type tyrosine-protein phosphatase gamma, and trypsin-1 were upregulated in the CSF of MS subtypes compared to controls. This CSF profile and associated brain lesion spectrum highlight non-inflammatory mechanisms in differentiating CNS diseases and MS subtypes and the uniqueness of SPMS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603109/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603109&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41598-021-83591-5&gt;10.1038/s41598-021-83591-5&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603109/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":8,"discovery_date":"2021-02-23T11:11:00","title":"Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Nat Neurosci. 2021 Feb 18. doi: 10.1038/s41593-021-00801-z. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neurodegeneration occurring in multiple sclerosis (MS) contributes to the progression of disability. It is therefore important to identify and neutralize the mechanisms that promote neurodegeneration in MS. Here, we report that oxidized phosphatidylcholines (OxPCs) found in MS lesions, previously identified as end-product markers of oxidative stress, are potent drivers of neurodegeneration. Cultured neurons and oligodendrocytes were killed by OxPCs, and this was ameliorated by microglia. After OxPC injection, mouse spinal cords developed focal demyelinating lesions with prominent axonal loss. The depletion of microglia that accumulated in OxPC lesions exacerbated neurodegeneration. Single-cell RNA sequencing of lesioned spinal cords identified unique subsets of TREM2&lt;sup&gt;high&lt;/sup&gt; mouse microglia responding to OxPC deposition. TREM2 was detected in human MS lesions, and TREM2&lt;sup&gt;-/-&lt;/sup&gt; mice exhibited worsened OxPC lesions. These results identify OxPCs as potent neurotoxins and suggest that enhancing microglia-mediated OxPC clearance via TREM2 could help prevent neurodegeneration in MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603230/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603230&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1038/s41593-021-00801-z&gt;10.1038/s41593-021-00801-z&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603230/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":7,"discovery_date":"2021-02-23T11:11:00","title":"Binocular Vision in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Clin Optom (Auckl). 2021 Feb 12;13:39-49. doi: 10.2147/OPTO.S286862. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;PURPOSE: Oculomotor disorders have been reported in multiple sclerosis (MS) in up to 80% of cases. There have been studies evaluating binocular vision in several neurological diseases, but not in MS. Considering that a high percentage of eye-movement anomalies have been reported, the aim of this study was to analyze binocular vision in these subjects.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: A total of 59 participants with MS - 21 with monocular optic neuritis, eleven with binocular optic neuritis, and 27 without optic neuritis - and 26 age-matched controls were enrolled. Binocular vision was analyzed using near point of convergence (NPC), positive and negative fusional vergence for far and near distance, measurement of heterophoria at both distances with cover and modified Thorington tests, and random-dot stereoscopy.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The percentage of subjects with abnormal NPC values was highest in the MS group, followed by the MSONm (MS with optic neuritis in one eye), MSONb (MS with optic neuritis in both eyes), and control groups. MS patients showed an esophoric trend at near distance. Positive fusional vergence showed no significant differences between control and MS groups, but higher variability in recovery was found in MS groups. Negative fusional vergence at near distance showed significant differences between the control group and the two MS groups, with optic neuritis for both break-point and recovery values. A high percentage of patients with MS had alterations on stereopsis.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Alterations in binocular vision were present in MS, with divergence at near distance and stereopsis the most affected parameters. Likewise, MS patients with optic neuritis showed worse binocular vision.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603529/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603529&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7886387/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7886387&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.2147/OPTO.S286862&gt;10.2147/OPTO.S286862&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603529/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":6,"discovery_date":"2021-02-23T11:11:00","title":"The Therapeutic Targets of Fingolimod (FTY720) Are Involved in Pathological Processes in the Frontal Cortex of Alzheimers Disease Patients: A Network Pharmacology Study","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Front Aging Neurosci. 2021 Feb 2;13:609679. doi: 10.3389/fnagi.2021.609679. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;&lt;b&gt;Background:&lt;/b&gt; The sphingosine-1-phosphate receptor (S1PR) modulator fingolimod (FTY720), which is commonly used as an immunomodulator in multiple sclerosis treatment, has recently been found to reduce pathological changes in the brain tissue of Alzheimer&#x27;s disease (AD) animal models, but this has yet to be verified in human brain tissue. In this study, network pharmacology methods were applied to determine the potential pharmacological mechanisms of fingolimod in the frontal cortex of AD patients. &lt;b&gt;Methods:&lt;/b&gt; The pharmacological macromolecular targets of fingolimod and fingolimod phosphate were downloaded from SwissTarget and DrugBank. Systematic intersection analysis of the expression profiles of brain frontal cortex tissues (423 AD tissues and 266 control tissues) was performed to obtain AD-associated fingolimod targets (F-ADGs). Immune cell infiltration analysis and a primary mouse cortical culture RNA-seq drug screen database were used to identify immune-related F-ADGs and cortex-related F-ADGs. Then, the expression values of F-ADGs were correlated with the disease severity score (MMSE score) of AD patients to identify severity-related F-ADGs. We also analyzed miRNA expression microarray data in the frontal cortex of AD patients associated with disease severity to obtain severity-related F-ADG-miRNAs. &lt;b&gt;Results:&lt;/b&gt; A total of 188 F-ADGs were detected in the frontal cortices of AD patients and were enriched in biological processes such as synaptic signaling, inflammatory response, and response to oxygen-containing compounds. Eleven immune-related F-ADGs (like FPR1, BLNK.) and 17 cortex-related F-ADGs (like ALDH1L1, DUSP1.) were detected. Other F-ADGs, such as S1PR1 and GABBR2, although not classified into the above two categories, were still predicted by bioinformatics methods to play an important role in the development of AD. Two F-ADGs (GNAQ and MMP14) and 28 miRNAs (like miR- 323a-3p, miR-181a-5p.) were found to be associated with AD severity (MMSE 0-27 group). Fifteen F-ADGs (like ALDH1L1, FPR1, and IL6.) and 46 miRNAs (like miR-212-5p, miR-93-5p.) were found to be associated with mild or moderate dementia AD patients&#x27; severity (MMSE11-22 subgroup). &lt;b&gt;Conclusions:&lt;/b&gt; Fingolimod may affect the brain frontal cortex function of AD patients in many different ways, such as affecting immune cell infiltration, nerve cell, or glial cell function, and synaptic function. miRNAs may also be involved. ALDH1L1, FPR1, S1PR1, and GABBR2 may be core drug targets.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603656/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603656&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7884771/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7884771&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.3389/fnagi.2021.609679&gt;10.3389/fnagi.2021.609679&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603656/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":5,"discovery_date":"2021-02-23T11:11:00","title":"Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Can J Infect Dis Med Microbiol. 2021 Jan 31;2021:6616763. doi: 10.1155/2021/6616763. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (&lt;i&gt;p&lt;/i&gt;=560). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (&lt;i&gt;p&lt;/i&gt; â¤ 0.001). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33603936/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33603936&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7870309/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7870309&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/6616763&gt;10.1155/2021/6616763&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33603936/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":4,"discovery_date":"2021-02-23T11:11:00","title":"Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Case Rep Neurol Med. 2021 Jan 28;2021:5952724. doi: 10.1155/2021/5952724. eCollection 2021.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;INTRODUCTION: Spinal neurosarcoidosis is a rare disease that can manifest as myelopathy, radiculopathy, or cauda equine syndrome. Spinal epidural lipomatosis is also a rare condition resulting from overgrowth of epidural fat tissue causing compressive myelopathy. To our knowledge, there are no reports linking epidural lipomatosis and spinal neurosarcoidosis. &lt;i&gt;Case Report&lt;/i&gt;. We describe a case of progressive myelitis in the presence of concomitant spinal neurosarcoidosis and epidural lipomatosis which was a challenging diagnosis with complete response to treatment after addressing both diseases. Both etiologies are inflammatory in nature and share similar expression of inflammatory factors such as TNF-&lt;i&gt;Î±&lt;/i&gt; and IL-1&lt;i&gt;Î²&lt;/i&gt;.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: The common inflammatory process involved in these two diseases might explain a pathophysiological interconnection between both diseases that may underlie their concomitant development in our patient. If these two diseases are interconnected, in their pathophysiological mechanism remains a hypothesis that will need further investigation.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33604089/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33604089&lt;/a&gt; | PMC:&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/PMC7869444/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;PMC7869444&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1155/2021/5952724&gt;10.1155/2021/5952724&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33604089/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":3,"discovery_date":"2021-02-23T11:11:00","title":"Patient Satisfaction With the Quality of Counseling Provided by Advanced Practice Nurses Specialized in Multiple Sclerosis: A Quantitative Analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neurosci Nurs. 2021 Feb 17. doi: 10.1097/JNN.0000000000000578. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: The challenges in dealing with multiple sclerosis (MS) have increased considerably in recent years. In addition to neurologists, MS nurse specialists are key to the management of MS patients, but there is a lack of evidence regarding their quality of counseling. METHODS: The data collection took place between October 2018 and March 2019 in the outpatient clinic of a university hospital. The quality of counseling was assessed using the APN-BQ, an instrument that contains 19 items that can be assigned to 4 dimensions. Participants were asked to rate their satisfaction on a scale from 0 to 3. General satisfaction was assessed on a scale from 0 to 100. RESULTS: The participants (n = 110) rated the quality of counseling and their general satisfaction high. The mean (SD) of the structure quality dimension was 2.64 (0.44), and satisfaction with length and frequency of consultations (2.53 [0.63]) scored better than outcome quality (1.99 [0.62]) and process quality (2.13 [0.60]). CONCLUSION: Overall, there was a high rate of satisfaction with the quality of counseling. In addition to the length and frequency of consultations, MS patients particularly appreciated the availability and expertise of MS nurse specialists.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33605649/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33605649&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1097/JNN.0000000000000578&gt;10.1097/JNN.0000000000000578&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33605649/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":2,"discovery_date":"2021-02-23T11:11:00","title":"Is Migraine Associated to Brain Anatomical Alterations? New Data and Coordinate-Based Meta-analysis","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Brain Topogr. 2021 Feb 19. doi: 10.1007/s10548-021-00824-6. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;A growing number of studies investigate brain anatomy in migraine using voxel- (VBM) and surface-based morphometry (SBM), as well as diffusion tensor imaging (DTI). The purpose of this article is to identify consistent patterns of anatomical alterations associated with migraine. First, 19 migraineurs without aura and 19 healthy participants were included in a brain imaging study. T1-weighted MRIs and DTI sequences were acquired and analyzed using VBM, SBM and tract-based spatial statistics. No significant alterations of gray matter (GM) volume, cortical thickness, cortical gyrification, sulcus depth and white-matter tract integrity could be observed. However, migraineurs displayed decreased white matter (WM) volume in the left superior longitudinal fasciculus. Second, a systematic review of the literature employing VBM, SBM and DTI was conducted to investigate brain anatomy in migraine. Meta-analysis was performed using Seed-based d Mapping via permutation of subject images (SDM-PSI) on GM volume, WM volume and cortical thickness data. Alterations of GM volume, WM volume, cortical thickness or white-matter tract integrity were reported in 72%, 50%, 56% and 33% of published studies respectively. Spatial distribution and direction of the disclosed effects were highly inconsistent across studies. The SDM-PSI analysis revealed neither significant decrease nor significant increase of GM volume, WM volume or cortical thickness in migraine. Overall there is to this day no strong evidence of specific brain anatomical alterations reliably associated to migraine. Possible explanations of this conflicting literature are discussed. Trial registration number: NCT02791997, registrated February 6th, 2015.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33606142/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33606142&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1007/s10548-021-00824-6&gt;10.1007/s10548-021-00824-6&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33606142/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":1,"discovery_date":"2021-02-23T11:11:00","title":"COVID-19, HHV6 and MOG antibody: A perfect storm","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 12;353:577521. doi: 10.1016/j.jneuroim.2021.577521. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery with gancyclovir, high dose corticosteroids, and plasma exchange. To our knowledge, this is the first case of HHV6 reactivation in the central nervous system in the setting of COVID19 infection and the first case of MOG-IgG myelitis in the setting of SARS-CoV-2 and HHV6 coinfection.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Patients with neurological manifestations in the setting of COVID19-related immunodeficiency should be tested for opportunistic infections including HHV6. Viral infection is a known trigger for MOG-IgG and therefore this antibody should be checked in patients with SARS-CoV-2 associated demyelination.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33607505/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210220104920&amp;v=2.14.2&quot;&gt;33607505&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1016/j.jneuroim.2021.577521&gt;10.1016/j.jneuroim.2021.577521&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33607505/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210220104920&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null}]